

# The Ministry of Health, Labour and Welfare Ministerial Notification No. 316

Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Pharmacopoeia (Ministerial Notification No. 285, 2006) as follows\*, and the revised Japanese Pharmacopoeia shall come into effect on October 1, 2007. However, in the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as “previous Pharmacopoeia”) [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as “new Pharmacopoeia”)] and drugs which have been approved as of October 1, 2007 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceutical Affairs Law (hereinafter referred to as “drugs exempted from approval”)], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on March 31, 2009. In the case of drugs which are listed in the new Pharmacopoeia (excluding those listed in the previous Pharmacopoeia) and drugs which have been approved as of October 1, 2007 as prescribed under Paragraph 1, Article 14 of the same law (including those exempted from approval), they may be accepted as those being not listed in the new Pharmacopoeia before and on March 31, 2009. Further, Standards listed in the section 9.01 Reference Standards of the General Tests, Processes and Apparatus of the previous Pharmacopoeia at the end of application of this notification may be treated under the previous regulation irrespective of the prescription of the section 9.01(1) Reference Standards of the General Tests, Processes and Apparatus of the new Pharmacopoeia.

**Yoichi Masuzoe**

The Minister of Health, Labour and Welfare

September 28, 2007

(The text referred to by the term “as follows” are omitted here. All of them are made available for public exhibition at the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, at each Regional Bureau of Health and Welfare, and at each Prefectural Office in Japan).

\*The term “as follows” here indicates the contents of Supplement I to the Japanese Pharmacopoeia Fifteenth Edition from General Notice to Ultraviolet-visible Reference Spectra (pp. 1789 - 1997).

# CONTENTS

<b>Preface</b> .....	i	9.22 Standard Solutions .....	1817
<b>Supplement I to The Japanese Pharmacopoeia, Fifteenth Edition</b> .....	<b>1789–1997</b>	9.41 Reagents, Test Solutions .....	1817
General Notices .....	1789	9.42 Solid Supports/Column Packings for Chromatography .....	1824
General Rules for Crude Drugs .....	1791	<b>Official Monographs</b> .....	1825
General Rules for Preparations .....	1793	<b>Crude Drugs</b> .....	1937
General Tests, Processes and Apparatus ...	1795	<b>Infrared Reference Spectra</b> .....	<b>1971–1986</b>
1.09 Qualitative Tests .....	1795	<b>Ultraviolet-visible Reference Spectra</b> ....	<b>1987–1997</b>
2.01 Liquid Chromatography .....	1795	<b>General Information</b>	
2.02 Gas Chromatography .....	1799	8. International Harmonization Implemented in the Japanese Pharmacopoeia Fifteenth Edition .....	1999
2.48 Water Determination (Karl Fischer Method) .....	1801	12. Microbial Attributes of Non-sterile Pharmaceutical Products .....	2004
2.49 Optical Rotation Determination .....	1801	21. Quality Control of Water for Pharmaceutical Use .....	2006
4.01 Bacterial Endotoxins Test .....	1802	31. Purity Tests on Crude Drugs Using Genetic Information .....	2007
4.05 Microbiological Examination of Non- sterile Products .....	1802	<b>Index</b> .....	2011
6.01 Test for Metal Particles in Ophthalmic Ointments .....	1813	<b>Index in Latin Name</b> .....	2027
6.08 Insoluble Particulate Matter Test for Ophthalmic Solutions .....	1813	<b>Index in Japanese</b> .....	2029
6.10 Dissolution Test .....	1813		
6.11 Foreign Insoluble Matter Test for Ophthalmic Solutions .....	1814		
9.01 Reference Standards .....	1814		
9.21 Standard Solutions for Volumetric Analysis .....	1817		

# PREFACE

The 15th Edition of the Japanese Pharmacopoeia (JP) was promulgated by Ministerial Notification No. 285 of the Ministry of Health, Labour and Welfare (MHLW) on March 31, 2006.

In July 2006, the Committee on JP established the basic principles for the preparation of the JP 16th Edition, setting out the roles and characteristics of the JP, the definite measures for the revision, and the date of the revision.

At the above Committee, the five basic principles of JP, which we refer to as the “five pillars” were established as follows: 1) Including all drugs which are important from the viewpoint of health care and medical treatment; 2) Making qualitative improvement by introducing the latest science and technology; 3) Promoting internationalization; 4) Making prompt partial revision as necessary and facilitating smooth administrative operation; and 5) Ensuring transparency regarding the revision, and disseminating the JP to the public. It was agreed that the Committee on JP should make efforts, on the basis of these principles, to ensure that the JP is used more effectively in the fields of health care and medical treatment by taking appropriate measurements, including getting the understanding and cooperation of other parties concerned.

It was agreed that the JP should provide an official standard, being required to assure the quality of medicines in Japan in response to the progress of science and technology and medical demands at the time. It should define the standards for specifications, as well as the methods of testing to assure overall quality of all drugs in principle, and it should have a role in clarifying the criteria for quality assurance of drugs that are recognized to be essential for public health and medical treatment.

The JP has been prepared with the aid of the knowledge and experience of many professionals in the pharmaceutical field. Therefore, the JP should have the characteristics of an official standard, which might be widely used by all parties concerned. It should provide information and understanding about the quality of drugs to the public, and it should be conducive to smooth and effective regulatory control of the quality of drugs, as well as promoting and maintaining international consistency and harmonization of technical requirements.

It was also agreed that JP articles should cover

drugs, which are important from the viewpoint of health care and medical treatment, clinical results and frequency of use, as soon as possible after they reach the market.

The target date for the publication of JP 16th Edition (the Japanese edition) was set as April 2011.

JP Expert Committees are organized with the following panels: Panel on the Principles of Revisions; Sub-committee on the Principles of Revisions; Panel on Medicinal Chemicals; Panel on Antibiotics; Panel on Biologicals; Panel on Crude Drugs; Panel on Pharmaceutical Excipients; Panel on Physico-Chemical Methods; Panel on Preparations; Panel on Physical Methods; Panel on Biological Tests; Panel on Nomenclature; Panel on International Harmonization; Panel on Pharmaceutical Water; and Panel on Reference Standards. Furthermore, three working groups under the Panel on Medicinal Chemicals are established to expedite discussion of revision drafts of Monographs.

In the Committee on JP, Takao Hayakawa took the role of chairman from March 2006 to September 2007.

In addition to the regular revision every five years in line with the basic principles for the preparation of the JP it was agreed that partial revision should be done as necessary to take account of recent progress of science and in the interests of international harmonization.

In accordance with the above principles, the panels initiated deliberations on selection of articles, and on revisions for General Notices, General Rules for Crude Drugs, General Rules for Preparations, General Tests, Monographs and so on.

Draft revisions covering subjects in General Notices, General Rules for Crude Drugs, General Rules for Preparations, General Tests and Monographs, for which discussions were finished between September 2005 and March 2007, were prepared for a supplement to the JP 15. They were examined by the Committee on JP in April 2007, followed by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC) in June 2007, and then submitted to the Minister of MHLW.

Numbers of discussions in the panels to prepare the supplement drafts were as follows: Panel on Principles of Revisions (7); Sub-committee on the Principles of Revisions (6); Panel on Medicinal Chemicals (33, including the working groups); Panel on Antibiotics (9); Panel on Biologicals (8); Panel on Crude Drugs (17); Panel on Pharmaceutical Excipients (7); Panel on Physico-Chemical Methods (12); Panel on Prepara-

tions (10); Panel on Physical Methods (8); Panel on Biological Tests (7); Panel on Nomenclature (9); Panel on International Harmonization (2); and Panel on Pharmaceutical Water (7).

It should be noted that in the preparation of the drafts for the supplement, generous cooperation was given by the Technical Committee of the Pharmaceutical Manufacturer's Association of Osaka and of Tokyo, the Tokyo Crude Drugs Association, the Japan Pharmaceutical Excipients Council, the Japan Kampo Medicine Manufacturers' Association, the Japan Flavor and Fragrance Materials Association, the Japan Medical Plants Federation, the Japan Pharmaceutical Manufacturers Association, and the Japan Oilseeds Processors Association.

In consequence of this revision, the JP 15th Edition carries 1567 articles, owing to the addition of 90 articles and the deletion of 6 articles.

The principles of description and the salient points of the revision in this Supplement are as follows:

1. The Supplement I to JP 15th Edition comprises the following items, in order: Notification of MHLW; Contents; Preface; General Notices; General Rules for Crude Drugs; General Rules for Preparations; General Tests, Processes and Apparatus; Official Monographs; Infrared Reference Spectra; and Ultraviolet-visible Reference Spectra; then followed by General Information; and as an appendix a Cumulative Index containing references to the main volume and the Supplement I.

2. The articles in General Rules for Preparations, Official Monographs, Infrared Reference Spectra and Ultraviolet-visible Reference Spectra are respectively placed in alphabetical order.

3. The following items in each monograph are put in the order shown below, except that unnecessary items are omitted depending on the nature of the drug:

- (1) English title
- (2) Commonly used name(s)
- (3) Latin title (only for crude drugs)
- (4) Title in Japanese
- (5) Structural formula or empirical formula
- (6) Molecular formula and molecular mass
- (7) Chemical name
- (8) Origin
- (9) Limits of the content of the ingredient(s) and/or the unit of potency
- (10) Labeling requirements
- (11) Method of preparation
- (12) Description/Description of crude drugs
- (13) Identification tests
- (14) Specific physical and/or chemical values

- (15) Purity tests
- (16) Loss on drying or ignition, or water
- (17) Residue on ignition, total ash or acid-insoluble ash
- (18) Tests being required for pharmaceutical preparations and other special tests
- (19) Isomer ratio
- (20) Assay or the content of the ingredient(s)
- (21) Containers and storage
- (22) Expiration date
- (23) Others

4. In each monograph, the following physical and chemical values representing the properties and quality of the drug are given in the order indicated below, except that unnecessary items are omitted depending on the nature of the drug:

- (1) Alcohol number
- (2) Absorbance
- (3) Congealing point
- (4) Refractive index
- (5) Osmolarity
- (6) Optical rotation
- (7) Viscosity
- (8) pH
- (9) Specific gravity
- (10) Boiling point
- (11) Melting point
- (12) Acid value
- (13) Saponification value
- (14) Ester value
- (15) Hydroxyl value
- (16) Iodine value

5. Identification tests comprise the following items, which are generally put in the order given below:

- (1) Coloration reactions
- (2) Precipitation reactions
- (3) Decomposition reactions
- (4) Derivatives
- (5) Infrared and/or ultraviolet-visible absorption spectrometry
- (6) Special reactions
- (7) Cations
- (8) Anions

6. Purity tests comprise the following items, which are generally put in the order given below, except that unnecessary items are omitted depending on the nature of the drug:

- (1) Color
- (2) Odor
- (3) Clarity and/or color of solution
- (4) Acidity or alkalinity
- (5) Acidity

- (6) Alkalinity
- (7) Chloride
- (8) Sulfate
- (9) Sulfite
- (10) Nitrate
- (11) Nitrite
- (12) Carbonate
- (13) Bromide
- (14) Iodide
- (15) Soluble halide
- (16) Thiocyanide
- (17) Selenium
- (18) Cationic salts
- (19) Ammonium
- (20) Heavy metals
- (21) Iron
- (22) Manganese
- (23) Chromium
- (24) Bismuth
- (25) Tin
- (26) Aluminum
- (27) Zinc
- (28) Cadmium
- (29) Mercury
- (30) Copper
- (31) Lead
- (32) Silver
- (33) Alkaline earth metals
- (34) Arsenic
- (35) Foreign matter
- (36) Related substances
- (37) Residual solvent
- (38) Other impurities
- (39) Readily carbonizable substances

7. The abbreviations used for the principal units, "mol", "mmol", "mmol/L" and "Pa·s" were added to and "pH" was deleted from the paragraph 9 of the General Notices.

8. The following items of the General Rules for Preparations were revised:

- (1) Extracts
- (2) Ophthalmic Ointments
- (3) Tinctures
- (4) Ophthalmic Solutions
- (5) Fluidextracts

9. The following item was added to the General Tests, Processes and Apparatus:

6.11 Foreign Insoluble Matter Test for Ophthalmic Solutions

10. The following items of the General Tests, Processes and Apparatus were revised:

- (1) 1.09 Qualitative Tests
- (2) 2.01 Liquid Chromatography
- (3) 2.02 Gas Chromatography
- (4) 2.48 Water Determination (Karl Fisher Method)
- (5) 2.49 Optical Rotation Determination
- (6) 4.01 Bacterial Endotoxins Test
- (7) 4.05 Microbial Limit Test
- (8) 6.01 Test for Metal Particles in Ophthalmic Ointments
- (9) 6.08 Insoluble Particulate Matter Test for Ophthalmic Solutions
- (10) 6.10 Dissolution Test

11. The following Reference Standards were newly added:

Amlexanox  
Amlodipine Besilate  
Clobetasol Propionate  
Enalapril Maleate  
Manidipine Hydrochloride  
Mizoribine  
Nabumetone  
Nizatidine  
Ozagrel Sodium  
Vincristine Sulfate  
Zidovudine

12. The following Reference Standards were deleted.

Fosfestrol  
Hypromellose Phthalate  
Sulfapyrazone  
Tubocurarine Chloride Hydrochloride

13. English and Latin titles of drugs were based, in principle, on the International Nonproprietary Names for Pharmaceutical Substances, and the chemical names were based on the Rules of the International Union of Pure and Applied Chemistry (IUPAC).

14. Molecular formulas of organic compounds begin with C and then H, followed by other involved elements in the alphabetical order of the symbols of the elements.

15. Structural formula of drug represents, as far as possible, the steric configuration.

16. The test procedures in monographs were written in full, except within the same monograph and in the monographs for preparations having a corresponding monograph of their principal material substances.

17. The following monographs were added:  
Acemetacin  
Alminoprofen

Alminoprofen Tablets  
Alprostadil Injection  
Amikacin Sulfate Injection  
Amlexanox  
Amlexanox Tablets  
Amlodipine Besilate  
Amosulalol Hydrochloride  
Amosulalol Hydrochloride Tablets  
Ampicillin Sodium for Injection  
Azelastrine Hydrochloride  
Aztreonam for Injection  
Benzylpenicillin Potassium for Injection  
Biotin  
Bisoprolol Fumarate  
Bisoprolol Fumarate Tablets  
Bucillamine Tablets  
Buformin Hydrochloride  
Buformin Hydrochloride Enteric-coated Tablets  
Buformin Hydrochloride Tablets  
Buprenorphine Hydrochloride  
Cefadroxil Capsules  
Cefadroxil for Syrup  
Cefazolin Sodium for Injection  
Cefmetazole Sodium for Injection  
Ceftazidime for Injection  
Cetirizine Hydrochloride  
Cetirizine Hydrochloride Tablets  
Chlorphenesin Carbamate Tablets  
Cibenzoline Succinate  
Cibenzoline Succinate Tablets  
Cilazapril Hydrate  
Cilazapril Tablets  
Clindamycin Phosphate Injection  
Clobetasol Propionate  
Clorazepate Dipotassium  
Clorazepate Dipotassium Capsules  
L-Cysteine  
L-Cysteine Hydrochloride Hydrate  
Domperidone  
Doxorubicin Hydrochloride for Injection  
Emorfazone  
Enalapril Maleate  
Enalapril Maleate Tablets  
Erythromycin Enteric-Coated Tablets  
Etizolam Fine Granules  
Etizolam Tablets  
Felbinac  
L-Glutamine  
Griseofulvin Tablets  
Ibuprofen  
Isoxsuprine Hydrochloride  
Isoxsuprine Hydrochloride Tablets  
Itraconazole

Josamycin Tablets  
Labetalol Hydrochloride  
Labetalol Hydrochloride Tablets  
Manidipine Hydrochloride  
Manidipine Hydrochloride Tablets  
Minocycline Hydrochloride for Injection  
Mitomycin C for Injection  
Mizoribine  
Mizoribine Tablets  
Nabumetone  
Nabumetone Tablets  
Nafamostat Mesilate  
Nizatidine  
Nizatidine Capsules  
Omeprazole  
Ozagrel Sodium  
Ozagrel Sodium for Injection  
Peplomycin Sulfate for Injection  
Piperacillin Hydrate  
Rokitamycin Tablets  
L-Serine  
Sodium Starch Glycolate  
Tobramycin Injection  
L-Tyrosine  
Ubenimex  
Zidovudine  
Aralia Rhizome  
Powdered Corydalis Tuber  
Crataegus Fruit  
Hangekobokuto Extract  
Keishibukuryogan Extract  
Leonurus Herb  
Lilium Bulb  
Peucedanum Root  
Powdered Turmeric

**18.** The following monographs were revised:

Acetylcholine Chloride for Injection  
Ajmaline Tablets  
Aminophylline Injection  
Amitriptyline Hydrochloride Tablets  
L-Arginine Hydrochloride Injection  
Ascorbic Acid Injection  
Baclofen Tablets  
Betahistine Mesilate  
Bisacodyl Suppositories  
Calcium Chloride Injection  
Calcium Folate  
Camostat Mesilate  
Cefalotin Sodium  
Cefatrizine Propylene Glycolate  
Chlordiazepoxide Tablets  
Chlorphenesin Carbamate  
Chlorpromazine Hydrochloride Injection

Chlorpromazine Hydrochloride Tablets  
Chlorpropamide Tablets  
Cilostazol Tablets  
Creosote  
Cyanocobalamin  
Cyanocobalamin Injection  
Deferoxamine Mesilate  
Dehydrocholic Acid Injection  
Deslanoside Injection  
Dextran 40  
Anhydrous Dibasic Calcium Phosphate  
Dibasic Calcium Phosphate Hydrate  
Dopamine Hydrochloride Injection  
Edrophonium Chloride Injection  
Ephedrine Hydrochloride Injection  
Ephedrine Hydrochloride Tablets  
Famotidine for Injection  
Faropenem Sodium Hydrate  
Faropenem Sodium Tablets  
Faropenem Sodium for Syrup  
Folic Acid Injection  
Folic Acid Tablets  
Fructose Injection  
Gabexate Mesilate  
Glucose Injection  
Hydralazine Hydrochloride Tablets  
Hypromellose Phthalate  
Idoxuridine Ophthalmic Solution  
Imipramine Hydrochloride Tablets  
Indometacin Capsules  
Isotonic Sodium Chloride Solution  
Anhydrous Lactose  
Levallorphan Tartrate Injection  
Magnesium Sulfate Injection  
D-Mannitol Injection  
Medazepam  
Mefruside Tablets  
Methyldopa Tablets  
Morphine Hydrochloride Tablets  
Neostigmine Methylsulfate Injection  
Nicardipine Hydrochloride Injection  
Nicorandil  
Nicotinic Acid Injection  
Noradrenaline Injection  
Papaverine Hydrochloride Injection  
Pethidine Hydrochloride Injection  
Prednisolone Sodium Succinate for Injection  
Protamine Sulfate  
Protamine Sulfate Injection  
Pyridoxine Hydrochloride Injection  
Reserpine Injection  
Riboflavin Sodium Phosphate Injection  
Ringer's Solution  
Roxithromycin  
Salicylic Acid  
Sodium Bicarbonate Injection  
10% Sodium Chloride Injection  
Sodium Citrate Injection for Transfusion  
Sodium Thiosulfate Injection  
Sulbactam Sodium  
Sulpyrine Injection  
Sultamicillin Tosilate Hydrate  
Suxamethonium Chloride for Injection  
Suxamethonium Chloride Injection  
Talc  
Teceleukin for Injection (Genetical Recombination)  
Thiamine Chloride Hydrochloride Injection  
Thiopental Sodium for Injection  
Tipepidine Hibenazate Tablets  
Trimetazidine Hydrochloride  
Vincristine Sulfate  
Water for Injection  
Xylitol Injection  
Alpinia Offcinarum Rhizome  
Anemarrhena Rhizome  
Angelica Dahurica Root  
Apricot Kernel  
Asiasarum Root  
Asparagus Tuber  
Atractylodes Rhizome  
Powdered Atractylodes Rhizome  
Belladonna Extract  
Calumba  
Powdered Calumba  
Cimicifuga Rhizome  
Clematis Root  
Cnidium Rhizome  
Powdered Cnidium Rhizome  
Condurango Fluidextract  
Coptis Rhizome  
Powdered Coptis Rhizome  
Corydalis Tuber  
Cyperus Rhizome  
Powdered Cyperus Rhizome  
Dioscorea Rhizome  
Powdered Dioscorea Rhizome  
Fritillaria Bulb  
Gastrodia Tuber  
Gentian  
Powdered Gentian  
Glehnia Root  
Glycyrrhiza Extract  
Crude Glycyrrhiza Extract  
Hochuekkito Extract  
Imperata Rhizome  
Ipecac

Powdered Ipecac  
 Japanese Gentian  
 Powdered Japanese Gentian  
 Japanese Valerian  
 Powdered Japanese Valerian  
 Kakkonto Extract  
 Kamishoyosan Extract  
 Lindera Root  
 Lithospermum Root  
 Lycium Bark  
 Magnolia Bark  
 Powdered Magnolia Bark  
 Mulberry Bark  
 Notopterygium Rhizome  
 Nuphar Rhizome  
 Nux Vomica Extract  
 Panax Japonicus Rhizome  
 Powdered Panax Japonicus Rhizome  
 Peach Kernel  
 Powdered Peach Kernel  
 Perilla Herb  
 Platycodon Fluidextract  
 Polygala Root  
 Powdered Polygala Root  
 Polygonum Root  
 Polyporus Sclerotium  
 Powdered Polyporus Sclerotium  
 Processed Aconite Root  
 Powdered Processed Aconite Root  
 Processed Ginger  
 Rehmannia Root  
 Ryokeijutsukanto Extract  
 Saposchnikovia Root  
 Saussurea Root  
 Scopolia Extract  
 Scopolia Rhizome  
 Scutellaria Root  
 Powdered Scutellaria Root  
 Senega  
 Powdered Senega  
 Smilax Rhizome  
 Powdered Smilax Rhizome  
 Sophora Root  
 Powdered Sophora Root  
 Turmeric  
 Uva Ursi Fluidextract  
 Zedoary

**19.** The following monographs were deleted:

Fosfestrol  
 Fosfestrol Tablets  
 Sulfinpyrazone  
 Sulfinpyrazone Tablets  
 Tubocurarine Chloride Hydrochloride Hydrate

Tubocurarine Chloride Hydrochloride Injection

Those who were engaged in the preparation of Supplement I to JP 15 are as follows:

Norio Aimi	Yuuichi Kikuchi
Fumiaki Akahori	Mitsukazu Kitada
Mitsuo Aoki	Fumiyuki Kiuchi
Kiichi Aonuki	Junko Kizu
Nobuo Aoyagi**	Takashi Kobayashi
Keiko Arimoto	Masayoshi Kohase
Hiroshi Asama	Shigeo Kojima
Kazuhide Ashizawa	Hiroyasu Kokubo
Shinichiro Aso	Katsuko Komatsu
Yukio Aso	Akio Komura
Takashi Bamba	Tetsuya Konda
Makoto Emura	Toshifumi Konda
Hiroyuki Fuchino	Kenji Kondo
Shigeyuki Fujikura	Seizo Kondo
Akihiko Fujise	Takao Kunisada
Goro Funamoto	Masaaki Kurihara
Yukihiko Goda	Fumiyo Kusu
Ruri Hanajiri	Kumiko Kusuyama
Kouji Hasegawa	Masako Maeda
Mitsuru Hashida	Midori Makita
Rika Hatano	Yoshihisa Matsuda
Takao Hayakawa*	Norio Matsuki
Masahiro Hayashi	Eiichi Mikami
Yoshinori Hayashi	Tsuyoshi Miyagawa
Kenji Higuchi	Satoshi Minobe
Fusayoshi Hirayama	Tsuyoshi Miura
Yukio Hiyama	Hiroto Miyamoto
Kunimoto Hotta	Naoki Miyata
Masashi Hyuga	Michinao Mizugaki
Nobukazu Igoshi	Taiichi Mizuta
Kenichi Inui	Kaoru Morikawa
Akiko Ishii	Osamu Morita
Yuji Ito	Takashi Morita
Takashi Itoh	Toshimi Murai
Masao Izaki	Masashi Muroi
Kenichi Izutsu	Hiroaki Nagashige
Akemi Kai	Shinsaku Nakagawa
Kazuaki Kakehi	Emi Nakajima
Takemine Kanai	Hiroshi Nakamura
Motoko Kanke	Tatsuya Nakano
Hirohito Katayama	Tatsumi Nakashima
Noriko Katori	Mitsuo Nanaura
Nobuo Kawahara	Masaaki Naotsuka
Toru Kawanishi	Masao Nasu
Yoshihiko Kawarasaki	Shingo Niimi
Nana Kawasaki	Hiroshi Nishimura
Toshisuke Kawasaki	Shukichi Ochiai
Yoshiaki Kawashima	Atsuyuki Ohtsuki
Keiji Kijima	Ryozo Oishi



Minoru Okada  
Satoshi Okada  
Kimiya Okazaki  
Tsuneo Okubo  
Haruhiro Okuda  
Masami Otsuka  
Tadashi Ouchi  
Kazuhiro Owada  
Kenji Saiki  
Yoshikazu Sakagami  
Eiji Sakai  
Tomoaki Sakamoto  
Hideki Sasaki  
Hiroshi Sasaki  
Tsuguo Sasaki  
Motoyoshi Satake  
Kyoko Sato

Michiko Sekiguchi  
Setsuko Sekita  
Yasuo Shimada  
Kesamitsu Shimizu  
Kyoko Shimura  
Osamu Shirota  
Hisashi Sonobe  
Shoko Sueyoshi  
Shinji Sugaya  
Hisakazu Sunada  
Hideyo Suzuki  
Yoshikazu Takahashi  
Toshio Takachi  
Kikuo Takatera  
Tadahiro Takeda  
Yasushi Takeda  
Toyoshige Tanabe

Haruo Tanaka  
Toshihiro Tanaka  
Kenichi Tanamoto\*\*  
Tsuyoshi Tanimoto  
Susumu Terabayashi  
Reiko Teraoka  
Keijiro Terashita  
Masafumi Teshigawara  
Hiroshi Tokunaga  
Kiyoshi Tomioka  
Motowo Tomita  
Hideya Tsuge  
Yosuke Tsuji  
Eriko Uchida

Yoshimasa Uehara  
Kazuichi Umemoto  
Haruo Watanabe  
Takehiko Yajima  
Teruhide Yamaguchi  
Keiichi Yamamoto  
Keiji Yamamoto  
Tosuke Yamamoto  
Takeshi Yamazaki  
Masato Yasuhara  
Hikaru Yoden  
Chikako Yomota  
Hitoo Yoshida  
Sumie Yoshioka

\*: Chairman, the Committee on JP

\*\* : Acting Chairman, the Committee on JP

# GENERAL NOTICES

**Change the paragraph 9 to read:**

9. The following abbreviations are used for the principal units.

meter	m
centimeter	cm
millimeter	mm
micrometer	$\mu\text{m}$
nanometer	nm
kilogram	kg
gram	g
milligram	mg
microgram	$\mu\text{g}$
nanogram	ng
picogram	pg
mole	mol
millimole	mmol
Celsius degree	$^{\circ}\text{C}$
square centimeter	$\text{cm}^2$
liter	L
milliliter	mL
microliter	$\mu\text{L}$
megahertz	MHz

per centimeter	$\text{cm}^{-1}$
newton	N
kilopascal	kPa
pascal	Pa
mole per liter	mol/L
millimole per liter	mmol/L
pascal second	$\text{Pa}\cdot\text{s}$
millipascal second	$\text{mPa}\cdot\text{s}$
square millimeter per second	$\text{mm}^2/\text{s}$
lux	lx
mass per cent	%
mass parts per million	ppm
mass parts per billion	ppb
volume per cent	vol%
volume parts per million	vol ppm
mass per volume per cent	w/v%
endotoxin unit	EU

Note: "ppm" used in the Nuclear Magnetic Resonance Spectroscopy indicates the chemical shift, and "w/v%" is used in the formula or composition of preparations.

# GENERAL RULES FOR CRUDE DRUGS

## ***Change the paragraph 1 to read:***

1. Crude drugs in the monographs include medicinal parts obtained from plants or animals, cell inclusions and secretes separated from the origins, their extracts, and minerals. General Rules for Crude Drugs and Crude Drugs Test are applicable to the following:

Acacia, Achyranthes Root, Agar, Akebia Stem, Alisma Rhizome, Aloe, Alpinia Officinarum Rhizome, Amomum Seed, Anemarrhena Rhizome, Angelica Dahurica Root, Apricot Kernel, Aralia Rhizome, Areca, Artemisia Capillaris Flower, Asiasarum Root, Asparagus Tuber, Astragalus Root, Atractylodes Lancea Rhizome, Atractylodes Rhizome, Bear Bile, Bearberry Leaf, Belladonna Root, Benincasa Seed, Benzoin, Bitter Cardamon, Bitter Orange Peel, Bupleurum Root, Burdock Fruit, Calumba, Capsicum, Cardamon, Cassia Seed, Catalpa Fruit, Chrysanthemum Flower, Cimicifuga Rhizome, Cinnamon Bark, Citrus Unshiu Peel, Clematis Root, Clove, Cnidium Monnieri Fruit, Cnidium Rhizome, Coix Seed, Condurango, Coptis Rhizome, Cornus Fruit, Corydalis Tuber, Crataegus Fruit, Cyperus Rhizome, Digenea, Dioscorea Rhizome, Dolichos Seed, Eleutherococcus Senticosus Rhizome, Ephedra Herb, Epimedium Herb, Eucommia Bark, Evodia Fruit, Fennel, Forsythia Fruit, Fritillaria Bulb, Gambir, Gardenia Fruit, Gastrodia Tuber, Gentian, Geranium Herb, Ginger, Ginseng, Glehnia Root, Glycyrrhiza, Gypsum, Hemp Fruit, Honey, Houttuynia Herb, Immature Orange, Imperata Rhizome, Ipecac, Japanese Angelica Root, Japanese Gentian, Japanese Valerian, Jujube, Jujube Seed, Leonurus Herb, Lilium Bulb, Lindera Root, Lithospermum Root, Longgu, Lonicera Leaf and Stem, Loquat Leaf, Lycium Bark, Lycium Fruit, Magnolia Bark, Magnolia Flower, Mallotus Bark, Mentha Herb, Moutan Bark, Mulberry Bark, Nelumbo Seed, Notopterygium Rhizome, Nuphar Rhizome, Nux Vomica, Ophiopogon Tuber, Oriental Bezoar, Oyster Shell, Panax Japonicus Rhizome, Peach Kernel, Peony Root, Perilla Herb, Peucedanum Root, Phar-

bitis Seed, Phellodendron Bark, Picrasma Wood, Pinellia Tuber, Plantago Herb, Plantago Seed, Platycodon Root, Polygala Root, Polygonatum Rhizome, Polygonum Root, Polyporus Sclerotium, Poria Sclerotium, Powdered Acacia, Powdered Agar, Powdered Alisma Rhizome, Powdered Aloe, Powdered Amomum Seed, Powdered Atractylodes Lancea Rhizome, Powdered Atractylodes Rhizome, Powdered Calumba, Powdered Capsicum, Powdered Cinnamon Bark, Powdered Clove, Powdered Cnidium Rhizome, Powdered Coix Seed, Powdered Coptis Rhizome, Powdered Corydalis Tuber, Powdered Cyperus Rhizome, Powdered Dioscorea Rhizome, Powdered Fennel, Powdered Gambir, Powdered Gardenia Fruit, Powdered Gentian, Powdered Geranium Herb, Powdered Ginger, Powdered Ginseng, Powdered Glycyrrhiza, Powdered Ipecac, Powdered Japanese Angelica Root, Powdered Japanese Gentian, Powdered Japanese Valerian, Powdered Magnolia Bark, Powdered Moutan Bark, Powdered Oyster Shell, Powdered Panax Japonicus Rhizome, Powdered Peach Kernel, Powdered Peony Root, Powdered Phellodendron Bark, Powdered Picrasma Wood, Powdered Platycodon Root, Powdered Polygala Root, Powdered Polyporus Sclerotium, Powdered Poria Sclerotium, Powdered Processed Aconite Root, Powdered Rhubarb, Powdered Rose Fruit, Powdered Scutellaria Root, Powdered Senega, Powdered Senna Leaf, Powdered Smilax Rhizome, Powdered Sophora Root, Powdered Sweet Hydrangea Leaf, Powdered Swertia Herb, Powdered Tragacanth, Powdered Turmeric, Powdered Zanthoxylum Fruit, Processed Aconite Root, Processed Ginger, Prunella Spike, Pueraria Root, Red Ginseng, Rehmannia Root, Rhubarb, Rice Starch, Rose Fruit, Rosin, Safflower, Saffron, Saposchnikovia Root, Sappan Wood, Saussurea Root, Schisandra Fruit, Schizonepeta Spike, Scopolia Rhizome, Scutellaria Root, Senega, Senna Leaf, Sinomenium Stem, Smilax Rhizome, Sophora Root, Sweet Hydrangea Leaf, Swertia Herb, Turmeric, Toad Venom, Tragacanth, Tribulus Fruit, Trichosanthes Root, Uncaria Hook, Zanthoxylum Fruit, Zedoary.

# GENERAL RULES FOR PREPARATIONS

## 7. Extracts

### **Change (1) to read:**

(1) Extracts are prepared by evaporating the extractives of crude drugs. Generally, there are two kinds of Extracts which are:

- (i) viscous extracts (ii) dry extracts

## 8. Fluidextracts

### **Change (4) to read:**

(4) Unless otherwise specified, Fluidextracts meet the requirements of the Heavy Metals Limit Test <1.07> when the test solution and the control solution are prepared as follows.

Test solution: Ignite 1.0 g of Fluidextracts to ash, warm with 3 mL of dilute hydrochloric acid, filter, and wash the residue with two 5 mL portions of water. Add 1 drop of phenolphthalein TS to the combined filtrate and washings, add ammonia TS dropwise until the solution becomes a pale red, filter, if necessary, and add 2 mL of dilute acetic acid and water to make 50 mL.

Control solution: Proceed with 3 mL of dilute hydrochloric acid as directed in the preparation of test solution, and add 3.0 mL of Standard Lead Solution and water to make 50 mL.

## 17. Ophthalmic Ointments

### **Change (5) to read:**

(5) Unless otherwise specified, Ophthalmic Ointments meet the requirements of the Test for Metal Particles in Ophthalmic Ointments <6.01>.

## 18. Ophthalmic Solutions

### **Change (8), (9) to read:**

(8) Ophthalmic Solutions prepared as aqueous solution and aqueous vehicles attached to Ophthalmic Solutions, unless otherwise specified, meet the requirement of the Foreign Insoluble Matter Test for Ophthalmic Solutions <6.11>. The containers of Ophthalmic Solutions should have

a transparency which does not interfere with the test for foreign matter.

(9) Unless otherwise specified, Ophthalmic Solutions meet the Insoluble Particulate Matter Test for Ophthalmic Solutions <6.08>.

## 27. Tinctures

### **Change (2) to read:**

(2) Unless otherwise specified, Tinctures are usually prepared from coarse powder or fine cuttings of crude drug substance(s) either by maceration or by percolation as described below.

Maceration: Place crude drugs in a suitable container, and add the total volume or about three-fourths of the total volume of a solvent to be used. Stopper, and allow the container to stand at ordinary temperature with occasional stirring for about 5 days or until the soluble constituents have satisfactorily dissolved. Filter the liquid through cloth. In the case where about three-fourths of the total volume of the solvent is added, wash the residue with a suitable quantity of the solvent, press, and combine the filtrate and washings to make up the volume. In the case where the total volume of the solvent is added, sufficient solvent may be added, if necessary, to make up for the decreasing amount. Allow the mixture to stand for about 2 days, and obtain a clear liquid by decantation or filtration.

Percolation: Pour the solvent in small portions on crude drugs placed in a container, and mix well to moisten the crude drugs. Stopper the container, and allow it to stand for about 2 hours at room temperature. Pack the contents as tightly as possible in a suitable percolator, open the lower opening, and slowly pour sufficient solvent to cover the crude drugs. When the percolate begins to drip, close the opening, and allow the mixture to stand for 2 to 3 days at room temperature. Open the opening, and allow the percolate to drip at a rate of 1 to 3 mL per minute. Add an appropriate quantity of the solvent, and continue to percolate until the desired volume has passed. Mix thoroughly, allow standing for 2 days, and obtain a clear liquid by decantation or filtration. The time of standing and the flow rate may be varied depending on the kind and amount of crude drugs to be percolated.

Tinctures prepared by either of the above methods for which the content of the drug substance is specified are prepared by assaying the drug substance using a portion of the sample and adjusting, if necessary, with the percolate or with the solvent to the specified content.

# GENERAL TESTS, PROCESSES AND APPARATUS

## **Change the introduction to read:**

General Tests, Processes and Apparatus includes common methods for tests, useful test methods for quality recognition of drugs and other articles related to them. Unless otherwise specified, the procedures for acid-neutralizing capacity determination of gastrointestinal medicines, alcohol number determination, ammonium determination, arsenic determination, atomic absorption spectrophotometry, test for bacterial endotoxins, boiling point determination, distilling range determination, chloride determination, conductivity measurement, congealing point determination, determination of bulk and tapped densities, digestion test, disintegration test, dissolution test, endpoint detection in titrimetry, test of extractable volume for injection, flame coloration, fluorometry, foreign insoluble matter test for injections, foreign insoluble matter test for ophthalmic solutions, gas chromatography, heavy metals determination, test for glass containers for injections, infrared spectrophotometry, insoluble particulate matter test for injections, insoluble particulate matter test for ophthalmic solutions, iron determination, liquid chromatography, loss on drying determination, loss on ignition determination, melting point determination, test for metal particles in ophthalmic ointments, methanol determination, microbial assay for antibiotics, test for microbial limit, test for microbial limit for crude drugs, mineral oil determination, nitrogen determination, nuclear magnetic resonance spectroscopy, optical rotation determination, osmolarity determination, oxygen flask combustion method, particle size distribution test for preparations, pH determination, test for plastic containers, powder particle density determination, powder particle size determination, test for pyrogen, qualitative test, test for readily carbonizable substances, refractive index determination, residual solvents test, residue on ignition determination, test for rubber closure for aqueous infusions, specific gravity and density determination, specific surface area determination, test for sterility, sulfate determination, thermal analysis, thin-layer chromatography, test for total organic carbon, ultravioletvisible spectrophotometry, uniformity of dosage units (test for content uniformity, mass variation test), viscosity determination, vitamin A assay, water determination, and X-ray powder diffraction are performed as directed in the corresponding articles under the General Tests, Processes and Apparatus. The tests for melting point of fats, congealing point of fatty acids, specific gravity, acid value, saponification value, ester value, hydroxyl value, unsaponifiable matter and iodine value of fats and fatty oils are performed as directed in the corresponding items under Fats and Fatty Oils Test, and sampling, preparation of sample for analysis, microscopic

examination, purity test, loss on drying, total ash, acid-insoluble ash, extract content, and essential oil content of crude drugs are performed as directed in the corresponding items under Crude Drugs Test.

The number of each test method is a category number given individually. The number in brackets (< >) appeared in monograph indicates the number corresponding to the general test method.

## 1.09 Qualitative Tests

### **Add the following next to Mercurous salt:**

#### **Mesilate**

(1) To mesilates add twice its mass of sodium hydroxide, heat gently to melt, and continue heating for 20 to 30 seconds. After cooling, add a little amount of water, then add dilute hydrochloric acid, and warm: the gas evolved changes moistened potassium iodate-starch paper to blue.

(2) To mesilates add threefold its mass of sodium nitrate and anhydrous sodium carbonate, mix, and heat gradually. After cooling, dissolve the residue in diluted hydrochloric acid (1 in 5), and filter if necessary. The filtrate yields a white precipitate upon addition of barium chloride TS.

## 2.01 Liquid Chromatography

### **Change to read:**

Liquid Chromatography is a method to develop a mixture injected into a column prepared with a suitable stationary phase by passing a liquid as a mobile phase through the column, in order to separate the mixture into its components by making use of the difference of retention capacity against the stationary phase, and to determine the components. This method can be applied to a liquid or soluble sample, and is used for identification, purity test, and quantitative determination.

A mixture injected into the column is distributed between the mobile phase and the stationary phase with a characteristic ratio ( $k$ ) for each component.

$$k = \frac{\text{amount of compound in the stationary phase}}{\text{amount of compound in the mobile phase}}$$

The ratio  $k$  represents the mass distribution ratio  $k'$  in liquid chromatography.

Since the relation given below exists among the ratio ( $k$ ), the time for which the mobile phase is passed through the column ( $t_0$ : time measured from the time of injection of a

compound with  $k=0$  to the time of elution at the peak maximum), and the retention time ( $t_R$ : time measured from the time of injection of a compound to be determined to the time of elution at the peak maximum), the retention time for a compound on a column has a characteristic value under fixed chromatographic conditions.

$$t_R = (1 + k) t_0$$

### Apparatus

Basically, the apparatus required for the liquid chromatographic procedure consists of a pumping system for the mobile phase, a sample injection port, a column, a detector and a recorder. A mobile phase component regulator, a thermostat for the column, a pumping system for reaction reagents and a chemical reaction chamber are also used, if necessary. The pumping system serves to deliver the mobile phase and the reagents into the column and connecting tube at a constant flow rate. The sample injection port is used to deliver a quantity of the sample to the apparatus with high reproducibility. The column is a tube with a smooth interior, made of inert metal, etc., in which a packing material for liquid chromatography is uniformly packed. A column with a stationary phase chemically bound on the inside wall instead of the column packed with the packing material may be used. The detector is used to detect a property of the samples which is different from that of the mobile phase, and may be an ultraviolet or visible spectrophotometer, fluorometric detector, differential refractometer, electrochemical detector, chemiluminescence detector, electric conductivity detector, mass spectrophotometer, etc. The output signal is usually proportional to the concentration of samples at amounts of less than a few  $\mu\text{g}$ . The recorder is used to record the output signals of the detector. As required, a data processor may be used as the recorder to record or output the chromatogram, retention times or amounts of the components. The mobile phase component regulator is used to vary the ratio of the mobile phase components in a stepwise or gradient fashion.

### Procedure

Fix the detector, column and mobile phase to the apparatus, and adjust the flow rate and the column temperature to the values described in the operating conditions specified in the individual monograph. Inject a volume of the sample solution or the standard solution specified in the individual monograph with the sample injector into the column through the sample injection port. The separated components are detected by the detector, and recorded by the recorder as a chromatogram. If the components to be analyzed have no readily detectable physical properties such as absorbance or fluorescence, the detection is achieved by changing the components to suitable derivatives. Usually, the derivatization is performed as a pre- or post-column labeling.

### Identification and purity test

Identification of a component of a sample is performed by confirming agreement of the retention time of the sample with that of an authentic specimen, or by confirming that

the peak shape of the sample is unchanged after mixing the sample with an authentic specimen.

In general, the purity of the sample is determined by comparing the sample solution with a standard solution which is prepared by diluting the sample solution to a concentration corresponding to the specified limit amount of the impurity, or by the peak area percentage method. Unless otherwise specified, if a sample is separated into isomers in the chromatogram, the isomer ratio is calculated by using the peak area percentage method.

The peak area percentage method is a method to calculate the proportion of the components from the ratio of the peak area of each component to the sum of the peak areas of every peak recorded in the chromatogram. In order to obtain accurate results in evaluating the proportion of the components, it is necessary to correct the area of each component based on the relative response factor to the principal component.

### Assay

(1) Internal standard method—In the internal standard method, choose a stable compound as an internal standard which shows a retention time close to that of the compound to be assayed, and whose peak is well separated from all other peaks in the chromatogram. Prepare several kinds of standard solutions containing a fixed amount of the internal standard and several graded amounts of the authentic specimen specified in the individual monograph. Based on the chromatogram obtained by injection of a fixed volume of individual standard solutions, calculate the ratio of peak area or peak height of the authentic specimen to that of the internal standard, and prepare a calibration curve by plotting these ratios on the ordinate against the amount of the authentic specimen or the ratio of the amount of the authentic specimen to that of the internal standard on the abscissa. The calibration curve is usually obtained as a straight line passing through the origin. Then, prepare a sample solution containing the internal standard in the same amount as in the standard solutions used for the preparation of the calibration curve according to the method specified in the individual monograph, perform the liquid chromatography under the same operating conditions as for the preparation of the calibration curve, calculate the ratio of the peak area or peak height of the objective compound to that of the internal standard, and read the amount of the compound from the calibration curve.

In an individual monograph, generally one of the standard solutions with a concentration within the linear range of the calibration curve and a sample solution with a concentration close to that of the standard solution are prepared, and the chromatography is performed with these solutions under fixed conditions to determine the amount of the objective compound.

(2) Absolute calibration curve method—Prepare standard solutions with several graded amounts of the authentic specimen, and inject accurately a fixed volume of these standard solutions. With the chromatogram obtained, prepare a calibration curve by plotting the peak areas or peak heights

on the ordinate against the amount of the authentic specimen on the abscissa. The calibration curve is generally obtained as a straight line passing through the origin. Then, prepare a sample solution according to the method specified in the individual monograph, perform the liquid chromatography under the same conditions as for the preparation of the calibration curve, measure the peak area or peak height of the objective compound, and read the amount of the compound from the calibration curve.

In an individual monograph, generally one of the standard solutions with a concentration within the linear range of the calibration curve and a sample solution with a concentration close to that of the standard solution are prepared, and the chromatography is performed with these solutions under a fixed condition to obtain the amount of the component. In this method, all procedures, such as the injection procedure, must be carried out under a strictly constant condition.

#### Method for peak measuring

Generally, the following methods are used.

##### (1) Peak height measuring method

(i) Peak height method: Measure the distance between the maximum of the peak and the intersecting point of a perpendicular line from the maximum of the peak to the horizontal axis of recording paper with a tangent linking the baselines on both sides of the peak.

(ii) Automatic peak height method: Measure the signals from the detector as the peak height using a data processing system.

##### (2) Peak area measuring method

(i) Width at half-height method: Multiply the peak width at the half-height by the peak height.

(ii) Automatic integration method: Measure the signals from the detector as the peak area using a data processing system.

#### System suitability

System suitability is an integral part of analytical methods using chromatography, and is used to ensure that the performance of the chromatographic systems used is adequate for the analysis of the drug to be tested, as the suitability of the method for the evaluation of the quality of the drug was verified. System suitability test should be carried out at every series of drug analysis. The test procedures and acceptance criteria of system suitability must be prescribed in the test method of the drug. Sample analysis is not acceptable unless the requirements of system suitability have been met.

In system suitability test of the chromatographic systems, the evaluation of "System performance" and "System repeatability" is usually required. For purity tests, the evaluation of "Test for required detectability" may also be required.

##### (1) Test for required detectability

For purity tests, when it is confirmed that the target impurity is distinctly detected at the concentration of its specification limit, it is considered verified that the system used has adequate performance to achieve its intended use.

For quantitative purity tests, "Test for required detectability" is usually required, and in order to confirm, in some degree, the linearity of response near its specification limit, the range of expected response to the injection of a certain volume of target impurity solution at the concentration of its specification limit should be prescribed. For limit test, "Test for required detectability" is not required, if the test is performed by comparing the response from sample solution with that from standard solution at the concentration of its specification limit. "Test for required detectability" is also not required, if it is confirmed that the impurity can be detected at its specification limit by the evaluation of "System repeatability" or some other procedure.

(2) System performance

When it is confirmed that the specificity for determining the test ingredient is ensured, it is considered verified that the system used has adequate performance to achieve its intended use.

In assay, "System performance" should be defined by the resolution between the test ingredient and a target substance to be separated (a closely eluting compound is preferable), and when appropriate, by their order of elution. In purity tests, both the resolution and the order of elution between the test ingredient and a target substance to be separated (a closely eluting compound is preferable) should be prescribed. In addition, if necessary, the symmetry factor of the test ingredient should be prescribed together with them. However, if there is no suitable target substance to be separated, it is acceptable to define "System performance" using the number of theoretical plates and the symmetry factor of the test ingredient.

##### (2) System performance

(3) System repeatability

When it is confirmed that the degree of variation (precision) of the response of the test ingredient is at a level that meets the requirement of "System repeatability", it is considered verified that the system used has adequate performance to achieve its intended use.

The allowable limit of "System repeatability" is normally defined as the relative standard deviation (*RSD*) of the response of the test ingredient in replicate injections of standard solution. It is acceptable to confirm the repeatability of the system not only by replicate injections of standard solution before sample injections, but also by divided injections of standard solution before and after sample injections, or by interspersed injections of standard solution among sample injections.

##### (3) System repeatability

In principle, total number of replicate injections should be 6. However, in the case that a long time is necessary for one analysis, such as the analysis using the gradient method, or the analysis of samples containing late eluting components, it may be acceptable to decrease the number of replicate injections by adopting new allowable limit of "System repeatability" which can guarantee a level of "System repeatability" equivalent to that at 6 replicate injections.

The allowable limit of "System repeatability" should be set at an appropriate level based on the validation data when the suitability of the method for the evaluation of the quality of the drug was verified.

**Point to consider on changing the operating conditions**

Among the operating conditions specified in the individual monograph, inside diameter and length of the column, particle size of the packing material, column temperature, composition ratio of the mobile phase, composition of buffer solutions in the mobile phase, pH of the mobile phase, concentration of ion-pair forming agents in the mobile phase, ionic strength of the mobile phase, flow rate of the mobile phase, number and timing of mobile phase composition changes in gradient program, flow rate of mobile phase in gradient program, composition and flow rate of derivatizing reagents, and reaction time and chamber temperature in chemical reaction may be modified within the ranges in which the liquid chromatographic system used conforms to the requirements of system suitability.

**Terminology**


**S/N ratio:** It is defined by the following formula.

$$S/N = \frac{2H}{h}$$

*H*: Peak height of the target ingredient peak from the baseline (the median value of background noise),

*h*: Width of background noise of the chromatogram of sample solution or solvent blank around the peak of the target ingredient.

The baseline and background noise are measured over a range 20 times of peak width at the center point of peak height of the target ingredient. When a solvent blank is used, measure over almost the same range as mentioned above around the point where the target ingredient elutes.



**Symmetry factor:** It shows the degree of symmetry of a peak in the chromatogram, and is defined as *S* in the following equation.

$$S = \frac{W_{0.05h}}{2f}$$

*W*<sub>0.05h</sub>: Width of the peak at one-twentieth of the peak height,

*f*: Distance between the perpendicular from the peak maximum and the leading edge of the peak at one-twentieth of the peak height,

where *W*<sub>0.05h</sub> and *f* have the same unit.

**Relative standard deviation:** Generally, it is defined as *RSD* (%) in the following equation.

$$RSD (\%) = \frac{100}{\bar{X}} \times \sqrt{\frac{\sum_{i=1}^n (x_i - \bar{X})^2}{n-1}}$$

*x<sub>i</sub>*: Observed value,

$\bar{X}$ : Mean of observed values,

*n*: Number of replicate measurements.


**Complete separation of peak:** It means that the resolution between two peaks is not less than 1.5. It is also called as ‘‘baseline separation’’.

**Peak-valley ratio:** It indicates the degree of separation between 2 peaks on a chromatogram when baseline separation cannot be attained, and is defined as *p/v* by the following formula.

$$p/v = \frac{H_p}{H_v}$$

*H<sub>p</sub>*: peak height from the baseline of the minor peak,

*H<sub>v</sub>*: height from the baseline of the lowest point (peak valley) of the curve between major and minor peaks.



**Separation factor:** It shows the relation between the retention times of peaks in the chromatogram, and is defined as  $\alpha$  in the following equation.

$$\alpha = \frac{t_{R2} - t_0}{t_{R1} - t_0}$$

*t*<sub>R1</sub>, *t*<sub>R2</sub>: Retention times of two compounds used for the resolution measurement (*t*<sub>R1</sub> < *t*<sub>R2</sub>),

*t*<sub>0</sub>: Time of passage of the mobile phase through the column (time measured from the time of injection of a compound with *k* = 0 to the time of elution at the peak maximum).

The separation factor ( $\alpha$ ) indicates thermodynamic difference in partition of two compounds. It is basically the ratio of their partition equilibrium coefficients or of their mass-distribution ratios, and is obtained from the chromatogram as the ratio of the retention times of the two compounds.

**Resolution:** It shows the relation between the retention time and the peak width of peaks in the chromatogram, and is defined as *R<sub>S</sub>* in the following equation.



$$R_S = 1.18 \times \frac{t_{R2} - t_{R1}}{W_{0.5h1} + W_{0.5h2}}$$

$t_{R1}$ ,  $t_{R2}$ : Retention times of two compounds used for the measurement of resolution ( $t_{R1} < t_{R2}$ ),

$W_{0.5h1}$ ,  $W_{0.5h2}$ : Peak widths at half peak height,

where  $t_{R1}$ ,  $t_{R2}$ ,  $W_{0.5h1}$  and  $W_{0.5h2}$  have the same unit.

**Number of theoretical plates:** It indicates the extent of band broadening of a compound in the column, and is generally defined as  $N$  in the following equation.

$$N = 5.54 \times \frac{t_R^2}{W_{0.5h}^2}$$

$t_R$ : Retention time of compound,

$W_{0.5h}$ : Width of the peak at half peak height,

where  $t_R$  and  $W_{0.5h}$  have the same unit.

**Note** Avoid the use of authentic specimens, internal standards, reagents or solvents containing substances that may interfere with the determination.

## 2.02 Gas Chromatography

### Change to read:

Gas Chromatography is a method to develop a mixture injected into a column prepared with a suitable stationary phase by passing a gas (carrier gas) as a mobile phase through the column, in order to separate the mixture into its components by making use of the difference of retention capacity against the stationary phase, and to determine the components. This method can be applied to a gaseous or vaporizable sample, and is used for identification, purity test, and quantitative determination.

A mixture injected into the column is distributed between the mobile phase and the stationary phase with a characteristic ratio ( $k$ ) for each component.

$$k = \frac{\text{amount of compound in the stationary phase}}{\text{amount of compound in the mobile phase}}$$

Since the relation given below exists among the ratio ( $k$ ), the time for which the mobile phase is passed through the column ( $t_0$ : time measured from the time of injection of a compound with  $k = 0$  to the time of elution at the peak maximum), and the retention time ( $t_R$ : time measured from the time of injection of a compound to be determined to the time of elution at the peak maximum), the retention time for a compound on a column has a characteristic value under fixed chromatographic conditions.

$$t_R = (1 + k)t_0$$

### Apparatus

Basically, the apparatus required for the gas chromatographic procedure consists of a carrier gas-introducing port and flow regulator, a sample injection port, a column, a column oven, a detector and a recorder. Gas introducing

port and flow regulator for a combustion gas, a burning supporting gas and an accessory gas and sample injection port for headspace are also used, if necessary. The carrier gas-introducing port and flow regulator serves to deliver the carrier gas into the column at a constant flow rate, and usually consist of a pressure regulation valve, a flow rate regulation valve and a pressure gauge. The sample injection port is used to deliver a quantity of the sample to the flow line of carrier gas with high reproducibility. There are sample injection ports for packed column and for capillary column. There are both divided injection mode and non-divided injection mode to sample injection port for capillary column. The columns are usually classified as packed column or capillary column. The packed column is a tube made of inert metal, glass or synthetic resin, in which a packing material for gas chromatography is uniformly packed. The packed column with not more than 1 mm in inside diameter is also called a packed capillary column (micro packed column). A capillary column is a tube made of inert metal, glass, quartz or synthetic resin, whose inside wall is bound chemically with stationary phase for gas chromatography. The column oven has the setting capacity for a column with required length and the temperature regulation system for keeping the constant column temperature. The detector is used to detect a component separated on the column, and may be an alkaline thermal ionization detector, a flame photometry detector, mass spectrophotometer, hydrogen flame-ionization detector, an electron capture detector, a thermal conductivity detector, etc. The recorder is used to record the output signals of the detector.

### Procedure

Unless otherwise specified, proceed by the following method. Fix the detector, column and carrier gas to the apparatus, and adjust the flow rate and the column temperature to the values described in the operating conditions specified in the individual monograph. Inject a volume of the sample solution or the standard solution specified in the individual monograph with the sample injector into the column system through the sample injection port. The separated components are detected by the detector, and recorded by the recorder as a chromatogram.

### Identification and purity test

Identification of a component of a sample is performed by confirming agreement of the retention time of the sample with that of an authentic specimen, or by confirming that the peak shape of the sample is unchanged after mixing the sample with an authentic specimen.

In general, the purity of the sample is determined by comparing the sample solution with a standard solution which is prepared by diluting the sample solution to a concentration corresponding to the specified limit amount of the impurity, or by the peak area percentage method. Unless otherwise specified, if a sample is separated into isomers in the chromatogram, the isomer ratio is calculated by using the peak area percentage method.

The peak area percentage method is a method to calculate the proportion of the components from the ratio of the peak

area of each component to the sum of the peak areas of every peak recorded in the chromatogram. In order to obtain accurate results in evaluating the proportion of the components, it is necessary to correct the area of each component based on its relative response factor to the principal component.

#### **Assay**

In general, perform the assay by using the internal standard method. The absolute calibration curve method is used when a suitable internal standard is not available. Perform the assay by using the standard addition method when the effect of the component other than the compound to be assayed on the quantitative determination is not negligible against a result of the determination.

(1) **Internal standard method**—In the internal standard method, choose a stable compound as an internal standard which shows a retention time close to that of the compound to be assayed, and whose peak is well separated from all other peaks in the chromatogram. Prepare several kinds of standard solutions containing a fixed amount of the internal standard and several graded amounts of the authentic specimen specified in the individual monograph. Based on the chromatogram obtained by injection of a fixed volume of individual standard solutions, calculate the ratio of peak area or peak height of the authentic specimen to that of the internal standard, and prepare a calibration curve by plotting these ratios on the ordinate against the amount of the authentic specimen or the ratio of the amount of the authentic specimen to that of the internal standard on the abscissa. The calibration curve is usually obtained as a straight line passing through the origin. Then, prepare a sample solution containing the internal standard in the same amount as in the standard solutions used for the preparation of the calibration curve according to the method specified in the individual monograph, perform the gas chromatography under the same operating conditions as for the preparation of the calibration curve, calculate the ratio of the peak area or peak height of the objective compound to that of the internal standard, and read the amount of the compound from the calibration curve.

In an individual monograph, generally one of the standard solutions with a concentration within the linear range of the calibration curve and a sample solution with a concentration close to that of the standard solution are prepared, and the chromatography is performed with these solutions under fixed conditions to determine the amount of the objective compound.

(2) **Absolute calibration curve method**—Prepare standard solutions with several graded amounts of the authentic specimen, and inject accurately a fixed volume of these standard solutions. With the chromatogram obtained, prepare a calibration curve by plotting the peak areas or peak heights on the ordinate against the amount of the authentic specimen on the abscissa. The calibration curve is generally obtained as a straight line passing through the origin. Then, prepare a sample solution according to the method specified in the individual monograph, perform the gas chromatography

under the same conditions as for the preparation of the calibration curve, measure the peak area or peak height of the objective compound, and read the amount of the compound from the calibration curve.

In an individual monograph, generally one of the standard solutions with a concentration within the linear range of the calibration curve and a sample solution with a concentration close to that of the standard solution are prepared, and the chromatography is performed with these solutions under a fixed condition to obtain the amount of the component. In this method, all procedures, such as the injection procedure, must be carried out under a strictly constant condition.

(3) **Standard addition method**—Pipet a fixed volume of more than 4 sample solutions, add exactly the standard solution so that stepwise increasing amounts of the object compound are contained in the solutions except 1 sample solution, diluted exactly each solution with and without standard solution to a definite volume, and use each solution as the sample solution. Based on the chromatogram obtained by exact injection of a fixed volume of individual sample solutions, measure the peak area or peak height of individual sample solutions. Calculate the concentration of standard objective compound added into each sample solution, plot the amounts (concentration) of added standard object compound on the abscissa and the peak area or peak height on the ordinate on the graph, extend the calibration curve obtained by linking the plots, and determine the amount of object compound to be assayed from the distance between the origin and the intersecting point of the calibration curve with the abscissa. This method is available only in the case that the calibration curve is a straight line, and passes through the origin when the absolute calibration curve method is employed. In this method, all procedures must be carried out under a strictly constant condition.

#### **Method for peak measuring**

Generally, the following methods are used.

##### (1) **Peak height measuring method**

(i) **Peak height method**: Measure the distance between the maximum of the peak and the intersecting point of a perpendicular line from the maximum of the peak to the horizontal axis of recording paper with a tangent linking the baselines on either side of the peak.

(ii) **Automatic peak height method**: Measure the signals from the detector as the peak height using a data processing system.

##### (2) **Peak area measuring method**

(i) **Width at half-height method**: Multiply the peak width at the half-height by the peak height.

(ii) **Automatic integration method**: Measure the signals from the detector as the peak area using a data processing system.

#### **System suitability**

Refer to “System suitability” described under 2.01 Liquid Chromatography.

**Point to consider in changing the operating conditions**

Among the operating conditions specified in the individual monograph, inside diameter and length of column, particle size of packing material, concentration or thickness of stationary phase, column temperature, temperature rising-rate, kind and flow rate of carrier gas, and split ratio may be modified within the ranges in which the gas chromatographic system used conforms to the requirements of system suitability. Headspace sample injection device and its operating conditions may be also modified, provided that they give equivalent or more accuracy and precision.

**Terminology**

The definition of terms described under 2.01 Liquid Chromatography shall apply in 2.02 Gas Chromatography.

**Note** Avoid the use of authentic specimens, internal standards, reagents or solvents containing substances that may interfere with the determination.

## 2.48 Water Determination (Karl Fischer Method)

**Change to read the following part under 1. Volumetric titration:**

**Preparation of test solutions and standard solutions****(1) Karl Fischer TS for water determination**

Prepare according to the following method (i), (ii) or (iii). Additives may be added for the purpose of improving the stability or other performances if it is confirmed that they give almost the same results as those obtained from the specified method.

**(i) Preparation 1**

Dissolve 63 g of iodine in 100 mL of pyridine for Karl Fischer method, cool the solution in ice bath, and pass dried sulfur dioxide gas through this solution until the mass increase of the solution reaches 32 g. Then make up to 500 mL by adding chloroform for Karl Fischer method or methanol for Karl Fischer method, and allow to stand for more than 24 hours before use.

**(ii) Preparation 2**

Dissolve 102 g of imidazole for Karl Fischer method in 350 mL of diethylene glycol monoethyl ether for water determination, cool the solution in ice bath, and pass dried sulfur dioxide gas through this solution until the mass increase of the solution reaches 64 g, keeping the temperature between 25°C and 30°C. Then dissolve 50 g of iodine in this solution, and allow to stand for more than 24 hours before use.

**(iii) Preparation 3**

Pass dried sulfur dioxide gas through 220 mL of propylene carbonate for water determination until the mass increase of the solvent reaches 32 g. To this solution, add 180 mL of propylene carbonate, or diethylene glycol monoethyl ether for water determination, in which 81 g of 2-methylaminopyridine for Karl Fischer method is dissolved and cooled in ice bath. Then dissolve 36 g of iodine in this solu-

tion, and allow to stand for more than 24 hours before use.

These Karl Fischer TSs, prepared by any one of the above methods, must be standardized before every use, because of its activity change with the lapse of time. Further preserve the TS in a cold place, protecting it from light and moisture.

**Standardization**—According to the procedure described below, take a suitable quantity of methanol for Karl Fischer method in a dried titration flask, and titrate the solvent with a Karl Fischer TS to make the inside of the flask anhydrous. Then, weigh about 30 mg of water accurately and put it in the titration flask quickly, and titrate the water dissolved in the solvent with a Karl Fischer TS to the end point, under vigorous stirring. Calculate the water equivalence factor,  $f$  (mg/mL), corresponding to the amount of water (H<sub>2</sub>O) in mg per 1 mL of the Karl Fischer TS by using the following equation:

$$f(\text{mg/mL}) = \frac{\text{Amount of water taken (H}_2\text{O) (mg)}}{\text{Volume of Karl Fischer TS consumed for titration of water (H}_2\text{O) (mL)}}$$

**Change to read:**

## 2.49 Optical Rotation Determination

Optical Rotation Determination is a method for the measurement of the angular rotation of the sample using a polarimeter.

Generally, the vibrations of light take place on planes perpendicular to the direction of the beam. In case of the ordinary light, the directions of the planes are unrestricted, while in case of the plane polarized light, commonly called as polarized light, the vibrations take place on only one plane that includes the advancing direction of the beam. And it is called that these beams have plane of polarization. Some drugs in the liquid state or in solution have a property of rotating the plane of the polarized light either to the right or to the left. This property is referred to as optical activity or optical rotation, and is inherently related to the chemical constitution of the substance.

The optical rotation is a degree of rotation of polarized plane, caused by the optically active substance or its solution, and it is measured by the polarimeter. This value is proportional to the length of the polarimeter tube, and is also related to the solution concentration, the temperature and the measurement wavelength. The character of the rotation is indicated by the direction of the rotation, when facing to the advancing direction of the polarized light. Thus in case of rotation to the right, it is called dextrorotatory and expressed by placing plus sign (+), while in case of rotation to the left, it is called levorotatory and expressed by placing minus sign (–) before the figure of the angular rotation. For example, +20° means 20° of rotation to the right, while –20° means 20° of rotation to the left.

The angular rotation  $\alpha_x$  means degree of rotation, when it

is measured at  $t^{\circ}\text{C}$  by using specific monochromatic light  $x$  (expressed by wavelength of light source or the specific beam name). Usually, the measurement is performed at  $20^{\circ}\text{C}$  or  $25^{\circ}\text{C}$ , with a polarimeter tube of 100 mm in length, and with the D line of sodium lamp.

The specific rotation is expressed by the following equation:

$$[\alpha]_x^t = \frac{100 \alpha}{lc}$$

$t$ : The temperature of measurement.

$x$ : The wavelength or the name of the specific monochromatic light (in the case of the Sodium D line, it is described as D).

$\alpha$ : The angle, in degrees, of rotation of the plane of the polarized light.

$l$ : The thickness of the layer of sample solution, *i.e.*, the length of the polarimeter tube (mm).

$c$ : Drug concentration in g/mL. When an intact liquid drug is used for the direct measurement without dilution by an appropriate solvent,  $c$  equals to its density (g/mL). However, unless otherwise specified, the specific gravity is conventionally used in stead of the density.

The description in the monograph, for example, “ $[\alpha]_D^{20}$ :  $-33.0 - -36.0^{\circ}$  (after drying, 1 g, water, 20 mL, 100 mm),” means the measured specific rotation  $[\alpha]_D^{20}$  should be in the range of  $-33.0^{\circ}$  and  $-36.0^{\circ}$ , when 1 g of accurately weighed sample dried under the conditions, specified in the test item of Loss on drying, is taken, and dissolved in water to make exactly 20 mL, then put in the polarimeter tube of 100 mm length, of which temperature is kept at  $20^{\circ}\text{C}$ .

## 4.01 Bacterial Endotoxins Test

**Change to read the Preparation of Standard Endotoxin Stock Solution as follows:**

### Preparation of Standard Endotoxin Stock Solution

Prepare Standard Endotoxin Stock Solution by dissolving Endotoxin Reference Standard in water for bacterial endotoxins test (BET). Endotoxin is expressed in Endotoxin Units (EU). One EU is equal to one International Unit (IU) of endotoxin.

## 4.05 Microbial Limit Test

**Change to read as follows:**

## 4.05 Microbiological Examination of Non-sterile Products

This chapter includes microbial enumeration tests and tests for specified micro-organisms. For the test, use a mixture of several portions selected at random from the bulk or

from the contents of a sufficient number of containers. If test specimens are diluted with fluid medium, the test should be performed quickly. In performing the test, precautions must be taken to prevent biohazard.

### I. Microbiological Examination of Non-sterile Products: Microbial Enumeration Tests

These tests are harmonized with the European Pharmacopoeia and the U.S. Pharmacopoeia.

#### 1 Introduction

The tests described hereafter will allow quantitative enumeration of mesophilic bacteria and fungi which may grow under aerobic conditions.

The tests are designed primarily to determine whether a substance or preparation complies with an established specification for microbiological quality. When used for such purposes follow the instructions given below, including the number of samples to be taken and interpret the results as stated below.

The methods are not applicable to products containing viable micro-organisms as active ingredients.

Alternative microbiological procedures, including automated methods, may be used, provided that their equivalence to the Pharmacopoeial method has been demonstrated.

#### 2 General Procedures

Carry out the determination under conditions designed to avoid extrinsic microbial contamination of the product to be examined. The precautions taken to avoid contamination must be such that they do not affect any micro-organisms which are to be revealed in the test.

If the product to be examined has antimicrobial activity, this is insofar as possible removed or neutralized. If inactivators are used for this purpose their efficacy and their absence of toxicity for micro-organisms must be demonstrated.

If surface-active substances are used for sample preparation, their absence of toxicity for micro-organisms and their compatibility with inactivators used must be demonstrated.

#### 3 Enumeration Methods

Use the membrane filtration method, or the plate-count methods, as prescribed. The most probable number (MPN) method is generally the least accurate method for microbial counts, however, for certain product groups with very low bioburden, it may be the most appropriate method.

The choice of a method is based on factors such as the nature of the product and the required limit of micro-organisms. The method chosen must allow testing of a sufficient sample size to judge compliance with the specification. The suitability of the chosen method must be established.

#### 4 Growth Promotion Test and Suitability of the Counting Method

##### 4-1 General considerations

The ability of the test to detect micro-organisms in the presence of product to be tested must be established.

Suitability must be confirmed if a change in testing performance, or the product, which may affect the outcome of the

Table 4.05-I-1 Preparation and use of test micro-organisms

Micro-organism	Preparation of test strain	Growth promotion		Suitability of counting method in the presence of the product	
		Total aerobic microbial count	Total yeasts and moulds count	Total aerobic microbial count	Total yeasts and moulds count
<i>Staphylococcus aureus</i>  such as ATCC 6538, NCIMB 9518, CIP 4.83 or NBRC 13276	Casein soya bean digest agar or casein soya bean digest broth 30 – 35°C 18 – 24 h	Casein soya bean digest agar and casein soya bean digest broth ≤ 100 CFU 30 – 35°C ≤ 3 days		Casein soya bean digest agar/ MPN casein soya bean digest broth ≤ 100 CFU 30 – 35°C ≤ 3 days	
<i>Pseudomonas aeruginosa</i>  such as ATCC 9027, NCIMB 8626, CIP 82.118 or NBRC 13275	Casein soya bean digest agar or casein soya bean digest broth 30 – 35°C 18 – 24 h	Casein soya bean digest agar and casein soya bean digest broth ≤ 100 CFU 30 – 35°C ≤ 3 days		Casein soya bean digest agar/MPN casein soya bean digest broth ≤ 100 CFU 30 – 35°C ≤ 3 days	
<i>Bacillus subtilis</i>  such as ATCC 6633, NCIMB 8054, CIP 52.62 or NBRC 3134	Casein soya bean digest agar or casein soya bean digest broth 30 – 35°C 18 – 24 h	Casein soya bean digest agar and casein soya bean digest broth ≤ 100 CFU 30 – 35°C ≤ 3 days		Casein soya bean digest agar/MPN casein soya bean digest broth ≤ 100 CFU 30 – 35°C ≤ 3 days	
<i>Candida albicans</i>  such as ATCC 10231, NCPF 3179, IP 48.72 or NBRC 1594	Sabouraud-dextrose agar or Sabouraud-dextrose broth 20 – 25°C 2 – 3 days	Casein soya bean digest agar ≤ 100 CFU 30 – 35°C ≤ 5 days	Sabouraud-dextrose agar ≤ 100 CFU 20 – 25°C ≤ 5 days	Casein soya bean digest agar ≤ 100 CFU 30 – 35°C ≤ 5 days MPN: not applicable	Sabouraud-dextrose agar ≤ 100 CFU 20 – 25°C ≤ 5 days
<i>Aspergillus niger</i>  such as ATCC 16404, IMI 149007, IP 1431.83 or NBRC 9455	Sabouraud-dextrose agar or potato-dextrose agar 20 – 25°C 5 – 7 days, or until good sporulation is achieved	Casein soya bean digest agar ≤ 100 CFU 30 – 35°C ≤ 5 days	Sabouraud-dextrose agar ≤ 100 CFU 20 – 25°C ≤ 5 days	Casein soya bean digest agar ≤ 100 CFU 30 – 35°C ≤ 5 days MPN: not applicable	Sabouraud-dextrose agar ≤ 100 CFU 20 – 25°C ≤ 5 days

test is introduced.

#### 4-2 Preparation of test strains

Use standardised stable suspensions of test strains or prepare as stated below.

Seed lot culture maintenance techniques (seed-lot systems) are used so that the viable micro-organisms used for inoculation are not more than 5 passages removed from the original master seed-lot. Grow each of the bacterial and fungal test strains separately as described in Table 4.05-I-1.

Use buffered sodium chloride-peptone solution pH 7.0 or phosphate buffer solution pH 7.2 to make test suspensions; to suspend *A. niger* spores, 0.05 per cent of polysorbate 80 may be added to the buffer. Use the suspensions within 2 h or within 24 h if stored at 2 – 8°C. As an alternative to preparing and then diluting a fresh suspension of vegetative cells of *A. niger* or *B. subtilis*, a stable spore suspension is

prepared and then an appropriate volume of the spore suspension is used for test inoculation. The stable spore suspension may be maintained at 2 – 8°C for a validated period of time.

#### 4-3 Negative control

To verify testing conditions a negative control is performed using the chosen diluent in place of the test preparation. There must be no growth of micro-organisms.

#### 4-4 Growth promotion of the media

Test each batch of ready-prepared medium and each batch of medium, prepared either from dehydrated medium or from the ingredients described.

Inoculate portions/plates of casein soya bean digest broth and casein soya bean digest agar with a small number (not more than 100 CFU) of the micro-organisms indicated in Table 4.05-I-1, using a separate portion/plate of medium for

each. Inoculate plates of *Sabouraud-dextrose agar* with a small number (not more than 100 CFU) of the micro-organisms indicated in Table 4.05-I-1, using a separate plate of medium for each. Incubate in the conditions described in Table 4.05-I-1.

For solid media, growth obtained must not differ by a factor greater than 2 from the calculated value for a standardized inoculum. For a freshly prepared inoculum, growth of the micro-organisms comparable to that previously obtained with a previously tested and approved batch of medium occurs.

Liquid media are suitable if clearly visible growth of the micro-organisms comparable to that previously obtained with a previously tested and approved batch of medium occurs.

#### **4-5 Suitability of the counting method in the presence of product**

##### **4-5-1 Preparation of the sample**

The method for sample preparation depends on the physical characteristics of the product to be tested. If none of the procedures described below can be demonstrated to be satisfactory, an alternative procedure must be developed.

*Water-soluble products*—Dissolve or dilute (usually a 1 in 10 dilution is prepared) the product to be examined in *buffered sodium chloride-peptone solution pH 7.0*, *phosphate buffer solution pH 7.2* or *casein soya bean digest broth*. If necessary adjust to pH 6–8. Further dilutions, where necessary, are prepared with the same diluent.

*Non-fatty products insoluble in water*—Suspend the product to be examined (usually a 1 in 10 dilution is prepared) in *buffered sodium chloride-peptone solution pH 7.0*, *phosphate buffer solution pH 7.2* or *casein soya bean digest broth*. A surface-active agent such as 1 g/L of polysorbate 80 may be added to assist the suspension of poorly wettable substances. If necessary adjust to pH 6–8. Further dilutions, where necessary, are prepared with the same diluent.

*Fatty products*—Dissolve in isopropyl myristate, sterilised by filtration or mix the product to be examined with the minimum necessary quantity of sterile polysorbate 80 or another non-inhibitory sterile surface-active reagent, heated if necessary to not more than 40°C, or in exceptional cases to not more than 45°C. Mix carefully and if necessary maintain the temperature in a water-bath. Add sufficient of the pre-warmed chosen diluent to make a 1 in 10 dilution of the original product. Mix carefully whilst maintaining the temperature for the shortest time necessary for the formation of an emulsion. Further serial tenfold dilutions may be prepared using the chosen diluent containing a suitable concentration of sterile polysorbate 80 or another non-inhibitory sterile surface-active reagent.

*Fluids or solids in aerosol form*—Aseptically transfer the product into a membrane filter apparatus or a sterile container for further sampling. Use either the total contents or a defined number of metered doses from each of the containers tested.

*Transdermal patches*—Remove the protective cover sheets (“release liner”) of the transdermal patches and place them, adhesive side upwards, on sterile glass or plastic trays. Cover

the adhesive surface with sterile porous material, for example sterile gauze, to prevent the patches from sticking together, and transfer the patches to a suitable volume of the chosen diluent containing inactivators such as polysorbate 80 and/or lecithin. Shake the preparation vigorously for at least 30 min.

##### **4-5-2 Inoculation and dilution**

Add to the sample prepared as described above (4-5-1) and to a control (with no test material included) a sufficient volume of the microbial suspension to obtain an inoculum of not more than 100 CFU. The volume of the suspension of the inoculum should not exceed 1 per cent of the volume of diluted product.

To demonstrate acceptable microbial recovery from the product, the lowest possible dilution factor of the prepared sample must be used for the test. Where this is not possible due to antimicrobial activity or poor solubility, further appropriate protocols must be developed.

If inhibition of growth by the sample cannot otherwise be avoided, the aliquot of the microbial suspension may be added after neutralization, dilution or filtration.

##### **4-5-3 Neutralization/removal of antimicrobial activity**

The number of micro-organisms recovered from the prepared sample diluted as described in 4-5-2 and incubated following the procedure described in 4-5-4, is compared to the number of micro-organisms recovered from the control preparation.

If growth is inhibited (reduction by a factor greater than 2), then modify the procedure for the particular enumeration test to ensure the validity of the results. Modification of the procedure may include, for example, (1) an increase in the volume of the diluent or culture medium, (2) incorporation of a specific or general neutralizing agents into the diluent, (3) membrane filtration or (4) a combination of the above measures.

*Neutralizing agents*—Neutralizing agents may be used to neutralize the activity of antimicrobial agents (Table 4.05-I-2). They may be added to the chosen diluent or the medium preferably before sterilization. If used, their efficacy and their absence of toxicity for micro-organisms must be demonstrated by carrying out a blank with neutralizer and without product.

If no suitable neutralizing method can be found, it can be assumed that the failure to isolate the inoculated organism is attributable to the microbicidal activity of the product. This information serves to indicate that the article is not likely to be contaminated with the given species of the micro-organism. However, it is possible that the product only inhibits some of the micro-organisms specified herein, but does not inhibit others not included amongst the test strains or for which the latter are not representative. Then, perform the test with the highest dilution factor compatible with microbial growth and the specific acceptance criterion.

##### **4-5-4 Recovery of micro-organism in the presence of product**

For each of the micro-organisms listed in Table 4.05-I-1, separate tests are performed. Only micro-organisms of the added test strain are counted.

Table 4.05-I-2 Common neutralizing agents/method for interfering substances

Interfering substance	Potential neutralizing agents/method
Glutaraldehyde, Mercurials	Sodium hydrogen sulfite (Sodium bisulfite)
Phenolics, Alcohol, Aldehydes, Sorbate	Dilution
Aldehydes	Glycine
Quaternary Ammonium Compounds (QACs), Parahydroxybenzoates (Parabens), Bis-biguanides	Lecithin
QAC, Parabens, Iodine	Polysorbate
Mercurials	Thioglycollate
Mercurials, Halogens, Aldehydes	Thiosulfate
EDTA (edetate)	Mg or Ca ions

#### 4-5-4-1 Membrane filtration

Use membrane filters having a nominal pore size not greater than  $0.45 \mu\text{m}$ . The type of filter material is chosen in such a way that the bacteria-retaining efficiency is not affected by the components of the sample to be investigated. For each of the micro-organisms listed in Table 4.05-I-1, one membrane filter is used.

Transfer a suitable amount of the sample prepared as described under 4-5-1 to 4-5-3 (preferably representing 1 g of the product, or less if large numbers of CFU are expected) to the membrane filter, filter immediately and rinse the membrane filter with an appropriate volume of diluent.

For the determination of total aerobic microbial count (TAMC), transfer the membrane filter to the surface of *casein soya bean digest agar*. For the determination of total combined yeasts/moulds count (TYMC) transfer the membrane to the surface of *Sabouraud-dextrose agar*. Incubate the plates as indicated in Table 4.05-I-1. Perform the counting.

#### 4-5-4-2 Plate-count methods

Perform plate-count methods at least in duplicate for each medium and use the mean count of the result.

##### 4-5-4-2-1 Pour-plate method

For Petri dishes 9 cm in diameter, add to the dish 1 mL of the sample prepared as described under 4-5-1 to 4-5-3 and 15 – 20 mL of *casein soya bean digest agar* or *Sabouraud-dextrose agar*, both media being at not more than  $45^\circ\text{C}$ . If larger Petri dishes are used, the amount of agar medium is increased accordingly. For each of the micro-organisms listed in Table 4.05-I-1, at least 2 Petri dishes are used.

Incubate the plates as indicated in Table 4.05-I-1. Take the arithmetic mean of the counts per medium and calculate the number of CFU in the original inoculum.

##### 4-5-4-2-2 Surface-spread method

For Petri dishes 9 cm in diameter, add 15 – 20 mL of *casein soya bean digest agar* or *Sabouraud-dextrose agar* at about  $45^\circ\text{C}$  to each Petri dish and allow to solidify. If larger

Petri dishes are used, the volume of the agar is increased accordingly. Dry the plates, for example in a laminar-air-flow cabinet or in an incubator. For each of the micro-organisms listed in Table 4.05-I-1, at least 2 Petri dishes are used. Spread a measured volume of not less than 0.1 mL of the sample prepared as described under 4-5-1 to 4-5-3 over the surface of the medium. Incubate and count as prescribed under 4-5-4-2-1.

#### 4-5-4-3 Most-probable-number (MPN) method

The precision and accuracy of the MPN method is less than that of the membrane filtration method or the plate-count method. Unreliable results are obtained particularly for the enumeration of moulds. For these reasons the MPN method is reserved for the enumeration of TAMC in situations where no other method is available. If the use of the method is justified, proceed as follows.

Prepare a series of at least 3 serial tenfold dilutions of the product as described under 4-5-1 to 4-5-3. From each level of dilution, 3 aliquots of 1 g or 1 mL are used to inoculate 3 tubes with 9 – 10 mL of *casein soya bean digest broth*. If necessary a surface-active agent such as polysorbate 80, or an inactivator of antimicrobial agents may be added to the medium. Thus, if 3 levels of dilution are prepared 9 tubes are inoculated.

Incubate all tubes at  $30 - 35^\circ\text{C}$  for not more than 3 days. If reading of the results is difficult or uncertain owing to the nature of the product to be examined, subculture in the same broth, or *casein soya bean digest agar*, for 1 – 2 days at the same temperature and use these results. Determine the most probable number of micro-organisms per gram or millilitre of the product to be examined from Table 4.05-I-3.

#### 4-6 Results and interpretation

When verifying the suitability of the membrane filtration method or the plate-count method, a mean count of any of the test organisms not differing by a factor greater than 2 from the value of the control defined in 4-5-2 in the absence of the product must be obtained. When verifying the

suitability of the MPN method the calculated value from the inoculum must be within 95 per cent confidence limits of the results obtained with the control.

If the above criteria cannot be met for one or more of the organisms tested with any of the described methods, the method and test conditions that come closest to the criteria are used to test the product.

## 5 Testing of Products

### 5-1 Amount used for the test

Unless otherwise prescribed, use 10 g or 10 mL of the product to be examined taken with the precautions referred to above. For fluids or solids in aerosol form, sample 10 containers. For transdermal patches, sample 10 patches.

The amount to be tested may be reduced for active substances that will be formulated in the following conditions: the amount per dosage unit (e.g. tablet, capsule, injection) is less than or equal to 1 mg or the amount per gram or millilitre (for preparations not presented in dose units) is less than 1 mg. In these cases, the amount of sample to be tested is not less than the amount present in 10 dosage units or 10 g or 10 mL of the product.

For materials used as active substances where sample quantity is limited or batch size is extremely small (i.e. less than 1000 mL or 1000 g), the amount tested shall be 1 per cent of the batch unless a lesser amount is prescribed or justified and authorised.

For products where the total number of entities in a batch is less than 200 (e.g. samples used in clinical trials), the sample size may be reduced to 2 units, or 1 unit if the size is less than 100.

Select the sample(s) at random from the bulk material or from the available containers of the preparation. To obtain the required quantity, mix the contents of a sufficient number of containers to provide the sample.

### 5-2 Examination of the product

#### 5-2-1 Membrane filtration

Use a filtration apparatus designed to allow the transfer of the filter to the medium. Prepare the sample using a method that has been shown suitable as described in section 4 and transfer the appropriate amount to each of 2 membrane filters and filter immediately. Wash each filter following the procedure shown to be suitable.

For the determination of TAMC, transfer one of the membrane filters to the surface of *casein soya bean digest agar*. For the determination of TYMC, transfer the other membrane to the surface of *Sabouraud-dextrose agar*. Incubate the plate of *casein soya bean digest agar* at 30 – 35°C for 3 – 5 days and the plate of *Sabouraud-dextrose agar* at 20 – 25°C for 5 – 7 days. Calculate the number of CFU per gram or per millilitre of product.

When examining transdermal patches, filter 10 per cent of the volume of the preparation described under 4-5-1 separately through each of 2 sterile filter membranes. Transfer one membrane to *casein soya bean digest agar* for TAMC and the other membrane to *Sabouraud-dextrose agar* for TYMC.

### 5-2-2 Plate-count methods

#### 5-2-2-1 Pour-plate method

Prepare the sample using a method that has been shown to be suitable as described in section 4. Prepare for each medium at least 2 Petri dishes for each level of dilution. Incubate the plates of *casein soya bean digest agar* at 30 – 35°C for 3 – 5 days and the plates of *Sabouraud-dextrose agar* at 20 – 25°C for 5 – 7 days. Select the plates corresponding to a given dilution and showing the highest number of colonies less than 250 for TAMC and 50 for TYMC. Take the arithmetic mean per culture medium of the counts and calculate the number of CFU per gram or per millilitre of product.

#### 5-2-2-2 Surface-spread method

Prepare the sample using a method that has been shown to be suitable as described in section 4. Prepare at least 2 Petri dishes for each medium and each level of dilution. For incubation and calculation of the number of CFU proceed as described for the pour-plate method.

#### 5-2-2-3 Most-probable-number method

Prepare and dilute the sample using a method that has been shown to be suitable as described in section 4. Incubate all tubes for 3 – 5 days at 30 – 35°C. Subculture if necessary, using the procedure shown to be suitable. Record for each level of dilution the number of tubes showing microbial growth. Determine the most probable number of micro-organisms per gram or millilitre of the product to be examined from Table 4.05-I-3.

### 5-3 Interpretation of the results

The total aerobic microbial count (TAMC) is considered to be equal to the number of CFU found using *casein soya bean digest agar*; if colonies of fungi are detected on this medium, they are counted as part of TAMC. The total combined yeasts/mould count (TYMC) is considered to be equal to the number of CFU found using *Sabouraud-dextrose agar*; if colonies of bacteria are detected on this medium, they are counted as part of TYMC. When the TYMC is expected to exceed the acceptance criterion due to the bacterial growth, *Sabouraud-dextrose agar* containing antibiotics may be used. If the count is carried out by the MPN method the calculated value is the TAMC.

When an acceptance criterion for microbiological quality is prescribed it is interpreted as follows:

- 10<sup>1</sup> CFU: maximum acceptable count = 20,
- 10<sup>2</sup> CFU: maximum acceptable count = 200,
- 10<sup>3</sup> CFU: maximum acceptable count = 2000, and so forth.

The recommended solutions and media are described in *Tests for specified micro-organisms*.

## II. Microbiological Examination of Non-sterile Products: Tests for Specified Micro-organisms

These tests are harmonized with the European Pharmacopoeia and the U.S. Pharmacopoeia.

### 1 Introduction

The tests described hereafter will allow determination of



Table 4.05-I-3 Most-probable-number values of micro-organisms

Observed combinations of numbers of tubes showing growth in each set			MPN per g or per mL of product	95 per cent confidence limits
Number of g or mL of product per tube				
0.1	0.01	0.001		
0	0	0	Less than 3	0 – 9.4
0	0	1	3	0.1 – 9.5
0	1	0	3	0.1 – 10
0	1	1	6.1	1.2 – 17
0	2	0	6.2	1.2 – 17
0	3	0	9.4	3.5 – 35
1	0	0	3.6	0.2 – 17
1	0	1	7.2	1.2 – 17
1	0	2	11	4 – 35
1	1	0	7.4	1.3 – 20
1	1	1	11	4 – 35
1	2	0	11	4 – 35
1	2	1	15	5 – 38
1	3	0	16	5 – 38
2	0	0	9.2	1.5 – 35
2	0	1	14	4 – 35
2	0	2	20	5 – 38
2	1	0	15	4 – 38
2	1	1	20	5 – 38
2	1	2	27	9 – 94
2	2	0	21	5 – 40
2	2	1	28	9 – 94
2	2	2	35	9 – 94
2	3	0	29	9 – 94
2	3	1	36	9 – 94
3	0	0	23	5 – 94
3	0	1	38	9 – 104
3	0	2	64	16 – 181
3	1	0	43	9 – 181
3	1	1	75	17 – 199
3	1	2	120	30 – 360
3	1	3	160	30 – 380
3	2	0	93	18 – 360
3	2	1	150	30 – 380
3	2	2	210	30 – 400
3	2	3	290	90 – 990
3	3	0	240	40 – 990
3	3	1	460	90 – 1980
3	3	2	1100	200 – 4000
3	3	3	More than 1100	

the absence of, or limited occurrence of specified micro-organisms which may be detected under the conditions described.

The tests are designed primarily to determine whether a

substance or preparation complies with an established specification for microbiological quality. When used for such purposes follow the instructions given below, including the number of samples to be taken and interpret the results

as stated below.

Alternative microbiological procedures, including automated methods may be used, provided that their equivalence to the Pharmacopoeial method has been demonstrated.

## 2 General Procedures

The preparation of samples is carried out as described in *Microbial enumeration tests*.

If the product to be examined has antimicrobial activity, this is insofar as possible removed or neutralized as described in *Microbial enumeration tests*.

If surface-active substances are used for sample preparation, their absence of toxicity for micro-organisms and their compatibility with inactivators used must be demonstrated as described in *Microbial enumeration tests*.

## 3 Growth Promoting and Inhibitory Properties of the Media and Suitability of the Test

The ability of the test to detect micro-organisms in the presence of the product to be tested must be established. Suitability must be confirmed if a change in testing performance, or the product, which may affect the outcome of the test is introduced.

### 3-1 Preparation of test strains

Use standardised stable suspensions of test strains or prepare as stated below. Seed lot culture maintenance techniques (seed-lot systems) are used so that the viable micro-organisms used for inoculation are not more than 5 passages removed from the original master seed-lot.

#### 3-1-1 Aerobic micro-organisms

Grow each of the bacterial test strains separately in containers containing *casein soya bean digest broth* or on *casein soya bean digest agar* at 30 – 35°C for 18 – 24 hours. Grow the test strain for *Candida albicans* separately on *Sabouraud-dextrose agar* or in *Sabouraud-dextrose broth* at 20 – 25°C for 2–3 days.

*Staphylococcus aureus* such as ATCC 6538, NCIMB 9518, CIP 4.83 or NBRC 13276,

*Pseudomonas aeruginosa* such as ATCC 9027, NCIMB 8626, CIP 82.118 or NBRC 13275,

*Escherichia coli* such as ATCC 8739, NCIMB 8545, CIP 53.126 or NBRC 3972,

*Salmonella enterica* subsp. *enterica* serovar Typhimurium such as ATCC 14028

or, as an alternative,

*Salmonella enterica* subsp. *enterica* serovar Abony such as NBRC 100797, NCTC 6017 or CIP 80.39,

*Candida albicans* such as ATCC 10231, NCPF 3179, IP 48.72 or NBRC 1594.

Use *buffered sodium chloride-peptone solution pH 7.0* or *phosphate buffer solution pH 7.2* to make test suspensions. Use the suspensions within 2 hours or within 24 hours if stored at 2 – 8°C.

#### 3-1-2 Clostridia

Use *Clostridium sporogenes* such as ATCC 11437 (NBRC 14293, NCIMB 12343, CIP 100651) or ATCC 19404 (NCTC 532 or CIP 79.3). Grow the clostridial test strain under anaerobic conditions in *reinforced medium for Clostridia* at 30 – 35°C for 24 – 48 hours. As an alternative to preparing

and then diluting down a fresh suspension of vegetative cells of *Cl. sporogenes*, a stable spore suspension is used for test inoculation. The stable spore suspension may be maintained at 2 – 8°C for a validated period.

### 3-2 Negative control

To verify testing conditions a negative control is performed using the chosen diluent in place of the test preparation. There must be no growth of micro-organisms.

### 3-3 Growth promotion and inhibitory properties of the media

Test each batch of ready-prepared medium and each batch of medium prepared either from dehydrated medium or from ingredients.

Verify suitable properties of relevant media as described in Table 4.05-II-1.

*Test for growth promoting properties, liquid media:* inoculate a portion of the appropriate medium with a small number (not more than 100 CFU) of the appropriate micro-organism. Incubate at the specified temperature for not more than the shortest period of time specified in the test. Clearly visible growth of the micro-organism comparable to that previously obtained with a previously tested and approved batch of medium occurs.

*Test for growth promoting properties, solid media:* perform surface-spread method, inoculating each plate with a small number (not more than 100 CFU) of the appropriate micro-organism. Incubate at the specified temperature for not more than the shortest period of time specified in the test. Growth of the micro-organism comparable to that previously obtained with a previously tested and approved batch of medium occurs.

*Test for inhibitory properties, liquid or solid media:* inoculate the appropriate medium with at least 100 CFU of the appropriate micro-organism. Incubate at the specified temperature for not less than the longest period of time specified in the test. No growth of the test micro-organism occurs.

*Test for indicative properties:* perform surface-spread method, inoculating each plate with a small number (not more than 100 CFU) of the appropriate micro-organism. Incubate at the specified temperature for a period of time within the range specified in the test. Colonies are comparable in appearance and indication reactions to those previously obtained with a previously tested and approved batch of medium.

### 3-4 Suitability of the test method

For each product to be tested perform sample preparation as described in the relevant paragraph in section 4. Add each test strain at the time of mixing, in the prescribed growth medium. Inoculate the test strains individually. Use a number of micro-organisms equivalent to not more than 100 CFU in the inoculated test preparation.

Perform the test as described in the relevant paragraph in section 4 using the shortest incubation period prescribed.

The specified micro-organisms must be detected with the indication reactions as described in section 4.

Any antimicrobial activity of the product necessitates a modification of the test procedure (see 4-5-3 of *Microbial Enumeration Tests*).

Table 4.05-II-1 Growth promoting, inhibitory and indicative properties of media

Medium	Property	Test strains
<b>Test for bile-tolerant gram-negative bacteria</b>		
<i>Enterobacteria enrichment broth-Mossel</i>	Growth promoting	<i>E. coli</i> <i>P. aeruginosa</i>
	Inhibitory	<i>S. aureus</i>
<i>Violet red bile glucose agar</i>	Growth promoting + Indicative	<i>E. coli</i> <i>P. aeruginosa</i>
<b>Test for <i>Escherichia coli</i></b>		
<i>MacConkey broth</i>	Growth promoting	<i>E. coli</i>
	Inhibitory	<i>S. aureus</i>
<i>MacConkey agar</i>	Growth promoting + Indicative	<i>E. coli</i>
<b>Test for <i>Salmonella</i></b>		
<i>Rappaport Vassiliadis Salmonella enrichment broth</i>	Growth promoting	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Typhimurium or <i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Abony
	Inhibitory	<i>S. aureus</i>
<i>Xylose, lysine, deoxycholate agar</i>	Growth promoting + Indicative	<i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Typhimurium or <i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Abony
	Indicative	<i>E. coli</i>
<b>Test for <i>Pseudomonas aeruginosa</i></b>		
<i>Cetrimide agar</i>	Growth promoting	<i>P. aeruginosa</i>
	Inhibitory	<i>E. coli</i>
<b>Test for <i>Staphylococcus aureus</i></b>		
<i>Mannitol salt agar</i>	Growth promoting + Indicative	<i>S. aureus</i>
	Inhibitory	<i>E. coli</i>
<b>Test for Clostridia</b>		
<i>Reinforced medium for Clostridia</i>	Growth promoting	<i>Cl. sporogenes</i>
<i>Columbia agar</i>	Growth promoting	<i>Cl. sporogenes</i>
<b>Test for <i>Candida albicans</i></b>		
<i>Sabouraud dextrose broth</i>	Growth promoting	<i>C. albicans</i>
<i>Sabouraud dextrose agar</i>	Growth promoting + Indicative	<i>C. albicans</i>

If for a given product the antimicrobial activity with respect to a micro-organism for which testing is prescribed cannot be neutralised, then it is to be assumed that the inhibited micro-organism will not be present in the product.

#### 4 Testing of Products

##### 4-1 Bile-tolerant gram-negative bacteria

##### 4-1-1 Sample preparation and pre-incubation

Prepare a sample using a 1 in 10 dilution of not less than 1

Table 4.05-II-2 Interpretation of results

Results for each quantity of product			Probable number of bacteria per gram or mL of product
0.1 g or 0.1 mL	0.01 g or 0.01 mL	0.001 g or 0.001 mL	
+	+	+	more than 10 <sup>3</sup>
+	+	–	less than 10 <sup>3</sup> and more than 10 <sup>2</sup>
+	–	–	less than 10 <sup>2</sup> and more than 10
–	–	–	less than 10

g of the product to be examined as described in *Microbial enumeration tests*, but using *casein soya bean digest broth* as the chosen diluent, mix and incubate at 20 – 25°C for a time sufficient to resuscitate the bacteria but not sufficient to encourage multiplication of the organisms (usually 2 hours but not more than 5 hours).

#### 4-1-2 Test for absence

Unless otherwise prescribed use the volume corresponding to 1 g of the product, as prepared in 4-1-1 to inoculate *enterobacteria enrichment broth-Mossel*. Incubate at 30 – 35°C for 24 – 48 hours. Subculture on plates of *violet red bile glucose agar*. Incubate at 30 – 35°C for 18 – 24 hours.

The product complies with the test if there is no growth of colonies.

#### 4-1-3 Quantitative test

##### 4-1-3-1 Selection and subculture

Inoculate suitable quantities of *enterobacteria enrichment broth-Mossel* with the preparation as described under 4-1-1 and/or dilutions of it containing respectively 0.1 g, 0.01 g and 0.001 g (or 0.1 mL, 0.01 mL and 0.001 mL) of the product to be examined. Incubate at 30 – 35°C for 24 – 48 hours. Subculture each of the cultures on a plate of *violet red bile glucose agar*. Incubate at 30 – 35°C for 18 – 24 hours.

##### 4-1-3-2 Interpretation

Growth of colonies constitutes a positive result. Note the smallest quantity of the product that gives a positive result and the largest quantity that gives a negative result. Determine from Table 4.05-II-2 the probable number of bacteria.

#### 4-2 *Escherichia coli*

##### 4-2-1 Sample preparation and pre-incubation

Prepare a sample using a 1 in 10 dilution of not less than 1 g of the product to be examined as described in *Microbial enumeration tests* and use 10 mL or the quantity corresponding to 1 g or 1 mL to inoculate a suitable amount (determined as described under 3-4) of *casein soya bean digest broth*, mix and incubate at 30 – 35°C for 18 – 24 hours.

##### 4-2-2 Selection and subculture

Shake the container, transfer 1 mL of *casein soya bean digest broth* to 100 mL of *MacConkey broth* and incubate at 42 – 44°C for 24 – 48 hours. Subculture on a plate of *MacConkey agar* at 30 – 35°C for 18 – 72 hours.

#### 4-2-3 Interpretation

Growth of colonies indicates the possible presence of *E. coli*. This is confirmed by identification tests.

The product complies with the test if no colonies are present or if the identification tests are negative.

#### 4-3 *Salmonella*

##### 4-3-1 Sample preparation and pre-incubation

Prepare the product to be examined as described in *Microbial enumeration tests* and use the quantity corresponding to not less than 10 g or 10 mL to inoculate a suitable amount (determined as described under 3-4) of *casein soya bean digest broth*, mix and incubate at 30 – 35°C for 18 – 24 hours.

##### 4-3-2 Selection and subculture

Transfer 0.1 mL of *casein soya bean digest broth* to 10 mL of *Rappaport Vassiliadis Salmonella enrichment broth* and incubate at 30 – 35°C for 18 – 24 hours. Subculture on plates of *xylose, lysine, deoxycholate agar*. Incubate at 30 – 35°C for 18 – 48 hours.

##### 4-3-3 Interpretation

The possible presence of *Salmonella* is indicated by the growth of well-developed, red colonies, with or without black centres. This is confirmed by identification tests.

The product complies with the test if colonies of the types described are not present or if the confirmatory identification tests are negative.

#### 4-4 *Pseudomonas aeruginosa*

##### 4-4-1 Sample preparation and pre-incubation

Prepare a sample using a 1 in 10 dilution of not less than 1 g of the product to be examined as described in *Microbial enumeration tests* and use 10 mL or the quantity corresponding to 1 g or 1 mL to inoculate a suitable amount (determined as described under 3-4) of *casein soya bean digest broth* and mix. When testing transdermal patches, filter the volume of sample corresponding to 1 patch of the preparation described in *Microbial enumeration tests* (4-5-1) through a sterile filter membrane and place in 100 mL of *casein soya bean digest broth*. Incubate at 30 – 35°C for 18 – 24 hours.

##### 4-4-2 Selection and subculture

Subculture on a plate of *cetrimide agar* and incubate at 30 – 35°C for 18 – 72 hours.

**4-4-3 Interpretation**

Growth of colonies indicates the possible presence of *P. aeruginosa*. This is confirmed by identification tests.

The product complies with the test if colonies are not present or if the confirmatory identification tests are negative.

**4-5 Staphylococcus aureus****4-5-1 Sample preparation and pre-incubation**

Prepare a sample using a 1 in 10 dilution of not less than 1 g of the product to be examined as described in *Microbial enumeration tests* and use 10 mL or the quantity corresponding to 1 g or 1 mL to inoculate a suitable amount (determined as described under 3-4) of *casein soya bean digest broth* and homogenise. When testing transdermal patches, filter the volume of sample corresponding to 1 patch of the preparation described in *Microbial enumeration tests* (4-5-1) through a sterile filter membrane and place in 100 mL of *casein soya bean digest broth*. Incubate at 30 – 35°C for 18 – 24 hours.

**4-5-2 Selection and subculture**

Subculture on a plate of *mannitol salt agar* and incubate at 30 – 35°C for 18 – 72 hours.

**4-5-3 Interpretation**

The possible presence of *S. aureus* is indicated by the growth of yellow/white colonies surrounded by a yellow zone. This is confirmed by identification tests.

The product complies with the test if colonies of the types described are not present or if the confirmatory identification tests are negative.

**4-6 Clostridia****4-6-1 Sample preparation and heat treatment**

Prepare the product to be examined as described in *Microbial enumeration tests*.

Take 2 equal portions corresponding to not less than 1 g or 1 mL of the product to be examined. Heat 1 portion at 80°C for 10 min and cool rapidly. Do not heat the other portion.

**4-6-2 Selection and subculture**

Transfer the quantity corresponding to 1 g or 1 mL of the product to be examined from each of the mixed portions to 2 containers (38 mm × 200 mm) or other containers containing 100 mL of *reinforced medium for Clostridia*. Incubate under anaerobic conditions at 30 – 35°C for 48 hours. After incubation, make subcultures from each tube on *Columbia agar* and incubate under anaerobic conditions at 30 – 35°C for 48 hours.

**4-6-3 Interpretation**

The occurrence of anaerobic growth of rods (with or without endospores) giving a negative catalase reaction indicates the presence of Clostridia.

If no anaerobic growth of micro-organisms is detected on *Columbia agar* or the catalase test is positive, the product complies with the test.

**4-7 Candida albicans****4-7-1 Sample preparation and pre-incubation**

Prepare the product to be examined as described in *Microbial enumeration tests* and use 10 mL or the quantity corresponding to not less than 1 g or 1 mL to inoculate 100

mL of *Sabouraud-dextrose broth* and mix. Incubate at 30 – 35°C for 3-5 days.

**4-7-2 Selection and subculture**

Subculture on a plate of *Sabouraud-dextrose agar* and incubate at 30 – 35°C for 24 – 48 hours.

**4-7-3 Interpretation**

Growth of white colonies may indicate the presence of *C. albicans*. This is confirmed by identification tests.

The product complies with the test if such colonies are not present or if the confirmatory identification tests are negative.

*The following section is given for information.*

**5 Recommended Solutions and Culture Media**

The following solutions and culture media have been found satisfactory for the purposes for which they are prescribed in the test for microbial contamination in the Pharmacopoeia. Other media may be used if they have similar growth promoting and inhibitory properties.

*Stock buffer solution.* Transfer 34 g of potassium dihydrogen phosphate to a 1000 mL volumetric flask, dissolve in 500 mL of purified water, adjust to pH 7.2 ± 0.2 with sodium hydroxide, add purified water to volume and mix. Dispense in containers and sterilize. Store at a temperature of 2 – 8°C.

*Phosphate buffer solution pH 7.2*

Prepare a mixture of purified water and stock buffer solution (800:1 V/V) and sterilize.

*Buffered sodium chloride-peptone solution pH 7.0*

Potassium dihydrogen phosphate	3.6 g
Disodium hydrogen phosphate dihydrate	7.2 g
	equivalent to
	0.067 mol phosphate
Sodium chloride	4.3 g
Peptone (meat or casein)	1.0 g
Purified water	1000 mL
Sterilize in an autoclave using a validated cycle.	

*Casein soya bean digest broth*

Pancreatic digest of casein	17.0 g
Papaic digest of soya bean	3.0 g
Sodium chloride	5.0 g
Dipotassium hydrogen phosphate	2.5 g
Glucose monohydrate	2.5 g
Purified water	1000 mL

Adjust the pH so that after sterilization it is 7.3 ± 0.2 at 25°C. Sterilize in an autoclave using a validated cycle.

*Casein soya bean digest agar*

Pancreatic digest of casein	15.0 g
Papaic digest of soya bean	5.0 g
Sodium chloride	5.0 g
Agar	15.0 g
Purified water	1000 mL

Adjust the pH so that after sterilization it is 7.3 ± 0.2 at 25°C. Sterilize in an autoclave using a validated cycle.

*Sabouraud-dextrose agar*

Glucose	40.0 g
Mixture of peptic digest of animal tissue and pancreatic digest of casein (1:1)	10.0 g
Agar	15.0 g
Purified water	1000 mL

Adjust the pH so that after sterilization it is  $5.6 \pm 0.2$  at  $25^{\circ}\text{C}$ . Sterilize in an autoclave using a validated cycle.

*Potato dextrose agar*

Infusion from potatoes	200 g
Glucose	20.0 g
Agar	15.0 g
Purified water	1000 mL

Adjust the pH so that after sterilization it is  $5.6 \pm 0.2$  at  $25^{\circ}\text{C}$ . Sterilize in an autoclave using a validated cycle.

*Sabouraud-dextrose broth*

Glucose	20.0 g
Mixture of peptic digest of animal tissue and pancreatic digest of casein (1:1)	10.0 g
Purified water	1000 mL

Adjust the pH so that after sterilization it is  $5.6 \pm 0.2$  at  $25^{\circ}\text{C}$ . Sterilize in an autoclave using a validated cycle.

*Enterobacteria enrichment broth-Mossel*

Pancreatic digest of gelatin	10.0 g
Glucose monohydrate	5.0 g
Dehydrated ox bile	20.0 g
Potassium dihydrogen phosphate	2.0 g
Disodium hydrogen phosphate dihydrate	8.0 g
Brilliant green	15 mg
Purified water	1000 mL

Adjust the pH so that after heating it is  $7.2 \pm 0.2$  at  $25^{\circ}\text{C}$ . Heat at  $100^{\circ}\text{C}$  for 30 min and cool immediately.

*Violet red bile glucose agar*

Yeast extract	3.0 g
Pancreatic digest of gelatin	7.0 g
Bile salts	1.5 g
Sodium chloride	5.0 g
Glucose monohydrate	10.0 g
Agar	15.0 g
Neutral red	30 mg
Crystal violet	2 mg
Purified water	1000 mL

Adjust the pH so that after heating it is  $7.4 \pm 0.2$  at  $25^{\circ}\text{C}$ . Heat to boiling; do not heat in an autoclave.

*MacConkey broth*

Pancreatic digest of gelatin	20.0 g
Lactose monohydrate	10.0 g
Dehydrated ox bile	5.0 g
Bromocresol purple	10 mg
Purified water	1000 mL

Adjust the pH so that after sterilization it is  $7.3 \pm 0.2$  at  $25^{\circ}\text{C}$ . Sterilize in an autoclave using a validated cycle.

*MacConkey agar*

Pancreatic digest of gelatin	17.0 g
Peptones (meat and casein)	3.0 g
Lactose monohydrate	10.0 g
Sodium chloride	5.0 g
Bile salts	1.5 g
Agar	13.5 g
Neutral red	30 mg
Crystal violet	1 mg
Purified water	1000 mL

Adjust the pH so that after sterilization it is  $7.1 \pm 0.2$  at  $25^{\circ}\text{C}$ . Boil for 1 min with constant shaking then sterilize in an autoclave using a validated cycle.

*Rappaport Vassiliadis Salmonella enrichment broth*

Soya peptone	4.5 g
Magnesium chloride hexahydrate	29.0 g
Sodium chloride	8.0 g
Dipotassium hydrogen phosphate	0.4 g
Potassium dihydrogen phosphate	0.6 g
Malachite green	36 mg
Purified water	1000 mL

Dissolve, warming slightly. Sterilize in an autoclave using a validated cycle, at a temperature not exceeding  $115^{\circ}\text{C}$ . The pH is to be  $5.2 \pm 0.2$  at  $25^{\circ}\text{C}$  after heating and autoclaving.

*Xylose, lysine, deoxycholate agar*

Xylose	3.5 g
L-Lysine	5.0 g
Lactose monohydrate	7.5 g
Sucrose	7.5 g
Sodium chloride	5.0 g
Yeast extract	3.0 g
Phenol red	80 mg
Agar	13.5 g
Sodium deoxycholate	2.5 g
Sodium thiosulfate	6.8 g
Ammonium iron (III) citrate	0.8 g
Purified water	1000 mL

Adjust the pH so that after heating it is  $7.4 \pm 0.2$  at  $25^{\circ}\text{C}$ . Heat to boiling, cool to  $50^{\circ}\text{C}$  and pour into Petri dishes. Do not heat in an autoclave.

*Cetrimide agar*

Pancreatic digest of gelatin	20.0 g
Magnesium chloride	1.4 g
Dipotassium sulfate	10.0 g
Cetrimide	0.3 g
Agar	13.6 g
Purified water	1000 mL
Glycerol	10.0 mL

Heat to boiling for 1 min with shaking. Adjust the pH so that after sterilization it is  $7.2 \pm 0.2$  at  $25^{\circ}\text{C}$ . Sterilize in an autoclave using a validated cycle.

*Mannitol salt agar*

Pancreatic digest of casein	5.0 g
Peptic digest of animal tissue	5.0 g

Beef extract	1.0 g
D-Mannitol	10.0 g
Sodium chloride	75.0 g
Agar	15.0 g
Phenol red	25 mg
Purified water	1000 mL

Heat to boiling for 1 min with shaking. Adjust the pH so that after sterilization it is  $7.4 \pm 0.2$  at  $25^\circ\text{C}$ . Sterilize in an autoclave using a validated cycle.

#### *Reinforced medium for Clostridia*

Beef extract	10.0 g
Peptone	10.0 g
Yeast extract	3.0 g
Soluble starch	1.0 g
Glucose monohydrate	5.0 g
Cysteine hydrochloride	0.5 g
Sodium chloride	5.0 g
Sodium acetate	3.0 g
Agar	0.5 g
Purified water	1000 mL

Hydrate the agar, dissolve by heating to boiling with continuous stirring. If necessary, adjust the pH so that after sterilization it is about  $6.8 \pm 0.2$  at  $25^\circ\text{C}$ . Sterilize in an autoclave using a validated cycle.

#### *Columbia agar*

Pancreatic digest of casein	10.0 g
Meat peptic digest	5.0 g
Heart pancreatic digest	3.0 g
Yeast extract	5.0 g
Corn starch	1.0 g
Sodium chloride	5.0 g
Agar, according to gelling power	10.0 g to 15.0 g
Purified water	1000 mL

Hydrate the agar, dissolve by heating to boiling with continuous stirring. If necessary, adjust the pH so that after sterilization it is  $7.3 \pm 0.2$  at  $25^\circ\text{C}$ . Sterilize in an autoclave using a validated cycle. Allow to cool to  $45 - 50^\circ\text{C}$ ; add, where necessary, gentamicin sulfate corresponding to 20 mg of gentamicin base and pour into Petri dishes.

## 6.01 Test for Metal Particles in Ophthalmic Ointments

### **Change the Preparation of test sample to read:**

#### **Preparation of test sample**

The test should be carried out in a clean place. Take 10 ophthalmic ointments to be tested, and extrude 5 g each of their contents into separate flat-bottomed petri dishes 60 mm in diameter. Cover the dishes, and heat between  $85^\circ\text{C}$  and  $110^\circ\text{C}$  for 2 hours to dissolve bases completely. Allow the samples to cool to room temperature without agitation to solidify the contents. When the amount of the content is 5 g or less, extrude the contents as completely as practicable, and proceed in the same manner as described above.

### **Add the following next to Procedure:**

#### **Evaluation**

The preparation complies with the test if the total number of metal particles of a size equal to or greater than  $50 \mu\text{m}$  found in 10 units tested, is not more than 50, and also the number of dishes containing more than 8 particles is not more than 1. If this requirement is not met, repeat the test with a further 20 units in the same manner, and if the total number of the particles found in the total of 30 units is not more than 150, and also the number of dishes containing more than 8 particles is not more than 3, the preparation complies with the test.

## 6.08 Insoluble Particulate Matter Test for Ophthalmic Solutions

### **Add the following next to Procedure:**

#### **Evaluation**

The preparation complies with the test if the calculated number per mL of insoluble particles of a size equal to or greater than  $300 \mu\text{m}$  is not more than 1.

## 6.10 Dissolution Test

### **Change the Apparatus for Paddle Method (Apparatus 2) to read:**

**Apparatus for Paddle Method (Apparatus 2)**—Use the assembly from Apparatus 1, except that a paddle formed from a blade and a shaft is used as the stirring element. The shaft is positioned so that its axis is not more than 2 mm from the vertical axis of the vessel, at any point, and rotates smoothly without significant wobble that could affect the results. The vertical center line of the blade passes through the axis of the shaft so that the bottom of the blade is flush with the bottom of the shaft. The paddle conforms to the specifications shown in Fig. 6.10-2. The distance of  $25 \pm 2$  mm between the bottom of the blade and the inside bottom of the vessel is maintained during the test. The metallic or suitably inert, rigid blade and shaft comprise a single entity. A suitable two-part detachable design may be used provided the assembly remains firmly engaged during the test. The paddle blade and shaft may be coated with a suitable coating so as to make them inert. The dosage unit is allowed to sink to the bottom of the vessel before rotation of the blade is started. A small, loose piece of nonreactive material, such as not more than a few turns of wire helix or such one shown in Fig. 6.10-2a, may be attached to the dosage unit that would otherwise float. Other validated sinker devices may also be used. ♦If the use of sinker is specified, unless otherwise specified, use the sinker device shown in Fig. 6.10-2a. ♦





Fig. 6. 10-2 Apparatus 2, Paddle stirring element



All dimensions are expressed in mm.

A: Acid-resistant wire clasp  
B: Acid-resistant wire support

Fig. 6. 10-2a Alternative sinker

Add the following:

### 6.11 Foreign Insoluble Matter Test for Ophthalmic Solutions

Foreign Insoluble Matter Test for Ophthalmic Solutions is a test method to examine foreign insoluble matters in ophthalmic solutions.

When inspect with the unaided eyes at a position of luminous intensity of 3000 - 5000 lx under an incandescent lamp after cleaning the exterior of containers, Ophthalmic Solutions must be clear and free from readily detectable foreign insoluble matters.

## 9.01 Reference Standards

### Change to read:

Reference Standards are the reference substances prepared to a specified quality necessary with regard to their intended use as prescribed in monographs of the Pharmacopoeia.

The Japanese Pharmacopoeia Reference Standards are as follows:

- \* A: Assay
- AF: Anti-factor IIa activity
- B: Bacterial Endotoxins Test <4.01>
- C: Content ratio of active principle
- D: Dissolution
- DG: Digestion Test <4.03>
- HB: Heparin-binding capacity
- I: Identification
- IS: Isomer ratio
- M: Melting Point Determination <2.60>
- P: Purity
- T: Thermal Analysis <2.52>
- U: Uniformity of dosage units
- V: Vitamin A Assay <2.55>

(1) The reference standards which are prepared by those who have been registered to prepare them by the Minister of Health, Labour and Welfare, according to the Ministerial ordinance established by the Minister separately.

Reference Standard	Intended Use*
Aceglutamide	I, P, A
Acetaminophen	I, A
Adrenaline Bitartrate	P
Alprostadi	I, P, A
p-Aminobenzoyl Glutamic Acid	P
Amitriptyline Hydrochloride	I, U, D, A
Amlexanox	I, U, D, A
Amlodipine Besilate	I, A
Anhydrous Lactose	I
Ascorbic Acid	A
Aspirin	A
Atropine Sulfate	I, A
Azathioprine	I, A
Baclofen	I, U, D, A
Baicalin	I, A
Beclometasone Dipropionate	I, A
Berberine Chloride	I, A
Betamethasone	I, P, U, D, A
Betamethasone Sodium Phosphate	I, A
Betamethasone Valerate	I, A
Bisacodyl	I, U, A
Caffeine	A
Calcium Folate	I, A
Calcium Oxalate Monohydrate	T
Camostat Mesilate	I, A



<i>d</i> -Camphor	A	Hydrochlorothiazide	I, A
<i>dl</i> -Camphor	A	Hydrocortisone	I, P, A
Carbidopa	I, P, A	Hydrocortisone Acetate	I, A
Cellulose	I	Hydrocortisone Sodium Phosphate	I, A
Chlordiazepoxide	I, P, U, A	Hydrocortisone Succinate	I, A
Chlormadinone Acetate	I, A	Idoxuridine	I, A
Chlorpheniramine Maleate	I, U, A	Imipramine Hydrochloride	I, U, D, A
Cholecalciferol	I, A	Indomethacin	I, P, U, D, A
Ciclosporin	I, P, A	Insulin	P, A
Cilostazol	I, U, D, A	Interleukin-2	A
Cisplatin	I, A	Isoflurane	I, P, A
Clobetasol Propionate	I, A	Kallidinogenase	A
Clofibrate	I, A	Lactose	I
Clomifene Citrate	I, A	Lactulose	P, A
Cortisone Acetate	I, A	Lanatoside C	I, P, U, D, A
Cyanocobalamin	I, P, A	Limaprost	P, A
Deferoxamine Mesilate	I, A	Low-molecular Mass Heparin	AF, A
Deslanoside	I, P, A	Loxoprofen	A
Dexamethasone	I, A	Lysozyme	A
Diclofenamide	I, P, D, A	Maltose	A
Diethylcarbamazine Citrate	A	Manidipine Hydrochloride	I, U, D, A
Digitoxin	I, U, D, A	Mecobalamin	I, A
Digoxin	I, U, D, A	Melting Point Standard-Acetanilide	M
Dihydroergotoxine Mesilate	A	Melting Point Standard-Acetophenetidine	M
Dobutamine Hydrochloride	I, A	Melting Point Standard-Caffeine	M
Edrophonium Chloride	I, A	Melting Point Standard-Sulfanilamide	M
Elcatonin	A	Melting Point Standard-Sulfapyridine	M
Enalapril Maleate	I, U, D, A	Melting Point Standard-Vanillin	M
Endotoxin	B	Menatetrenone	I, P, A
Epiostanol	P, A	Mestranol	I, A
Ergocalciferol	I, A	Methotrexate	I, A
Ergometrine Maleate	P, U, A	Methoxsalen	I, A
Estradiol Benzoate	I, P, A	Methyldopa	I, U, A
Estriol	I, U, D, A	Methylergometrine Maleate	I, U, D, A
Ethenzamide	A	Methylprednisolone Succinate	I, P, A
Ethinylestradiol	I, U, D, A	Methyltestosterone	I, U, A
Ethyl Aminobenzoate	A	Metildigoxin	I, A
Ethyl Icosapentate	I, P, A	Mexiletine Hydrochloride	I, P, A
Etoposide	I, A	Mizoribine	I, U, D, A
Fluocinolone Acetonide	I, A	Nabumetone	I, D, A
Fluocinonide	I, A	Neostigmine Methylsulfate	I, A
Fluorometholone	I, A	Nicotinamide	I, A
Fluoxymesterone	I, A	Nicotinic Acid	I, A
Folic Acid	I, U, A	Nilvadipine	I, U, D, A
Furosemide	I, U, D, A	Nizatidine	I, U, D, A
Fursultiamine Hydrochloride	I, A	Noradrenaline Bitartrate	P, A
Gabexate Mesilate	I, P, A	Norgestrel	I, U, D, A
Ginsenoside Rb <sub>1</sub>	I, A	Oxytocin	P, A
Ginsenoside Rg <sub>1</sub>	I, A	Ozagrel Sodium	I, A
Gitoxin	P	Paeoniflorin	I, A
Glycyrrhizinic Acid	I, A	Pentobarbital	P, A
Gonadorelin Acetate	I, A	Perphenazine	I, U, D, A
Guaifenesin	I, A	Phytonadione	A
Heparin Sodium	HB, A	Potassium Sucrose Octasulfate	P, A
High-molecular Mass Urokinase	A	Povidone	I
Human Chorionic Gonadotrophin	A	Pravastatin 1,1,3,3-tetramethylbutylammonium	I, A
Human Insulin	I, A		
Human Menopausal Gonadotrophin	P, A		

Prednisolone	I, U, D, A	Amoxicillin	I, A
Prednisolone Acetate	I, A	Amphotericin B	I, P, A
Prednisolone Succinate	I, A	Ampicillin	I, P, A
Primidone	A	Arbekacin Sulfate	I, A
Probenecid	I, D, A	Aspoxicillin	I, P, A
Prochlorperazine Maleate	I, A	Astromycin Sulfate	I, A
Progesterone	I, A	Azithromycin	I, A
Protamine Sulfate	P	Aztreonam	I, P, A
Puerarin	I, A	Bacampicillin Hydrochloride	I, A
Pyridoxine Hydrochloride	I, A	Bacitracin	I, A
Ranitidine Hydrochloride	I, A	Bekanamycin Sulfate	I, A
Reserpine	I, U, D, A	Benzylpenicillin Potassium	I, A
Retinol Acetate	I, V	Bleomycin A <sub>2</sub> Hydrochloride	A
Retinol Palmitate	I, V	Carumonam Sodium	I, P, A
Riboflavin	I, A	Cefaclor	I, P, U, D, A
Ritodrine Hydrochloride	I, U, D, A	Cefadroxil	I, U, D, A
Roxatidine Acetate Hydrochloride	I, U, D, A	Cefalexin	A
Saccharated Pepsin	A	Cefalotin Sodium	I, P, A
Scopolamine Hydrobromide	I, A	Cefapirin Sodium	I, A
Sennoside A	I, A	Cefatrizine Propylene Glycolate	I, A
Sennoside B	A	Cefazolin	P, A
Serum Gonadotrophin	A	Cefbuperazone	A
Spirolactone	I, A	Cefcapene Pivoxil Hydrochloride	I, U, A
Sulfadiazine Silver	I, A	Cefdinir	I, P, D, A
Swertiamarin	I, A	Cefditoren Pivoxil	I, U, D, A
Testosterone Propionate	I, A	Cefepime Dihydrochloride	I, A
Thiamine Chloride Hydrochloride	I, P, A	Cefixime	I, P, A
Thiamylal	A	Cefmenoxime Hydrochloride	I, P, A
Thrombin	A	Cefmetazole	A
Tocopherol	I, P, A	Cefminox Sodium	I, A
Tocopherol Acetate	I, A	Cefodizime Sodium	I, P, A
Tocopherol Nicotinate	I, A	Cefoperazone	A
Tocopherol Succinate	A	Cefotaxime	P, A
Tolazamide	I, A	Cefotetan	I, P, A
Tolbutamide	D	Cefotiam Hexetil Hydrochloride	I, P, IS, A
Tolnaftate	I, A	Cefotiam Hydrochloride	I, P, A
Tranexamic Acid	I, P, D, A	Cefozopran Hydrochloride	I, A
Triamcinolone	I, A	Cefpiramide	P, A
Triamcinolone Acetonide	I, A	Cefpirome Sulfate	I, A
Trichlormethiazide	I, U, D, A	Cefpodoxime Proxetil	I, IS, A
Trihexyphenidyl Hydrochloride	I, U, D, A	Cefroxadine	I, A
Tyrosine	A, DG	Cefsulodin Sodium	I, P, A
Ubidecarenone	I, A	Ceftazidime	I, A
Ulinastatin	A	Ceferam Pivoxil Mesitylene Sulfonate	A
Vasopressin	A	Ceftibuten Hydrochloride	A
Vinblastine Sulfate	I, U, A	Ceftizoxime	P, A
Vincristine Sulfate	I, A	Ceftriaxone Sodium	I, A
Warfarin Potassium	I, U, A	Cefuroxime Axetil	I, P, IS, A
Zidovudine	I, A	Cefuroxime Sodium	I, A
		Chloramphenicol	I, A
(2) The reference standards which are prepared by National Institute of Infectious Diseases.		Chloramphenicol Palmitate	I, A
		Chloramphenicol Succinate	A
		Ciclacillin	I, A
		Clarithromycin	I, P, U, D, A
		Clindamycin Hydrochloride	I, U, D, A
		Clindamycin Phosphate	I, P, A
		Cloxacillin Sodium	I, P, A
		Colistin Sodium Methanesulfonate	I, A
Reference Standard	Intended Use*		
Aclarubicin	A		
Actinomycin D	I, A		
Amikacin Sulfate	I, A		

Colistin Sulfate	A
Cycloserine	I, A
Daunorubicin Hydrochloride	I, A
Demethylchlortetracycline Hydrochloride	I, P, A
Dibekacin Sulfate	I, P, A
Dicloxacillin Sodium	I, A
Diethanolammonium Fusidate	A
Doxorubicin Hydrochloride	I, A
Doxycycline Hydrochloride	I, A
Enviomycin Sulfate	A
Epirubicin Hydrochloride	I, P, A
Erythromycin	I, P, A
Faropenem Sodium	I, P, U, A
Flomoxef Triethylammonium	P, A
Fosfomycin Phenethylammonium	A
Fradiomycin Sulfate	I, A
Gentamicin Sulfate	I, A
Gramicidin	I, A
Griseofulvin	I, P, U, A
Idarubicin Hydrochloride	I, U, A
Imipenem	I, U, A
Isepamicin Sulfate	I, P, A
Josamycin	I, C, U, A
Josamycin Propionate	I, A
Kanamycin Monosulfate	I, P, A
Latamoxef Ammonium	P, A
Lenampicillin Hydrochloride	I, A
Leucomycin A <sub>5</sub>	C, A
Lincomycin Hydrochloride	I, P, A
Lithium Clavulanate	A
Meropenem	I, A
Micronomicin Sulfate	I, A
Midecamycin	I, A
Midecamycin Acetate	I, A
Minocycline Hydrochloride	I, P, A
Mitomycin C	I, U, A
Mupirocin Lithium	P, A
Netilmicin Sulfate	I, A
Nystatin	I, P, A
Oxytetracycline Hydrochloride	I, A
Panipenem	A
Peplomycin Sulfate	I, A
Phenethicillin Potassium	A
Pimaricin	I, A
Piperacillin	I, A
Pirarubicin	I, P, A
Pivmecillinam Hydrochloride	I, P, A
Polymixin B Sulfate	I, A
Pyrrrolnitrin	I, A
Ribostamycin Sulfate	I, A
Rifampicin	I, P, A
Rokitamycin	I, U, D, A
Roxithromycin	I, P, A
Siccanin	I, A
Sisomicin Sulfate	I, A
Spectinomycin Hydrochloride	I, A
Spiramycin Acetate II	C, A

Streptomycin Sulfate	I, A
Sulbactam	P, A
Sulbenicillin Sodium	I, A
Sultamicillin Tosilate	I, A
Talampicillin Hydrochloride	I, A
Teicoplanin	I, A
Tetracycline Hydrochloride	I, P, A
Tobramycin	I, A
Trichomycin	A
Vancomycin Hydrochloride	I, A
Zinostatin Stimalamer	I, A

## 9.21 Standard Solutions for Volumetric Analysis

### Add the following:

#### Zinc sulfate, 0.02 mol/L

1000 mL of this solution contains 5.7516 g of zinc sulfate heptahydrate ( $ZnSO_4 \cdot 7H_2O$ : 287.58).

*Preparation*—Before use, dilute 0.1 mol/L zinc sulfate VS with water to make exactly 5 times the initial volume.

## 9.22 Standard Solutions

### Add the following:

**Standard Aluminum Solution for Atomic Absorption Spectrophotometry** To exactly 10 mL of Standard Aluminum Stock Solution add water to make exactly 100 mL. Prepare before use. Each mL of this solution contains 0.100 mg of aluminum (Al).

**Standard Iron Stock Solution** Dissolve exactly 4.840 g of iron (III) chloride hexahydrate in diluted hydrochloric acid (9 in 25) to make exactly 100 mL.

**Standard Iron Solution for Atomic Absorption Spectrophotometry** To exactly 5 mL of Standard Iron Stock Solution add water to make exactly 200 mL. Prepare before use. Each mL of this solution contains 0.250 mg of iron (Fe).

**Standard Magnesium Stock Solution** Dissolve exactly 8.365 g of magnesium chloride hexahydrate in 2 mol/L hydrochloric acid TS to make exactly 1000 mL.

**Standard Magnesium Solution for Atomic Absorption Spectrophotometry** To exactly 1 mL of Standard Magnesium Stock Solution add water to make exactly 100 mL. Prepare before use. Each mL of this solution contains 0.0100 mg of magnesium (Mg).

## 9.41 Reagents, Test Solutions

### Change the following to read:

**Albiflorin**  $C_{23}H_{28}O_{11} \cdot xH_2O$  White powder having no odor. Freely soluble in water, in methanol and in ethanol

(99.5).

**Identification** Determine the absorption spectrum of a solution of albiflorin in diluted methanol (1 in 2) (1 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 230 nm and 234 nm.

**Purity** (1) Related substances 1—Dissolve 1 mg of albiflorin in 1 mL of methanol, and perform the test with 10  $\mu$ L of this solution as directed in the Identification (2) under Peony Root: any spot other than the principal spot which appears at around *Rf* 0.2 does not appear.

(2) Related substances 2—Dissolve 1 mg of albiflorin in 10 mL of diluted methanol (1 in 2), and use this solution as the sample solution. Perform the test with 10  $\mu$ L of the sample solution as directed in the Assay under Peony Root, and measure the peak areas about 2 times as long as the retention time of peoniflorin: the total area of the peaks other than albiflorin from the sample solution is not larger than 1/10 times the total area of the peaks other than the solvent peak.

**Amygdalin for thin-layer chromatography**  $C_{20}H_{27}NO_{11}$   
A white, odorless powder. Soluble in water, sparingly soluble in methanol, and practically insoluble in ethanol (99.5).

**Identification** Determine the absorption spectrum of a solution of amygdalin for thin-layer chromatography in methanol (1 in 1000) as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 250 nm and 254 nm, between 255 nm and 259 nm, between 261 nm and 265 nm, and between 267 nm and 271 nm.

**Purity** Related substances—Dissolve 5 mg of amygdalin for thin-layer chromatography in 2 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 100 mL, and use this solution as the standard solution. Perform the test with 10  $\mu$ L each of the sample solution and standard solution as directed in the Identification under Peach Kernel: any spot other than the principal spot at the *Rf* value of about 0.3 obtained from the sample solution is not more intense than the spot from the standard solution.

**Capsaicin for component determination** See (*E*)-capsaicin for component determination.

**Capsaicin for thin-layer chromatography** See (*E*)-capsaicin for thin-layer chromatography.

**Chlorogenic acid for thin-layer chromatography** See (*E*)-chlorogenic acid for thin-layer chromatography.

**Cinnamaldehyde for thin-layer chromatography** See (*E*)-cinnamaldehyde for thin-layer chromatography.

**Dehydrocorydaline nitrate for component determination**  $C_{22}H_{24}N_2O_7$  Yellow, crystals or crystalline powder. It is sparingly soluble in methanol, and slightly soluble in water and in ethanol (99.5). *Melting point*: about 240°C (with decomposition).

**Absorbance** <2.24>  $E_{1\text{cm}}^{1\%}$  (333 nm): 577 – 642 (3 mg, water, 500 mL). Use the sample dried in a desiccator (silica gel) for not less than 1 hour for the test.

**Purity** (1) Related substances 1—Dissolve 5.0 mg of

dehydrocorydaline nitrate for component determination in 1 mL of a mixture of water and methanol (1:1), and use this solution as the sample solution. Pipet 0.5 mL of the sample solution, add a mixture of water and methanol (1:1) to make exactly 50 mL, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop immediately with a mixture of methanol, a solution of ammonium acetate (3 in 10) and acetic acid (100) (20:1:1) to a distance of about 10 cm, and air-dry the plate. Spray Dragendorff's TS on the plate, air-dry, and spray sodium nitrite TS: the spots other than the principal spot from the sample solution are not more intense than the spot from the standard solution.

(2) Related substances 2—Dissolve 5.0 mg of dehydrocorydaline nitrate for component determination in 10 mL of the mobile phase, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 5  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and measure each peak area from these solutions by the automatic integration method: the total area of peaks other than dehydrocorydaline from the sample solution is not larger than the peak area of dehydrocorydaline from the standard solution.

**Operating conditions**

Column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Component determination under Corydalis Tuber.

Detector: Ultraviolet absorption photometer (wavelength: 230 nm)

Time span of measurement: About 3 times as long as the retention time of dehydrocorydaline, beginning after the peak of nitric acid.

**System suitability**

System performance and system repeatability: Proceed as directed in the system suitability in the Component determination under Corydalis Tuber.

Test for required detectability: To exactly 1 mL of the standard solution add the mobile phase to make exactly 20 mL. Confirm that the peak area of dehydrocorydaline obtained from 5  $\mu$ L of this solution is equivalent to 3.5 to 6.5% of that from 5  $\mu$ L of the standard solution.

**[6]-Gingerol for thin-layer chromatography**  $C_{17}H_{26}O_4$   
A yellow-white to yellow, liquid or solid. Freely soluble in methanol, in ethanol (99.5) and in diethyl ether, and practically insoluble in water.

**Identification** Determine the absorption spectrum of a solution of [6]-gingerol for thin-layer chromatography in ethanol (99.5) (7 in 200,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 279 nm and 283 nm.

**Purity** Related substances—Dissolve 1.0 mg of [6]-gingerol for thin-layer chromatography in exactly 2 mL of

methanol. Perform the test with 10  $\mu\text{L}$  of this solution as directed in the Identification under Ginger: any spot other than the principal spot at the *Rf* value of about 0.3 does not appear.

**Magnolol for component determination** Use magnolol for thin-layer chromatography meeting the following additional specifications.

*Absorbance* <2.24>  $E_{1\text{cm}}^{1\%}$  (290 nm): 270 – 293 (10 mg, methanol, 500 mL). Use the sample dried in a desiccator (silica gel) for not less than 1 hour for the sample.

*Purity* Related substances—Dissolve 5.0 mg of magnolol for component determination in 10 mL of the mobile phase, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the area of each peak from these solutions by the automatic integration method: the total area of peaks other than the peak of magnolol from the sample solution is not larger than the peak area of magnolol from the standard solution.

Operating conditions

Detector, column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the component determination under Magnolia Bark.

Time span of measurement: About 3 times as long as the retention time of magnolol.

System suitability

System performance, and system repeatability: Proceed as directed in the system suitability in the component determination under Magnolia Bark.

Test for required detectability: To exactly 1 mL of the standard solution add the mobile phase to make exactly 20 mL. Confirm that the peak area of magnolol obtained with 10  $\mu\text{L}$  of this solution is equivalent to 3.5 to 6.5% of that with 10  $\mu\text{L}$  of the standard solution.

### Add the following:

**Alminoprofen for assay**  $\text{C}_{13}\text{H}_{17}\text{NO}_2$  [Same as the monograph Alminoprofen. When dried, it contains not less than 99.5% of alminoprofen ( $\text{C}_{13}\text{H}_{17}\text{NO}_2$ ).]

#### 6-Amidino-2-naphthol methanesulfonate

$\text{C}_{11}\text{H}_{10}\text{N}_2\text{O}\cdot\text{CH}_4\text{O}_3\text{S}$  A white to pale yellow crystalline powder. Melting point: about 233°C (with decomposition).

*Purity* A solution obtained by dissolving 0.5 g of 6-amidino-2-naphthol methanesulfonate in 10 mL of methanol is clear.

**Aminopyrine**  $\text{C}_{13}\text{H}_{17}\text{N}_3\text{O}$  White to pale yellow crystals or crystalline powder.

*Melting point* <2.60>: 107 – 109°C

**Amosulalol hydrochloride for assay**  $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_5\text{S}\cdot\text{HCl}$  [Same as the monograph Amosulalol Hydrochloride. It contains not less than 99.0% of amosulalol hydrochloride

( $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_5\text{S}\cdot\text{HCl}$ ), calculated on the anhydrous basis.]

**Amygdalin for component determination** Amygdalin for thin-layer chromatography. However, it meets the following requirements:

*Absorbance* <2.24>  $E_{1\text{cm}}^{1\%}$  (263 nm): 55 – 58 [20 mg, methanol, 20 mL; separately determine the water <2.48> (5 mg, coulometric titration) and calculate on the anhydrous basis].

*Purity* Related substances—Dissolve 5 mg of amygdalin for component determination in 10 mL of the mobile phase, and use this as the sample solution. Pipet 1 mL of the sample solution, add the mobile phase to make exactly 100 mL, and use this as the standard solution. Perform the test with exactly 10  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the total area of the peaks other than amygdalin from the sample solution is not larger than the peak area of amygdalin from the standard solution.

Operating conditions

Detector, column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay (3) under Keishibukuryogan Extract.

Time span of measurement: About 3 times as long as the retention time of amygdalin.

System suitability

Test for required detectability: Pipet 1 mL of the standard solution, and add the mobile phase to make exactly 20 mL. Confirm that the peak area of amygdalin obtained with 10  $\mu\text{L}$  of this solution is equivalent to 3.5 to 6.5% of that with 10  $\mu\text{L}$  of the standard solution.

System performance and system repeatability: Proceed as directed in the system suitability in the Assay (3) under Keishibukuryogan Extract.

**Bisoprolol fumarate for assay** ( $\text{C}_{18}\text{H}_{31}\text{NO}_4$ ) $_2\cdot\text{C}_4\text{H}_4\text{O}_4$  [Same as the monograph Bisoprolol Fumarate. However, when dried, it contains not less than 99.0% of bisoprolol fumarate [( $\text{C}_{18}\text{H}_{31}\text{NO}_4$ ) $_2\cdot\text{C}_4\text{H}_4\text{O}_4$ ]. Also, when performing the Purity (2) under Bisoprolol Fumarate, the total area of the peaks other than bisoprolol is not greater than 1/5 times the peak area of bisoprolol from the standard solution].

Purify as follows if needed.

*Purification method*—Dissolve, with heating, 2 g of Bisoprolol Fumarate in 200 mL of ethyl acetate, add 0.5 g of activated carbon, shake well, and filter using a glass filter (G4). Place the filtrate in ice water for 2 hours while occasional shaking. Collect the crystals that precipitate out using a glass filter (G3). Dry the crystals obtained in vacuum at 80°C for 5 hours using phosphorus (V) oxide as a desiccant.

**Bromothymol blue-sodium hydroxide-ethanol TS** Dissolve 50 mg of bromothymol blue in 4 mL of diluted 0.2 mol/L sodium hydroxide TS (1 in 10) and 20 mL of ethanol (99.5), and add water to make 100 mL.

**Bucillamine for assay**  $\text{C}_7\text{H}_{13}\text{NO}_3\text{S}_2$  [Same as the monograph Bucillamine. However, when dried, it contains not

less than 99.0% of buccillamine ( $C_7H_{13}NO_3S_2$ ). Furthermore, it conforms to the following test.]

**Purity** Related substances—Dissolve 60 mg of buccillamine for assay in 20 mL of a mixture of water and methanol (1:1) and use this solution as the sample solution. Pipet 1 mL of this solution, add the mixture of water and methanol (1:1) to make exactly 100 mL, and use this solution as the standard solution. When the test is performed according to the Purity (3) under Buccillamine, the total area of the peaks other than the buccillamine peak from the sample solution is not larger than the peak area of buccillamine from the standard solution.

**Buformin hydrochloride for assay**  $C_6H_{15}N_5.HCl$  [Same as the monograph Buformin Hydrochloride. When dried, it contains not less than 99.5% of buformin hydrochloride ( $C_6H_{15}N_5.HCl$ ).]

**Butyl benzoate**  $C_6H_5COOCH_2CH_2CH_2CH_3$  A clear and colorless liquid.

*Refractive index* <2.45>  $n_D^{20}$ : 1.495 – 1.500

*Specific gravity* <2.56>  $d_{20}^{20}$ : 1.006 – 1.013

**n-Butylboronic acid**  $C_4H_{11}BO_2$  White flakes.

*Melting point* <2.60>: 90 – 92°C

**(E)-Capsaicin for component determination** Use (E)-capsaicin for thin-layer chromatography meeting the following additional specifications.

*Absorbance* <2.24>  $E_{1\text{cm}}^{1\%}$  (281 nm): 97 – 105 (10 mg, methanol, 200 mL). Use the sample dried in a desiccator (in vacuum, phosphorus (V) oxide, 40°C) for 5 hours for the test.

**Purity** Related substances—Dissolve 10 mg of capsaicin for component determination in 50 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and measure each peak area from these solutions by the automatic integration method: the total area of the peaks other than capsaicin from the sample solution is not larger than the peak area of capsaicin from the standard solution.

**Operating conditions**

Detector, column, column temperature, mobile phase, and flow rate: Proceed the operating conditions in the Component determination under Capsicum.

Time span of measurement: About 3 times as long as the retention time of capsaicin beginning after the solvent peak.

**System suitability**

System performance, and system repeatability: Proceed the system suitability in the Component determination under Capsicum.

Test for required detectability: Pipet 1 mL of the standard solution, and add methanol to make exactly 20 mL. Confirm that the peak area of capsaicin from 20  $\mu\text{L}$  of this solution is equivalent to 3.5 to 6.5% of that of capsaicin from 20  $\mu\text{L}$  of the standard solution.

#### (E)-Capsaicin for thin-layer chromatography

$C_{18}H_{27}NO_3$  White crystals, having a strong irritative odor. Very soluble in methanol, freely soluble in ethanol (95) and in diethyl ether, and practically insoluble in water.

*Melting point* <2.60>: 64.5 – 66.5°C

**Purity** Related substances—Dissolve 20 mg of capsaicin for thin-layer chromatography in 2 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 100 mL, and use this solution as the standard solution. Perform the test with 10  $\mu\text{L}$  each of the sample solution and standard solution as directed in the Identification under Capsicum: any spot other than the principal spot at the  $R_f$  value of about 0.5 from the sample solution is not more intense than the spot from the standard solution.

**Cesium chloride**  $CsCl$  White crystals or crystalline powder. Very soluble in water, and freely soluble in ethanol (99.5).

*Loss on drying* <2.41>: Not more than 1.0% (1 g, 110°C, 2 hours).

*Content*: not less than 99.0%. Assay—Weigh accurately about 0.5 g, previously dried, and dissolve in water to make exactly 200 mL. Pipet 20 mL of this solution, add 30 mL of water, and titrate <2.50> with 0.1 mol/L silver nitrate VS (indicator: fluorescein sodium TS).

Each mL of 0.1 mol/L silver nitrate VS  
= 16.84 mg of CsCl

**Cesium chloride TS** To 25.34 g of cesium chloride add water to make 1000 mL.

**Cetirizine hydrochloride for assay**  $C_{21}H_{25}ClN_2O_3.2HCl$  [Same as the monograph Cetirizine Hydrochloride. When dried, it contains not less than 99.5% of cetirizine hydrochloride ( $C_{21}H_{25}ClN_2O_3.2HCl$ ).]

#### 3'-Chloro-3'-deoxythymidine for liquid chromatography

$C_{10}H_{13}N_2O_4Cl$  Occurs as a white powder.

**Purity**—Dissolve 10 mg of 3'-chloro-3'-deoxythymidine for liquid chromatography in the mobile phase to make 100 mL. Perform the test with 10  $\mu\text{L}$  of this solution as directed in the Purity (3) under Zidovudine: a peak is not observed at the retention time for zidovudine.

#### (E)-Chlorogenic acid for thin-layer chromatography

$C_{16}H_{18}O_9.xH_2O$  A white powder. Freely soluble in methanol and in ethanol (99.5), and sparingly soluble in water. Melting point: about 205°C (with decomposition).

**Purity** Related substances—Dissolve 1.0 mg of chlorogenic acid for thin-layer chromatography in 2 mL of methanol, and use this solution as the sample solution. Perform the test with this solution as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu\text{L}$  of the sample solution on a plate of silica gel for thin-layer chromatography, develop the plate with a mixture of ethyl acetate, water and formic acid (6:1:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): no spot other than the principal spot at around  $R_f$  0.5 appears.

**Chlorphenesin carbamate for assay**  $C_{10}H_{12}ClNO_4$  [Same as the monograph Chlorphenesin Carbamate. When dried, it contains not less than 99.0% of chlorphenesin carbamate ( $C_{10}H_{12}ClNO_4$ ).]

**Cibenzoline succinate for assay**  $C_{18}H_{18}N_2 \cdot C_4H_6O_4$  [Same as the monograph Cibenzoline Succinate. When dried, it contains not less than 99.0% of cibenzoline succinate ( $C_{18}H_{18}N_2 \cdot C_4H_6O_4$ ) and meets the following requirement.]

**Purity:** Related substances—Dissolve 0.10 g in 2 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, and add methanol to make exactly 100 mL. To exactly 1 mL of this solution add methanol to make exactly 10 mL, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and ammonia solution (28) (20:3:2) to a distance of about 10 cm, air-dry the plate, and dry at 80°C for 30 minutes. After cooling, examine under ultraviolet light (main wavelength: 254 nm); the spot other than the principal spot obtained with the sample solution is not more intense than the spot with the standard solution. On standing the plate for 30 minutes in the tank saturated with iodine vapor, the spot other than the principal spot obtained with the sample solution is not more intense than the spot with the standard solution.

**Cilazapril**  $C_{22}H_{31}N_3O_5 \cdot H_2O$  [Same as the monograph Cilazapril Hydrate]

**Cilazapril for assay**  $C_{22}H_{31}N_3O_5 \cdot H_2O$  [Same as the monograph Cilazapril Hydrate. It contains not less than 99.0% of cilazapril ( $C_{22}H_{31}N_3O_5$ ), calculated on the anhydrous basis.]

**(E)-Cinnamaldehyde for thin-layer chromatography**  $C_9H_8O$  A colorless or light yellow liquid, having a characteristic aromatic odor. Very soluble in methanol and in ethanol (99.5), and practically insoluble in water.

**Absorbance** <2.24>  $E_{1\text{cm}}^{1\%}$  (285 nm): 1679 – 1943 (5 mg, methanol, 2000 mL)

**Purity** Related substances—Dissolve 10 mg in 2 mL of methanol. Perform the test with 1  $\mu$ L of this solution as directed in the Identification (3) under Kakkonto Extract: no spot other than the principal spot ( $R_f$  value is about 0.4) appears.

**Clorazepate dipotassium for assay**  $C_{16}H_{10}ClKN_2O_3 \cdot KOH$  [Same as the monograph Clorazepate Dipotassium. When dried it contains not less than 99.0% of clorazepate dipotassium ( $C_{16}H_{10}ClKN_2O_3 \cdot KOH$ ).]

**1-[(2R,5S)-2,5-Dihydro-5-(hydroxymethyl)-2-furyl] thymine for thin-layer chromatography**  $C_{10}H_{12}N_2O_4$  Occurs as a white powder.

**Purity**—Dissolve 0.1 g of 1-[(2R,5S)-2,5-dihydro-5-(hydroxymethyl)-2-furyl]thymine for thin-layer chro-

matography in 100 mL of methanol and perform the test as directed in the Purity (2) under Zidovudine: spots other than the principal spot with an  $R_f$  value of about 0.23 are not observed.

**Dilute sodium pentacyanonitrosylferrate (III)-potassium hexacyanoferrate (III) TS** To 5 mL of a solution of sodium pentacyanonitrosylferrate (III) dihydrate (3 in 50), 5 mL of a solution of potassium hexacyanoferrate (III) (13 in 200) and 2.5 mL of a solution of sodium hydroxide (1 in 10) add water to make 25 mL, and mix. Use after the color of the solution changes from dark red to light yellow. Prepare at the time of use.

**1,2-Dinitrobenzene**  $C_6H_4(NO_2)_2$  Occurs as yellowish white to brownish yellow crystals or a crystalline powder.

**Identification:** Determine the infrared absorption spectrum of 1,2-dinitrobenzene as directed in the paste method under Infrared Spectrophotometry <2.25>: it exhibits absorption at the wave numbers of about 3100  $cm^{-1}$ , 1585  $cm^{-1}$ , 1526  $cm^{-1}$ , 1352  $cm^{-1}$ , and 793  $cm^{-1}$ .

**Melting point** <2.60>: 116 – 119°C

**Enalapril maleate**  $C_{20}H_{28}N_2O_5 \cdot C_4H_4O_4$  [Same as the namesake monograph]

**2-Ethylhexyl parahydroxybenzoate**  $C_{15}H_{22}O_3$  Pale yellow, clear viscous liquid. Miscible with methanol (99.5). Practically insoluble in water.

**Content:** not less than 98.0%. **Assay**—Proceed as directed in the Assay under Ethyl Parahydroxybenzoate.

Each mL of 1 mol/L sodium hydroxide VS  
= 250.3 mg of  $C_{15}H_{22}O_3$

**Etizolam for assay**  $C_{17}H_{15}ClN_4S$  [Same as the monograph Etizolam. When dried, it contains not less than 99.0% of etizolam ( $C_{17}H_{15}ClN_4S$ ).]

**[6]-Gingerol for component determination** [6]-Gingerol for thin-layer chromatography. However, it meets the following requirements:

**Absorbance** <2.24>  $E_{1\text{cm}}^{1\%}$  (281 nm): 101 – 112 [7 mg, ethanol (99.5), 200 mL].

**Purity** Related substances—Dissolve 5 mg of [6]-gingerol for component determination in 5 mL of methanol, and use this as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 50 mL, and use this as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the total area of the peaks other than [6]-gingerol from the sample solution is not larger than the peak area of [6]-gingerol from the standard solution.

**Operating conditions**

Detector, column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay (3) under Hangekobokuto Extract.

**Time span of measurement:** About 6 times as long as the

retention time of [6]-gingerol.

System suitability

Test for required detectability: Pipet 1 mL of the standard solution, and add methanol to make exactly 20 mL. Confirm that the peak area of [6]-gingerol obtained with 10  $\mu$ L of this solution is equivalent to 3.5 to 6.5% of that with 10  $\mu$ L of the standard solution.

System performance and system repeatability: Proceed as directed in the system suitability in the Assay (3) under Hangekobokuto Extract.

**4-Hydroxyisophthalic acid**  $\text{HO}C_6\text{H}_3(\text{COOH})_2$  White crystals or powder.

*Content*: not less than 98.0%. *Assay*—Weigh accurately about 0.14 g, dissolve in 50 mL of ethanol (95), and titrate <2.50> with 0.1 mol/L sodium hydroxide VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L sodium hydroxide VS  
= 9.106 mg of  $\text{C}_8\text{H}_6\text{O}_5$

**Hyperoside for thin-layer chromatography**  $\text{C}_{21}\text{H}_{20}\text{O}_{12}$  Yellow crystals or crystalline powder. Slightly soluble in methanol, very slightly soluble in ethanol (99.5), and practically insoluble in water. Melting point: about 220°C (with decomposition).

*Identification*: Determine the absorption spectrum of a solution of hyperoside for thin-layer chromatography in methanol (1 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 255 nm and 259 nm.

*Purity* Related substances—Dissolve 1 mg of hyperoside for thin-layer chromatography in 20 mL of methanol. Perform the test with 10  $\mu$ L of this solution as directed in the Identification under Crataegus Fruit: any spot other than the principal spot of around Rf 0.5 does not appear.

**Isoxsuprine hydrochloride for assay**  $\text{C}_{18}\text{H}_{23}\text{NO}_3 \cdot \text{HCl}$  [Same as the monograph Isoxsuprine Hydrochloride]

**Labetalol hydrochloride**  $\text{C}_{19}\text{H}_{24}\text{N}_2\text{O}_3 \cdot \text{HCl}$  [Same as the namesake monograph]

**Labetalol hydrochloride for assay**  $\text{C}_{19}\text{H}_{24}\text{N}_2\text{O}_3 \cdot \text{HCl}$  [Same as the monograph Labetalol Hydrochloride. However, when dried, it contains not less than 99.0% of labetalol hydrochloride ( $\text{C}_{19}\text{H}_{24}\text{N}_2\text{O}_3 \cdot \text{HCl}$ ).]

**Lanthanum chloride TS** To 58.65 g of lanthanum (III) oxide add 100 mL of hydrochloric acid, and boil. After cooling, add water to make 1000 mL.

**Magnolol for thin-layer chromatography**  $\text{C}_{18}\text{H}_{18}\text{O}_2$  Odorless, white crystals or crystalline powder. Freely soluble in methanol and in ethanol (99.5), and practically insoluble in water. Melting point: about 102°C.

*Identification*: Determine the absorption spectrum of a solution of magnolol for thin-layer chromatography in methanol (1 in 50,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 287 nm and 291 nm.

*Purity* Related substances—Dissolve 1.0 mg of magnolol for thin-layer chromatography in 1 mL of methanol, and use this solution as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L of the sample solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography, develop the plate with a mixture of hexane, acetone and acetic acid (100) (20:15:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): any spot other than the principal spot of around Rf 0.5 does not appear.

**Miconazole nitrate**  $\text{C}_{18}\text{H}_{14}\text{Cl}_4\text{N}_2\text{O} \cdot \text{HNO}_3$  [Same as the namesake monograph]

**Minocycline hydrochloride**  $\text{C}_{23}\text{H}_{27}\text{N}_3\text{O}_7 \cdot \text{HCl}$  [Same as the namesake monograph]

**Nile blue**  $\text{C}_{20}\text{H}_{20}\text{ClN}_3\text{O}$  Blue-green powder.

**3-Nitroaniline**  $\text{C}_6\text{H}_6\text{N}_2\text{O}_2$  Yellow crystals or crystalline powder.

*Melting point* <2.60>: 112 – 116°C

**Nodakenin for thin-layer chromatography**  $\text{C}_{20}\text{H}_{24}\text{O}_9$  White powder. Slightly soluble in water and in methanol, and very slightly soluble in ethanol (99.5). Melting point: about 220°C (with decomposition).

*Identification*: Determine the absorption spectrum of a solution of nodakenin for thin-layer chromatography in methanol (1 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 333 nm and 337 nm.

*Optical rotation* <2.49>:  $[\alpha]_D^{20}$ : +50 – +68° (5 mg, methanol, 10 mL, 100 mm).

*Purity* Related substances—Dissolve 1 mg of nodakenin for thin-layer chromatography in 3 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 100 mL, and use this solution as the standard solution. Proceed with 5  $\mu$ L each of these solutions as directed in the Identification (2) under Peucedanum Root: the spot other than the principal spot of around Rf 0.3 from the sample solution is not more intense than the spot from the standard solution.

**Oleic acid**  $\text{C}_{18}\text{H}_{34}\text{O}_2$  Occurs as a colorless or pale yellow transparent liquid and has a slightly distinct odor. It is miscible with ethanol (95) and with diethyl ether, and practically insoluble in water.

*Specific gravity* <2.56>  $d_{20}^{20}$ : about 0.9

*Content*: not less than 99.0%. *Assay*—To 40  $\mu$ L of oleic acid to be examined add 1 mL of a solution of boron trifluoride in methanol (3 in 20), mix, and heat on a water bath for 3 minutes. After cooling, add 10 mL of petroleum ether and 10 mL of water, shake, collect the ether layer after allowing to stand, and use as the sample solution. Perform the test with 0.2  $\mu$ L of the sample solution as directed under Gas Chromatography <2.02> according to the following conditions, determine each peak area by the automatic integration method, and calculate the amount of methyl oleate by the area percentage method.



## Operating conditions

Detector: A hydrogen flame-ionization detector

Column: A glass column 3 mm in inside diameter and 2 m in length, packed with siliceous earth for gas chromatography (149 – 177  $\mu\text{m}$ ) coated with methyl polyacrylate in a rate of 5 – 10%.

Column temperature: A constant temperature of about 220°C.

Carrier gas: Helium

Flow rate: Adjust the flow rate so that the retention time of methyl oleate is about 10 minutes.

Time span of measurement: About 2 times as long as the retention time of methyl oleate, beginning after the solvent peak.

**(±)-Praeruptorin A for thin-layer chromatography**

$\text{C}_{21}\text{H}_{22}\text{O}_7$  White crystals or crystalline powder. Soluble in methanol, sparingly slightly soluble in ethanol (99.5), and practically insoluble in water.

*Identification:* Determine the absorption spectrum of a solution of (±)-praeruptorin A for thin-layer chromatography in methanol (1 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 320 nm and 324 nm.

*Melting point* <2.60>: 152 – 156°C

*Purity* Related substances—Dissolve 2 mg of (±)-praeruptorin A for thin-layer chromatography in 2 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 100 mL, and use this solution as the standard solution. Proceed with 5  $\mu\text{L}$  each of these solutions as directed in the Identification (1) under Peucedanum Root: the spot other than the principal spot of around *Rf* 0.3 from the sample solution is not more intense than the spot from the standard solution.

**Rosmarinic acid for component determination** Rosmarinic acid for thin-layer chromatography. However, it meets the following requirements:

*Absorbance* <2.24>  $E_{1\text{cm}}^{1\%}$  (332 nm): 526 – 559 [5 mg, ethanol (99.5), 500 mL].

*Purity* Related substances—Dissolve 5 mg of rosmarinic acid for component determination in 20 mL of the mobile phase, and use this as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 50 mL, and use this as the standard solution. Perform the test with exactly 10  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the total area of the peaks other than rosmarinic acid from the sample solution is not larger than the peak area of rosmarinic acid from the standard solution.

## Operating conditions

Detector: An ultraviolet absorption photometer (wavelength: 240 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle di-

ameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of diluted phosphoric acid (1 in 1000) and acetonitrile (4:1).

Flow rate: Adjust the flow rate so that the retention time of rosmarinic acid is about 14 minutes.

Time span of measurement: About 4 times as long as the retention time of rosmarinic acid.

## System suitability

Test for required detectability: Pipet 1 mL of the standard solution, and add methanol to make exactly 20 mL. Confirm that the peak area of rosmarinic acid obtained with 10  $\mu\text{L}$  of this solution is equivalent to 3.5 to 6.5% of that with 10  $\mu\text{L}$  of the standard solution.

System performance: When the procedure is run with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of rosmarinic acid are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the peak area of rosmarinic acid is not more than 1.5%.

**Rosmarinic acid for thin-layer chromatography**

$\text{C}_{18}\text{H}_{16}\text{O}_8$  White to pale yellow crystals or crystalline powder. Freely soluble in ethanol (99.5), and slightly soluble in water. Melting point: about 205°C (with decomposition).

*Identification:* Determine the absorption spectrum of a solution of rosmarinic acid for thin-layer chromatography in ethanol (99.5) (1 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 217 nm and 221 nm, between 290 nm and 294 nm, and between 330 nm and 334 nm.

*Purity* Related substances—Dissolve 10 mg of rosmarinic acid for thin-layer chromatography in 2 mL of ethanol (99.5), and use this solution as the sample solution. Pipet 1 mL of the sample solution, add ethanol (99.5) to make exactly 50 mL, and use this solution as the standard solution. Proceed with 10  $\mu\text{L}$  each of the sample solution and standard solution as directed in the Identification (2) under Hangekobokuto Extract: the spot other than the principal spot of around *Rf* 0.5 from the sample solution is not more intense than the spot from the standard solution.

**Sodium di-2-ethylhexyl sulfosuccinate**

$\text{C}_8\text{H}_{17}\text{COOCH}_2(\text{C}_8\text{H}_{17}\text{COO})\text{CHSO}_3\text{Na}$  White or translucent white mucilaginous soft masses. Sparingly soluble in water.

*Purity* Clarity and color of solution: A solution prepared by dissolving 1.0 g in 100 mL of water is clear and colorless.

*Loss on drying* <2.41>: not more than 5.0% (1 g, 105°C, 2 hours).

**Sodium dihydrogen phosphate TS, pH 2.2** Dissolve 1.56 g of sodium dihydrogen phosphate dihydrate in 800 mL of water, adjust the pH to 2.2 with phosphoric acid, and add

water to make 1000 mL.

**1 mol/L Sulfuric acid TS** Add 60 mL of sulfuric acid in 1000 mL of water slowly with stirring, then allow to cool.

**5 mol/L Sulfuric acid TS** Add 300 mL of sulfuric acid in 1000 mL of water slowly with stirring, then allow to cool.

**Thymine for liquid chromatography**  $C_5H_6N_2O_2$  Occurs as a white powder.

*Purity*—Dissolve 10 mg of the substance to be examined in 100 mL of methanol, add the mobile phase to make exactly 250 mL, and use this solution as the sample solution. Pipet 5 mL of this solution, add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Pipet 10  $\mu$ L each of these solutions and perform the test as directed in the Purity (3) under Zidovudine. Determine the area of each peak in the sample and standard solutions by the automatic integration method: the total area of peaks other than thymine from the sample solution is not larger than that from the standard solution. However, the time span of measurement is about 10 times the retention time of thymine, beginning after the solvent peak.

**Thymol for spraying test solution**  $C_{10}H_{14}O$  White crystals or crystalline powder, having an aromatic odor. Very soluble in methanol and in ethanol (99.5), and practically insoluble in water.

*Identification*: Determine the infrared absorption spectrum as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>: it exhibits absorption at the wave numbers of about 2960  $cm^{-1}$ , 1420  $cm^{-1}$ , 1290  $cm^{-1}$ , 1090  $cm^{-1}$  and 810  $cm^{-1}$ .

*Melting point* <2.60>: 49 – 52°C

*Purity*: Other phenols—Shake vigorously 1.0 g of the substance to be examined with 20 mL of warm water for 1 minute, and filter. To 5 mL of the filtrate add 1 drop of a solution of iron (III) chloride hexahydrate (27 in 100); the solution reveals a green but not a blue to purple color.

**Thymol-sulfuric acid-methanol TS for spraying** Dissolve 1.5 g of thymol for spraying test solution in 100 mL of methanol, and add 5.7 mL of sulfuric acid.

**Triphenylmethanol for thin-layer chromatography**  $C_{19}H_{15}OH$  Occurs as a white powder.

*Purity*—Dissolve 0.1 g of triphenylmethanol for thin-layer chromatography in 100 mL of methanol and perform the test as directed in the Purity (2) under Zidovudine: spots other than the principal spot with an  $R_f$  value of about 0.73 are not observed.

## 9.42 Solid Supports/Column Packings for Chromatography

### *Add the following:*

**Porous styrene-divinylbenzene copolymer for liquid chromatography** A porous styrene-divinylbenzene copolymer prepared for liquid chromatography.


**Strongly basic ion exchange resin for column chromatography** Prepared for column chromatography.

# Official Monographs

**Add the following:**

## Acemetacin

アセメタシン



$C_{21}H_{18}ClNO_6$ : 415.82

2-[2-[1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyloxy]acetic acid [53164-05-9]

Acemetacin, when dried, contains not less than 99.0% and not more than 101.0% of  $C_{21}H_{18}ClNO_6$ .

**Description** Acemetacin occurs as a light yellow crystalline powder.

It is soluble in acetone, sparingly soluble in methanol, slightly soluble in ethanol (99.5), and practically insoluble in water.

**Identification (1)** To 1 mg of Acemetacin add 1 mL of concentrated chromotropic acid TS, and heat in a water bath for 5 minutes: a red-purple color develops.

(2) Determine the absorption spectrum of a solution of Acemetacin in methanol (1 in 50,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(3) Determine the infrared absorption spectrum of Acemetacin as directed in the potassium bromide disk method under Infrared Spectrometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

(4) Perform the test with Acemetacin as directed under Flame Coloration Test <1.04> (2): a green color appears.

**Melting point** <2.60> 151 – 154°C

**Purity (1)** Heavy metals <1.07>—Proceed with 1.0 g of Acemetacin according to Method 4, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

(2) Related substances—Dissolve 0.40 g of Acemetacin in 10 mL of acetone, and use this solution as the sample solution. Pipet 1 mL of the sample solution, and add acetone to make exactly 50 mL. Pipet 1 mL of this solution, add acetone to make exactly 10 mL, and use this solution as

the standard solution. Perform the test with these solutions as directed under Thin Layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin layer chromatography. Develop the plate with a mixture of hexane, 4-methyl-2-pentanone and acetic acid (100) (3:2:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): not more than 2 spots other than the principal spot appear from the sample solution, and these spots are not more intense than the spot obtained from the standard solution.

**Loss on drying** <2.41> Not more than 0.5% (1 g, 105°C, 2 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.35 g of Acemetacin, previously dried, dissolve in 20 mL of acetone, add 10 mL of water, and then titrate <2.50> with 0.1 mol/L sodium hydroxide VS (potentiometric titration). Perform a blank determination in the same method, and make any necessary correction.

Each mL of 0.1 mol/L sodium hydroxide VS  
= 41.58 mg of  $C_{21}H_{18}ClNO_6$

**Containers and storage** Containers—Tight containers.

## Acetylcholine Chloride for Injection

注射用アセチルコリン塩化物

**Add the following next to Residue on ignition:**

**Uniformity of dosage units** <6.02> It meets the requirement of the Mass variation test.

**Foreign insoluble matter** <6.06> Perform the test according to Method 2: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Ajimaline Tablets

アジマリン錠

### Add the following next to Identification:

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Ajimaline Tablets add 150 mL of 2nd fluid for dissolution test, shake to disintegrate the tablet, then add 2nd fluid for dissolution test to make exactly 200 mL, and filter this solution through a membrane filter with a pore size not exceeding 0.8  $\mu\text{m}$ . Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate equivalent to about 0.5 mg of ajimaline ( $\text{C}_{20}\text{H}_{26}\text{N}_2\text{O}_2$ ), add 2nd fluid for dissolution test to make exactly 10 mL, and use this solution as the sample solution. Separately, weigh accurately about 25 mg of ajimaline for assay, previously dried in vacuum at 80°C for 3 hours, dissolve in 2nd fluid for dissolution test to make exactly 500 mL, and use this solution as the standard solution. Determine the absorbances at 288 nm,  $A_T$  and  $A_S$ , of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>.


$$\begin{aligned} &\text{Amount (mg) of ajimaline (C}_{20}\text{H}_{26}\text{N}_2\text{O}_2) \\ &= W_S \times (A_T/A_S) \times (1/V) \times 4 \end{aligned}$$

$W_S$ : Amount (mg) of ajimaline for assay

### Add the following:

## Alminoprofen

アルミノプロフェン



$\text{C}_{13}\text{H}_{17}\text{NO}_2$ : 219.28

(2*RS*)-2-[4-(2-Methylprop-2-en-1-yl)amino]phenyl]propanoic acid [39718-89-3]

Alminoprofen, when dried, contains not less than 99.0% and not more than 101.0% of  $\text{C}_{13}\text{H}_{17}\text{NO}_2$ .

**Description** Alminoprofen occurs as white to pale yellow crystals or crystalline powder.

It is freely soluble in ethanol (99.5) and in acetic acid (100), and very slightly soluble in water.

It gradually turns brown on exposure to light.

A solution of Alminoprofen in ethanol (99.5) (1 in 10) shows no optical rotation.

**Identification** (1) Determine the absorption spectrum of a solution of Alminoprofen in ethanol (99.5) (3 in 500,000) as directed under Ultraviolet-visible Spectrophotometry

<2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Alminoprofen as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Melting point** <2.60> 106 – 108°C

**Purity** (1) Heavy metals <1.07>—Proceed with 2.0 g of Alminoprofen according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 1.0 g of Alminoprofen according to Method 3, and perform the test (not more than 2 ppm).

(3) Related substances—Conduct this procedure using light-resistant vessels. Dissolve 50 mg of Alminoprofen in 100 mL of the mobile phase, and use this solution as the sample solution. Pipet 2 mL of the sample solution, add the mobile phase to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 5  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area of these solutions by the automatic integration method: the area of the peak other than alminoprofen obtained from the sample solution is not larger than 1/5 times the peak area of alminoprofen from the standard solution. Furthermore, the total area of the peaks other than alminoprofen from the sample solution is not larger than the peak area of alminoprofen from the standard solution.

**Operating conditions**—

**Detector:** An ultraviolet absorption photometer (wavelength: 254 nm).

**Column:** A stainless steel column 6.0 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

**Column temperature:** A constant temperature of about 25°C.

**Mobile phase:** A mixture of methanol and diluted acetic acid (100) (1 in 1000) (4:1).

**Flow rate:** Adjust the flow rate so that the retention time of alminoprofen is about 5 minutes.

**Time span of measurement:** About 5 times as long as the retention time of alminoprofen, beginning after the solvent peak.

**System suitability**—

**Test for required detectability:** Pipet 1 mL of the standard solution, and add the mobile phase to make exactly 10 mL. Confirm that the peak area of alminoprofen obtained from 5  $\mu\text{L}$  of this solution is equivalent to 7 to 13% of that from 5  $\mu\text{L}$  of the standard solution.

**System performance:** Dissolve 10 mg each of Alminoprofen and butyl parahydroxybenzoate in 100 mL of

methanol. Pipet 10 mL of this solution, and add methanol to make exactly 50 mL. When the procedure is run with 5  $\mu$ L of this solution under the above operating conditions, alminoprofen and butyl parahydroxybenzoate are eluted in this order with the resolution between these peaks being not less than 2.0.

**System repeatability:** When the test is repeated 6 times with 5  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of alminoprofen is not more than 2.0%.

**Loss on drying** <2.41> Not more than 0.5% (1 g, in vacuum, phosphorus (V) oxide, 1 hour).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.3 g of Alminoprofen, previously dried, dissolve in 50 mL of acetic acid (100), and titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS  
= 21.93 mg of C<sub>13</sub>H<sub>17</sub>NO<sub>2</sub>

**Containers and storage** Containers—Well-closed containers.

Storage—Light-resistant.

**Add the following:**

## Alminoprofen Tablets

アルミノプロフェン錠

Alminoprofen Tablets contain not less than 93.0% and not more than 107.0% of the labeled amount of alminoprofen (C<sub>13</sub>H<sub>17</sub>NO<sub>2</sub>: 219.28).

**Method of preparation** Prepare as directed under Tablets, with Alminoprofen.

**Identification** Take an amount of powdered Alminoprofen Tablets, equivalent to 30 mg of Alminoprofen according to the labeled amount, add ethanol (99.5) to make 100 mL, shake thoroughly, and centrifuge. To 2 mL of the supernatant liquid add ethanol (99.5) to make 100 mL, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 253 nm and 257 nm, and between 298 nm and 302 nm.

**Purity** Related substances—Conduct this procedure using light-resistant vessels. Powder 10 tablets of Alminoprofen Tablets, weigh a portion of the powder equivalent to 50 mg of Alminoprofen according to the labeled amount, add 50 mL of the mobile phase, shake for 15 minutes, add the mobile phase to make exactly 100 mL, centrifuge, and use the supernatant liquid as the sample solution. Pipet 2 mL of the sample solution, add the mobile phase to make exactly 200 mL, and use this solution as the standard solution. Perform

the test with exactly 5  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.07> according to the conditions described in the Purity (3) under Alminoprofen. Determine each peak area of each solution by the automatic integration method: the area of the peak other than alminoprofen obtained from the sample solution is not larger than 1/2 times the peak area of alminoprofen from the standard solution. Furthermore, the total area of the peaks other than alminoprofen from the sample solution is not larger than 2 times the peak area of alminoprofen from the standard solution.

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Alminoprofen Tablets add 5 mL of water, shake until the tablet is disintegrated, add 50 mL of ethanol (99.5), shake for 20 minutes, then add ethanol (99.5) to make exactly 100 mL, and centrifuge. Pipet 3 mL of the supernatant liquid, add ethanol (99.5) to make exactly 50 mL. Pipet  $V$  mL of this solution, add ethanol (99.5) to make exactly  $V'$  mL so that each mL contains about 6  $\mu$ g of alminoprofen (C<sub>13</sub>H<sub>17</sub>NO<sub>2</sub>), and use this solution as the sample solution. Then, proceed as directed in the Assay.

Amount (mg) of alminoprofen (C<sub>13</sub>H<sub>17</sub>NO<sub>2</sub>)  
=  $W_S \times (A_T/A_S) \times (V'/V) \times (1/3)$

$W_S$ : Amount (mg) of alminoprofen for assay

**Dissolution** <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of 2nd fluid for dissolution test as the dissolution medium, the dissolution rate in 45 minutes of Alminoprofen Tablets is not less than 80%.

Start the test with 1 tablet of Alminoprofen Tablets, withdraw not less than 20 mL of the medium at specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45  $\mu$ m. Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, add 0.05 mol/L sodium hydroxide TS to make exactly  $V'$  mL so that each mL contains about 8.9  $\mu$ g of alminoprofen (C<sub>13</sub>H<sub>17</sub>NO<sub>2</sub>) according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 30 mg of alminoprofen for assay, previously dried in vacuum for 1 hour using phosphorus (V) oxide as the desiccant, and dissolve in 0.05 mol/L sodium hydroxide TS to make exactly 100 mL. Pipet 3 mL of this solution, add 0.05 mol/L sodium hydroxide TS to make exactly 100 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , at 245 nm of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>.

Dissolution rate (%) with respect to the labeled amount of alminoprofen (C<sub>13</sub>H<sub>17</sub>NO<sub>2</sub>)

=  $W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 27$

$W_S$ : Amount (mg) of alminoprofen for assay

C: Labeled amount (mg) of alminoprofen (C<sub>13</sub>H<sub>17</sub>NO<sub>2</sub>) in 1 tablet

**Assay** Weigh accurately the mass of not less than 20 tablets of Alminoprofen Tablets, and powder. Weigh accurately an amount equivalent to about 60 mg of alminoprofen ( $C_{13}H_{17}NO_2$ ), add ethanol (99.5) and shake well, add ethanol (99.5) to make exactly 200 mL, and centrifuge. Pipet 2 mL of the supernatant liquid, add ethanol (99.5) to make exactly 100 mL, and use this solution as the sample solution. Separately, weigh accurately about 30 mg of alminoprofen for assay, previously dried in vacuum for 1 hour using phosphorus (V) oxide as the desiccant, dissolve in ethanol (99.5) to make exactly 100 mL. Pipet 2 mL of this solution, add ethanol (99.5) to make exactly 100 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , at the wavelength of maximum absorption at about 255 nm of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>.

$$\begin{aligned} &\text{Amount (mg) of alminoprofen (C}_{13}\text{H}_{17}\text{NO}_2) \\ &= W_S \times (A_T/A_S) \times 2 \end{aligned}$$

$W_S$ : Amount (mg) of alminoprofen for assay

**Containers and storage** Containers—Well-closed containers.

### Add the following:

## Alprostadil Injection

アルプロスタジル注射液

Alprostadil Injection is an emulsion-type injection.

It contains not less than 80.0% and not more than 125.0% of the labeled amount of alprostadil ( $C_{20}H_{34}O_5$ ; 354.48).

**Method of preparation** Prepare as directed under Injections, with Alprostadil.

**Description** Alprostadil Injection occurs as a white emulsion and is slightly viscous. It has a distinctive odor.

**Identification** To a quantity of Alprostadil Injection, corresponding to 10  $\mu\text{g}$  of Alprostadil according to the labeled amount, add 2 mL of acetonitrile, shake well, and centrifuge. To 3.5 mL of the supernatant liquid add 7 mL of diluted phosphoric acid (1 in 1000), and then run this solution on a column (prepared by filling a 10 mm inside diameter, 9 mm long chromatography tube with 0.4 g of 70  $\mu\text{m}$  octadecylsilanized silica gel for pretreatment) prewashed with 10 mL of methanol and then 10 mL of water. Wash the column with 10 mL of water and then 20 mL of petroleum ether, followed by elution with 2.5 mL of a mixture of methanol and water (4:1). Remove the solvent from the effluent under reduced pressure, dissolve the residue in 100  $\mu\text{L}$  of ethyl acetate, and use this solution as the sample solution. Separately, dissolve 1 mg of Alprostadil Reference Standard in 10 mL of ethyl acetate, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot the

entire volume of the sample solution and 100  $\mu\text{L}$  of the standard solution on a plate of silica gel for thin-layer chromatography. Then, develop the plate with a mixture of ethyl acetate, ethanol (99.5) and acetic acid (100) (100:5:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly a solution of phosphomolybdic acid *n*-hydrate in ethanol (99.5) (1 in 10) on the plate, and heat at 100°C for 5 minutes: the color of the spot obtained from the standard solution and the spot corresponding to that location obtained from the sample solution is dark blue.

**pH** Being specified separately.

**Purity (1)** Heavy metals <1.07>—Proceed with 4.0 mL of Alprostadil Injection according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 5 ppm).

(2) Prostaglandin  $A_1$ —Use the sample solution obtained in the Assay as the sample solution. Separately, weigh accurately about 10 mg of prostaglandin  $A_1$ , previously dried for 4 hours in a desiccator (in vacuum, phosphorus (V) oxide), and dissolve in ethanol (99.5) to make exactly 100 mL. Pipet 2.5 mL of this solution, and add the mobile phase to make exactly 50 mL. Pipet 1 mL of this solution, add exactly 1 mL of the internal standard solution, and use this solution as the standard solution. Perform the test with 40  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, determine the ratios,  $Q_T$  and  $Q_S$ , of the peak area of prostaglandin  $A_1$  to that of the internal standard, and calculate the amount of prostaglandin  $A_1$  converted to alprostadil using the following equation: not more than 3.0  $\mu\text{g}$  per a volume, equivalent to 5  $\mu\text{g}$  of alprostadil ( $C_{20}H_{34}O_5$ ).

Amount ( $\mu\text{g}$ ) of prostaglandin  $A_1$  ( $C_{20}H_{32}O_4$ ), converted to alprostadil

$$= W_S \times (Q_T/Q_S) \times (1/2) \times 1.054$$

$W_S$ : Amount (mg) of prostaglandin  $A_1$

**Internal standard solution**—Dissolve 50 mg of 1-naphthol in 20 mL of ethanol (99.5). To 3 mL of this solution add the mobile phase to make 100 mL.

**Operating conditions**—

Proceed as directed in the operating conditions in the Assay.

**System suitability**—

Test for required detectability: To exactly 1 mL of the standard solution add the mobile phase to make exactly 5 mL. Confirm that the peak area of prostaglandin  $A_1$  obtained with 40  $\mu\text{L}$  of this solution is equivalent to 14 to 26% of that with 40  $\mu\text{L}$  of the standard solution.

System performance, and system repeatability: Proceed as directed in the system suitability in the Assay.

(3) Peroxide—Pipet 4 mL of Alprostadil Injection, place in a glass-stoppered flask, add 15 mL of a mixture of acetic acid (100) and isooctane (3:2), previously having undergone a 30 minute nitrogen substitution, and dissolve with gentle shaking. To this solution add 0.5 mL of saturat-

ed potassium iodide TS, replace the inside of the vessel with nitrogen, and shake for exactly 5 minutes. Then, add 0.5 mL of starch TS, shake vigorously, add 15 mL of water, and shake vigorously. Under a stream of nitrogen, titrate <2.50> with 0.01 mol/L sodium thiosulfate VS until the color of the solution disappears. Separately, perform a blank determination using 4 mL of water, and make any necessary correction. Calculate the amount of peroxides using the following equation: not more than 0.5 meq/L.

$$\text{Amount (meq/L) of peroxides} = V \times 2.5$$

*V*: Amount (mL) of 0.01 mol/L sodium thiosulfate VS consumed

(4) Free fatty acids—Pipet 3 mL of Alprostadil Injection, add exactly 15 mL of a mixture of 2-propanol, heptane and 0.5 mol/L sulfuric acid TS (40:10:1), and shake for 1 minute. After leaving for 10 minutes, add exactly 9 mL of heptane and exactly 9 mL of water, shake the test tube by inverting 10 times, leave for 15 minutes, and pipet 9 mL of the supernatant liquid. To this solution, add 3 mL of a solution prepared by combining 1 volume of Nile blue solution (1 in 5000) washed 5 times with heptane and 9 volumes of ethanol (99.5), and use this solution as the sample solution. Titrate <2.50> this solution with 0.02 mol/L sodium hydroxide VS under a stream of nitrogen. Separately, dissolve 5.65 g of oleic acid in heptane to make exactly 200 mL, and use this solution as the standard solution. Pipet 25 mL of the standard solution, add 2 drops of phenolphthalein TS, titrate <2.50> with 0.1 mol/L potassium hydroxide-ethanol VS until a light red color develops, and determine the correction factor *f*. Pipet 30 mL of the standard solution and add heptane to make exactly 200 mL. Pipet 3 mL of this solution, add exactly 15 mL of a mixture of 2-propanol, heptane and 0.5 mol/L sulfuric acid TS (40:10:1), and shake for 1 minute. After leaving for 10 minutes, add exactly 6 mL of heptane and exactly 12 mL of water, shake the test tube by inverting 10 times, and then titrate <2.50> in the same manner as for the sample solution. Determine the volume (mL),  $V_T$  and  $V_S$ , of 0.02 mol/L sodium hydroxide VS consumed by the sample and standard solutions: the amount of free fatty acid is not more than 12.0 meq/L.

$$\text{Amount (meq/L) of free fatty acids} = (V_T/V_S) \times f \times 15$$

**Bacterial endotoxins** <4.01> Less than 10 EU/mL.

**Extractable volume** <6.05> It meets the requirement.

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: no easily detectable foreign matter is observed.

**Sterility** <4.06> Perform the test according to the Membrane filter method: it meets the requirement. However, use the sample solution consisting of equal volume of Alprostadil Injection and a solution prepared by adding water to 0.1 g of polysorbate 80 to make 100 mL.

**Particle diameter** Being specified separately.

**Assay** Measure exactly a volume of Alprostadil Injection corresponding to 5  $\mu\text{g}$  of alprostadil ( $\text{C}_{20}\text{H}_{34}\text{O}_5$ ), add exactly

1 mL of the internal standard solution, shake, and use this solution as the sample solution. Separately, weigh accurately about 5 mg of Alprostadil Reference Standard, previously dried in a desiccator (in vacuum, phosphorus (V) oxide) for 4 hours, dissolve in ethanol (99.5) to make exactly 50 mL, and use this solution as standard stock solution. Pipet 2.5 mL of the standard stock solution, add the mobile phase to make exactly 50 mL, pipet 1 mL, add exactly 1 mL of the internal standard solution, and use this solution as the standard solution. Perform the test with 40  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions using an apparatus equipped with an automatic pretreatment device (using a postcolumn reaction), and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of alprostadil to that of the internal standard.

$$\begin{aligned} \text{Amount } (\mu\text{g}) \text{ of alprostadil } (\text{C}_{20}\text{H}_{34}\text{O}_5) \\ = W_S \times (Q_T/Q_S) \times (1/2) \end{aligned}$$

$W_S$ : Amount (mg) of Alprostadil Reference Standard

**Internal standard solution**—Dissolve 50 mg of 1-naphthol in 20 mL of ethanol (99.5). To 3 mL of this solution add the mobile phase to make 100 mL.

**Operating conditions**—

**Equipment**: Liquid chromatograph consisting of 2 pumps for pumping the mobile phase and the reaction reagent, an automatic pretreatment device, column, reaction coil, detector, and recording apparatus. Use a reaction coil that is maintained at a constant temperature.

**Detector**: An ultraviolet absorption photometer (wavelength: 278 nm).

**Column**: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

**Column temperature**: A constant temperature of about 60°C.

**Reaction coil**: Polytetrafluoroethylene tube 0.5 mm in inside diameter and 10 m in length.

**Mobile phase**: Dissolve 9.07 g of potassium dihydrogen phosphate in water to make 1000 mL and adjust the pH to 6.3 by adding a solution prepared by dissolving 9.46 g of disodium hydrogen phosphate in water to make 1000 mL. To 1 volume of this solution add 9 volumes of water. To 3 volumes of this solution add 1 volume of acetonitrile for liquid chromatography.

**Reaction reagent**: Potassium hydroxide TS.

**Reaction temperature**: A constant temperature of about 60°C.

**Mobile phase flow rate**: Adjust the flow rate so that the retention time of alprostadil is about 7 minutes.

**Reaction reagent flow rate**: 0.5 mL per minute.

**Automatic pretreatment device**: Composed of a pretreatment column, pump for pumping pretreatment column wash solution, and routing valve for 2 high pressure flow paths.

**Pretreatment column**: A stainless steel column 4 mm in inside diameter and 2.5 cm in length, packed with octadecyl-

silanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

Pretreatment column wash solution: Ethanol (99.5).


Flow rate of wash solution: A constant flow rate of about 2.0 mL per minute.

Flow path operating conditions: Change the flow path operating conditions at the times shown in the table below using the valves shown in the figure.

Valve	Time of switchover (minutes)				
	0	9.0	9.1	*1)	*2)
RVA	0	0	1	0	0
RVB	0	1	1	1	0

\*1) After the internal standard has completely eluted

\*2) 0.1 minutes after \*1)



- A: RVA valve
- B: RVB valve
- C: Sample injector
- D: Mobile phase
- E: Column for pressure correction
- F: Column
- G: Pretreatment column
- H: Wash solution
- I: Drain
- J: Pump

**Figure** Components of automatic pretreatment system

#### System suitability—

System performance: Dissolve 10 mg of prostaglandin A<sub>1</sub>, previously dried in a desiccator (in vacuum, phosphorus (V) oxide) for 4 hours, in ethanol (99.5) to make 100 mL. To 2.5 mL of this solution add 2.5 mL of the standard stock solution, and add the mobile phase to make 50 mL. To 1 mL of this solution add 1 mL of the internal standard solution, shake, and perform the test under the above conditions with 40  $\mu\text{L}$  of the solution. Alprostadil, prostaglandin A<sub>1</sub> and the internal standard are eluted in this order, and the resolution between the peaks of alprostadil and prostaglandin A<sub>1</sub> is not less than 10, and that between prostaglandin A<sub>1</sub> and the internal standard is not less than 2.0.

System repeatability: When the test is repeated 6 times with 40  $\mu\text{L}$  of the standard solution under the above conditions, the relative standard deviation of the ratio of the peak

area of alprostadil to that of the internal standard is not more than 2.0%.

**Containers and storage** Containers—Hermetic containers.

Storage—Light-resistant, not exceeding 5°C, avoiding freezing.

#### Add the following:

### Amikacin Sulfate Injection

アミカシン硫酸塩注射液

Amikacin Sulfate Injection is an aqueous injection.

It contains not less than 90.0% and not more than 115.0% of the labeled amount of amikacin (C<sub>22</sub>H<sub>43</sub>N<sub>5</sub>O<sub>13</sub>: 585.60).

**Method of preparation** Prepare as directed under Injections, with Amikacin Sulfate.

**Description** Amikacin Sulfate Injection occurs as a colorless or pale yellow clear liquid.

**Identification** To a volume of Amikacin Sulfate Injection, equivalent to 0.1 g (potency) of Amikacin Sulfate according to the labeled amount, add water to make 4 mL, and use this solution as the sample solution. Separately, dissolve 25 mg (potency) of Amikacin Sulfate Reference Standard in 1 mL of water, and use this solution as the standard solution. Then, proceed as directed in the Identification (2) under Amikacin Sulfate.

**Osmotic pressure ratio** Being specified separately.

**pH** <2.54> 6.0 – 7.5

**Bacterial endotoxins** <4.01> Less than 0.50 EU/mg (potency).

**Extractable volume** <6.05> It meets the requirement.

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Assay** Take exactly a volume of Amikacin Sulfate Injection, equivalent to about 0.1 g (potency) of Amikacin Sulfate, and add water to make exactly 100 mL. Separately, weigh accurately an amount of Amikacin Sulfate Reference Standard, equivalent to about 50 mg (potency), and add water to make exactly 50 mL. Take exactly 200  $\mu\text{L}$  each of these solutions into stoppered test tubes, then proceed as directed in the Assay under Amikacin Sulfate.

$$\text{Amount [mg (potency)] of amikacin (C}_{22}\text{H}_{43}\text{N}_5\text{O}_{13}) \\ = W_S \times (H_T/H_S) \times 2$$



$W_S$ : Amount [mg (potency)] of Amikacin Sulfate Reference Standard

**Container and storage** Containers—Hermetic containers.

## Aminophylline Injection

アミノフィリン注射液

**Add the following next to Identification:**

**Bacterial endotoxins** <4.01> Less than 0.6 EU/mg.

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Amitriptyline Hydrochloride Tablets

アミトリプチリン塩酸塩錠

**Add the following next to Identification:**

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Amitriptyline Hydrochloride Tablets add 50 mL of diluted methanol (1 in 2), shake to disintegrate the tablet, then add diluted methanol (1 in 2) to make exactly 100 mL, and filter. Discard the first 20 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, add methanol to make exactly  $V'$  mL so that each mL contains about 10  $\mu$ g of amitriptyline hydrochloride ( $C_{20}H_{23}N.HCl$ ), and use this solution as the sample solution. Then, proceed as directed in the Assay.


Amount (mg) of amitriptyline hydrochloride ( $C_{20}H_{23}N.HCl$ )  
 $= W_S \times (A_T/A_S) \times (V'/V) \times (1/20)$

$W_S$ : Amount (mg) of Amitriptyline Hydrochloride Reference Standard

**Add the following:**

## Amlexanox

アンレキサノクス



$C_{16}H_{14}N_2O_4$ : 298.29

2-Amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano[2,3-b]pyridine-3-carboxylic acid  
 [68302-57-8]

Amlexanox, when dried, contains not less than 98.0% and not more than 102.0% of  $C_{16}H_{14}N_2O_4$ .

**Description** Amlexanox occurs as white to yellowish white crystals or crystalline powder.

It is very slightly soluble in ethanol (99.5), and practically insoluble in water.

It dissolves in diluted sodium hydroxide TS (1 in 3).

**Identification (1)** Determine the absorption spectrum of a solution of Amlexanox in ethanol (99.5) (1 in 250,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Amlexanox Reference Standard prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelengths.

**(2)** Determine the infrared absorption spectrum of Amlexanox as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Amlexanox Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Purity (1) Chloride** <1.03>—Dissolve 1.0 g of Amlexanox in 20 mL of water and 10 mL of sodium hydroxide TS, add 15 mL of dilute nitric acid and water to make 50 mL, centrifuge, and then filter the supernatant liquid. To 25 mL of this filtrate add water to make 50 mL. Perform the test using this solution as the test solution. The control solution consists of 5 mL of sodium hydroxide TS, 7.5 mL of dilute nitric acid, 0.30 mL of 0.01 mol/L hydrochloric acid VS, and water added to make 50 mL (not more than 0.021%).

**(2) Heavy metals** <1.07>—Proceed with 1.0 g of Amlexanox according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

**(3) Related substances**—(i) Dissolve 30 mg of Amlexanox in 50 mL of the mobile phase, and use this solution as the sample solution. Pipet 1 mL of the sample solution, and add the mobile phase to make exactly 50 mL. Pipet 1 mL of this solution, add the mobile phase to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography

<2.01> according to the following conditions. Determine each peak area of these solutions by the automatic integration method: the area of the peak other than amlexanox obtained from the sample solution is not larger than 2 times the peak area of amlexanox from the standard solution.

*Operating conditions—*

The detector, column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay.

Time span of measurement: Until completion of the elution of amlexanox beginning after the solvent peak.

*System suitability—*

Test for required detectability: Pipet 10 mL of the standard solution, and add the mobile phase to make exactly 100 mL. Confirm that the peak area of amlexanox obtained from 10  $\mu$ L of this solution is equivalent to 7 to 13% of that from 10  $\mu$ L of the standard solution.

System performance: Proceed as directed in the system suitability in the Assay.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of amlexanox is not more than 2.0%.

(ii) Dissolve 30 mg of Amlexanox in 50 mL of the mobile phase, and use this solution as the sample solution. Pipet 1 mL of the sample solution, and add the mobile phase to make exactly 50 mL. Pipet 1 mL of this solution, add the mobile phase to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area of these solutions by the automatic integration method: the area of the peak other than amlexanox obtained from the sample solution is not larger than 2 times the peak area of amlexanox from the standard solution.

*Operating conditions—*

Detector, column, and column temperature: Proceed as directed in the operating conditions in the Assay.

Mobile phase: Dissolve 7.2 g of disodium hydrogen phosphate dodecahydrate in water to make 1000 mL. Adjust the pH of this solution to 8.0 by adding a solution prepared by dissolving 3.1 g of sodium dihydrogen phosphate dihydrate in 1000 mL of water. To 400 mL of this solution add 600 mL of acetonitrile.

Flow rate: To 15 mL of a solution of benzophenone in the mobile phase (3 in 1,000,000) add the mobile phase to make 20 mL. Adjust the flow rate so that the retention time of benzophenone is about 6.5 minutes when perform the test with 10  $\mu$ L of this solution under the conditions described above.

Time span of measurement: About 3 times as long as the retention time of benzophenone, beginning after the peak of amlexanox.

*System suitability—*

Test for required detectability: Pipet 5 mL of the standard solution, and add the mobile phase to make exactly 50 mL. Confirm that the peak area of amlexanox obtained from 10

$\mu$ L of this solution is equivalent to 7 to 13% of that from 10  $\mu$ L of the standard solution.

System performance: Pipet 1 mL of the sample solution, and add the mobile phase to make 100 mL. To 5 mL of this solution add 15 mL of the solution of benzophenone in the mobile phase (3 in 1,000,000). When perform the test with 10  $\mu$ L of this solution according to the above conditions, amlexanox and benzophenone are eluted in this order with the resolution between these peaks being not less than 10.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of amlexanox is not more than 2.0%.

(iii) The total amount of related substances, when calculated according to the following formula, is not more than 0.5%.

$$\begin{aligned} &\text{Total amount (\% of related substances)} \\ &= \{(A_{T1}/A_{S1}) + (A_{T2}/A_{S2})\} \times (1/10) \end{aligned}$$

$A_{T1}$ : Total area of the peaks other than amlexanox from the sample solution obtained in (i)

$A_{T2}$ : Total area of the peaks other than amlexanox from the sample solution obtained in (ii)

$A_{S1}$ : Peak area of amlexanox from the standard solution obtained in (i)

$A_{S2}$ : Peak area of amlexanox from the standard solution obtained in (ii)

**Loss on drying** <2.41> Not more than 0.3% (1 g, 105°C, 2 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 30 mg each of Amlexanox and Amlexanox Reference Standard, both dried, and dissolve them separately in the mobile phase to make exactly 50 mL. Pipet 5 mL each of these solutions, and add exactly 15 mL of the internal standard solution, and use these solutions as the sample solution and the standard solution, respectively. Perform the test with 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of amlexanox to that of the internal standard, respectively.

$$\text{Amount (mg) of } C_{16}H_{14}N_2O_4 = W_S \times (Q_T/Q_S)$$

$W_S$ : Amount (mg) of Amlexanox Reference Standard

*Internal standard solution*—A solution of 3-nitroaniline in the mobile phase (1 in 4000).

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.0 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: Dissolve 17.9 g of disodium hydrogen

phosphate dodecahydrate in water to make 1000 mL. Adjust the pH of this solution to 8.0 by adding a solution prepared by dissolving 7.8 g of sodium dihydrogen phosphate dihydrate in 1000 mL of water. To 760 mL of this solution add 240 mL of acetonitrile.

Flow rate: Adjust the flow rate so that the retention time of amlexanox is about 10 minutes.

*System suitability*—

System performance: When the procedure is run with 10  $\mu$ L of the standard solution according to the above conditions, amlexanox and the internal standard are eluted in this order with the resolution between these peaks being not less than 2.0.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above conditions, the relative standard deviation of the ratio of the peak area of amlexanox to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Well-closed containers.

**Add the following:**

## Amlexanox Tablets

アンレキサノクス錠

Amlexanox Tablets contain not less than 93.0% and not more than 107.0% of the labeled amount of amlexanox ( $C_{16}H_{14}N_2O_4$ ; 298.29).

**Method of preparation** Prepare as directed under Tablets, with Amlexanox.

**Identification** (1) Take an amount of powdered Amlexanox Tablets, equivalent to 10 mg of Amlexanox according to the labeled amount, add 100 mL of ethanol (99.5), shake vigorously, and filter. Pipet 1 mL of the filtrate, add 25 mL of ethanol (99.5), and use this solution as the sample solution. Determine the absorption spectrum of the sample solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits absorption maxima between 240 nm and 244 nm, between 285 nm and 289 nm, and between 341 nm and 352 nm.

(2) Observe the sample solution obtained in (1) under ultraviolet light (main wavelength: 365 nm): the solution shows a bluish-white fluorescence.

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Take 1 tablet of Amlexanox Tablets, add exactly 0.6 mL of the internal standard solution per 1 mg of amlexanox ( $C_{16}H_{14}N_2O_4$ ), add the mobile phase to make exactly  $V$  mL so there is about 167  $\mu$ g of amlexanox ( $C_{16}H_{14}N_2O_4$ ) per 1 mL, disintegrate the tablet, and then shake vigorously for 5 minutes. Centrifuge this solution, and use the supernatant liquid as the sample solution. Separately, weigh accurately

about 30 mg of Amlexanox Reference Standard, previously dried at 105°C for 2 hours, and dissolve in the mobile phase to make exactly 50 mL. Pipet 25 mL of this solution, add exactly 10 mL of the internal standard solution, add the mobile phase to make 100 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Amlexanox.

$$\begin{aligned} & \text{Amount (mg) of amlexanox (C}_{16}\text{H}_{14}\text{N}_2\text{O}_4) \\ & = W_S \times (Q_T/Q_S) \times (V/200) \end{aligned}$$

$W_S$ : Amount (mg) of Amlexanox Reference Standard

*Internal standard solution*—A solution of 3-nitroaniline in the mobile phase (1 in 500).

**Dissolution** <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of 2nd fluid for dissolution test as the dissolution medium, the dissolution rate in 45 minutes of Amlexanox Tablets is not less than 80%.

Start the test with 1 tablet of Amlexanox Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45  $\mu$ m. Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, add the dissolution medium to make exactly  $V'$  mL so that each mL contains about 5.6  $\mu$ g of amlexanox ( $C_{16}H_{14}N_2O_4$ ) according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 28 mg of Amlexanox Reference Standard, previously dried at 105°C for 2 hours, and dissolve in 2 mL of dilute sodium hydroxide TS, add the dissolution medium to make exactly 50 mL. Pipet 1 mL of this solution, add the dissolution medium to make exactly 100 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , at 350 nm of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>.

Dissolution rate (%) with respect to the labeled amount of amlexanox ( $C_{16}H_{14}N_2O_4$ )

$$= W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 18$$

$W_S$ : Amount (mg) of Amlexanox Reference Standard

$C$ : Labeled amount (mg) of amlexanox ( $C_{16}H_{14}N_2O_4$ ) in 1 tablet

**Assay** Weigh accurately not less than 20 Amlexanox Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 15 mg of amlexanox ( $C_{16}H_{14}N_2O_4$ ), add exactly 10 mL of the internal standard solution, add 80 mL of the mobile phase, shake vigorously for 5 minutes, and then add the mobile phase to make 100 mL. Centrifuge this solution, and use the supernatant liquid as the sample solution. Separately, weigh accurately about 30 mg of Amlexanox Reference Standard, previously dried at 105°C for 2 hours, and dissolve in the mobile phase to make exactly 50 mL. Pipet 25 mL of this solution, add exactly 10 mL of the internal standard solution, add the mobile phase to make 100 mL, and use this solution as the standard solu-

tion. Then, proceed as directed in the Assay under Amlexanox.

$$\begin{aligned} \text{Amount (mg) of amlexanox (C}_{16}\text{H}_{14}\text{N}_2\text{O}_4) \\ = W_S \times (Q_T/Q_S) \times (1/2) \end{aligned}$$

$W_S$ : Amount (mg) of Amlexanox Reference Standard


**Internal standard solution**—A solution of 3-nitroaniline in the mobile phase (1 in 500).

**Containers and storage** Containers—Tight containers.

### Add the following:

## Amlodipine Besilate

アムロジピンベシル酸塩



$\text{C}_{20}\text{H}_{25}\text{ClN}_2\text{O}_5 \cdot \text{C}_6\text{H}_5\text{O}_3\text{S}$ : 567.05

3-Ethyl 5-methyl (4*RS*)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate monobenzenesulfonate [111470-99-6]

Amlodipine Besilate contains not less than 98.0% and not more than 102.0% of  $\text{C}_{20}\text{H}_{25}\text{ClN}_2\text{O}_5 \cdot \text{C}_6\text{H}_5\text{O}_3\text{S}$ , calculated on the anhydrous basis.

**Description** Amlodipine Besilate occurs as a white to yellowish white crystalline powder.

It is freely soluble in methanol, soluble in ethanol (99.5), and slightly soluble in water.

A solution of Amlodipine Besilate in methanol (1 in 100) shows no optical rotation.

Melting point: about 198°C (with decomposition).

**Identification (1)** Determine the absorption spectrum of a solution of Amlodipine Besilate in 0.01 mol/L hydrochloric acid-methanol TS (1 in 40,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Amlodipine Besilate Reference Standard prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Amlodipine Besilate as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Amlodipine Besilate Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) To 30 mg of Amlodipine Besilate add 0.1 g of sodi-

um nitrate and 0.1 g of anhydrous sodium carbonate, mix, and gradually ignite. After cooling, dissolve the residue in 2 mL of dilute hydrochloric acid and 10 mL of water, filter if necessary, and add barium chloride TS: a white precipitate is formed.

**Purity (1)** Heavy metals <1.07>—Proceed with 1.0 g of Amlodipine Besilate according to Method 4, and perform the test. Prepare the control solution with 2.5 mL of Standard Lead Solution (not more than 25 ppm).

(2) Related substances—Dissolve 0.10 g of Amlodipine Besilate in 50 mL of a mixture of water and acetonitrile (1:1), and use this solution as the sample solution. Pipet 1 mL of the sample solution, and add the mixture of water and acetonitrile (1:1) to make exactly 100 mL. Pipet 3 mL of this solution, add the mixture of water and acetonitrile (1:1) to make exactly 10 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the area of the peak having the relative retention time of 0.90 with respect to amlodipine, obtained from the sample solution is not larger than the peak area of amlodipine from the standard solution, and the area of the peak other than amlodipine, other than benzenesulfonic acid having the relative retention time of about 0.15 with respect to amlodipine, and other than the peak mentioned above is not larger than 1/3 times the peak area of amlodipine from the standard solution. Furthermore, total peak area for peaks other than amlodipine and benzenesulfonic acid of the sample solution is not larger than 2.7 times the peak area of amlodipine from the standard solution.

**Operating conditions**—

Detector: An ultraviolet absorption photometer (wavelength: 237 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (3  $\mu\text{m}$  in particle diameter).

Column temperature: A constant temperature of about 35°C.

Mobile phase A: A mixture of water and trifluoroacetic acid (5000:1).

Mobile phase B: A mixture of acetonitrile and trifluoroacetic acid (5000:1).

Flowing of the mobile phase: Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 30	80→20	20→80
30 – 45	20	80

Flow rate: 1.0 mL per minute.

Time span of measurement: About 3 times as long as the retention time of amlodipine, beginning after the solvent peak.

**System suitability—**

Test for required detectability: Pipet 1 mL of the standard solution, and add a mixture of water and acetonitrile (1:1) to make exactly 10 mL. Confirm that the peak area of amlodipine obtained with 10  $\mu$ L of this solution is equivalent to 7 to 13% of that with 10  $\mu$ L of the standard solution.

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of amlodipine are not less than 70,000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of amlodipine is not more than 2.0%.

(3) Residual solvent—Being specified separately.

**Water** <2.48> Not more than 0.5% (1 g, volumetric titration, direct titration).

**Residue on ignition** <2.44> Not more than 0.2% (1 g).

**Assay** Weigh accurately about 35 mg each of Amlodipine Besilate and Amlodipine Besilate Reference Standard (separately determine the water <2.48> using the same manner as Amlodipine Besilate), dissolve them separately in the mobile phase to make exactly 250 mL. Pipet 5 mL each of these solutions, add exactly 5 mL each of the internal standard solution, add the mobile phase to make 25 mL, and use these solutions as the sample solution and standard solution. Perform the test with 20  $\mu$ L of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of amlodipine to that of the internal standard.

$$\begin{aligned} &\text{Amount (mg) of } C_{20}H_{25}ClN_2O_5 \cdot C_6H_6O_3S \\ &= W_S \times (Q_T / Q_S) \end{aligned}$$

$W_S$ : Amount (mg) of Amlodipine Besilate Reference Standard, calculated on the anhydrous basis

**Internal standard solution**—A solution of isobutyl parahydroxybenzoate in the mobile phase (3 in 20,000).

**Operating conditions—**

Detector: An ultraviolet absorption photometer (wavelength: 237 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: A mixture of methanol and a solution of potassium dihydrogen phosphate (41 in 10,000) (13:7).

Flow rate: Adjust the flow rate so that the retention time of amlodipine is about 8 minutes.

**System suitability—**

System performance: When the procedure is run with 20  $\mu$ L of the standard solution under the above operating conditions, amlodipine and the internal standard are eluted in

this order with the resolution between these peaks being not less than 3.


System repeatability: When the test is repeated 6 times with 20  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of amlodipine to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Well-closed containers.

Storage—Light-resistant.

**Add the following:****Amosulalol Hydrochloride**

アモスラロール塩酸塩



$C_{18}H_{24}N_2O_5 \cdot HCl$ : 416.92

5-((1*RS*)-1-Hydroxy-2-[[2-(2-methoxyphenoxy)ethyl]amino]ethyl)-2-methylbenzenesulfonamide monohydrochloride [70958-86-0]

Amosulalol Hydrochloride contains not less than 98.5% and not more than 101.0% of  $C_{18}H_{24}N_2O_5 \cdot HCl$ , calculated on the anhydrous basis.

**Description** Amosulalol Hydrochloride occurs as white crystals or a white crystalline powder. It has a bitter taste.

It is very soluble in formic acid, freely soluble in methanol, and sparingly soluble in water and in ethanol (99.5).

It is hygroscopic.

A solution of Amosulalol Hydrochloride in methanol (1 in 100) shows no optical rotation.

**Identification (1)** Determine the absorption spectrum of a solution of Amosulalol Hydrochloride (1 in 20,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Amosulalol Hydrochloride as directed in the potassium chloride disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) A solution of Amosulalol Hydrochloride (1 in 100) responds to the Qualitative Tests <1.09> for chloride.

**Melting point** <2.60> 158 – 162°C

**Purity (1)** Heavy metals <1.07>—Place 1.0 g of Amosulalol Hydrochloride in a porcelain crucible, add 1.5 mL of sulfuric acid, cover loosely, and heat gently to carbonize. After cooling, add 2 mL of nitric acid, heat carefully until white fumes no longer are evolved, and then heat intensely to 500 – 600°C to incinerate. After cooling, add 2 mL of hydrochloric acid, proceed according to Method 2, and perform the test. The control solution, processed in the same manner as the test solution using the same amounts of reagents, is prepared by combining 2.0 mL of Standard Lead Solution and water to make 50 mL (not more than 20 ppm).

(2) Related substances—Dissolve 0.10 g of Amosulalol Hydrochloride in 20 mL of the mobile phase, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mobile phase to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area of both solutions by the automatic integration method: the total area of the peaks other than amosulalol obtained from the sample solution is not larger than 2/5 times the peak area of amosulalol from the standard solution.

**Operating conditions**—

Detector: An ultraviolet absorption photometer (wavelength: 272 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 30°C.

Mobile phase: Dissolve 1.36 g of potassium dihydrogen phosphate in water to make 1000 mL, and adjust to pH 5.7 by adding a solution prepared by dissolving 3.58 g of disodium hydrogen phosphate dodecahydrate in water to make 1000 mL. To 670 mL of this solution add 330 mL of acetonitrile.

Flow rate: Adjust the flow rate so that the retention time of amosulalol is about 7 minutes.

Time span of measurement: About 2 times as long as the retention time of amosulalol, beginning after the solvent peak.

**System suitability**—

Test for required detectability: Pipet 1 mL of the standard solution, and add the mobile phase to make exactly 10 mL. Confirm that the peak area of amosulalol obtained with 10  $\mu$ L of this solution is equivalent to 7 to 13% of that with 10  $\mu$ L of the standard solution.

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of amosulalol are not less than 4000 and not more than 1.7, respectively.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of amosulalol is not more than 1.0%.

**Water** <2.48> Not more than 4.0% (1 g, volumetric titration, direct titration).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.6 g of Amosulalol Hydrochloride, dissolve in 3 mL of formic acid, add 80 mL of a mixture of acetic acid (100) and acetic anhydride (3:2), and titrate <2.50> within 5 minutes with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination using the same procedure, and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS  
= 41.69 mg of  $C_{18}H_{24}N_2O_5S.HCl$

**Containers and storage** Containers—Tight containers.

**Add the following:**

## Amosulalol Hydrochloride Tablets

アモスラロール塩酸塩錠

Amosulalol Hydrochloride Tablets contain not less than 95.0% and not more than 105.0% of the labeled amount of amosulalol hydrochloride ( $C_{18}H_{24}N_2O_5S.HCl$ : 416.92).

**Method of preparation** Prepare as directed under Tablets, with Amosulalol Hydrochloride.

**Identification** To a quantity of powdered Amosulalol Hydrochloride Tablets, equivalent to 50 mg of Amosulalol Hydrochloride according to the labeled amount, add 25 mL of 0.1 mol/L hydrochloric acid TS, shake well, and then centrifuge. To 2.5 mL of the supernatant liquid add water to make 100 mL. Determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 270 nm and 274 nm, and a shoulder between 275 nm and 281 nm.

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Take 1 tablet of Amosulalol Hydrochloride Tablets, disintegrate by adding 2 mL of 0.1 mol/L hydrochloric acid TS, add 15 mL of methanol, and shake well. Add methanol to make exactly  $V$  mL so that each mL contains about 0.4 mg of amosulalol hydrochloride ( $C_{18}H_{24}N_2O_5S.HCl$ ), and centrifuge. Pipet 5 mL of the supernatant liquid, add exactly 2 mL of the internal standard solution and the mobile phase to make 20 mL, and use this solution as the sample solution. Separately, weigh accurately about 20 mg of amosulalol hydrochloride for assay (separately determine the water <2.48> in the same manner as Amosulalol Hydrochloride),

and dissolve in methanol to make exactly 50 mL. Pipet 5 mL of this solution, add exactly 2 mL of the internal standard solution, add the mobile phase to make 20 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay.

$$\begin{aligned} & \text{Amount (mg) of amosulalol hydrochloride} \\ & (\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_5\text{S}\cdot\text{HCl}) \\ & = W_S \times (Q_T/Q_S) \times (V/50) \end{aligned}$$

$W_S$ : Amount (mg) of amosulalol hydrochloride for assay, calculated on the anhydrous basis

**Internal standard solution**—A solution of ethyl parahydroxybenzoate in methanol (1 in 6250).

**Dissolution** <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rate in 30 minutes of Amosulalol Hydrochloride Tablets is not less than 75%.

Start the test with 1 tablet of Amosulalol Hydrochloride Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.5  $\mu\text{m}$ . Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, add water to make exactly  $V'$  mL so that each mL contains about 5.5  $\mu\text{g}$  of amosulalol hydrochloride ( $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_5\text{S}\cdot\text{HCl}$ ) according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 22 mg of amosulalol hydrochloride for assay (separately determine the water <2.48> in the same manner as Amosulalol Hydrochloride), and dissolve in water to make exactly 200 mL. Pipet 5 mL of this solution, add water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 50  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the amosulalol peak areas,  $A_T$  and  $A_S$ , of both solutions.

Dissolution rate (%) with respect to the labeled amount of amosulalol hydrochloride ( $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_5\text{S}\cdot\text{HCl}$ )

$$= W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times (45/2)$$

$W_S$ : Amount (mg) of amosulalol hydrochloride for assay, calculated on the anhydrous basis

$C$ : Labeled amount (mg) of amosulalol hydrochloride ( $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_5\text{S}\cdot\text{HCl}$ ) in 1 tablet

**Operating conditions**—

Detector: An ultraviolet absorption photometer (wavelength: 272 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

Column temperature: A constant temperature of about 30°C.

Mobile phase: Dissolve 1.36 g of potassium dihydrogen phosphate in water to make 1000 mL, and adjust to pH 5.7

by adding a solution prepared by dissolving 3.58 g of disodium hydrogen phosphate dodecahydrate in water to make 1000 mL. To 670 mL of this solution add 330 mL of acetonitrile.

Flow rate: Adjust the flow rate so that the retention time of amosulalol is about 5 minutes.

**System suitability**—

System performance: When the procedure is run with 50  $\mu\text{L}$  of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of amosulalol are not less than 4000 and not more than 1.7, respectively.

System repeatability: When the test is repeated 6 times with 50  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the peak area of amosulalol is not more than 1.0%.

**Assay** Take 10 Amosulalol Hydrochloride Tablets, add 20 mL of 0.1 mol/L hydrochloric acid TS, and shake well to disintegrate. Add 120 mL of methanol, again shake well, add methanol to make exactly 200 mL, and then centrifuge. Pipet a volume of supernatant liquid corresponding to about 5 mg of amosulalol hydrochloride ( $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_5\text{S}\cdot\text{HCl}$ ), add exactly 5 mL of the internal standard solution, add the mobile phase to make 50 mL, and use this solution as the sample solution. Separately, weigh accurately about 25 mg of amosulalol hydrochloride for assay (separately determine the water <2.48> in the same manner as Amosulalol Hydrochloride), and dissolve in methanol to make exactly 25 mL. Pipet 5 mL of this solution, add exactly 5 mL of the internal standard solution, add the mobile phase to make 50 mL, and use this solution as the standard solution. Perform the test with 10  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of amosulalol to that of the internal standard.

$$\begin{aligned} & \text{Amount (mg) of amosulalol hydrochloride} \\ & (\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_5\text{S}\cdot\text{HCl}) \\ & = W_S \times (Q_T/Q_S) \times (1/5) \end{aligned}$$

$W_S$ : Amount (mg) of amosulalol hydrochloride for assay, calculated on the anhydrous basis

**Internal standard solution**—A solution of ethyl parahydroxybenzoate in methanol (1 in 6250).

**Operating conditions**—

Detector: An ultraviolet absorption photometer (wavelength: 272 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: A mixture of diluted acetic acid (100) (1 in 25), acetonitrile and a solution of ammonium acetate (1 in 250) (5:3:2).

Flow rate: Adjust the flow rate so that the retention time

of amosulalol is about 4 minutes.

*System suitability*—

**System performance:** When the procedure is run with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, amosulalol and the internal standard are eluted in this order with the resolution between these peaks being not less than 7.

**System repeatability:** When the test is repeated 6 times with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of amosulalol to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

**Add the following:**

## Ampicillin Sodium for Injection

注射用アンピシリンナトリウム

Ampicillin Sodium for Injection is a preparation for injection which is dissolved before use.

It contains not less than 90.0% and not more than 110.0% of the labeled amount of ampicillin ( $\text{C}_{16}\text{H}_{19}\text{N}_3\text{O}_4\text{S}$ : 349.40).

**Method of preparation** Prepare as directed under Injections, with Ampicillin Sodium.

**Description** Ampicillin Sodium for Injection occurs as white to light yellowish white crystals or crystalline powder.

**Identification** Proceed as directed in the Identification (1) under Ampicillin Sodium.

**Osmotic pressure ratio** Being specified separately.

**pH** <2.54> The pH of a solution prepared by dissolving an amount of Ampicillin Sodium for Injection, equivalent to 1.0 g (potency) of Ampicillin Sodium according to the labeled amount, in 10 mL of water is 8.0 to 10.0.

**Purity** Clarity and color of solution—Dissolve an amount of Ampicillin Sodium for Injection, equivalent to 0.25 g (potency) of Ampicillin Sodium according to the labeled amount, in 0.75 mL of water: the solution is clear. Perform the test with the solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: the absorbance at 400 nm is not more than 0.40.

**Water** <2.48> Not more than 3.0% (0.2 g, volumetric titration, direct titration).

**Bacterial endotoxins** <4.01> Less than 0.075 EU/mg (potency).

**Uniformity of dosage units** <6.02> It meets the requirement of the Mass variation test.

**Foreign insoluble matter** <6.06> Perform the test according to Method 2: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Assay** Weigh accurately the mass of the contents of not less than 10 containers of Ampicillin Sodium for Injection. Weigh accurately an amount of a portion of the contents, equivalent to about 50 mg (potency) of Ampicillin Sodium, add exactly 5 mL of the internal standard solution and dissolve. Then add the mobile phase to make 50 mL, and use this solution as the sample solution. Separately, weigh accurately an amount of Ampicillin Reference Standard, equivalent to about 50 mg (potency), add exactly 5 mL of the internal standard solution and dissolve. Then add the mobile phase to make 50 mL, and use this solution as the standard solution. Perform the test with 10  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of ampicillin to that of the internal standard.

$$\begin{aligned} \text{Amount [mg (potency)] of ampicillin (C}_{16}\text{H}_{19}\text{N}_3\text{O}_4\text{S)} \\ = W_S \times (Q_T/Q_S) \end{aligned}$$

$W_S$ : Amount [mg (potency)] of Ampicillin Reference Standard

**Internal standard solution**—A solution of guaifenesin in the mobile phase (1 in 200).

**Operating conditions**—

**Detector:** An ultraviolet absorption photometer (wavelength: 230 nm).

**Column:** A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

**Column temperature:** A constant temperature of about 25°C.

**Mobile phase:** Dissolve 5.94 mg of diammonium hydrogen phosphate in 850 mL of water, add 100 mL of acetonitril, add phosphoric acid to adjust the pH to 5.0, then add water to make exactly 1000 mL.

**Flow rate:** Adjust the flow rate so that the retention time of ampicillin is about 6 minutes.

*System suitability*—

**System performance:** When the procedure is run with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, ampicillin and the internal standard are eluted in this order with the resolution between these peaks being not less than 26.

**System repeatability:** When the test is repeated 6 times with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of ampicillin to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Hermetic containers.



## L-Arginine Hydrochloride Injection

L-アルギニン塩酸塩注射液

**Delete the Pyrogen and add the following next to pH:**

**Bacterial endotoxins** <4.01> Less than 0.50 EU/mL.

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Ascorbic Acid Injection

アスコルビン酸注射液

**Add the following next to pH:**

**Bacterial endotoxins** <4.01> Less than 0.15 EU/mg.

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.


**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Add the following:**

## Azelastine Hydrochloride

アゼラスチン塩酸塩



$C_{22}H_{24}ClN_3O \cdot HCl$ : 418.36

4-[(4-Chlorophenyl)methyl]-2-[(4*R,S*)-(1-methylazepan-4-yl)]phthalazin-1(2*H*)-one monohydrochloride [79307-93-0]

Azelastine Hydrochloride, when dried, contains not less than 99.0% and not more than 101.0% of  $C_{22}H_{24}ClN_3O \cdot HCl$ .

**Description** Azelastine Hydrochloride occurs as a white crystalline powder.

It is freely soluble in formic acid, and slightly soluble in water and in ethanol (99.5).

Melting point: about 225°C (with decomposition).

A solution of Azelastine Hydrochloride (1 in 200) shows no optical rotation.

**Identification** (1) Determine the absorption spectrum of a solution of Azelastine Hydrochloride (3 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Azelastine Hydrochloride as directed in the potassium chloride disk method under Infrared Spectrophotometry <2.25>: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) To 10 mL of a saturated solution of Azelastine Hydrochloride add 1 mL of dilute nitric acid, and filter to separate formed crystals: the filtrate responds to the Qualitative Tests <1.09> (2) for chloride.

**Purity** (1) Heavy metals <1.07>—Proceed with 1.0 g of Azelastine Hydrochloride according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 1.0 g of Azelastine Hydrochloride according to Method 3, and perform the test (not more than 2 ppm).

(3) Related substances—Dissolve 50 mg of Azelastine Hydrochloride in 100 mL of the mobile phase, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area of these solutions by the automatic integration method: each peak area other than azelastine obtained from the sample solution is not larger than 1/10 times the peak area of azelastine from the standard solution, and the total area of the peaks other than the peak of azelastine from the sample solution is not larger than 1/2 times the peak area of azelastine from the standard solution.

**Operating conditions**—

Detector: An ultraviolet absorption photometer (wavelength: 240 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 35°C.

Mobile phase: A mixture of water, acetonitrile and perchloric acid (660:340:1).

Flow rate: Adjust the flow rate so that the retention time of azelastine is about 10 minutes.

Time span of measurement: About 2 times as long as the retention time of azelastine, beginning after the solvent peak.

*System suitability*—

Test for required detectability: Pipet 5 mL of the standard solution, and add the mobile phase to make exactly 50 mL. Confirm that the peak area of azelastine obtained from 20  $\mu$ L of this solution is equivalent to 7 to 13% of that from 20  $\mu$ L of the standard solution.

System performance: When the procedure is run with 20  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of azelastine is not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 20  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of azelastine is not more than 1.0%.

**Loss on drying** <2.41> Not more than 1.0% (1 g, 105 °C, 2 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.6 g of previously dried Azelastine Hydrochloride, dissolve in 5 mL of formic acid, add 70 mL of acetic anhydride, and titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS  
= 41.84 mg of  $C_{22}H_{24}ClN_3O.HCl$

**Containers and storage** Containers—Tight containers.

Storage—Light-resistant.

**Add the following:**

## Aztreonam for Injection

注射用アズトレオナム

Aztreonam for Injection is a preparation for injection which is dissolved before use.

It contains not less than 93.0% and not more than 107.0% of the labeled amount of aztreonam ( $C_{13}H_{17}N_5O_8S_2$ : 435.43).

**Method of preparation** Prepare as directed under Injections, with Aztreonam.

**Description** Aztreonam for Injection is white to yellowish white masses or powder.

**Identification** (1) Dissolve an amount of Aztreonam for Injection, equivalent to 6 mg (potency) of Aztreonam ac-

ording to the labeled amount, in 1 mL of hydroxylammonium chloride-ethanol TS, allow to stand for 3 minutes, add 1 mL of acidic ammonium iron (III) sulfate TS, and mix: a red-brown color develops.

(2) Dissolve an amount of Aztreonam for Injection, equivalent to 3 mg (potency) of Aztreonam according to the labeled amount, in 100 mL of water, and determine the absorption spectrum of the solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 289 nm and 293 nm.

**pH** <2.54> The pH of a solution prepared by dissolving an amount of Aztreonam for Injection, equivalent to 1.0 g (potency) of Aztreonam according to the labeled amount, in 10 mL of water is 4.5 to 7.0.

**Purity** Clarity and color of solution—Dissolve an amount of Aztreonam for Injection, equivalent to 1.0 g (potency) of Aztreonam according to the labeled amount, in 10 mL of water: the solution is clear, and its absorbance <2.24> at 450 nm is not more than 0.06.

**Water** <2.48> Not more than 2.0% (0.5 g, volumetric titration, direct titration).

**Bacterial endotoxins** <4.01> Less than 0.10 EU/mg (potency).

**Uniformity of dosage units** <6.02> It meets the requirement of the Mass variation test.

**Foreign insoluble matter** <6.06> Perform the test according to Method 2: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Assay** Take an amount of Aztreonam for Injection, equivalent to about 5 g (potency) of Aztreonam, dissolve the contents with a suitable amount of water, and transfer to a 100-mL volumetric flask. Wash each container with water, combine the washings and the solution, and add water to make exactly 100 mL. Pipet 10 mL of this solution, and add water to make exactly 50 mL. Pipet 2 mL of this solution, add exactly 10 mL of the internal standard solution and water to make 100 mL, and use this solution as the sample solution. Separately, weigh accurately an amount of Aztreonam Reference Standard, equivalent to about 20 mg (potency), dissolve in a suitable amount of water, add exactly 10 mL of the internal standard solution and water to make 100 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Aztreonam.

Amount [mg (potency)] of aztreonam ( $C_{13}H_{17}N_5O_8S_2$ )  
=  $W_s \times (Q_T/Q_S) \times 250$

$W_s$ : Amount [mg (potency)] of Aztreonam Reference Standard

*Internal standard solution*—A solution of 4-aminobenzoic acid (1 in 6250).

**Containers and storage** Containers—Hermetic containers.  
Storage—Light-resistant.

## Baclofen Tablets

バクロフェン錠

### Add the following next to Identification:

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Baclofen Tablets add 5 mL of 0.1 mol/L hydrochloric acid TS, disperse the tablet into small particles with the aid of ultrasonic waves, then shake for 10 minutes, and add 0.1 mol/L hydrochloric acid TS to make exactly  $V$  mL so that each mL contains about 0.5 mg of baclofen ( $C_{10}H_{12}ClNO_2$ ). Centrifuge, pipet 5 mL of the supernatant liquid, add 2 drops of phenolphthalein TS, neutralize with dilute sodium hydroxide TS, then add water to make exactly 50 mL, and use this solution as the sample solution. Separately, weigh accurately about 25 mg of Baclofen Reference Standard (separately determine the water <2.48> in the same manner as Baclofen), and dissolve in 0.1 mol/L hydrochloric acid TS to make exactly 50 mL. Pipet 5 mL of this solution, add 2 drops of phenolphthalein TS, neutralize with dilute sodium hydroxide TS, then add water to make exactly 50 mL, and use this solution as the standard solution. To exactly 2 mL each of the sample solution and standard solution add 4 mL of ninhydrin-tin (II) chloride TS, mix, heat on a water bath for 20 minutes, then immediately shake vigorously for 2 minutes. After cooling, add a mixture of water and 1-propanol (1:1) to make them exactly 25 mL, and determine the absorbances,  $A_T$  and  $A_S$ , of them at 570 nm as directed under Ultraviolet-visible Spectrophotometry <2.24>, using a solution obtained with 2 mL of water by the same procedure as above as the blank.

$$\begin{aligned} \text{Amount (mg) of baclofen (C}_{10}\text{H}_{12}\text{ClNO}_2\text{)} \\ = W_S \times (A_T/A_S) \times (V/50) \end{aligned}$$

$W_S$ : Amount (mg) of Baclofen Reference Standard, calculated on the anhydrous basis

### Add the following:

## Benzylpenicillin Potassium for Injection

注射用ベンジルペニシリンカリウム

Benzylpenicillin Potassium for Injection is a preparation for injection which is dissolved before use.

It contains not less than 93.0% and not more than 107.0% of the labeled amount of benzylpenicillin potassium ( $C_{16}H_{17}KN_2O_4S$ : 372.48).

**Method of preparation** Prepare as directed under Injections, with Benzylpenicillin Potassium.

**Description** Benzylpenicillin Potassium for Injection occurs as white crystals or crystalline powder.

**Identification** Proceed as directed in the Identification (2) under Benzylpenicillin Potassium.

**Osmotic pressure ratio** Being specified separately.

**pH** <2.54> The pH of a solution prepared by dissolving an amount of Benzylpenicillin Potassium for Injection, equivalent to  $1.0 \times 10^5$  Units of Benzylpenicillin Potassium according to the labeled amount, in 10 mL of water is 5.0 to 7.5.

**Purity** Clarity and color of solution—A solution prepared by dissolving an amount of Benzylpenicillin Potassium for Injection, equivalent to  $1.0 \times 10^6$  Units of Benzylpenicillin Potassium according to the labeled amount, in 10 mL of water is clear. Perform the test with this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: the absorbance at 400 nm is not more than 0.10.

**Loss on drying** <2.41> Not more than 1.2% (3 g, in vacuum, below 0.67 kPa, 60°C, 3 hours).

**Bacterial endotoxins** <4.01> Less than  $1.25 \times 10^{-4}$  EU/Unit.

**Uniformity of dosage units** <6.02> It meets the requirement of the Mass variation test.

**Foreign insoluble matter** <6.06> Perform the test according to Method 2: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Assay** Weigh accurately the mass of the contents of not less than 10 containers of Benzylpenicillin Potassium for Injection. Weigh accurately an amount of a portion of the contents, equivalent to about  $6 \times 10^4$  Units of Benzylpenicillin Potassium, dissolve in water to make exactly 20 mL, and use this solution as the sample solution. Separately, weigh accurately an amount of Benzylpenicillin Potassium Reference Standard, equivalent to about  $6 \times 10^4$  Units, dissolve in water to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 5  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine the peak area of benzylpenicillin,  $A_T$  and  $A_S$ , from each solution.

$$\begin{aligned} \text{Amount (unit) of Benzylpenicillin Potassium} \\ (\text{C}_{16}\text{H}_{17}\text{KN}_2\text{O}_4\text{S}) \\ = W_S \times (A_T/A_S) \end{aligned}$$

$W_S$ : Amount (unit) of Benzylpenicillin Potassium Reference Standard

**Operating conditions—**

**Detector:** An ultraviolet absorption photometer (wavelength: 254 nm).

**Column:** A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (7  $\mu$ m in particle diameter).

**Column temperature:** A constant temperature of about 25°C.

**Mobile phase:** To a mixture of diammonium hydrogen phosphate solution (33 in 5000) and acetonitril (19:6), add phosphoric acid to adjust the pH of this solution to 8.0.

**Flow rate:** Adjust the flow rate so that the retention time of benzylpenicillin is about 7.5 minutes.

**System suitability—**

**System performance:** When the procedure is run with 5  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of benzylpenicillin are not less than 6000 and not more than 2.0, respectively.

**System repeatability:** When the test is repeated 6 times with 5  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of benzylpenicillin is not more than 1.0%.

**Containers and storage** Containers—Hermetic containers.

## Betahistine Mesilate

ベタヒスチンメシル酸塩


**Change the Identification (3) to read:**

**Identification (3)** A 30 mg portion of Betahistine Mesilate responds to the Qualitative Tests <1.09> (2) for mesilate.

**Add the following:**

## Biotin

ビオチン



$C_{10}H_{16}N_2O_3S$ : 244.31

5-[(3a*S*,4*S*,6a*R*)-2-Oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl]pentanoic acid [58-85-5]

Biotin, when dried, contains not less than 98.5% and not more than 101.0% of  $C_{10}H_{16}N_2O_3S$ .

**Description** Biotin occurs as white crystals or a white crystalline powder.

It is very slightly soluble in water and in ethanol (99.5).

It dissolves in dilute sodium hydroxide TS.

Melting point: about 231°C (with decomposition).

**Identification** Determine the infrared absorption spectrum of Biotin as directed in the potassium bromide disc method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Optical rotation** <2.49>  $[\alpha]_D^{20}$ : +89 – +93° (after drying, 0.4 g, dilute sodium hydroxide TS, 20 mL, 100 mm).

**Purity (1)** Clarity and color of solution—Dissolve 1.0 g of Biotin in 10 mL of 0.5 mol/L sodium hydroxide TS: the solution is clear and colorless.

(2) Heavy metals <1.07>—Proceed with 2.0 g of Biotin according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(3) Arsenic <1.11>—Place 0.7 g of Biotin in a Kjeldahl flask, add 5 mL of nitric acid and 2 mL of sulfuric acid, place a small funnel on the mouth of the flask, and carefully heat until white fumes are evolved. After cooling, add 2 mL of nitric acid twice, heat, add 2 mL of hydrogen peroxide (30) several times, and heat until the color of the solution becomes colorless or pale yellow. After cooling, add 2 mL of saturated ammonium oxalate solution, and heat to concentrate until white fumes are evolved again. After cooling, add water to make 5 mL, and perform the test using this solution as the test solution (not more than 2.8 ppm).

(4) Related substances—Dissolve 0.10 g of Biotin in 10 mL of diluted ammonia solution (28) (7 in 100), and use this solution as the sample solution. Pipet 1 mL of this solution, and add diluted ammonia solution (28) (7 in 100) to make exactly 100 mL. Pipet 10 mL of this solution, add diluted ammonia solution (28) (7 in 100) to make exactly 50 mL, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of 1-butanol, water, and acetic acid (100) (5:2:1) to a distance of about 10 cm, air-dry the plate, and then dry for 30 minutes at 105°C. Spray the plate evenly with a mixture of a solution of 4-dimethylaminocinnamaldehyde in ethanol (99.5) (1 in 500) and a solution of sulfuric acid in ethanol (99.5) (1 in 50) (1:1): the spots other than the principal spot obtained from the sample solution are not more intense than the spot from the standard solution.

**Loss on drying** <2.41> Not more than 0.5% (0.5 g, 105°C, 4 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.25 g of Biotin, previously dried, dissolve by adding exactly 20 mL of 0.1 mol/L sodium hydroxide VS, and titrate <2.50> the excess sodium hydroxide with 0.1 mol/L hydrochloric acid VS (indicator: 2 drops of phenolphthalein TS). Perform a blank determination in the same manner.

Each mL of 0.1 mol/L sodium hydroxide VS  
= 24.43 mg of  $C_{10}H_{16}N_2O_3S$

**Containers and storage** Containers—Tight containers.

## Bisacodyl Suppositories

ビスコジル坐剤

### Add the following next to Identification:

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 suppository of Bisacodyl Suppositories add tetrahydrofuran to make a solution containing about 0.2 mg of bisacodyl (C<sub>22</sub>H<sub>19</sub>NO<sub>4</sub>) in each mL, warm to 40°C, and shake to dissolve. After cooling, add tetrahydrofuran to make exactly *V* mL so that each mL contains about 10 μg of bisacodyl (C<sub>22</sub>H<sub>19</sub>NO<sub>4</sub>). Pipet 5 mL of this solution, and proceed as directed in the Assay.

$$\begin{aligned} &\text{Amount (mg) of bisacodyl (C}_{22}\text{H}_{19}\text{NO}_4) \\ &= W_S \times (Q_T/Q_S) \times (V/50) \end{aligned}$$


*W<sub>S</sub>*: Amount (mg) of Bisacodyl Reference Standard

**Internal standard solution**—A solution of ethyl parahydroxybenzoate in acetonitrile (3 in 100,000).

### Add the following:

## Bisoprolol Fumarate

ビソプロロール fumarate 酸塩



(C<sub>18</sub>H<sub>31</sub>NO<sub>4</sub>)<sub>2</sub>·C<sub>4</sub>H<sub>4</sub>O<sub>4</sub>; 766.96  
(2*RS*)-1-(4-{[2-(1-Methylethoxy)ethoxy]methyl}phenoxy)-3-[(1-methylethyl)amino]propan-2-ol hemifumarate  
[104344-23-2]

Bisoprolol Fumarate, when dried, contains not less than 98.5% and not more than 101.0% of (C<sub>18</sub>H<sub>31</sub>NO<sub>4</sub>)<sub>2</sub>·C<sub>4</sub>H<sub>4</sub>O<sub>4</sub>.

**Description** Bisoprolol Fumarate occurs as white crystals or a white crystalline powder.

It is very soluble in water and in methanol, and freely soluble in ethanol (99.5) and in acetic acid (100).

A solution of Bisoprolol Fumarate (1 in 10) shows no optical rotation.

**Identification** (1) Determine the absorption spectrum of a solution of Bisoprolol Fumarate in methanol (1 in 10,000) as directed under Ultraviolet-visible Spectrophotometry

<2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Bisoprolol Fumarate as directed in the potassium bromide disc method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Melting point** <2.60> 101 – 105°C

**Purity** (1) Heavy metals <1.07>—Proceed with 2.0 g of Bisoprolol Fumarate according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Related substances—Dissolve 50 mg of Bisoprolol Fumarate in 100 mL of a mixture of water and acetonitrile (4:1), and use this solution as the sample solution. Pipet 1 mL of this solution, add the mixture of water and acetonitrile (4:1) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area of both solutions by the automatic integration method: the area of the peaks other than bisoprolol obtained from the sample solution is not larger than 1/2 times the peak area of bisoprolol from the standard solution. Furthermore, the total of the areas of all peaks other than bisoprolol from the sample solution is not larger than the peak area of bisoprolol from the standard solution.

**Operating conditions**—

**Detector:** An ultraviolet absorption photometer (wavelength: 225 nm).

**Column:** A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

**Column temperature:** A constant temperature of about 40°C.

**Mobile phase:** Dissolve 4.08 g of potassium dihydrogen phosphate in 1000 mL of water, and adjust to pH 2.5 with phosphoric acid. To 800 mL of this solution add 200 mL of acetonitrile.

**Flow rate:** Adjust the flow rate so that the retention time of bisoprolol is about 8 minutes.

**Time span of measurement:** About 2 times as long as the retention time of bisoprolol, beginning after the fumaric acid peak.

**System suitability**—

**Test for required detectability:** Pipet 2 mL of the standard solution, and add a mixture of water and acetonitrile (4:1) to make exactly 20 mL. Confirm that the peak area of bisoprolol obtained from 20 μL of this solution is equivalent to 7 to 13% of that from 20 μL of the standard solution.

**System performance:** When the procedure is run with 20 μL of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of bisoprolol are not less than 5000 and

not more than 1.5, respectively.

**System repeatability:** When the test is repeated 6 times with 20  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the peak area of bisoprolol is not more than 1.5%.

**Loss on drying** <2.41> Not more than 0.5% (1 g, in vacuum, phosphorus (V) oxide, 80°C, 5 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.6 g of Bisoprolol Fumarate, previously dried, dissolve in 70 mL of acetic acid (100), and titrate <2.50> with 0.1 mol/L perchloric acid VS (indicator: 2 drops of crystal violet TS). The endpoint of titration is when the purple color of the solution turns blue and then blue-green. Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS  
= 38.35 mg of  $(\text{C}_{18}\text{H}_{31}\text{NO}_4)_2 \cdot \text{C}_4\text{H}_4\text{O}_4$

**Containers and storage** Containers—Tight containers.

### Add the following:

## Bisoprolol Fumarate Tablets

ビソプロロール fumarate 錠

Bisoprolol Fumarate Tablets contain not less than 95.0% and not more than 105.0% of the labeled amount of bisoprolol fumarate [ $(\text{C}_{18}\text{H}_{31}\text{NO}_4)_2 \cdot \text{C}_4\text{H}_4\text{O}_4$ ; 766.96].

**Method of preparation** Prepare as directed under Tablets, with Bisoprolol Fumarate.

**Identification** To a quantity of powdered Bisoprolol Fumarate Tablets, equivalent to 10 mg of Bisoprolol Fumarate according to the labeled amount, add 60 mL of methanol, shake vigorously for 10 minutes, add methanol to make 100 mL, and filter through a membrane filter with a pore size not exceeding 0.45  $\mu\text{m}$ . Determine the absorption spectrum of the filtrate as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 271 nm and 275 nm.

**Uniformity of dosage units** <6.02>—Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Take 1 tablet of Bisoprolol Fumarate Tablets, disintegrate by adding 8 mL of water, and add water to make exactly 10 mL, and then filter through a membrane filter with a pore size not exceeding 0.45  $\mu\text{m}$ . Discard the first 3 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, add water to make exactly  $V'$  mL so that each mL contains about 0.1 mg of bisoprolol fumarate [ $(\text{C}_{18}\text{H}_{31}\text{NO}_4)_2 \cdot \text{C}_4\text{H}_4\text{O}_4$ ], and use as the sample solution. Separately, weigh accurately about 20 mg of bisoprolol fumarate for assay, previously dried under reduced pressure at 80°C for 5 hours, using phosphorus (V)

oxide as a desiccant, dissolve in water to make exactly 200 mL, and use as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , of the sample solution and standard solution at 271.5 nm as directed under Ultraviolet-visible Spectrophotometry <2.24>.

Amount (mg) of bisoprolol fumarate [ $(\text{C}_{18}\text{H}_{31}\text{NO}_4)_2 \cdot \text{C}_4\text{H}_4\text{O}_4$ ]  
=  $W_S \times (A_T/A_S) \times (V'/V) \times (1/20)$

$W_S$ : Amount (mg) of bisoprolol fumarate for assay

**Dissolution** <6.10>—When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of 2nd fluid for dissolution test as the dissolution medium, the dissolution rate in 30 minutes of Bisoprolol Fumarate Tablets is not less than 85%.

Start the test with 1 tablet of Bisoprolol Fumarate Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45  $\mu\text{m}$ . Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, add the dissolution medium to make exactly  $V'$  mL so that each mL contains about 2.8  $\mu\text{g}$  of bisoprolol fumarate [ $(\text{C}_{18}\text{H}_{31}\text{NO}_4)_2 \cdot \text{C}_4\text{H}_4\text{O}_4$ ] according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 14 mg of bisoprolol fumarate for assay, previously dried in vacuum at 80°C for 5 hours using phosphorus (V) oxide as a desiccant, and dissolve in the dissolution medium to make exactly 100 mL. Pipet 2 mL of this solution, add the dissolution medium to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 50  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the bisoprolol peak areas,  $A_T$  and  $A_S$ , of both solutions.

Dissolution rate (%) with respect to the labeled amount of bisoprolol fumarate [ $(\text{C}_{18}\text{H}_{31}\text{NO}_4)_2 \cdot \text{C}_4\text{H}_4\text{O}_4$ ]

=  $W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 18$

$W_S$ : Amount (mg) of bisoprolol fumarate for assay

$C$ : Labeled amount (mg) of bisoprolol fumarate [ $(\text{C}_{18}\text{H}_{31}\text{NO}_4)_2 \cdot \text{C}_4\text{H}_4\text{O}_4$ ] in 1 tablet

**Operating conditions**—

Detector, column, column temperature, and flow rate: Proceed as directed in the operating conditions in the Assay.

Mobile phase: Dissolve 4.08 g of potassium dihydrogen phosphate in 1000 mL of water, and adjust to pH 2.5 with phosphoric acid. To 750 mL of this solution add 250 mL of acetonitrile.

**System suitability**—

System performance: When the procedure is run with 50  $\mu\text{L}$  of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of bisoprolol are not less than 3000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 50  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the peak

area of bisoprolol is not more than 2.0%.

**Assay** Weigh accurately not less than 20 Bisoprolol Fumarate Tablets and powder. Weigh accurately a portion of the powder, equivalent to about 20 mg of bisoprolol fumarate  $[(C_{18}H_{31}NO_4)_2 \cdot C_4H_4O_4]$ , add exactly 70 mL of a mixture of water and acetonitrile (3:1) and exactly 10 mL of the internal standard solution, shake vigorously for 10 minutes, and add the mixture of water and acetonitrile (3:1) to make 100 mL. Filter this solution through a membrane filter with a pore size not exceeding  $0.45 \mu\text{m}$ , discard the first 3 mL of the filtrate, and use the subsequent filtrate as the sample solution. Separately, weigh accurately about 20 mg of bisoprolol fumarate for assay, previously dried in vacuum at  $80^\circ\text{C}$  for 5 hours using phosphorus (V) oxide as the desiccant, add exactly 10 mL of the internal standard solution, dissolve in the mixture of water and acetonitrile (3:1) to make 100 mL, and use this solution as the standard solution. Perform the test with  $20 \mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of bisoprolol to that of the internal standard.

Amount (mg) of bisoprolol fumarate  $[(C_{18}H_{31}NO_4)_2 \cdot C_4H_4O_4]$   
 $= W_S \times (Q_T/Q_S)$

$W_S$ : Amount (mg) of bisoprolol fumarate for assay

**Internal standard solution**—A solution of isopropyl parahydroxybenzoate in the mixture of water and acetonitrile (3:1) (1 in 250).

**Operating conditions**—

**Detector**: An ultraviolet absorption photometer (wavelength: 225 nm).

**Column**: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octylsilanized silica gel for liquid chromatography ( $5 \mu\text{m}$  in particle diameter).

**Column temperature**: A constant temperature of about  $40^\circ\text{C}$ .

**Mobile phase**: Dissolve 4.08 g of potassium dihydrogen phosphate in 1000 mL of water, and adjust to pH 2.5 with phosphoric acid. To 800 mL of this solution add 200 mL of acetonitrile.

**Flow rate**: Adjust the flow rate so that the retention time of bisoprolol is about 8 minutes.

**System suitability**—

**System performance**: When the procedure is run with  $20 \mu\text{L}$  of the standard solution under the above operating conditions, fumaric acid, bisoprolol and the internal standard are eluted in this order with the resolution between the peaks of bisoprolol and the internal standard being not less than 12.

**System repeatability**: When the test is repeated 6 times with  $20 \mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of bisoprolol to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

**Add the following:**

## Bucillamine Tablets

ブシラミン錠

Bucillamine Tablets contain not less than 95.0% and not more than 105.0% of the labeled amount of bucillamine ( $C_7H_{13}NO_3S_2$ ; 223.31).

**Method of preparation** Prepare as directed under Tablets, with Bucillamine.

**Identification (1)** To a quantity of powdered Bucillamine Tablets, equivalent to 0.1 g of Bucillamine according to the labeled amount, add 0.1 g of sodium hydrogen carbonate and 10 mL of water, shake well, filter, and add 1 or 2 drops of ninhydrin TS to the filtrate: it exhibits a red-brown color.

**(2)** To a quantity of powdered Bucillamine Tablets, equivalent to 0.1 g of Bucillamine according to the labeled amount, add 25 mL of water, shake well, and filter. To 5 mL of the filtrate, add 2 mL of dilute sodium hydroxide TS and 1 or 2 drops of sodium pentacyanonitrosylferrate (III) TS: it exhibits a red-purple color.

**Uniformity of dosage units** <6.02>—Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Store the sample solution and standard solution in a cold place until performing the measurements. Take 1 tablet of Bucillamine Tablets, add exactly 1 mL of the internal standard solution per 0.1 g of bucillamine ( $C_7H_{13}NO_3S_2$ ), then add 3 mL of water and 6 mL of methanol per 0.1 g of bucillamine ( $C_7H_{13}NO_3S_2$ ), and stir well until the tablet completely disintegrated. To 1 mL of this solution add the mobile phase to make 25 mL, filter through a membrane filter with a pore size not exceeding  $0.45 \mu\text{m}$ , and use the filtrate as the sample solution. Then, proceed as directed in the Assay.

Amount (mg) of bucillamine ( $C_7H_{13}NO_3S_2$ )  
 $= W_S \times (Q_T/Q_S) \times C \times (1/200)$

$W_S$ : Amount (mg) of bucillamine for assay

$C$ : Labeled amount (mg) of bucillamine ( $C_7H_{13}NO_3S_2$ ) in 1 tablet

**Internal standard solution**—A solution of 4-fluorobenzoic acid in methanol (1 in 100).

**Dissolution** <6.10>—When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rate in 30 minutes of Bucillamine Tablets is not less than 80%.

Store the sample solution and standard solution in a cold place until performing the measurements. Start the test with 1 tablet of Bucillamine Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding  $0.45 \mu\text{m}$ . Discard the first 10 mL of the filtrate, and use the subsequent filtrate as the sample solution. Separately, weigh accurately an amount of bucillamine

for assay equivalent to the labeled amount of the tablet, previously dried in vacuum at 60°C for 6 hours using phosphorus (V) oxide as a desiccant, and dissolve in methanol to make exactly 10 mL. Pipet 1 mL of this solution, add water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the bucillamine peak areas,  $A_T$  and  $A_S$ , of both solutions.

Dissolution rate (%) with respect to the labeled amount of bucillamine ( $C_7H_{13}NO_3S_2$ )

$$= W_S \times (A_T/A_S) \times (1/C) \times 90$$

$W_S$ : Amount (mg) of bucillamine for assay

$C$ : Labeled amount (mg) of bucillamine ( $C_7H_{13}NO_3S_2$ ) in 1 tablet

#### Operating conditions—

Detector, column, and column temperature: Proceed as directed in the operating conditions in the Assay.

Mobile phase: A mixture of diluted phosphoric acid (1 in 1000) and methanol (11:9).

Flow rate: Adjust the flow rate so that the retention time of bucillamine is about 4 minutes.

#### System suitability—

System performance: When the procedure is run with 20  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of bucillamine are not less than 3000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 20  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of bucillamine is not more than 2.0%.

**Assay** Store the sample solution and standard solution in a cold place until performing the measurements. Take 10 tablets of Bucillamine Tablets, add exactly 1 mL of the internal standard solution per 0.1 g of bucillamine ( $C_7H_{13}NO_3S_2$ ), add 3 mL of water and 6 mL of methanol, and stir well until the tablets completely disintegrated. To 1 mL of this solution add the mobile phase to make 25 mL, filter through a membrane filter with a pore size not exceeding 0.45  $\mu$ m, and use this solution as the sample solution. Separately, weigh accurately about 0.2 g of bucillamine for assay, previously dried in vacuum for 6 hours at 60°C using phosphorus (V) oxide as a desiccant, add exactly 2 mL of the internal standard solution, and add 6 mL of water and 12 mL of methanol. To 1 mL of this solution add 25 mL of the mobile phase, filter through a membrane filter with a pore size not exceeding 0.45  $\mu$ m, and use this solution as the standard solution. Perform the test with 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of bucillamine to that of the internal standard.

$$\begin{aligned} &\text{Amount (mg) of bucillamine (} C_7H_{13}NO_3S_2 \text{)} \\ &= W_S \times (Q_T/Q_S) \times C \times (1/200) \end{aligned}$$

$W_S$ : Amount (mg) of bucillamine for assay

$C$ : Labeled amount (mg) of bucillamine ( $C_7H_{13}NO_3S_2$ ) in 1 tablet

**Internal standard solution**—A solution of 4-fluorobenzoic acid in methanol (1 in 100).

#### Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of diluted phosphoric acid (1 in 1000) and methanol (3:2).

Flow rate: Adjust the flow rate so that the retention time of bucillamine is about 5 minutes.

#### System suitability—

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, bucillamine and the internal standard are eluted in this order with the resolution between these peaks being not less than 3.


System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of bucillamine to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

### Add the following:

## Buformin Hydrochloride

ブホルミン塩酸塩



$C_6H_{15}N_5 \cdot HCl$ : 193.68

1-Butylbiguanide hydrochloride [1190-53-0]

Buformin Hydrochloride, when dried, contains not less than 98.5% and not more than 101.0% of  $C_6H_{15}N_5 \cdot HCl$ .

**Description** Buformin Hydrochloride occurs as a white crystalline powder.

It is freely soluble in water and in ethanol (99.5).

**Identification (1)** To 5 mL of a solution of Buformin Hydrochloride (1 in 2000) add 1 mL of dilute sodium pentacyanonitrosylferrate (III)-potassium hexacyanoferrate



(III) TS: a red-brown color develops.

(2) Determine the absorption spectrum of a solution of Buformin Hydrochloride (1 in 125,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(3) Determine the infrared absorption spectrum of Buformin Hydrochloride as directed in the potassium chloride disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

(4) A solution of Buformin Hydrochloride (1 in 20) responds to the Qualitative Tests <1.09> for chlorides.

**Melting point** <2.60> 175 – 180°C

**Purity** (1) Heavy metals <1.07>—Proceed with 1.0 g of Buformin Hydrochloride according to Method 1, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 1.0 g of Buformin Hydrochloride according to Method 1, and perform the test (not more than 2 ppm).

(3) Related substances—Dissolve 0.10 g of Buformin Hydrochloride in 200 mL of the mobile phase, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area of both solutions by the automatic integration method: the area of the peak other than buformin obtained from the sample solution is not larger than 1/5 times the peak area of buformin from the standard solution. Furthermore, the total of the areas of all peaks other than the buformin peak from the sample solution is not larger than 1/2 times the peak area of buformin from the standard solution.

**Operating conditions**—

**Detector:** An ultraviolet absorption photometer (wavelength: 230 nm).

**Column:** A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

**Column temperature:** A constant temperature of about 35°C.

**Mobile phase:** A mixture of a solution of sodium perchlorate monohydrate in diluted phosphoric acid (1 in 1000) (7 in 250) and acetonitrile (7:1).

**Flow rate:** Adjust the flow rate so that the retention time of buformin is about 6 minutes.

**Time span of measurement:** About 2 times as long as the retention time of buformin, beginning after the solvent peak.

**System suitability**—

Test for required detectability: Pipet 1 mL of the standard

solution, and add the mobile phase to make exactly 10 mL. Confirm that the peak area of buformin obtained from 10  $\mu$ L of this solution is equivalent to 7 to 13% of that from 10  $\mu$ L of the standard solution.

**System performance:** When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of buformin are not less than 5000 and not more than 2.0, respectively.

**System repeatability:** When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of buformin is not more than 1.0%.

**Loss on drying** <2.41> Not more than 0.5% (1 g, 105°C, 3 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.15 g of Buformin Hydrochloride, previously dried, dissolve in 50 mL of a mixture of acetic anhydride and acetic acid (100) (7:3), and immediately titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS  
= 9.684 mg of  $C_6H_{15}N_5.HCl$

**Containers and storage** Containers—Tight containers.

**Add the following:**

## Buformin Hydrochloride Enteric-coated Tablets

ブホルミン塩酸塩腸溶錠

Buformin Hydrochloride Enteric-coated Tablets contain not less than 93.0% and not more than 107.0% of the labeled amount of buformin hydrochloride ( $C_6H_{15}N_5.HCl$ : 193.68).

**Method of preparation** Prepare as directed under Tablets, with Buformin Hydrochloride.

**Identification** To a quantity of powdered Buformin Hydrochloride Enteric-coated Tablets, equivalent to 0.1 g of Buformin Hydrochloride according to the labeled amount, add 10 mL of water, shake well, and then filter. To 4 mL of the filtrate add 1 mL of a mixture of hydrogen peroxide TS, sodium pentacyanonitrosylferrate (III) TS and a solution of sodium hydroxide (1 in 10) (2:1:1): the solution exhibits a red to red-purple color.

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Buformin Hydrochloride Enteric-coated Tablets add 5 mL of a mixture of ethanol (99.5) and acetone

(1:1), disperse the pellicle to smaller using ultrasonic waves, add exactly 10 mL of the internal standard solution per 50 mg of buformin hydrochloride ( $C_6H_{15}N_5.HCl$ ), and then add diluted acetonitrile (1 in 2) to make  $13V/20$  mL. Disintegrate the tablet using ultrasonic waves, then shake for 20 minutes, and add diluted acetonitrile (1 in 2) to make a solution, volume  $V$  mL, containing about 0.5 mg of buformin hydrochloride ( $C_6H_{15}N_5.HCl$ ) per mL. Centrifuge this solution, pipet 1 mL of the supernatant liquid, and add the mobile phase to make 50 mL. If necessary, filter this solution through a membrane filter with a pore size not exceeding  $0.5 \mu m$ , and use the filtrate as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} &\text{Amount (mg) of buformin hydrochloride } (C_6H_{15}N_5.HCl) \\ &= W_S \times (Q_T/Q_S) \times (V/50) \end{aligned}$$

$W_S$ : Amount (mg) of buformin hydrochloride for assay

*Internal standard solution*—A solution of *p*-acetanisidide in diluted acetonitrile (1 in 2) (1 in 150).

**Dissolution** <6.10> When the tests are performed at 50 revolutions per minute according to the Paddle method, using 900 mL each of 1st fluid for dissolution test and 2nd fluid for dissolution test as the dissolution medium, the dissolution rate in 120 minutes of Buformin Hydrochloride Enteric-coated Tablets using the 1st fluid is not more than 5%, and that in 90 minutes of Buformin Hydrochloride Enteric-coated Tablets using the 2nd fluid is not less than 80%.

Start the test with 1 tablet of Buformin Hydrochloride Enteric-coated Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding  $0.5 \mu m$ . Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, add the relevant dissolution medium to make exactly  $V'$  mL so that each mL contains about  $56 \mu g$  of buformin hydrochloride ( $C_6H_{15}N_5.HCl$ ) according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 28 mg of buformin hydrochloride for assay, previously dried at  $105^\circ C$  for 3 hours, and dissolve in the relevant dissolution medium to make exactly 100 mL. Pipet 4 mL of this solution, add the relevant dissolution medium to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly  $20 \mu L$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the buformin peak areas,  $A_T$  and  $A_S$ , of both solutions.

Dissolution rate (%) with respect to the labeled amount of buformin hydrochloride ( $C_6H_{15}N_5.HCl$ )

$$= W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 180$$

$W_S$ : Amount (mg) of buformin hydrochloride for assay

$C$ : Labeled amount (mg) of buformin hydrochloride ( $C_6H_{15}N_5.HCl$ ) in 1 tablet

*Operating conditions*—

Detector: An ultraviolet absorption photometer (wavelength: 230 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography ( $5 \mu m$  in particle diameter).

Column temperature: A constant temperature of about  $35^\circ C$ .

Mobile phase: A mixture of a solution of sodium perchlorate in diluted phosphoric acid (1 in 1000) (7 in 500) and acetonitrile (7:1).

Flow rate: Adjust the flow rate so that the retention time of buformin is about 6 minutes.

*System suitability*—

System performance: When the procedure is run with  $20 \mu L$  of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of buformin are not less than 3000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with  $20 \mu L$  of the standard solution under the above operating conditions, the relative standard deviation of the peak area of buformin is not more than 2.0%.

**Assay** Add 20 mL of a mixture of ethanol (99.5) and acetone (1:1) to an amount of Buformin Hydrochloride Enteric-coated Tablets equivalent to 0.5 g of buformin hydrochloride ( $C_6H_{15}N_5.HCl$ ), disperse the pellicles to smaller using ultrasonic waves, and then add 100 mL of diluted acetonitrile (1 in 2). Disintegrate the tablets with the aid of ultrasonic waves, shake for 20 minutes, and then add diluted acetonitrile (1 in 2) to make exactly 200 mL. Centrifuge this solution, pipet 10 mL of the supernatant liquid, add exactly 5 mL of the internal standard solution, and then add diluted acetonitrile (1 in 2) to make 50 mL. Pipet 1 mL of this solution, and add the mobile phase to make 50 mL. If necessary, filter this solution through a membrane filter with a pore size not exceeding  $0.5 \mu m$ , and use the filtrate as the sample solution. Separately, weigh accurately about 25 mL of buformin hydrochloride for assay, previously dried at  $105^\circ C$  for 3 hours, dissolve in an adequate amount of diluted acetonitrile (1 in 2), add exactly 5 mL of the internal standard solution, and then add diluted acetonitrile (1 in 2) to make 50 mL. To 1 mL of this solution add the mobile phase to make 50 mL, and use this solution as the standard solution. Perform the test with  $10 \mu L$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of buformin to that of the internal standard.

$$\begin{aligned} &\text{Amount (mg) of buformin hydrochloride } (C_6H_{15}N_5.HCl) \\ &= W_S \times (Q_T/Q_S) \times 20 \end{aligned}$$

$W_S$ : Amount (mg) of buformin hydrochloride for assay

*Internal standard solution*—A solution of *p*-acetanisidide in diluted acetonitrile (1 in 2) (1 in 150).

*Operating conditions*—

Detector: An ultraviolet absorption photometer (wavelength: 233 nm).

Column: A stainless steel column 4.6 mm in inside di-

ameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

Column temperature: A constant temperature of about 35°C.

Mobile phase: A mixture of a solution of sodium perchlorate (7 in 250) and acetonitrile (7:1).

Flow rate: Adjust the flow rate so that the retention time of buformin is about 7 minutes.

*System suitability*—

System performance: When the procedure is run with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, buformin and the internal standard are eluted in this order with the resolution between these peaks being not less than 5.

System repeatability: When the test is repeated 6 times with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of buformin to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Well-closed containers.

**Add the following:**

## Buformin Hydrochloride Tablets

ブホルミン塩酸塩錠

Buformin Hydrochloride Tablets contain not less than 95.0% and not more than 105.0% of the labeled amount of buformin hydrochloride ( $\text{C}_6\text{H}_{15}\text{N}_5\cdot\text{HCl}$ ; 193.68).

**Method of preparation** Prepare as directed under Tablets, with Buformin Hydrochloride.

**Identification** To a quantity of powdered Buformin Hydrochloride Tablets, equivalent to 1 g of Buformin Hydrochloride according to the labeled amount, add 100 mL of water, shake well, and then filter. To 4 mL of the filtrate add 1 mL of dilute sodium pentacyanonitrosylferrate (III)-potassium hexacyanoferrate (III) TS: the solution exhibits a red-brown color.

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Take 1 tablet of Buformin Hydrochloride Tablets, add water to make exactly 200 mL, and then treat with ultrasonic waves for 5 minutes. Take 40 mL of this solution and centrifuge. Pipet  $V$  mL of the supernatant liquid equivalent to about 0.5 mg of buformin hydrochloride ( $\text{C}_6\text{H}_{15}\text{N}_5\cdot\text{HCl}$ ), add water to make exactly 100 mL, and use this solution as the sample solution. Separately, weigh accurately about 50 mg of buformin hydrochloride for assay, previously dried at 105°C for 3 hours, and dissolve in water to make exactly 200 mL. Pipet 2 mL of this solution, add water to make exactly

100 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , of the sample solution and standard solution at 233 nm as directed under Ultraviolet-visible Spectrophotometry <2.24>.

$$\begin{aligned} \text{Amount (mg) of buformin hydrochloride } (\text{C}_6\text{H}_{15}\text{N}_5\cdot\text{HCl}) \\ = W_S \times (A_T/A_S) \times (2/V) \end{aligned}$$

$W_S$ : Amount (mg) of buformin hydrochloride for assay

**Dissolution** <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rate in 15 minutes of Buformin Hydrochloride Tablets is not less than 80%.

Start the test with 1 tablet of Buformin Hydrochloride Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.5  $\mu\text{m}$ . Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, and add water to make exactly  $V'$  mL so that each mL contains about 5.6  $\mu\text{g}$  of buformin hydrochloride ( $\text{C}_6\text{H}_{15}\text{N}_5\cdot\text{HCl}$ ) according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 28 mg of buformin hydrochloride for assay, previously dried at 105°C for 3 hours, and dissolve in water to make exactly 100 mL. Pipet 2 mL of this solution, add water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>, and determine the absorbances,  $A_T$  and  $A_S$ , at 233 nm.

Dissolution rate (%) with respect to the labeled amount of buformin hydrochloride ( $\text{C}_6\text{H}_{15}\text{N}_5\cdot\text{HCl}$ )

$$= W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 18$$

$W_S$ : Amount (mg) of buformin hydrochloride for assay

$C$ : Labeled amount (mg) of buformin hydrochloride ( $\text{C}_6\text{H}_{15}\text{N}_5\cdot\text{HCl}$ ) in 1 tablet

**Assay** Weigh accurately not less than 20 Buformin Hydrochloride Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 60 mg of buformin hydrochloride ( $\text{C}_6\text{H}_{15}\text{N}_5\cdot\text{HCl}$ ), add water to make exactly 200 mL, and treat with ultrasonic waves for 5 minutes. Take 40 mL of this solution, centrifuge, pipet 2 mL of the supernatant liquid, add water to make exactly 100 mL, and use this solution as the sample solution. Separately, weigh accurately about 60 mg of buformin hydrochloride for assay, previously dried at 105°C for 3 hours, and dissolve in water to make exactly 200 mL. Pipet 2 mL of this solution, add water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>, and determine the absorbances,  $A_T$  and  $A_S$ , at 233 nm.

$$\begin{aligned} \text{Amount (mg) of buformin hydrochloride } (\text{C}_6\text{H}_{15}\text{N}_5\cdot\text{HCl}) \\ = W_S \times (A_T/A_S) \end{aligned}$$


$W_S$ : Amount (mg) of buformin hydrochloride for assay

**Containers and storage** Containers—Well-closed containers.

**Add the following:**

## Buprenorphine Hydrochloride

ブプレノルフィン塩酸塩



$C_{29}H_{41}NO_4 \cdot HCl$ : 504.10

(2*S*)-2-[(5*R*,6*R*,7*R*,14*S*)-17-(Cyclopropylmethyl)-4,5-epoxy-3-hydroxy-6-methoxy-6,14-ethanomorphinan-7-yl]-3,3-dimethylbutan-2-ol monohydrochloride [53152-21-9]

Buprenorphine Hydrochloride, when dried, contains not less than 98.5% and not more than 101.0% of  $C_{29}H_{41}NO_4 \cdot HCl$ .

**Description** Buprenorphine Hydrochloride occurs as white to yellowish white, crystals or a crystalline powder.

It is freely soluble in methanol and in acetic acid (100), and sparingly soluble in water and in ethanol (99.5).

Melting point: about 268°C (with decomposition).

**Identification (1)** Determine the absorption spectrum of a solution of Buprenorphine Hydrochloride (1 in 5000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Buprenorphine Hydrochloride as directed in the potassium chloride disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) A solution of Buprenorphine Hydrochloride (1 in 100) responds to the Qualitative Tests <1.09> for chloride.

**Optical rotation** <2.49>  $[\alpha]_D^{20}$ :  $-92$  –  $-98^\circ$  (after drying, 0.4 g, methanol, 20 mL, 100 mm).

**pH** <2.54> The pH of a solution prepared by dissolving 1.0 g of Buprenorphine Hydrochloride in 200 mL of water is between 4.0 and 6.0.

**Purity (1)** Clarity and color of solution—A solution obtained by dissolving 0.1 g of Buprenorphine Hydrochloride in 10 mL of water is clear and colorless.

(2) Heavy metals <1.07>—Proceed with 1.0 g of Buprenorphine Hydrochloride according to Method 4, and perform the test. Prepare the control solution with 1.0 mL of Standard Lead Solution (not more than 10 ppm).

(3) Related substances—Dissolve 0.10 g of Buprenor-

phine Hydrochloride in 20 mL of the mobile phase, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area of both solutions by the automatic integration method: the area of each peak other than buprenorphine obtained from the sample solution is not larger than 1/4 times the peak area of buprenorphine from the standard solution. Furthermore, the total area of the peaks other than buprenorphine from the sample solution is not larger than 13/20 times the peak area of buprenorphine from the standard solution.

**Operating conditions**—

**Detector:** An ultraviolet absorption photometer (wavelength: 288 nm).

**Column:** A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

**Column temperature:** A constant temperature of about 40°C.

**Mobile phase:** A mixture of methanol, ammonium acetate solution (1 in 100), and acetic acid (100) (6000:1000:1).

**Flow rate:** Adjust the flow rate so that the retention time of buprenorphine is about 17 minutes.

**Time span of measurement:** About 2.5 times as long as the retention time of buprenorphine, beginning after the solvent peak.

**System suitability**—

**Test for required detectability:** Pipet 5 mL of the standard solution, and add the mobile phase to make exactly 50 mL. Confirm that the peak area of buprenorphine obtained from 20  $\mu$ L of this solution is equivalent to 7 to 13% of that from 20  $\mu$ L of the standard solution.

**System performance:** When the procedure is run with 20  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of buprenorphine are not less than 6500 and not more than 1.2, respectively.

**System repeatability:** When the test is repeated 6 times with 20  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of buprenorphine is not more than 2.0%.

**Loss on drying** <2.41> Not more than 1.0% (1 g, 115°C, 3 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.5 g of Buprenorphine Hydrochloride, previously dried, dissolve in 5 mL of acetic acid (100), add 50 mL of acetic anhydride, and titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS  
= 50.41 mg of  $C_{29}H_{41}NO_4 \cdot HCl$

**Containers and storage** Containers—Well-closed containers.

## Calcium Chloride Injection

塩化カルシウム注射液

### Add the following next to Extractable volume:

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Calcium Folate

ホリナートカルシウム

### Change the Description and the Identification to read:

**Description** Calcium Folate occurs as a white to light yellow, crystalline powder.

It is sparingly soluble in water, and practically insoluble in methanol and in ethanol (99.5).

**Identification** (1) Determine the absorption spectrum of a solution of Calcium Folate (1 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Calcium Folate Reference Standard prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Calcium Folate as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) A solution of Calcium Folate (1 in 100) responds to the Qualitative Tests <1.09> (2) and (3) for calcium salt.

### Add the following next to Identification:

**Optical rotation** <2.49>  $[\alpha]_D^{20}$ : +14 – +19° (0.1 g calculated on the anhydrous basis, water, 10 mL, 100 mm).

**pH** <2.54> To 1.25 g of Calcium Folate add 50 mL of freshly boiled and cooled water, and warm to 40°C, if necessary, to dissolve: the pH of this solution is between 6.8 and 8.0.

### Change the Purity to read:

**Purity** (1) Clarity and color of solution—To 1.25 g of Calcium Folate add 50 mL of freshly boiled and cooled water, and warm to 40°C, if necessary, to dissolve: the solution is clear, and the absorbance at 420 nm of it, determined as directed under Ultraviolet-visible Spectrophotometry <2.24>, is not more than 0.25.

(2) Heavy metals <1.07>—Proceed with 0.40 g of Calcium Folate according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 50 ppm).

(3) Related substances—Dissolve 10 mg of Calcium Folate in 25 mL of water, and use this solution as the sample solution. Pipet 2 mL of the sample solution, add water to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 20  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the area of the peak other than folinate obtained from the sample solution is not larger than the peak area of folinate from the standard solution, and the total area of the peaks other than the peak of folinate from the sample solution is not larger than 5 times the peak area of folinate from the standard solution.

*Operating conditions*—

Detector, column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay.

Time span of measurement: About 2.5 times as long as the retention time of folinate, beginning after the solvent peak.

*System suitability*—

Test for required detectability: Pipet 5 mL of the standard solution, and add water to make exactly 50 mL. Confirm that the peak area of folinate obtained from 20  $\mu$ L of this solution is equivalent to 7 to 13% of that from 20  $\mu$ L of the standard solution.

System performance: Proceed as directed in the system suitability in the Assay.

System repeatability: When the test is repeated 6 times with 20  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of folinate is not more than 2.0%.

### Change the Water to read:

**Water** <2.48> Not less than 7.0% and not more than 17.0% (0.2 g, volumetric titration, direct titration).

### Change the Assay to read:

**Assay** Weigh accurately about 10 mg each of Calcium Folate and Calcium Folate Reference Standard (separately determine the water <2.48> in the same manner as Calcium Folate), dissolve in water to make them exactly 25 mL. Pipet 5 mL each of these solutions, add the mobile phase to make exactly 25 mL, and use these solutions as the sample solution and the standard solution, respectively. Per-

form the test with exactly 20  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of folinate of both solutions.

$$\begin{aligned} &\text{Amount (mg) of } \text{C}_{20}\text{H}_{21}\text{CaN}_7\text{O}_7 \\ &= W_S \times (A_T/A_S) \end{aligned}$$

$W_S$ : Amount (mg) of Calcium Folate Reference Standard, calculated on the anhydrous basis

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

Column temperature: A constant temperature of about 45°C.

Mobile phase: A mixture of disodium hydrogen phosphate dodecahydrate solution (287 in 100,000), methanol and tetrabutylammonium hydroxide TS (385:110:4), adjusted to pH7.5 with phosphoric acid.

Flow rate: Adjust the flow rate so that the retention time of folinate is about 10 minutes.

*System suitability—*

System performance: Dissolve 10 mg each of Calcium Folate and folic acid in 100 mL of the mobile phase. When the procedure is run with 20  $\mu\text{L}$  of this solution under the above operating conditions, folinate and folic acid are eluted in this order with the resolution between these peaks being not less than 10.

System repeatability: When the test is repeated 6 times with 20  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the peak area of folinate is not more than 1.0%.

## Camostat Mesilate

カモスタットメシル酸塩

**Change the Identification (3) to read:**

**Identification (3)** A 0.1 g portion of Camostat Mesilate responds to the Qualitative Tests <1.09> (1) for mesilate.

**Add the following:**

## Cefadroxil Capsules

セファドロキシルカプセル

Cefadroxil Capsules contain not less than 95.0% and not more than 105.0% of the labeled amount of cefadroxil ( $\text{C}_{16}\text{H}_{17}\text{N}_3\text{O}_5\text{S}$ : 363.39).

**Method of preparation** Prepare as directed under Capsules, with Cefadroxil.

**Identification** Dissolve the contents of Cefadroxil Capsules, equivalent to 10 mg (potency) of Cefadroxil according to the labeled amount, in 500 mL of water, and filter. Determine the absorption spectrum of the filtrate as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 228 nm and 232 nm, and between 261 nm and 265 nm.

**Water <2.48>** Not more than 7.0% (0.15 g, volumetric titration, direct titration).

**Uniformity of dosage units <6.02>** Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Place 1 capsule of Cefadroxil Capsules in 300 mL of water, disperse with the aid of ultrasonic waves, shake for 30 minutes, and add water to make exactly 500 mL. Pipet 5 mL of this solution, and add water to make exactly  $V$  mL so that each mL contains about 0.1 mg (potency) of Cefadroxil. Filter the solution, discard the first 10 mL of the filtrate, and use the subsequent filtrate as the sample solution. Separately, weigh accurately about 20 mg (potency) of Cefadroxil Reference Standard, dissolve in water to make exactly 200 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Cefadroxil.

$$\begin{aligned} &\text{Amount [mg (potency)] of cefadroxil } (\text{C}_{16}\text{H}_{17}\text{N}_3\text{O}_5\text{S}) \\ &= W_S \times (A_T/A_S) \times (V/2) \end{aligned}$$

$W_S$ : Amount [mg (potency)] of Cefadroxil Reference Standard

**Dissolution <6.10>** When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of 0.05 mol/L acetic acid-sodium acetate buffer solution, pH 4.0 as the dissolution medium, the dissolution rate in 90 minutes of Cefadroxil Capsules is not less than 80%.

Start the test with 1 capsule of Cefadroxil Capsules, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45  $\mu\text{m}$ . Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, add water to make exactly  $V'$  mL so that each mL contains about 22  $\mu\text{g}$  (potency) of Cefadroxil according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 22 mg (potency) of Cefadroxil Reference Standard, and add water to make exactly 100 mL. Pipet 5 mL of this solution, add water to

make exactly 50 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , at 263 nm of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>, using water as the blank.

Dissolution rate (%) with respect to the labeled amount of cefadroxil ( $C_{16}H_{17}N_3O_5S$ )

$$= W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 90$$

$W_S$ : Amount [mg (potency)] of Cefadroxil Reference Standard

$C$ : Labeled amount [mg (potency)] of cefadroxil in 1 capsule

**Assay** Take out the contents of 20 Cefadroxil Capsules, and combine. Weigh accurately the mass of the combined contents, and powder. Weigh accurately a portion of the powder, equivalent to about 50 mg (potency) of Cefadroxil, add 300 mL of water, shake for 30 minutes, then add water to make exactly 500 mL, and filter. Discard the first 10 mL of the filtrate, and use the subsequent filtrate as the sample solution. Separately, weigh accurately an amount of Cefadroxil Reference Standard, equivalent to about 20 mg (potency), dissolve in water to make exactly 200 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Cefadroxil.

$$\begin{aligned} &\text{Amount [mg (potency)] of cefadroxil } (C_{16}H_{17}N_3O_5S) \\ &= W_S \times (A_T/A_S) \times (5/2) \end{aligned}$$

$W_S$ : Amount [mg (potency)] of Cefadroxil Reference Standard

**Containers and storage** Containers—Tight containers.

### Add the following:

## Cefadroxil for Syrup

シロップ用セファドロキシル

Cefadroxil for Syrup is a preparation for syrup which is suspended before use.

It contains not less than 95.0% and not more than 110.0% of the labeled amount of cefadroxil ( $C_{16}H_{17}N_3O_5S$ ; 363.39).

**Method of preparation** Prepare as directed under Syrups, with Cefadroxil.

**Identification** Dissolve an amount of Cefadroxil for Syrup, equivalent to 10 mg (potency) of Cefadroxil according to the labeled amount, in 500 mL of water, and determine the absorption spectrum of the solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 228 nm and 232 nm, and between 261 nm and 265 nm.

**Water** <2.48> Not more than 3.0% (0.5 g, volumetric titration, direct titration).

**Uniformity of dosage units** <6.02> The syrup in single-unit container meets the requirement of the Mass variation test.

**Dissolution** <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method (put the sample in the dissolution medium so that it disperses), using 900 mL of water as the dissolution medium, the dissolution rate in 15 minutes of Cefadroxil for Syrup is not less than 85 %.

Start the test with accurately weighed amount of Cefadroxil for Syrup, equivalent to about 0.1 g (potency) of Cefadroxil according to the labeled amount, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45  $\mu$ m. Discard the first 10 mL of the filtrate, pipet 4 mL of the subsequent filtrate, add water to make exactly 20 mL, and use this solution as the sample solution. Separately, weigh accurately about 22 mg (potency) of Cefadroxil Reference Standard, and dissolve in water to make exactly 100 mL. Pipet 5 mL of this solution, add water to make exactly 50 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , at 263 nm of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>.

Dissolution rate (%) with respect to the labeled amount of cefadroxil ( $C_{16}H_{17}N_3O_5S$ )

$$= (W_S/W_T) \times (A_T/A_S) \times (1/C) \times 450$$

$W_S$ : Amount [mg (potency)] of Cefadroxil Reference Standard

$W_T$ : Amount (g) of sample

$C$ : Labeled amount [mg (potency)] of cefadroxil in 1 g

**Assay** Weigh accurately an amount of powdered Cefadroxil for Syrup, equivalent to about 50 mg (potency) of Cefadroxil, dissolve in water to make exactly 500 mL, and use this solution as the sample solution. Separately, weigh accurately an amount of Cefadroxil Reference Standard, equivalent to about 20 mg (potency), dissolve in water to make exactly 200 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Cefadroxil.

$$\begin{aligned} &\text{Amount [mg (potency)] of cefadroxil } (C_{16}H_{17}N_3O_5S) \\ &= W_S \times (A_T/A_S) \times (5/2) \end{aligned}$$

$W_S$ : Amount [mg (potency)] of Cefadroxil Reference Standard

**Containers and storage** Containers—Tight containers.

## Cefalotin Sodium

セファロチンナトリウム

### **Change the origin/limits of content to read:**

Cefalotin Sodium contains not less than 920  $\mu\text{g}$  (potency) and not more than 980  $\mu\text{g}$  (potency) per mg, calculated on the anhydrous basis. The potency of Cefalotin Sodium is expressed as mass (potency) of cefalotin ( $\text{C}_{16}\text{H}_{16}\text{N}_2\text{O}_6\text{S}_2$ ; 396.44).

## Cefatrizine Propylene Glycolate

セファトリジンプロピレングリコール

### **Change the origin/limits of content to read:**

Cefatrizine Propylene Glycolate contains not less than 816  $\mu\text{g}$  (potency) and not more than 876  $\mu\text{g}$  (potency) per mg, calculated on the anhydrous basis. The potency of Cefatrizine Propylene Glycolate is expressed as mass (potency) of cefatrizine ( $\text{C}_{18}\text{H}_{18}\text{N}_6\text{O}_5\text{S}_2$ ; 462.50).

### **Add the following:**

## Cefazolin Sodium for Injection

注射用セファゾリンナトリウム

Cefazolin Sodium for Injection is a preparation for injection which is dissolved before use.

It contains not less than 90.0% and not more than 110.0% of the labeled amount of cefazolin ( $\text{C}_{14}\text{H}_{14}\text{N}_8\text{O}_4\text{S}_3$ ; 454.51).

**Method of preparation** Prepare as directed under Injections, with Cefazolin Sodium.

**Description** Cefazolin Sodium for Injection occurs as white to light yellowish white crystals or crystalline powder or masses.

**Identification (1)** Determine the absorption spectrum of a solution of Cefazolin Sodium for Injection (1 in 50,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>; it exhibits a maximum between 270 nm and 274 nm.

(2) Cefazolin Sodium for Injection responds to the Qualitative Tests <1.09> (1) for chloride.

**Osmotic pressure ratio** Being specified separately.

**pH <2.54>** The pH of a solution prepared by dissolving an amount of Cefazolin Sodium for Injection, equivalent to 1.0 g (potency) of Cefazolin Sodium according to the labeled amount, in 10 mL of water is 4.5 to 6.5.

**Purity (1)** Clarity and color of solution—Conduct this procedure within 10 minutes after the preparation of the solutions. A solution prepared by dissolving an amount of Cefazolin Sodium for Injection, equivalent to 1.0 g (potency) of Cefazolin Sodium according to the labeled amount, in 10 mL of water is clear, and the absorbance of this solution at 400 nm, determined as directed under Ultraviolet-visible Spectrophotometry <2.24>, is not more than 0.35.

(2) Related substances—Dissolve an amount of Cefazolin Sodium for Injection, equivalent to 0.10 g (potency) of Cefazolin Sodium according to the labeled amount, in 20 mL of 0.1 mol/L phosphate buffer solution, pH 7.0, and use this solution as the sample solution. Prepare the sample solution before use. Perform the test with 5  $\mu\text{L}$  of the sample solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method. Calculate the amount of each peak by the area percentage method: each area of the peaks other than cefazolin is not more than 1.5%. Furthermore the total area of the peaks other than cefazolin is not more than 2.5%. For these calculations, use the area of the peak, having the relative retention time of about 0.2 with respect to cefazolin, after multiplying by the relative response factor, 1.43.

**Operating conditions—**

Detector, column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay under Cefazolin Sodium.

Time span of measurement: About 3 times as long as the retention time of cefazolin, beginning after the solvent peak.

**System suitability—**

Test for required detectability: Pipet 8 mL of the sample solution, add 0.1 mol/L phosphate buffer solution, pH 7.0 to make exactly 50 mL, and use this solution as the solution for system suitability test. Pipet 1 mL of the solution for system suitability test, add 0.1 mol/L phosphate buffer solution, pH 7.0 to make exactly 20 mL. Confirm that the peak area of cefazolin obtained from 5  $\mu\text{L}$  of this solution is equivalent to 3 to 7% of that from 5  $\mu\text{L}$  of the solution for system suitability test.

System performance: Proceed as directed in the system suitability in the Assay under Cefazolin Sodium.

System repeatability: When the test is repeated 6 times with 5  $\mu\text{L}$  of the solution for system suitability test under the above operating conditions, the relative standard deviation of the peak area of cefazolin is not more than 1.0%.

**Water <2.48>** Not more than 3.0% (0.5 g, volumetric titration, direct titration). Use a mixture of formamide for Karl Fischer method and methanol for Karl Fischer method (2:1) instead of methanol for Karl Fischer method.

**Bacterial endotoxins <4.01>** Less than 0.05 EU/mg (potency).

**Uniformity of dosage units <6.02>** It meets the requirement of the Mass variation test.

**Foreign insoluble matter <6.06>** Perform the test according to Method 2: it meets the requirement.



**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Assay** Weigh accurately the mass of the contents of not less than 10 containers of Cefazolin Sodium for Injection. Weigh accurately an amount of the contents, equivalent to about 50 mg (potency) of Cefazolin Sodium, dissolve in the internal standard solution to make exactly 50 mL, and use this solution as the sample solution. Separately, weigh accurately an amount of Cefazolin Reference Standard, equivalent to about 50 mg (potency), dissolve in the internal standard solution to make exactly 50 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Cefazolin Sodium.

$$\begin{aligned} &\text{Amount [mg (potency)] of cefazolin (C}_{14}\text{H}_{14}\text{N}_8\text{O}_4\text{S}_3) \\ &= W_S \times (Q_T/Q_S) \end{aligned}$$

$W_S$ : Amount [mg (potency)] of Cefazolin Reference Standard

**Internal standard solution**—A solution of *p*-acetanisidide in 0.1 mol/L phosphate buffer solution, pH 7.0 (11 in 20,000).

**Containers and storage** Containers—hermetic containers. Plastic containers for aqueous injections may be used.

### Add the following:

## Cefmetazole Sodium for Injection

注射用セフメタゾールナトリウム

Cefmetazole Sodium for Injection is a preparation for injection which is dissolved before use.

It contains not less than 90.0% and not more than 110.0% of the labeled amount of cefmetazole (C<sub>15</sub>H<sub>17</sub>N<sub>7</sub>O<sub>5</sub>S<sub>3</sub>: 471.53).

**Method of preparation** Prepare as directed under Injections, with Cefmetazole Sodium.

**Description** Cefmetazole Sodium for Injection is a white to light yellow powder or masses.

It is hygroscopic.

**Identification (1)** Determine the absorption spectrum of a solution of Cefmetazole Sodium for Injection (1 in 40,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

**(2)** Determine the infrared absorption spectrum of Cefmetazole Sodium for Injection as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**pH** <2.54> Take an amount of Cefmetazole Sodium for Injection equivalent to 1.0 g (potency) of Cefmetazole Sodium according to the labeled amount, and dissolve in 10 mL of water: the pH of the solution is 4.2 to 6.2.

**Purity (1)** Clarity and color of solution—Dissolve an amount of Cefmetazole Sodium for Injection, equivalent to 1.0 g (potency) of Cefmetazole Sodium according to the labeled amount, in 10 mL of water: the solution is clear and the color is not darker than the following control solution.

Control solution: Pipet 5 mL of Iron (III) Chloride Colorimetric Stock Solution and 0.5 mL of Cobalt (II) Chloride Colorimetric Stock Solution, and add water to make exactly 50 mL. Pipet 15 mL of this solution, and add water to make exactly 20 mL.

**(2)** Related substances—Proceed as directed in the Purity (4) under Cefmetazole Sodium.

**Bacterial endotoxins** <4.01> Less than 0.06 EU/mg (potency).

**Uniformity of dosage units** <6.02> It meets the requirement of the Mass variation test.

**Foreign particulate matter** <6.06> Perform the test according to Method 2: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Assay** Take 10 containers of Cefmetazole Sodium for Injection, dissolve the contents of each in the mobile phase, rinse each of the containers with the mobile phase, combine the rinse with the respective previous solution, and add the mobile phase to make exactly 500 mL. Take exactly a volume of this solution equivalent to about 0.2 g (potency) of Cefmetazole Sodium, and add the mobile phase to make exactly 100 mL. Pipet 1 mL of this solution, add exactly 10 mL of the internal standard solution, and use this solution as the sample solution. Separately, weigh accurately an amount of Cefmetazole Reference Standard, equivalent to about 50 mg (potency), and dissolve in the mobile phase to make exactly 25 mL. Pipet 1 mL of this solution, add exactly 10 mL of the internal standard solution, and use this solution as the standard solution. Then, proceed as directed in the Assay under Cefmetazole Sodium.

$$\begin{aligned} &\text{Amount [mg (potency)] of cefmetazole (C}_{15}\text{H}_{17}\text{N}_7\text{O}_5\text{S}_3) \\ &= W_S \times (Q_T/Q_S) \times 4 \end{aligned}$$

$W_S$ : Amount [mg (potency)] of Cefmetazole Reference Standard

**Internal standard solution**—A solution of methyl parahydroxybenzoate in the mobile phase (1 in 10,000).

**Containers and storage** Containers—Hermetic containers. Plastic containers for aqueous injections may be used.

**Add the following:****Ceftazidime for Injection**

注射用セフトアジジム

Ceftazidime for Injection is a preparation for injection which is dissolved before use.

It contains not less than 93.0% and not more than 107.0% of the labeled amount of ceftazidime (C<sub>22</sub>H<sub>22</sub>N<sub>6</sub>O<sub>7</sub>S<sub>2</sub>: 546.58).

**Method of preparation** Prepare as directed under Injections, with Ceftazidime Hydrate.

**Description** Ceftazidime for Injection is a white to pale yellowish white powder.

**Identification** Determine the absorption spectrum of a solution of Ceftazidime for Injection (1 in 100,000) in phosphate buffer solution, pH 6.0, as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 255 nm and 259 nm.

**pH** <2.54> Dissolve an amount of Ceftazidime for Injection, equivalent to 1.0 g (potency) of Ceftazidime Hydrate according to the labeled amount, in 10 mL of water: the pH of this solution is 5.8 to 7.8.

**Purity** Clarity and color of solution—Dissolve 5 g of disodium hydrogen phosphate and 1 g of potassium dihydrogen phosphate in water to make 100 mL. In 10 mL of this solution dissolve an amount of Ceftazidime for Injection, equivalent to 1.0 g (potency) of Ceftazidime Hydrate according to the labeled amount: the solution is clear and colorless. Also, determine the absorption spectra of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: the absorbance at 420 nm is not more than 0.3.

**Loss on drying** <2.41> Not more than 14.0% (0.1 g, in vacuum not exceeding 0.67 kPa, 60°C, 3 hours).

**Bacterial endotoxins** <4.01> Less than 0.067 EU/mg (potency).

**Uniformity of dosage units** <6.02> It meets the requirement of the Mass variation test.

**Foreign insoluble matter** <6.06> Perform the test according to Method 2: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filter method: it meets the requirement.

**Assay** Weigh accurately the mass of the contents of not less than 10 containers of Ceftazidime for Injection. Weigh accurately an amount of Ceftazidime Hydrate, equivalent to about 0.25 g (potency), and dissolve in 0.05 mol/L phosphate buffer solution, pH 7.0, to make exactly 250 mL. Pipet 10 mL of this solution, add exactly 5 mL of the internal standard solution, add more 0.05 mol/L phosphate

buffer solution, pH 7.0, to make 50 mL, and use this solution as the sample solution. Separately, weigh accurately an amount of Ceftazidime Reference Standard, equivalent to about 25 mg (potency), and dissolve in 0.05 mol/L phosphate buffer solution, pH 7.0, to make exactly 25 mL. Pipet 10 mL of this solution, add exactly 5 mL of the internal standard solution, then add 0.05 mol/L phosphate buffer solution, pH 7.0, to make 50 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Ceftazidime Hydrate.

$$\begin{aligned} &\text{Amount [mg (potency)] of ceftazidime (C}_{22}\text{H}_{22}\text{N}_6\text{O}_7\text{S}_2) \\ &= W_S \times (Q_T/Q_S) \times 10 \end{aligned}$$


W<sub>S</sub>: Amount [mg(potency)] of Ceftazidime Reference Standard

**Internal standard solution**—A solution of dimedon in 0.05 mol/L phosphate buffer solution, pH 7.0 (11 in 10,000).

**Containers and storage** Containers—Hermetic containers. Storage—Light-resistant.

**Add the following:****Cetirizine Hydrochloride**

セチリジン塩酸塩

C<sub>21</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>3</sub>·2HCl: 461.812-(2-[4-[(*RS*)-(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy)acetic acid dihydrochloride [83881-52-1]

Cetirizine Hydrochloride, when dried, contains not less than 99.0% and not more than 101.0% of C<sub>21</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>3</sub>·2HCl.

**Description** Cetirizine Hydrochloride occurs as a white crystalline powder.

It is very soluble in water, and slightly soluble in ethanol (99.5).

It dissolves in 0.1 mol/L hydrochloric acid TS.

A solution of Cetirizine Hydrochloride (1 in 10) shows no optical rotation.

**Identification (1)** Determine the absorption spectrum of a solution of Cetirizine Hydrochloride in 0.1 mol/L hydrochloric acid TS (1 in 50,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

**(2)** Determine the infrared absorption spectrum of Cetirizine Hydrochloride as directed in the potassium chloride disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum:

both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) A solution of Cetirizine Hydrochloride (1 in 100) responds to the Qualitative Tests <1.09> for chloride.

**Purity (1)** Heavy metals <1.07>—Proceed with 2.0 g of Cetirizine Hydrochloride according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Related substances—Dissolve 0.10 g of Cetirizine Hydrochloride in 50 mL of the mobile phase, and use this solution as the sample solution. Pipet 2 mL of the sample solution, add the mobile phase to make exactly 50 mL. Pipet 5 mL of this solution, add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area of each solution by the automatic integration method: the area of each peak other than cetirizine obtained from the sample solution is not larger than the peak area of cetirizine from the standard solution. Furthermore, the total area of the peaks other than cetirizine from the sample solution is not larger than 2.5 times the peak area of cetirizine from the standard solution.

**Operating conditions—**

Detector: An ultraviolet absorption photometer (wavelength: 230 nm).

Column: A stainless steel column 4.0 mm in inside diameter and 25 cm in length, packed with silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: A mixture of acetonitrile and diluted 0.5 mol/L sulfuric acid TS (2 in 25) (47:3).

Flow rate: Adjust the flow rate so that the retention time of cetirizine is about 9 minutes.

Time span of measurement: About 3 times as long as the retention time of cetirizine, beginning after the solvent peak.

**System suitability—**

Test for required detectability: Pipet 5 mL of the standard solution, and add the mobile phase to make exactly 10 mL. Confirm that the peak area of cetirizine obtained from 10  $\mu$ L of this solution is equivalent to 35 to 65% of that from 10  $\mu$ L of the standard solution.

System performance: Dissolve 20 mg of Cetirizine Hydrochloride in the mobile phase to make 100 mL. To 5 mL of this solution, add 3 mL of a solution of aminopyrine in the mobile phase (1 in 2500), and add the mobile phase to make 20 mL. When the procedure is run with 10  $\mu$ L of this solution under the above operating conditions, cetirizine and aminopyrine are eluted in this order with the resolution between these peaks being not less than 7.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of cetirizine is not more than 2.0%.

**Loss on drying <2.41>** Not more than 0.5% (1 g, in vacu-

um, 60°C, 3 hours).

**Residue on ignition <2.44>** Not more than 0.2% (1 g).

**Assay** Weigh accurately about 0.1 g of Cetirizine Hydrochloride, previously dried, dissolve in 70 mL of a mixture of acetone and water (7:3), and titrate <2.50> to the second equivalence point with 0.1 mol/L sodium hydroxide VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L sodium hydroxide VS  
= 15.39 mg of  $C_{21}H_{25}ClN_2O_3 \cdot 2HCl$

**Containers and storage** Containers—Well-closed containers.

**Add the following:**

## Cetirizine Hydrochloride Tablets

セチリジン塩酸塩錠

Cetirizine Hydrochloride Tablets contain not less than 95.0% and not more than 105.0% of the labeled amount of cetirizine hydrochloride ( $C_{21}H_{25}ClN_2O_3 \cdot 2HCl$ ; 461.81).

**Method of preparation** Prepare as directed under Tablets, with Cetirizine Hydrochloride.

**Identification** To a quantity of powdered Cetirizine Hydrochloride Tablets, equivalent to 10 mg of Cetirizine Hydrochloride according to the labeled amount, add about 70 mL of 0.1 mol/L hydrochloric acid TS, shake, add 0.1 mol/L hydrochloric acid TS to make 100 mL, and filter. To 4 mL of the filtrate add 0.1 mol/L hydrochloric acid TS to make 25 mL, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 230 nm and 234 nm.

**Uniformity of dosage units <6.02>** Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Take 1 tablet of Cetirizine Hydrochloride Tablets, add 4V/5 mL of sodium 1-heptanesulfonate solution (1 in 5000) adjusted to pH 3.0 with 0.5 mol/L sulfuric acid TS, treat with ultrasonic waves for 20 minutes, adjust the volume to exactly V mL, by adding sodium 1-heptanesulfonate solution (1 in 5000) adjusted to pH 3.0 with 0.5 mol/L sulfuric acid TS, so that each mL contains about 0.2 mg of cetirizine hydrochloride ( $C_{21}H_{25}ClN_2O_3 \cdot 2HCl$ ), and filter through a membrane filter with a pore size not exceeding 0.45  $\mu$ m. Discard the first 3 mL of the filtrate, pipet 5 mL of the subsequent filtrate, add exactly 2 mL of the internal standard solution, add acetonitrile to make 10 mL, and use this solution as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} &\text{Amount (mg) of cetirizine hydrochloride} \\ &(\text{C}_{21}\text{H}_{25}\text{ClN}_2\text{O}_3 \cdot 2\text{HCl}) \\ &= W_S \times (Q_T/Q_S) \times (V/100) \end{aligned}$$

$W_S$ : Amount (mg) of cetirizine hydrochloride for assay

*Internal standard solution*—A solution of propyl parahydroxybenzoate in the mobile phase (1 in 1000).

**Assay** Weigh accurately not less than 20 Cetirizine Hydrochloride Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 10 mg of cetirizine hydrochloride ( $\text{C}_{21}\text{H}_{25}\text{ClN}_2\text{O}_3 \cdot 2\text{HCl}$ ), add 40 mL of sodium 1-heptanesulfonate solution (1 in 5000) adjusted to pH 3.0 with 0.5 mol/L sulfuric acid TS, treat with ultrasonic waves for 20 minutes, add sodium 1-heptanesulfonate solution (1 in 5000), adjusted to pH 3.0 with 0.5 mol/L sulfuric acid TS, to make exactly 50 mL, and filter through a membrane with a pore size not exceeding 0.45  $\mu\text{m}$ . Discard the first 3 mL of the filtrate, pipet 5 mL of the subsequent filtrate, add exactly 2 mL of the internal standard solution, add acetonitrile to make exactly 10 mL, and use this solution as the sample solution. Separately, weigh accurately about 20 mg of cetirizine hydrochloride for assay, previously dried in vacuum at 60°C for 3 hours, and add sodium 1-heptanesulfonate solution (1 in 5000), adjusted to pH 3.0 with 0.5 mol/L sulfuric acid TS, to make exactly 100 mL. Pipet 5 mL of this solution, add exactly 2 mL of the internal standard solution, add acetonitrile to make 10 mL, and use this solution as the standard solution. Perform the test with 20  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of cetirizine to that of the internal standard.

$$\begin{aligned} &\text{Amount (mg) of cetirizine hydrochloride} \\ &(\text{C}_{21}\text{H}_{25}\text{ClN}_2\text{O}_3 \cdot 2\text{HCl}) \\ &= W_S \times (Q_T/Q_S) \times (1/2) \end{aligned}$$

$W_S$ : Amount (mg) of cetirizine hydrochloride for assay

*Internal standard solution*—A solution of propyl parahydroxybenzoate in the mobile phase (1 in 1000).

*Operating conditions*—

Detector: An ultraviolet absorption photometer (wavelength: 230 nm).

Column: A stainless steel column 4.0 mm in inside diameter and 25 cm in length, packed with octylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: A mixture of a solution of sodium 1-heptanesulfonate (1 in 2900) and acetonitrile (29:21), adjusted to pH 3.0 with 0.5 mol/L sulfuric acid TS.

Flow rate: Adjust the flow rate so that the retention time of cetirizine is about 5 minutes.

*System suitability*—

System performance: When the procedure is run with 20  $\mu\text{L}$  of the standard solution under the above operating con-

ditions, cetirizine and the internal standard are eluted in this order with the resolution between these peaks being not less than 7.

System repeatability: When the test is repeated 6 times with 20  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of cetirizine to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Well-closed containers.

## Chlordiazepoxide Tablets

クロルジアゼポキシド錠

### Add the following next to Purity:

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Conduct this procedure using light-resistant vessels. To 1 tablet of Chlordiazepoxide Tablets add 1 mL of water, shake to disintegrate the tablet, then add 20 mL of methanol, shake, add methanol to make exactly 25 mL, and filter through a membrane filter with a pore size not exceeding 0.5  $\mu\text{m}$ . Discard the first 5 mL of the filtrate, take exactly  $V$  mL of the subsequent filtrate equivalent to about 2 mg of chlordiazepoxide ( $\text{C}_{16}\text{H}_{14}\text{ClN}_3\text{O}$ ), add exactly 1 mL of the internal standard solution, then add methanol to make 20 mL, and use this solution as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} &\text{Amount (mg) of chlordiazepoxide (C}_{16}\text{H}_{14}\text{ClN}_3\text{O}) \\ &= W_S \times (Q_T/Q_S) \times (5/V) \end{aligned}$$

$W_S$ : Amount (mg) of Chlordiazepoxide Reference Standard

*Internal standard solution*—A solution of isobutyl salicylate in methanol (1 in 20).

## Chlorphenesin Carbamate

クロルフェネシンカルバミン酸エステル

### Change the Description to read:

**Description** Chlorphenesin Carbamate occurs as white crystals or a crystalline powder.

It is freely soluble in methanol, in ethanol (95) and in pyridine, and slightly soluble in water.

A solution of Chlorphenesin Carbamate in ethanol (95) (1 in 20) shows no optical rotation.

### Change the Identification (2) to read:

#### Identification

(2) Determine the infrared absorption spectrum of

Chlorphenesin Carbamate, as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

### Change the Purity (3) to read:

#### Purity

(3) Chlorphenesin-2-carbamate—Dissolve 0.10 g of Chlorphenesin Carbamate in 20 mL of a mixture of hexane for liquid chromatography and 2-propanol (7:3), and use this solution as the sample solution. Perform the test with 10  $\mu$ L of the sample solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine the peak area,  $A_a$ , of chlorphenesin carbamate and the peak area,  $A_b$ , of chlorphenesin-2-carbamate by the automatic integration method: the ratio,  $A_b/(A_a + A_b)$ , is not more than 0.007.

#### Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 280 nm).

Column: A stainless steel column 4 mm in inside diameter and 30 cm in length, packed with silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of hexane for liquid chromatography, 2-propanol and acetic acid (100) (700:300:1).

Flow rate: Adjust the flow rate so that the retention time of chlorphenesin carbamate is about 9 minutes.

#### System suitability—

Test for required detection: Pipet 1 mL of the sample solution, add a mixture of hexane for liquid chromatography and 2-propanol (7:3) to make exactly 100 mL, and use this solution as the solution for system suitability test. To exactly 5 mL of the solution for system suitability test add the mixture of hexane for liquid chromatography and 2-propanol (7:3) to make exactly 10 mL. Confirm that the peak area of chlorphenesin carbamate obtained from 10  $\mu$ L of this solution is equivalent to 40 to 60% of that of chlorphenesin carbamate obtained from 10  $\mu$ L of the solution for system suitability test.

System performance: Dissolve 0.1 g of Chlorphenesin Carbamate in 50 mL of methanol. To 25 mL of this solution add 25 mL of dilute sodium hydroxide TS, and warm at 60°C for 20 minutes. To 20 mL of this solution add 5 mL of 1 mol/L hydrochloric acid TS, shake well with 20 mL of ethyl acetate, and allow to stand to separate the upper layer. When the procedure is run with 10  $\mu$ L of this layer under the above operating conditions, chlorphenesin, chlorphenesin carbamate and chlorphenesin-2-carbamate are eluted in this order, with the relative retention times of chlorphenesin and chlorphenesin-2-carbamate with respect to chlorphenesin carbamate being about 0.7 and about 1.2, respectively, and with the resolution between the peaks of chlorphenesin and chlorphenesin carbamate being not less than 2.0.

System repeatability: When the test is repeated 6 times

with 10  $\mu$ L of the solution for system suitability test under the above operating conditions, the relative standard deviation of the peak areas of chlorphenesin carbamate is not more than 2.0%.

### Add the following next to Purity (3):

(4) Related substances—Dissolve 0.10 g of Chlorphenesin Carbamate in 10 mL of ethanol (95), and use this solution as the sample solution. Pipet 1 mL of the sample solution, add ethanol (95) to make exactly 20 mL. Pipet 2 mL of this solution, add ethanol (95) to make exactly 20 mL, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 50  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and ammonia solution (28) (17:2:1) to a distance of about 10 cm, and air-dry the plate. Allow the plate to stand in iodine vapor for 20 minutes: the spot other than the principal spot from the sample solution is not more than one, and it is not more intense than the spot from the standard solution.

### Add the following:

## Chlorphenesin Carbamate Tablets

クロルフェネシンカルバミン酸エステル錠

Chlorphenesin Carbamate Tablets contain not less than 93.0% and not more than 107.0% of the labeled amount of chlorphenesin carbamate ( $C_{10}H_{12}ClNO_4$ : 245.66).

**Method of preparation** Prepare as directed under Tablets, with Chlorphenesin Carbamate.

**Identification** To a quantity of powdered Chlorphenesin Carbamate Tablets, equivalent to 0.15 g of Chlorphenesin Carbamate according to the labeled amount, add 60 mL of ethanol (95), treat with ultrasonic waves, and add ethanol (95) to make 100 mL. Centrifuge 20 mL of this solution, add ethanol (95) to 1 mL of the supernatant liquid to make 100 mL, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 226 nm and 230 nm, between 279 nm and 283 nm, and between 286 nm and 290 nm.

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Chlorphenesin Carbamate Tablets add 10 mL of water to disintegrate the tablet, add 70 mL of a mixture of water and methanol (1:1), treat with ultrasonic waves for 15 minutes with occasional stirring, then add the mixture of water and methanol (1:1) to make exactly 100 mL. Centrifuge this solution, pipet  $V$  mL of the supernatant liquid equivalent to about 2.5 mg of chlorphenesin carbamate

(C<sub>10</sub>H<sub>12</sub>ClNO<sub>4</sub>), add the mixture of water and methanol (1:1) to make exactly 25 mL, and use this solution as the sample solution. Separately, weigh accurately about 50 mg of chlorphenesin carbamate for assay, previously dried in a desiccator (in vacuum, silica gel) for 4 hours, and dissolve in the mixture of water and methanol (1:1) to make exactly 50 mL. Pipet 2 mL of this solution, add the mixture of water and methanol (1:1) to make exactly 20 mL, and use this solution as the standard solution. Determine the absorbances at 280 nm,  $A_T$  and  $A_S$ , of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>.

$$\begin{aligned} & \text{Amount (mg) of chlorphenesin carbamate} \\ & \text{(C}_{10}\text{H}_{12}\text{ClNO}_4\text{)} \\ & = W_S \times (A_T/A_S) \times (1/V) \times 5 \end{aligned}$$

$W_S$ : Amount (mg) of chlorphenesin carbamate for assay

**Dissolution** <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rate in 15 minutes of Chlorphenesin Carbamate Tablets is not less than 85%.

Start the test with 1 tablet of Chlorphenesin Carbamate Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45  $\mu\text{m}$ . Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, add water to make exactly  $V'$  mL so that each mL contains about 0.14 mg of chlorphenesin carbamate (C<sub>10</sub>H<sub>12</sub>ClNO<sub>4</sub>) according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 28 mg of chlorphenesin carbamate for assay, previously dried in a desiccator (in vacuum, silica gel) for 4 hours, dissolve in 1 mL of methanol, and add water to make exactly 50 mL. Pipet 5 mL of this solution, add water to make exactly 20 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , at 278 nm of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>.

Dissolution rate (%) with respect to the labeled amount of chlorphenesin carbamate (C<sub>10</sub>H<sub>12</sub>ClNO<sub>4</sub>)

$$= W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 450$$

$W_S$ : Amount (mg) of chlorphenesin carbamate for assay

$C$ : Labeled amount (mg) of chlorphenesin carbamate (C<sub>10</sub>H<sub>12</sub>ClNO<sub>4</sub>) in 1 tablet

**Assay** Weigh accurately the mass of not less than 20 Chlorphenesin Carbamate Tablets, and powder them in an agate mortar. Weigh accurately a portion of the powder, equivalent to about 0.25 g of chlorphenesin carbamate (C<sub>10</sub>H<sub>12</sub>ClNO<sub>4</sub>), add 30 mL of ethyl acetate, disperse using ultrasonic waves, then add ethyl acetate to make exactly 50 mL. Centrifuge 20 mL of this solution, pipet 2 mL of the supernatant liquid, add exactly 2 mL of the internal standard solution, add ethyl acetate to make 20 mL, and use this solution as the sample solution. Separately, weigh accurately about 0.1 g of chlorphenesin carbamate for assay, previous-

ly dried in a desiccator (in vacuum, silica gel) for 4 hours, and dissolve in ethyl acetate to make exactly 50 mL. Pipet 5 mL of this solution, add exactly 2 mL of the internal standard solution, then add ethyl acetate to make 20 mL, and use this solution as the standard solution. Perform the test with 10  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of chlorphenesin carbamate to that of the internal standard.

$$\begin{aligned} & \text{Amount (mg) of chlorphenesin carbamate (C}_{10}\text{H}_{12}\text{ClNO}_4\text{)} \\ & = W_S \times (Q_T/Q_S) \times (5/2) \end{aligned}$$

$W_S$ : Amount (mg) of chlorphenesin carbamate for assay

**Internal standard solution**—A solution of ethenzamide in ethyl acetate (1 in 400).

**Operating conditions**—

**Detector**: An ultraviolet absorption photometer (wavelength: 280 nm).

**Column**: A stainless steel column 4 mm in inside diameter and 30 cm in length, packed with silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

**Column temperature**: A constant temperature of about 40°C.

**Mobile phase**: A mixture of hexane for liquid chromatography, 2-propanol and acetic acid (100) (700:300:1).

**Flow rate**: Adjust the flow rate so that the retention time of chlorphenesin carbamate is about 9 minutes.

**System suitability**—

**System performance**: Proceed as directed in the Purity (3) under Chlorphenesin Carbamate.

**System repeatability**: When the test is repeated 6 times with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of chlorphenesin carbamate to that of the internal standard is not more than 1.5%.

**Containers and storage** Containers—Well-closed containers.

## Chlorpromazine Hydrochloride Injection

クロルプロマジン塩酸塩注射液

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Chlorpromazine Hydrochloride Tablets

クロルプロマジン塩酸塩錠

### Add the following next to Identification:

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Conduct this procedure using light-resistant vessels. To 1 tablet of Chlorpromazine Hydrochloride Tablets add an amount of a mixture of diluted phosphoric acid (1 in 500) and ethanol (99.5) (1:1) so that each mL contains about 0.83 mg of chlorpromazine hydrochloride ( $C_{17}H_{19}ClN_2S \cdot HCl$ ), treat with the ultrasonic waves for 5 minutes, then shake vigorously for 20 minutes, and add the mixture of diluted phosphoric acid (1 in 500) and ethanol (99.5) (1:1) to make exactly  $V$  mL so that each mL contains about 0.5 mg of chlorpromazine hydrochloride ( $C_{17}H_{19}ClN_2S \cdot HCl$ ). Filter through a membrane filter with a pore size not exceeding  $0.45 \mu m$ . Discard the first 3 mL of the filtrate, pipet 2.5 mL of the subsequent filtrate, add exactly 5 mL of the internal standard solution, then add the mixture of diluted phosphoric acid (1 in 500) and ethanol (99.5) (1:1) to make 25 mL, and use this solution as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} & \text{Amount (mg) of chlorpromazine hydrochloride} \\ & (C_{17}H_{19}ClN_2S \cdot HCl) \\ & = W_S \times (Q_T/Q_S) \times (V/50) \end{aligned}$$

$W_S$ : Amount (mg) of chlorpromazine hydrochloride for assay

**Internal standard solution**—A solution of ethyl parahydroxybenzoate in the mixture of diluted phosphoric acid (1 in 500) and ethanol (99.5) (1:1) (1 in 4500).

## Chlorpropamide Tablets

クロルプロパミド錠

### Add the following next to Identification:

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Chlorpropamide Tablets add 75 mL of the mobile phase, treat with the ultrasonic waves for 20 minutes with occasional strong shaking, then add the mobile phase to make exactly  $V$  mL so that each mL contains about 2.5 mg of Chlorpropamide. Centrifuge the solution, pipet 2 mL of the supernatant liquid, add the mobile phase to make exactly 100 mL, and use this solution as the sample solution. Then, proceed as directed in the Assay.


$$\begin{aligned} & \text{Amount (mg) of chlorpropamide } (C_{10}H_{13}ClN_2O_3S) \\ & = W_S \times (A_T/A_S) \times (V/20) \end{aligned}$$

$W_S$ : Amount (mg) of chlorpropamide for assay

### Add the following:

## Cibenzoline Succinate

シベンゾリンコハク酸塩



$C_{18}H_{18}N_2 \cdot C_4H_6O_4$ : 380.44  
2-[(1*RS*)-2,2-Diphenylcyclopropan-1-yl]-4,5-dihydro-1*H*-imidazole monosuccinate [100678-32-8]

Cibenzoline Succinate, when dried, contains not less than 98.5% and not more than 101.0% of  $C_{18}H_{18}N_2 \cdot C_4H_6O_4$ .

**Description** Cibenzoline Succinate occurs as a white crystalline powder.

It is freely soluble in methanol and in acetic acid (100), and sparingly soluble in water and in ethanol (99.5).

A solution of Cibenzoline Succinate in methanol (1 in 10) shows no optical rotation.

**Identification (1)** Determine the absorption spectrum of a solution of Cibenzoline Succinate (1 in 50,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Cibenzoline Succinate as directed in the paste method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) Shake 0.4 g of Cibenzoline Succinate with 2.5 mL of sodium hydroxide TS and 5 mL of ethyl acetate, allow to stand, and to 1 mL of the water layer so obtained add 0.5 mL of 1 mol/L hydrochloric acid TS and 0.5 mL of iron (III) chloride TS: a blown precipitate is formed.

**Melting point** <2.60> 163 – 167°C

**pH** <2.54> Dissolve 0.20 g of Cibenzoline Succinate in 10 mL of water: the pH of this solution is between 4.0 and 6.0.

**Purity (1)** Clarity and color of solution—A solution obtained by dissolving 0.20 g of Cibenzoline Succinate in 10 mL of water is clear and colorless.

(2) Heavy metals <1.07>—Proceed with 1.0 g of Cibenzoline Succinate according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard

Lead Solution (not more than 20 ppm).

(3) Arsenic <1.11>—Prepare the test solution with 1.0 g of Cibenzoline Succinate according to Method 3, using a solution of magnesium nitrate hexahydrate in ethanol (95) (1 in 25), and perform the test (not more than 2 ppm).

(4) Related substances—Dissolve 0.10 g of Cibenzoline Succinate in 10 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, and add methanol to make exactly 100 mL. Pipet 5 mL and 2 mL of this solution, add methanol to make them exactly 10 mL, and use these solutions as the standard solution (1) and the standard solution (2). Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solutions (1) and (2) on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and ammonia solution (28) (20:3:2) to a distance of about 10 cm, air-dry the plate, and dry more at 80°C for 30 minutes. After cooling, examine under ultraviolet light (main wavelength: 254 nm): the spot other than the principal spot obtained with the sample solution is not more intense than the spot with the standard solution (1). Allow the plate to stand for 30 minutes in iodine vapor: the spot other than the principal spot obtained with the sample solution is not more intense than the spot with the standard solution (1), and the spot, which is more intense than the spot with the standard solution (2), is not more than two.

**Loss on drying** <2.41> Not more than 0.3% (1 g, 105°C, 2 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.4 g of Cibenzoline Succinate, previously dried, dissolve in 50 mL of acetic acid (100), and titrate <2.50> with 0.1 mol/L perchloric acid VS until the color of the solution changes from violet to blue-green through blue (indicator: 2 drops of crystal violet TS). Perform a blank determination in the same manner, and make any necessary correction.

$$\begin{aligned} \text{Each mL of 0.1 mol/L perchloric acid VS} \\ = 38.04 \text{ mg of } C_{18}H_{18}N_2 \cdot C_4H_6O_4 \end{aligned}$$

**Containers and storage** Containers—Tight containers.

**Add the following:**

## Cibenzoline Succinate Tablets

シベンゾリンコハク酸塩錠

Cibenzoline Succinate Tablets contain not less than 95.0% and not more than 105.0% of the labeled amount of cibenzoline succinate ( $C_{18}H_{18}N_2 \cdot C_4H_6O_4$ ; 380.44).

**Method of preparation** Prepare as directed under Tablets, with Cibenzoline Succinate.

**Identification** To a quantity of powdered Cibenzoline Succinate Tablets, equivalent to 50 mg of Cibenzoline Succinate according to the labeled amount, add 100 mL of water, shake for 10 minutes, and centrifuge. To 2 mL of the supernatant liquid add water to make 50 mL, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 221 nm and 225 nm.

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Cibenzoline Succinate Tablets add a suitable amount of water so that each mL contains about 10 mg of cibenzoline succinate ( $C_{18}H_{18}N_2 \cdot C_4H_6O_4$ ), and allow standing for 10 minutes while occasional shaking. To this solution add methanol so that each mL contains about 2 mg of cibenzoline succinate ( $C_{18}H_{18}N_2 \cdot C_4H_6O_4$ ), add exactly 1 mL of the internal standard solution per 10 mg of cibenzoline succinate ( $C_{18}H_{18}N_2 \cdot C_4H_6O_4$ ), then add methanol so that each mL contains about 1 mg of cibenzoline succinate ( $C_{18}H_{18}N_2 \cdot C_4H_6O_4$ ). Centrifuge the solution, and use the supernatant liquid as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} \text{Amount (mg) of cibenzoline succinate } (C_{18}H_{18}N_2 \cdot C_4H_6O_4) \\ = W_S \times (Q_T / Q_S) \times (C / 100) \end{aligned}$$

$W_S$ : Amount (mg) of cibenzoline succinate for assay

$C$ : Labeled amount (mg) of cibenzoline succinate ( $C_{18}H_{18}N_2 \cdot C_4H_6O_4$ ) in 1 tablet

**Internal standard solution**—Dissolve 0.1 g of 2-ethylhexyl parahydroxybenzoate in methanol to make 100 mL.

**Dissolution** <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rate in 15 minutes of Cibenzoline Succinate Tablets is not less than 80%.

Start the test with 1 tablet of Cibenzoline Succinate Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45  $\mu$ m. Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, add water to make exactly  $V'$  mL so that each mL contains about 11  $\mu$ g of cibenzoline succinate ( $C_{18}H_{18}N_2 \cdot C_4H_6O_4$ ) according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 28 mg of cibenzoline succinate for assay, previously dried at 105°C for 2 hours, and dissolve in water to make exactly 100 mL. Pipet 2 mL of this solution, add water to make exactly 50 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , of the sample solution and standard solution at 222 nm as directed under Ultraviolet-visible Spectrophotometry <2.24>.

Dissolution rate (%) with respect to the labeled amount of cibenzoline succinate ( $C_{18}H_{18}N_2 \cdot C_4H_6O_4$ )

$$= W_S \times (A_T / A_S) \times (V' / V) \times (1 / C) \times 36$$



$W_S$ : Amount (mg) of cibenzoline succinate for assay  
 $C$ : Labeled amount (mg) of cibenzoline succinate ( $C_{18}H_{18}N_2 \cdot C_4H_6O_4$ ) in 1 tablet

**Assay** Weigh accurately not less than 20 Cibenzoline Succinate Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 0.1 g of cibenzoline succinate ( $C_{18}H_{18}N_2 \cdot C_4H_6O_4$ ), add 10 mL of water, shake, and add 40 mL of methanol and exactly 10 mL of the internal standard solution. Shake for 20 minutes, add methanol to make 100 mL, centrifuge, and use the supernatant liquid as the sample solution. Separately, weigh accurately about 0.1 g of cibenzoline succinate for assay, previously dried at 105°C for 2 hours, add 10 mL of water and 40 mL of methanol to dissolve, then add exactly 10 mL of the internal standard solution and methanol to make 100 mL, and use this solution as the standard solution. Perform the test with 5  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of cibenzoline to that of the internal standard.

Amount (mg) of cibenzoline succinate ( $C_{18}H_{18}N_2 \cdot C_4H_6O_4$ )  
 $= W_S \times (Q_T / Q_S)$

$W_S$ : Amount (mg) of cibenzoline succinate for assay

**Internal standard solution**—Dissolve 0.1 g of 2-ethylhexyl parahydroxybenzoate in methanol to make 100 mL.

**Operating conditions**—

**Detector**: An ultraviolet absorption photometer (wavelength: 254 nm).

**Column**: A stainless steel column 4.6 mm in inside diameter and 5 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (3  $\mu$ m in particle diameter).

**Column temperature**: A constant temperature of about 25°C.

**Mobile phase**: Dissolve 2.67 g of sodium di-2-ethylhexyl sulfosuccinate in 2000 mL of a mixture of water, acetonitrile and diluted phosphoric acid (1 in 10) (1000:1000:1).

**Flow rate**: Adjust the flow rate so that the retention time of cibenzoline is about 3 minutes.

**System suitability**—

**System performance**: When the procedure is run with 5  $\mu$ L of the standard solution under the above operating conditions, cibenzoline and the internal standard are eluted in this order with the resolution between these peaks being not less than 6.


**System repeatability**: When the test is repeated 6 times with 5  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of cibenzoline to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

**Add the following:**

## Cilazapril Hydrate

シラザプリル水和物



$C_{22}H_{31}N_3O_5 \cdot H_2O$ : 435.51  
 (1*S*,9*S*)-9-[(1*S*)-(1-Ethoxycarbonyl-3-phenylpropyl)amino]-10-oxooctahydro-6*H*-pyridazino[1,2-*a*][1,2]diazepine-1-carboxylic acid monohydrate [92077-78-6]

Cilazapril Hydrate contains not less than 98.5% and not more than 101.0% of cilazapril ( $C_{22}H_{31}N_3O_5$ ; 417.50), calculated on the anhydrous basis.

**Description** Cilazapril Hydrate occurs as white to yellowish white crystals or crystalline powder.

It is very soluble in methanol, freely soluble in ethanol (99.5) and in acetic acid (100), and slightly soluble in water.

It gradually turns yellow on exposure to light.

Melting point: about 101°C (with decomposition).

**Identification (1)** To 4 mL of a solution of Cilazapril Hydrate (1 in 1000) add 2 mL of Dragendorff's TS: an orange precipitate is produced.

(2) Determine the infrared absorption spectrum of Cilazapril Hydrate as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Optical rotation** <2.49>  $[\alpha]_D^{20}$ :  $-53 - -58^\circ$  (0.2 g calculated on the anhydrous basis, methanol, 20 mL, 100 mm).

**Purity (1) Chloride** <1.03>—Perform the test using 1.0 g of Cilazapril Hydrate. Prepare the control solution with 0.25 mL of 0.01 mol/L hydrochloric acid VS (not more than 0.009%).

(2) **Sulfate** <1.14>—Dissolve 1.0 g of Cilazapril Hydrate in 40 mL of water and 1.5 mL of dilute hydrochloric acid, and add water to make 50 mL. Perform the test using this solution as the test solution. Prepare the control solution with 0.40 mL of 0.005 mol/L sulfuric acid VS (not more than 0.019%).

(3) **Heavy metals** <1.07>—Proceed with 1.0 g of Cilazapril Hydrate according to Method 4, and perform the test. However, use 10 mL of a solution of magnesium nitrate hexahydrate in ethanol (95) (1 in 8). Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

(4) **Related substances**—Dissolve 0.10 g of Cilazapril Hydrate in 20 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 100 mL, and use this solution as

the standard solution (1). Pipet 3 mL of the standard solution (1), add methanol to make exactly 10 mL, and use this solution as the standard solution (2). Separately, pipet 2 mL of the standard solution (1), add methanol to make exactly 10 mL, and use this solution as the standard solution (3). Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 20  $\mu$ L each of the sample solution and three standard solutions on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol, acetic acid (100), hexane, and water (62:15:10:10:3) to a distance of about 15 cm, and air-dry the plate. Leave the plate in iodine vapor for 2 hours, and examine the plate under ultraviolet light (main wavelength: 254 nm): of the spots other than the principal spot with an *Rf* value close to 0.40 obtained from the sample solution, the spot in the vicinity of *Rf* value 0.17 is not more intense than the spot from the standard solution (1), and the spot in the vicinity of *Rf* value 0.44 is not more intense than the spot from the standard solution (2). The number of all other spot does not exceed 3, and of these spots, no more than one is more intense than the spot from the standard solution (3) and none are more intense than the spot from the standard solution (2).

**Water** <2.48> 3.5 – 5.0% (0.3 g, volumetric titration, direct titration).

**Residue on ignition** <2.44> Not more than 0.1% (0.5 g).

**Assay** Weigh accurately about 0.2 g of Cilazapril Hydrate, dissolve in 50 mL of acetic acid (100), and titrate <2.50> with 0.02 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner and make any necessary correction.

Each mL of 0.02 mol/L perchloric acid VS  
= 8.350 mg of  $C_{22}H_{31}N_3O_5$

**Containers and storage** Containers—Tight containers.

Storage—Light-resistant.

### Add the following:

## Cilazapril Tablets

シラザプリル錠

Cilazapril Tablets contain not less than 93.0% and not more than 107.0% of the labeled amount of cilazapril ( $C_{22}H_{31}N_3O_5$ ; 417.50).

**Method of preparation** Prepare as directed under Tablets, with Cilazapril Hydrate.

**Identification** To a quantity of powdered Cilazapril Tablets, equivalent to 2 mg of cilazapril ( $C_{22}H_{31}N_3O_5$ ) according to the labeled amount, add 2 mL of a mixture of acetonitrile and ethyl acetate (3:1), shake, treat with ultrasonic waves for 30 seconds, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 5

mg of cilazapril in 5 mL of the mixture of acetonitrile and ethyl acetate (3:1), and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 20  $\mu$ L each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol, acetic acid (100), hexane and water (62:15:10:10:3) to a distance of about 15 cm, and air-dry the plate. Place the plate in iodine vapor for 2 hours, and immediately examine under ultraviolet light (main wavelength: 254 nm): the spots obtained from the sample and standard solutions are dark brown and they show the same *Rf* value.

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Cilazapril Tablets add 5 mL of a mixture of water and acetonitrile (7:3), shake well until disintegration, add the mixture of water and acetonitrile (7:3) to make exactly *V* mL so that each mL contains about 25  $\mu$ g of cilazapril ( $C_{22}H_{31}N_3O_5$ ), and centrifuge. Pipet 4 mL of the supernatant liquid, add exactly 1 mL of the internal standard solution, add the mixture of water and acetonitrile (7:3) to make 10 mL, and use this solution as the sample solution. Separately, weigh accurately about 26 mg of cilazapril for assay (separately determine the water <2.48> in the same manner as Cilazapril Hydrate), and dissolve in the mixture of water and acetonitrile (7:3) to make exactly 50 mL. Pipet 2 mL of this solution, add exactly 10 mL of the internal standard solution, add the mixture of water and acetonitrile (7:3) to make 100 mL, and use this solution as the standard solution. Perform the test with 100  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of cilazapril to that of the internal standard.

$$\begin{aligned} &\text{Amount (mg) of cilazapril } (C_{22}H_{31}N_3O_5) \\ &= W_S \times (Q_T/Q_S) \times (V/1000) \end{aligned}$$

$W_S$ : Amount (mg) of cilazapril for assay, calculated on the anhydrous basis

**Internal standard solution**—A solution of dimethyl phthalate in a mixture of water and acetonitrile (7:3) (1 in 12,500).

**Operating conditions**—

Proceed as directed in the operating conditions in the Assay.

**System suitability**—

System performance: When the procedure is run with 100  $\mu$ L of the standard solution under the above conditions, cilazapril and the internal standard are eluted in this order with the resolution between these peaks being not less than 6.

System repeatability: When the test is repeated 6 times with 100  $\mu$ L of the standard solution under the above conditions, the relative standard deviation of the ratio of the peak area of cilazapril to that of the internal standard is not more than 2.0%.

**Dissolution** <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rate in 15 minutes of Cilazapril Tablets is not less than 85%.

Start the test with 1 tablet of Cilazapril Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45  $\mu\text{m}$ . Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, and add water to make exactly  $V'$  mL so that each mL contains about 0.28  $\mu\text{g}$  of cilazapril ( $\text{C}_{22}\text{H}_{31}\text{N}_3\text{O}_5$ ) according to the labeled amount. Pipet 10 mL of the solution, add exactly 5 mL of acetonitrile, and use this solution as the sample solution. Separately, weigh accurately about 29 mg of cilazapril for assay (separately determine the water <2.48> in the same manner as Cilazapril Hydrate), and dissolve in water to make exactly 100 mL. Pipet 5 mL of the solution, add water to make exactly 100 mL. Then, pipet 2 mL of this solution, add water to make exactly 100 mL. Pipet 10 mL of this solution, add exactly 5 mL of acetonitrile, and use this solution as the standard solution. Perform the test with exactly 100  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas of cilazapril,  $A_T$  and  $A_S$ , of both solutions.

Dissolution rate (%) with respect to the labeled amount of cilazapril ( $\text{C}_{22}\text{H}_{31}\text{N}_3\text{O}_5$ )

$$= W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times (9/10)$$

$W_S$ : Amount (mg) of cilazapril for assay, calculated on the anhydrous basis

$C$ : Labeled amount (mg) of cilazapril ( $\text{C}_{22}\text{H}_{31}\text{N}_3\text{O}_5$ ) in 1 tablet

**Operating conditions—**

Detector: An ultraviolet absorption photometer (wavelength: 210 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: To a solution consisting of 180 mL of tetrahydrofuran for liquid chromatography, 120 mL of acetonitrile for liquid chromatography and 3 mL of triethylamine add water to make 1000 mL, and adjust the pH to 2.5 with phosphoric acid.

Flow rate: Adjust the flow rate so that the retention time of cilazapril is about 10 minutes.

**System suitability—**

System performance: When the procedure is run with 100  $\mu\text{L}$  of the standard solution under the above conditions, the number of theoretical plates and the symmetry factor of the peak of cilazapril are not less than 3000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 100  $\mu\text{L}$  of the standard solution under the above condi-

tions, the relative standard deviation of the peak area of cilazapril is not more than 2.0%.

**Assay** Weigh accurately 20 Cilazapril Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 1 mg of cilazapril ( $\text{C}_{22}\text{H}_{31}\text{N}_3\text{O}_5$ ), add 30 mL of a mixture of water and acetonitrile (7:3), and treat with ultrasonic waves for 5 minutes. Next, add exactly 5 mL of the internal standard solution, add the mixture of water and acetonitrile (7:3) to make 50 mL, and centrifuge. Filter the supernatant liquid through a membrane filter with a pore size not exceeding 0.5  $\mu\text{m}$ , and use the filtrate as the sample solution. Separately, weigh accurately about 26 mg of cilazapril for assay (separately determine the water <2.48> in the same manner as Cilazapril Hydrate), and dissolve in the mixture of water and acetonitrile (7:3) to make exactly 50 mL. Pipet 2 mL of this solution, add exactly 5 mL of the internal standard solution, add the mixture of water and acetonitrile (7:3) to make 50 mL, and use this solution as the standard solution. Perform the test with 50  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of cilazapril to that of the internal standard.

$$\begin{aligned} &\text{Amount (mg) of cilazapril } (\text{C}_{22}\text{H}_{31}\text{N}_3\text{O}_5) \\ &= W_S \times (Q_T/Q_S) \times (1/25) \end{aligned}$$

$W_S$ : Amount (mg) of cilazapril for assay, calculated on the anhydrous basis

**Internal standard solution—**A solution of dimethyl phthalate in a mixture of water and acetonitrile (7:3) (1 in 12,500).

**Operating conditions—**

Detector: An ultraviolet absorption photometer (wavelength: 210 nm).

Column: A stainless steel column 6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

Column temperature: A constant temperature of about 23°C.

Mobile phase: To a solution consisting of 180 mL of tetrahydrofuran for liquid chromatography, 120 mL of acetonitrile for liquid chromatography and 3 mL of triethylamine add water to make 1000 mL, and adjust the pH to 2.5 with phosphoric acid.

Flow rate: Adjust the flow rate so that the retention time of cilazapril is about 10 minutes.

**System suitability—**

System performance: When the procedure is run with 50  $\mu\text{L}$  of the standard solution under the above conditions, cilazapril and the internal standard are eluted in this order with the resolution between these peaks being not less than 6.

System repeatability: When the test is repeated 6 times with 50  $\mu\text{L}$  of the standard solution under the above conditions, the relative standard deviation of the ratio of the peak area of cilazapril to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

## Cilostazol Tablets

シロスタゾール錠

### Change the Assay to read:

**Assay** Weigh accurately not less than 20 Cilostazol Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 50 mg of cilostazol ( $C_{20}H_{27}N_5O_2$ ), add exactly 5 mL of the internal standard solution and methanol to make 50 mL, and shake well for 10 minutes. To 1 mL of this solution add methanol to make 10 mL, filter through a membrane filter with a pore size not exceeding 0.5  $\mu\text{m}$ , and use the filtrate as the sample solution. Separately, weigh accurately about 50 mg of Cilostazol Reference Standard, previously dried at 105°C for 2 hours, dissolve in a suitable amount of methanol, and add exactly 5 mL of the internal standard solution, and add methanol to make 50 mL. To 1 mL of this solution add methanol to make 10 mL, and use this solution as the standard solution. Perform the test with 10  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of cilostazol to that of the internal standard.

Amount (mg) of cilostazol ( $C_{20}H_{27}N_5O_2$ ) =  $W_S \times (Q_T/Q_S)$

$W_S$ : Amount (mg) of Cilostazol Reference Standard

**Internal standard solution**—A solution of benzophenone in methanol (1 in 250).

**Operating conditions**—

Proceed as directed in the operating conditions in the Assay under Cilostazol.

**System suitability**—

System performance: Proceed as directed in the system suitability in the Assay under Cilostazol.

System repeatability: When the test is repeated 6 times with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of cilostazol to that of the internal standard is not more than 1.5%.

### Add the following:

## Clindamycin Phosphate Injection

クリンダマイシンリン酸エステル注射液

Clindamycin Phosphate Injection is an aqueous injection.

It contains not less than 90.0% and not more than 110.0% of the labeled amount of clindamycin phosphate ( $C_{18}H_{34}ClN_2O_8PS$ ; 504.96).

**Method of preparation** Prepare as directed under Injections, with Clindamycin Phosphate.

**Description** Clindamycin Phosphate Injection is a clear, colorless or light yellow liquid.

**Identification** To a volume of Clindamycin Phosphate Injection, equivalent to 0.15 g (potency) of Clindamycin Phosphate according to the labeled amount, add 4 mL of water, 2 mL of 8 mol/L sodium hydroxide TS and 0.1 mL of sodium pentacyanonitrosylferrate (III) TS, mix, heat in a water bath for 10 minutes, and add 2 mL of hydrochloric acid: a blue-green color develops.

**Osmotic pressure ratio** Being specified separately.

**pH** <2.54> 6.0 – 7.0

**Bacterial endotoxins** <4.01> Less than 0.1 EU/mg (potency).

**Extractable volume** <6.05> It meets the requirement.

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Assay** Measure exactly a volume of Clindamycin Phosphate Injection, equivalent to about 0.3 g (potency) of Clindamycin Phosphate, and add the mobile phase to make exactly 100 mL. Pipet 7 mL of this solution, add exactly 25 mL of the internal standard solution and the mobile phase to make 100 mL, and use this solution as the sample solution. Separately, weigh accurately an amount of Clindamycin Phosphate Reference Standard, equivalent to about 20 mg (potency), dissolve in exactly 25 mL of the internal standard solution, add the mobile phase to make 100 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Clindamycin Phosphate.

Amount [mg (potency)] of clindamycin phosphate  
( $C_{18}H_{34}ClN_2O_8PS$ )  
=  $W_S \times (Q_T/Q_S) \times (100/7)$

$W_S$ : Amount [mg (potency)] of Clindamycin Phosphate Reference Standard


**Internal standard solution**—A solution of methyl parahydroxybenzoate in the mobile phase (3 in 50,000).

**Containers and storage** Containers—Hermetic containers.

## Add the following:

## Clobetasol Propionate

クロベタゾールプロピオン酸エステル

C<sub>25</sub>H<sub>32</sub>ClFO<sub>5</sub>: 466.97

21-Chloro-9-fluoro-11β,17-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-propanoate [25122-46-7]

Clobetasol Propionate, when dried, contains not less than 97.0% and not more than 102.0% of C<sub>25</sub>H<sub>32</sub>ClFO<sub>5</sub>.

**Description** Clobetasol Propionate occurs as a white to pale yellowish white crystalline powder.

It is soluble in methanol and in ethanol (99.5), and practically insoluble in water.

It gradually turns yellow by light.

Melting point: about 196°C (with decomposition).

**Identification** Determine the infrared absorption spectra of Clobetasol Propionate as directed in the paste method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Clobetasol Propionate Reference Standard: both spectra exhibit similar intensities of absorbance at the same wave numbers.

**Optical rotation** <2.49> [α]<sub>D</sub><sup>20</sup>: +109 – +115° (after drying, 0.1 g, methanol, 10 mL, 100 mm).

**Purity** (1) Heavy metals <1.07>—Proceed with 1.0 g of Clobetasol Propionate according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

(2) Related substances—Dissolve 10 mg of Clobetasol Propionate in 100 mL of the mobile phase, and use this solution as the sample solution. Pipet 5 mL of the sample solution, add the mobile phase to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 10 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area of these solutions by the automatic integration method: the area of the peak other than clobetasol propionate obtained from the sample solution is not larger than 2/5 times the peak area of clobetasol propionate from the standard solution. Furthermore, the total area of the peaks other than clobetasol propionate from the sample solution is not larger than the peak area of clobetasol propionate from the standard solution.

## Operating conditions—

Detector, column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay.

Time span of measurement: About 2.5 times as long as the retention time of clobetasol propionate, beginning after the solvent peak.

## System suitability—

Test for required detectability: Pipet 2 mL of the standard solution, and add the mobile phase to make exactly 50 mL. Confirm that the peak area of clobetasol propionate obtained from 10 μL of this solution is equivalent to 2.8 to 5.2 % of that from 10 μL of the standard solution.

System performance: Dissolve 20 mg of Clobetasol Propionate in 20 mL of methanol. To 5 mL of this solution add 10 mL of a solution of beclometasone dipropionate in methanol (1 in 1000), and then add the mobile phase to make 50 mL. When the procedure is run with 10 μL of this solution under the above conditions, clobetasol propionate and beclometasone dipropionate are eluted in this order with the resolution between these peaks being not less than 8.

System repeatability: When the test is repeated 6 times with 10 μL of the standard solution under the above conditions, the relative standard deviation of the peak area of clobetasol propionate is not more than 2.0%.

**Loss on drying** <2.41> Not more than 0.5% (1 g, 105°C, 3 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g, platinum crucible).

**Assay** Weigh accurately about 10 mg each of Clobetasol Propionate and Clobetasol Propionate Reference Standard, both previously dried, dissolve each in the mobile phase, add exactly 100 mL of the internal standard solution, add the mobile phase to make 250 mL, and use these solutions as the sample solution and standard solution. Perform the test with 10 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of clobetasol propionate to that of the internal standard.

$$\begin{aligned} \text{Amount (mg) of C}_{25}\text{H}_{32}\text{ClFO}_5 \\ = W_S \times (Q_T/Q_S) \end{aligned}$$

$W_S$ : Amount (mg) of Clobetasol Propionate Reference Standard

**Internal standard solution**—A solution of beclometasone dipropionate in the mobile phase (1 in 5000).

## Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 240 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: Dissolve 7.80 g of sodium dihydrogen phosphate dihydrate in 900 mL of water, adjust the pH to 2.5 with phosphoric acid, and then add water to make 1000 mL. To 425 mL of this solution add 475 mL of acetonitrile and 100 mL of methanol.

Flow rate: Adjust the flow rate so that the retention time of clobetasol propionate is about 10 minutes.

*System suitability*—

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above conditions, clobetasol propionate and the internal standard are eluted in this order with the resolution between these peaks being not less than 8.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above conditions, the relative standard deviation of the ratio of the peak area of clobetasol propionate to that of the internal standard is not more than 1.0%.


**Containers and storage** Containers—Tight containers.

Storage—Light-resistant.

**Add the following:**

## Clorazepate Dipotassium

クロラゼパ酸二カリウム



$C_{16}H_{10}ClKN_2O_3 \cdot KOH$ : 408.92

Monopotassium 7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylate mono (potassium hydroxide) [57109-90-7]

Clorazepate Dipotassium, when dried, contains not less than 98.5% and not more than 101.0% of  $C_{16}H_{10}ClKN_2O_3 \cdot KOH$ .

**Description** Clorazepate Dipotassium occurs as white to light yellow, crystals or crystalline powder.

It is freely soluble in water, and very slightly soluble in ethanol (99.5).

It dissolves in acetic acid (100).

The pH of a solution obtained by dissolving 1 g of Clorazepate Dipotassium in 100 mL of water is between 11.5 and 12.5.

It gradually turns yellow on exposure to light.

**Identification (1)** Carefully and gradually ignite to redness 30 mg of Clorazepate Dipotassium with 50 mg of sodium. After cooling, add 3 drops of ethanol (99.5) and 5 mL of water, mix well, and filter: the filtrate responds to the Qualitative Tests <1.09> for chloride.

(2) Determine the absorption spectrum of a solution of Clorazepate Dipotassium (1 in 200,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(3) Determine the infrared absorption spectrum of Clorazepate Dipotassium as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

(4) Clorazepate Dipotassium responds to the Qualitative Tests <1.09> (1) for potassium salt.

**Purity (1) Chloride <1.03>**—Dissolve 1.0 g of Clorazepate Dipotassium in 20 mL of water, add 20 mL of acetone, 6 mL of dilute nitric acid and water to make 50 mL. Perform the test with this solution as the test solution. Prepare the control solution as follows: To 0.40 mL of 0.01 mol/L hydrochloric acid VS add 20 mL of acetone, 6 mL of dilute nitric acid and water to make 50 mL (not more than 0.014 %).

(2) Heavy metals <1.07>—Proceed with 1.0 g of Clorazepate Dipotassium according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

(3) Arsenic <1.11>—Prepare the test solution with 1.0 g of Clorazepate Dipotassium according to Method 3, and perform the test (not more than 2 ppm).

(4) Related substances—Dissolve 15 mg of Clorazepate Dipotassium in 25 mL of a mixture of water, potassium carbonate solution (97 in 1000) and acetonitrile (3:1:1), and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mixture of water, potassium carbonate solution (97 in 1000) and acetonitrile (3:1:1) to make exactly 200 mL, and use this solution as the standard solution. Prepare these solutions quickly and perform the test within 3 minutes. Perform the test with exactly 5  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the peak area of nordiazepam, having the relative retention time of about 3.0 with respect to clorazepic acid, obtained from the sample solution is not larger than the peak area of clorazepic acid from the standard solution, the area of the peak other than clorazepic acid and nordiazepam is not larger than 1/5 times the peak area of clorazepic acid from the standard solution, and the total area of the peaks other than clorazepic acid from the sample solution is not larger than 2 times the peak area of clorazepic acid from the standard solution. For this comparison, use the peak area of nordiazepam, having the relative retention time of about 3.0 with respect to clorazepic acid, after multiplying by the relative response factor, 0.64.

*Operating conditions*—

Detector: An ultraviolet absorption photometer (wavelength: 232 nm).

**Column:** A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilylated silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

**Column temperature:** A constant temperature of about 25°C.

**Mobile phase:** Dissolve 13.8 g of sodium dihydrogen phosphate dihydrate in 500 mL of water, and adjust to pH 8.0 with sodium hydroxide TS. To 100 mL of this solution add 400 mL of acetonitrile and 300 mL of water.

**Flow rate:** Adjust the flow rate so that the retention time of clorazepic acid is about 1.3 minutes.

**Time span of measurement:** About 10 times as long as the retention time of clorazepic acid, beginning after the solvent peak.

**System suitability—**

**Test for required detectability:** To exactly 5 mL of the standard solution add the mixture of water, potassium carbonate solution (97 in 1000) and acetonitrile (3:1:1) to make exactly 25 mL. Confirm that the peak area of clorazepic acid obtained from 5  $\mu\text{L}$  of this solution is equivalent to 15 to 25 % of that from 5  $\mu\text{L}$  of the standard solution.

**System performance:** When the procedure is run with 5  $\mu\text{L}$  of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of clorazepic acid are not less than 3000 and not more than 1.5, respectively.

**System repeatability:** When the test is repeated 6 times with 5  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the peak area of clorazepic acid is not more than 1.5%.

**Loss on drying** <2.41> Not more than 0.5% (1 g, in vacuum, phosphorus (V) oxide, 60°C, 5 hours).

**Assay** Weigh accurately about 0.15 g of Clorazepate Dipotassium, previously dried, dissolve in 100 mL of acetic acid (100), and titrate <2.50> with 0.1 mol/L perchloric acid VS until the color of solution changes from violet to blue-green through blue (indicator: 3 drops of crystal violet TS). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS  
= 13.63 mg of  $\text{C}_{16}\text{H}_{10}\text{ClKN}_2\text{O}_3\cdot\text{KOH}$

**Containers and storage** Containers—Tight containers.  
Storage—Light-resistant.

**Add the following:**

## Clorazepate Dipotassium Capsules

クロラゼパ酸二カリウムカプセル

Clorazepate Dipotassium Capsules contain not less than 93.0% and not more than 107.0% of the labeled amount of clorazepate dipotassium ( $\text{C}_{16}\text{H}_{10}\text{ClKN}_2\text{O}_3\cdot\text{KOH}$ ; 408.92).

**Method of preparation** Prepare as directed under Capsules, with Clorazepate Dipotassium.

**Identification** To 10 mL of the sample solution obtained in the Assay add water to make 20 mL. Determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 228 nm and 232 nm.

**Purity** Related substances—Take out the contents of Clorazepate Dipotassium Capsules, and powder. To a portion of the powder, equivalent to 15 mg of Clorazepate Dipotassium according to the labeled amount, add a mixture of water, potassium carbonate solution (97 in 1000) and acetonitrile (3:1:1) to make 25 mL, and mix for 10 minutes. Filter the solution through a membrane filter with a pore size not exceeding 0.45  $\mu\text{m}$ , discard the first 5 mL of the filtrate, and use the subsequent filtrate as the sample solution. Pipet 1 mL of the sample solution, add a mixture of water, potassium carbonate solution (97 in 1000) and acetonitrile (3:1:1) to make exactly 200 mL, and use this solution as the standard solution. Then, proceed as directed in the Purity (4) under Clorazepate Dipotassium: the peak area of nordiazepam, having the relative retention time of about 3.0 with respect to clorazepic acid, obtained from the sample solution is not larger than 3 times the peak area of clorazepic acid from the standard solution, and the total area of the peaks other than clorazepic acid and nordiazepam from the sample solution is not larger than the peak area of clorazepic acid from the standard solution. For this comparison, use the peak area of nordiazepam after multiplying by the relative response factor, 0.64.

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 capsule of Clorazepate Dipotassium Capsules add 70 mL of water, shake for 15 minutes, and add water to make exactly 100 mL. Centrifuge the solution, pipet  $V$  mL of the supernatant liquid, add water to make exactly  $V'$  mL so that each mL contains about 12  $\mu\text{g}$  of clorazepate dipotassium ( $\text{C}_{16}\text{H}_{10}\text{ClKN}_2\text{O}_3\cdot\text{KOH}$ ), and use this solution as the sample solution. Then, proceed as directed in the Assay.

Amount (mg) of clorazepate dipotassium  
( $\text{C}_{16}\text{H}_{10}\text{ClKN}_2\text{O}_3\cdot\text{KOH}$ )  
=  $W_S \times (A_T/A_S) \times (V'/V) \times (2/25)$

$W_S$ : Amount (mg) of clorazepate dipotassium for assay

**Dissolution** <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method using the sinker, using 900 mL of water as the dissolution medium, the dissolution rate in 30 minutes of Clorazepate Dipotassium Capsules is not less than 80%.

Start the test with 1 capsule of Clorazepate Dipotassium Capsules, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45  $\mu\text{m}$ . Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, add water to make exactly  $V'$  mL so that

each mL contains about 8.3  $\mu\text{g}$  of clorazepate dipotassium ( $\text{C}_{16}\text{H}_{10}\text{ClKN}_2\text{O}_3\cdot\text{KOH}$ ) according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 21 mg of clorazepate dipotassium for assay, previously dried in vacuum over phosphorus (V) oxide at 60°C for 5 hours, and dissolve in water to make exactly 100 mL. Pipet 4 mL of this solution, add water to make exactly 100 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , at 252 nm of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>.

Dissolution rate (%) with respect to the labeled amount of clorazepate dipotassium ( $\text{C}_{16}\text{H}_{10}\text{ClKN}_2\text{O}_3\cdot\text{KOH}$ )

$$= W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 36$$

$W_S$ : Amount (mg) of clorazepate dipotassium for assay

$C$ : Labeled amount (mg) of clorazepate dipotassium ( $\text{C}_{16}\text{H}_{10}\text{ClKN}_2\text{O}_3\cdot\text{KOH}$ ) in 1 capsule

**Assay** Carefully take out the contents of not less than 20 Clorazepate Dipotassium Capsules, weigh accurately the mass of the contents, and powder. Weigh accurately a portion of the powder, equivalent to about 15 mg of clorazepate dipotassium ( $\text{C}_{16}\text{H}_{10}\text{ClKN}_2\text{O}_3\cdot\text{KOH}$ ), add 70 mL of water, shake for 15 minutes, and add water to make exactly 100 mL. Centrifuge the solution, pipet 4 mL of the supernatant liquid, add water to make exactly 50 mL, and use this solution as the sample solution. Separately, weigh accurately about 15 mg of clorazepate dipotassium for assay, previously dried in vacuum over phosphorus (V) oxide at 60°C for 5 hours, and dissolve in water to make exactly 100 mL. Pipet 4 mL of this solution, add water to make exactly 50 mL, and use this solution as the standard solution. Perform the test with the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>, and determine the absorbances,  $A_T$  and  $A_S$ , at 252 nm.

$$\begin{aligned} &\text{Amount (mg) of clorazepate dipotassium} \\ &(\text{C}_{16}\text{H}_{10}\text{ClKN}_2\text{O}_3\cdot\text{KOH}) \\ &= W_S \times (A_T/A_S) \end{aligned}$$

$W_S$ : Amount (mg) of clorazepate dipotassium for assay

**Containers and storage** Containers—Tight containers.

## Creosote

**Change the title of the monograph as follows:**

## Wood Creosote

木クレオソート

## Cyanocobalamin

シアノコバラミン

**Change the Identification (2) and (3) to read:**

### Identification

(2) Mix 1 mg of Cyanocobalamin with 50 mg of potassium hydrogen sulfate, and fuse by igniting. Cool, break up the mass with a glass rod, add 3 mL of water, and dissolve by boiling. Add 1 drop of phenolphthalein TS, then add dropwise sodium hydroxide TS until a light red color just develops. Add 0.5 g of sodium acetate trihydrate, 0.5 mL of dilute acetic acid and 0.5 mL of a solution of disodium 1-nitroso-2-naphthol-3,6-disulfonate (1 in 500): a red to orange-red color is immediately produced. Then add 0.5 mL of hydrochloric acid, and boil for 1 minute: the red color does not disappear.

(3) Transfer 5 mg of Cyanocobalamin to a 50-mL distilling flask, dissolve in 5 mL of water, and add 2.5 mL of hypophosphorous acid. Connect the flask with a short condenser, and dips its tip into a test tube containing 1 mL of a solution of sodium hydroxide (1 in 50). Heat gently for 10 minutes, then distil 1 mL into a test tube. To the test tube add 4 drops of a saturated solution of ammonium iron (II) sulfate hexahydrate, shake gently, then add about 30 mg of sodium fluoride, and heat the contents to boil. Immediately add dropwise diluted sulfuric acid (1 in 7) until a clear solution results, then add 3 to 5 drops more of diluted sulfuric acid (1 in 7): a blue to blue-green color develops.

**Change the Purity (2) to read:**

### Purity

(2) Related substances—Conduct this procedure using light-resistant vessels. Dissolve 10 mg of Cyanocobalamin in 10 mL of the mobile phase, and use this solution as the sample solution. Pipet 3 mL of the sample solution, add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the total area of the peak other than cyanocobalamin obtained from the sample solution is not larger than the peak area of cyanocobalamin from the standard solution.

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 361 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

Column temperature: A constant temperature of about 30°C.

Mobile phase: Dissolve 10 g of anhydrous disodium hydrogen phosphate in 1000 mL of water, and adjust to pH 3.5 with phosphoric acid. To 147 mL of this solution add 53



mL of methanol.

Flow rate: Adjust the flow rate so that the retention time of cyanocobalamin is about 7 minutes.

Time span of measurement: About 4 times as long as the retention time of cyanocobalamin, beginning after the solvent peak.

**System suitability**—

Test for required detectability: Pipet 1 mL of the sample solution, add the mobile phase to make exactly 100 mL, and use this solution as the solution for system suitability test. Pipet 1 mL of the solution for system suitability test, and add the mobile phase to make exactly 10 mL. Confirm that the peak area of cyanocobalamin obtained with 20  $\mu$ L of this solution is equivalent to 7 to 13% of that with 20  $\mu$ L of the solution for system suitability test.

System performance: Perform this procedure quickly after the solution is prepared. To 25 mg of cyanocobalamin add 10 mL of water, and warm, if necessary, to dissolve. After cooling, add 0.5 mL of sodium toluenesulfonchloramide TS, 0.5 mL of 0.05 mol/L hydrochloric acid TS and water to make 25 mL, mix, and allow the solution to stand for 5 minutes. To 1 mL of the solution add the mobile phase to make 10 mL. When the procedure is run with 20  $\mu$ L of the solution under the above operating conditions, two principal peaks appear with the resolution between these peaks being not less than 2.5.

System repeatability: When the test is repeated 6 times with 20  $\mu$ L of the solution for system suitability test under the above operating conditions, the relative standard deviation of the peak area of cyanocobalamin is not more than 3.0%.

## Cyanocobalamin Injection

シアノコバラミン注射液

**Change the Description to read:**

**Description** Cyanocobalamin Injection is a clear, light red to red liquid.

**Add the following next to Identification:**

**Bacterial endotoxins** <4.01> Less than 0.30 EU/ $\mu$ g.

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.


**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Add the following:**

## L-Cysteine

L-システイン



$C_3H_7NO_2S$ : 121.16

(2R)-2-Amino-3-sulfanylpropanoic acid [52-90-4]

L-Cysteine contains not less than 98.5% and not more than 101.0% of  $C_3H_7NO_2S$ , calculated on the dried basis.

**Description** L-Cysteine occurs as white crystals or a white crystalline powder. It has a characteristic odor and a pungent taste.

It is freely soluble in water, and practically insoluble in ethanol (99.5).

It dissolves in 1 mol/L hydrochloric acid TS.

**Identification** Determine the infrared absorption spectrum of L-Cysteine as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Optical rotation** <2.49>  $[\alpha]_D^{20}$ : +8.0 – +10.0° (2 g calculated on the dried basis, 1 mol/L hydrochloric acid TS, 25 mL, 100 mm).

**pH** <2.54> The pH of a solution prepared by dissolving 1.25 g of L-Cysteine in 50 mL of water is 4.7 to 5.7.

**Purity** (1) Clarity and color of solution—Dissolve 1.0 g of L-Cysteine in 20 mL of water: the solution is clear and colorless.

(2) Chloride <1.03>—Dissolve 0.30 g of L-Cysteine in 10 mL of diluted nitric acid (1 in 4), add 10 mL of hydrogen peroxide (30), heat for 20 minutes in a boiling water bath, cool, and then add water to make 50 mL. Perform the test using this solution as the test solution. Prepare the control solution with 0.35 mL of 0.01 mol/L hydrochloric acid VS (not more than 0.041%).

(3) Sulfate <1.14>—Dissolve 0.6 g of L-Cysteine in 30 mL of water and 3 mL of dilute hydrochloric acid, and add water to make 50 mL. Perform the test using this solution as the test solution. Prepare the control solution as follows: To 0.35 mL of 0.005 mol/L sulfuric acid VS add 3 mL of dilute hydrochloric acid and water to make 50 mL. Prepare the test solution and the control solution with 4 mL of barium chloride TS, respectively (not more than 0.028%).

(4) Ammonium <1.02>—Perform the test with 0.25 g of L-Cysteine, using the distillation under reduced pressure. Prepare the control solution with 5.0 mL of Standard Ammonium Solution (not more than 0.02%).

(5) Heavy metals <1.07>—Proceed with 1.0 g of L-Cysteine according to Method 4, and perform the test.

Prepare the control solution with 1.0 mL of Standard Lead Solution (not more than 10 ppm).

(6) Iron <1.10>—Prepare the test solution with 1.0 g of L-Cysteine according to Method 1, and perform the test using Method A. Prepare the control solution with 1.0 mL of Standard Iron Solution (not more than 10 ppm).

(7) Related substances—Dissolve 0.10 g of L-Cysteine in *N*-ethylmaleimide solution (1 in 50) to make 10 mL, leave for 30 minutes, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add water to make exactly 10 mL, pipet 1 mL of this solution, add water to make exactly 50 mL, and use this solution as the standard solution (1). Separately, dissolve 0.10 g of L-cystine in 0.5 mol/L hydrochloric acid TS to make 20 mL. Pipet 1 mL of this solution, add water to make 100 mL, and use this solution as the standard solution (2). Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solutions (1) and (2) on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of 1-butanol, water, and acetic acid (100) (3:1:1) to a distance of about 10 cm, and dry the plate for 30 minutes at 80°C. Spray the plate evenly with a solution of ninhydrin in a mixture of methanol and acetic acid (100) (97:3) (1 in 100), and then heat at 80°C for 10 minutes: the spot obtained from the sample solution corresponding to the spot obtained from the standard solution (2) is not more intense than the spot from the standard solution (2). Also, the spots other than the principal spot and the spots mentioned above from the sample solution are not more intense than the spot from the standard solution (1).

**Loss on drying** <2.41> Not more than 0.5% (1 g, in vacuum, phosphorus (V) oxide, 3 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.2 g of L-Cysteine, place it in a stoppered flask, and dissolve in 20 mL of water. Dissolve 4 g of potassium iodide in this solution, immediately place in ice cold water, add 5 mL of dilute hydrochloric acid and exactly 25 mL of 0.05 mol/L iodine VS, leave in a dark place for 20 minutes, and then titrate <2.50> an excess amount of iodine with 0.1 mol/L sodium thiosulfate VS (indicator: starch TS). Perform a blank determination using the same method.


Each mL of 0.05 mol/L iodine VS = 12.12 mg of C<sub>3</sub>H<sub>7</sub>NO<sub>2</sub>S

**Containers and storage** Containers—Tight containers.

**Add the following:**

## L-Cysteine Hydrochloride Hydrate

L-システイン塩酸塩水和物



C<sub>3</sub>H<sub>7</sub>NO<sub>2</sub>S.HCl.H<sub>2</sub>O: 175.63

(2*R*)-2-Amino-3-sulfanylpropanoic acid monohydrochloride monohydrate [7048-04-6]

L-Cysteine Hydrochloride Hydrate contains not less than 98.5% and not more than 101.0% of L-cysteine hydrochloride (C<sub>3</sub>H<sub>7</sub>NO<sub>2</sub>S.HCl: 157.62), calculated on the dried basis.

**Description** L-Cysteine Hydrochloride Hydrate occurs as white crystals or crystalline powder. It has a characteristic odor and a strong acid taste.

It is very soluble in water, and soluble in ethanol (99.5).

It dissolves in 6 mol/L hydrochloric acid TS.

**Identification** (1) Determine the infrared absorption spectrum of L-Cysteine Hydrochloride Hydrate as directed in the potassium chloride disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

(2) To 10 mL of a solution of L-Cysteine Hydrochloride Hydrate (1 in 50) add 1 mL of hydrogen peroxide (30), heat on a water bath for 20 minutes, and cool: the solution responds to the Qualitative Tests <1.09> (2) for chloride.

**Optical rotation** <2.49> [ $\alpha$ ]<sub>D</sub><sup>20</sup>: +6.0 – +7.5° (2 g, calculated on the dried basis, 6 mol/L hydrochloric acid TS, 25 mL, 100 mm).

**pH** <2.54> The pH of a solution prepared by dissolving 1.0 g of L-Cysteine Hydrochloride Hydrate in 100 mL of water is between 1.3 and 2.3.

**Purity** (1) Clarity and color of solution—A solution obtained by dissolving 1.0 g of L-Cysteine Hydrochloride Hydrate in 10 mL of water is clear and colorless.

(2) Sulfate <1.14>—Dissolve 0.8 g of L-Cysteine Hydrochloride Hydrate in 30 mL of water and 3 mL of dilute hydrochloric acid, and add water to make 50 mL. Perform the test using this solution as the test solution. Prepare the control solution as follows: To 0.35 mL of 0.005 mol/L sulfuric acid VS add 3 mL of dilute hydrochloric acid and water to make 50 mL. To both of the test solution and the control solution add 4 mL of barium chloride TS (not more than 0.021%).

(3) Ammonium <1.02>—Perform the test with 0.25 g of L-Cysteine Hydrochloride Hydrate using the distillation under reduced pressure. Prepare the control solution with 5.0 mL of Standard Ammonium Solution (not more than 0.02%).

(4) Heavy metals <1.07>—Proceed with 1.0 g of

L-Cysteine Hydrochloride Hydrate according to Method 4, and perform the test. Prepare the control solution with 1.0 mL of Standard Lead Solution (not more than 10 ppm).

(5) Iron <1.10>—Prepare the test solution with 1.0 g of L-Cysteine Hydrochloride Hydrate according to Method 1, and perform the test according to Method A. Prepare the control solution with 1.0 mL of Standard Iron Solution (not more than 10 ppm).

(6) Related substances—Dissolve 0.10 g of L-Cysteine Hydrochloride Hydrate in *N*-ethylmaleimide solution (1 in 50) to make 10 mL, allow to stand for 30 minutes, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add water to make exactly 10 mL. Pipet 1 mL of this solution, add water to make exactly 50 mL, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-Layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Then develop with a mixture of 1-butanol, water and acetic acid (100) (3:1:1) to a distance of about 10 cm, and dry the plate at 80°C for 30 minutes. Spray evenly a solution of ninhydrin in a mixture of methanol and acetic acid (100) (97:3) (1 in 100) on the plate, and then heat at 80°C for 10 minutes: the spot other than the principal spot obtained with the sample solution is not more intense than the spot with the standard solution.

**Loss on drying** <2.41> 8.5 – 12.0% (1 g, in vacuum, phosphorus (V) oxide, 20 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.25 g of L-Cysteine Hydrochloride Hydrate, place in a glass-stoppered flask, and dissolve in 20 mL of water. Dissolve 4 g of potassium iodide in this solution, soak immediately in ice cold water, add 5 mL of dilute hydrochloric acid and exactly 25 mL of 0.05 mol/L iodine VS, allow to stand for 20 minutes in a dark place, titrate <2.50> the excess of iodine with 0.1 mol/L sodium thiosulfate VS (indicator: starch TS). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.05 mol/L iodine VS  
= 15.76 mg of  $C_3H_7NO_2S.HCl$

**Containers and storage** Containers—Tight containers.

## Deferoxamine Mesilate

デフェロキサミンメシル酸塩

**Change the Identification (2) to read:**

### Identification

(2) A 50 mg portion of Deferoxamine Mesilate responds to the Qualitative Tests <1.09> (1) for mesilate.

## Dehydrocholic Acid Injection

デヒドロコール酸注射液

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Deslanoside Injection

デスラノシド注射液

**Add the following next to Identification:**

**Bacterial endotoxins** <4.01> Less than 500 EU/mg.

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Dextran 40

デキストラン 40

**Delete the Pyrogen and add the following next to Residue on ignition:**

**Bacterial endotoxins** <4.01> Less than 2.5 EU/g.

**Change to read:****Anhydrous Dibasic Calcium Phosphate**

無水リン酸水素カルシウム

CaHPO<sub>4</sub>: 136.06  
[7757-93-9]

This monograph is harmonized with the European Pharmacopoeia and the U.S. Pharmacopoeia. The parts of the text that are not harmonized are marked with symbols (♦ ◆).

Anhydrous Dibasic Calcium Phosphate contains not less than 98.0% and not more than 103.0% of CaHPO<sub>4</sub>.

♦**Description** Anhydrous Dibasic Calcium Phosphate occurs as white, crystalline powder or granules.

It is practically insoluble in water and in ethanol (99.5).

It dissolves in dilute hydrochloric acid and in dilute nitric acid.◆

**Identification (1)** Dissolve 0.1 g of Anhydrous Dibasic Calcium Phosphate in 10 mL of 2 mol/L hydrochloric acid TS by warming, add 2.5 mL of ammonia TS dropwise with shaking, and add 5 mL of ammonium oxalate TS: a white precipitate is produced.

**(2)** Dissolve 0.1 g of Anhydrous Dibasic Calcium Phosphate in 5 mL of dilute nitric acid, and add 2 mL of hexaammonium heptamolybdate TS after warming at 70°C for 1 to 2 minutes: a yellow precipitate is produced.

**Purity (1)** Acid-insoluble substances—Dissolve 5.0 g of Anhydrous Dibasic Calcium Phosphate in 40 mL of water and 10 mL of hydrochloric acid, and boil gently for 5 minutes. After cooling, collect the insoluble substance using a filter paper for assay. Wash with water until no more turbidity of the washings is produced when silver nitrate TS is added. Ignite to incinerate the residue and the filter paper at 600 ± 50°C: the mass is not more than 10 mg (not more than 0.2%).

**(2)** Chloride <1.03>—Dissolve 0.20 g of Anhydrous Dibasic Calcium Phosphate in 20 mL of water and 13 mL of dilute nitric acid, add water to make 100 mL, and filter, if necessary. Perform the test using a 50-mL portion of this solution as the test solution. Prepare the control solution with 0.70 mL of 0.01 mol/L hydrochloric acid VS (not more than 0.248%).

**(3)** Sulfate <1.14>—Dissolve 0.5 g of Anhydrous Dibasic Calcium Phosphate in 5 mL of water and 5 mL of dilute hydrochloric acid, add water to make 100 mL, and filter, if necessary. Take 20 mL of this solution, add 1 mL of dilute hydrochloric acid, and add water to make 50 mL. Perform the test using this solution as the test solution. Prepare the control solution with 1.0 mL of 0.005 mol/L sulfuric acid VS (not more than 0.48%).

**(4)** Carbonate—Mix 1.0 g of Anhydrous Dibasic Calci-

um Phosphate with 5 mL of freshly boiled and cooled water, and add immediately 2 mL of hydrochloric acid: no effervescence occurs.

♦**(5)** Heavy metals <1.07>—Dissolve 0.65 g of Anhydrous Dibasic Calcium Phosphate in a mixture of 5 mL of water and 5 mL of dilute hydrochloric acid by warming, cool, and add ammonia TS until precipitates begin to form in the solution. Dissolve the precipitates by adding a small amount of dilute hydrochloric acid dropwise, add 10 mL of hydrochloric acid-ammonium acetate buffer solution, pH 3.5, and water to make 50 mL, and perform the test using this solution as the test solution. Prepare the control solution as follows: to 10 mL of hydrochloric acid-ammonium acetate buffer solution, pH 3.5, add 2.0 mL of Standard Lead Solution and water to make 50 mL (not more than 31 ppm).◆

**(6)** Barium—Heat 0.5 g of Anhydrous Dibasic Calcium Phosphate with 10 mL of water, add 1 mL of hydrochloric acid dropwise with stirring, and filter after cooling, if necessary. Add 2 mL of potassium sulfate TS to this solution, and allow to stand for 10 minutes: no turbidity forms.

♦**(7)** Arsenic <1.11>—Dissolve 1.0 g of Anhydrous Dibasic Calcium Phosphate in 5 mL of dilute hydrochloric acid, and perform the test with this solution as the test solution (not more than 2 ppm).◆

**Loss on ignition** <2.43> Not less than 6.6% and not more than 8.5% (1 g, 800 – 825°C, constant mass).

**Assay** Weigh accurately about 0.4 g of Anhydrous Dibasic Calcium Phosphate, dissolve in 12 mL of dilute hydrochloric acid, and add water to make exactly 200 mL. Pipet 20 mL of this solution, add exactly 25 mL of 0.02 mol/L disodium dihydrogen ethylenediamine tetraacetate VS, 50 mL of water and 5 mL of ammonia-ammonium chloride buffer solution, pH 10.7, and titrate <2.50> the excess of disodium dihydrogen ethylenediamine tetraacetate with 0.02 mol/L zinc sulfate VS (indicator: 25 mg of eriochrome black T-sodium chloride indicator). Perform a blank determination in the same manner.

Each mL of 0.02 mol/L disodium dihydrogen ethylenediamine tetraacetate VS

= 2.721 mg of CaHPO<sub>4</sub>

♦**Containers and storage** Containers—Well-closed containers.◆

**Change to read:****Dibasic Calcium Phosphate Hydrate**

リン酸水素カルシウム水和物

CaHPO<sub>4</sub>·2H<sub>2</sub>O: 172.09

[7789-77-7]

This monograph is harmonized with the European Pharmacopoeia and the U.S. Pharmacopoeia. The parts of the text that are not harmonized are marked with symbols (◆ ◆).

Dibasic Calcium Phosphate Hydrate contains not less than 98.0% and not more than 105.0% of CaHPO<sub>4</sub>·2H<sub>2</sub>O.

◆**Description** Dibasic Calcium Phosphate Hydrate occurs as a white, crystalline powder.

It is practically insoluble in water and in ethanol (99.5).

It dissolves in dilute hydrochloric acid and in dilute nitric acid.◆

**Identification (1)** Dissolve 0.1 g of Dibasic Calcium Phosphate Hydrate in 10 mL of 2 mol/L hydrochloric acid TS by warming, add 2.5 mL of ammonia TS dropwise with shaking, and add 5 mL of ammonium oxalate TS: a white precipitate is produced.

(2) Dissolve 0.1 g of Dibasic Calcium Phosphate Hydrate in 5 mL of dilute nitric acid, and add 2 mL of hexaammonium heptamolybdate TS after warming at 70°C for 1 to 2 minutes: a yellow precipitate is produced.

**Purity (1)** Acid-insoluble substance—Dissolve 5.0 g of Dibasic Calcium Phosphate Hydrate in 40 mL of water and 10 mL of hydrochloric acid, and boil gently for 5 minutes. After cooling, collect the insoluble substance using a filter paper for assay. Wash with water until no more turbidity of the washing is produced when silver nitrate TS is added. Ignite to incinerate the residue and filter paper at 600 ± 50°C: the mass is not more than 10 mg (not more than 0.2%).

(2) Chloride <1.03>—Dissolve 0.20 g of Dibasic Calcium Phosphate Hydrate in 20 mL of water and 13 mL of dilute nitric acid, add water to make 100 mL, and filter, if necessary. Perform the test using a 50-mL portion of this solution as the test solution. Prepare the control solution with 0.70 mL of 0.01 mol/L hydrochloric acid VS (not more than 0.248%).

(3) Sulfate <1.14>—Dissolve 0.5 g of Dibasic Calcium Phosphate Hydrate in 5 mL of water and 5 mL of dilute hydrochloric acid, add water to make 100 mL, and filter, if necessary. Take 20 mL of this solution, add 1 mL of dilute hydrochloric acid, and add water to make 50 mL. Perform the test using this solution as the test solution. Prepare the control solution with 1.0 mL of 0.005 mol/L sulfuric acid VS (not more than 0.48%).

(4) Carbonate—Mix 1.0 g of Dibasic Calcium Phosphate Hydrate with 5 mL of freshly boiled and cooled water,

and add immediately 2 mL of hydrochloric acid: no effervescence occurs.

◆(5) Heavy metals <1.07>—Dissolve 0.65 g of Dibasic Calcium Phosphate Hydrate in a mixture of 5 mL of water and 5 mL of dilute hydrochloric acid by warming, cool, and add ammonia TS until precipitates begin to form in the solution. Dissolve the precipitates by adding a small amount of dilute hydrochloric acid dropwise, add 10 mL of hydrochloric acid-ammonium acetate buffer solution, pH 3.5, and water to make 50 mL, and perform the test using this solution as the test solution. Prepare the control solution as follows: to 10 mL of hydrochloric acid-ammonium acetate buffer solution, pH 3.5, add 2.0 mL of Standard Lead Solution and water to make 50 mL (not more than 31 ppm).◆

(6) Barium—Heat 0.5 g of Dibasic Calcium Phosphate Hydrate with 10 mL of water, add 1 mL of hydrochloric acid dropwise with stirring, and filter after cooling, if necessary. Add 2 mL of potassium sulfate TS to this solution, and allow to stand for 10 minutes: no turbidity forms.

◆(7) Arsenic <1.11>—Dissolve 1.0 g of Dibasic Calcium Phosphate Hydrate in 5 mL of dilute hydrochloric acid, and perform the test with this solution as the test solution (not more than 2 ppm).◆

**Loss on ignition <2.43>** Not less than 24.5% and not more than 26.5% (1 g, 800 – 825°C, constant mass).

**Assay** Weigh accurately about 0.4 g of Dibasic Calcium Phosphate Hydrate, dissolve in 12 mL of dilute hydrochloric acid, and add water to make exactly 200 mL. Pipet 20 mL of this solution, add exactly 25 mL of 0.02 mol/L disodium dihydrogen ethylenediamine tetraacetate VS, 50 mL of water and 5 mL of ammonia-ammonium chloride buffer solution, pH 10.7, and titrate <2.50> the excess of disodium dihydrogen ethylenediamine tetraacetate with 0.02 mol/L zinc sulfate VS (indicator: 25 mg of eriochrome black T-sodium chloride indicator). Perform a blank determination in the same manner.


Each mL of 0.02 mol/L disodium dihydrogen ethylenediamine tetraacetate VS

= 3.442 mg of CaHPO<sub>4</sub>·2H<sub>2</sub>O

◆**Containers and storage** Containers—Well-closed containers.◆

**Add the following:****Domperidone**

ドンペリドン

C<sub>22</sub>H<sub>24</sub>ClN<sub>5</sub>O<sub>2</sub>; 425.915-Chloro-1-[1-[3-(2-oxo-2,3-dihydro-1*H*-benzimidazol-1-yl)propyl]piperidin-4-yl]-1,3-dihydro-2*H*-benzimidazol-2-one [57808-66-9]

Domperidone, when dried, contains not less than 99.0% and not more than 101.0% of C<sub>22</sub>H<sub>24</sub>ClN<sub>5</sub>O<sub>2</sub>.

**Description** Domperidone occurs as a white to pale yellow, crystalline powder or powder.

It is freely soluble in acetic acid (100), slightly soluble in methanol and in ethanol (99.5), very slightly soluble in 2-propanol, and practically insoluble in water.

Melting point: about 243°C (with decomposition).

**Identification (1)** Determine the absorption spectrum of a solution of Domperidone in a mixture of 2-propanol and 0.1 mol/L hydrochloric acid TS (9:1) (1 in 50,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Domperidone as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Purity (1)** Heavy metals <1.07>—Proceed with 2.0 g of Domperidone according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Related substances—Dissolve 30 mg of Domperidone in 100 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 10 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area of each solution by the automatic integration method: the area of each peak other than domperidone obtained from the sample solution is not larger than 1/2 times the peak area of domperidone from the standard solution. Furthermore, the

total area of the peaks other than domperidone from the sample solution is not larger than the peak area of domperidone from the standard solution.

**Operating conditions—**

**Detector:** An ultraviolet absorption photometer (wavelength: 287 nm).

**Column:** A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

**Column temperature:** A constant temperature of about 35°C.

**Mobile phase:** Dissolve 2.72 g of dipotassium hydrogen phosphate in water to make 1000 mL, and adjust the pH to 3.5 of this solution with a solution prepared by dissolving 2.31 g of phosphoric acid in water to make 1000 mL. To 500 mL of this solution add 500 mL of methanol.

**Flow rate:** Adjust the flow rate so that the retention time of domperidone is about 9 minutes.

**Time span of measurement:** About 4 times as long as the retention time of domperidone, beginning after the solvent peak.

**System suitability—**

**Test for required detectability:** Pipet 2 mL of the standard solution, and add methanol to make exactly 5 mL. Confirm that the peak area of domperidone obtained from 10 μL of this solution is equivalent to 30 to 50% of that from 10 μL of the standard solution.

**System performance:** Dissolve 10 mg of Domperidone and 20 mg of ethyl parahydroxybenzoate in 100 mL of methanol. When the procedure is run with 10 μL of this solution under the above operating conditions, domperidone and ethyl parahydroxybenzoate are eluted in this order with the resolution between these peaks being not less than 1.5.

**System repeatability:** When the test is repeated 6 times with 10 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of domperidone is not more than 3.0%.

**Loss on drying <2.41>** Not more than 0.5% (1 g, 105°C, 4 hours).

**Residue on ignition <2.44>** Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.5 g of Domperidone, previously dried, dissolve in 50 mL of acetic acid (100), and titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS  
= 42.59 mg of C<sub>22</sub>H<sub>24</sub>ClN<sub>5</sub>O<sub>2</sub>

**Containers and storage** Containers—Well-closed containers.

Storage—Light-resistant.

## Dopamine Hydrochloride Injection

ドパミン塩酸塩注射液

### Add the following next to Extractable volume:

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

### Add the following:

## Doxorubicin Hydrochloride for Injection

注射用ドキソルビン塩酸塩

Doxorubicin Hydrochloride for Injection is a preparation for injection, which is dissolved before use.

It contains not less than 90.0% and not more than 110.0% of the labeled amount of doxorubicin hydrochloride ( $C_{27}H_{29}NO_{11} \cdot HCl$ ; 579.98).

**Method of preparation** Prepare as directed under Injections, with Doxorubicin Hydrochloride.

**Description** Doxorubicin Hydrochloride for Injection occurs as red-orange, powder or masses.

**Identification** Dissolve an amount of Doxorubicin Hydrochloride for Injection, equivalent to 10 mg (potency) of Doxorubicin Hydrochloride according to the labeled amount, in methanol to make 100 mL. To 5 mL of this solution add methanol to make 50 mL, and determine the absorption spectrum of the solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 231 nm and 235 nm, between 250 nm and 254 nm, between 477 nm and 481 nm, and between 493 nm and 497 nm, and exhibits a shoulder between 528 nm and 538 nm.

**pH** <2.54> The pH of a solution, prepared by dissolving an amount of Doxorubicin Hydrochloride for Injection equivalent to 10 mg (potency) of Doxorubicin Hydrochloride according to the labeled amount in 2 mL of water, is 5.0 to 6.0.

**Purity** Clarity and color of solution—Dissolve an amount of Doxorubicin Hydrochloride for Injection, equivalent to 50 mg (potency) of Doxorubicin Hydrochloride according to the labeled amount, in 10 mL of water: the solution is clear and red.

**Water** <2.48> Not more than 4.0% (0.25 g, volumetric titration, direct titration).

**Bacterial endotoxins** <4.01> Less than 2.50 EU/mg (potency).

**Uniformity of dosage units** <6.02> It meets the requirement of the Mass variation test.

**Foreign insoluble matter** <6.06> Perform the test according to Method 2: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Assay** Weigh accurately the mass of the contents of not less than 10 containers of Doxorubicin Hydrochloride for Injection. Weigh accurately an amount of the contents, equivalent to about 10 mg (potency) of Doxorubicin Hydrochloride, add exactly 5 mL of the internal standard solution and the mobile phase to make 100 mL, and use the solution as the sample solution. Separately, weigh accurately an amount of Doxorubicin Hydrochloride Reference Standard, equivalent to 10 mg (potency), add exactly 5 mL of the internal standard solution and the mobile phase to make 100 mL, and use this solution as the standard solution. Perform the test with 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01>, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of doxorubicin to that of the internal standard.

$$\begin{aligned} &\text{Amount [mg (potency)] of doxorubicin hydrochloride} \\ & (C_{27}H_{29}NO_{11} \cdot HCl) \\ & = W_S \times (Q_T / Q_S) \end{aligned}$$

$W_S$ : Amount [mg (potency)] of Doxorubicin Hydrochloride Reference Standard

**Internal standard solution**—A solution of butyl parahydroxybenzoate in the mobile phase (1 in 1000).

**Operating conditions**—

**Detector**: An ultraviolet absorption photometer (wavelength: 254 nm).

**Column**: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

**Column temperature**: A constant temperature of about 25°C.

**Mobile phase**: Dissolve 3 g of sodium lauryl sulfate in 1000 mL of diluted phosphoric acid (7 in 5000). To this solution add 1000 mL of acetonitrile.

**Flow rate**: Adjust the flow rate so that the retention time of doxorubicin is about 8 minutes.

**System suitability**—

**System performance**: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, doxorubicin and the internal standard are eluted in this order with the resolution between these peaks being not less than 5, and the symmetry factor of the peak of doxorubicin is between 0.8 and 1.2.

**System repeatability**: When the test is repeated 6 times

with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of doxorubicin to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Hermetic containers.

## Edrophonium Chloride Injection

エドロホニウム塩化物注射液

### Add the following next to pH:

**Bacterial endotoxins** <4.01> Less than 15 EU/mg.

### Add the following next to Extractable volume:

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.


**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

### Add the following:

## Emorfazone

エモルファゾン



$\text{C}_{11}\text{H}_{17}\text{N}_3\text{O}_3$ ; 239.27

4-Ethoxy-2-methyl-5-(morpholin-4-yl)pyridazin-3(2H)-one [38957-41-4]

Emorfazone, when dried, contains not less than 98.5% and not more than 101.0% of  $\text{C}_{11}\text{H}_{17}\text{N}_3\text{O}_3$ .

**Description** Emorfazone occurs as colorless crystals or a white to light yellow crystalline powder.

It is very soluble in ethanol (99.5), and freely soluble in water and in acetic anhydride.

It dissolves in 1 mol/L hydrochloric acid TS.

It gradually turns yellow and decomposes on exposure to light.

**Identification** (1) Dissolve 20 mg of Emorfazone in 2 mL of 1 mol/L hydrochloric acid TS, and add 5 drops of Reinecke's TS: light red floating matters are formed.

(2) Determine the absorption spectrum of a solution of Emorfazone (1 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(3) Determine the infrared absorption spectrum of Emorfazone as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Melting point** <2.60> 89 – 92°C (after drying).

**Purity** (1) Chloride <1.03>—Perform the test with 1.0 g of Emorfazone. Prepare the control solution with 0.50 mL of 0.01 mol/L hydrochloric acid VS (not more than 0.018%).

(2) Heavy metals <1.07>—Proceed with 2.0 g of Emorfazone according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(3) Arsenic <1.11>—Prepare the test solution with 2.0 g of Emorfazone according to Method 3, and perform the test (not more than 1 ppm).

(4) Related substances—Conduct this procedure using light-resistant vessels. Dissolve 0.5 g of Emorfazone in 50 mL of the mobile phase, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: each peak area other than emorfazone obtained from the sample solution is not larger than 1/10 times the peak area of emorfazone from the standard solution, and the total area of the peaks other than the peak of emorfazone from the sample solution is not larger than 1/2 times the peak area of emorfazone from the standard solution.

**Operating conditions**—

**Detector:** An ultraviolet absorption photometer (wavelength: 254 nm).

**Column:** A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

**Column temperature:** A constant temperature of about 25°C.

**Mobile phase:** A mixture of water and methanol (11:10).

**Flow rate:** Adjust the flow rate so that the retention time of emorfazone is about 5 minutes.

**Time span of measurement:** About 2.5 times as long as the retention time of emorfazone, beginning after the solvent peak.

**System suitability**—

**Test for required detectability:** Pipet 1 mL of the standard solution, add the mobile phase to make exactly 20 mL. Confirm that the peak area of emorfazone obtained with 20  $\mu\text{L}$  of this solution is equivalent to 3.5 to 6.5% of that with 20  $\mu\text{L}$  of the standard solution.

**System performance:** Dissolve 16 mg of Emorfazone and 30 mg of 2,4-dinitrophenylhydrazine in 100 mL of



methanol. When the procedure is run with 20  $\mu\text{L}$  of this solution under the above operating conditions, emorfazone and 2,4-dinitrophenylhydrazine are eluted in this order with the resolution between these peaks being not less than 2.5.

System repeatability: When the test is repeated 6 times with 20  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the peak area of emorfazone is not more than 1.0%.

**Loss on drying** <2.41> Not more than 0.5% (1 g, in vacuum, 60°C, 4 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.2 g of Emorfazone, previously dried, dissolve in 60 mL of acetic anhydride, and titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.


Each mL of 0.1 mol/L perchloric acid VS  
= 23.93 mg of  $\text{C}_{11}\text{H}_{17}\text{N}_3\text{O}_3$

**Containers and storage** Containers—Tight containers.  
Storage—Light-resistant.

### Add the following:

## Enalapril Maleate

エナラプリルマレイン酸塩



$\text{C}_{20}\text{H}_{28}\text{N}_2\text{O}_5 \cdot \text{C}_4\text{H}_4\text{O}_4$ ; 492.52  
(2*S*)-1-[(2*S*)-2-[(1*S*)-1-Ethoxycarbonyl-3-phenylpropylamino]propanoyl]pyrrolidine-2-carboxylic acid monomaleate [76095-16-4]

Enalapril Maleate, when dried, contains not less than 98.0% and not more than 102.0% of  $\text{C}_{20}\text{H}_{28}\text{N}_2\text{O}_5 \cdot \text{C}_4\text{H}_4\text{O}_4$ .

**Description** Enalapril Maleate occurs as white crystals or a white crystalline powder.

It is freely soluble in methanol, sparingly soluble in water and in ethanol (99.5), and slightly soluble in acetonitrile.

Melting point: about 145°C (with decomposition).

**Identification (1)** Determine the infrared absorption spectra of Enalapril Maleate as directed in the potassium bromide disc method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Enalapril Maleate Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers.

(2) To 20 mg of Enalapril Maleate add 5 mL of 1 mol/L

hydrochloric acid TS, shake, add 5 mL of diethyl ether, and shake for 5 minutes. Take 3 mL of the upper layer, distil off the diethyl ether on a water bath, add 5 mL of water to the residue with shaking, and add 1 drop of potassium permanganate TS: the red color of the test solution immediately disappears.

**Optical rotation** <2.49>  $[\alpha]_D^{20}$ :  $-41.0 - -43.5^\circ$  (after drying, 0.25 g, methanol, 25 mL, 100 mm).

**Purity (1)** Heavy metals <1.07>—Proceed with 2.0 g of Enalapril Maleate according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Related substances—Dissolve 30 mg of Enalapril Maleate in 100 mL of a mixture of sodium dihydrogen phosphate TS, pH 2.5 and acetonitrile (19:1), and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mixture of sodium dihydrogen phosphate TS, pH 2.5 and acetonitrile (19:1) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 50  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area of these solutions by the automatic integration method: the area of the peak other than maleic acid and enalapril obtained from the sample solution is not larger than the peak area of enalapril from the standard solution. Furthermore, the total area of the peaks other than maleic acid and enalapril from the sample solution is not larger than twice the peak area of enalapril from the standard solution.

**Operating conditions**—

Detector, column, column temperature, mobile phases, mobile phase flow, and flow rate: Proceed as directed in the operating conditions in the Assay.

Time span of measurement: About 2 times as long as the retention time of enalapril, beginning after the peak of maleic acid.

**System suitability**—

Test for required detectability: Pipet 1 mL of the standard solution, and add a mixture of sodium dihydrogen phosphate TS, pH 2.5 and acetonitrile (19:1) to make exactly 10 mL. Confirm that the peak area of enalapril obtained from 50  $\mu\text{L}$  of this solution is equivalent to 7 to 13% of that from 50  $\mu\text{L}$  of the standard solution.

System performance: When the procedure is run with 50  $\mu\text{L}$  of the standard solution under the above conditions, the number of theoretical plates and the symmetry factor of the peak of enalapril are not less than 3000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 50  $\mu\text{L}$  of the standard solution under the above conditions, the relative standard deviation of the peak area of enalapril is not more than 2.0%.

**Loss on drying** <2.41> Not more than 1.0% (1 g, in vacuum, 60°C, 2 hours).

**Residue on ignition** <2.44> Not more than 0.2% (1 g).

**Assay** Weigh accurately about 30 mg each of Enalapril Maleate and Enalapril Maleate Reference Standard, both previously dried, and dissolve in a mixture of sodium dihydrogen phosphate TS, pH 2.5 and acetonitrile (19:1) to make exactly 100 mL, and use these solutions as the sample solution and standard solution. Perform the test with exactly 50  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas of enalapril,  $A_T$  and  $A_S$ , of both solutions.

$$\begin{aligned} &\text{Amount (mg) of } C_{20}H_{28}N_2O_5 \cdot C_4H_4O_4 \\ &= W_S \times (A_T/A_S) \end{aligned}$$

$W_S$ : Amount (mg) of Enalapril Maleate Reference Standard

*Operating conditions—*

**Detector:** An ultraviolet absorption photometer (wavelength: 215 nm).

**Column:** A stainless steel column 4.1 mm in inside diameter and 15 cm in length, packed with porous styrene-divinylbenzene copolymer for liquid chromatography (5  $\mu$ m in particle diameter).

**Column temperature:** A constant temperature of about 70°C.

**Mobile phase A:** Dissolve 3.1 g of sodium dihydrogen phosphate dihydrate in 900 mL of water, adjust the pH to 6.8 with a solution of sodium hydroxide (1 in 4), and add water to make 1000 mL. To 950 mL of this solution, add 50 mL of acetonitrile for liquid chromatography.

**Mobile phase B:** Dissolve 3.1 g of sodium dihydrogen phosphate dihydrate in 900 mL of water, adjust the pH to 6.8 with a solution of sodium hydroxide (1 in 4), and add water to make 1000 mL. To 340 mL of this solution, add 660 mL of acetonitrile for liquid chromatography.

**Mobile phase flow:** Control the concentration gradient by changing the ratio of the mobile phases A and B as follows.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0	95	5
0 – 20	95 → 40	5 → 60
20 – 25	40	60

Flow rate: 1.4 mL per minute.

*System suitability—*

**System performance:** When the procedure is run with 50  $\mu$ L of the standard solution under the above conditions, the number of theoretical plates and the symmetry factor of the peak of enalapril are not less than 3000 and not more than 2.0, respectively.

**System repeatability:** When the test is repeated 6 times with 50  $\mu$ L of the standard solution under the above conditions, the relative standard deviation of the peak area of enalapril is not more than 1.0%.

**Containers and storage** Containers—Well-closed containers.

**Add the following:**

## Enalapril Maleate Tablets

エナラプリルマレイン酸塩錠

Enalapril Maleate Tablets contain not less than 93.0% and not more than 107.0% of the labeled amount of enalapril maleate ( $C_{20}H_{28}N_2O_5 \cdot C_4H_4O_4$ : 492.52).

**Method of preparation** Prepare as directed under Tablets, with Enalapril Maleate.

**Identification** To a quantity of powdered Enalapril Maleate Tablets equivalent to 50 mg of Enalapril Maleate according to the labeled amount, add 20 mL of methanol, shake, centrifuge, and then use the supernatant liquid as the sample solution. Separately, dissolve 25 mg of enalapril maleate in 10 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-Layer Chromatography <2.03>. Spot 20  $\mu$ L each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of water, acetone, 1-butanol, acetic acid (100) and toluene (1:1:1:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): the  $R_f$  values of the 2 spots obtained from the sample solution and the 2 spots obtained from the standard solution are equivalent.

**Purity** Enalaprilat and enalapril diketopiperazine—Use the sample solution obtained in the Assay as the sample solution. Pipet 1 mL of the sample solution, add sodium dihydrogen phosphate TS, pH 2.2 to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 50  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area of both solutions by the automatic integration method: the peak area of enalaprilat, having the relative retention time of about 0.5 with respect to enalapril obtained from the sample solution, is not larger than 2 times the peak area of enalapril from the standard solution. Also, the peak area of enalapril diketopiperazine, having the relative retention time of about 1.5 is not larger than the peak area of enalapril from the standard solution.

*Operating conditions—*

Proceed as directed in the operating conditions in the Assay.

*System suitability—*

**Test for required detectability:** Pipet 1 mL of the standard solution, and add sodium dihydrogen phosphate TS, pH 2.2 to make exactly 10 mL. Confirm that the peak area of enalapril obtained from 50  $\mu$ L of this solution is equivalent to 7 to 13% of that from 50  $\mu$ L of the standard solution.

**System performance:** Proceed as directed in the system suitability in the Assay.

**System repeatability:** When the test is repeated 6 times

with 50  $\mu\text{L}$  of the standard solution under the above conditions, the relative standard deviation of the peak area of enalapril is not more than 2.0%.

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Take 1 tablet of Enalapril Maleate Tablets, add  $V/2$  mL of sodium dihydrogen phosphate TS, pH 2.2, treat with ultrasonic waves for 15 minutes, shake for 30 minutes, and add sodium dihydrogen phosphate TS, pH 2.2 to make exactly  $V$  mL so that 1 mL of the solution contains about 0.1 mg of enalapril maleate ( $\text{C}_{20}\text{H}_{28}\text{N}_2\text{O}_5 \cdot \text{C}_4\text{H}_4\text{O}_4$ ). Treat this solution with ultrasonic waves for 15 minutes, filter through a membrane filter with a pore size not exceeding 0.45  $\mu\text{m}$ , and use the filtrate as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} \text{Amount (mg) of enalapril maleate } (\text{C}_{20}\text{H}_{28}\text{N}_2\text{O}_5 \cdot \text{C}_4\text{H}_4\text{O}_4) \\ = W_S \times (A_T/A_S) \times (V/200) \end{aligned}$$

$W_S$ : Amount (mg) of Enalapril Maleate Reference Standard

**Dissolution** <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rates in 15 minutes of a 2.5- and 5-mg tablet of Enalapril Maleate Tablets and in 30 minutes of a 10-mg tablet of Enalapril Maleate Tablets are not less than 85%, respectively.

Start the test with 1 tablet of Enalapril Maleate Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45  $\mu\text{m}$ . Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, add water to make exactly  $V'$  mL so that each mL contains about 2.8  $\mu\text{g}$  of enalapril maleate ( $\text{C}_{20}\text{H}_{28}\text{N}_2\text{O}_5 \cdot \text{C}_4\text{H}_4\text{O}_4$ ) according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 14 mg of Enalapril Maleate Reference Standard, previously dried in vacuum at 60°C for 2 hours, and dissolve in water to make exactly 500 mL. Pipet 5 mL of this solution, add water to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 50  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the enalapril peak areas,  $A_T$  and  $A_S$ , of both solutions.

$$\begin{aligned} \text{Dissolution rate (\%)} \text{ with respect to the labeled amount of} \\ \text{enalapril maleate } (\text{C}_{20}\text{H}_{28}\text{N}_2\text{O}_5 \cdot \text{C}_4\text{H}_4\text{O}_4) \\ = W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 18 \end{aligned}$$

$W_S$ : Amount (mg) of Enalapril Maleate Reference Standard

$C$ : Labeled amount (mg) of enalapril maleate ( $\text{C}_{20}\text{H}_{28}\text{N}_2\text{O}_5 \cdot \text{C}_4\text{H}_4\text{O}_4$ ) in 1 tablet

**Operating conditions**—

Detector, column, column temperature, and flow rate: Proceed as directed in the operating conditions in the Assay.

Mobile phase: Dissolve 1.88 g of sodium dihydrogen phosphate dihydrate in 900 mL of water, adjust the pH to 2.2 with phosphoric acid, and add water to make 1000 mL. To 750 mL of this solution add 250 mL of acetonitrile.

**System suitability**—

System performance: When the procedure is run with 50  $\mu\text{L}$  of the standard solution under the above conditions, the number of theoretical plates and the symmetry factor of the peak of enalapril are not less than 300 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 50  $\mu\text{L}$  of the standard solution under the above conditions, the relative standard deviation of the peak area of enalapril is not more than 2.0%.

**Assay** Weigh accurately not less than 20 Enalapril Maleate Tablets, and powder. Weigh accurately a portion of the powder equivalent to about 10 mg of enalapril maleate ( $\text{C}_{20}\text{H}_{28}\text{N}_2\text{O}_5 \cdot \text{C}_4\text{H}_4\text{O}_4$ ), add 50 mL of sodium dihydrogen phosphate TS, pH 2.2, treat with ultrasonic waves for 15 minutes, shake for 30 minutes, and then add sodium dihydrogen phosphate TS, pH 2.2 to make exactly 100 mL. Treat this solution with ultrasonic waves for 15 minutes, filter through a membrane filter with a pore size not exceeding 0.45  $\mu\text{m}$ , and use this filtrate as the sample solution. Separately, weigh accurately about 20 mg of Enalapril Maleate Reference Standard, previously dried in vacuum at 60°C for 2 hours, dissolve in sodium dihydrogen phosphate TS, pH 2.2 to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 50  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the enalapril peak areas,  $A_T$  and  $A_S$ , of both solutions.

$$\begin{aligned} \text{Amount (mg) of enalapril maleate } (\text{C}_{20}\text{H}_{28}\text{N}_2\text{O}_5 \cdot \text{C}_4\text{H}_4\text{O}_4) \\ = W_S \times (A_T/A_S) \times (1/2) \end{aligned}$$

$W_S$ : Amount (mg) of Enalapril Maleate Reference Standard

**Operating conditions**—

Detector: An ultraviolet absorption photometer (wavelength: 215 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

Column temperature: A constant temperature of about 50°C.

Mobile phase: A mixture of sodium dihydrogen phosphate TS, pH 2.2 and acetonitrile (3:1).

Flow rate: Adjust the flow rate so that the retention time of enalapril is about 5 minutes.

**System suitability**—

System performance: Heat to fusion about 20 mg of enalapril maleate. After cooling, add 50 mL of acetonitrile, and treat with ultrasonic waves to dissolve. To 1 mL of this solution, add the standard solution to make 50 mL, and use this solution as the solution for system suitability test. When the procedure is run with 50  $\mu\text{L}$  of the solution for system

suitability test under the above conditions, enalapril and enalapril diketopiperazine, which has a relative retention time of 1.5 to enalapril, are eluted in this order with the resolution between these peaks being not less than 2.0.

System repeatability: When the test is repeated 6 times with 50  $\mu$ L of the solution for system suitability test under the above conditions, the relative standard deviation of the peak area of enalapril is not more than 1.0%.

**Containers and storage** Containers—Well-closed containers.

## Ephedrine Hydrochloride Injection

エフェドリン塩酸塩注射液

### Add the following next to Extractable volume:

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Ephedrine Hydrochloride Tablets

エフェドリン塩酸塩錠

### Add the following next to Identification:

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Ephedrine Hydrochloride Tablets add  $V$  mL of water so that each mL contains 0.25 mg of ephedrine hydrochloride ( $C_{10}H_{15}NO \cdot HCl$ ), then add exactly  $V/4$  mL of the internal standard solution, disperse the tablet into small particles using ultrasonic waves, then stir for a further 10 minutes in the same way. Shake this solution for 10 minutes, centrifuge, and use the supernatant liquid as the sample solution. Separately, weigh accurately about 25 mg of ephedrine hydrochloride for assay, previously dried at 105°C for 3 hours, dissolve in water to make exactly 100 mL. Pipet 20 mL of this solution, add exactly 5 mL of the internal standard solution, and use this solution as the standard solution. Then, proceed as directed in the Assay.

Amount (mg) of ephedrine hydrochloride ( $C_{10}H_{15}NO \cdot HCl$ )  
 $= W_S \times (Q_T/Q_S) \times (V/100)$

$W_S$ : Amount (mg) of ephedrine hydrochloride for assay

**Internal standard solution**—A solution of etilefrine hydrochloride (1 in 2000).

### Add the following:

## Erythromycin Enteric-Coated Tablets

エリスロマイシン腸溶錠

Erythromycin Enteric-Coated Tablets contain not less than 90.0% and not more than 110.0% of the labeled amount of erythromycin ( $C_{37}H_{67}NO_{13}$ ; 733.93).

**Method of preparation** Prepare as directed under Tablets, with Erythromycin.

**Identification** To a quantity of powdered Erythromycin Enteric-Coated Tablets, equivalent to 10 mg (potency) of Erythromycin according to the labeled amount, add 1 mL of methanol, shake well, filter, and use the filtrate as the sample solution. Separately, dissolve 10 mg of Erythromycin Reference Standard in 1 mL of methanol, and use this solution as the standard solution. Then, proceed as directed in the Identification (2) under Erythromycin.

**Loss on drying** <2.41> Not more than 10.0% (0.2 g, in vacuum not exceeding 0.67 kPa, 60°C, 3 hours).

**Uniformity of dosage units** <6.02> It meets the requirement of the Mass variation test.

**Disintegration** <6.09> It meets the requirement.

**Assay** Perform the test according to the Cylinder-plate method as directed under Microbial Assay for Antibiotics <4.02> according to the following conditions.

(i) Test organism, culture medium, and standard solutions—

Proceed as directed in the Assay under Erythromycin.

(ii) Sample solutions—Weigh accurately the mass of not less than 20 Erythromycin Enteric-Coated Tablets, and pulverize into a powder. Weigh accurately a portion of the powder, equivalent to about 25 mg (potency) of Erythromycin, add 25 mL of methanol, shake vigorously, add 0.1 mol/L phosphate buffer solution, pH 8.0, to make exactly 100 mL, and filter. Take exactly an appropriate volume of the filtrate, add 0.1 mol/L phosphate buffer solution, pH 8.0, to prepare solutions containing 20  $\mu$ g (potency) and 5  $\mu$ g (potency) per mL, and use these solutions as the high and low concentration sample solutions, respectively.

**Containers and storage** Containers—Well-closed containers.

**Add the following:****Etizolam Fine Granules**

エチゾラム細粒

Etizolam Fine Granules contain not less than 93.0% and not more than 107.0% of the labeled amount of etizolam ( $C_{17}H_{15}ClN_4S$ ; 342.85).

**Method of preparation** Prepare fine particles as directed under Powders, with Etizolam.

**Identification (1)** To a quantity of powdered Etizolam Fine Granules, equivalent to 5 mg of Etizolam according to the labeled amount, add 10 mL of methanol, shake, and filter through a membrane filter with a pore size not exceeding  $0.45\ \mu\text{m}$ . Evaporate the filtrate to dryness on a water bath, cool, and then dissolve the residue in 2 mL of sulfuric acid. The solution gives off a light yellow-green fluorescent when exposed to ultraviolet light (main wavelength: 365 nm).

(2) To a quantity of powdered Etizolam Fine Granules, equivalent to 1 mg of Etizolam according to the labeled amount, add 80 mL of 0.1 mol/L hydrochloric acid TS, shake, and then filter. Determine the absorption spectrum of the filtrate as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits absorption maxima between 249 nm and 253 nm, and between 292 nm and 296 nm, when perform the measurement within 10 minutes.

**Uniformity of dosage units <6.02>** The granules in single-unit container meet the requirement of the Mass variation test.

**Dissolution <6.10>** When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rate in 30 minutes of Etizolam Fine Granules is not less than 75%.

Start the test with an accurately weighed amount of Etizolam Fine Granules, equivalent to about 1 mg of etizolam ( $C_{17}H_{15}ClN_4S$ ) according to the labeled amount, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding  $0.45\ \mu\text{m}$ . Discard the first 10 mL of filtrate, pipet the subsequent 2 mL, add exactly 2 mL of acetonitrile, and use this solution as the sample solution. Separately, weigh accurately about 28 mg of etizolam for assay, previously dried at  $105^\circ\text{C}$  for 3 hours, and dissolve in methanol to make exactly 50 mL. Pipet 5 mL of this solution, and add water to make exactly 100 mL. Pipet 4 mL of this solution, and add water to make exactly 100 mL. Pipet 2 mL of this solution, add exactly 2 mL of acetonitrile, and use this solution as the standard solution. Perform the test with exactly  $50\ \mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the enalapril peak areas,  $A_T$  and  $A_S$ , of both solutions.

Dissolution rate (%) with respect to the labeled amount of etizolam ( $C_{17}H_{15}ClN_4S$ )

$$= (W_S/W_T) \times (A_T/A_S) \times (1/C) \times (18/5)$$

$W_S$ : Amount (mg) of etizolam for assay

$W_T$ : Amount (g) of sample

C: Labeled amount (mg) of etizolam ( $C_{17}H_{15}ClN_4S$ ) in 1 g

**Operating conditions—**

Detector: An ultraviolet absorption photometer (wavelength: 243 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography ( $5\ \mu\text{m}$  in particle diameter).

Column temperature: A constant temperature of about  $30^\circ\text{C}$ .

Mobile phase: A mixture of water and acetonitrile (1:1).

Flow rate: Adjust the flow rate so that the retention time of etizolam is about 7 minutes.

**System suitability—**

System performance: When the procedure is run with  $50\ \mu\text{L}$  of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of etizolam are not less than 3000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with  $50\ \mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the peak area of etizolam is not more than 2.0%.

**Particle size <6.03>** It meets the requirement.

**Assay** Weigh accurately an amount of Etizolam Fine Granules, equivalent to about 4 mg of etizolam ( $C_{17}H_{15}ClN_4S$ ), add 30 mL of water, and stir. Add 60 mL of methanol, stir for 20 minutes, add methanol to make exactly 100 mL, and centrifuge. Pipet 5 mL of the supernatant liquid, add exactly 10 mL of the internal standard solution, add diluted methanol (7 in 10) to make 25 mL, and use this solution as the sample solution. Separately, weigh accurately about 0.1 g of etizolam for assay, previously dried at  $105^\circ\text{C}$  for 3 hours, and dissolve in diluted methanol (7 in 10) to make exactly 100 mL. Pipet 2 mL of this solution, and add diluted methanol (7 in 10) to make exactly 100 mL. Pipet 10 mL of this solution, add exactly 10 mL of the internal standard solution, add diluted methanol (7 in 10) to make 25 mL, and use this solution as the standard solution. Perform the test with  $10\ \mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of etizolam to that of the internal standard.

Amount (mg) of etizolam ( $C_{17}H_{15}ClN_4S$ )

$$= W_S \times (Q_T/Q_S) \times (1/25)$$

$W_S$ : Amount (mg) of etizolam for assay

**Internal standard solution—**A solution of ethyl parahydroxybenzoate in diluted methanol (7 in 10) (1 in 50,000).

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 240 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 35°C.

Mobile phase: Dissolve 1.36 g of potassium dihydrogen phosphate in water to make 1000 mL, and adjust the pH to 3.5 with diluted phosphoric acid (1 in 10). To 550 mL of this solution add 450 mL of acetonitrile.

Flow rate: Adjust the flow rate so that the retention time of etizolam is about 6 minutes.

*System suitability—*

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the internal standard and etizolam are eluted in this order with the resolution between these peaks being not less than 3.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of etizolam to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

Storage—Light-resistant.

**Add the following:****Etizolam Tablets**

エチゾラム錠

Etizolam Tablets contain not less than 93.0% and not more than 107.0% of the labeled amount of etizolam (C<sub>17</sub>H<sub>15</sub>ClN<sub>4</sub>S: 342.85).

**Method of preparation** Prepare as directed under Tablets, with Etizolam.

**Identification (1)** To a quantity of powdered Etizolam Tablets, equivalent to 5 mg of Etizolam according to the labeled amount, add 10 mL of methanol, shake, and filter. Evaporate the filtrate to dryness on a water bath, cool, and then dissolve the residue in 2 mL of sulfuric acid. The solution gives off a light yellow-green fluorescence when exposed to ultraviolet light (main wavelength: 365 nm).

**(2)** To a quantity of powdered Etizolam Tablets, equivalent to 1 mg of Etizolam according to the labeled amount, add 80 mL of 0.1 mol/L hydrochloric acid TS, shake, and then filter through a membrane filter with a pore size not exceeding 0.45  $\mu$ m. Determine the absorption spectrum of this filtrate as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits absorption maxima between 249 nm and 253 nm, and between 292 nm and 296 nm

when perform the measurement within 10 minutes.

**Uniformity of dosage units <6.02>** Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Take 1 tablet of Etizolam Tablets, add 2.5 mL of water, and stir until it disintegrates. Add 20 mL of methanol, stir for 20 minutes, add methanol to make exactly 25 mL, and centrifuge. Pipet *V* mL of the supernatant liquid, add exactly 10 mL of the internal standard solution, add diluted methanol (9 in 10) to make 25 mL so that each mL contains about 8  $\mu$ g of etizolam (C<sub>17</sub>H<sub>15</sub>ClN<sub>4</sub>S), and use this solution as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} & \text{Amount (mg) of etizolam (C}_{17}\text{H}_{15}\text{ClN}_4\text{S)} \\ & = W_S \times (Q_T/Q_S) \times (1/V) \times (1/20) \end{aligned}$$

*W<sub>S</sub>*: Amount (mg) of etizolam for assay

*Internal standard solution*—A solution of ethyl parahydroxybenzoate in diluted methanol (9 in 10) (1 in 50,000).

**Dissolution <6.10>** When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rate in 30 minutes of Etizolam Tablets is not less than 70%.

Start the test with 1 tablet of Etizolam Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45  $\mu$ m. Discard the first 10 mL of the filtrate, pipet *V* mL of the subsequent filtrate, add water to make exactly *V'* mL so that each mL contains about 0.56  $\mu$ g of etizolam (C<sub>17</sub>H<sub>15</sub>ClN<sub>4</sub>S) according to the labeled amount. Pipet 2 mL of the solution, add exactly 2 mL of acetonitrile, and use this solution as the sample solution. Separately, weigh accurately about 28 mg of etizolam for assay, previously dried at 105°C for 3 hours, dissolve in 50 mL of methanol, and add water to make exactly 100 mL. Pipet 5 mL of this solution, add water to make exactly 100 mL. Pipet 4 mL of this solution, add water to make exactly 100 mL. Pipet 2 mL of this solution, add exactly 2 mL of acetonitrile, and use this solution as the standard solution. Perform the test with exactly 50  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas of etizolam, *A<sub>T</sub>* and *A<sub>S</sub>*, of both solutions.

Dissolution rate (%) with respect to the labeled amount of etizolam (C<sub>17</sub>H<sub>15</sub>ClN<sub>4</sub>S)

$$= W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times (9/5)$$

*W<sub>S</sub>*: Amount (mg) of etizolam for assay

*C*: Labeled amount (mg) of etizolam (C<sub>17</sub>H<sub>15</sub>ClN<sub>4</sub>S) in 1 tablet

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 243 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized

silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

Column temperature: A constant temperature of about 30°C.

Mobile phase: A mixture of water and acetonitrile (1:1).

Flow rate: Adjust the flow rate so that the retention time of etizolam is about 7 minutes.

*System suitability*—

System performance: When the procedure is run with 50  $\mu\text{L}$  of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of etizolam are not less than 3000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 50  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the peak area of etizolam is not more than 2.0%.

**Assay** To 20 Etizolam Tablets add 50 mL of water, and stir until they disintegrate. Add 400 mL of methanol, stir for 20 minutes, add methanol to make exactly 500 mL, and centrifuge. Pipet an amount of the supernatant liquid, equivalent to about 0.2 mg of etizolam ( $\text{C}_{17}\text{H}_{15}\text{ClN}_4\text{S}$ ), add exactly 10 mL of the internal standard solution, add diluted methanol (9 in 10) to make 25 mL, and use this solution as the sample solution. Separately, weigh accurately about 100 mg of etizolam for assay, previously dried at 105°C for 3 hours, and dissolve in diluted methanol (9 in 10) to make exactly 100 mL. Pipet 2 mL of this solution, and add diluted methanol (9 in 10) to make exactly 100 mL. Pipet 10 mL of this solution, add exactly 10 mL of the internal standard solution, add diluted methanol (9 in 10) to make 25 mL, and use this solution as the standard solution. Perform the test with 10  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of etizolam to that of the internal standard.

$$\begin{aligned} & \text{Amount (mg) of etizolam (C}_{17}\text{H}_{15}\text{ClN}_4\text{S)} \\ & = W_S \times (Q_T/Q_S) \times (1/500) \end{aligned}$$

$W_S$ : Amount (mg) of etizolam for assay

*Internal standard solution*—A solution of ethyl parahydroxybenzoate in diluted methanol (9 in 10) (1 in 50,000).

*Operating conditions*—

Detector: An ultraviolet absorption photometer (wavelength: 240 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  particle diameter).

Column temperature: A constant temperature of about 35°C.

Mobile phase: Dissolve 1.36 g of potassium dihydrogen phosphate in water to make 1000 mL, and adjust the pH to 3.5 with diluted phosphoric acid (1 in 10). To 550 mL of this solution add 450 mL of acetonitrile.

Flow rate: Adjust the flow rate so that the retention time

of etizolam is about 6 minutes.

*System suitability*—

System performance: When the procedure is run with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the internal standard and etizolam are eluted in this order with the resolution between these peaks being not less than 3.

System repeatability: When the test is repeated 6 times with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of etizolam to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

Storage—Light-resistant.

## Famotidine for Injection

注射用ファモチジン

**Add the following next to Bacterial endotoxins:**

**Uniformity of dosage units** <6.02> It meets the requirement of the Mass variation test.

**Foreign insoluble matter** <6.06> Perform the test according to Method 2: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Faropenem Sodium Hydrate

ファロペネムナトリウム水和物

**Change the Purity to read:**

**Purity**

(1) Heavy metals <1.07>—Proceed with 2.0 g of Faropenem Sodium Hydrate according to Method 4, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Related substances—Dissolve a quantity of Faropenem Sodium Hydrate equivalent to 0.10 g (potency) in 200 mL of water, and use this solution as the sample solution. Pipet 2 mL of the sample solution, add water to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 20  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the peak area of the epimer, having the relative retention time of about 1.1 with respect to faropenem, obtained from the sample solution is not larger than 3/10 times the peak area of faropenem from the standard solution, and the total area of the peaks other than the peak of faropenem

from the sample solution is not larger than 1/2 times the peak area of faropenem from the standard solution.

*Operating conditions—*

Column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay.

Detector: An ultraviolet absorption photometer (wavelength: 240 nm).

Time span of measurement: About 6 times as long as the retention time of faropenem, beginning after the solvent peak.

*System suitability—*

Test for required detectability: To exactly 2 mL of the standard solution add water to make exactly 20 mL. Confirm that the peak area of faropenem obtained with 20  $\mu$ L of this solution is equivalent to 7 to 13% of that with 20  $\mu$ L of the standard solution.

System performance: When the procedure is run with 20  $\mu$ L of the standard solution obtained in the Assay under the above operating conditions, *m*-hydroxyacetophenone and faropenem are eluted in this order with the resolution between these peaks being not less than 1.5.

System repeatability: When the test is repeated 6 times with 20  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of faropenem is not more than 2.0%.

## Faropenem Sodium for Syrup

シロップ用ファロペネムナトリウム

**Add the following next to Identification:**

**Purity** Related substances—Powder Faropenem Sodium for Syrup, if necessary. To a part of the powder, equivalent to about 25 mg (potency) of Faropenem Sodium Hydrate according to the labeled amount, add about 10 mL of water, shake well, then add water to make exactly 50 mL, and filter. Discard the first 10 mL of the filtrate, and use the subsequent filtrate as the sample solution. Pipet 2 mL of the sample solution, add water to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 20  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area of both solutions by the automatic integration method: the area of the peak of cleaved derivative, having the relative retention time of about 0.71 with respect to faropenem, obtained from the sample solution is not larger than 1.5 times the peak area of faropenem from the standard solution, and the total area of the peaks other than the peak of faropenem from the sample solution is not larger than 2 times the peak area of faropenem from the standard solution. For these calculations use the area of the peak of cleaved derivative, having the relative retention time of 0.71, after multiplying by the relative response factor 0.37.

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 240 nm).

Column: A stainless steel column 4 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase A: Dissolve 6.12 g of potassium dihydrogen phosphate, 1.79 g of disodium hydrogen phosphate dodecahydrate and 1.61 g of tetra *n*-butylammonium bromide in water to make 1000 mL.

Mobile phase B: A mixture of the mobile phase A and acetonitrile (1:1).

Flowing of mobile phase: Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 54	84→30	16→70

Flow rate: About 1.5 mL per minute

Time span of measurement: About 2.5 times as long as the retention time of faropenem, beginning after the solvent peak.

*System suitability—*

Test for required detectability: To exactly 2 mL of the standard solution add water to make exactly 20 mL. Confirm that the peak area of faropenem obtained with 20  $\mu$ L of this solution is equivalent to 7 to 13% of that with 20  $\mu$ L of the standard solution.

System performance: When the procedure is run with 20  $\mu$ L of the standard solution obtained in the Assay under the above operating conditions, *m*-hydroxyacetophenone and faropenem are eluted in this order with the resolution between these peaks being not less than 11.

System repeatability: When the test is repeated 6 times with 20  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of faropenem is not more than 3.0%.

## Faropenem Sodium Tablets

ファロペネムナトリウム錠

**Add the following next to Identification:**

**Purity** Related substances—Powder not less than 5 Faropenem Sodium Tablets. To a part of the powder, equivalent to about 25 mg (potency) of Faropenem Sodium Hydrate according to the labeled amount, add about 10 mL of water, shake well, then add water to make exactly 50 mL, and filter. Discard the first 10 mL of the filtrate, and use the subsequent filtrate as the sample solution. Pipet 2 mL of the sample solution, add water to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 20  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01>



according to the following conditions, and determine each peak area of both solutions by the automatic integration method: the area of the peak of cleaved derivative, having the relative retention time of about 0.71 with respect to faropenem, obtained from the sample solution is not larger than 1.5 times the peak area of faropenem from the standard solution, and the total area of the peaks other than the peak of faropenem from the sample solution is not larger than 2.5 times the peak area of faropenem from the standard solution. For these calculation, use the area of the peak of cleaved derivative, having the relative retention time of 0.71, after multiplying by the relative response factor 0.37.

**Operating conditions—**

**Detector:** An ultraviolet absorption photometer (wavelength: 240 nm).

**Column:** A stainless steel column 4 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

**Column temperature:** A constant temperature of about 40°C.

**Mobile phase A:** Dissolve 6.12 g of potassium dihydrogen phosphate, 1.79 g of disodium hydrogen phosphate dodecahydrate and 1.61 g of tetra *n*-butylammonium bromide in water to make 1000 mL.

**Mobile phase B:** A mixture of the mobile phase A and acetonitrile (1:1).

**Flowing of mobile phase:** Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 54	84→30	16→70

**Flow rate:** About 1.5 mL per minute

**Time span of measurement:** About 2.5 times as long as the retention time of faropenem, beginning after the solvent peak.

**System suitability—**

**Test for required detectability:** To exactly 2 mL of the standard solution add water to make exactly 20 mL. Confirm that the peak area of faropenem obtained with 20  $\mu$ L of this solution is equivalent to 7 to 13% of that with 20  $\mu$ L of the standard solution.

**System performance:** When the procedure is run with 20  $\mu$ L of the standard solution obtained in the Assay under the above operating conditions, *m*-hydroxyacetophenone and faropenem are eluted in this order with the resolution between these peaks being not less than 11.

**System repeatability:** When the test is repeated 6 times with 20  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of faropenem is not more than 3.0%.


**Add the following next to Uniformity of dosage units:**

**Disintegration <6.09>** It meets the requirement.

**Add the following:**

**Felbinac**

フェルビナク



$C_{14}H_{12}O_2$ : 212.24

Biphenyl-4-ylacetic acid [5728-52-9]

Felbinac, when dried, contains not less than 98.5% and not more than 101.0% of  $C_{14}H_{12}O_2$ .

**Description** Felbinac occurs as white to pale yellowish white crystals or crystalline powder.

It is soluble in methanol and in acetone, sparingly soluble in ethanol (95), and practically insoluble in water.

**Identification (1)** Determine the absorption spectrum of a solution of Felbinac in methanol (95) (1 in 200,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

**(2)** Determine the infrared absorption spectrum of Felbinac as directed in the potassium bromide disc method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Melting point <2.60>** 163 – 166°C

**Purity (1) Chloride <1.03>**—Dissolve 1.0 g of Felbinac in 40 mL of acetone, add 6 mL of dilute nitric acid and water to make 50 mL. Perform the test using this solution as the test solution. Prepare the control solution by combining 0.3 mL of 0.01 mol/L hydrochloric acid VS, 40 mL of acetone and 6 mL of dilute nitric acid, and add water to make 50 mL (not more than 0.011%).

**(2) Heavy metals <1.07>**—Proceed with 1.0 g of Felbinac according to Method 2, and perform the test. Prepare the control solution with 1.0 mL of Standard Lead Solution (not more than 10 ppm).

**(3) Related substances**—Dissolve 0.10 g of Felbinac in 10 mL of acetone, and use this solution as the sample solution. Pipet 2 mL of this solution, and add acetone to make exactly 100 mL. Pipet 5 mL of this solution, add acetone to make exactly 50 mL, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of heptane, acetone, and acetic acid (100) (50:25:1) to a distance of about 12 cm, and air-dry the plate. Examine the plate under ultraviolet light (main wavelength: 254 nm): spots other than the principal spot from the sample solution are not more in-

tense than the spot from the standard solution.

**Loss on drying** <2.41> Not more than 0.3% (1 g, 105°C, 3 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.5 g of Felbinac, previously dried, dissolve in 50 mL of methanol, add 15 mL of water, and titrate <2.50> with 0.1 mol/L sodium hydroxide VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.

$$\begin{aligned} \text{Each mL of 0.1 mol/L sodium hydroxide VS} \\ = 21.22 \text{ mg of } C_{14}H_{12}O_2 \end{aligned}$$

**Containers and storage** Containers—Tight containers.

## Folic Acid Injection

葉酸注射液

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Folic Acid Tablets

葉酸錠

**Add the following next to Identification:**

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Folic Acid Tablets add 50 mL of dilute sodium hydroxide TS, shake frequently, and filter. Wash the residue with dilute sodium hydroxide TS, combine the filtrate and the washings, then add dilute sodium hydroxide TS to make exactly 100 mL, and use this solution as the sample stock solution. Pipet 30 mL of this solution, add 20 mL of dilute hydrochloric acid and water to make exactly 100 mL. Pipet 60 mL of this solution, add 0.5 g of zinc powder, shake frequently, allow to stand for 20 minutes, and filter the solution through a dried filter paper. Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, add water to make exactly  $V'$  mL so that each mL contains about 15  $\mu$ g of folic acid ( $C_{19}H_{19}N_7O_6$ ), and use this solution as the sample solution. Separately, weigh accurately about 50 mg of Folic Acid Reference Standard (separately determine the water <2.48> in the same manner as Folic Acid), and dissolve in dilute sodium hydroxide TS to make exactly 100 mL. Pipet 30 mL of this solutions, add 20 mL of dilute

hydrochloric acid and water to make exactly 100 mL. Pipet 60 mL of this solution, add 0.5 g of zinc powder, shake frequently, allow to stand for 20 minutes, and filter the solution through a dried filter paper. Discard the first 10 mL of the filtrate, pipet 10 mL of the subsequent filtrate, add water to make exactly 100 mL, and use this solution as the standard solution. Pipet 4 mL each of the sample solution and standard solution, add 1 mL of water, 1 mL of dilute hydrochloric acid and 1 mL of sodium nitrite solution (1 in 1000) to them, mix, and allow to stand for 2 minutes. To these solutions add 1 mL of a solution of ammonium amidosulfate (1 in 200), shake, and allow them to stand for 2 minutes. To these solutions add 1 mL of a solution of *N,N*-diethyl-*N'*-1-naphthylethylenediamine oxalate (1 in 1000), shake, allow to stand for 10 minutes, and add water to make exactly 20 mL. Separately, pipet 30 mL of the sample stock solution, add 20 mL of dilute hydrochloric acid, and add water to make exactly 100 mL. Pipet  $V$  mL of this solution, and add water to make exactly  $V'$  mL so that each mL contains about 15  $\mu$ g of folic acid ( $C_{19}H_{19}N_7O_6$ ). With exactly 4 mL of this solution perform the same procedure described above for obtaining the sample solution, and use the solution so obtained as the blank solution. Determine the absorbances at 550 nm,  $A_T$ ,  $A_S$  and  $A_C$ , of the solutions obtained from the sample solution and standard solution, and the blank solution as directed under Ultraviolet-visible Spectrophotometry <2.24>, using a control solution obtained with 4 mL of water in the same manner as described above.

$$\begin{aligned} \text{Amount (mg) of folic acid } (C_{19}H_{19}N_7O_6) \\ = W_S \times \{(A_T - A_C)/A_S\} \times (V'/V) \times (1/10) \end{aligned}$$

$W_S$ : Amount (mg) of Folic Acid Reference Standard, calculated on the anhydrous basis

**Delete the following two Monographs:**

### Fosfestrol

ホスフェストロール

### Fosfestrol Tablets

ホスフェストロール錠

## Fructose Injection

果糖注射液

**Delete the Pyrogen and add the following next to Residue on ignition:**

**Bacterial endotoxins** <4.01> Less than 0.5 EU/mL.

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Gabexate Mesilate

ガベキサートメシル酸塩

### Change the Identification (4) to read:

**Identification** (4) A 0.1 g portion of Gabexate Mesilate responds to the Qualitative Tests <1.09> (1) for mesilate.

## Glucose Injection

ブドウ糖注射液

### Add the following next to Extractable volume:

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.


**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

### Add the following:

## L-Glutamine

L-グルタミン



$C_5H_{10}N_2O_3$ ; 146.14

(2S)-2,5-Diamino-5-oxopentanoic acid [56-85-9]

L-Glutamine, when dried, contains not less than 99.0% and not more than 101.0% of  $C_5H_{10}N_2O_3$ .

**Description** L-Glutamine occurs as white crystals or a crystalline powder. It has a slight characteristic taste.

It is freely soluble in formic acid, soluble in water, and practically insoluble in ethanol (99.5).

**Identification** Determine the infrared absorption spectrum of L-Glutamine as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Optical rotation** <2.49>  $[\alpha]_D^{20}$ : +6.3 – +7.3° Weigh accurately about 2 g of L-Glutamine, previously dried, add 45

mL of water, warm to 40°C to dissolve, and after cooling, add water to make exactly 50 mL. Determine the optical rotation of this solution in a 100-mm cell, within 60 minutes.

**pH** <2.54> The pH of a solution prepared by dissolving 1.0 g of L-Glutamine in 50 mL of water is between 4.5 and 6.0.

**Purity** (1) Clarity and color of solution—A solution obtained by dissolving 0.5 g of L-Glutamine in 20 mL of water is clear and colorless.

(2) Chloride <1.03>—Perform the test with 0.5 g of L-Glutamine. Prepare the control solution with 0.30 mL of 0.01 mol/L hydrochloric acid VS (not more than 0.021%).

(3) Sulfate <1.14>—Perform the test with 0.6 g of L-Glutamine. Prepare the control solution with 0.35 mL of 0.005 mol/L sulfuric acid VS (not more than 0.028%).

(4) Ammonium <1.02>—Perform the test with 0.10 g of L-Glutamine, using the distillation under reduced pressure. Prepare the control solution with 10.0 mL of Standard Ammonium Solution. The temperature of the water bath is 45°C (not more than 0.1%).

(5) Heavy metals <1.07>—Proceed with 1.0 g of L-Glutamine according to Method 1, and perform the test. Prepare the control solution with 1.0 mL of Standard Lead Solution (not more than 10 ppm).

(6) Iron <1.10>—Prepare the test solution with 1.0 g of L-Glutamine according to Method 1, and perform the test according to Method A. Prepare the control solution with 1.0 mL of Standard Iron Solution (not more than 10 ppm).

(7) Related substances—Dissolve 0.10 g of L-Glutamine in 10 mL of water, and use this solution as the sample solution. Pipet 1 mL of this solution, add water to make exactly 10 mL. Pipet 1 mL of this solution, add water to make exactly 50 mL, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Then develop with a mixture of 1-butanol, water and acetic acid (100) (3:1:1) to a distance of about 10 cm, and dry the plate at 80°C for 30 minutes. Spray evenly a solution of ninhydrin in a mixture of methanol and acetic acid (100) (97:3) (1 in 100) on the plate, and heat at 80°C for 10 minutes: the spot other than the principal spot obtained with the sample solution is not more intense than the spot with the standard solution.

**Loss on drying** <2.41> Not more than 0.3% (1 g, 105°C, 3 hours).

**Residue on Ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.15 g of L-Glutamine, previously dried, dissolve in 3 mL of formic acid, add 50 mL of acetic acid (100), and titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS  
= 14.61 mg of  $C_5H_{10}N_2O_3$

**Containers and storage** Containers—Tight containers.

**Add the following:**

## Griseofulvin Tablets

グリセオフルビン錠

Griseofulvin Tablets contain not less than 95.0% and not more than 105.0% of the labeled amount of griseofulvin (C<sub>17</sub>H<sub>17</sub>ClO<sub>6</sub>; 352.77).

**Method of preparation** Prepare as directed under Tablets, with Griseofulvin.

**Identification** To a quantity of powdered Griseofulvin Tablets, equivalent to 15 mg (potency) of Griseofulvin according to the labeled amount, add 100 mL of ethanol (95), shake vigorously, and filter. To 1 mL of the filtrate add ethanol (95) to make 10 mL, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 234 nm and 238 nm, between 290 nm and 294 nm, and between 323 nm and 328 nm.

**Uniformity of dosage units** <6.02>—Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Take 1 tablet of Griseofulvin Tablets, add  $V/5$  mL of water, treat with ultrasonic waves to disintegrate the tablet, add *N,N*-dimethylformamide to make  $5V/8$  mL, shake vigorously for 20 minutes, add *N,N*-dimethylformamide to make exactly  $V$  mL so that each mL contains 1.25 mg (potency) of Griseofulvin, and centrifuge. Pipet 8 mL of the supernatant liquid, add exactly 20 mL of the internal standard solution, add water to make 100 mL, filter through a membrane filter with a pore size not exceeding 0.5  $\mu$ m, discard the first 5 mL of the filtrate, and use the subsequent filtrate as the sample solution. Then, proceed as directed under the Assay.

$$\begin{aligned} &\text{Amount [mg (potency)] of griseofulvin (C}_{17}\text{H}_{17}\text{ClO}_6) \\ &= W_S \times (Q_T/Q_S) \times (V/32) \end{aligned}$$

$W_S$ : Amount [mg (potency)] of Griseofulvin Reference Standard

**Internal standard solution**—A solution of butyl parahydroxybenzoate in acetonitrile (1 in 2000).

**Disintegration** <6.09> It meets the requirement.

**Assay** Weigh accurately not less than 20 Griseofulvin Tablets, and pulverize into a powder. Weigh accurately a portion of the powder, equivalent to about 0.5 g (potency) of Griseofulvin, add 50 mL of water, and treat with ultrasonic waves. Add 100 mL of *N,N*-dimethylformamide, shake vigorously for 20 minutes, and add *N,N*-dimethylformamide to make exactly 250 mL. Centrifuge this solution, pipet 5 mL of the supernatant liquid, add exactly 20 mL of the internal standard solution, add water to make 100 mL,

filter through a membrane filter with a pore size not exceeding 0.5  $\mu$ m, discard the first 5 mL of the filtrate, and use the subsequent filtrate as the sample solution. Separately, weigh accurately an amount of Griseofulvin Reference Standard, equivalent to about 40 mg (potency), and dissolve in *N,N*-dimethylformamide to make exactly 20 mL. Pipet 5 mL of this solution, add exactly 20 mL of the internal standard solution, add water to make 100 mL, and use this solution as the standard solution. Perform the test with 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of griseofulvin to that of the internal standard.

$$\begin{aligned} &\text{Amount [mg (potency)] of griseofulvin (C}_{17}\text{H}_{17}\text{ClO}_6) \\ &= W_S \times (Q_T/Q_S) \times (25/2) \end{aligned}$$

$W_S$ : Amount [mg (potency)] of Griseofulvin Reference Standard

**Internal standard solution**—A solution of butyl parahydroxybenzoate in acetonitrile (1 in 2000).

**Operating conditions**—

Proceed as directed in the operating conditions in the Assay under Griseofulvin.

**System suitability**—

**System performance:** When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, griseofulvin and the internal standard are eluted in this order with the resolution between these peaks being not less than 4.

**System repeatability:** When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of griseofulvin to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

## Hydralazine Hydrochloride Tablets

ヒドララジン塩酸塩錠

**Add the following next to Identification:**

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Hydralazine Hydrochloride Tablets add 25 mL of 0.1 mol/L hydrochloric acid TS, disperse the tablet into a small particles using ultrasonic waves, then shake well, add 0.1 mol/L hydrochloric acid TS to make exactly 50 mL, and centrifuge. Pipet  $V$  mL of the supernatant liquid, add 0.1 mol/L hydrochloric acid TS to make exactly  $V'$  mL so that each mL contains about 10  $\mu$ g of hydralazine hydrochloride (C<sub>8</sub>H<sub>8</sub>N<sub>4</sub>.HCl), and use this solution as the sample solution. Separately, weigh accurately about 25 mg of hydralazine hydrochloride for assay, previously dried at 105°C for 3 hours, dissolve in 0.1 mol/L hydrochloric acid

TS to make exactly 50 mL. Pipet 2 mL of this solution, add 0.1 mol/L hydrochloric acid TS to make exactly 100 mL, and use this solution as the standard solution. Determine the absorbances at 260 nm,  $A_{T1}$  and  $A_{S1}$ , and at 350 nm,  $A_{T2}$  and  $A_{S2}$ , of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>.

$$\text{Amount (mg) of hydralazine hydrochloride (C}_8\text{H}_8\text{N}_4\cdot\text{HCl)} \\ = W_S \times \{(A_{T1} - A_{T2}) / (A_{S1} - A_{S2})\} \times (V' / V) \times (1/50)$$

$W_S$ : Amount (mg) of hydralazine hydrochloride for assay

### Change to read:

## Hypromellose Phthalate

ヒプロメロースフタル酸エステル

[9050-31-1]

This monograph is harmonized with the European Pharmacopoeia and the U.S. Pharmacopoeia. The parts of the text that are not harmonized are marked with symbols (◆ ◆).

Hypromellose Phthalate is a monophthalic acid ester of hypromellose.

It contains methoxy group ( $-\text{OCH}_3$ ; 31.03), hydroxypropoxy group ( $-\text{OCH}_2\text{CHOHCH}_3$ ; 75.09), and carboxybenzoyl group ( $-\text{COC}_6\text{H}_4\text{COOH}$ ; 149.12).

It contains not less than 21.0% and not more than 35.0% of carboxybenzoyl group, calculated on the anhydrous basis.

◆ Its substitution type and its viscosity in millipascal second (mPa·s) are shown on the label.

Substitution Type	Carboxybenzoyl group (%)	
	Min.	Max.
200731	27.0	35.0
220824	21.0	27.0

◆

◆ **Description** Hypromellose Phthalate occurs as white powder or granules.

It is practically insoluble in water, in acetonitrile and in ethanol (99.5).

It becomes a viscous liquid when a mixture of methanol and dichloromethane (1:1) or a mixture of ethanol (99.5) and acetone (1:1) is added.

It dissolves in sodium hydroxide TS. ◆

◆ **Identification** Determine the infrared absorption spectrum of Hypromellose Phthalate as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers. ◆

**Viscosity** <2.53> To 10 g of Hypromellose Phthalate, previ-

ously dried at 105°C for 1 hour, add 90 g of a mixture of methanol and dichloromethane in equal mass ratio, and stir to dissolve. Determine the viscosity at  $20 \pm 0.1^\circ\text{C}$  as directed in Method 1 under Viscosity Determination: the viscosity is not less than 80% and not more than 120% of the labeled unit.

**Purity** (1) Chloride <1.03>—Dissolve 1.0 g of Hypromellose Phthalate in 40 mL of 0.2 mol/L sodium hydroxide VS, add 1 drop of phenolphthalein TS, and add dilute nitric acid dropwise with vigorous stirring until the red color is discharged. Further add 20 mL of dilute nitric acid with stirring. Heat on a water bath with stirring until the gelatinous precipitate formed turns to granular particles. After cooling, centrifuge, and take off the supernatant liquid. Wash the precipitate with three 20-mL portions of water by centrifuging each time, combine the supernatant liquid and the washings, add water to make 200 mL, and filter. Perform the test with 50 mL of the filtrate. Control solution: To 0.50 mL of 0.01 mol/L hydrochloric acid VS add 10 mL of 0.2 mol/L sodium hydroxide VS and 7 mL of dilute nitric acid, and add water to make 50 mL (not more than 0.07%).

◆ (2) Heavy metals <1.07>—Proceed with 2.0 g of Hypromellose Phthalate according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm). ◆

(3) Phthalic acid—Weigh accurately about 0.2 g of Hypromellose Phthalate, add about 50 mL of acetonitrile to dissolve partially with the aid of ultrasonic waves, add 10 mL of water, and dissolve further with the ultrasonic waves. After cooling, add acetonitrile to make exactly 100 mL, and use this solution as the sample solution. Separately, weigh accurately about 12.5 mg of phthalic acid, dissolve in about 125 mL of acetonitrile by mixing, add 25 mL of water, then add acetonitrile to make exactly 250 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas of phthalic acid,  $A_T$  and  $A_S$ , of both solutions: amount of phthalic acid ( $\text{C}_8\text{H}_6\text{O}_4$ ; 166.13) is not more than 1.0%.

$$\text{Amount (\%)} \text{ of phthalic acid} = (W_S / W_T) \times (A_T / A_S) \times 40$$

$W_S$ : Amount (mg) of phthalic acid

$W_T$ : Amount (mg) of sample, calculated on the anhydrous basis

### Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 235 nm).

Column: A stainless steel column about 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilylated silica gel for liquid chromatography (3 to 10  $\mu\text{m}$  in particle diameter).

Column temperature: A constant temperature of about 20°C.

Mobile phase: A mixture of 0.1% trifluoroacetic acid and acetonitrile (9:1).

Flow rate: About 2.0 mL per minute.

*System suitability*—

♦System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of phthalic acid are not less than 2500 and not more than 1.5, respectively. ♦

System repeatability: When repeat the test 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of phthalic acid is not more than 1.0%.

**Water** <2.48> Not more than 5.0% (1 g, direct titration, using a mixture of ethanol (99.5) and dichloromethane (3:2) instead of methanol for Karl Fischer method).

**Residue on ignition** <2.44> Not more than 0.2% (1 g).

**Assay** Weigh accurately about 1 g of Hypromellose Phthalate, dissolve in 50 mL of a mixture of ethanol (95), acetone and water (2:2:1), and titrate <2.50> with 0.1 mol/L sodium hydroxide VS (indicator: 2 drops of phenolphthalein TS). Perform a blank determination in the same manner, and make any necessary correction.

$$\begin{aligned} \text{Amount (\%)} & \text{ of carboxybenzoyl group (C}_8\text{H}_5\text{O}_3) \\ & = \{(0.01 \times 149.1 \times V) / W\} - \{(2 \times 149.1 \times P) / 166.1\} \end{aligned}$$

*P*: Amount (%) of phthalic acid obtained in the Purity (3)


*V*: Amount (mL) of 0.1 mol/L sodium hydroxide VS consumed

*W*: Amount (g) of sample, calculated on the anhydrous basis

**Containers and storage** Containers—Tight containers.

**Add the following:****Ibudilast**

イブジラスト



C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O: 230.31

1-[2-(1-Methylethyl)pyrazolo[1,5-*a*]pyridin-3-yl]-2-methylpropan-1-one [50847-11-5]

Ibudilast, when dried, contains not less than 98.5% and not more than 101.0% of C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O.

**Description** Ibudilast occurs as a white crystalline powder.

It is very soluble in methanol, freely soluble in ethanol (99.5) and in acetic anhydride, and very slightly soluble in water.

**Identification** (1) Determine the absorption spectrum of a solution of Ibudilast in methanol (1 in 250,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and

compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Ibudilast as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Melting point** <2.60> 54 – 58°C

**Purity** (1) Heavy metals <1.07>—Proceed with 1.0 g of Ibudilast according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

(2) Related substances—Dissolve 50 mg of Ibudilast in 50 mL of the mobile phase, and use this solution as the sample solution. Pipet 1 mL of the sample solution, and add the mobile phase to make exactly 50 mL. Pipet 1 mL of this solution, add the mobile phase to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.07> according to the following conditions, and determine each peak area by the automatic integration method: the peak area other than ibudilast obtained from the sample solution is not larger than the peak area of ibudilast from the standard solution, and the total area of the peaks other than ibudilast from the sample solution is not larger than 3 times the peak area of ibudilast from the standard solution.

*Operating conditions*—

**Detector:** An ultraviolet absorption photometer (wavelength: 292 nm).

**Column:** A stainless steel column 2.6 mm in inside diameter and 15 cm in length, packed with silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

**Column temperature:** A constant temperature of about 25°C.

**Mobile phase:** A mixture of hexane and ethyl acetate (50:1)

**Flow rate:** Adjust the flow rate so that the retention time of ibudilast is about 9 minutes.

**Time span of measurement:** About 4 times as long as the retention time of ibudilast, beginning after the solvent peak.

*System suitability*—

**Test for required detectability:** To exactly 5 mL of the standard solution add the mobile phase to make exactly 10 mL. Confirm that the peak area of ibudilast obtained with 10  $\mu$ L of this solution is equivalent to 40 to 60% of that with 10  $\mu$ L of the standard solution.

**System performance:** To 5 mL of the sample solution add the mobile phase to make 50 mL. To 2 mL of this solution add the mobile phase to make 20 mL. When the procedure is run with 10  $\mu$ L of this solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of ibudilast are not less than 3500 and not more than 2.0, respectively.

**System repeatability:** When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operat-

ing conditions, the relative standard deviation of the peak area of ibudilast is not more than 3.0%.

**Loss on drying** <2.41> Not more than 0.3% (1 g, in vacuum, 4 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.2 g of Ibudilast, previously dried, dissolve in 50 mL of acetic anhydride, and titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.

$$\begin{aligned} \text{Each mL of 0.1 mol/L perchloric acid VS} \\ = 23.03 \text{ mg of } C_{14}H_{18}N_2O \end{aligned}$$

**Containers and storage** Containers—Tight containers.

## Idoxuridine Ophthalmic Solution

イドクスウリジン点眼液

**Add the following next to Purity:**

**Foreign insoluble matter** <6.11> It meets the requirement.

**Insoluble particulate matter** <6.08> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Imipramine Hydrochloride Tablets

イミプラミン塩酸塩錠

**Add the following next to Identification:**

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Imipramine Hydrochloride Tablets add exactly 40 mL of 0.01 mol/L hydrochloric acid TS, disperse the tablet into a small particles using ultrasonic waves, then shake well. Centrifuge the solution, pipet  $V$  mL of the supernatant liquid, add water to make exactly  $V'$  mL so that each mL contains about 20  $\mu$ g of imipramine hydrochloride ( $C_{19}H_{24}N_2 \cdot HCl$ ), and use this solution as the sample solution. Separately, weigh accurately about 25 mg of Imipramine Hydrochloride Reference Standard, previously dried at 105°C for 2 hours, dissolve in 0.01 mol/L hydrochloric acid TS to make exactly 100 mL. Pipet 2 mL of this solution, add water to make exactly 25 mL, and use this solution as the standard solution. Determine the absorbances at 251 nm,  $A_{T1}$  and  $A_{S1}$ , and at 330 nm,  $A_{T2}$  and  $A_{S2}$ , of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>.

$$\begin{aligned} \text{Amount (mg) of imipramine hydrochloride } (C_{19}H_{24}N_2 \cdot HCl) \\ = W_S \times \{(A_{T1} - A_{T2}) / (A_{S1} - A_{S2})\} \times (V' / V) \times (4 / 125) \end{aligned}$$

$W_S$ : Amount (mg) of Imipramine Hydrochloride Reference Standard

## Indometacin Capsules

インドメタシンカプセル

**Add the following next to Purity:**

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Take out the content of 1 capsule of Indometacin Capsules, and dissolve in methanol to make exactly  $V$  mL so that each mL contains about 1 mg of indometacin ( $C_{19}H_{16}ClNO_4$ ). Filter the solution, discard the first 10 mL of the filtrate, pipet 5 mL of the subsequent filtrate, add exactly 3 mL of the internal standard solution, then add the mobile phase to make 100 mL, and use this solution as the sample solution. Separately, weigh accurately about 25 mg of Indometacin Reference Standard, previously dried at 105°C for 4 hours, dissolve in methanol to make exactly 25 mL. Pipet 5 mL of this solution, add exactly 3 mL of the internal standard solution, then add the mobile phase to make 100 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay.

$$\begin{aligned} \text{Amount (mg) of indometacin } (C_{19}H_{16}ClNO_4) \\ = W_S \times (Q_T / Q_S) \times (V / 25) \end{aligned}$$

$W_S$ : Amount (mg) of Indometacin Reference Standard

**Internal standard solution**—A solution of butyl parahydroxybenzoate in methanol (1 in 1000).

## Isotonic Sodium Chloride Solution

生理食塩液

**Add the following next to Extractable volume:**


**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Add the following:****Isoxsuprine Hydrochloride**

イソクスプリン塩酸塩

 $C_{18}H_{23}NO_3 \cdot HCl$ : 337.84

(1*RS*,2*SR*)-1-(4-Hydroxyphenyl)-2-[[*(2SR)*-1-phenoxypropan-2-yl]amino]propan-1-ol monohydrochloride [579-56-6]

Isoxsuprine Hydrochloride, when dried, contains not less than 99.0% and not more than 101.0% of  $C_{18}H_{23}NO_3 \cdot HCl$ .

**Description** Isoxsuprine Hydrochloride occurs as a white, powder or crystalline powder.

It is soluble in formic acid and in methanol, and slightly soluble in water and in ethanol (99.5).

Melting point: about 204°C (with decomposition).

A solution of Isoxsuprine Hydrochloride in methanol (1 in 50) shows no optical rotation.

**Identification (1)** Determine the absorption spectrum of a solution of Isoxsuprine Hydrochloride (1 in 20,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Isoxsuprine Hydrochloride as directed in the potassium chloride disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) Dissolve 0.5 g of Isoxsuprine Hydrochloride in 50 mL of water by warming, and cool: the solution responds to the Qualitative Tests <1.09> (2) for chloride.

**pH** <2.54> Dissolve 0.5 g of Isoxsuprine Hydrochloride in 50 mL of water by warming, and cool: the pH of the solution is between 4.5 and 6.0.

**Purity (1)** Clarity and color of solution—Dissolve 0.1 g of Isoxsuprine Hydrochloride in 10 mL of water, warm if necessary, and cool: the solution is clear and colorless.

(2) Heavy metals <1.07>—Proceed with 1.0 g of Isoxsuprine Hydrochloride according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

(3) Related substances—Dissolve 20 mg of Isoxsuprine Hydrochloride in 20 mL of the mobile phase, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard

solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method: each peak area other than isoxsuprine obtained from the sample solution is not larger than the peak area of isoxsuprine from the standard solution, and the total area of the peaks other than the peak of isoxsuprine from the sample solution is not larger than 2 times the peak area of isoxsuprine from the standard solution.

**Operating conditions—**

Detector: An ultraviolet absorption photometer (wavelength: 269 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: Dissolve 4.3 g of diammonium hydrogen phosphate and 3.2 g of sodium 1-pentane sulfonate in water to make 1000 mL, and adjust to pH 2.5 with phosphoric acid. To 770 mL of this solution add 230 mL of acetonitrile.

Flow rate: Adjust the flow rate so that the retention time of isoxsuprine is about 18 minutes.

Time span of measurement: About 3 times as long as the retention time of isoxsuprine, beginning after the solvent peak.

**System suitability—**

Test for required detectability: Pipet 1 mL of the standard solution, and add the mobile phase to make exactly 10 mL. Confirm that the peak area of isoxsuprine obtained with 10  $\mu$ L of this solution is equivalent to 7 to 13% of that with 10  $\mu$ L of the standard solution.

System performance: To 1 mL of the sample solution add 2.5 mL of a solution of methyl parahydroxybenzoate (1 in 25,000) and the mobile phase to make 50 mL. When the procedure is run with 10  $\mu$ L of this solution under the above operating conditions, methyl parahydroxybenzoate and isoxsuprine are eluted in this order with the resolution between these peaks being not less than 4.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of isoxsuprine is not more than 2.5%.

**Loss on drying** <2.41> Not more than 0.5% (1 g, 105°C, 1 hour).

**Residue on ignition** <2.44> Not more than 0.2% (1 g).

**Assay** Weigh accurately about 0.3 g of Isoxsuprine Hydrochloride, previously dried, dissolve in 5 mL of formic acid, add 50 mL of a mixture of acetic anhydride and acetic acid (100) (7:3), and titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS  
= 33.78 mg of  $C_{18}H_{23}NO_3 \cdot HCl$



**Containers and storage** Containers—Well-closed containers.

**Add the following:**

## Isoxsuprine Hydrochloride Tablets

イソクスブリン塩酸塩錠

Isoxsuprine Hydrochloride Tablets contain not less than 95.0% and not more than 105.0% of the labeled amount of isoxsuprine hydrochloride ( $C_{18}H_{23}NO_3 \cdot HCl$ ; 337.84).

**Method of preparation** Prepare as directed under Tablets, with Isoxsuprine Hydrochloride.

**Identification** To a quantity of powdered Isoxsuprine Hydrochloride Tablets, equivalent to 10 mg of Isoxsuprine Hydrochloride according to the labeled amount, add 150 mL of water, shake, and then add water to make 200 mL. Centrifuge this solution, filter the supernatant liquid through a membrane filter with a pore size not exceeding  $0.45 \mu m$ , discard the first 10 mL of filtrate, and determine the absorption spectrum of the subsequent filtrate as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 267 nm and 271 nm, and between 272 nm and 276 nm.

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Add methanol to 1 tablet of Isoxsuprine Hydrochloride Tablets, and shake to disintegrate. Add methanol to make exactly  $V$  mL so that each mL contains about 0.4 mg of isoxsuprine hydrochloride ( $C_{18}H_{23}NO_3 \cdot HCl$ ). Centrifuge this solution, and use the supernatant liquid as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} & \text{Amount (mg) of isoxsuprine hydrochloride} \\ & (C_{18}H_{23}NO_3 \cdot HCl) \\ & = W_S \times (A_T/A_S) \times V \times (1/100) \end{aligned}$$

$W_S$ : Amount (mg) of isoxsuprine hydrochloride for assay

**Dissolution** <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rate in 15 minutes of Isoxsuprine Hydrochloride Tablets is not less than 80%.

Start the test with 1 tablet of Isoxsuprine Hydrochloride Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding  $0.45 \mu m$ . Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, add water to make exactly  $V'$  mL so that each mL contains about  $11 \mu g$  of isoxsuprine hydrochloride ( $C_{18}H_{23}NO_3 \cdot HCl$ ) according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 28 mg of isoxsuprine hydrochloride for as-

say, previously dried at  $105^\circ C$  for 1 hour, and dissolve in water to make exactly 100 mL. Pipet 4 mL of this solution, add water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly  $10 \mu L$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the isoxsuprine peak areas,  $A_T$  and  $A_S$ , of both solutions.

Dissolution rate (%) with respect to the labeled amount of isoxsuprine hydrochloride ( $C_{18}H_{23}NO_3 \cdot HCl$ )

$$= W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 36$$

$W_S$ : Amount (mg) of isoxsuprine hydrochloride for assay

$C$ : Labeled amount (mg) of isoxsuprine hydrochloride ( $C_{18}H_{23}NO_3 \cdot HCl$ ) in 1 tablet

**Operating conditions**—

Proceed as directed in the operating conditions in the Assay.

**System suitability**—

System performance: When the procedure is run with  $10 \mu L$  of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of isoxsuprine are not less than 2000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with  $10 \mu L$  of the standard solution under the above operating conditions, the relative standard deviation of the peak area of isoxsuprine is not more than 2.0%.

**Assay** Weigh accurately not less than 20 Isoxsuprine Hydrochloride Tablets, and powder. Weigh accurately a portion of the powder equivalent to about 40 mg of isoxsuprine hydrochloride ( $C_{18}H_{23}NO_3 \cdot HCl$ ), add 60 mL of methanol, shake for 20 minutes, and then add methanol to make exactly 100 mL. Centrifuge a portion of this solution, filter the supernatant liquid through a membrane filter with a pore size not exceeding  $0.45 \mu m$ , discard the first 10 mL of filtrate, and use the subsequent filtrate as the sample solution. Separately, weigh accurately about 40 mg of isoxsuprine hydrochloride for assay, previously dried at  $105^\circ C$  for 1 hour, and dissolve in methanol to make exactly 100 mL. Filter through a membrane filter with a pore size not exceeding  $0.45 \mu m$ , discard the first 10 mL of the filtrate, and use the subsequent filtrate as the standard solution. Perform the test with exactly  $10 \mu L$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of isoxsuprine in each solution.

$$\begin{aligned} & \text{Amount (mg) of isoxsuprine hydrochloride} \\ & (C_{18}H_{23}NO_3 \cdot HCl) \\ & = W_S \times (A_T/A_S) \end{aligned}$$

$W_S$ : Amount (mg) of isoxsuprine hydrochloride for assay

**Operating conditions**—

Detector: An ultraviolet absorption photometer (wavelength: 269 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized

silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: Dissolve 4.3 g of diammonium hydrogen phosphate and 3.2 g of sodium 1-pentane sulfonate in water to make 1000 mL, and adjust to pH 2.5 with phosphoric acid. To 600 mL of this solution add 400 mL of methanol.

Flow rate: Adjust the flow rate so that the retention time of isoxsuprine is about 9 minutes.

System suitability—

System performance: To exactly 1 mL of the standard solution add the mobile phase to make exactly 50 mL. When the procedure is run with 10  $\mu$ L of this solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of isoxsuprine are not less than 2000 and not more than 2.0, respectively.



System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of isoxsuprine is not more than 1.0%.

**Containers and storage** Containers—Well-closed containers.

### Add the following:

## Itraconazole

イトラコナゾール



$C_{35}H_{38}Cl_2N_8O_4$ : 705.63

4-(4-{4-[4-({(2*RS*,4*SR*)-2-(2,4-Dichlorophenyl)-2-[(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl] methoxy)phenyl]piperazin-1-yl} phenyl)-2-[(1*RS*)-1-methylpropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one 4-(4-{4-[4-({(2*SR*,4*RS*)-2-(2,4-Dichlorophenyl)-2-[(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl] methoxy)phenyl]piperazin-1-yl} phenyl)-2-[(1*RS*)-1-methylpropyl]-2,4-dihydro-3*H*-1,2,4-triazol-3-one [84625-61-6]

Itraconazole contains not less than 98.5% and not more than 101.0% of  $C_{35}H_{38}Cl_2N_8O_4$ , calculated on the dried basis.

**Description** Itraconazole occurs as a white powder.

It is soluble in *N,N*-dimethylformamide, very slightly soluble in ethanol (99.5), and practically insoluble in water and in 2-propanol.

A solution of Itraconazole in *N,N*-dimethylformamide (1 in 100) shows no optical rotation.

**Identification (1)** Determine the absorption spectrum of a solution of Itraconazole in 2-propanol (1 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Itraconazole, previously dried, as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) Perform the test with Itraconazole as directed under Flame Coloration Test <1.04> (2): a green color appears.

**Melting point** <2.60> 166 – 170°C

**Purity (1)** Heavy metals <1.07>—Proceed with 1.0 g of Itraconazole according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

(2) Related substances—Dissolve 0.10 g of Itraconazole in 10 mL of a mixture of methanol and tetrahydrofuran (1:1), and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mixture of methanol and tetrahydrofuran (1:1) to make exactly 100 mL. Pipet 5 mL of this solution, add the mixture of methanol and tetrahydrofuran (1:1) to make exactly 10 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area of each solution by the automatic integration method: the area of each peak other than itraconazole obtained from the sample solution is not larger than the peak area of itraconazole from the standard solution. Furthermore, the total area of the peaks other than itraconazole from the sample solution is not larger than 2.5 times the peak area of itraconazole from the standard solution.

**Operating conditions**—

Detector: An ultraviolet absorption photometer (wavelength: 225 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 10 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (3  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 30°C.

Mobile phase A: A solution of Tetrabutylammonium hydrogensulfate (17 in 625).

Mobile phase B: Acetonitrile.

Flowing of the mobile phase: Control the gradient by mix-

ing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 20	80→50	20→50
20 – 25	50	50

Flow rate: 1.5 mL per minute.

Time span of measurement: About 2 times as long as the retention time of itraconazole, beginning after the solvent peak.

*System suitability*—

Test for required detectability: To exactly 1 mL of the standard solution add the mixture of methanol and tetrahydrofuran (1:1) to make exactly 10 mL. Confirm that the peak area of itraconazole obtained from 10  $\mu$ L of this solution is equivalent to 7 to 13% of that from 10  $\mu$ L of the standard solution.

System performance: Dissolve 1 mg of Itraconazole and 1 mg of miconazole nitrate in 20 mL of the mixture of methanol and tetrahydrofuran (1:1). When the procedure is run with 10  $\mu$ L of this solution under the above operating conditions, miconazole and itraconazole are eluted in this order with the resolution between these peaks being not less than 2.0.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of itraconazole is not more than 2.0%.

**Loss on drying** <2.41> Not more than 0.5% (1 g, 105°C, 4 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.3 g of Itraconazole, dissolve in 70 mL of a mixture of 2-butanone and acetic acid (100) (7:1), and titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS  
= 35.28 mg of  $C_{35}H_{38}Cl_2N_8O_4$

**Containers and storage** Containers—Tight containers.

**Add the following:**

## Josamycin Tablets

ジヨ サマイシン錠

Josamycin Tablets contain not less than 90.0% and not more than 110.0% of the labeled amount of josamycin ( $C_{42}H_{69}NO_{15}$ : 827.99).

**Method of preparation** Prepare as directed under Tablets, with Josamycin.

**Identification** To a quantity of powdered Josamycin Tablets, equivalent to 10 mg (potency) of Josamycin according to the labeled amount, add 100 mL of methanol, shake vigorously, and centrifuge. To 5 mL of the supernatant liquid, add methanol to make 50 mL, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 229 nm and 233 nm.

**Loss on drying** <2.41> Not more than 5.0% (0.5 g, in vacuum, 60°C, 3 hours).

**Uniformity of dosage units** <6.02>—Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Take 1 tablet of Josamycin Tablets, add 5 mL of water, and shake vigorously to disintegrate the tablet. Add methanol and then use ultrasonic waves to disperse the particles, add methanol to make exactly  $V$  mL so that each mL contains about 2 mg (potency) of Josamycin, and centrifuge. Pipet 3 mL of the supernatant liquid, and add methanol to make exactly 100 mL. Pipet 10 mL of this solution, add methanol to make exactly 50 mL, and use this solution as the sample solution. Separately, accurately weigh about 50 mg (potency) of Josamycin Reference Standard, dissolve in 5 mL of water and methanol to make exactly 25 mL. Pipet 3 mL of this solution, and add methanol to make exactly 100 mL. Pipet 10 mL of this solution, add methanol to make exactly 50 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , of the sample solution and the standard solution at 231 nm as directed under Ultraviolet-visible Spectrophotometry <2.24>. However,  $\bar{X}$  in the formula for calculation of acceptance value is the result of the assay.

$$\begin{aligned} &\text{Amount [mg (potency)] of josamycin } (C_{42}H_{69}NO_{15}) \\ &= W_S \times (A_T/A_S) \times (V/25) \end{aligned}$$

$W_S$ : Amount [mg (potency)] of Josamycin Reference Standard

**Disintegration** <6.09> It meets the requirement.

**Assay** Perform the test according to the Cylinder-plate method as directed under Microbial Assay for Antibiotics <4.02> according to the following conditions.

(i) Test organism, culture medium, and standard solutions—Proceed as directed in the Assay under Josamycin.



(ii) Sample solutions—Weigh accurately the mass of not less than 20 Josamycin Tablets and pulverize into a powder. Weigh accurately a portion of the powder, equivalent to about 0.3 g (potency) of Josamycin, add 50 mL of methanol, shake vigorously, and add water to make exactly 1000 mL. Take exactly an appropriate amount of this solution, add water to prepare solutions containing 30  $\mu$ g (potency) and 7.5  $\mu$ g (potency) per mL, and use these solutions as the high and low concentration sample solutions, respectively.

**Containers and storage** Containers—Tight containers.

Add the following:

## Labetalol Hydrochloride

ラベタロール塩酸塩



$C_{19}H_{24}N_2O_3 \cdot HCl$ : 364.87

2-Hydroxy-5-[(1*S*)-1-hydroxy-2-[(1*S*)-1-methyl-3-phenylpropylamino]ethyl]benzamide monohydrochloride  
2-Hydroxy-5-[(1*R*)-1-hydroxy-2-[(1*S*)-1-methyl-3-phenylpropylamino]ethyl]benzamide monohydrochloride  
[32780-64-6]

Labetalol Hydrochloride, when dried, contains not less than 98.5% and not more than 101.0% of  $C_{19}H_{24}N_2O_3 \cdot HCl$ .

**Description** Labetalol Hydrochloride occurs as a white crystalline powder.

It is freely soluble in methanol, and sparingly soluble in water and in ethanol (99.5).

It dissolves in 0.05 mol/L sulfuric acid TS.

Melting point: about 181°C (with decomposition).

**Identification (1)** Determine the absorption spectrum of a solution of Labetalol Hydrochloride in 0.05 mol/L sulfuric acid TS (1 in 20,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Labetalol Hydrochloride as directed in the potassium chloride disc method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) A solution of Labetalol Hydrochloride (1 in 50) responds to the Qualitative Tests <1.09> for chloride.

**pH** <2.54> The pH of a solution prepared by dissolving 0.5 g of Labetalol Hydrochloride in 50 mL of water is between 4.0 and 5.0.

**Purity (1)** Heavy metals <1.07>—Proceed with 1.0 g of Labetalol Hydrochloride according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of

Standard Lead Solution (not more than 20 ppm).

(2) Related substances—Dissolve 0.8 g of Labetalol Hydrochloride in 10 mL of methanol, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 200 mL, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, 2-propanol, water, and ammonia solution (28) (25:15:8:2) to a distance of about 10 cm, and air-dry the plate. Allow the plate to stand in iodine vapor for 30 minutes: the spots other than the principal spot from the sample solution do not exceed 2 in number and are not more intense than the spot obtained from the standard solution.

**Loss on drying** <2.41> Not more than 1.0% (1 g, 105°C, 3 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Isomer ratio** Dissolve 5 mg of Labetalol Hydrochloride in 0.7 mL of a solution of *n*-butylboronic acid in anhydrous pyridine (3 in 250), allow to stand for 20 minutes, and use this solution as the sample solution. Perform the test with 2  $\mu$ L of the sample solution as directed under Gas Chromatography <2.02> according to the following conditions. Determine the areas of two adjacent peaks,  $A_a$  and  $A_b$ , where  $A_a$  is the peak area of the shorter retention time and  $A_b$  is the peak area of the longer retention time, using the automatic integration method: the ratio  $A_b/(A_a + A_b)$  is between 0.45 and 0.55.

**Operating conditions**—

Detector: A hydrogen flame-ionization detector.

Column: A fused silica column 0.53 mm in inside diameter and 25 m in length, coated inside with methyl silicone polymer for gas chromatography in 5  $\mu$ m thickness.

Column temperature: A constant temperature of about 290°C.

Injection port temperature: A constant temperature of about 350°C.

Detector temperature: A constant temperature of about 350°C.

Carrier gas: Helium

Flow rate: Adjust the flow rate so that the retention time of the peak showing earlier elution of the two peaks of labetalol is about 9 minutes.

**System suitability**—

System performance: Proceed with 2  $\mu$ L of the sample solution under the above conditions: the resolution between the two labetalol peaks is not less than 1.5.

System repeatability: Repeat the test 6 times under the above conditions with 2  $\mu$ L of the sample solution: the relative standard deviation of the ratio of the peak area of labetalol with the shorter retention time to that of the longer retention time is not more than 2.0%.

**Assay** Weigh accurately about 0.3 g of Labetalol Hydrochloride, previously dried, dissolve in 100 mL of a

mixture of acetic anhydride and acetic acid (100) (7:3), and titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS  
= 36.49 mg of  $C_{19}H_{24}N_2O_3 \cdot HCl$

**Containers and storage** Containers—Tight containers.

**Add the following:**

## Labetalol Hydrochloride Tablets

ラベタロール塩酸塩錠

Labetalol Hydrochloride Tablets contain not less than 93.0% and not more than 107.0% of the labeled amount of labetalol hydrochloride ( $C_{19}H_{24}N_2O_3 \cdot HCl$ ; 364.87).

**Method of preparation** Prepare as directed under Tablets, with Labetalol Hydrochloride.

**Identification (1)** To a quantity of powdered Labetalol Hydrochloride Tablets equivalent to 5 mg of Labetalol Hydrochloride according to the labeled amount, add 100 mL of 0.05 mol/L sulfuric acid TS, shake, and filter. Determine the absorption spectrum of the filtrate as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 300 nm and 304 nm.

(2) To a quantity of powdered Labetalol Hydrochloride Tablets equivalent to 0.25 g of Labetalol Hydrochloride according to the labeled amount, add 25 mL of methanol, shake vigorously for 30 minutes, filter, and use the filtrate as the sample solution. Separately, dissolve 10 mg of labetalol hydrochloride in 1 mL of methanol, and use this solution as the standard solution. Perform the test using these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, 2-propanol, water, and ammonia solution (28) (25:15:8:2) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): the principal spot obtained from the sample solution and the spot obtained from the standard solution show the same  $R_f$  value.

**Uniformity of dosage units <6.02>** Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Labetalol Hydrochloride Tablets add 5 mL of 0.5 mol/L sulfuric acid TS and 30 mL of water, shake vigorously for 30 minutes, add water to make exactly 50 mL, and filter. Discard the first 5 mL of the filtrate, pipet 4 mL of the subsequent filtrate, add 0.05 mol/L sulfuric acid TS to make exactly  $V$  mL so that each mL contains about 40  $\mu$ g

of labetalol hydrochloride ( $C_{19}H_{24}N_2O_3 \cdot HCl$ ), and use this solution as the sample solution. Separately, weigh accurately about 20 mg of labetalol hydrochloride for assay, previously dried at 105°C for 3 hours, and dissolve in 0.05 mol/L sulfuric acid TS to make exactly 50 mL. Pipet 5 mL of this solution, add 0.05 mol/L sulfuric acid TS to make exactly 50 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , of the sample solution and standard solution at 302 nm as directed under Ultraviolet-visible Spectrophotometry <2.24>.

Amount (mg) of labetalol hydrochloride ( $C_{19}H_{24}N_2O_3 \cdot HCl$ )  
=  $W_S \times (A_T/A_S) \times (V/40)$

$W_S$ : Amount (mg) of labetalol hydrochloride for assay

**Dissolution <6.10>** When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rate in 30 minutes of Labetalol Hydrochloride Tablets is not less than 75%.

Start the test with 1 tablet of Labetalol Hydrochloride Tablets, withdraw not less than 20 mL of the medium at specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.8  $\mu$ m. Discard the first 10 mL of the filtrate, pipet  $V'$  mL of the subsequent filtrate, and add water to make exactly  $V'$  mL so that each mL contains about 50  $\mu$ g of labetalol hydrochloride ( $C_{19}H_{24}N_2O_3 \cdot HCl$ ) according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 50 mg of labetalol hydrochloride for assay, previously dried at 105°C for 3 hours, and dissolve in water to make exactly 100 mL. Pipet 10 mL of this solution, add water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>, and determine the absorbances,  $A_T$  and  $A_S$ , at 302 nm.

Dissolution rate (%) with respect to the labeled amount of labetalol hydrochloride ( $C_{19}H_{24}N_2O_3 \cdot HCl$ )

=  $W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 90$

$W_S$ : Amount (mg) of labetalol hydrochloride for assay

$C$ : Labeled amount (mg) of labetalol hydrochloride ( $C_{19}H_{24}N_2O_3 \cdot HCl$ ) in 1 tablet

**Assay** Weigh accurately not less than 20 Labetalol Hydrochloride Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 1 g of labetalol hydrochloride ( $C_{19}H_{24}N_2O_3 \cdot HCl$ ), add 100 mL of 0.5 mol/L sulfuric acid TS and 600 mL of water, shake vigorously for 30 minutes, add water to make exactly 1000 mL, and filter. Discard the first 5 mL of the filtrate, pipet 5 mL of the subsequent filtrate, and add 0.05 mol/L sulfuric acid TS to make exactly 25 mL. Pipet 5 mL of this solution, add 0.05 mol/L sulfuric acid TS to make exactly 25 mL, and use this solution as the sample solution. Separately, weigh accurately about 40 mg of labetalol hydrochloride for assay, previously dried at 105°C for 3 hours, and dissolve in 0.05 mol/L sulfuric acid TS to make exactly 100 mL. Pipet 5 mL of this so-

lution, add 0.05 mol/L sulfuric acid TS to make exactly 50 mL, and use this solution as the standard solution. Perform the test with the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>, and determine the absorbances,  $A_T$  and  $A_S$ , at 302 nm.

Amount (mg) of labetalol hydrochloride ( $C_{19}H_{24}N_2O_3 \cdot HCl$ )  
 $= W_S \times (A_T/A_S) \times 25$

$W_S$ : Amount (mg) of labetalol hydrochloride for assay

**Containers and storage** Containers—Tight containers.

## Anhydrous Lactose

無水乳糖

**Change the origin/limits of content to read:**

Anhydrous Lactose is  $\beta$ -lactose or a mixture of  $\beta$ -lactose and  $\alpha$ -lactose.

◆The relative quantities of  $\alpha$ -lactose and  $\beta$ -lactose in Anhydrous Lactose is labeled as the isomer ratio.◆

**Change the Identification to read:**

◆**Identification** Determine the infrared absorption spectrum of Anhydrous Lactose, previously dried, as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Anhydrous Lactose Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers.◆

## Levallorphan Tartrate Injection

レバロルフアン酒石酸塩注射液

**Add the following next to Identification:**

**Bacterial endotoxins** <4.01> Less than 150 EU/mg.

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Magnesium Sulfate Injection

硫酸マグネシウム注射液

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according

to Method 1: it meets the requirement.


**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Add the following:**

## Manidipine Hydrochloride

マニジピン塩酸塩



$C_{35}H_{38}N_4O_6 \cdot 2HCl$ : 683.62

3-[2-[4-(Diphenylmethyl)piperazin-1-yl]ethyl]-5-methyl (4*RS*)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate dihydrochloride  
 [126229-12-7]

Manidipine Hydrochloride, when dried, contains not less than 98.5% and not more than 101.0% of  $C_{35}H_{38}N_4O_6 \cdot 2HCl$ .

**Description** Manidipine Hydrochloride occurs as white to pale yellow crystals or crystalline powder.

It is freely soluble in dimethylsulfoxide, sparingly soluble in methanol, slightly soluble in ethanol (99.5), and practically insoluble in water.

A solution of Manidipine Hydrochloride in dimethylsulfoxide (1 in 100) shows no optical rotation.

Manidipine Hydrochloride turns slightly brown-yellowish white on exposure to light.

Melting point: about 207°C (with decomposition).

**Identification (1)** Determine the absorption spectrum of a solution of Manidipine Hydrochloride in methanol (1 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Manidipine Hydrochloride Reference Standard prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Manidipine Hydrochloride as directed in the potassium chloride disc method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Manidipine Hydrochloride Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) Add 10 mL of water to 0.1 g of Manidipine Hydrochloride, shake vigorously, and filter. Add 1 drop of

ammonia TS to 3 mL of the filtrate, allow to stand 5 minutes, and filter. The filtrate responds to the Qualitative Tests <1.09> (2) for chlorides.

**Purity (1)** Heavy metals <1.07>— Proceed with 1.0 g of Manidipine Hydrochloride according to Method 2, and perform the test. Prepare the control solution with 1.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 2.0 g of Manidipine Hydrochloride according to Method 4, and perform the test (not more than 1 ppm).

(3) Related substances—Dissolve 20 mg of Manidipine Hydrochloride in 200 mL of a mixture of water and acetonitrile (1:1), and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mixture of water and acetonitrile (1:1) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 20  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area from both solutions by the automatic integration method: the area of the peaks other than manidipine obtained from the sample solution is not larger than 1/5 times the manidipine peak area from the standard solution. Furthermore, the total of the areas of all peaks other than the manidipine peak from the sample solution is not larger than 7/10 times the peak area of manidipine from the standard solution.

**Operating conditions—**

Detector, column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay.

Time span of measurement: About 3.5 times as long as the retention time of manidipine, beginning after the solvent peak.

**System suitability—**

Test for required detectability: Pipet 10 mL of the standard solution, add a mixture of water and acetonitrile (1:1) to make exactly 100 mL. Confirm that the peak area of manidipine obtained from 20  $\mu$ L of this solution is equivalent to 8 to 12% of that from 20  $\mu$ L of the standard solution.

System performance: Dissolve 50 mg of Manidipine Hydrochloride in a mixture of water and acetonitrile (1:1) to make 50 mL. To 10 mL of this solution add 5 mL of a solution of butyl benzoate in acetonitrile (7 in 5000) and the mixture of water and acetonitrile (1:1) to make 100 mL. When the procedure is run with 20  $\mu$ L of this solution under the above operating conditions, manidipine and butyl benzoate are eluted in this order with the resolution between these peaks being not less than 5.

System repeatability: When the test is repeated 6 times with 20  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of manidipine is not more than 2.0%.

**Loss on drying <2.41>** Not more than 1.5% (1 g, 105°C, 4 hours).

**Residue on ignition <2.44>** Not more than 0.2% (1 g).

**Assay** Weigh accurately about 0.1 g of Manidipine

Hydrochloride, previously dried, and dissolve in a mixture of water and acetonitrile (1:1) to make exactly 50 mL. Pipet 5 mL of this solution, add exactly 5 mL of the internal standard solution, add the mixture of water and acetonitrile (1:1) to make 100 mL, and use this solution as the sample solution. Separately, weigh accurately about 25 mg of Manidipine Hydrochloride Reference Standard, previously dried, and dissolve in the mixture of water and acetonitrile (1:1) to make exactly 50 mL. Pipet 20 mL of this solution, add exactly 5 mL of the internal standard solution, add the mixture of water and acetonitrile (1:1) to make 100 mL, and use this solution as the standard solution. Perform the test with 20  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of manidipine to that of the internal standard.

$$\begin{aligned} &\text{Amount (mg) of } C_{35}H_{38}N_4O_6 \cdot 2HCl \\ &= W_S \times (Q_T / Q_S) \times 4 \end{aligned}$$

$W_S$ : Amount (mg) of Manidipine Hydrochloride Reference Standard

**Internal standard solution—**A solution of butyl benzoate in acetonitrile (7 in 5000).

**Operating conditions—**

Detector: An ultraviolet absorption photometer (wavelength: 228 nm).

Column: A stainless steel column 4.0 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: Dissolve 13.6 g of potassium dihydrogen phosphate in water to make 1000 mL, and adjust to pH 4.6 with diluted potassium hydroxide TS (1 in 10). To 490 mL of this solution add 510 mL of acetonitrile.

Flow rate: Adjust the flow rate so that the retention time of manidipine is about 10 minutes.

**System suitability—**

System performance: When the procedure is run with 20  $\mu$ L of the standard solution under the above operating conditions, manidipine and the internal standard are eluted in this order with the resolution between these peaks being not less than 5.

System repeatability: When the test is repeated 6 times with 20  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of manidipine to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

Storage—Light-resistant.

**Add the following:****Manidipine Hydrochloride Tablets**

マニジピン塩酸塩錠

Manidipine Hydrochloride Tablets contain not less than 92.0% and not more than 108.0% of the labeled amount of manidipine hydrochloride ( $C_{35}H_{38}N_4O_6 \cdot 2HCl$ ; 683.62).

**Method of preparation** Prepare as directed under Tablets, with Manidipine Hydrochloride.

**Identification** To a quantity of powdered Manidipine Hydrochloride Tablets, equivalent to 10 mg of Manidipine Hydrochloride according to the labeled amount, add 5 mL of methanol, shake vigorously, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 10 mg of Manidipine Hydrochloride Reference Standard in 5 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate and diethylamine (200:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): the principal spot obtained from the sample solution and the spot obtained from the standard solution show the same  $R_f$  value.

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Conduct this procedure using light-resistant vessels. To 1 tablet of Manidipine Hydrochloride Tablets, add exactly 1 mL of the internal standard solution per 1 mg of manidipine hydrochloride ( $C_{35}H_{38}N_4O_6 \cdot 2HCl$ ), disintegrate by adding a mixture of water and acetonitrile (1:1) to make  $V$  mL so that each mL contains about 0.1 mg of manidipine hydrochloride ( $C_{35}H_{38}N_4O_6 \cdot 2HCl$ ), shake vigorously for 10 minutes, and filter through a membrane filter with a pore size not exceeding 0.45  $\mu$ m. Discard the first 1 mL of the filtrate, and use the subsequent filtrate as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} & \text{Amount (mg) of manidipine hydrochloride} \\ & (C_{35}H_{38}N_4O_6 \cdot 2HCl) \\ & = W_S \times (Q_T/Q_S) \times (V/250) \end{aligned}$$

$W_S$ : Amount (mg) of Manidipine Hydrochloride Reference Standard

**Internal standard solution**—A solution of butyl benzoate in acetonitrile (7 in 10,000).

**Dissolution** <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of 0.05 mol/L acetic acid-sodium acetate buffer solution, pH 4.0, as the dissolution medium, the dissolution rate

in 45 minutes of Manidipine Hydrochloride Tablets is not less than 75%.

Conduct this procedure using light-resistant vessels. Start the test with 1 tablet of Manidipine Hydrochloride Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45  $\mu$ m. Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, and add the dissolution medium to make exactly  $V'$  mL so that each mL contains about 5.6  $\mu$ g of manidipine hydrochloride ( $C_{35}H_{38}N_4O_6 \cdot 2HCl$ ) according to the labeled amount. Pipet 2 mL of this solution, add exactly 2 mL of methanol, and use this solution as the sample solution. Separately, weigh accurately about 25 mg of Manidipine Hydrochloride Reference Standard, previously dried, dissolve in a mixture of water and acetonitrile (1:1) to make exactly 50 mL. Pipet 1 mL of this solution, and add the dissolution medium to make exactly 100 mL. Pipet 2 mL of this solution, add exactly 2 mL of methanol, and use this solution as the standard solution. Perform the test with exactly 20  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the manidipine peak areas,  $A_T$  and  $A_S$ , of both solutions.

Dissolution rate (%) with respect to the labeled amount of manidipine hydrochloride ( $C_{35}H_{38}N_4O_6 \cdot 2HCl$ )

$$= W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 18$$

$W_S$ : Amount (mg) of Manidipine Hydrochloride Reference Standard

$C$ : Labeled amount (mg) of manidipine hydrochloride ( $C_{35}H_{38}N_4O_6 \cdot 2HCl$ ) in 1 tablet

**Operating conditions**—

**Detector**: An ultraviolet absorption photometer (wavelength: 228 nm).

**Column**: A stainless steel column 4.0 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

**Column temperature**: A constant temperature of about 25°C.

**Mobile phase**: A mixture of acetonitrile and a solution of potassium dihydrogen phosphate (681 in 100,000) (3:2).

**Flow rate**: Adjust the flow rate so that the retention time of manidipine is about 6 minutes.

**System suitability**—

**System performance**: When the procedure is run with 20  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of manidipine are not less than 1500 and not more than 1.5, respectively.

**System repeatability**: When the test is repeated 6 times with 20  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of manidipine is not more than 2.0%.

**Assay** Conduct this procedure using light-resistant vessels. Weigh accurately not less than 20 Manidipine Hydrochloride



Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 10 mg of manidipine hydrochloride ( $C_{35}H_{38}N_4O_6 \cdot 2HCl$ ), add exactly 10 mL of the internal standard solution, add a mixture of water and acetonitrile (1:1) to make 100 mL, shake vigorously for 10 minutes, and filter through a membrane filter with a pore size not exceeding  $0.45 \mu m$ . Discard the first 1 mL of the filtrate, and use the subsequent filtrate as the sample solution. Separately, weigh accurately about 25 mg of Manidipine Hydrochloride Reference Standard, previously dried, and dissolve in the mixture of water and acetonitrile (1:1) to make 50 mL. Pipet 20 mL of this solution, add exactly 10 mL of the internal standard solution, add the mixture of water and acetonitrile (1:1) to make 100 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Manidipine Hydrochloride.

$$\begin{aligned} & \text{Amount (mg) of manidipine hydrochloride} \\ & (C_{35}H_{38}N_4O_6 \cdot 2HCl) \\ & = W_S \times (Q_T/Q_S) \times (2/5) \end{aligned}$$

$W_S$ : Amount (mg) of Manidipine Hydrochloride Reference Standard

*Internal standard solution*—A solution of butyl benzoate in acetonitrile (7 in 10,000).

**Containers and storage** Containers—Tight containers.  
Storage—Light-resistant.

## D-Mannitol Injection

D-マンニトール注射液

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Medazepam

メダゼパム

**Change the origin/limits of content to read:**

Medazepam, when dried, contains not less than 98.5% and not more than 101.0% of  $C_{16}H_{15}ClN_2$ .

**Change the Description to read:**

**Description** Medazepam occurs as white to light yellow crystals or crystalline powder.

It is freely soluble in methanol, in ethanol (99.5), in acetic acid (100) and in diethyl ether, and practically insoluble in

water.

It gradually turns yellow on exposure to light.

**Change the Identification to read:**

**Identification (1)** Dissolve 10 mg of Medazepam in 3 mL of citric acid-acetic acid TS: a deep orange color develops. Heat in a water bath for 3 minutes: the color changes to dark red.

**(2)** Determine the absorption spectrum of a solution of Medazepam in methanol (1 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

**(3)** Determine the infrared absorption spectrum of Medazepam as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**(4)** Perform the test with Medazepam as directed under Flame Coloration Test <1.04> (2): a green color appears.

## Mefruside Tablets

メフルシド錠

**Add the following next to Identification:**

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Mefruside Tablets add 40 mL of methanol, disintegrate the tablet using ultrasonic waves with occasional stirring, then further treat with ultrasonic waves for 10 minutes, and add methanol to make exactly  $V$  mL of a solution containing about 0.5 mg of mefruside ( $C_{13}H_{19}ClN_2O_5S_2$ ) per mL. Centrifuge the solution, pipet 5 mL of the supernatant liquid, add methanol to make exactly 20 mL, and use this solution as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} & \text{Amount (mg) of mefruside } (C_{13}H_{19}ClN_2O_5S_2) \\ & = W_S \times (A_T/A_S) \times (V/125) \end{aligned}$$

$W_S$ : Amount (mg) of mefruside for assay

## Methyldopa Tablets

メチルドパ錠

**Add the following next to Identification:**

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Methyldopa Tablets add 50 mL of 0.05

mol/L sulfuric acid TS, shake for 15 minutes, then add 0.05 mol/L sulfuric acid TS to make exactly 100 mL, and filter. Discard the first 20 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate equivalent to about 5 mg of methyl dopa ( $C_{10}H_{13}NO_4$ ), add exactly 5 mL of iron (II) tartrate TS, then add ammonia-ammonium acetate buffer solution, pH 8.5, to make exactly 100 mL, and use this solution as the sample solution. Separately, weigh accurately about 0.11 g of Methyl dopa Reference Standard (separately determine the loss on drying <2.41> at 125°C for 2 hours), and dissolve in 0.05 mol/L sulfuric acid TS to make exactly 100 mL. Pipet 5 mL of this solution, add exactly 5 mL of iron (II) tartrate TS, then add ammonia-ammonium acetate buffer solution, pH 8.5, to make exactly 100 mL, and use this solution as the standard solution. Determine the absorbances at 520 nm,  $A_T$  and  $A_S$ , of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>.

$$\begin{aligned} & \text{Amount (mg) of methyl dopa } (C_{10}H_{13}NO_4) \\ & = W_S \times (A_T/A_S) \times (5/V) \end{aligned}$$

$W_S$ : Amount (mg) of Methyl dopa Reference Standard, calculated on the dried basis

### Add the following:

## Minocycline Hydrochloride for Injection

注射用ミノサイクリン塩酸塩

Minocycline Hydrochloride for Injection is a preparation for injection which is dissolved before use.

It contains not less than 90.0% and not more than 110.0% of the labeled amount of minocycline ( $C_{23}H_{27}N_3O_7$ : 457.48).

**Method of preparation** Prepare as directed under Injections, with Minocycline Hydrochloride.

**Description** Minocycline Hydrochloride for Injection occurs as a yellow to yellow-brown powder or flakes.

**Identification** Dissolve 4 mg of Minocycline Hydrochloride for Injection in 250 mL of a solution of hydrochloric acid in methanol (19 in 20,000). Determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 221 nm and 225 nm, between 261 nm and 265 nm, and between 354 nm and 358 nm.

**pH** <2.54> The pH of a solution, prepared by dissolving an amount of Minocycline Hydrochloride for Injection, equivalent to 0.1 g (potency) of Minocycline Hydrochloride according to the labeled amount, in 10 mL of water is 2.0 to 3.5.

**Purity** Related substances—Conduct this procedure rapidly after the preparation of the sample solution. Take an amount of Minocycline Hydrochloride for Injection,

equivalent to 0.1 g (potency) of Minocycline Hydrochloride according to the labeled amount, dissolve in the mobile phase to make 100 mL. Pipet 25 mL of this solution, add the mobile phase to make exactly 50 mL, and use this solution as the sample solution. Perform the test with 20  $\mu$ L of the sample solution as directed under Liquid Chromatography <2.07> according to the following conditions, and determine each peak area by the automatic integration method. Calculate the amounts of each peak by the area percentage method: the amount of epiminomycine, having the relative retention time of about 0.83 with respect to minocycline, is not more than 6.0%.

**Operating conditions**—

Detector, column, column temperature, mobile phase and flow rate: Proceed as directed in the operating conditions in the Assay.

Time span of measurement: About 2.5 times as long as the retention time of minocycline, beginning after the solvent peak.

**System suitability**—

Test for required detectability: Pipet 2 mL of the standard solution obtained in the Assay, add the mobile phase to make exactly 100 mL, and use this solution as the solution for system suitability test. Pipet 5 mL of the solution for system suitability test, add the mobile phase to make exactly 100 mL. Confirm that the peak area of minocycline obtained from 20  $\mu$ L of this solution is equivalent to 3.5 to 6.5 % of that from 20  $\mu$ L of the solution for system suitability test.

System performance: Proceed as directed in the system suitability in the Assay.

System repeatability: When the test is repeated 6 times with 20  $\mu$ L of the solution for system suitability test under the above operating conditions, the relative standard deviation of the peak area of minocycline is not more than 2.0%.

**Water** <2.48> Weigh accurately the mass of the content of one container of Minocycline Hydrochloride for Injection, dissolve in exactly 2 mL of methanol for water determination, and perform the test with exactly 1 mL of this solution as directed in the Volumetric titration (back titration): not more than 3.0%.

**Bacterial endotoxins** <4.01> Less than 1.25 EU/mg (potency).

**Uniformity of dosage units** <6.02> It meets the requirement of the Mass variation test.

**Foreign insoluble matter** <6.06> Perform the test according to Method 2: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Assay** Weigh accurately an amount of Minocycline Hydrochloride for Injection, equivalent to about 0.1 g (potency) of Minocycline Hydrochloride, dissolve in the mo-

bile phase to make exactly 100 mL. Pipet 25 mL of this solution, add the mobile phase to make exactly 50 mL, and use this solution as the sample solution. Separately, weigh accurately an amount of Minocycline Hydrochloride Reference Standard, equivalent to about 25 mg (potency), dissolve in the mobile phase to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 20  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak area of minocycline,  $A_T$  and  $A_S$ , of each solution.

$$\begin{aligned} \text{Amount [mg (potency)] of minocycline (C}_{23}\text{H}_{27}\text{N}_3\text{O}_7) \\ = W_S \times (A_T/A_S) \times 4 \end{aligned}$$

$W_S$ : Amount [mg (potency)] of Minocycline Hydrochloride Reference Standard

#### Operating conditions—

Detector, column, column temperature, and flow rate: Proceed as directed in the operating conditions in the Assay under Minocycline Hydrochloride.

Mobile phase: Adjust the pH to 6.5 of a mixture of ammonium oxalate monohydrate solution (7 in 250), *N,N*-dimethylformamide and 0.1 mol/L disodium dihydrogen ethylenediamine tetraacetate TS (11:5:4) with tetrabutylammonium hydroxide TS.

#### System suitability—

System performance: Dissolve 50 mg of minocycline hydrochloride in water to make 25 mL. Heat 5 mL of this solution on a water bath for 60 minutes, then add water to make 25 mL. When the procedure is run with 20  $\mu$ L of this solution under the above operating conditions, epiminocycline and minocycline are eluted in this order with the resolution between these peaks being not less than 2.5.

System repeatability: When the test is repeated 6 times with 20  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of minocycline is not more than 2.0%.

**Containers and storage** Containers—Hermetic containers.

#### Add the following:

### Mitomycin C for Injection

#### 注射用マイトマイシン C

Mitomycin C for Injection is a preparation for injection, which is dissolved before use.

It contains not less than 90.0% and not more than 110.0% of the labeled amount of mitomycin C ( $\text{C}_{15}\text{H}_{18}\text{N}_4\text{O}_5$ : 334.33).

**Method of preparation** Prepare as directed under Injections, with Mitomycin C.

**Description** Mitomycin C for Injection occurs as a blue-purple powder.

**Identification** Dissolve an amount of Mitomycin C for Injection, equivalent to 2 mg (potency) of Mitomycin C according to the labeled amount, in 200 mL of water, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 216 nm and 220 nm, and between 362 nm and 366 nm.

**pH** <2.54> The pH of a solution, prepared by dissolving 0.25 g of Mitomycin C for Injection in 20 mL of water, is 5.5 to 8.5.

**Loss on drying** <2.41> Not more than 1.0% (0.4 g, in vacuum not exceeding 0.67 kPa, phosphorus (V) oxide, 60°C, 3 hours).

**Bacterial endotoxins** <4.01> Less than 10 EU/mg (potency).

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 container of Mitomycin C for Injection add exactly  $V$  mL of *N,N*-dimethylacetamide so that each mL contains about 0.5 mg (potency) of Mitomycin C, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, weigh accurately about 25 mg (potency) of Mitomycin C Reference Standard, add *N,N*-dimethylacetamide to make exactly 50 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Mitomycin C.

$$\begin{aligned} \text{Amount [mg (potency)] of mitomycin C (C}_{15}\text{H}_{18}\text{N}_4\text{O}_5) \\ = W_S \times (A_T/A_S) \times (V/50) \end{aligned}$$

$W_S$ : Amount [mg (potency)] of Mitomycin C Reference Standard

**Foreign insoluble matter** <6.06> Perform the test according to Method 2: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Assay** Weigh accurately the mass of the contents of not less than 10 containers of Mitomycin C for Injection. Weigh accurately an amount of the contents, equivalent to about 10 mg (potency) of Mitomycin C, add exactly 20 mL of *N,N*-dimethylacetamide, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, weigh accurately an amount of Mitomycin C Reference Standard, equivalent to about 25 mg (potency), dissolve in *N,N*-dimethylacetamide to make exactly 50 mL, and use this solution as the standard solution. Then, proceed as directed in the Assay under Mitomycin C.

$$\begin{aligned} \text{Amount [mg (potency)] of mitomycin C (C}_{15}\text{H}_{18}\text{N}_4\text{O}_5) \\ = W_S \times (A_T/A_S) \times (2/5) \end{aligned}$$


$W_S$ : Amount [mg (potency)] of Mitomycin C Reference Standard

**Containers and storage** Containers—Hermetic containers.

**Add the following:**

**Mizoribine**

ミゾリビン



$C_9H_{13}N_3O_6$ ; 259.22

5-Hydroxy-1- $\beta$ -D-ribofuranosyl-1H-imidazole-4-carboxamide [50924-49-7]

Mizoribine contains not less than 98.0% and not more than 102.0% of  $C_9H_{13}N_3O_6$ , calculated on the anhydrous basis.

**Description** Mizoribine occurs as a white to yellowish white crystalline powder.

It is freely soluble in water, and practically insoluble in methanol and in ethanol (99.5).

**Identification (1)** Determine the absorption spectrum of a solution of Mizoribine (1 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Mizoribine Reference Standard prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Mizoribine as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Mizoribine Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Optical rotation** <2.49>  $[\alpha]_D^{20}$ :  $-25 - -27^\circ$  (0.5 g calculated on the anhydrous basis, water, 25 mL, 100 mm).

**Purity (1)** Heavy metals <1.07>—Proceed with 1.0 g of Mizoribine according to Method 1, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

(2) Related substances—Dissolve 0.10 g of Mizoribine in the mobile phase to make 50 mL, and use this solution as the sample solution. Pipet 5 mL of the sample solution, and add the mobile phase to make exactly 50 mL. Pipet 1 mL of this solution, add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 5  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area of both solutions by the automatic integration method: the areas of the peaks other than mizoribine obtained from

the sample solution are not larger than the mizoribine peak area from the standard solution.

**Operating conditions**—

Column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay.

Detector: An ultraviolet absorption photometer (wavelength: 220 nm).

Time span of measurement: About 3 times as long as the retention time of mizoribine, beginning after the solvent peak.

**System suitability**—

Test for required detectability: Pipet 1 mL of the standard solution, and add the mobile phase to make exactly 5 mL. Confirm that the peak area of mizoribine obtained from 5  $\mu$ L of this solution is equivalent to 14 to 26% of that from 5  $\mu$ L of the standard solution.

System performance: When the procedure is run with 5  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of mizoribine are not less than 10,000 and not more than 1.4, respectively.

System repeatability: When the test is repeated 6 times with 5  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of mizoribine is not more than 2.0%.

**Water** <2.48> Not more than 0.5% (0.5 g, volumetric titration, direct titration).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.1 g of Mizoribine, and dissolve in the mobile phase to make exactly 50 mL. Pipet 5 mL of this solution, add the mobile phase to make exactly 50 mL, and use this solution as the sample solution. Separately, weigh accurately about 10 mg of Mizoribine Reference Standard (separately determine the water <2.48> using the same manner as Mizoribine), dissolve in the mobile phase to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 5  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas of mizoribine,  $A_T$  and  $A_S$ , of both solutions.

$$\begin{aligned} &\text{Amount (mg) of } C_9H_{13}N_3O_6 \\ &= W_S \times (A_T/A_S) \times 10 \end{aligned}$$

$W_S$ : Amount (mg) of Mizoribine Reference Standard, calculated on the anhydrous basis

**Operating conditions**—

Detector: An ultraviolet absorption photometer (wavelength: 279 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: Diluted phosphoric acid (1 in 1500).

Flow rate: Adjust the flow rate so that the retention time of mizoribine is about 9 minutes.

*System suitability*—

System performance: When the procedure is run with 5  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of mizoribine are not less than 10,000 and not more than 1.4, respectively.

System repeatability: When the test is repeated 6 times with 5  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of mizoribine is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

**Add the following:**

## Mizoribine Tablets

ミゾリビン錠

Mizoribine Tablets contain not less than 93.0% and not more than 107.0% of the labeled amount of mizoribine ( $C_9H_{13}N_3O_6$ : 259.22).

**Method of preparation** Prepare as directed under Tablets, with Mizoribine.

**Identification** To a quantity of powdered Mizoribine Tablets, equivalent to 0.1 g of Mizoribine according to the labeled amount, add 5 mL of water, shake, filter, and use the filtrate as the sample solution. Separately, dissolve 20 mg of Mizoribine Reference Standard in 1 mL of water, and use this solution as the standard solution. Perform the test with the sample solution and standard solution as directed under Thin-Layer Chromatography <2.03>. Spot 1  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Then develop the plate with a mixture of methanol, ammonia solution (28) and 1-propanol (2:1:1) to a distance of about 10 cm, and air-dry the plate. Allow the plate to stand in iodine vapor: the principal spot from the sample solution and the spot from the standard solution show a red-brown color and the same  $R_f$  value.

**Purity** Related substances—To a quantity of powdered Mizoribine Tablets, equivalent to 0.10 g of Mizoribine according to the labeled amount, add 30 mL of the mobile phase, shake, then add the mobile phase to make 50 mL. Filter the solution through a membrane filter with a pore size not exceeding 0.5  $\mu$ m and use the filtrate as the sample solution. Pipet 2 mL of the sample solution, add the mobile phase to make exactly 20 mL. Pipet 1 mL of the solution, add the mobile phase to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 5  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area of each

solution by the automatic integration method: the area of the peak, having the relative retention time of about 0.3 with respect to mizoribine, obtained from the sample solution is not larger than the peak area of mizoribine from the standard solution, and the area of each peak other than mizoribine from the sample solution is not larger than 2/5 times the peak area of mizoribine from the standard solution.

*Operating conditions*—

Column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay under Mizoribine.

Detector: An ultraviolet absorption photometer (wavelength: 220 nm).

Time span of measurement: About 3 times as long as the retention time of mizoribine, beginning after the solvent peak.

*System suitability*—

Test for required detectability: To exactly 1 mL of the standard solution add the mobile phase to make exactly 5 mL. Confirm that the peak area of mizoribine obtained from 5  $\mu$ L of this solution is equivalent to 14 to 26% of that from 5  $\mu$ L of the standard solution.

System performance: When the procedure is run with 5  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of mizoribine are not less than 10,000 and not more than 1.4, respectively.

System repeatability: When the test is repeated 6 times with 5  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of mizoribine is not more than 2.0%.

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Mizoribine Tablets add 50 mL of water, shake until the tablet is disintegrated, and add water to make exactly 100 mL. Filter the solution, discard not less than 10 mL of the first filtrate, pipet  $V$  mL of the subsequent filtrate, add water to make exactly  $V'$  mL so that each mL contains about 5  $\mu$ g of mizoribine ( $C_9H_{13}N_3O_6$ ), and use this solution as the sample solution. Separately, weigh accurately about 25 mg of Mizoribine Reference Standard (separately determine the water <2.48> in the same manner as Mizoribine), and dissolve in water to make exactly 100 mL. Pipet 2 mL of the solution, add water to make exactly 100 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , at 279 nm of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>.

$$\begin{aligned} &\text{Amount of mizoribine (C}_9\text{H}_{13}\text{N}_3\text{O}_6\text{)} \\ &= W_S \times (A_T/A_S) \times (V'/V) \times (1/50) \end{aligned}$$

$W_S$ : Amount (mg) of Mizoribine Reference Standard, calculated on the anhydrous basis

**Dissolution** <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rate

in 45 minutes of Mizoribine Tablets is not less than 80%.

Start the test with 1 tablet of Mizoribine Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.5  $\mu\text{m}$ . Discard not less than 10 mL of the first filtrate, pipet  $V$  mL of the subsequent filtrate, add water to make exactly  $V'$  mL so that each mL contains about 14  $\mu\text{g}$  of mizoribine ( $\text{C}_9\text{H}_{13}\text{N}_3\text{O}_6$ ) according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 28 mg of Mizoribine Reference Standard (separately determine the water <2.48> in the same manner as Mizoribine), and dissolve in water to make exactly 100 mL. Pipet 1 mL of this solution, add water to make exactly 20 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , at 279 nm of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>.

Dissolution rate (%) with respect to the labeled amount of mizoribine ( $\text{C}_9\text{H}_{13}\text{N}_3\text{O}_6$ )

$$= W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 45$$

$W_S$ : Amount (mg) of Mizoribine Reference Standard, calculated on the anhydrous basis

$C$ : Labeled amount (mg) of mizoribine ( $\text{C}_9\text{H}_{13}\text{N}_3\text{O}_6$ ) in 1 tablet

**Assay** Weigh accurately not less than 20 Mizoribine Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 25 mg of mizoribine ( $\text{C}_9\text{H}_{13}\text{N}_3\text{O}_6$ ), add 50 mL of water and shake, then add water to make exactly 100 mL. Filter the solution, discard not less than 10 mL of the first filtrate, pipet 2 mL of the subsequent filtrate, add water to make exactly 100 mL, and use this solution as the sample solution. Separately, weigh accurately about 25 mg of Mizoribine Reference Standard (separately determine the water <2.48> in the same manner as Mizoribine), and dissolve in water to make exactly 100 mL. Pipet 2 mL of the solution, add water to make exactly 100 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , at 279 nm of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>.

Amount (mg) of mizoribine ( $\text{C}_9\text{H}_{13}\text{N}_3\text{O}_6$ ) =  $W_S \times (A_T/A_S)$

$W_S$ : Amount (mg) of Mizoribine Reference Standard, calculated on the anhydrous basis

**Containers and storage** Containers—Tight containers.

## Morphine Hydrochloride Tablets

モルヒネ塩酸塩錠

### Add the following next to Identification:

**Uniformity of dosage units** <6.02> Perform the test according to the following method; it meets the requirement of the

Content uniformity test.

To 1 tablet of Morphine Hydrochloride Tablets add exactly 1 mL of the internal standard solution per 2 mg of morphine hydrochloride hydrate ( $\text{C}_{17}\text{H}_{19}\text{NO}_3 \cdot \text{HCl} \cdot 3\text{H}_2\text{O}$ ), disperse the tablet into a small particles using ultrasonic waves, then treat with ultrasonic waves for 15 minutes with occasional stirring, and add water to make  $V$  mL so that each mL contains about 0.4 mg of morphine hydrochloride hydrate ( $\text{C}_{17}\text{H}_{19}\text{NO}_3 \cdot \text{HCl} \cdot 3\text{H}_2\text{O}$ ). Filter the solution, and use the filtrate as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} &\text{Amount (mg) of morphine hydrochloride hydrate} \\ &(\text{C}_{17}\text{H}_{19}\text{NO}_3 \cdot \text{HCl} \cdot 3\text{H}_2\text{O}) \\ &= W_S \times (Q_T/Q_S) \times (V/50) \times 1.1679 \end{aligned}$$


$W_S$ : Amount (mg) of morphine hydrochloride for assay, calculated on the anhydrous basis

**Internal standard solution**—A solution of etilefrine hydrochloride (1 in 500).

### Add the following:

## Nabumetone

ナブメトン



$\text{C}_{15}\text{H}_{16}\text{O}_2$ : 228.29

4-(6-Methoxynaphthalen-2-yl)butan-2-one [42924-53-8]

Nabumetone contains not less than 98.0% and not more than 101.0% of  $\text{C}_{15}\text{H}_{16}\text{O}_2$ , calculated on the anhydrous basis.

**Description** Nabumetone occurs as white to yellowish white crystals or a crystalline powder.

It is soluble in acetonitrile, sparingly soluble in methanol and in ethanol (99.5), and practically insoluble in water.

**Identification (1)** Determine the absorption spectrum of a solution of Nabumetone in methanol (1 in 30,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Nabumetone Reference Standard prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Nabumetone as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Nabumetone Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Melting point** <2.60> 79 – 84°C

**Purity (1)** Heavy metals <1.07>—Proceed with 1.0 g of Nabumetone according to Method 2, and perform the test. Prepare the control solution with 1.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Related substances—Dissolve 20 mg of Nabumetone in 20 mL of acetonitrile, and use this solution as the sample solution. Pipet 5 mL of the sample solution, add acetonitrile to make exactly 50 mL. Pipet 1 mL of this solution, add acetonitrile to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area of both solutions by the automatic integration method: the peak area of the related substance G obtained from the sample solution is not larger than 3/5 times the peak area of nabumetone from the standard solution, and each peak area other than nabumetone and the related substance G from the sample solution is not larger than 1/5 times the peak area of nabumetone from the standard solution. Furthermore, the total area of the peaks other than nabumetone from the sample solution is not larger than 1.6 times the peak area of nabumetone from the standard solution. For these calculations, use each peak area of the related substances A, B, C, D, E, F and G, which are having the relative retention time of about 0.73, 0.85, 0.93, 1.2, 1.9, 2.6 and 2.7 with respect to nabumetone, after multiplying by their relative response factors, 0.12, 0.94, 0.25, 0.42, 1.02, 0.91 and 0.1, respectively.

**Operating conditions—**

Detector, column, and column temperature: Proceed as directed in the operating conditions in the Assay.

Mobile phase A: A mixture of water and acetic acid (100) (999:1).

Mobile phase B: A mixture of acetonitrile and tetrahydrofuran (7:3).

Flowing of mobile phase: Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 12	60	40
12 – 28	60→20	40→80

Flow rate: 1.3 mL per minute.

Time span of measurement: About 3 times as long as the retention time of nabumetone, beginning after the solvent peak.

**System suitability—**

Test for required detectability: Pipet 2 mL of the standard solution, and add acetonitrile to make exactly 10 mL. Confirm that the peak area of nabumetone obtained from 10  $\mu$ L of this solution is equivalent to 14 to 26% of that from 10  $\mu$ L of the standard solution.

System performance: Proceed as directed in the system suitability in the Assay.

System repeatability: When the test is repeated 6 times

with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of nabumetone is not more than 5.0%.

**Water** <2.48> Not more than 0.2% (1 g, volumetric titration, direct titration).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 20 mg each of Nabumetone and Nabumetone Reference Standard (separately determine the water <2.48> in the same manner as Nabumetone), dissolve them in acetonitrile to make exactly 20 mL, and use these solutions as the sample solution and the standard solution, respectively. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak area of nabumetone,  $A_T$  and  $A_S$ , from each solution.

$$\text{Amount (mg) of } C_{15}H_{16}O_2 = W_S \times (A_T/A_S)$$

$W_S$ : Amount (mg) of Nabumetone Reference Standard, calculated on the anhydrous basis

**Operating conditions—**

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (4  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: To 600 mL of a mixture of water and acetic acid (100) (999:1) add 400 mL of a mixture of acetonitrile and tetrahydrofuran (7:3).

Flow rate: Adjust the flow rate so that the retention time of nabumetone is about 10 minutes.

**System suitability—**

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of nabumetone are not less than 6000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of nabumetone is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

**Add the following:****Nabumetone Tablets**

ナブメトン錠

Nabumetone Tablets contain not less than 95.0% and not more than 105.0% of the labeled amount of nabumetone ( $C_{15}H_{16}O_2$ : 228.29).

**Method of preparation** Prepare as directed under Tablets, with Nabumetone.

**Identification** To a quantity of powdered Nabumetone Tablets, equivalent to 80 mg of Nabumetone according to the labeled amount, add 50 mL of methanol, shake for 10 minutes and centrifuge the solution. To 1 mL of the supernatant liquid, add methanol to make 50 mL, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 259 nm and 263 nm, between 268 nm and 272 nm, between 316 nm and 320 nm, and between 330 nm and 334 nm.

**Uniformity of dosage units** <6.02> It meets the requirement of the Mass variation test.

**Dissolution** <6.10> When the test is performed at 75 revolutions per minute according to the Paddle method, using 900 mL of a solution of polysorbate 80 (dissolving 3 g of polysorbate 80 in water to make 100 mL) as the dissolution medium, the dissolution rate in 60 minutes of Nabumetone Tablets is not less than 70%.

Start the test with 1 tablet of Nabumetone Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.5  $\mu\text{m}$ . Discard the first 10 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, add a solution, prepared by adding to 20 mL of ethanol (99.5) the dissolution medium to make 50 mL, to make exactly  $V'$  mL so that each mL contains about 89  $\mu\text{g}$  of nabumetone ( $C_{15}H_{16}O_2$ ) according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 22 mg of Nabumetone Reference Standard (separately determine the water <2.48> in the same manner as Nabumetone), and dissolve in ethanol (99.5) to make exactly 100 mL. Pipet 10 mL of this solution, add the dissolution medium to make exactly 25 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , at 331 nm of the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>, using a solution prepared by adding to 20 mL of ethanol (99.5) the dissolution medium to make 50 mL as the blank.

Dissolution rate (%) with respect to the labeled amount of nabumetone ( $C_{15}H_{16}O_2$ )

$$= W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 360$$

$W_S$ : Amount (mg) of Nabumetone Reference Standard, calculated on the anhydrous basis

$C$ : Labeled amount (mg) of nabumetone ( $C_{15}H_{16}O_2$ ) in 1 tablet

**Assay** Weigh accurately not less than 20 tablets of Nabumetone Tablets, and powder. Weigh accurately a portion of the powder, equivalent to about 0.2 g of nabumetone ( $C_{15}H_{16}O_2$ ), add 10 mL of water and shake, add 40 mL of methanol, shake for 30 minutes, and then add methanol to make exactly 100 mL. Centrifuge this solution, pipet 5 mL of the supernatant liquid, add exactly 5 mL of the internal standard solution, then add methanol to make 50 mL, and use this solution as the sample solution. Separately, weigh accurately about 40 mg of Nabumetone Reference Standard (separately determine the water <2.48> in the same manner as Nabumetone), dissolve by adding 50 mL of methanol and exactly 20 mL of the internal standard solution, then add methanol to make 200 mL, and use this solution as the standard solution. Perform the test with 10  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of nabumetone to that of the internal standard.

Amount (mg) of nabumetone ( $C_{15}H_{16}O_2$ ) =  $W_S \times (Q_T/Q_S) \times 5$

$W_S$ : Amount (mg) of Nabumetone Reference Standard, calculated on the anhydrous basis

**Internal standard solution**—Dissolve 0.12 g of 2-ethylhexyl parahydroxybenzoate in methanol to make 100 mL.

**Operating conditions**—

**Detector**: An ultraviolet absorption photometer (wavelength: 254 nm).

**Column**: A stainless steel column 4 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

**Column temperature**: A constant temperature of about 25°C.

**Mobile phase**: A mixture of acetonitrile, water and acetic acid (100) (550:450:1).

**Flow rate**: Adjust the flow rate so that the retention time of nabumetone is about 6 minutes.

**System suitability**—

**System performance**: When the procedure is run with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, nabumetone and the internal standard are eluted in this order with the resolution between these peaks being not less than 13.


**System repeatability**: When the test is repeated 6 times with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of nabumetone to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Well-closed containers.



**Add the following:****Nafamostat Mesilate**

ナファモスタットメシル酸塩

C<sub>19</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub>·2CH<sub>3</sub>O<sub>3</sub>S: 539.586-Amidinonaphthalen-2-yl 4-guanidinobenzoate  
bis(methanesulfonate) [82956-11-4]

Nafamostat Mesilate, when dried, contains not less than 99.0% and not more than 101.0% of C<sub>19</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub>·2CH<sub>3</sub>O<sub>3</sub>S.

**Description** Nafamostat Mesilate occurs as a white crystalline powder.

It is freely soluble in formic acid, soluble in water, and practically insoluble in ethanol (99.5).

It dissolves in 0.01 mol/L hydrochloric acid TS.

Melting point: about 262°C (with decomposition).

**Identification (1)** Determine the absorption spectrum of a solution of Nafamostat Mesilate in 0.01 mol/L hydrochloric acid TS (1 in 200,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Nafamostat Mesilate as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) A 0.1-g portion of Nafamostat Mesilate responds to the Qualitative Tests <1.09> (1) for mesilate.

**pH** <2.54> The pH of a solution prepared by dissolving 1.0 g of Nafamostat Mesilate in 50 mL of water is between 4.7 and 5.7.

**Purity (1)** Clarity and color of solution—A solution prepared by dissolving 1.0 g of Nafamostat Mesilate in 50 mL of water is clear and colorless.

(2) Heavy metals <1.07>—Proceed with 2.0 g of Nafamostat Mesilate according to Method 4, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(3) Related substances—Conduct this procedure using light-resistant vessels. Dissolve 0.10 g of Nafamostat Mesilate in 100 mL of the mobile phase, and use this solution as the sample solution. Pipet 10 mL of the sample solution, add the mobile phase to make exactly 100 mL. Then pipet 5 mL of this solution, add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10 μL each of the sample solution

and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area of each solution by the automatic integration method: the area of each peak other than nafamostat obtained from the sample solution is not larger than 1/5 times the peak area of nafamostat from the standard solution. Furthermore, the total area of the peaks other than nafamostat from the sample solution is not larger than the peak area of nafamostat from the standard solution.

**Operating conditions—**

Detector: An ultraviolet absorption photometer (wavelength: 260 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: Dissolve 6.07 g of sodium 1-heptane sulfonate in 1000 mL of diluted acetic acid (100) (3 in 500). To 700 mL of this solution add 300 mL of acetonitrile.

Flow rate: Adjust the flow rate so that the retention time of nafamostat is about 7 minutes.

Time span of measurement: About 4 times as long as the retention time of nafamostat, beginning after the solvent peak.

**System suitability—**

Test for required detectability: Pipet 5 mL of the standard solution, and add the mobile phase to make exactly 50 mL. Pipet 15 mL of this solution, and add the mobile phase to make exactly 100 mL. Confirm that the peak area of nafamostat obtained from 10 μL of this solution is equivalent to 1.1 to 1.9% of that from 10 μL of the standard solution.

System performance: Dissolve 0.1 g of nafamostat mesilate in the mobile phase to make 100 mL. To 10 mL of this solution add the mobile phase to make 100 mL. To 5 mL of this solution add 5 mL of a solution of 6-amidino-2-naphthol methanesulfonate in the mobile phase (1 in 20,000). When the procedure is run with 10 μL of this solution under the above operating conditions, 6-amidino-2-naphthol and nafamostat are eluted in this order with the resolution between these peaks being not less than 6.

System repeatability: When the test is repeated 6 times with 10 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of nafamostat is not more than 2.0%.

**Loss on drying** <2.41> Not more than 0.5% (1 g, 105°C, 3 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.25 g of Nafamostat Mesilate, previously dried, dissolve in 4 mL of formic acid, add 50 mL of acetic anhydride, and titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS  
= 26.98 mg of  $C_{19}H_{17}N_5O_2 \cdot 2CH_4O_3S$

**Containers and storage** Containers—Tight containers.

## Neostigmine Methylsulfate Injection

ネオスチグミンメチル硫酸塩注射液

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Nicardipine Hydrochloride Injection

ニカルジピン塩酸塩注射液

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Nicorandil

ニコランジル

**Change the Identification to read:**

**Identification (1)** Determine the absorption spectrum of a solution of Nicorandil (1 in 50,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Nicorandil as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

## Nicotinic Acid Injection

ニコチン酸注射液

**Add the following next to Identification:**

**Bacterial endotoxins** <4.01> Less than 3.0 EU/mg.

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.


**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Add the following:**

## Nizatidine

ニザチジン



$C_{12}H_{21}N_5O_2S_2$ : 331.46

(1E)-N-[2-[(2-[(Dimethylamino)methyl]thiazol-4-yl)methyl]sulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine [76963-41-2]

Nizatidine, when dried, contains not less than 98.0% and not more than 101.0% of  $C_{12}H_{21}N_5O_2S_2$ .

**Description** Nizatidine occurs as a white to pale yellowish white crystalline powder, and has a characteristic odor.

It is soluble in methanol, sparingly soluble in water, and slightly soluble in ethanol (99.5).

**Identification (1)** Determine the absorption spectrum of a solution of Nizatidine in methanol (1 in 100,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Nizatidine Reference Standard prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Nizatidine, previously dried, as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of dried Nizatidine Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Melting point** <2.60> 130 – 135°C (after drying).

**Purity (1)** Heavy metals <1.07>—Proceed with 2.0 g of Nizatidine according to Method 4, and perform the test using 3 mL of sulfuric acid. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Related substances—Dissolve 50 mg of Nizatidine in 10 mL of a mixture of the mobile phase A and mobile phase B (19:6), and use this solution as the sample solution. Pipet 3 mL of the sample solution, add the mixture of the mobile phase A and mobile phase B (19:6) to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 50  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area from both solutions by the automatic integration method: the area of the peaks other than nizatidine peak obtained from the sample solution is not larger than 1/5 times the nizatidine peak area from the standard solution. Furthermore, the total of the areas of peaks other than the nizatidine peak from the sample solution is not larger than the peak area of nizatidine from the standard solution.

**Operating conditions—**

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase A: Dissolve 5.9 g of ammonium acetate in 760 mL of water, add 1 mL of diethylamine, and adjust to pH 7.5 with acetic acid (100).

Mobile phase B: Methanol.

Flowing of mobile phase: Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 3	76	24
3 – 20	76→50	24→50
20 – 45	50	50

Flow rate: 1.0 mL per minute.

Time span of measurement: About 3 times as long as the retention time of nizatidine, beginning after the solvent peak.

**System suitability—**

Test for required detectability: Pipet 5 mL of the standard solution, and add a mixture of the mobile phase A and mobile phase B (19:6) to make exactly 25 mL. Confirm that the peak area of nizatidine obtained from 50  $\mu$ L of this solution is equivalent to 15 to 25% of that from 50  $\mu$ L of the standard solution.

System performance: When the procedure is run with 50  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of nizatidine are not less than 20,000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times

with 50  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of nizatidine is not more than 2.0%.

**Loss on drying <2.41>** Not more than 0.5% (2 g, 100°C, 1 hour).

**Residue on ignition <2.44>** Not more than 0.1% (1 g).

**Assay** Weigh accurately about 15 mg each of Nizatidine and Nizatidine Reference Standard, both previously dried, dissolve each in the mobile phase to make exactly 50 mL, and use these solutions as the sample solution and the standard solution, respectively. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine the peak area of nizatidine,  $A_T$  and  $A_S$ , from each solution.

$$\text{Amount (mg) of } C_{12}H_{21}N_5O_2S_2 = W_S \times (A_T/A_S)$$

$W_S$ : Amount (mg) of Nizatidine Reference Standard

**Operating conditions—**

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: Dissolve 5.9 g of ammonium acetate in 760 mL of water, add 1 mL of diethylamine, and adjust to pH 7.5 with acetic acid (100). To this solution add 240 mL of methanol.

Flow rate: Adjust the flow rate so that the retention time of nizatidine is about 10 minutes.

**System suitability—**

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of nizatidine are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of nizatidine is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

**Add the following:**

## Nizatidine Capsules

ニザチジンカプセル

Nizatidine Capsules contain not less than 95.0% and not more than 105.0% of the labeled amount of nizatidine ( $C_{12}H_{21}N_5O_2S_2$ : 331.46).

**Method of preparation** Prepare as directed under Capsules, with Nizatidine.

**Identification** Take out the contents of Nizatidine Capsules, and powder. To a portion of the powder, equivalent to 50 mg of Nizatidine according to the labeled amount, add 50 mL of methanol, shake well, and filter. Pipet 1 mL of the filtrate, and add methanol to make 100 mL. Determine the absorption spectrum of the solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 239 nm and 244 nm, and between 323 nm and 327 nm.

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Take out the contents from 1 capsule of Nizatidine Capsules, add exactly 50 mL of the mobile phase per 75 mg of Nizatidine, and shake vigorously for 10 minutes. Centrifuge this solution, pipet  $V$  mL of the supernatant liquid, add exactly 5 mL of the internal standard solution, and add the mobile phase to make  $V'$  mL so that each mL contains about 0.3 mg of nizatidine ( $C_{12}H_{21}N_5O_2S_2$ ). Use this solution as the sample solution. Then, proceed as directed in the Assay.

$$\begin{aligned} &\text{Amount (mg) of nizatidine (C}_{12}\text{H}_{21}\text{N}_5\text{O}_2\text{S}_2) \\ &= W_S \times (Q_T/Q_S) \times (V'/V) \end{aligned}$$

$W_S$ : Amount (mg) of Nizatidine Reference Standard

**Internal standard solution**—A solution of phenol in the mobile phase (1 in 100).

**Dissolution** <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using a sinker, using 900 mL of water as the dissolution medium, the dissolution rate in 15 minutes of Nizatidine Capsules is not less than 80%.

Start the test with 1 capsule of Nizatidine Capsules, withdraw not less than 10 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding 0.45  $\mu\text{m}$ . Discard the first 2 mL of the filtrate, pipet  $V$  mL of the subsequent filtrate, and add water to make exactly  $V'$  mL so that each mL contains about 10  $\mu\text{g}$  of nizatidine ( $C_{12}H_{21}N_5O_2S_2$ ) according to the labeled amount. Use this solution as the sample solution. Separately, weigh accurately about 25 mg of Nizatidine Reference Standard, previously dried at 100°C for 1 hour, and dissolve in water to make exactly 100 mL. Pipet 2 mL of this solution, add water to make exactly 50 mL, and use this solution as the standard solution. Perform the test with the sample solution and standard solution as directed under Ultraviolet-visible Spectrophotometry <2.24>, and determine the absorbances,  $A_T$  and  $A_S$ , at 314 nm.

Dissolution rate (%) with respect to the labeled amount of nizatidine ( $C_{12}H_{21}N_5O_2S_2$ )

$$= W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 36$$

$W_S$ : Amount (mg) of Nizatidine Reference Standard

$C$ : Labeled amount (mg) of nizatidine ( $C_{12}H_{21}N_5O_2S_2$ ) in 1 capsule

**Assay** Take out the contents of not less than 10 Nizatidine Capsules, weigh accurately the mass of the contents, and powder. Weigh accurately a portion of the powder, equivalent to about 0.15 g of nizatidine ( $C_{12}H_{21}N_5O_2S_2$ ), add exactly 50 mL of the mobile phase, shake vigorously for 10 minutes, and centrifuge. Pipet 5 mL of the supernatant liquid, add exactly 5 mL of the internal standard solution, add the mobile phase to make 50 mL, and use this solution as the sample solution. Separately, weigh accurately about 15 mg of Nizatidine Reference Standard, previously dried at 100°C for 1 hour, dissolve in 30 mL of the mobile phase, add exactly 5 mL of the internal standard solution, add the mobile phase to make 50 mL, and use this solution as the standard solution. Perform the test with 10  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of nizatidine to that of the internal standard.

$$\begin{aligned} &\text{Amount (mg) of nizatidine (C}_{12}\text{H}_{21}\text{N}_5\text{O}_2\text{S}_2) \\ &= W_S \times (Q_T/Q_S) \times 10 \end{aligned}$$

$W_S$ : Amount (mg) of Nizatidine Reference Standard

**Internal standard solution**—A solution of phenol in the mobile phase (1 in 100).

**Operating conditions**—

**Detector**: An ultraviolet absorption photometer (wavelength: 254 nm).

**Column**: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

**Column temperature**: A constant temperature of about 40°C.

**Mobile phase**: Dissolve 5.9 g of ammonium acetate in 760 mL of water, add 1 mL of diethylamine, and adjust to pH 7.5 with acetic acid (100). To this solution add 240 mL of methanol.

**Flow rate**: Adjust the flow rate so that the retention time of nizatidine is about 10 minutes.

**System suitability**—

**System performance**: When the procedure is run with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the internal standard and nizatidine are eluted in this order with the resolution between these peaks being not less than 3.

**System repeatability**: When the test is repeated 6 times with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of nizatidine to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

## Noradrenaline Injection

ノルアドレナリン注射液

### Add the following next to Purity:

**Bacterial endotoxins** <4.01> Less than 300 EU/mg.

### Add the following next to Extractable volume:

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.


**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

### Add the following:

## Omeprazole

オメプラゾール



$C_{17}H_{19}N_3O_3S$ : 345.42

(*RS*)-5-Methoxy-2-[[[4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl]-1*H*-benzimidazole [73590-58-6]

Omeprazole, when dried, contains not less than 99.0% and not more than 101.0% of  $C_{17}H_{19}N_3O_3S$ .

**Description** Omeprazole occurs as a white to yellowish white crystalline powder.

It is freely soluble in *N,N*-dimethylformamide, sparingly soluble in ethanol (99.5), and practically insoluble in water.

A solution of Omeprazole in *N,N*-dimethylformamide (1 in 25) shows no optical rotation.

It gradually turns yellowish white on exposure to light.

Melting point: about 150°C (with decomposition).

**Identification (1)** Add phosphate buffer solution, pH 7.4, to 1 mL of a solution of Omeprazole in ethanol (99.5) (1 in 1000) to make 50 mL. Determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Omeprazole as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Purity (1)** Clarity and color of solution—Dissolve 0.5 g of Omeprazole in 25 mL of *N,N*-dimethylformamide: the solution is clear and colorless or light yellow. Perform the test with this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: the absorbance at 420 nm is not more than 0.3.

(2) Heavy metals <1.07>—Proceed with 2.0 g of Omeprazole according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(3) Related substances—Conduct the procedure soon after preparation of the sample solution. Dissolve 50 mg of Omeprazole in 50 mL of the mobile phase, and use this solution as the sample solution. Perform the test with 10  $\mu$ L of the sample solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each of the peak areas of the sample solution by the automatic integration method, and calculate the amounts of them by the area percentage method: each of the amount other than omeprazole is not more than 0.1%, and the total amount of the peaks other than omeprazole is not more than 0.5%.

**Operating conditions—**

**Detector:** An ultraviolet absorption photometer (wavelength: 280 nm).

**Column:** A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

**Column temperature:** A constant temperature of about 25°C.

**Mobile phase:** Dissolve 2.83 g of disodium hydrogen phosphate dodecahydrate and 0.21 g of sodium dihydrogen phosphate dihydrate in water to make 1000 mL. If necessary, adjust the pH to 7.6 with diluted phosphoric acid (1 in 100). Add 11 volumes of acetonitrile to 29 volumes of this solution.

**Flow rate:** Adjust the flow rate so that the retention time of omeprazole is about 8 minutes.

**Time span of measurement:** About 10 times as long as the retention time of omeprazole, beginning after the solvent peak.

**System suitability—**

**Test for required detectability:** Pipet 5 mL of the sample solution, and add the mobile phase to make exactly 100 mL. Pipet 5 mL of this solution, add the mobile phase to make exactly 50 mL, and use this solution as the solution for system suitability test. Pipet 5 mL of the solution, and add the mobile phase to make exactly 25 mL. Confirm that the peak area of omeprazole obtained from 10  $\mu$ L of this solution is equivalent to 15 to 25% of that from 10  $\mu$ L of the solution for system suitability test.

**System performance:** Dissolve 10 mg of Omeprazole and 25 mg of 1,2-dinitrobenzene in 5 mL of sodium borate solution (19 in 5000) and 95 mL of ethanol (99.5). When the procedure is run with 10  $\mu$ L of this solution under the above conditions, omeprazole and 1,2-dinitrobenzene are eluted in this order with the resolution between these peaks being not less than 10.

System repeatability: When the test is repeated 6 times with 10  $\mu\text{L}$  of the solution for system suitability test under the above operating conditions, the relative standard deviation of the peak area of omeprazole is not more than 2.0%.

**Loss on drying** <2.41> Not more than 0.2% (1 g, in vacuum, phosphorus (V) oxide, 50°C, 2 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.4 g of Omeprazole, previously dried, dissolve in 70 mL of *N,N*-dimethylformamide, and titrate <2.50> with 0.1 mol/L tetramethylammonium hydroxide VS (potentiometric titration). Separately, perform a blank determination using the same method on a solution consisting of 70 mL of *N,N*-dimethylformamide and 12 mL of water, and make any necessary correction.


Each mL of 0.1 mol/L tetramethylammonium hydroxide VS = 34.54 mg of  $\text{C}_{17}\text{H}_{19}\text{N}_3\text{O}_3\text{S}$

**Containers and storage** Containers—Tight containers.  
Storage—Light-resistant, in a cold place.

### Add the following:

## Ozagrel Sodium

オザゲレルナトリウム



$\text{C}_{13}\text{H}_{11}\text{N}_2\text{NaO}_2$ : 250.23  
Monosodium (2*E*)-3-[4-(1*H*-imidazol-1-ylmethyl)phenyl]prop-2-enoate [189224-26-8]

Ozagrel Sodium, when dried, contains not less than 98.0% and not more than 102.0% of  $\text{C}_{13}\text{H}_{11}\text{N}_2\text{NaO}_2$ .

**Description** Ozagrel Sodium occurs as white crystals or crystalline powder.

It is freely soluble in water, soluble in methanol, and practically insoluble in ethanol (99.5).

**Identification** (1) Determine the absorption spectrum of a solution of Ozagrel Sodium (1 in 200,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Ozagrel Sodium Reference Standard prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Ozagrel Sodium as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Ozagrel Sodium Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) A solution of Ozagrel Sodium (1 in 20) responds to

the Qualitative Tests <1.09> for sodium salt.

**pH** <2.54> The pH of a solution prepared by dissolving 0.5 g of Ozagrel Sodium in 10 mL of water is between 9.5 and 10.5.

**Purity** (1) Clarity and color of solution—Dissolve 0.5 g of Ozagrel Sodium in 10 mL of water: the solution is clear and colorless.

(2) Chloride <1.03>—Dissolve 2.0 g of Ozagrel Sodium in 30 mL of water, add 1 mL of acetic acid (100) and water to make 50 mL, shake, and allow to stand for 30 minutes. Filter the solution, discard the first 5 mL of the filtrate, and to 25 mL of the subsequent filtrate add 6 mL of dilute nitric acid and water to make 50 mL. Perform the test with this solution as the test solution. Prepare the control solution as follows: To 0.35 mL of 0.01 mol/L hydrochloric acid VS add 0.5 mL of acetic acid (100), 6 mL of dilute nitric acid and water to make 50 mL (not more than 0.012%).

(3) Heavy metals <1.07>—Proceed with 2.0 g of Ozagrel Sodium according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(4) Related substances—Dissolve 50 mg of Ozagrel Sodium in 100 mL of the mobile phase, and use this solution as the sample solution. Perform the test with 5  $\mu\text{L}$  of the sample solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method, and calculate the amount of them by the area percentage method: each of the amount other than ozagrel is not more than 0.2%, and the total amount other than ozagrel is not more than 0.5%.

**Operating conditions**—

Column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay.

Detector: An ultraviolet absorption photometer (wavelength: 220 nm).

Time span of measurement: About 2 times as long as the retention time of ozagrel, beginning after the solvent peak.

**System suitability**—

Test for required detectability: Pipet 1 mL of the sample solution, and add the mobile phase to make exactly 200 mL, and use this solution as the solution for system suitability test. Pipet 2 mL of the solution for system suitability test, and add the mobile phase to make exactly 10 mL. Confirm that the peak area of ozagrel obtained from 5  $\mu\text{L}$  of this solution is equivalent to 15 to 25% of that from 5  $\mu\text{L}$  of the solution for system suitability test.

System performance: When the procedure is run with 5  $\mu\text{L}$  of the solution for system suitability test under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of ozagrel are not less than 6000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 5  $\mu\text{L}$  of the solution for system suitability test under the above operating conditions, the relative standard deviation of the peak area of ozagrel is not more than 2.0%.

**Loss on drying** <2.41> Not more than 0.5% (1 g, 105°C, 4 hours).

**Assay** Weigh accurately about 25 mg each of Ozagrel Sodium and Ozagrel Sodium Reference Standard, both previously dried, and dissolve each in methanol to make exactly 25 mL. Pipet 5 mL each of these solutions, add exactly 5 mL of the internal standard solution, and use these solutions as the sample solution and the standard solution, respectively. Perform the test with 1  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak area of ozagrel to that of the internal standard.

$$\begin{aligned} &\text{Amount (mg) of } C_{13}H_{11}N_2NaO_2 \\ &= W_S \times (Q_T/Q_S) \end{aligned}$$

$W_S$ : Amount (mg) of Ozagrel Sodium Reference Standard

**Internal standard solution**—A solution of benzoic acid in methanol (1 in 100).

**Operating conditions**—

**Detector**: An ultraviolet absorption photometer (wavelength: 272 nm).

**Column**: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

**Column temperature**: A constant temperature of about 25°C.

**Mobile phase**: A mixture of a solution of ammonium acetate (3 in 1000) and methanol (4:1).

**Flow rate**: Adjust the flow rate so that the retention time of ozagrel is about 10 minutes.

**System suitability**—

**System performance**: When the procedure is run with 1  $\mu$ L of the standard solution under the above operating conditions, the internal standard and ozagrel are eluted in this order with the resolution between these peaks being not less than 2.0, and the symmetry factor of the peak of ozagrel is not more than 2.0.

**System repeatability**: When the test is repeated 6 times with 1  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak area of ozagrel to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

Storage—Light-resistant.

**Add the following:**

## Ozagrel Sodium for Injection

注射用オザゲレルナトリウム

Ozagrel Sodium for Injection is a preparation for injection which is dissolved before use.

It contains not less than 95.0% and not more than 105.0% of the labeled amount of ozagrel sodium ( $C_{13}H_{11}N_2NaO_2$ ; 250.23).

**Method of preparation** Prepare as directed under Injections, with Ozagrel Sodium.

**Description** Ozagrel Sodium for Injection occurs as white masses or powder.

**Identification** Dissolve an amount of Ozagrel Sodium for Injection, equivalent to 40 mg of Ozagrel Sodium according to the labeled amount, in water to make 40 mL. To 1 mL of this solution add water to make 200 mL, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 269 nm and 273 nm.

**pH** Being specified separately.

**Purity** Related substances—Dissolve an amount of Ozagrel Sodium for Injection, equivalent to 0.20 g of Ozagrel Sodium according to the labeled amount, in the mobile phase to make 100 mL. To 5 mL of this solution add the mobile phase to make 20 mL, and use this solution as the sample solution. Then, proceed as directed in the Purity (4) under Ozagrel Sodium.

**Bacterial endotoxins** <4.01> Less than 3.7 EU/mg.

**Uniformity of dosage units** <6.02> It meets the requirements of the Mass variation test.

**Foreign insoluble matter** <6.06> Perform the test according to Method 2: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Assay** Dissolve an amount of Ozagrel Sodium for Injection, equivalent to about 0.4 g of ozagrel sodium ( $C_{13}H_{11}N_2NaO_2$ ), in water to make exactly 200 mL. Pipet 5 mL of this solution, add exactly 10 mL of the internal standard solution and 5 mL of water, mix, and use this solution as the sample solution. Separately, weigh accurately about 25 mg of Ozagrel Sodium Reference Standard, and dissolve in methanol to make exactly 25 mL. Pipet 5 mL of this solution, add exactly 5 mL of the internal standard solution, and use this solution as the standard solution. Then, proceed as directed in the Assay under Ozagrel Sodium.

$$\begin{aligned} &\text{Amount (mg) of ozagrel sodium } (C_{13}H_{11}N_2NaO_2) \\ &= W_S \times (Q_T/Q_S) \times 16 \end{aligned}$$

$W_S$ : Amount (mg) of Ozagrel Sodium Reference Standard

**Internal standard solution**—A solution of benzoic acid in methanol (1 in 100).

**Containers and storage** Containers—Hermetic containers.

## Papaverine Hydrochloride Injection

パパベリン塩酸塩注射液

### Add the following next to Identification:

**Bacterial endotoxins** <4.01> Less than 6.0 EU/mg.

### Add the following next to Extractable volume:

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

### Add the following:

## Peplomycin Sulfate for Injection

注射用ペプロマイシン硫酸塩

Peplomycin Sulfate for Injection is a preparation for injection which is dissolved before use.

It contains not less than 90.0% and not more than 115.0% of the labeled amount of peplomycin ( $C_{61}H_{88}N_{18}O_{21}S_2$ : 1473.59).

**Method of preparation** Prepare as directed under Injections, with Peplomycin Sulfate.

**Description** Peplomycin Sulfate for Injection occurs as white light masses or powder.

**Identification** Take an amount of Peplomycin Sulfate for Injection, equivalent to 10 mg (potency) of Peplomycin Sulfate according to the labeled amount, and dissolve in 15  $\mu$ L of Copper (II) sulfate TS and water to make 2 mL. Apply this solution to the column (prepared by filling a 15 mm inside diameter and 15 cm long chromatography tube with 15 mL of strongly basic ion exchange resin (Cl type) for column chromatography (75 – 150  $\mu$ m in particle diameter) and run off. Then wash the column using water at 2.5 mL per minute, collect about 30 mL of the effluent. Add water to the effluent to make 250 mL, and determine the absorption spectrum of this solution as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits maxima between 242 nm and 246 nm, and between 291 nm and 295 nm. Further determine the absorbances  $A_1$  and  $A_2$ , at 243 nm and 293 nm, respectively: the ratio  $A_1/A_2$  is 1.20 to 1.30.

**Osmotic pressure ratio** Being specified separately.

**pH** <2.54> The pH of a solution prepared by dissolving an amount of Peplomycin Sulfate for Injection, equivalent to 50 mg (potency) of Peplomycin Sulfate according to the labeled amount, in 10 mL of water is 4.5 to 6.0.

**Purity** Clarity and color of solution—A solution prepared by dissolving an amount of Peplomycin Sulfate for Injection, equivalent to 10 mg (potency) of Peplomycin Sulfate according to the labeled amount, in 10 mL of water is clear and colorless.

**Loss on drying** <2.41> Not more than 4.0% (60 mg, in vacuum, phosphorus (V) oxide, 60°C, 3 hours). Perform the sampling preventing from moisture absorption.

**Bacterial endotoxins** <4.01> Less than 1.5 EU/mg (potency).

**Uniformity of dosage units** <6.02> It meets the requirement of the Mass variation test.

**Foreign insoluble matter** <6.06> Perform the test according to Method 2: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Assay** Perform the test according to the Cylinder-plate method as directed under Microbial Assay for Antibiotics <4.02> according to the following conditions.

(i) Test organism, culture medium, liquid medium for suspending test organisms, preparation of seeded agar layer, preparation of cylinder-agar plate and the standard solutions—Proceed as directed in the Assay under Peplomycin Sulfate.

(ii) Sample solutions—Weigh accurately the mass of the contents of not less than 10 containers of Peplomycin Sulfate for Injection. Weigh accurately an amount of the contents, equivalent to about 10 mg (potency) of Peplomycin Sulfate, dissolve in 0.1 mol/L phosphate buffer solution, pH 6.8, to make exactly 100 mL. Measure exactly a suitable quantity of this solution, add 0.1 mol/L phosphate buffer solution, pH 6.8 so that each mL contains 4  $\mu$ g (potency) and 2  $\mu$ g (potency), and use these solutions as the high concentration sample solution and the low concentration sample solution, respectively.

**Containers and storage** Containers—Hermetic containers.

## Pethidine Hydrochloride Injection

ペチジン塩酸塩注射液

### Add the following next to Identification:

**Bacterial endotoxins** <4.01> Less than 6.0 EU/mg.

### Add the following next to Extractable volume:

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.




**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Add the following:**

## Piperacillin Hydrate

ピペラシリン水和物



$C_{23}H_{27}N_5O_7S \cdot H_2O$ : 535.57

(2*S*,5*R*,6*R*)-6-[(2*R*)-2-[(4-Ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetamino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid monohydrate [66258-76-2]

Piperacillin Hydrate contains not less than 970  $\mu$ g (potency) and not more than 1020  $\mu$ g (potency) per mg, calculated on the anhydrous basis. The potency of Piperacillin Hydrate is expressed as mass (potency) of piperacillin ( $C_{23}H_{27}N_5O_7S$ : 517.55).

**Description** Piperacillin Hydrate occurs as a white crystalline powder.

It is freely soluble in methanol, soluble in ethanol (99.5) and in dimethylsulfoxide, and very slightly soluble in water.

**Identification** (1) Determine the infrared absorption spectrum of Piperacillin Hydrate as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Piperacillin Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers.

(2) Determine the spectrum of a solution of Piperacillin Hydrate in deuterated dimethylsulfoxide for nuclear magnetic resonance spectroscopy (1 in 3) as directed under Nuclear Magnetic Resonance Spectroscopy <2.21> ( $^1H$ ), using tetramethylsilane for nuclear magnetic resonance spectroscopy as an internal reference compound: it exhibits a triple signal A at about  $\delta$  1.1 ppm, a single signal B at about  $\delta$  4.2 ppm, and a multiple signal C at about  $\delta$  7.4 ppm, and the ratio of the integrated intensity of each signal, A:B:C, is about 3:1:5.

**Optical rotation** <2.49>  $[\alpha]_D^{20}$ : +162 – +172° (0.2 g, methanol, 20 mL, 100 mm).

**Purity** (1) Heavy metal <1.07>—Proceed with 2.0 g of Piperacillin Hydrate according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Related substances 1—Conduct this procedure rapidly after the preparation of the sample solution and standard

solution. Dissolve 20 mg of Piperacillin Hydrate in 20 mL of the mobile phase, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mobile phase to make exactly 200 mL, and use this solution as the standard solution (1). Pipet 2 mL of the standard solution (1), add the mobile phase to make exactly 10 mL, and use this solution as the standard solution (2). Perform the test with exactly 20  $\mu$ L each of the sample solution and the standard solutions (1) and (2) as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the total area of the peaks, having the relative retention time of about 0.38 and about 0.50 with respect to piperacillin, obtained from the sample solution is not larger than twice the peak area of piperacillin from the standard solution (2), the total area of the peaks, having the relative retention time of about 0.82 and about 0.86 with respect to piperacillin, obtained from the sample solution is not larger than the peak area of piperacillin from the standard solution (2), and the area of the peak other than piperacillin and other than the peaks having the relative retention time of about 0.38, about 0.50, about 0.82 and about 0.86 with respect to piperacillin, obtained from the sample solution, is not larger than the peak area of piperacillin from the standard solution (2). Furthermore, the total area of the peaks other than piperacillin obtained from the sample solution is not larger than the peak area of piperacillin from the standard solution (1).

**Operating conditions**—

Detector, column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay.

Time span of measurement: About 3 times as long as the retention time of piperacillin, beginning after the solvent peak.

**System suitability**—

Test for required detectability: Confirm that the peak area of piperacillin obtained from 20  $\mu$ L of the standard solution (2) is equivalent to 15 to 25% of that from 20  $\mu$ L of the standard solution (1).

System performance: When the procedure is run with 20  $\mu$ L of the standard solution (1) under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of piperacillin are not less than 3000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 20  $\mu$ L of the standard solution (2) under the above operating conditions, the relative standard deviation of the peak area of piperacillin is not more than 3.0%.

(3) Related substances 2—Dissolve 20 mg of Piperacillin Hydrate in 20 mL of the mobile phase, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add the mobile phase to make exactly 200 mL, and use this solution as the standard solution (1). Pipet 2 mL of the standard solution (1), add the mobile phase to make exactly 10 mL, and use this solution as the standard solution (2). Perform the test with exactly 20  $\mu$ L each of the sample solution, and the standard solutions (1) and (2) as directed under Liq-

uid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the area of the peak, having the relative retention time of about 6.6 with respect to piperacillin, obtained from the sample solution is not larger than three times the peak area of piperacillin from the standard solution (2), and the area of the peaks other than the peak of piperacillin and the peak having the relative retention time of about 6.6 with respect to piperacillin from the sample solution are not larger than 1.4 times the peak area of piperacillin from the standard solution (2). Furthermore, the total area of the peaks other than the peak of piperacillin from the sample solution is not larger than the area of the peak of piperacillin from the standard solution (1). For these calculations, use the area of the peak, having the relative retention time of about 6.6 with respect to piperacillin, after multiplying by the relative response factor, 2.0.

*Operating conditions—*

Detector, column and column temperature: Proceed as directed in the operating conditions in the Assay.

Mobile phase: Take 60.1 g of acetic acid (100) and 101.0 g of triethylamine, add water to make 1000 mL. To 25 mL of this solution add 300 mL of acetonitrile and 25 mL of dilute acetic acid, and add water to make 1000 mL.

Flow rate: Adjust the flow rate so that the retention time of piperacillin is about 1.2 minutes.

Time span of measurement: About 8 times as long as the retention time of piperacillin, beginning after the piperacillin peak.

*System suitability—*

Test for required detectability: Confirm that the peak area of piperacillin obtained from 20  $\mu$ L of the standard solution (2) is equivalent to 15 to 25% of that from 20  $\mu$ L of the standard solution (1).

System performance: When the procedure is run with 20  $\mu$ L of the standard solution (1) under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of piperacillin are not less than 1500 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 20  $\mu$ L of the standard solution (2) under the above operating conditions, the relative standard deviation of the peak area of piperacillin is not more than 4.0%.

(4) Residual solvents <2.46>—Transfer exactly 10 mg of Piperacillin Hydrate to an about 3 mL-vial, add exactly 1 mL of saturated sodium hydrogen carbonate solution to dissolve and stop the vial tightly. After heating this at 90°C for 10 minutes, use the gas inside the container as the sample gas. Separately, measure exactly 1 mL of ethyl acetate, dissolve in water to make exactly 200 mL. Pipet 10 mL of this solution, add water to make exactly 20 mL. Pipet 2  $\mu$ L of this solution in an about 3-mL vial containing exactly 1 mL of saturated sodium hydrogen carbonate solution, and stop the vial tightly. Run the procedure similarly to the sample, and use the gas as the standard gas. Perform the test with exactly 0.5 mL each of the sample gas and standard gas as directed under Gas Chromatography <2.02> according to the following conditions, and determine the peak area of ethyl

acetate by the automatic integration method: the peak area of ethyl acetate obtained from the sample gas is not larger than that from the standard gas.

*Operating conditions—*

Detector: A hydrogen flame-ionization detector.

Column: A glass column 3 mm in inside diameter and 1 m in length, packed with porous styrene-divinyl benzene copolymer for gas chromatography (average pore diameter of 0.0085  $\mu$ m, 300 – 400 m<sup>2</sup>/g) with the particle size of 125 to 150  $\mu$ m.

Column temperature: A constant temperature of about 145°C.

Carrier gas: Nitrogen

Flow rate: Adjust the flow rate so that the retention time of ethyl acetate is about 4 minutes.

*System suitability—*

System performance: Take 1 mL of saturated sodium hydrogen carbonate solution in an about 3 mL-vial, add 2  $\mu$ L each of ethyl acetate solution (1 in 400) and acetone solution (1 in 400), and stop the vial tightly. When the procedure is run under the above operating conditions, acetone and ethyl acetate are eluted in this order with the resolution between these peaks being not less than 2.0.

System repeatability: Take 1 mL of saturated sodium hydrogen carbonate solution in an about 3 mL-vial, add 2  $\mu$ L of ethyl acetate solution (1 in 400), stop the vial tightly, and perform the test under the above operating conditions. When the procedure is repeated 6 times, the relative standard deviation of the peak area of ethyl acetate is not more than 10%.

**Water** <2.48> Not less than 3.2% and not more than 3.8% (0.5 g, volumetric titration, direct titration).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Bacterial endotoxins** <4.01> Less than 0.07 EU/mg (potency).

**Assay** Weigh accurately an amount of Piperacillin Hydrate and Piperacillin Reference Standard, equivalent to about 50 mg (potency), dissolve each in the mobile phase to make 50 mL. Pipet 5 mL each of these solutions, add exactly 5 mL of the internal standard solution, and use these solutions as the sample solution and standard solution, respectively. Perform the test with 5  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and calculate the ratios,  $Q_T$  and  $Q_S$ , of the peak height of piperacillin to that of the internal standard.

$$\begin{aligned} &\text{Amount } [\mu\text{g (potency)}] \text{ of piperacillin (C}_{23}\text{H}_{27}\text{N}_5\text{O}_7\text{S)} \\ &= W_S \times (Q_T/Q_S) \times 1000 \end{aligned}$$

$W_S$ : Amount [mg (potency)] of Piperacillin Reference Standard

*Internal standard solution*—A solution of acetanilide in the mobile phase (1 in 5000).

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wave-

length: 254 nm).

Column: A stainless steel column 4 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: Take 60.1 g of acetic acid (100) and 101.0 g of triethylamine, add water to make 1000 mL. To 25 mL of this solution add 210 mL of acetonitrile and 25 mL of dilute acetic acid, and add water to make 1000 mL.

Flow rate: Adjust the flow rate so that the retention time of piperacillin is about 5 minutes.

*System suitability*—

System performance: When the procedure is run with 5  $\mu$ L of the standard solution under the above operating conditions, the internal standard and piperacillin are eluted in this order with the resolution between these peaks being not less than 3.

System repeatability: When the test is repeated 6 times with 5  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the ratio of the peak height of piperacillin to that of the internal standard is not more than 1.0%.

**Containers and storage** Containers—Tight containers.

## Prednisolone Sodium Succinate for Injection

注射用プレドニゾロンコハク酸エステルナトリウム

**Add the following next to Loss on drying:**

**Bacterial endotoxins** <4.01> Less than 2.4 EU/mg of prednisolone (C<sub>21</sub>H<sub>28</sub>O<sub>5</sub>).

**Uniformity of dosage units** <6.02> It meets the requirement of the Mass variation test.

**Foreign insoluble matter** <6.06> Perform the test according to Method 2: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Protamine Sulfate

プロタミン硫酸塩

**Change the origin/limits of content to read:**

Protamine Sulfate is the sulfate of protamine prepared from the mature spermary of fish belonging to the family *Salmonidae*.

It has a property to bind with heparin.

It binds with not less than 100 Units of heparin per mg, calculated on the dried basis.

**Change the Description to read:**

**Description** Protamine Sulfate occurs as a white powder. It is sparingly soluble in water.

**Add the following next to Identification:**

**pH** <2.54> Dissolve 1.0 g of Protamine Sulfate in 100 mL of water: the pH of this solution is between 6.5 and 7.5.

**Change the Purity (2) to read**

**Purity (2)** Absorbance—Dissolve 0.10 g of Protamine Sulfate in 10 mL of water, and determine the absorption spectrum as directed under Ultraviolet-visible Spectrophotometry <2.24>: the absorbance between 260 nm and 280 nm is not more than 0.1.

**Delete the Potency as antiheparin, and add the following next to Purity:**

**Loss on drying** <2.41> Not more than 5.0% (1 g, 105°C, 3 hours).

**Nitrogen content** Weigh accurately about 10 mg of Protamine Sulfate, and perform the test as directed under Nitrogen Determination <1.08>: the amount of nitrogen (N:14.01) is 22.5 – 25.5%, calculated on the dried basis.

**Heparin-binding capacity**

(i) Sample solution (a)—Weigh accurately about 15 mg of Protamine Sulfate, and dissolve in water to make exactly 100 mL. Repeat this procedure 3 times, and use the solutions so obtained as the sample solutions (a<sub>1</sub>), (a<sub>2</sub>) and (a<sub>3</sub>).

(ii) Sample solution (b)—Pipet 10 mL each of the sample solutions (a<sub>1</sub>), (a<sub>2</sub>) and (a<sub>3</sub>), add exactly 5 mL of water to them, and use these solutions as the sample solutions (b<sub>1</sub>), (b<sub>2</sub>) and (b<sub>3</sub>).

(iii) Sample solution (c)—Pipet 10 mL each of the sample solutions (a<sub>1</sub>), (a<sub>2</sub>) and (a<sub>3</sub>), add exactly 20 mL of water to them, and use these solutions as the sample solutions (c<sub>1</sub>), (c<sub>2</sub>) and (c<sub>3</sub>).

(iv) Standard solution—Dissolve Heparin Sodium Reference Standard in water to make a solution containing exactly about 20 Units per mL.

(v) Procedure—Transfer exactly 2 mL of the sample solution to a cell for spectrophotometer, add the standard solution dropwise while mixing, and determine the transmittance at 500 nm as directed under Ultraviolet-visible Spectrophotometry <2.24>. Continue the addition until a sharp change in the transmittance is observed, and note the volume, *V* mL, of the standard solution added. Repeat this procedure 2 times for each sample solution.

(vi) Calculation—Calculate the amount of heparin bound with 1 mg of the sample by the following formula from the volume of titrant on each sample solution, and calculate the average of 18 results obtained. The assay is not valid unless each relative standard deviation of 6 results ob-

tained from the sample solution (a), sample solution (b) and sample solution (c) is not more than 5%, respectively, and also unless each relative standard deviation of 6 results obtained from 3 sets, ( $a_1, b_1, c_1$ ), ( $a_2, b_2, c_2$ ) and ( $a_3, b_3, c_3$ ) is not more than 5%, respectively.

Amount (heparin Unit) of heparin bound to 1 mg of Protamine Sulfate

$$= S \times V \times (50/W_T) \times d$$

$S$ : Amount (heparin Unit) of heparin sodium in 1 mL of the standard solution

$W_T$ : Amount (mg) of the sample, calculated on the dried basis

$d$ : Dilution factor for each sample solution from the sample solution (a)

**Sulfate content** Weigh accurately about 0.15 g of Protamine Sulfate, dissolve in 75 mL of water, add 5 mL of 3 mol/L hydrochloric acid TS, and heat to boil. Add gradually 10 mL of barium chloride TS while boiling, and allow to stand for 1 hour while heating. Filter the precipitate formed, wash the precipitate with warm water several times, and transfer the precipitate into a tared crucible. Dry the precipitate, and incinerate by ignition to constant mass: the amount of sulfate ( $SO_4$ ) is 16 – 22%, calculated on the dried basis, where 1 g of the residue is equivalent to 0.4117 g of  $SO_4$ .

## Protamine Sulfate Injection

プロタミン硫酸塩注射液

**Delete the Potency as antiheparin, and add the following next to Extractable volume:**

**Heparin-binding capacity** Proceed the test as directed in the Heparin-binding capacity under Protamine Sulfate, changing the sample solution (a) as below: it binds with not less than 100 Units of heparin per mg of the labeled amount.

(i) Sample solution (a)—Pipet as amount of Protamine Sulfate Injection, equivalent to 15.0 mg of Protamine Sulfate according to the labeled amount, add water to make exactly 100 mL. Repeat this procedure more 2 times, and use the solutions so obtained as the sample solutions ( $a_1$ ), ( $a_2$ ) and ( $a_3$ ).

## Pyridoxine Hydrochloride Injection

ピリドキシン塩酸塩注射液

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Reserpine Injection

レセルピン注射液

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Riboflavin Sodium Phosphate Injection

リボフラビンリン酸エステルナトリウム注射液

**Add the following next to Identification:**

**Bacterial endotoxins** <4.01> Less than 10 EU/mg.

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Ringer's Solution

リンゲル液

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Add the following:****Rokitamycin Tablets**

ロキタマイシン錠

Rokitamycin Tablets contain not less than 90.0% and not more than 110.0% of the labeled amount of rokitamycin ( $C_{42}H_{69}NO_{15}$ : 827.99).

**Method of preparation** Prepare as directed under Tablets, with Rokitamycin.

**Identification** Take an amount of powdered Rokitamycin Tablets, equivalent to 10 mg (potency) of Rokitamycin according to the labeled amount, add 20 mL of methanol, and centrifuge if necessary. To 1 mL of this solution add methanol to make 25 mL, and determine the absorption spectrum as directed under Ultraviolet-visible Spectrophotometry <2.24>: it exhibits a maximum between 230 nm and 233 nm.

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

Add 50 mL of water to 1 tablet of Rokitamycin Tablets, and disintegrate. Then add 10 mL of methanol, shake well, and add water to make exactly 100 mL. Centrifuge this solution if necessary, filter through a membrane filter with a pore size not exceeding  $0.5\ \mu\text{m}$ . Discard 5 mL of the first filtrate, pipet  $V$  mL of the subsequent filtrate, add water to make exactly  $V'$  mL so that each mL contains about  $20\ \mu\text{g}$  (potency) of Rokitamycin, and use this solution as the sample solution. Separately, weigh accurately about 20 mg (potency) of Rokitamycin Reference Standard, dissolve in 10 mL of methanol, and add water to make exactly 100 mL. Pipet 5 mL of this solution, add water to make exactly 50 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , at 232 nm of the sample solution and standard solution using water as the blank, as directed under Ultraviolet-visible Spectrophotometry <2.24>.

$$\begin{aligned} & \text{Amount [mg (potency)] of rokitamycin } (C_{42}H_{69}NO_{15}) \\ & = W_S \times (A_T/A_S) \times (V'/V) \times (1/10) \end{aligned}$$

$W_S$ : Amount [mg (potency)] of Rokitamycin Reference Standard

**Dissolution** <6.10> When the test is performed at 50 revolutions per minute according to the Paddle method, using 900 mL of water as the dissolution medium, the dissolution rate in 30 minutes of Rokitamycin Tablets is not less than 80%.

Start the test with 1 tablet of Rokitamycin Tablets, withdraw not less than 20 mL of the medium at the specified minute after starting the test, and filter through a membrane filter with a pore size not exceeding  $0.5\ \mu\text{m}$ . Discard 10 mL of the first filtrate, pipet  $V$  mL of the subsequent filtrate, add water to make exactly  $V'$  mL so that each mL contains about  $22\ \mu\text{g}$  (potency) of Rokitamycin according to the labeled amount, and use this solution as the sample solution. Separately, weigh accurately about 22 mg (potency) of

Rokitamycin Reference Standard, dissolve in 10 mL of methanol, and add water to make exactly 100 mL. Pipet 5 mL of the solution, add water to make exactly 50 mL, and use this solution as the standard solution. Determine the absorbances,  $A_T$  and  $A_S$ , at 232 nm of the sample solution and standard solution using water as the blank, as directed under Ultraviolet-visible Spectrophotometry <2.24>.

Dissolution rate (%) with respect to the labeled amount of rokitamycin ( $C_{42}H_{69}NO_{15}$ )

$$= W_S \times (A_T/A_S) \times (V'/V) \times (1/C) \times 90$$

$W_S$ : Amount [mg (potency)] of Rokitamycin Reference Standard

$C$ : Labeled amount [mg (potency)] of rokitamycin ( $C_{42}H_{69}NO_{15}$ ) in 1 tablet

**Assay** Perform the test according to the Cylinder-plate method as directed under Microbial Assay for Antibiotics <4.02> under the following conditions.

(i) Test organism, culture medium and standard solutions—Proceed as directed in the Assay under Rokitamycin.

(ii) Sample solutions—Weigh accurately not less than 20 tablets of Rokitamycin Tablets, and powder. Weigh accurately an amount of contents, equivalent to about 40 mg (potency) of Rokitamycin, add 50 mL of methanol, shake vigorously, then add 0.1 mol/L phosphate buffer solution, pH 4.5 to make exactly 100 mL, and centrifuge if necessary. Measure exactly a suitable quantity of this solution, add polysorbate 80 solution, prepared by adding 0.1 mol/L phosphate buffer solution, pH 8.0 to 0.1 g of polysorbate 80 to make 1000 mL, so that each mL contains  $2\ \mu\text{g}$  (potency) and  $0.5\ \mu\text{g}$  (potency), and use these solutions as the high concentration sample solution and the low concentration sample solution, respectively.

**Containers and storage** Containers—Tight containers.

**Roxithromycin**

ロキシスロマイシン

**Change the origin/limits of content to read:**

Roxithromycin is a derivative of erythromycin.

It contains not less than  $970\ \mu\text{g}$  (potency) and not more than  $1020\ \mu\text{g}$  (potency) per mg, calculated on the anhydrous basis. The potency of Roxithromycin is expressed as mass (potency) of roxithromycin ( $C_{41}H_{76}N_2O_{15}$ ).

## Salicylic Acid

サリチル酸

### **Change the origin/limits of content to read:**

Salicylic Acid, when dried, contains not less than 99.5% and not more than 101.0% of  $C_7H_6O_3$ .

### **Change the Description to read:**

**Description** Salicylic Acid occurs as white crystals or crystalline powder. It has a slightly acid, followed by an acrid taste.

It is freely soluble in ethanol (95) and in acetone, and slightly soluble in water.

### **Change the Identification to read:**

**Identification** (1) A solution of Salicylic Acid (1 in 500) responds to the Qualitative Tests <1.09> (1) and (3) for salicylate.

(2) Determine the absorption spectrum of a solution of Salicylic Acid in ethanol (95) (3 in 200,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(3) Determine the infrared absorption spectrum of Salicylic Acid as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

### **Change the Purity to read:**

**Purity** (1) Chloride <1.03>—Dissolve 5.0 g of Salicylic Acid in 90 mL of water by heating, cool, dilute with water to 100 mL, and filter. Discard the first 20 mL of the filtrate, take subsequent 30 mL of the filtrate, add 6 mL of dilute nitric acid and water to make 50 mL, and perform the test using this solution as the test solution. Prepare the control solution with 0.35 mL of 0.01 mol/L hydrochloric acid VS (not more than 0.008%).

(2) Sulfate <1.14>—To 20 mL of the filtrate obtained in (1) add 1 mL of dilute hydrochloric acid and water to make 50 mL, and perform the test using this solution as the test solution. Prepare the control solution with 0.40 mL of 0.005 mol/L sulfuric acid VS (not more than 0.019%).

(3) Heavy metals <1.07>—Dissolve 2.0 g of Salicylic Acid in 25 mL of acetone, add 4 mL of sodium hydroxide TS, 2 mL of dilute acetic acid and water to make 50 mL, and perform the test using this solution as the test solution. Prepare the control solution as follows: to 2.0 mL of Standard Lead Solution add 25 mL of acetone, 2 mL of dilute acetic acid and water to make 50 mL (not more than 10 ppm).

(4) Related substances—Dissolve 0.50 g of Salicylic Acid in the mobile phase to make exactly 100 mL, and use this so-

lution as the sample solution. Separately, dissolve exactly 10 mg of phenol, exactly 25 mg of 4-hydroxyisophthalic acid and exactly 50 mg of parahydroxybenzoic acid in the mobile phase to make exactly 100 mL. Pipet 1 mL of this solution, add the mobile phase to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the peak areas of parahydroxybenzoic acid, 4-hydroxyisophthalic acid and phenol obtained from the sample solution are not larger than the area of each respective peak from the standard solution, the area of the peak other than salicylic acid and other than the substances mentioned above is not larger than the peak area of 4-hydroxyisophthalic acid from the standard solution, and the total area of peaks other than salicylic acid is not larger than 2 times the peak area of parahydroxybenzoic acid from the standard solution.

### **Operating conditions—**

**Detector:** An ultraviolet absorption photometer (wavelength: 270 nm).

**Column:** A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

**Column temperature:** A constant temperature of about 35°C.

**Mobile phase:** A mixture of water, methanol and acetic acid (100) (60:40:1).

**Flow rate:** Adjust the flow rate so that the retention time of salicylic acid is about 17 minutes.

**Time span of measurement:** About 2 times as long as the retention time of salicylic acid, beginning after the solvent peak.

### **System suitability—**

**Test for required detectability:** Pipet 2 mL of the standard solution, and add the mobile phase to make exactly 10 mL. Confirm that the peak areas of parahydroxybenzoic acid, 4-hydroxyisophthalic acid and phenol obtained from 10  $\mu$ L of this solution are equivalent to 14 to 26% of the area of each respective peak from 10  $\mu$ L of the standard solution.

**System performance:** Dissolve 10 mg of phenol, 25 mg of 4-hydroxyisophthalic acid and 50 mg of parahydroxybenzoic acid in 100 mL of the mobile phase. To 1 mL of this solution add the mobile phase to make 10 mL. When the procedure is run with 10  $\mu$ L of this solution under the above operating conditions, parahydroxybenzoic acid, 4-hydroxyisophthalic acid and phenol are eluted in this order with the resolution between the peaks of 4-hydroxyisophthalic acid and phenol being not less than 4.


**System repeatability:** When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak areas of parahydroxybenzoic acid, 4-hydroxyisophthalic acid and phenol is not more than 2.0%, respectively.

**Change the Residue on ignition to read:**

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Add the following:****L-Serine**

L-セリン



$C_3H_7NO_3$ ; 105.09

(2S)-2-Amino-3-hydroxypropanoic acid [56-45-1]

L-Serine, when dried, contains not less than 98.5 and not more than 101.0% of  $C_3H_7NO_3$ .

**Description** L-Serine occurs as white crystals or a crystalline powder. It has a slight sweet taste.

It is freely soluble in water and in formic acid, and practically insoluble in ethanol (99.5).

It dissolves in 2 mol/L hydrochloric acid TS.

**Identification** Determine the infrared absorption spectrum of L-Serine as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Optical rotation** <2.49>  $[\alpha]_D^{20}$ : +14.0 – +16.0° (After drying, 2.5 g, 2 mol/L hydrochloric acid TS, 25 mL, 100 mm).

**pH** <2.54> The pH of a solution prepared by dissolving 1.0 g of L-Serine in 10 mL of water is between 5.2 and 6.2.

**Purity** (1) Clarity and color of solution—Dissolve 1.0 g of L-Serine in 10 mL of water: the solution is clear and colorless.

(2) Chloride <1.03>—Perform the test with 0.5 g of L-Serine. Prepare the control solution with 0.30 mL of 0.01 mol/L hydrochloric acid VS (not more than 0.021%).

(3) Sulfate <1.14>—Perform the test with 0.6 g of L-Serine. Prepare the control solution with 0.35 mL of 0.005 mol/L sulfuric acid VS (not more than 0.028%).

(4) Ammonium <1.02>—Perform the test with 0.25 g of L-Serine. Prepare the control solution with 5.0 mL of Standard Ammonium Solution (not more than 0.02%).

(5) Heavy metals <1.07>—Proceed with 2.0 g of L-Serine according to Method 1, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(6) Iron <1.10>—Prepare the test solution with 1.0 g of L-Serine according to Method 1, and perform the test according to Method A. Prepare the control solution with 1.0 mL of Standard Iron Solution (not more than 10 ppm).

(7) Related substances—Dissolve 0.10 g of L-Serine in 10 mL of water, and use this solution as the sample solution.

Pipet 1 mL of the sample solution, add water to make exactly 10 mL. Pipet 1 mL of this solution, add water to make exactly 50 mL, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Then develop with a mixture of 1-butanol, water and acetic acid (100) (3:1:1) to a distance of about 10 cm, and dry the plate at 80°C for 30 minutes. Spray evenly a solution of ninhydrin in a mixture of methanol and acetic acid (100) (97:3) (1 in 100) on the plate, and heat at 80°C for 10 minutes: the spot other than the principal spot obtained from the sample solution is not more intense than the spot from the standard solution.

**Loss on drying** <2.41> Not more than 0.3% (1 g, 105°C, 3 hours).

**Residue on Ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.11 g of L-Serine, previously dried, dissolve in 3 mL of formic acid, add 50 mL of acetic acid (100), and titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS  
= 10.51 mg of  $C_3H_7NO_3$

**Containers and storage** Containers—Tight containers.

**Sodium Bicarbonate Injection**

炭酸水素ナトリウム注射液

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**10% Sodium Chloride Injection**

10% 塩化ナトリウム注射液

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Sodium Citrate Injection for Transfusion

輸血用クエン酸ナトリウム注射液

### Add the following next to Extractable volume:

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

### Add the following:

## Sodium Starch Glycolate

デンプングリコール酸ナトリウム

Sodium Starch Glycolate [9063-38-1]

This monograph is harmonized with the European Pharmacopoeia and the U.S. Pharmacopoeia. The parts of the text that are not harmonized are marked with symbols (♦ ◆).

Sodium Starch Glycolate is the sodium salt of a carboxymethyl ether of starch or of a cross-linked carboxymethyl ether of starch.

There are two neutralization types of Sodium Starch Glycolate, Type A and Type B, and their insoluble matter in a mixture of ethanol (99.5) and water (8:2), when dried, contains not less than 2.8% and not more than 4.2%, and not less than 2.0% and not more than 3.4% of sodium (Na: 22.99), respectively.

♦The label states the type of neutralization.◆

♦**Description** Sodium Starch Glycolate occurs as a white powder, and has a characteristic salty taste.

It practically insoluble in ethanol (99.5).

It swells with water, and becomes viscous, pasty liquid.

It is hygroscopic.◆

**Identification** (1) Acidify 5 mL of a solution of Sodium Starch Glycolate (1 in 500) with dilute hydrochloric acid, then add one drop of iodine TS, and stir: a blue to violet color is produced.

♦(2) Determine the infrared absorption spectrum of Sodium Starch Glycolate as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.◆

(3) The sample solution obtained in the Purity (2) responds to the Qualitative Tests <1.09> (2) for sodium salt. Perform the test using 2 mL of the sample solution and 4 mL

of potassium hexahydroxoantimonate (V) TS.

**pH** <2.54> To 1 g of Sodium Starch Glycolate add 30 mL of water and stir: the pH of the resulting suspension of Type A is 5.5 – 7.5, and that of Type B is 3.0 – 5.0.

**Purity** ♦(1) Heavy metals <1.07>—Proceed with 1.0 g of Sodium Starch Glycolate according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).◆

(2) Iron

(i) Sample solution Take 2.5 g of Sodium Starch Glycolate in a silica or platinum crucible, add 2 mL of 5 mol/L sulfuric acid TS. Heat on a water bath, then ignite cautiously with a gas burner or preferably in an electric furnace at  $600 \pm 25^\circ\text{C}$ , and incinerate the residue completely. Allow to cool, add a few drops of 1 mol/L sulfuric acid TS, and heat and ignite as above. Allow to cool, add a few drops of ammonium carbonate TS, evaporate to dryness on a water bath, and heat and ignite as above. After cooling, dissolve the residue by adding 50 mL of water.

(ii) Standard solution Weigh accurately 863.4 mg of ammonium iron (III) sulfate dodecahydrate, dissolve in water, add 25 mL of 1 mol/L sulfuric acid TS, and add water to make exactly 500 mL. Pipet 10 mL of this solution, and add water to make exactly 100 mL. Pipet 5 mL of this solution, and add water to make exactly 100 mL. Each mL of this solution contains 1.0  $\mu\text{g}$  of iron (Fe).

(iii) Procedure Pipet 10 mL each of the sample solution and standard solution, and to each solution add 2 mL of citric acid solution (1 in 5) and 0.1 mL of thioglycolic acid. Then add ammonia solution (28) dropwise to render the solution alkaline, using litmus paper as an indicator. Add water to make 20 mL, and use these solutions as the test solution and the control solution, respectively. Allow these solutions to stand for 5 minutes, and compare the color of the solutions using white background: the color of the test solution is not deeper than that of the control solution (not more than 20 ppm).

(3) Sodium glycolate—Conduct this procedure without exposure to light, using light-resistant vessels.

(i) Sample solution Weigh accurately 0.200 g of Sodium Starch Glycolate in a beaker, add 4 mL of 6 mol/L acetic acid TS and 5 mL of water, and stir to dissolve. Add 50 mL of acetone and 1 g of sodium chloride, stir, and filter through a filter paper previously soaked with acetone. Rinse the beaker and the filter paper with acetone, combine the filtrate and washings, and add acetone to make exactly 100 mL. Allow to stand for 24 hours, and use the supernatant liquid as the sample solution.

(ii) Standard solution To exactly 0.310 g of glycolic acid, previously dried in a desiccator (silica gel) for 18 hours, add water to dissolve to make exactly 500 mL. Pipet 5 mL of this solution, add 4 mL of 6 mol/L acetic acid TS, and allow to stand for 30 minutes. Add 50 mL of acetone and 1 g of sodium chloride, proceed as (i) above, and use the supernatant liquid as the standard solution.

(iii) Procedure Pipet 2.0 mL each of the sample solution and standard solution into 25-mL stoppered test tubes,



and heat on a water bath for 20 minutes to remove acetone. After cooling, add 20.0 mL of 2,7-dihydroxynaphthalene TS to the residue, stopper the test tube, and heat on a water bath for 20 minutes. Cool under running water, and transfer whole quantity of the content to a 25-mL volumetric flask. Maintain the flask under running water, and add sulfuric acid to make 25 mL. Within 10 minutes, determine the absorbance of these solutions at 540 nm using water as the blank as directed under Ultraviolet-visible Spectrophotometry <2.24>; the absorbance of the sample solution is not larger than that of the standard solution (not more than 2.0%).

(4) Sodium chloride—Weigh accurately about 0.5 g of Sodium Starch Glycolate in a beaker, disperse in 100 mL of water, and add 1 mL of nitric acid. Titrate <2.50> with 0.1 mol/L silver nitrate VS (potentiometric titration): the amount of sodium chloride (NaCl: 58.44) is not more than 7.0%.

Each mL of 0.1 mol/L silver nitrate VS = 5.844 mg of NaCl

**Loss on drying** <2.41> Not more than 10.0% (1 g, 130°C, 90 minutes).

**Assay** To about 1 g of Sodium Starch Glycolate add 20 mL of a mixture of ethanol (99.5) and water (8:2), stir for 10 minutes, and filter. Repeat this procedure until no more turbidity is produced by adding silver nitrate TS, and dry the residue on the filter paper at 105°C to constant mass. Weigh accurately 0.7 g of the mass, add 80 mL of acetic acid (100), and heat the mixture under a reflux condenser on a water bath for 2 hours. After cooling, titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration).

Content (%) of sodium (Na) =  $(V \times 2.299 \times 100) / W$

*V*: Consumed amount (mL) of 0.1 mol/L perchloric acid VS

*W*: Mass (mg) of the dried residue

♦**Containers and storage** Containers—Tight containers.♦

## Sodium Thiosulfate Injection

チオ硫酸ナトリウム注射液

**Delete the Pyrogen and add the following next to Identification:**

**Bacterial endotoxins** <4.01> Less than 0.01 EU/mg.

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Sulbactam Sodium

スルバクタムナトリウム

**Change the origin/limits of content to read:**

Sulbactam Sodium contains not less than 875 μg (potency) and not more than 941 μg (potency) per mg, calculated on the anhydrous basis. The potency of Sulbactam Sodium is expressed as mass (potency) of sulbactam (C<sub>8</sub>H<sub>11</sub>NO<sub>5</sub>S: 233.24).

**Delete the following two Monographs:**

**Sulfinpyrazone**

スルフィンピラゾン

**Sulfinpyrazone Tablets**

スルフィンピラゾン錠

## Sulpyrine Injection

スルピリン注射液

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Sultamicillin Tosilate Hydrate

スルタミシリントシル酸塩水和物

**Change the origin/limits of content to read:**

Sultamicillin Tosilate Hydrate contains not less than 698 μg (potency) and not more than 800 μg (potency) per mg, calculated on the anhydrous basis and corrected by the amount of residual solvent. The potency of Sultamicillin Tosilate Hydrate is expressed as mass (potency) of sultamicillin (C<sub>25</sub>H<sub>30</sub>N<sub>4</sub>O<sub>9</sub>S<sub>2</sub>: 594.66).

## Suxamethonium Chloride for Injection

注射用スキサメトニウム塩化物

### Add the following next to Purity:

**Bacterial endotoxins** <4.01> Less than 1.5 EU/mg.

**Uniformity of dosage units** <6.02> It meets the requirement of the Mass variation test.

**Foreign insoluble matter** <6.06> Perform the test according to Method 2: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Suxamethonium Chloride Injection

スキサメトニウム塩化物注射液

### Add the following next to Purity:

**Bacterial endotoxins** <4.01> Less than 2.0 EU/mg.

### Add the following next to Extractable volume:

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Talc

タルク

### Change to read:

Talc is a fractured and screened native hydrous magnesium silicate. Pure talc is  $\text{Mg}_3\text{Si}_4\text{O}_{10}(\text{OH})_2$ : 379.27. Talc may contain related mineral substances consisting chiefly of chlorite (hydrous magnesium aluminum silicate), magnesite (magnesium carbonate), calcite (calcium carbonate) and dolomite (calcium magnesium carbonate).

It contains no asbestos.

It contains not less than 17.0% and not more than 19.5% of magnesium (Mg: 24.31).

**Description** Talc occurs as a white to grayish white, fine, crystalline powder.

It is unctuous, and adheres readily to the skin.

It is practically insoluble in water and in ethanol (99.5).

**Identification** Determine the infrared absorption spectrum of Talc as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>: it exhibits absorption at the wave numbers of about  $3680\text{ cm}^{-1}$ ,  $1018\text{ cm}^{-1}$  and  $669\text{ cm}^{-1}$ .

**Purity** (1) Acidity or alkalinity—To 2.5 g of Talc add 50 mL of freshly boiled and cooled water, and heat under a reflux condenser. Filter the liquid by suction, add 0.1 mL of bromothymol blue-sodium hydroxide-ethanol TS to 10 mL of the filtrate, and add 0.01 mol/L hydrochloric acid VS until the color of the solution changes: the necessary volume of the VS is not more than 0.4 mL. Separately, to 10 mL of the filtrate add 0.1 mL of phenolphthalein TS, and add 0.01 mol/L sodium hydroxide VS until the color of the solution changes to light red: the necessary volume of the VS is not more than 0.3 mL.

(2) Acid-soluble substances—Weigh accurately about 1 g of Talc, heat with 20 mL of dilute hydrochloric acid at  $50^\circ\text{C}$  for 15 minutes with stirring. Cool, add water to make exactly 50 mL, and filter. Centrifuge, if necessary, until the filtrate becomes clear. To 25 mL of the filtrate add 1 mL of dilute sulfuric acid, evaporate to dryness, and ignite to constant mass at  $800 \pm 25^\circ\text{C}$ : the amount of the residue is not more than 2.0%.

(3) Water-soluble substances—To 10.0 g of Talc add 50 mL of water, weigh the mass, and boil for 30 minutes, supplying water lost by evaporation. Cool, add water to restore the original mass, and filter. Centrifuge, if necessary, until the filtrate becomes clear. Evaporate 20 mL of the filtrate to dryness, and dry the residue at  $105^\circ\text{C}$  for 1 hour: the mass of the residue is not more than 4.0 mg.

(4) Iron—Weigh accurately about 10 g of Talc, add 50 mL of 0.5 mol/L hydrochloric acid VS gently while stirring, and heat under a reflux condenser on a water bath for 30 minutes. After cooling, transfer the content to a flask, and allow to precipitate the insoluble matter. Filter the supernatant liquid through a filter paper for quantitative analysis (No. 5B), leaving the precipitate in the flask as much as possible, wash the remaining precipitate in the flask with three 10-mL portions of hot water, and also wash the filter paper with 15 mL of hot water, and combine the washings and the filtrate. After cooling, add water to make exactly 100 mL, and use this solution as the sample stock solution. Pipet 2.5 mL of the stock solution, add 50 mL of 0.5 mol/L hydrochloric acid VS, then add water to make exactly 100 mL, and use this solution as the sample solution. Separately, to 50 mL each of 0.5 mol/L hydrochloric acid VS add exactly 2 mL, 2.5 mL, 3 mL and 4 mL of Standard Iron Solution for Atomic Absorption Spectrophotometry, add water to make them exactly 100 mL, and use these solutions as the standard solutions. Perform the test with the sample solution and standard solutions as directed under Atomic Absorption Spectrophotometry <2.23> according to the following conditions, and calculate the amount of iron from the calibration curve prepared from the absorbances of the stan-

standard solutions: not more than 0.25%.

Gas: Combustible gas—Acetylene.

Supporting gas—Air.

Lamp: Iron hollow-cathode lamp.

Wavelength: 248.3 nm.

(5) Aluminum—Pipet 5 mL of the sample stock solution obtained in the Assay, add 10 mL of cesium chloride TS and 10 mL of hydrochloric acid, then add water to make exactly 100 mL, and use this solution as the sample solution. Separately, to 10 mL of hydrochloric acid and 10 mL of cesium chloride TS add exactly 5 mL, 10 mL, 15 mL and 20 mL of Standard Aluminum Solution for Atomic Absorption Spectrophotometry, add water to make them exactly 100 mL, and use these solutions as the standard solutions. Perform the test with the sample solution and standard solutions as directed under Atomic Absorption Spectrophotometry <2.23> according to the following conditions, and calculate the amount of aluminum from the calibration curve prepared from the absorbances of the standard solutions: not more than 2.0%.

Gas: Combustible gas—Acetylene.

Supporting gas—Nitrous oxide.

Lamp: Aluminum hollow-cathode lamp.

Wavelength: 309.3 nm.

(6) Lead—Use the sample stock solution obtained in (4) as the sample solution. Separately, to 50 mL of 0.5 mol/L hydrochloric acid VS add exactly 5 mL, 7.5 mL, 10 mL and 12 mL of Standard Lead Solution, add water to make them exactly 100 mL, and use these solutions as the standard solutions. Perform the test with the sample solution and standard solutions as directed under Atomic Absorption Spectrophotometry <2.23> according to the following conditions, and calculate the amount of lead from the calibration curve prepared from the absorbances of the standard solutions: not more than 10 ppm.

Gas: Combustible gas—Acetylene.

Supporting gas—Air.

Lamp: Lead hollow-cathode lamp.

Wavelength: 217.0 nm.

(7) Calcium—Pipet 2.5 mL of the sample stock solution obtained in the Assay, add 10 mL of hydrochloric acid and 10 mL of lanthanum chloride TS, then add water to make exactly 100 mL, and use this solution as the sample solution. Separately, to 10 mL of hydrochloric acid and 10 mL of lanthanum chloride TS add exactly 1 mL, 2 mL, 3 mL and 4 mL of Standard Calcium Solution, add water to make them exactly 100 mL, and use these solutions as the standard solutions. Perform the test with the sample solution and standard solutions as directed under Atomic Absorption Spectrophotometry <2.23> according to the following conditions, and calculate the amount of calcium from the calibration curve prepared from the absorbances of the standard solutions: not more than 0.9%.

Gas: Combustible gas—Acetylene.

Supporting gas—Nitrous oxide.

Lamp: Calcium hollow-cathode lamp.

Wavelength: 422.7 nm.

(8) Arsenic <1.11>—To 0.5 g of Talc add 5 mL of dilute

sulfuric acid, and heat gently to boiling with shaking. Cool immediately, filter, and wash the residue with 5 mL of dilute sulfuric acid, then with 10 mL of water. Combine the filtrate and the washings, evaporate to 5 mL on a water bath, and perform the test with this solution as the test solution (not more than 4 ppm).

**Loss on ignition** <2.43> Not more than 7.0% (1 g, 1050 – 1100°C, constant mass).

**Assay** Weigh accurately about 0.5 g of Talc in a polytetrafluoroethylene dish, add 5 mL of hydrochloric acid, 5 mL of nitric acid and 5 mL of perchloric acid, then add 35 mL of hydrofluoric acid while mixing gently, and evaporate to dryness on a hot plate by heating gradually. Add 5 mL of hydrochloric acid to the residue, cover the dish with a watch glass, and heat to boil. After cooling, transfer the content to a volumetric flask while washing the watch glass and dish with water, further wash the dish with water, transfer the washings to the flask, then add water to make exactly 50 mL, and use this solution as the sample stock solution. Pipet 0.5 mL of the sample stock solution, and add water to make exactly 100 mL. Pipet 4 mL of this solution, add 10 mL of hydrochloric acid and 10 mL of lanthanum chloride TS, then add water to make exactly 100 mL, and use this solution as the sample solution. Separately, to 10 mL of hydrochloric acid and 10 mL of lanthanum chloride TS add exactly 2.5 mL, 3 mL, 4 mL and 5 mL of Standard Magnesium Solution for Atomic Absorption Spectrophotometry, add water to make them exactly 100 mL, and use these solutions as the standard solutions. Perform the test with the sample solution and standard solutions as directed under Atomic Absorption Spectrophotometry <2.23> according to the following conditions, and calculate the amount of magnesium from the calibration curve prepared from the absorbances of the standard solutions.

Gas: Combustible gas—Acetylene.

Supporting gas—Air.

Lamp: Magnesium hollow-cathode lamp.

Wavelength: 285.2 nm.

**Containers and storage** Containers—Well-closed containers.

## Teceleukin for Injection (Genetical Recombination)

注射用テセロイキン(遺伝子組換え)

### Change the Loss on drying to read:

**Loss on drying** Transfer the content of the vial of Teceleukin for Injection (Genetical Recombination) to a weighing bottle under the atmosphere not exceeding 10% relative humidity, and perform the test as directed in the Water content determination described in the Minimum Requirements for Biological Products: not more than 5%.

## Thiamine Chloride Hydrochloride Injection

チアミン塩化物塩酸塩注射液

### Add the following next to Identification:

**Bacterial endotoxins** <4.01> Less than 6.0 EU/mg.

### Add the following next to Extractable volume:

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

## Thiopental Sodium for Injection

注射用チオペンタールナトリウム

### Add the following next to Loss on drying:

**Bacterial endotoxins** <4.01> Less than 0.30 EU/mg.

**Uniformity of dosage units** <6.02> It meets the requirement of the Mass variation test.

**Foreign insoluble matter** <6.06> Perform the test according to Method 2: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

## Tipepidine Hibenzate Tablets

チベピジンヒベンズ酸塩錠

### Add the following next to Identification:

**Uniformity of dosage units** <6.02> Perform the test according to the following method: it meets the requirement of the Content uniformity test.

To 1 tablet of Tipepidine Hibenzate Tablets add 5 mL of diluted acetic acid (100) (1 in 2) and 15 mL of methanol per 11 mg of tipepidine hibenzate ( $C_{15}H_{17}NS_2 \cdot C_{14}H_{10}O_4$ ), and warm for 15 minutes with occasional shaking. After cooling, add diluted methanol (1 in 2) to make exactly  $V$  mL so that each mL contains about 0.44 mg of tipepidine hibenzate ( $C_{15}H_{17}NS_2 \cdot C_{14}H_{10}O_4$ ), and filter. Discard the first 10 mL of the filtrate, pipet 5 mL of the subsequent filtrate, add exactly 5 mL of the internal standard solution, then add diluted methanol (1 in 2) to make 25 mL, and use this solution as the sample solution. Then, proceed as directed in the Assay.

Amount (mg) of tipepidine hibenzate ( $C_{15}H_{17}NS_2 \cdot C_{14}H_{10}O_4$ )  
 $= W_S \times (Q_T/Q_S) \times (V/50)$

$W_S$ : Amount (mg) of tipepidine hibenzate for assay

**Internal standard solution**—A solution of dibucaine hydrochloride in methanol (1 in 2000).

### Add the following:

## Tobramycin Injection

トブラマイシン注射液

Tobramycin Injection is an aqueous injection.

It contains not less than 90.0% and not more than 110.0% of the labeled amount of tobramycin ( $C_{18}H_{37}N_5O_9$ : 467.51).

**Method of preparation** Prepare as directed under Injections, with Tobramycin.

**Description** Tobramycin Injection occurs as a colorless or very pale yellow clear liquid.

**Identification** To a volume of Tobramycin Injection, equivalent to 10 mg (potency) of Tobramycin according to the labeled amount, add water to make 1 mL, and use this solution as the sample solution. Separately, dissolve 10 mg (potency) of Tobramycin Reference Standard in 1 mL of water, and use this solution as the standard solution. Then, proceed as directed in the Identification (2) under Tobramycin.

**Osmotic pressure ratio** Being specified separately.

**pH** <2.54> 5.0 – 7.0

**Bacterial endotoxins** <4.01> Less than 0.50 EU/mg (potency).

**Extractable volume** <6.05> It meets the requirement.

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.

**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

**Assay** Perform the test according to the Cylinder-plate method as directed under Microbial Assay for Antibiotics <4.02> according to the following conditions.

(i) Test organism, culture medium, and standard solutions—Proceed as directed in the Assay under Tobramycin.

(ii) Sample solutions—To exactly 5 mL of Tobramycin Injection add 0.1 mol/L phosphate buffer solution, pH 8.0 so that each mL contains 1 mg (potency) of Tobramycin. Take exactly a suitable amount of this solution, add 0.1 mol/L phosphate buffer solution, pH 8.0 to make solutions

so that each mL contains 8  $\mu\text{g}$  (potency) and 2  $\mu\text{g}$  (potency), and use these solutions as the high and low concentration sample solutions, respectively.

**Containers and storage** Containers—Hermetic containers.

## Trimetazidine Hydrochloride

トリメタジジン塩酸塩

### Change the Purity (2) to read:

**Purity (2)** Related substances—Dissolve 0.2 g of Trimetazidine Hydrochloride in 50 mL of water, and use this solution as the sample solution. Pipet 2 mL of the sample solution, add water to make exactly 20 mL. Pipet 2 mL of this solution, add water to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area by the automatic integration method: the area of the peak other than trimetazidine obtained from the sample solution is not larger than 1.5 times that of trimetazidine from the standard solution, and the total area of the peaks other than trimetazidine from the sample solution is not larger than 2.5 times the peak area of trimetazidine from the standard solution.

**Operating conditions**—

**Detector:** An ultraviolet absorption photometer (wavelength: 240 nm).

**Column:** A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

**Column temperature:** A constant temperature of about 40°C.

**Mobile phase A:** Dissolve 2.87 g of sodium 1-heptanesulfonate in water to make 1000 mL, and adjust the pH to 3.0 with diluted phosphoric acid (1 in 10). Mix 3 volumes of this solution and 2 volumes of methanol.

**Mobile phase B:** Methanol.

**Flowing of the mobile phase:** Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 50	95 → 75	5 → 25

**Flow rate:** Adjust the flow rate so that the retention time of trimetazidine is about 25 minutes.

**Time span of measurement:** About 2 times as long as the retention time of trimetazidine, beginning after the solvent peak.

**System suitability**—

**Test for required detectability:** Pipet 5 mL of the standard solution, and add water to make exactly 20 mL. Confirm

that the peak area of trimetazidine obtained from 10  $\mu\text{L}$  of this solution is equivalent to 18 to 32% of that from 10  $\mu\text{L}$  of the standard solution.

**System performance:** When the procedure is run with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of trimetazidine are not less than 15,000 and not more than 1.5, respectively.

**System repeatability:** When the test is repeated 6 times with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the peak area of trimetazidine is not more than 2.0%.

### Delete the following two Monographs:

#### Tubocurarine Chloride Hydrochloride Hydrate

ツボクラリン塩化物塩酸塩水和物


#### Tubocurarine Chloride Hydrochloride Injection

ツボクラリン塩化物塩酸塩注射液

### Add the following:

## L-Tyrosine

L-チロジン



$\text{C}_9\text{H}_{11}\text{NO}_3$ : 181.19

(2S)-2-Amino-3-(4-hydroxyphenyl)propanoic acid  
[60-18-4]

L-Tyrosine, when dried, contains not less than 99.0% and not more than 101.0% of  $\text{C}_9\text{H}_{11}\text{NO}_3$ .

**Description** L-Tyrosine occurs as white crystals or a crystalline powder.

It is freely soluble in formic acid, and practically insoluble in water and in ethanol (99.5).

It dissolves in dilute hydrochloric acid and in ammonia TS.

**Identification (1)** Determine the absorption spectrum of a solution of L-Tyrosine in 0.1 mol/L hydrochloric acid (1 in 10,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

**(2)** Determine the infrared absorption spectrum of L-Tyrosine as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Optical rotation** <2.49>  $[\alpha]_D^{20}$ :  $-10.5$  –  $-12.5^\circ$  (after drying, 2.5 g, 1 mol/L hydrochloric acid TS, 50 mL, 100 mm).

**Purity** (1) Clarity and color of solution—Dissolve 1.0 g of L-Tyrosine in 20 mL of 1 mol/L hydrochloric acid TS: the solution is clear and colorless.

(2) Chloride <1.03>—Dissolve 0.5 g of L-Tyrosine in 12 mL of dilute nitric acid and 20 mL of water, and add water to make 50 mL. Perform the test using this solution as the test solution. Prepare the control solution as follows: To 0.30 mL of 0.01 mol/L hydrochloric acid VS add 12 mL of dilute nitric acid and water to make 50 mL (not more than 0.021%).

(3) Sulfate <1.14>—Dissolve 0.6 g of L-Tyrosine in 5 mL of dilute hydrochloric acid, and add water to make 45 mL. Perform the test using this solution as the test solution. Prepare the control solution as follows: To 0.35 mL of 0.005 mol/L sulfuric acid VS add 5 mL of dilute hydrochloric acid and water to make 45 mL. To the test solution and the control solution add 5 mL of barium chloride TS (not more than 0.028%).

(4) Ammonium <1.02>—Perform the test with 0.25 g of L-Tyrosine. Prepare the control solution with 5.0 mL of Standard Ammonium Solution (not more than 0.02%).

(5) Heavy metals <1.07>—Proceed with 1.0 g of L-Tyrosine according to Method 4, and perform the test. Prepare the control solution with 1.0 mL of Standard Lead Solution (not more than 10 ppm).

(6) Iron <1.10>—Prepare the test solution with 1.0 g of L-Tyrosine according to Method 3, and perform the test according to Method A. Prepare the control solution with 1.0 mL of Standard Iron Solution (not more than 10 ppm).

(7) Related substances—Dissolve 0.20 g of L-Tyrosine in 10 mL of diluted ammonia solution (28) (1 in 2), add water to make 20 mL, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add water to make exactly 10 mL, pipet 1 mL of this solution, add water to make exactly 50 mL, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Then develop with a mixture of 1-propanol and ammonia solution (28) (67:33) to a distance of about 10 cm, and dry the plate at 80°C for 30 minutes. Spray evenly a solution of ninhydrin in a mixture of methanol and acetic acid (100) (97:3) (1 in 100) on the plate, and then heat at 80°C for 10 minutes: the spot other than the principal spot obtained from the sample solution is not more intense than the spot from the standard solution.

**Loss on drying** <2.41> Not more than 0.3% (1 g, 105°C, 3 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.18 g of L-Tyrosine previously dried, dissolve in 6 mL of formic acid, add 50 mL of acetic acid (100), and titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric titration). Perform a blank determination in the same manner, and make any necessary cor-

rection.


Each mL of 0.1 mol/L perchloric acid VS  
= 18.12 mg of C<sub>9</sub>H<sub>11</sub>NO<sub>3</sub>

**Containers and storage** Containers—Tight containers.

**Add the following:**

## Ubenimex

ウベニメクス



C<sub>16</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>: 308.37

(2S)-2-[(2S,3R)-3-Amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid  
[58970-76-6]

Ubenimex, when dried, contains not less than 98.5% and not more than 101.0% of C<sub>16</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>.

**Description** Ubenimex occurs as a white crystalline powder.

It is freely soluble in acetic acid (100), slightly soluble in water, and very slightly soluble in ethanol (99.5).

It dissolves in 1 mol/L hydrochloric acid TS.

Melting point: about 230°C (with decomposition).

**Identification** (1) Determine the absorption spectrum of a solution of Ubenimex (1 in 2000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum: both spectra exhibit similar intensities of absorption at the same wave numbers.

**Optical rotation** <2.49>  $[\alpha]_D^{20}$ :  $-15.5$  –  $-17.5^\circ$  (after drying, 0.5 g, 1 mol/L hydrochloric acid TS, 50 mL, 100 mm).

**Purity** (1) Heavy metals <1.07>—Proceed with 2.0 g of Ubenimex according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Related substances—Dissolve 30 mg of Ubenimex in 10 mL of the mobile phase A, and use this solution as the sample solution. Pipet 2 mL of the sample solution, add the mobile phase A to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 20  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine each peak area of these solutions by the automatic integration method: the

area of the peak other than ubenimex obtained from the sample solution is not larger than 1/2 times the peak area of ubenimex from the standard solution. Furthermore, the total area of the peaks other than ubenimex from the sample solution is not larger than the peak area of ubenimex from the standard solution.

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 220 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase A: A mixture of diluted 0.1 mol/L potassium dihydrogen phosphate TS (13 in 20) and acetonitrile for liquid chromatography (17:3).

Mobile phase B: A mixture of acetonitrile for liquid chromatography and diluted 0.1 mol/L potassium dihydrogen phosphate TS (13 in 20) (2:1).

Flowing of the mobile phase: Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 20	100	0
20 – 60	100→0	0→100
60 – 70	0	100

Flow rate: Adjust the flow rate so that the retention time of ubenimex is about 14 minutes.

Time span of measurement: About 5 times as long as the retention time of ubenimex, beginning after the solvent peak.

*System suitability—*

Test for required detectability: Pipet 1 mL of the standard solution, and add the mobile phase A to make exactly 10 mL. Confirm that the peak area of ubenimex obtained from 20  $\mu$ L of this solution is equivalent to 7 to 13% of that from 20  $\mu$ L of the standard solution.

System performance: When the procedure is run with 20  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of ubenimex are not less than 5000 and not more than 2.0, respectively.

System repeatability: When the test is repeated 6 times with 20  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of ubenimex is not more than 2.0%.

**Loss on drying** <2.41> Not more than 0.5% (0.5 g, in vacuum, 80°C, 4 hours).

**Residue on ignition** <2.44> Not more than 0.1% (1 g).

**Assay** Weigh accurately about 0.5 g of Ubenimex, previously dried, dissolve in 60 mL of acetic acid (100), and titrate <2.50> with 0.1 mol/L perchloric acid VS (potentiometric

titration). Perform a blank determination in the same manner, and make any necessary correction.

Each mL of 0.1 mol/L perchloric acid VS  
= 30.84 mg of C<sub>16</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>

**Containers and storage** Containers—Tight containers.

## Vincristine Sulfate

ビンクリスチン硫酸塩

### Change the Description to read:

**Description** Vincristine Sulfate occurs as a white to light yellowish white powder.

It is very soluble in water, and practically insoluble in ethanol (99.5).

It is hygroscopic.

Optical rotation  $[\alpha]_D^{20}$ : +28.5 – +35.5° (0.2 g, calculated on the dried basis, water, 10 mL, 100 mm).

### Change the Identification to read:

#### Identification

(1) Determine the absorption spectrum of a solution of Vincristine Sulfate (1 in 50,000) as directed under Ultraviolet-visible Spectrophotometry <2.24>, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Vincristine Sulfate Reference Standard prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelengths.

(2) Determine the infrared absorption spectrum of Vincristine Sulfate as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Vincristine Sulfate Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers.

(3) A solution of Vincristine Sulfate (1 in 100) responds to the Qualitative Tests <1.09> for sulfate.

### Change the Purity to read:

**Purity** (1) Clarity and color of solution—Dissolve 50 mg of Vincristine Sulfate in 10 mL of water: the solution is clear and colorless.

(2) Related substances—Dissolve 10 mg of Vincristine Sulfate in 10 mL of water, and use this solution as the sample solution. Pipet 2 mL of the sample solution, add water to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 200  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine each peak area by the automatic integration method: the peak area of desacetyl vincristine and vinblastine, having the relative retention times of about 0.9 and about 1.6 with respect to vincristine, respectively, obtained

from the sample solution are not larger than 1/8 times and 3/20 times, respectively, the peak area of vincristine from the standard solution, and the area of the peak other than vincristine, desacetyl vincristine and vinblastine from the sample solution is not larger than 1/4 times the peak area of vincristine from standard solution. Furthermore, the total area of the peaks other than vincristine from the sample solution is not larger than the peak area of vincristine from the standard solution.

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 297 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase A: methanol.

Mobile phase B: A mixture of water and diethylamine (197:3), adjusted the pH to 7.5 with phosphoric acid.

Flowing of the mobile phase: Control the gradient by mixing the mobile phases A and B as directed in the following table.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 12	62	38
12 – 27	62→92	38→8

Flow rate: Adjust the flow rate so that the retention time of vincristine is about 15 minutes.

Time span of measurement: About 1.7 times as long as the retention time of vincristine, beginning after the solvent peak.

*System suitability—*

Test for required detectability: Pipet 5 mL of the standard solution, and add the mobile phase to make exactly 200 mL. Confirm that the peak area of vincristine obtained from 200  $\mu$ L of this solution is equivalent to 1.75 to 3.25% of that from 200  $\mu$ L of the standard solution.

System performance: Dissolve 15 mg each of Vincristine Sulfate and vinblastine sulfate in 100 mL of water. When the procedure is run with 200  $\mu$ L of this solution under the above operating conditions, vincristine and vinblastine are eluted in this order with the resolution between these peaks being not less than 4.

System repeatability: When the test is repeated 6 times with 200  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of vincristine is not more than 1.5%.

**Change the Loss on drying to read:**

**Loss on drying** Perform the test with about 10 mg of Vincristine Sulfate as directed in Method 2 under Thermal Analysis <2.52> according to the following conditions: not more than 12.0%.

*Operating conditions—*

Heating rate: 5°C/minute.

Temperature range: room temperature to 200°C.

Atmospheric gas: dried nitrogen.

Flow rate of atmospheric gas: 40 mL/minute.

**Change the Assay to read:**

**Assay** Weigh accurately about 10 mg each of Vincristine Sulfate and Vincristine Sulfate Reference Standard (separately determine the loss on drying in the same manner as Vincristine Sulfate), dissolve each in water to make exactly 10 mL, and use these solutions as the sample solution and the standard solution, respectively. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the vincristine peak areas,  $A_T$  and  $A_S$ , of both solutions.

$$\text{Amount (mg) of } C_{46}H_{56}N_4O_{10} \cdot H_2SO_4 = W_S \times (A_T/A_S)$$

$W_S$ : Amount (mg) of Vincristine Sulfate Reference Standard, calculated on the dried basis

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 297 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 25°C.

Mobile phase: Adjust the pH to 7.5 of a mixture of water and diethylamine (59:1) with phosphoric acid. To 300 mL of this solution add 700 mL of methanol.

Flow rate: Adjust the flow rate so that the retention time of vincristine is about 7 minutes.

*System suitability—*

System performance: Dissolve 5 mg each of Vincristine Sulfate and vinblastine sulfate in 5 mL of water. When the procedure is run with 10  $\mu$ L of this solution under the above operating conditions, vincristine and vinblastine are eluted in this order with the resolution between these peaks being not less than 4.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of vincristine is not more than 1.0%.

**Change the Containers and storage to read:**

**Containers and storage** Containers—Tight containers.

Storage—Light-resistant, and at not exceeding –20°C.

## Water for Injection

注射用水

**Add the following next to Extractable volume:**

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.



**Insoluble particulate matter** <6.07> It meets the requirement.

## Xylitol Injection

キシリトール注射液

### Add the following next to Extractable volume:

**Foreign insoluble matter** <6.06> Perform the test according to Method 1: it meets the requirement.


**Insoluble particulate matter** <6.07> It meets the requirement.

**Sterility** <4.06> Perform the test according to the Membrane filtration method: it meets the requirement.

### Add the following:

## Zidovudine

ジドブジン



$C_{10}H_{13}N_5O_4$ : 267.24

3'-Azido-3'-deoxythymidine [30516-87-1]

Zidovudine contains not less than 97.0% and not more than 102.0% of  $C_{10}H_{13}N_5O_4$ , calculated on the anhydrous basis.

**Description** Zidovudine occurs as a white to pale yellowish white powder.

It is freely soluble in methanol, soluble in ethanol (99.5), and sparingly soluble in water.

It gradually turns yellow-brown on exposure to light.

Melting point: about 124°C.

**Identification** Determine the infrared absorption spectrum of Zidovudine as directed in the potassium bromide disc method under Infrared Spectrophotometry <2.25>, and compare the spectrum with the Reference Spectrum or the spectrum of Zidovudine Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers. If any difference appears between the spectra, dissolve the sample and the Reference Standard separately in a small amount of water and dry them in a desiccator (in vacuum, phosphorus (V) oxide), and perform the test with the residues.

**Optical rotation** <2.49>  $[\alpha]_D^{25}$ : +60.5 – +63.0° (0.5 g calculated on the anhydrous basis, ethanol (99.5), 50 mL, 100

mm).

**Purity** (1) Heavy metals <1.07>— Proceed with 1.0 g of Zidovudine according to Method 4, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

(2) 1-[(2*R*,5*S*)-2,5-Dihydro-5-(hydroxymethyl)-2-furyl]thymine, triphenylmethanol, and other related substances—Dissolve 0.20 g of Zidovudine in methanol to make exactly 10 mL, and use this solution as the sample solution. Separately, add 1 mL of the sample solution to 20 mg each of thymine for liquid chromatography, 1-[(2*R*,5*S*)-2,5-dihydro-5-(hydroxymethyl)-2-furyl]thymine for thin-layer chromatography, and triphenylmethanol for thin-layer chromatography, and add methanol to dissolve to make exactly 100 mL. Pipet 5 mL of this solution, add methanol to make exactly 10 mL, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of chloroform and methanol (9:1) to a distance of about 12 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): the spot obtained from the sample solution that corresponds to the position of the 1-[(2*R*,5*S*)-2,5-dihydro-5-(hydroxymethyl)-2-furyl]thymine obtained from the standard solution is not more intense than the spot from the standard solution, and the spot other than the principal spot and spots other than thymine and 1-[(2*R*,5*S*)-2,5-dihydro-5-(hydroxymethyl)-2-furyl]thymine from the sample solution is not more intense than zidovudine spot from the standard solution. However, the 3 spots from the standard solution appear in ascending order of *R<sub>f</sub>* value thymine, 1-[(2*R*,5*S*)-2,5-dihydro-5-(hydroxymethyl)-2-furyl]thymine, and zidovudine. Furthermore, spray evenly on the plate a solution of vanillin in sulfuric acid (1 in 100): the spot from the sample solution corresponding to the spot of triphenylmethanol from the standard solution is not more intense than the spot from the standard solution.

(3) Thymine, 3'-chloro-3'-deoxythymidine, and other related substances—Use the sample solution obtained in the Assay as the sample solution. Separately, weigh accurately about 20 mg of thymine for liquid chromatography, dissolve in 100 mL of methanol, and add the mobile phase to make exactly 250 mL. Pipet 5 mL of this solution, add the mobile phase to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine the thymine peak areas,  $A_T$  and  $A_S$ , of the sample and standard solutions, and calculate the amount of thymine using the following formula: the amount is not more than 2.0%. Also, determine the peak area of each peak obtained from the sample solution by the automatic integration method, and calculate the amounts of related substances other than thymine by the area percentage method: the amount of 3'-chloro-3'-deoxythymidine, whose

relative retention time to zidovudine is 1.2, is not more than 1.0%, and is not more than 0.5% for all other related substances. Finally, the total amount of thymine, 3'-chloro-3'-deoxythymidine, and all related substances obtained above is not more than 3.0%.

$$\text{Amount (\% of thymine)} = (W_S/W_T) \times (A_T/A_S) \times 10$$

$W_S$ : Amount (mg) of thymine for liquid chromatography

$W_T$ : Amount (mg) of Zidovudine

*Operating conditions—*

Detector, column, column temperature, mobile phase, and flow rate: Proceed as directed in the operating conditions in the Assay.

Time span of measurement: About 2 times as long as the retention time of zidovudine, beginning after the solvent peak.

*System suitability—*

Test for required detectability: Pipet 2 mL of the sample solution, add the mobile phase to make exactly 100 mL, and use this solution as the solution for system suitability test. Pipet 1 mL of the solution for system suitability test, and add the mobile phase to make exactly 20 mL. Confirm that the peak area of zidovudine obtained from 10  $\mu$ L of this solution is equivalent to 3.5 to 6.5% of that from 10  $\mu$ L of the solution for system suitability test.

System performance and system repeatability: Proceed as directed in the system suitability in the Assay.

**Water** <2.48> Not more than 1.0% (0.25 g, coulometric titration).

**Residue on ignition** <2.44> Not more than 0.2% (0.5 g).

**Assay** Weigh accurately about 50 mg of Zidovudine and Zidovudine Reference Standard (separately determine the water <2.48> using the same manner as Zidovudine), and dissolve in the mobile phase to make exactly 50 mL. Pipet 10 mL of each solution, add the mobile phase to make them exactly 50 mL, and use these solutions as the sample and standard solutions, respectively. Perform the test with exactly 10

$\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine the peak areas of zidovudine,  $A_T$  and  $A_S$  of both solutions.

$$\text{Amount (mg) of } C_{10}H_{13}N_5O_4 = W_S \times (A_T/A_S)$$

$W_S$ : Amount (mg) of Zidovudine Reference Standard, calculated on the anhydrous basis

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 265 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (particle diameter: 5  $\mu$ m).

Column temperature: A constant temperature of about 25°C.

Mobile phase: A mixture of water and methanol (4:1).

Flow rate: Adjust the flow rate so that the retention time of zidovudine is about 15 minutes.

*System suitability—*

System performance: Dissolve 50 mg of Zidovudine in 50 mL of the mobile phase. Separately, dissolve 5 mg of 3'-chloro-3'-deoxythymidine for liquid chromatography in 50 mL of the mobile phase. Mix 10 mL and 1 mL of these solutions, respectively, and add the mobile phase to make 50 mL. When the procedure is run with 10  $\mu$ L of this solution under the above conditions, zidovudine and 3'-chloro-3'-deoxythymidine are eluted in this order with the resolution between these peaks being not less than 1.4, and the symmetry factor of the peak of zidovudine is not more than 1.5.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above conditions, the relative standard deviation of the peak area of zidovudine is not more than 2.0%.

**Containers and storage** Containers—Tight containers.

Storage—Light-resistant.

# Crude Drugs

## Alpinia Officinarum Rhizome

リョウキョウ

### Add the following next to Identification:

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of pulverized Alpinia Officinarum Rhizome according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Alpinia Officinarum Rhizome according to Method 4, and perform the test (not more than 5 ppm).

## Anemarrhena Rhizome

チモ

### Change the Purity to read:

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of pulverized Anemarrhena Rhizome according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Anemarrhena Rhizome according to Method 4, and perform the test (not more than 5 ppm).

(3) Foreign matter <5.01>—The amount of fiber, originating from the dead leaves, and other foreign matters contained in Anemarrhena Rhizome is not more than 3.0%.

## Angelica Dahurica Root

ビャクシ

### Change the Purity to read:

**Purity** (1) Leaf sheath—The amount of leaf sheath contained in Angelica Dahurica Root does not exceed 3.0%.

(2) Heavy metals <1.07>—Proceed with 3.0 g of pulverized Angelica Dahurica Root according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(3) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Angelica Dahurica Root according to Method 4, and perform the test (not more than 5 ppm).

(4) Foreign matter <5.01>—The amount of foreign matter other than leaf sheath contained in Angelica Dahurica Root is not more than 1.0%.

## Apricot Kernel

キョウニン

### Change the Identification to read:

**Identification** To 1.0 g of ground Apricot Kernel add 10 mL of methanol, immediately heat under a reflux condenser on a water bath for 10 minutes, cool, filter, and use the filtrate as the sample solution. Separately, dissolve 2 mg of amygdalin for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 20  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and water (20:5:4) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): a spot with a blueish white fluorescence appears at around Rf 0.7. Spray evenly thymol-sulfuric acid-methanol TS for spraying upon the plate, and heat at 105°C for 5 minutes: one of the spot among the several spots from the sample solution has the same color tone and Rf value with the red-brown spot from the standard solution.

### Add the following:

## Aralia Rhizome

*Araliae Cordatae Rhizoma*

ドクカツ

Aralia Rhizome is usually the rhizome of *Aralia cordata* Thunberg (*Araliaceae*).

**Description** Aralia Rhizome is curved, irregular cylindrical to masses occasionally with remains of short roots. 4 to 12 cm in length, 2.5 to 7 cm in diameter, often cut crosswise or lengthwise. 1 to several, enlarged dents by remains of stems on the upper part or rarely 1.5 to 2.5 cm in diameter, remains of short stem. The outer surface is dark brown to yellowish brown, with longitudinally wrinkles, bases or dents of root. The transverse section of rhizome reveals dark brown to yellowish brown, scattered brownish small spots with oil canals, and with numerous splits.

Odor, characteristic; taste, slightly bitter.

Under a microscope <5.01>, a transverse section of rhizome reveals the outermost layer to be cork layer, rarely composed of cork stone cells, followed these appeared sever-

al layers of collenchyma. Vascular bundle and medullary rays is distinct, pith broad. Phloem fibre bundles are sometimes observed at the outer portion of phloem. Oil canals composed of schizogenous intercellular space in cortex and pith. Cortex composed of vessels, xylem fibres, and occasionally thick-wall xylem parenchyma. Vascular bundles scattered on the pith. And, parenchymatous cells observed rosette aggregates of calcium oxalate. Starch grains composed of simple grains, 2- to 6- compound grains.

**Identification** To 1 g of pulverized *Aralia Rhizome* add 10 mL of methanol, shake for 5 minutes, filter, and use the filtrate as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L of the sample solution on a plate of silica gel for thin-layer chromatography, develop the plate with a mixture of hexane, ethyl acetate and acetic acid (100) (30:10:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly vanillin-sulfuric acid TS on the plate, and heat at 105°C for 5 minutes: a purple spot appears at around *R<sub>f</sub>* 0.6.

**Loss on drying** <5.01> Not more than 12.0%.

**Total ash** <5.01> Not more than 9.0%.

**Acid-insoluble ash** <5.01> Not more than 1.5%.

**Extract content** <5.01> Dilute ethanol-soluble extract: not less than 15.0%.

## Asiasarum Root

サイシン

### Change the Purity to read:

**Purity** (1) Terrestrial part—Any terrestrial parts are not found.

(2) Arsenic <1.11>—Prepare the test solution with 0.4 g of pulverized *Asiasarum Root* according to Method 4, and perform the test (not more than 5 ppm).

(3) Foreign matter <5.01>—The amount of foreign matter other than terrestrial part contained in *Asiasarum Root* is not more than 1.0%.

(4) Aristolochic acid I—To exactly 2.0 g of pulverized *Asiasarum Root* add exactly 50 mL of diluted methanol (3 in 4), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, dissolve exactly 1.0 mg of aristolochic acid I for crude drugs purity test in diluted methanol (3 in 4) to make exactly 100 mL. Pipet 1 mL of this solution, add diluted methanol (3 in 4) to make exactly 25 mL, and use this solution as the standard solution. Perform the test with exactly 20  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01>, according to the following conditions: the sample solution shows no peak at the retention time corresponding to aristolochic acid I from the standard solution. If the sample solution shows such a peak, repeat the test under different conditions to confirm that the peak in question is not

aristolochic acid I.

**Operating conditions**—

**Detector:** An ultraviolet or visible absorption photometer (wavelength: 400 nm).

**Column:** A stainless steel column 4.6 mm in inside diameter and 25 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

**Column temperature:** A constant temperature of about 40°C.

**Mobile phase:** A mixture of a solution prepared by dissolving 7.8 g of sodium dihydrogen phosphate dihydrate and 2 mL of phosphoric acid in water to make 1000 mL and acetonitrile (11:9).

**Flow rate:** Adjust the flow rate so that the retention time of aristolochic acid I is about 15 minutes.

**System suitability**—

**Test for required detectability:** Measure exactly 1 mL of the standard solution, and add diluted methanol (3 in 4) to make exactly 10 mL. Confirm that the ratio, *S/N*, of the signal (*S*) and noise (*N*) of aristolochic acid I obtained from 20  $\mu$ L of this solution is not less than 3. In this case, *S* means the peak height on the chromatogram not including noise obtained by drawing an average line of the detector output, and *N* is 1/2 of the difference between the maximum and minimum output signals of the baseline around the peak in the range of 20 times the width at half-height of the peak.

**System repeatability:** When the test is repeated 6 times with 20  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of aristolochic acid I is not more than 5.0%.

(5) Total BHC's and total DDT's <5.01>—Not more than 0.2 ppm, respectively.

## Asparagus Tuber

テンモンドウ

### Add the following next to Identification:

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of pulverized *Asparagus Tuber* according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized *Asparagus Tuber* according to Method 4, and perform the test (not more than 5 ppm).

## Atractylodes Rhizome

ビャクジュツ

### Change the Purity to read:

**Purity** (1) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized *Atractylodes Rhizome* according to Method 4, and perform the test (not more than 5 ppm).

(2) *Atractylodes lancea* rhizome—To 2.0 g of pulverized *Atractylodes* Rhizome add exactly 5 mL of hexane, shake for 5 minutes, filter, and use this filtrate as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L of the solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of hexane and acetone (7:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-dimethylaminobenzaldehyde TS for spraying on the plate, and heat at 100°C for 5 minutes: no green to grayish green spot appears at the *R<sub>f</sub>* value of between 0.3 and 0.6.

## Powdered *Atractylodes* Rhizome

ビャクジュツ末

### Change the Purity to read:

**Purity** (1) Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered *Atractylodes* Rhizome according to Method 4, and perform the test (not more than 5 ppm).

(2) *Atractylodes lancea* rhizome—To 2.0 g of Powdered *Atractylodes* Rhizome add exactly 5 mL of hexane, shake for 5 minutes, filter, and use this filtrate as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L of the solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of hexane and acetone (7:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-dimethylaminobenzaldehyde TS for spraying on the plate, and heat at 100°C for 5 minutes: no green to grayish green spot appears at the *R<sub>f</sub>* value of between 0.3 and 0.6.

## Belladonna Extract

ベラドンナエキス

### Add the following next to Identification:

**Purity** Heavy metals <1.07>—Prepare the test solution with 1.0 g of Belladonna Extract as directed in the Extracts (4) under General Rules for Preparations, and perform the test (not more than 30 ppm).

## Calumba

コロンボ

### Add the following next to Identification:

**Purity** Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Calumba according to Method 4, and perform the test (not more than 5 ppm).

## Powdered Calumba

コロンボ末

### Add the following next to Identification:

**Purity** Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered Calumba according to Method 4, and perform the test (not more than 5 ppm).

## Cimicifuga Rhizome

ショウマ

### Change the Purity to read:

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of pulverized *Cimicifuga* Rhizome according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized *Cimicifuga* Rhizome according to Method 4, and perform the test (not more than 5 ppm).

(3) Rhizome of *Astilbe thunbergii* Miquel—Under a microscope <5.01>, pulverized *Cimicifuga* Rhizome does not contain crystal druses in the parenchyma.

## Clematis Root

イレイセン

### Add the following next to Identification:

**Purity** Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Clematis Root according to Method 4, and perform the test (not more than 5 ppm).

## Cnidium Rhizome

センキュウ

### Add the following next to Description:

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of pulverized *Cnidium* Rhizome according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized *Cnidium* Rhizome according to Method 4, and perform the test (not more than 5 ppm).

## Powdered Cnidium Rhizome

センキュウ末

### **Change the Purity to read:**

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of Powdered Cnidium Rhizome according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered Cnidium Rhizome according to Method 4, and perform the test (not more than 5 ppm).

(3) Foreign matter—Under a microscope <5.01>, Powdered Cnidium Rhizome does not contain a large quantity of starch grains, stone cells, crystals of calcium oxalate or other foreign matter.

## Condurango Fluidextract

コンズランゴ流エキス

### **Add the following next to Identification:**

**Purity** Heavy metals <1.07>—Prepare the test solution with 1.0 g of Condurango Fluidextract as direct in the Fluidextracts (4) under General Rules for Preparations, and perform the test (not more than 30 ppm).

## Coptis Rhizome

オウレン

### **Add the following next to Identification:**

**Purity** Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Coptis Rhizome according to Method 4, and perform the test (not more than 5 ppm).

## Powdered Coptis Rhizome

オウレン末

### **Change the Purity to read:**

**Purity** (1) Phellodendron bark—Under a microscope <5.01>, crystal cell rows or mucilage masses are not observable. Stir 0.5 g of Powdered Coptis Rhizome with 2 mL of water: the solution does not become gelatinous.

(2) Curcuma—Place Powdered Coptis Rhizome on a filter paper, drop diethyl ether on it, and allow to stand. Remove the powder from the filter paper, and drop 1 drop of potassium hydroxide TS: no red-purple color develops. Under a microscope <5.01>, Powdered Coptis Rhizome does not contain gelatinized starch or secretory cells containing yellow-red resin.

(3) Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered Coptis Rhizome according to Method 4, and perform the test (not more than 5 ppm).

## Corydalis Tuber

エンゴサク

### **Change the Identification to read:**

**Identification** To 2 g of pulverized Corydalis Tuber add 10 mL of methanol, shake for 15 minutes, filter, and use the filtrate as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L of the sample solution on a plate of silica gel for thin-layer chromatography. Develop with a mixture of methanol, a solution of ammonium acetate (3 in 10) and acetic acid (100) (20:1:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): a yellow-green fluorescent spot at around *R<sub>f</sub>* 0.4 and a yellow fluorescent spot at around *R<sub>f</sub>* 0.35 appear. When spray evenly Dragendorff's TS for spraying on the plate, air-dry, and then spray sodium nitrite TS: a brown spot appears at around *R<sub>f</sub>* 0.6.

### **Add the following next to Identification:**

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of pulverized Corydalis Tuber according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Corydalis Tuber according to Method 4, and perform the test (not more than 5 ppm).

### **Add the following:**

## Powdered Corydalis Tuber

*Corydalis Tuber Pulveratum*

エンゴサク末

Powdered Corydalis Tuber is the powder of Corydalis Tuber.

It contains not less than 0.08% of dehydrocorydaline (as dehydrocorydaline nitrate), calculated on the basis of dried material.

**Description** Powdered Corydalis Tuber occurs as a greenish yellow to grayish yellow powder. Almost odorless; taste, bitter.

Under a microscope <5.01>, Powdered Corydalis Tuber reveals mainly, masses of gelatinized starch or light yellow to colorless parenchymatous cells containing starch grains, fragments of cork layers, light yellow stone cells, sclerenchymatous cells, reticulate vessels, spiral vessels and ring vessels; starch grains observed simple grains and 2- to 3-

compound grains.

**Identification** To 2 g of Powdered Corydalis Tuber add 10 mL of methanol, shake for 15 minutes, filter, and use the filtrate as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L of the sample solution on a plate of silica gel for thin-layer chromatography, develop the plate with a mixture of methanol, ammonium acetate solution (3 in 10) and acetic acid (100) (20:1:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): a yellow-green fluorescent spot and a yellow fluorescent spot appear at around *R<sub>f</sub>* 0.4 and at around *R<sub>f</sub>* 0.35, respectively. Separately, spray evenly Dragendorff's TS for spraying on the plate, air-dry, and then spray sodium nitrite TS: a brown spot appears at around *R<sub>f</sub>* 0.6.

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of Powdered Corydalis Tuber according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.4 g of Powdered Corydalis Tuber according to Method 4, and perform the test (not more than 5 ppm).

**Loss on drying** <5.01> Not more than 15.0%.

**Total ash** <5.01> Not more than 3.0%.

**Component determination** To about 1 g of Powdered Corydalis Tuber, accurately weighed, add 30 mL of a mixture of methanol and dilute hydrochloric acid (3:1), heat under a reflux condenser on a water bath for 30 minutes, and filter after cooling. To the residue add 15 mL of the mixture of methanol and dilute hydrochloric acid (3:1), and proceed in the same way as above. Combine the filtrate, add the mixture of methanol and dilute hydrochloric acid (3:1) to make exactly 50 mL, and use this solution as the sample solution. Separately, weigh accurately about 10 mg of dehydrocorydaline nitrate for component determination, previously dried in a desiccator (silica gel) for not less than 1 hour, dissolve in the mixture of methanol and dilute hydrochloric acid (3:1) to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 5  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of dehydrocorydaline.

Amount (mg) of dehydrocorydaline [as dehydrocorydaline nitrate ( $C_{22}H_{24}N_2O_7$ )]

$$= W_S \times (A_T/A_S) \times (1/4)$$

$W_S$ : Amount (mg) of dehydrocorydaline nitrate for component determination

**Operating conditions**—

Detector: An ultraviolet absorption photometer (wavelength: 340 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized

silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: Dissolve 17.91 g of disodium hydrogen phosphate dodecahydrate in 970 mL of water, and adjust to pH 2.2 with phosphoric acid. Dissolve 14.05 g of sodium perchlorate monohydrate in this solution, and add water to make exactly 1000 mL. Add 450 mL of acetonitrile, and dissolve 0.20 g of sodium lauryl sulfate in this solution.

Flow rate: Adjust the flow rate so that the retention time of dehydrocorydaline is about 24 minutes.

**System suitability**—

System performance: Dissolve 1 mg of dehydrocorydaline nitrate for component determination and 1 mg of berberine chloride in 20 mL of a mixture of water and acetonitrile (20:9). When the procedure is run with 5  $\mu$ L of this solution under the above operating conditions, berberine and dehydrocorydaline are eluted in this order with the resolution between these peaks being not less than 1.5.

System repeatability: When the test is repeated 6 times with 5  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of dehydrocorydaline is not more than 1.5%.

**Add the following:**

## Crataegus Fruit

*Crataegi Fructus*

サンザシ

Crataegus Fruit is the pseudocarp of 1) *Crataegus cuneata* Siebold et Zuccarini or 2) *Crataegus pinnatifida* Bunge var. *major* N. E. Brown (*Rosaceae*) without any treatment or cut crosswise or lengthwise.

**Description**

1) *Crataegus cuneata* Siebold et Zuccarini Nearly spherical fruits, 8 to 14 mm in diameter; externally yellowish brown to grayish brown, with fine reticulated wrinkles, remained dent of 4 to 6 mm in diameter at one end, often the base of calyx around the dent, short peduncle or scar at the other end. True fruits, usually five loculus, often split five, mericarp, 5 to 8 mm in length, light brown, usually, containing one seed into each mericarp.

Almost odorless; taste, slightly acid.

Under a microscope <5.01>, a transverse section of central parts reveals in the outermost layer composed of epidermis to be covered with comparatively thick cuticle layer, cuticle intrude into lateral cell walls of epidermis, and reveal wedge-like. Cell of the epidermis or 2- to 3-layer of parenchymatous cells beneath these observed contents of yellowish brown to red brown in color followed these appeared parenchyma. Vascular bundles and numerous stone cells appear single or gathered 2 to several cells scattered on the parenchyma, and observed solitary crystals and rosette aggregates

of calcium oxalate. Pericarp of true fruits composed of mainly sclerenchymatous cells, seed covered with seed coats, perisperm, endosperm, cotyledon observed inside seed coats; sclerenchymatous cells of true fruits and cells of seed coats containing solitary crystals of calcium oxalate.

2) *Crataegus pinnatifida* Bunge var. *major* N. E. Brown

Approximate to *Crataegus* Fruits 1), but it is a large size, 17 to 23 mm in diameter, the outer surface red brown and lustrous, spot-like scars of hairs are distinct. At one end remained dent, 7 to 9 mm in diameter, mericarp, 10 to 12 mm in length, yellowish brown in color, usually ripe seeds are absent.

Odor, characteristic; taste, acid.

Under a microscope <5.01>, a transverse section of the central parts approximate to 1), but it is a few stone cells on parenchyma.

**Identification** To 1 g of pulverized *Crataegus* Fruit add 5 mL of methanol, shake for 30 minutes, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of hyperoside for thin-layer chromatography in 20 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography, develop the plate with a mixture of ethyl acetate, 2-butanone, water and formic acid (5:3:1:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly dilute sulfuric acid on the plate, heat at 105°C for 5 minutes, and examine under ultraviolet light (main wavelength: 365 nm): one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the green fluorescent spot from the standard solution. This spot disappears gradually by allowing to cool, and appears again by heating.

**Loss on drying** <5.01> Not more than 17.0%.

**Total ash** <5.01> Not more than 4.0%.

**Extract content** <5.01> Dilute ethanol-soluble extract: not less than 8.0%.

## Cyperus Rhizome

コウブシ

**Add the following next to Description:**

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of pulverized *Cyperus* Rhizome according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized *Cyperus* Rhizome according to Method 4, and perform the test (not more than 5 ppm).

## Powdered Cyperus Rhizome

コウブシ末

**Change the Purity to read:**

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of Powdered *Cyperus* Rhizome according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered *Cyperus* Rhizome according to Method 4, and perform the test (not more than 5 ppm).

(3) Foreign matter—Under a microscope <5.01>, Powdered *Cyperus* Rhizome does not show extremely lignified cells, except stone cells, and crystals.

## Dioscorea Rhizome

サンヤク

**Add the following next to Identification:**

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of pulverized *Dioscorea* Rhizome according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized *Dioscorea* Rhizome according to Method 4, and perform the test (not more than 5 ppm).

## Powdered Dioscorea Rhizome

サンヤク末

**Add the following next to Identification:**

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of Powdered *Dioscorea* Rhizome according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered *Dioscorea* Rhizome according to Method 4, and perform the test (not more than 5 ppm).

## Fritillaria Bulb

バイモ

**Add the following next to Identification:**

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of pulverized *Fritillaria* Bulb according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g



of pulverized Fritillaria Bulb according to Method 4, and perform the test (not more than 5 ppm).

## Gastrodia Tuber

テンマ

### Add the following next to Identification:

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of pulverized Gastrodia Tuber according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Gastrodia Tuber according to Method 4, and perform the test (not more than 5 ppm).

## Gentian

ゲンチアナ

### Add the following next to Identification:

**Purity** Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Gentian according to Method 4, and perform the test (not more than 5 ppm).

## Powdered Gentian

ゲンチアナ末

### Change the Purity to read:

**Purity (1)** Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered Gentian according to Method 4, and perform the test (not more than 5 ppm).

(2) Foreign matter—Under a microscope <5.01>, stone cell and fiber are not observed.

## Glehnia Root

ハマボウフウ

### Add the following next to Description:

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of pulverized Glehnia Root according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Glehnia Root according to Method 4, and perform the test (not more than 5 ppm).

## Glycyrrhiza Extract

カンゾウエキス

### Change the Purity to read:

**Purity (1)** Heavy metals <1.07>—Prepare the test solution with 1.0 g of Glycyrrhiza Extract as directed in the Extracts (4) under General Rules for Preparations, and perform the test (not more than 30 ppm).

(2) Insoluble matter—Dissolve 2.0 g of Glycyrrhiza Extract in 18 mL of water, and filter. To 10 mL of the filtrate add 5 mL of ethanol (95): a clear solution results.

## Crude Glycyrrhiza Extract

カンゾウ粗エキス

### Change the Purity to read:

**Purity (1)** Heavy metals <1.07>—Prepare the test solution with 1.0 g of Crude Glycyrrhiza Extract as directed in the Extracts (4) under General Rules for Preparations, and perform the test (not more than 30 ppm).

(2) Water-insoluble substances—Boil 5.0 g of pulverized Crude Glycyrrhiza Extract with 100 mL of water. After cooling, filter the mixture through tared filter paper, wash with water, and dry the residue at 105°C for 5 hours: the mass of the residue is not more than 1.25 g.

(3) Foreign matter—The filtrate obtained in (2) does not have a strong bitter taste.

(4) Starch—To about 1 g of pulverized Crude Glycyrrhiza Extract add water to make 20 mL, shake the mixture thoroughly, and filter. Examine the insoluble substance on the filter paper under a microscope: the residue contains no starch grains.

### Add the following:

## Hangekobokuto Extract

半夏厚朴湯エキス

Hangekobokuto Extract contains not less than 2 mg and not more than 6 mg of magnolol, not less than 4 mg (for preparation prescribed 2 g of Perilla Herb) or not less than 6 mg (for preparation prescribed 3 g of Perilla Herb) of rosmarinic acid, and not less than 0.6 mg and not more than 2.4 mg (for preparation prescribed 1 g of Ginger) or not less than 0.8 mg and not more than 3.2 mg (for preparation prescribed 1.3 g of Ginger) or not less than 0.9 mg and not more than 3.6 mg (for preparation prescribed 1.5 g of Ginger) of [6]-gingerol per amount specified in the Method of preparation.

**Method of preparation** Prepare a dry extract or viscous extract as directed under Extracts, with 6 g of Pinellia Tuber, 5 g of Poria Sclerotium, 3 g of Magnolia Bark, 2 g of Perilla Herb and 1 g of Ginger, or with 6 g of Pinellia Tuber, 5 g of Poria Sclerotium, 3 g of Magnolia Bark, 3 g of Perilla Herb and 1 g of Ginger, or with 6 g of Pinellia Tuber, 5 g of Poria Sclerotium, 3 g of Magnolia Bark, 2 g of Perilla Herb and 1.3 g of Ginger, or with 6 g of Pinellia Tuber, 5 g of Poria Sclerotium, 3 g of Magnolia Bark, 2 g of Perilla Herb and 1.5 g of Ginger.

**Description** Hangekobokuto Extract is a light brown to black-brown, powder or viscous extract. It has a characteristic odor and has a bitter and astringent taste first then pungent later.

**Identification (1)** Shake 1.0 g of the dry extract (or 3.0 g of the viscous extract) with 10 mL of water, add 25 mL of diethyl ether, and shake. Take the diethyl ether layer, evaporate the layer under reduced pressure, dissolve the residue in 2 mL of diethyl ether, and use this solution as the sample solution. Separately, dissolve 1 mg of magnolol for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate and hexane (1:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the dark purple spot from the standard solution (Magnolia Bark).

(2) Shake 1.0 g of the dry extract (or 3.0 g of the viscous extract) with 10 mL of 0.1 mol/L hydrochloric acid TS, add 25 mL of diethyl ether, and shake. Take the diethyl ether layer, evaporate the layer under reduced pressure, dissolve the residue in 1 mL of methanol, and use this solution as the sample solution. Separately, dissolve 1 mg of rosmarinic acid for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, water and formic acid (60:1:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly iron (III) chloride TS on the plate: one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the dark purple spot from the standard solution (Perilla Herb).

(3) Shake 1.0 g of the dry extract (or 3.0 g of the viscous extract) with 10 mL of water, add 25 mL of diethyl ether, and shake. Take the diethyl ether layer, evaporate the layer under reduced pressure, dissolve the residue in 2 mL of diethyl ether, and use this solution as the sample solution. Separately, dissolve 1 mg of [6]-gingerol for thin-layer chromatography in 1 mL of methanol, and use this solution as

the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of hexane and acetone (2:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-dimethylaminobenzaldehyde TS for spraying on the plate, heat at 105°C for 5 minutes, and allow to cool: one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the blue-green spot from the standard solution (Ginger).

**Purity (1)** Heavy metals <1.07>—Prepare the test solution with 1.0 g of the dry extract (or an amount of the viscous extract, equivalent to 1.0 g of the dried substance) as directed in the Extracts (4) under General Rules for Preparations, and perform the test (not more than 30 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.67 g of the dry extract (or an amount of the viscous extract, equivalent to 0.67 g of the dried substance) according to Method 3, and perform the test (not more than 3 ppm).

**Loss on drying** <2.41> The dry extract: Not more than 11.0% (1 g, 105°C, 5 hours).

The viscous extract: Not more than 66.7% (1 g, 105°C, 5 hours).

**Total ash** <5.01> Not more than 14.0%, calculated on the dried basis.

**Assay (1)** Magnolol—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50 mL of diluted methanol (7 in 10), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of magnolol for component determination, previously dried in a desiccator (silica gel) for not less than 1 hour, and dissolve in diluted methanol (7 in 10) to make exactly 100 mL. Pipet 5 mL of this solution, add diluted methanol (7 in 10) to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, *A<sub>T</sub>* and *A<sub>S</sub>*, of magnolol.

$$\text{Amount (mg) of magnolol} = W_S \times (A_T/A_S) \times (1/8)$$

*W<sub>S</sub>*: Amount (mg) of magnolol for component determination

*Operating conditions*—

Detector: An ultraviolet absorption photometer (wavelength: 289 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of water, acetonitrile and acetic

acid (100) (50:50:1).

Flow rate: 1.0 mL per minute. (the retention time of magnolol is about 15 minutes.)

*System suitability*—

System performance: Dissolve 1 mg each of magnolol for component determination and honokiol in diluted methanol (7 in 10) to make 10 mL. When the procedure is run with 10  $\mu$ L of this solution under the above operating conditions, honokiol and magnolol are eluted in this order with the resolution between these peaks being not less than 2.5.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of magnolol is not more than 1.5%.

(2) Rosmarinic acid—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50 mL of diluted methanol (7 in 10), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of rosmarinic acid for component determination, dissolve in diluted methanol (7 in 10) to make exactly 200 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of rosmarinic acid.

$$\text{Amount (mg) of rosmarinic acid} = W_S \times (A_T/A_S) \times (1/4)$$

$W_S$ : Amount (mg) of rosmarinic acid for component determination

*Operating conditions*—

Detector: An ultraviolet absorption photometer (wavelength: 330 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 30°C.

Mobile phase: A mixture of water, acetonitrile and phosphoric acid (800:200:1).

Flow rate: 1.0 mL per minute. (the retention time of rosmarinic acid is about 11 minutes.)

*System suitability*—

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of rosmarinic acid are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of rosmarinic acid is not more than 1.5%.

(3) [6]-Gingerol—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50 mL of

diluted methanol (7 in 10), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of [6]-gingerol for component determination, dissolve in diluted methanol (7 in 10) to make exactly 100 mL. Pipet 5 mL of this solution, add methanol to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of [6]-gingerol.

$$\text{Amount (mg) of [6]-gingerol} = W_S \times (A_T/A_S) \times (1/20)$$

$W_S$ : Amount (mg) of [6]-gingerol for component determination

*Operating conditions*—

Detector: An ultraviolet absorption photometer (wavelength: 282 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 30°C.

Mobile phase: A mixture of water, acetonitrile and phosphoric acid (620:380:1).

Flow rate: 1.0 mL per minute. (the retention time of [6]-gingerol is about 15 minutes.)

*System suitability*—

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of [6]-gingerol are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of [6]-gingerol is not more than 1.5%.

**Containers and storage** Containers—Tight containers.

**Change to read:**

## Hochuekkito Extract

補中益氣湯エキス

Hochuekkito Extract contains not less than 16 mg and not more than 48 mg of hesperidin, not less than 0.3 mg and not more than 1.2 mg (for preparation prescribed 1 g of Bupleurum Root) or not less than 0.6 mg and not more than 2.4 mg (for preparation prescribed 2 g of Bupleurum Root) of saikosaponin b<sub>2</sub>, and not less than 12 mg and not more than 36 mg of glycyrrhizic acid (C<sub>42</sub>H<sub>62</sub>O<sub>16</sub>: 822.93) per a dried extract prepared as directed in the Method of preparation.

**Method of preparation** Prepare a dry extract or viscous extract as directed under Extracts, with 4 g of Ginseng, 4 g of *Atractylodes Rhizome* or *Atractylodes Lancea Rhizome*, 4 g of *Astragalus Root*, 3 g of *Japanese Angelica Root*, 2 g of *Citrus Unshiu Peel*, 2 g of *Jujube*, 2 g of *Bupleurum Root*, 1.5 g of *Glycyrrhiza*, 0.5 g of *Ginger* and 1 g of *Cimicifuga Rhizome*, or with 4 g of *Ginseng*, 4 g of *Atractylodes Rhizome* or *Atractylodes Lancea Rhizome*, 4 g of *Astragalus Root*, 3 g of *Japanese Angelica Root*, 2 g of *Citrus Unshiu Peel*, 2 g of *Jujube*, 1 g of *Bupleurum Root*, 1.5 g of *Glycyrrhiza*, 0.5 g of *Ginger* and 0.5 g of *Cimicifuga Rhizome*, or with 4 g of *Ginseng*, 4 g of *Atractylodes Rhizome*, 3 g of *Astragalus Root*, 3 g of *Japanese Angelica Root*, 2 g of *Citrus Unshiu Peel*, 2 g of *Jujube*, 2 g of *Bupleurum Root*, 1.5 g of *Glycyrrhiza*, 0.5 g of *Ginger* and 1 g of *Cimicifuga Rhizome*, or with 4 g of *Ginseng*, 4 g of *Atractylodes Rhizome*, 4 g of *Astragalus Root*, 3 g of *Japanese Angelica Root*, 2 g of *Citrus Unshiu Peel*, 2 g of *Jujube*, 1 g of *Bupleurum Root*, 1.5 g of *Glycyrrhiza*, 0.5 g of *Ginger* and 0.5 g of *Processed Ginger* and 0.5 g of *Cimicifuga Rhizome*.

**Description** Hochuekkito Extract occurs as a light brown to black-brown powder or viscous extract. It has a slight odor, and a sweet and bitter taste.

**Identification (1)** To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 30 mL of water, shake, then add 50 mL of 1-butanol, and shake. Take the 1-butanol layer, evaporate the layer under reduced pressure, add 3 mL of methanol to the residue, and use this solution as the sample solution. Separately, dissolve 1 mg of Ginsenoside Rb<sub>1</sub> Reference Standard in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography, develop the plate with a mixture of ethyl acetate, 1-propanol, water and acetic acid (100) (7:5:4:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly vanillin-sulfuric acid TS on the plate, heat at 105°C for 5 minutes, and allow to cool: one of the spot among the several spots from the sample solution has the same color tone and R<sub>f</sub> value with the purple spot from the standard solution (*Ginseng*).

(2) For preparation prescribed *Atractylodes Rhizome*—To 3.0 g of the dry extract (or 9.0 g of the viscous extract) add 30 mL of water, shake, then add 50 mL of diethyl ether, shake, and take the diethyl ether layer. Evaporate the layer under reduced pressure, add 1 mL of diethyl ether to the residue, and use this solution as the sample solution. Separately, dissolve 1 mg of atractylenolide III for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L of the sample solution and 10  $\mu$ L of the standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate and hexane (1:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly 1-naphthol-sulfuric acid TS

on the plate, heat at 105°C for 5 minutes, and allow to cool: one of the spot among the several spots from the sample solution has the same color tone and R<sub>f</sub> value with the red spot from the standard solution (*Atractylodes Rhizome*).

(3) For preparation prescribed *Atractylodes Lancea Rhizome*—To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 10 mL of water, shake, then add 25 mL of hexane, shake, and take the hexane layer. To the hexane layer add anhydrous sodium sulfate to dry, filter, evaporate the filtrate under reduced pressure, add 2 mL of hexane to the residue, and use this solution as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 20  $\mu$ L of the sample solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of hexane and acetone (7:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): a dark purple spot appears around R<sub>f</sub> 0.4, which shows a greenish brown color after spraying 4-dimethylaminobenzaldehyde TS for spraying, heating at 105°C for 5 minutes and allowing to cool (*Atractylodes Lancea Rhizome*).

(4) To 3.0 g of the dry extract (or 9.0 g of the viscous extract) add 40 mL of a solution of potassium hydroxide in methanol (1 in 50), shake for 15 minutes, centrifuge, and evaporate the supernatant liquid under reduced pressure. Add 30 mL of water to the residue, then add 20 mL of diethyl ether, shake, and take the water layer. To the water layer add 20 mL of 1-butanol, shake, and take the 1-butanol layer. To the 1-butanol layer add 20 mL of water, shake, take the 1-butanol layer, evaporate the layer under reduced pressure, add 1 mL of methanol to the residue, and use this solution as the sample solution. Separately, dissolve 1 mg of astragaloside IV for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of octadecylsilylized silica gel for thin-layer chromatography. Develop the plate with a mixture of methanol, water, 1-butanol and acetic acid (100) (60:30:10:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-dimethylaminobenzaldehyde TS for spraying on the plate, and heat at 105°C for 5 minutes: one of the spot among the several spots from the sample solution has the same color tone and R<sub>f</sub> value with the red-brown spot from the standard solution (*Astragalus Root*).

(5) To 3.0 g of the dry extract (or 9.0 g of the viscous extract) add 30 mL of water, shake, then add 50 mL of diethyl ether, shake, and take the diethyl ether layer. Evaporate the layer under reduced pressure, add 1 mL of diethyl ether to the residue, and use this solution as the sample solution. Separately, dissolve 1 mg of (*Z*)-ligustilide for thin-layer chromatography in 10 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chro-

matography. Develop the plate with a mixture of ethyl acetate and hexane (1:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): one of the spot among the several spots from the sample solution has the same color tone and *Rf* value with the bluish white fluorescent spot from the standard solution (Japanese Angelica Root).

(6) To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 30 mL of water, shake, then add 50 mL of 1-butanol, shake, and take the 1-butanol layer. Evaporate the layer under reduced pressure, add 3 mL of methanol to the residue, and use this solution as the sample solution. Separately, dissolve 1 mg of hesperidin for thin-layer chromatography in 2 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 2  $\mu\text{L}$  of the sample solution and 20  $\mu\text{L}$  of the standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, acetone, water and acetic acid (100) (10:6:3:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly 2,6-dibromo-*N*-chloro-1,4-benzoquinone monoimine TS on the plate, and expose to ammonia vapor: one of the spot among the several spots from the sample solution has the same color tone and *Rf* value with the blue spot from the standard solution (Citrus Unshiu Peel).

(7) To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 30 mL of water, shake, then add 50 mL of 1-butanol, shake, and take the 1-butanol layer. Evaporate the layer under reduced pressure, add 3 mL of methanol to the residue, and use this solution as the sample solution. Separately, dissolve 1 mg of saikosaponin  $b_2$  for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu\text{L}$  of the sample solution and 2  $\mu\text{L}$  of the standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, ethanol (99.5) and water (8:2:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-dimethylaminobenzaldehyde TS on the plate: one of the spot among the several spots from the sample solution has the same color tone and *Rf* value with the red spot from the standard solution (Bupleurum Root).

(8) To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 30 mL of water, shake, then add 50 mL of 1-butanol, and take the 1-butanol layer. Evaporate the layer under reduced pressure, add 3 mL of methanol to the residue, and use this solution as the sample solution. Separately, dissolve 1 mg of liquiritin for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu\text{L}$  each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and water (20:3:2) to a distance of about 10 cm, and air-dry the plate. Spray evenly dilute sulfuric acid on the plate, and heat at

105°C for 5 minutes: one of the spot among the several spots from the sample solution has the same color tone and *Rf* value with the yellow-brown spot from the standard solution (Glycyrrhiza).

(9) For preparation prescribed Ginger—To 3.0 g of the dry extract (or 9.0 g of the viscous extract) add 30 mL of water, shake, then add 50 mL of diethyl ether, shake, and take the diethyl ether layer. Evaporate the layer under reduced pressure, add 1 mL of diethyl ether to the residue, and use this solution as the sample solution. Separately, dissolve 1 mg of [6]-gingerol for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu\text{L}$  each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate and hexane (1:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-dimethylaminobenzaldehyde TS for spraying on the plate, heat at 105°C for 5 minutes, and allow to cool: one of the spot among the several spots from the sample solution has the same color tone and *Rf* value with the blue-green spot from the standard solution (Ginger).

(10) For preparation prescribed Processed Ginger—Put 10 g of the dry extract (or 30 g of the viscous extract) in a 300-mL hard-glass flask, add 100 mL of water and 1 mL of silicone resin, connect an apparatus for essential oil determination, and heat to boil under a reflux condenser. The graduated tube of the apparatus is to be previously filled with water to the standard line, and 2 mL of hexane is added to the graduated tube. After heating under reflux for about 1 hour, separate the hexane layer, and use this as the sample solution. Separately, dissolve 1 mg of [6]-shogaol for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 60  $\mu\text{L}$  of the sample solution and 10  $\mu\text{L}$  of the standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of cyclohexane and ethyl acetate (2:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-dimethylaminobenzaldehyde TS for spraying on the plate, heat at 105°C for 5 minutes, and allow to cool: one of the spot among the several spots from the sample solution has the same color tone and *Rf* value with the blue-green spot from the standard solution (Processed Ginger).

(11) To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 30 mL of water, shake, then add 50 mL of 1-butanol, and take the 1-butanol layer. Evaporate the layer under reduced pressure, add 3 mL of methanol to the residue, and use this solution as the sample solution. Use 3-(3-hydroxy-4-methoxyphenyl)-2-(*E*)-propenic acid-(*E*)-ferulic acid TS for thin-layer chromatography as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu\text{L}$  of the sample solution and 2  $\mu\text{L}$  of the standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, acetone and water

(20:12:3) to a distance of about 10 cm, and air-dry the plate. Spray evenly sulfuric acid on the plate, heat at 105°C for 5 minutes, and examine under ultraviolet light (main wavelength: 365 nm): one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the yellow fluorescent spot from the standard solution (*Cimicifuga Rhizome*).

**Purity (1)** Heavy metals <1.07>—Prepare the test solution with 1.0 g of the dry extract (or an amount of the viscous extract, equivalent to 1.0 g of the dried substance) as directed in the Extracts (4) under General Rules for Preparations, and perform the test (not more than 30 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.67 g of the dry extract (or an amount of the viscous extract, equivalent to 0.67 g of the dried substance) according to Method 3, and perform the test (not more than 3 ppm).

**Loss on drying** <2.41> The dry extract: Not more than 11.5% (1 g, 105°C, 5 hours).

The viscous extract: Not more than 66.7% (1g, 105°C, 5 hours).

**Total ash** <5.01> Not more than 9.0%, calculated on the dried basis.

**Assay (1)** Hesperidin—Weigh accurately about 0.1 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.1 g of the dried substance), add exactly 50 mL of diluted tetrahydrofuran (1 in 4), shake for 30 minutes, centrifuge, and use the supernatant liquid as the sample solution. Separately, weigh accurately about 10 mg of hesperidin for component determination, previously dried in a desiccator (silica gel) for not less than 24 hours, and dissolve in methanol to make exactly 100 mL. Pipet 10 mL of this solution, add diluted tetrahydrofuran (1 in 4) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, *A<sub>T</sub>* and *A<sub>S</sub>*, of hesperidin.

$$\text{Amount (mg) of hesperidin} = W_S \times (A_T/A_S) \times (1/20)$$

*W<sub>S</sub>*: Amount (mg) of hesperidin for component determination

**Operating conditions—**

Detector: An ultraviolet absorption photometer (wavelength: 285 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of water, acetonitrile and acetic acid (100) (82:18:1).

Flow rate: 1.0 mL/min. (the retention time of hesperidin is about 15 minutes.)

**System suitability—**

System performance: Dissolve 1 mg each of hesperidin for component determination and naringin for thin-layer chromatography in diluted methanol (1 in 2) to make 100 mL. When the procedure is run with 10 μL of this solution under the above operating conditions, naringin and hesperidin are eluted in this order with the resolution between these peaks being not less than 1.5.

System repeatability: When the test is repeated 6 times with 10 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of hesperidin is not more than 1.5%.

(2) Saikosaponin *b*<sub>2</sub>—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50 mL of diluted methanol (1 in 2), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of saikosaponin *b*<sub>2</sub> for component determination, previously dried in a desiccator (silica gel) for not less than 24 hours, and dissolve in diluted methanol (1 in 2) to make exactly 100 mL. Pipet 10 mL of this solution, add diluted methanol (1 in 2) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, *A<sub>T</sub>* and *A<sub>S</sub>*, of saikosaponin *b*<sub>2</sub>.

$$\text{Amount (mg) of saikosaponin } b_2 = W_S \times (A_T/A_S) \times (1/20)$$

*W<sub>S</sub>*: Amount (mg) of saikosaponin *b*<sub>2</sub> for component determination

**Operating conditions—**

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of 0.05 mol/L sodium dihydrogen phosphate TS and acetonitrile (5:3).

Flow rate: 1.0 mL/min. (the retention time of saikosaponin *b*<sub>2</sub> is about 12 minutes.)

**System suitability—**

System performance: When the procedure is run with 10 μL of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of saikosaponin *b*<sub>2</sub> are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of saikosaponin *b*<sub>2</sub> is not more than 1.5%.

(3) Glycyrrhizic acid—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50

mL of diluted methanol (1 in 2), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of Glycyrrhizic Acid Reference Standard (separately determine the water), dissolve in diluted methanol (1 in 2) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of glycyrrhizic acid.

$$\begin{aligned} & \text{Amount (mg) of glycyrrhizic acid (C}_{42}\text{H}_{62}\text{O}_{16}) \\ & = W_S \times (A_T/A_S) \times (1/2) \end{aligned}$$

$W_S$ : Amount (mg) of Glycyrrhizic Acid Reference Standard, calculated on the anhydrous basis

#### Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of diluted acetic acid (31) (1 in 15) and acetonitrile (13:7).

Flow rate: 1.0 mL/min. (the retention time of glycyrrhizic acid is about 12 minutes.)

#### System suitability—

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of glycyrrhizic acid are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of glycyrrhizic acid is not more than 1.5%.

**Containers and storage** Containers—Tight containers.

## Imperata Rhizome

ボウコン

#### Change the Purity to read:

**Purity (1)** Rootlet and scaly leaf—The amount of the rootlets and scaly leaves contained in Imperata Rhizome is not more than 3.0%.

**(2)** Heavy metals <1.07>—Proceed with 3.0 g of pulverized Imperata Rhizome according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

**(3)** Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Imperata Rhizome according to Method 4, and perform the test (not more than 5 ppm).

**(4)** Foreign matter <5.01>—The amount of foreign matter other than rootlets and scaly leaves is not more than 1.0%.

## Ipecac

トコソ

#### Add the following next to Identification:

**Purity** Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Ipecac according to Method 4, and perform the test (not more than 5 ppm).

## Powdered Ipecac

トコソ末

#### Change the Purity to read:

**Purity (1)** Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered Ipecac according to Method 4, and perform the test (not more than 5 ppm).

**(2)** Foreign matter—Under a microscope <5.01>, groups of stone cells and thick-walled fibers are not observed.

## Japanese Gentian

リュウタン

#### Add the following next to Identification:

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of pulverized Japanese Gentian according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

**(2)** Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Japanese Gentian according to Method 4, and perform the test (not more than 5 ppm).

## Powdered Japanese Gentian

リュウタン末

#### Change the Purity to read:

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of Powdered Japanese Gentian according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

**(2)** Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered Japanese Gentian according to Method 4, and perform the test (not more than 5 ppm).

**(3)** Foreign matter—Under a microscope <5.01>, Powdered Japanese Gentian usually reveals no stone cells and fibers. No starch grains; if any, very few.

## Japanese Valerian

カノコソウ

### Add the following next to Description:

**Purity** Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Japanese Valerian according to Method 4, and perform the test (not more than 5 ppm).

## Powdered Japanese Valerian

カノコソウ末

### Add the following next to Description:

**Purity** Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered Japanese Valerian according to Method 4, and perform the test (not more than 5 ppm).

## Kakkonto Extract

葛根湯エキス

### Change to read:

Kakkonto Extract contains not less than 9 mg and not more than 27 mg (for preparation prescribed 3 g of Ephedra Herb) or not less than 12 mg and not more than 36 mg (for preparation prescribed 4 g of Ephedra Herb) of total alkaloids [ephedrine ( $C_{10}H_{15}NO$ : 165.23) and pseudoephedrine ( $C_{10}H_{15}NO$ : 165.23)], not less than 14 mg and not less than 42 mg (for preparation prescribed 2 g of Peony Root) or not less than 21 mg and not more than 63 mg (for preparation prescribed 3 g of Peony Root) of peoniflorin ( $C_{23}H_{28}O_{11}$ : 480.46), and not less than 19 mg and not more than 57 mg of glycyrrhizic acid ( $C_{42}H_{62}O_{16}$ : 822.93) per the extract prepared as directed in the Method of preparation.

**Method of preparation** Prepare a dry extract or viscous extract as directed under Extracts, with 8 g of Pueraria Root, 4 g of Ephedra Herb, 4 g of Jujube, 3 g of Cinnamon Bark, 3 g of Peony Root, 2 g of Glycyrrhiza and 1 g of Ginger, or with 4 g of Pueraria Root, 4 g of Ephedra Herb, 3 g of Jujube, 2 g of Cinnamon Bark, 2 g of Peony Root, 2 g of Glycyrrhiza and 1 g of Ginger, or with 4 g of Pueraria Root, 3 g of Ephedra Herb, 3 g of Jujube, 2 g of Cinnamon Bark, 2 g of Peony Root, 2 g of Glycyrrhiza and 1 g of Ginger, or with 4 g of Pueraria Root, 3 g of Ephedra Herb, 3 g of Jujube, 2 g of Cinnamon Bark, 2 g of Peony Root, 2 g of Glycyrrhiza and 2 g of Ginger.

**Description** Kakkonto Extract occurs as a light brown to black-brown powder or viscous extract. It has a characteristic odor, and a sweet first, then hot, and slightly bitter taste.

**Identification (1)** To 1.0 g of the dry extract (or 3.0 g of the viscous extract) add 10 mL of water, shake, then add 10 mL of 1-butanol, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of Puerarin Reference Standard in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and water (20:3:2) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the bluish white fluorescent spot from the standard solution (Pueraria Root).

(2) To 1.0 g of the dry extract (or 3.0 g of the viscous extract) add 10 mL of water, shake, then add 10 mL of 1-butanol, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of ephedrine hydrochloride in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of 1-butanol, water and acetic acid (100) (7:2:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly ninhydrin TS on the plate, and heat at 105°C for 5 minutes: one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the red-purple spot from the standard solution (Ephedra Herb).

(3) Put 10 g of the dry extract (or 30 g of the viscous extract) in a 300-mL hard-glass flask, add 100 mL of water and 1 mL of silicone resin, connect the apparatus for essential oil determination, and heat to boil under a reflux condenser. The graduated tube of the apparatus is to be previously filled with water to the standard line, and 2 mL of hexane is added to the graduated tube. After heating under reflux for 1 hour, separate the hexane layer, and use the layer as the sample solution. Separately, dissolve 1 mg of (*E*)-cinnamaldehyde for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 20  $\mu$ L of the sample solution and 2  $\mu$ L of the standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of hexane and ethyl acetate (2:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly 2,4-dinitrophenylhydrazine TS on the plate: one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the yellow-orange spot from the standard solution (Cinnamon Bark).

(4) To 1.0 g of the dry extract (or 3.0 g of the viscous extract) add 10 mL of water, shake, then add 10 mL of 1-butanol, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of Peoniflorin Reference Standard in 1 mL of methanol, and use this



solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu\text{L}$  each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and water (20:3:2) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-methoxybenzaldehyde-sulfuric acid TS on the plate, and heat at 105°C for 5 minutes: one of the spot among the several spots from the sample solution has the same color tone and *Rf* value with the purple spot from the standard solution (Peony Root).

(5) To 1.0 g of the dry extract (or 3.0 g of the viscous extract) add 10 mL of water, shake, then add 10 mL of 1-butanol, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of liquiritin for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu\text{L}$  each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and water (20:3:2) to a distance of about 10 cm, and air-dry the plate. Spray evenly dilute sulfuric acid on the plate, and heat at 105°C for 5 minutes: one of the spot among the several spots from the sample solution has the same color tone and *Rf* value with the yellow-brown spot from the standard solution (Glycyrrhiza).

(6) To 1.0 g of the dry extract (or 3.0 g of the viscous extract) add 10 mL of water, shake, then add 25 mL of diethyl ether, shake, and take the diethyl ether layer. Evaporate the layer under reduced pressure, dissolve the residue in 2 mL of diethyl ether, and use the solution as the sample solution. Separately, dissolve 1 mg of [6]-gingerol for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu\text{L}$  of the sample solution and 5  $\mu\text{L}$  of the standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate and hexane (1:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-dimethylaminobenzaldehyde TS for spraying on the plate, heat at 105°C for 5 minutes, and allow to cool: one of the spot among the several spots from the sample solution has the same color tone and *Rf* value with the blue-green spot from the standard solution (Ginger).

**Purity (1)** Heavy metals <1.07>—Prepare the test solution with 1.0 g of the dry extract (or an amount of the viscous extract, equivalent to 1.0 g of the dried substance) as directed in the Extracts (4) under General Rules for Preparations, and perform the test (not more than 30 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.67 g of the dry extract (or an amount of the viscous extract, equivalent to 0.67 g of the dried substance) according to Method 3, and perform the test (not more than 3 ppm).

**Loss on drying** <2.41> The dry extract: Not more than 10.0% (1 g, 105°C, 5 hours).

The viscous extract: Not more than 66.7% (1 g, 105°C, 5 hours).

**Total ash** <5.01> Not more than 10.0%, calculated on the dried basis.

**Assay (1)** Total alkaloids (ephedrine and pseudoephedrine)—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50 mL of diluted methanol (1 in 2), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of ephedrine hydrochloride for assay, previously dried at 105°C for 3 hours, and dissolve in diluted methanol (1 in 2) to make exactly 100 mL. Pipet 10 mL of this solution, add diluted methanol (1 in 2) to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine the peak areas,  $A_{\text{TE}}$  and  $A_{\text{TP}}$ , of ephedrine and pseudoephedrine with the sample solution, and the peak area,  $A_{\text{S}}$ , of ephedrine with the standard solution.

Amount (mg) of total alkaloids [ephedrine ( $\text{C}_{10}\text{H}_{15}\text{NO}$ ) and pseudoephedrine ( $\text{C}_{10}\text{H}_{15}\text{NO}$ )]

$$= W_{\text{S}} \times \{(A_{\text{TE}} + A_{\text{TP}}) / A_{\text{S}}\} \times 0.819 \times (1/10)$$

$W_{\text{S}}$ : Amount (mg) of ephedrine hydrochloride for assay

**Operating conditions**—

Detector: An ultraviolet absorption photometer (wavelength: 210 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu\text{m}$  in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of a solution of sodium lauryl sulfate (1 in 130), acetonitrile and phosphoric acid (650:350:1).

Flow rate: 1.0 mL/min. (the retention time of ephedrine is about 27 minutes.)

**System suitability**—

System performance: Dissolve 1 mg each of ephedrine hydrochloride for assay and pseudoephedrine hydrochloride in diluted methanol (1 in 2) to make 10 mL. When the procedure is run with 10  $\mu\text{L}$  of this solution under the above operating conditions, pseudoephedrine and ephedrine are eluted in this order with the resolution between these peaks being not less than 1.5.

System repeatability: When the test is repeated 6 times with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the peak area of ephedrine is not more than 1.5%.

(2) Peoniflorin—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50 mL of diluted methanol (1 in 2), shake for 15 minutes, and filter.

Pipet 5 mL of the filtrate, flow through in a column packed with 2 g of polyamide for column chromatography, elute with water to make exactly 20 mL of eluate, and use this as the sample solution. Separately, weigh accurately about 10 mg of Peoniflorin Reference Standard (separately determine the water), and dissolve in diluted methanol (1 in 2) to make exactly 100 mL. Pipet 5 mL of this solution, add diluted methanol (1 in 2) to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of peoniflorin.

$$\begin{aligned} &\text{Amount (mg) of peoniflorin (C}_{23}\text{H}_{28}\text{O}_{11}) \\ &= W_S \times (A_T/A_S) \times (1/2) \end{aligned}$$

$W_S$ : Amount (mg) of Peoniflorin Reference Standard, calculated on the anhydrous basis

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 232 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 20°C.

Mobile phase: A mixture of water, acetonitrile and phosphoric acid (850:150:1).

Flow rate: 1.0 mL/min. (the retention time of peoniflorin is about 9 minutes.)

*System suitability—*

System performance: Dissolve 1 mg each of Peoniflorin Reference Standard and albiflorin in diluted methanol (1 in 2) to make 10 mL. When the procedure is run with 10  $\mu$ L of this solution under the above operating conditions, albiflorin and peoniflorin are eluted in this order with the resolution between these peaks being not less than 2.5.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of peoniflorin is not more than 1.5%.

(3) Glycyrrhizic acid—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50 mL of diluted methanol (1 in 2), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of Glycyrrhizic Acid Reference Standard (separately determine the water) dissolve in diluted methanol (1 in 2) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of glycyrrhizic acid.

$$\begin{aligned} &\text{Amount (mg) of glycyrrhizic acid (C}_{42}\text{H}_{62}\text{O}_{16}) \\ &= W_S \times (A_T/A_S) \times (1/2) \end{aligned}$$

$W_S$ : Amount (mg) of Glycyrrhizic Acid Reference Standard, calculated on the anhydrous basis

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of diluted acetic acid (31) (1 in 15) and acetonitrile (13:7).

Flow rate: 1.0 mL/min. (the retention time of glycyrrhizic acid is about 12 minutes.)

*System suitability—*

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of glycyrrhizic acid are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of glycyrrhizic acid is not more than 1.5%.

**Containers and storage** Containers—Tight containers.

## Kamishoyosan Extract

加味逍遙散エキス

**Change to read:**

Kamishoyosan Extract contains not less than 28 mg and not more than 84 mg of peoniflorin (C<sub>23</sub>H<sub>28</sub>O<sub>11</sub>: 480.46), not less than 25 mg and not more than 75 mg of geniposide, and not less than 12 mg and not more than 36 mg (for preparation prescribed 1.5 g of Glycyrrhiza) or not less than 16 mg and not more than 48 mg (for preparation prescribed 2 g of Glycyrrhiza) of glycyrrhizic acid (C<sub>42</sub>H<sub>62</sub>O<sub>16</sub>: 822.93) per the extract prepared as directed in the Method of preparation.

**Method of preparation** Prepare a dry extract or viscous extract as directed under Extracts, with 3 g of Japanese Angelica Root, 3 g of Peony Root, 3 g of Atractylodes Rhizome or Atractylodes Lancea Rhizome, 3 g of Poria Sclerotium, 3 g of Bupleurum Root, 2 g of Moutan Bark, 2 g of Gardenia Fruit, 2 g of Glycyrrhiza, 1 g of Ginger and 1 g of Mentha Herb, or with 3 g of Japanese Angelica Root, 3 g of Peony Root, 3 g of Atractylodes Rhizome or Atractylodes Lancea Rhizome, 3 g of Poria Sclerotium, 3 g of Bupleurum Root, 2 g of Moutan Bark, 2 g of Gardenia Fruit, 1.5 g of Glycyrrhiza.

rhiza, 1 g of Ginger and 1 g of Mentha Herb, or with 3 g of Japanese Angelica Root, 3 g of Peony Root, 3 g of Atractylodes Rhizome, 3 g of Poria Sclerotium, 3 g of Bupleurum Root, 2 g of Moutan Bark, 2 g of Gardenia Fruit, 1.5 g of Glycyrrhiza, 1.5 g of Ginger and 1 g of Mentha Herb, or with 3 g of Japanese Angelica Root, 3 g of Peony Root, 3 g of Atractylodes Rhizome, 3 g of Poria Sclerotium, 3 g of Bupleurum Root, 2 g of Moutan Bark, 2 g of Gardenia Fruit, 1.5 g of Glycyrrhiza, 0.5 g of Ginger and 1 g of Mentha Herb.

**Description** Kamishoyosan Extract occurs as a yellow-brown to black-brown powder or viscous extract. It has slightly a characteristic odor, and a sweet, slightly hot, then bitter taste.

**Identification (1)** To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 10 mL of water, shake, then add 5 mL of diethyl ether, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of (*Z*)-ligustilide for thin-layer chromatography in 10 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate and hexane (1:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): one of the spot among the several spots from the sample solution has the same color tone and *Rf* value with the bluish white fluorescent spot from the standard solution (Japanese Angelica Root).

(2) To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 10 mL of water, shake, then add 5 mL of 1-butanol, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of albiflorin in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and ammonia solution (28) (6:3:2) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-methoxybenzaldehyde-sulfuric acid TS on the plate, heat at 105°C for 5 minutes, and examine under ultraviolet light (main wavelength: 365 nm): one of the spot among the several spots from the sample solution has the same color tone and *Rf* value with the orange fluorescent spot from the standard solution (Peony Root).

(3) For preparation prescribed Atractylodes Rhizome—To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 10 mL of water, shake, then add 5 mL of diethyl ether, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of atractylenolide III for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer

chromatography. Develop the plate with a mixture of ethyl acetate and hexane (1:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly 1-naphthol-sulfuric acid TS on the plate, heat at 105°C for 5 minutes, and allow to cool: one of the spot among the several spots from the sample solution has the same color tone and *Rf* value with the red spot from the standard solution (Atractylodes Rhizome).

(4) For preparation prescribed Atractylodes Lancea Rhizome—To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 10 mL of water, shake, then add 25 mL of hexane, and shake. Take the hexane layer, add anhydrous sodium sulfate to dry, and filter. Evaporate the filtrate under reduced pressure, add 2 mL of hexane to the residue, and use this solution as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 20  $\mu$ L of the sample solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography, develop the plate with a mixture of hexane and acetone (7:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): a dark purple spot is observed at around *Rf* 0.4. The spot shows a greenish brown color after being sprayed 4-dimethylaminobenzaldehyde TS for spraying, heated at 105°C for 5 minutes, and allowed to cool (Atractylodes Lancea Rhizome).

(5) To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 10 mL of sodium hydroxide TS, shake, then add 5 mL of 1-butanol, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of saikosaponin *b*<sub>2</sub> for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L of the sample solution and 2  $\mu$ L of the standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, ethanol (99.5) and water (8:2:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-dimethylaminobenzaldehyde TS on the plate: one of the spot among the several spots from the sample solution has the same color tone and *Rf* value with the red spot from the standard solution (Bupleurum Root).

(6) To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 10 mL of water, shake, then add 15 mL of diethyl ether, and shake. Take the diethyl ether layer, evaporate the layer under reduced pressure, add 1 mL of diethyl ether to the residue, and use this solution as the sample solution. Separately, dissolve 1 mg of peonol for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography, develop the plate with a mixture of hexane and diethyl ether (5:3) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-methoxybenzaldehyde-sulfuric acid TS on the plate, and heat at 105°C for 5 minutes: one of the spot among the several spots from the sample solution has the same color tone and *Rf* value with the orange spot

from the standard solution (Moutan Bark).

(7) To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 10 mL of water, shake, then add 5 mL of 1-butanol, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of geniposide for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and ammonia solution (28) (6:3:2) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-methoxybenzaldehyde-sulfuric acid TS on the plate, and heat at 105°C for 5 minutes: one of the spot among the several spots from the sample solution has the same color tone and Rf value with the purple spot from the standard solution (Gardenia Fruit).

(8) To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 10 mL of water, shake, then add 5 mL of 1-butanol, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of liquiritin for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L of the sample solution and 5  $\mu$ L of the standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and water (20:3:2) to a distance of about 10 cm, and air-dry the plate. Spray evenly dilute sulfuric acid on the plate, and heat at 105°C for 5 minutes: one of the spot among the several spots from the sample solution has the same color tone and Rf value with the yellow-brown spot from the standard solution (Glycyrrhiza).

(9) To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 10 mL of water, shake, then add 5 mL of diethyl ether, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of [6]-gingerol for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate and hexane (1:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-dimethylaminobenzaldehyde TS for spraying on the plate, heat at 105°C for 5 minutes, and allow to cool: one of the spot among the several spots from the sample solution has the same color tone and Rf value with the blue-green spot from the standard solution (Ginger).

(10) To 2.0 g of the dry extract (or 6.0 g of the viscous extract) add 10 mL of diluted phosphoric acid (1 in 30), shake, then add 15 mL of ethyl acetate, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, shake 0.2 g of pulverized *Mentha Herb* with 10 mL of diluted phosphoric acid (1 in 30), add 15 mL of ethyl acetate, shake, centrifuge, and use the supernatant liquid as

the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, water and formic acid (10:1:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly vanillin-sulfuric acid TS on the plate, heat at 105°C for 5 minutes, and allow to cool: one of the spot among the several spots from the sample solution has the same color tone and Rf value with the red-purple spot (around Rf 0.6) from the standard solution (*Mentha Herb*).

**Purity (1)** Heavy metals <1.07>—Prepare the test solution with 1.0 g of the dry extract (or an amount of the viscous extract, equivalent to 1.0 g of the dried substance) as directed in the Extracts (4) under General Rules for Preparations, and perform the test (not more than 30 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.67 g of the dry extract (or an amount of the viscous extract, equivalent to 0.67 g of the dried substance) according to Method 3, and perform the test (not more than 3 ppm).

**Loss on drying** <2.41> The dry extract: Not more than 9.0% (1 g, 105°C, 5 hours).

The viscous extract: Not more than 66.7% (1 g, 105°C, 5 hours).

**Total ash** <5.01> Not more than 10.0%, calculated on the dried basis.

**Assay (1)** Peoniflorin—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50 mL of diluted methanol (1 in 2), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of Peoniflorin Reference Standard (separately determine the water), and dissolve in diluted methanol (1 in 2) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of peoniflorin.

$$\begin{aligned} &\text{Amount (mg) of peoniflorin (C}_{23}\text{H}_{28}\text{O}_{11}) \\ &= W_S \times (A_T/A_S) \times (1/2) \end{aligned}$$

$W_S$ : Amount (mg) of Peoniflorin Reference Standard, calculated on the anhydrous basis

**Operating conditions**—

Detector: An ultraviolet absorption photometer (wavelength: 232 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 20°C.

Mobile phase: A mixture of water, acetonitrile and phosphoric acid (850:150:1).

Flow rate: 1.0 mL/min. (the retention time of peoniflorin is about 9 minutes.)

*System suitability—*

System performance: Dissolve 1 mg each of Peoniflorin Reference Standard and albiflorin in diluted methanol (1 in 2) to make 10 mL. When the procedure is run with 10  $\mu$ L of this solution under the above operating conditions, albiflorin and peoniflorin are eluted in this order with the resolution between these peaks being not less than 2.5.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of peoniflorin is not more than 1.5%.

(2) Geniposide—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50 mL of diluted methanol (1 in 2), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of geniposide for component determination, previously dried in a desiccator (in vacuum, phosphorous (V) oxide) for 24 hours, dissolve in diluted methanol (1 in 2) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of geniposide.

$$\text{Amount (mg) of geniposide} = W_S \times (A_T/A_S) \times (1/2)$$

$W_S$ : Amount (mg) of geniposide for component determination

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 240 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of water, acetonitrile and phosphoric acid (900:100:1).

Flow rate: 1.0 mL/min. (the retention time of geniposide is about 10 minutes.)

*System suitability—*

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of geniposide are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of geniposide is not more than 1.5%.

(3) Glycyrrhizic acid—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50

mL of diluted methanol (1 in 2), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of Glycyrrhizic Acid Reference Standard (separately determine the water), dissolve in diluted methanol (1 in 2) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of glycyrrhizic acid.

$$\begin{aligned} \text{Amount (mg) of glycyrrhizic acid (C}_{42}\text{H}_{62}\text{O}_{16}) \\ = W_S \times (A_T/A_S) \times (1/2) \end{aligned}$$

$W_S$ : Amount (mg) of Glycyrrhizic Acid Reference Standard, calculated on the anhydrous basis

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of diluted acetic acid (31) (1 in 15) and acetonitrile (13:7).

Flow rate: 1.0 mL/min. (the retention time of glycyrrhizic acid is about 12 minutes.)

*System suitability—*

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of glycyrrhizic acid are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of glycyrrhizic acid is not more than 1.5%.

**Containers and storage** Containers—Tight containers.

**Add the following:**

**Keishibukuryogan Extract**

桂枝茯苓丸エキス

Keishibukuryogan Extract contains not less than 0.6 mg and not more than 2.4 mg (for preparation prescribed 3 g of Cinnamon Bark) or not less than 0.8 mg and not more than 3.2 mg (for preparation prescribed 4 g of Cinnamon Bark) of (*E*)-cinnamic acid, not less than 30 mg and not more than 90 mg (for preparation prescribed 3 g each of Moutan Bark and Peony Root) or not less than 40 mg and not more than 120 mg (for preparation prescribed 4 g each of Moutan Bark and Peony Root) of peoniflorin (C<sub>23</sub>H<sub>28</sub>O<sub>11</sub>:

480.46), and not less than 21 mg and not more than 63 mg (for preparation prescribed 3 g of Peach Kernel) or not less than 28 mg and not more than 84 mg (for preparation prescribed 4 g of Peach Kernel) of amygdalin per amount specified in the Method of preparation.

**Method of preparation** Prepare a dry extract or viscous extract as directed under Extracts, with 4 g of Cinnamon Bark, 4 g of Poria Sclerotium, 4 g of Moutan Bark, 4 g of Peach Kernel and 4 g of Peony Root, or prepare a dry extract by adding Light Anhydrous Silicic Acid to an extractive, prepared as directed under Extracts with 3 g of Cinnamon Bark, 3 g of Poria Sclerotium, 3 g of Moutan Bark, 3 g of Peach Kernel and 3 g of Peony Root.

**Description** Keishibukuryogan Extract is a light brown to black-brown, powder or viscous extract. It has a characteristic odor and has a taste slightly sweet first then bitter later.

**Identification (1)** Shake 1.0 g of the dry extract (or 3.0 g of the viscous extract) with 10 mL of water, add 25 mL of diethyl ether, and shake. Take the diethyl ether layer, evaporate the layer under reduced pressure, dissolve the residue in 2 mL of diethyl ether, and use this solution as the sample solution. Separately, dissolve 1 mg of (*E*)-cinnamic acid for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of hexane, ethyl acetate, formic acid and water (60:40:4:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the blue-purple spot from the standard solution (Cinnamon Bark).

(2) Shake 2.0 g of the dry extract (or 6.0 g of the viscous extract) with 10 mL of water, add 25 mL of diethyl ether, and shake. Take the diethyl ether layer, evaporate the layer under reduced pressure, dissolve the residue in 1 mL of diethyl ether, and use this solution as the sample solution. Separately, dissolve 1 mg of peonol for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of hexane and diethyl ether (5:3) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-methoxybenzaldehyde-sulfuric acid TS on the plate, and heat at 105°C for 5 minutes: one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the orange spot from the standard solution (Moutan Bark).

(3) Shake 1.0 g of the dry extract (or 3.0 g of the viscous extract) with 10 mL of methanol, filter, and use the filtrate

as the sample solution. Separately, dissolve 2 mg of amygdalin for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of 1-propanol, ethyl acetate and water (4:4:3) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-methoxybenzaldehyde-sulfuric acid TS on the plate, and heat at 105°C for 10 minutes: one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the green-brown spot from the standard solution (Peach Kernel).

(4) Shake 1.0 g of the dry extract (or 3.0 g of the viscous extract) with 10 mL of water, add 5 mL of 1-butanol, shake, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of albiflorin in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and ammonia water (28) (6:3:2) to a distance of about 10 cm, and air-dry the plate. Spray evenly 4-methoxybenzaldehyde-sulfuric acid TS on the plate, heat at 105°C for 5 minutes, and examine under ultraviolet light (main wavelength: 365 nm): one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the orange fluorescent spot from the standard solution (Peony Root).

**Purity (1)** Heavy metals <1.07>—Prepare the test solution with 1.0 g of the dry extract (or an amount of the viscous extract, equivalent to 1.0 g of the dried substance) as directed in the Extracts (4) under General Rules for Preparations, and perform the test (not more than 30 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.67 g of the dry extract (or an amount of the viscous extract, equivalent to 0.67 g of the dried substance) according to Method 3, and perform the test (not more than 3 ppm).

**Loss on drying <2.41>** The dry extract: Not more than 10.0% (1 g, 105°C, 5 hours).

The viscous extract: Not more than 66.7% (1 g, 105°C, 5 hours).

**Total ash <5.01>** Not more than 10.0%, calculated on the dried basis. However, for the dry extract prepared by adding Light Anhydrous Silicic Acid, between 9.0% and 18.0%.

**Assay (1)** (*E*)-Cinnamic acid—Conduct this procedure without exposure to light, using light-resistant vessels. Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50 mL of diluted methanol (1 in 2), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of (*E*)-cinnamic acid for component determination, previously dried in a desiccator (silica gel) for not less than

24 hours, and dissolve in diluted methanol (1 in 2) to make exactly 100 mL. Pipet 10 mL of this solution, add diluted methanol (1 in 2) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of (*E*)-cinnamic acid.

$$\begin{aligned} &\text{Amount (mg) of (E)-cinnamic acid} \\ &= W_S \times (A_T/A_S) \times (1/20) \end{aligned}$$

$W_S$ : Amount (mg) of (*E*)-cinnamic acid for component determination

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 273 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of water, acetonitrile and phosphoric acid (750:250:1).

Flow rate: 1.0 mL per minute. (the retention time of (*E*)-cinnamic acid is about 12 minutes.)

*System suitability—*

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of (*E*)-cinnamic acid are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of (*E*)-cinnamic acid is not more than 1.5%.

(2) Paeoniflorin—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50 mL of diluted methanol (1 in 2), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of Paeoniflorin Reference Standard (separately determine the water), dissolve in diluted methanol (1 in 2) to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of paeoniflorin.

$$\begin{aligned} &\text{Amount (mg) of paeoniflorin (C}_{23}\text{H}_{28}\text{O}_{11}) \\ &= W_S \times (A_T/A_S) \end{aligned}$$

$W_S$ : Amount (mg) of Paeoniflorin Reference Standard, calculated on the anhydrous basis

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 232 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 20°C.

Mobile phase: A mixture of water, acetonitrile and phosphoric acid (850:150:1).

Flow rate: 1.0 mL per minute. (the retention time of paeoniflorin is about 9 minutes.)

*System suitability—*

System performance: Dissolve 1 mg each of Paeoniflorin Reference Standard and albiflorin in diluted methanol (1 in 2) to make 10 mL. When the procedure is run with 10  $\mu$ L of this solution under the above operating conditions, albiflorin and paeoniflorin are eluted in this order with the resolution between these peaks being not less than 2.5.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of paeoniflorin is not more than 1.5%.

(3) Amygdalin—Weigh accurately about 0.5 g of the dry extract (or an amount of the viscous extract, equivalent to about 0.5 g of the dried substance), add exactly 50 mL of diluted methanol (1 in 2), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of amygdalin for component determination, previously dried in a desiccator (silica gel) for not less than 24 hours, dissolve in diluted methanol (1 in 2) to make exactly 50 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of amygdalin.

$$\text{Amount (mg) of amygdalin} = W_S \times (A_T/A_S)$$

$W_S$ : Amount (mg) of amygdalin for component determination

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 210 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 45°C.

Mobile phase: A mixture of 0.05 mol/L sodium dihydrogen phosphate TS and methanol (5:1).

Flow rate: 0.8 mL per minute. (the retention time of amygdalin is about 12 minutes.)

*System suitability—*

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of amygdalin are not less than 5000 and

not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of amygdalin is not more than 1.5%.

**Containers and storage** Containers—Tight containers.

### Add the following:

## Leonurus Herb

*Leonuri Herba*

ヤクモソウ

Leonurus Herb is the aerial part of *Leonurus japonicus* Houttuyn or *Leonurus sibiricus* Linné (*Labiatae*), collected during the flowering season.

**Description** Stem, leaves, and flowers usually cross sectioned, stems square, 0.2 to 3 cm in diameter, yellow-green to green-brown in color, covered densely with white short hairs; the pith white, a great parts of central of sections. Light in texture. Leaves opposite, petiolated, 3-dissected to 3-incised, each lobes split pinnately, and end lobes reveals linear-lanceolate, acute or acuminate, the upper surface light green, the lower surface bristle with white short hairs, grayish green. Flower, verticillate; sepal, tubular, and the upper end acerate with five lobes; light green to light green-brown in color, corolla labiate, light red-purple to light brown.

Odor, slightly; taste, slightly bitter, astringent.

Under a microscope <5.01>, a transverse section of stem reveals four ridge, a parts of the ridge of *Leonurus sibiricus* Linné protruding knobby. Epidermis, observed non-glandular hairs from 1 to 3 cells, glandular hairs with head of 1 to 4 celled or glandular scale with 8 cells. Each ridge parts, beneath epidermis, collenchyma developed, development of xylem fibres remarkably. Cortex composed of several layers parenchymatous cells. Collateral vascular bundle arranged in a circle. Phloem fibres observed at the outer portion of phloem. Parenchymatous cells of cortex and pith observe needle crystals or plate-like crystals of calcium oxalate.

**Identification** To 1 g of pulverized Leonurus Herb add 10 mL of methanol, shake for 10 minutes, centrifuge, and use the supernatant liquid as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L of the sample solution on a plate of silica gel for thin-layer chromatography, develop the plate with a mixture of water and methanol (1:1) to a distance of about 10 cm, and air-dry the plate. Spray evenly Dragendorff's TS for spraying followed by immediate spraying of sodium nitrite TS on the plate: a grayish brown spot appears at around *Rf* 0.5, which color fades soon and then disappears after air-drying the plate.

**Loss on drying** <5.01> Not more than 12.0%.

**Total ash** <5.01> Not more than 10.0%.

**Acid-insoluble ash** <5.01> Not more than 2.0%.

**Extract content** <5.01> Dilute ethanol-soluble extract: not less than 12.0%.

### Add the following:

## Lilium Bulb

*Lilii Bulbus*

ビャクゴウ

Lilium Bulb is the scaly leaves of *Lilium lancifolium* Thunberg, *Lilium brownii* F.E.Brown var. *colchesteri* Wilson, *Lilium brownii* F.E.Brown or *Lilium pumilum* De Candolle (*Liliaceae*), usually with the application of steaming.

**Description** Lilium Bulb reveals oblong with narrowed apex, lanceolate, or narrowly triangular boat-shaped, translucent, 1.3 to 6 cm in length, 0.5 to 2.0 cm in diameter, externally milky white to light yellowish brown occasionally purplish in color, nearly smooth; central portion somewhat thickened, circumferential portion thin, slightly waved, occasionally rolled inside; usually several lines of vascular bundles longitudinally in parallel are seen through parenchyma; hard in texture, easy to break; fractured surface horny and flat.

Odorless; taste, slightly acid and bitter.

Under a microscope <5.01>, the surface reveals epidermal cells rectangular to almost square, stomata nearly circular, the cells adjacent to stomata mostly 4 in number. Under a microscope <5.01>, a transverse section reveals the outermost layer composed of epidermal cells covered with smooth cuticle; beneath epidermis circular to quadrangular parenchymatous cells distributed evenly, palisade tissue not observed; in parenchyma of mesophyll collateral vascular bundles extended from adaxial side to abaxial side of scaly leaves are arranged almost in a transverse line; starch grains contained in parenchymatous cells, usually gelatinized.

**Identification** To 3 g of pulverized Lilium Bulb add 10 mL of 1-butanol, shake, add 10 mL of water, shake for 30 minutes, and centrifuge. Evaporate the supernatant liquid under reduced pressure, add 1 mL of methanol to the residue, shake gently, and use the supernatant liquid so obtained as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L of the sample solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and water (12:2:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): two spots appear at around *Rf* 0.3. When examine these spots under ultraviolet light (main wavelength: 365 nm) after spraying with sodium carbonate



TS, they appear as blue-purple fluorescent spots.

**Loss on drying** <5.01> Not more than 16.0%.

**Total ash** <5.01> Not more than 4.5%.

**Extract content** <5.01> Dilute ethanol-soluble extract: not less than 8.0%.

## Lindera Root

ウヤク

### Add the following next to Identification:

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of pulverized Lindera Root according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Lindera Root according to Method 4, and perform the test (not more than 5 ppm).

## Lithospermum Root

シコン

### Add the following next to Identification:

**Purity** Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Lithospermum Root according to Method 4, and perform the test (not more than 5 ppm).

## Lycium Bark

ジコッピ

### Add the following next to Identification:

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of pulverized Lycium Bark according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Lycium Bark according to Method 4, and perform the test (not more than 5 ppm).

## Magnolia Bark

コウボク

### Change the Component determination to read:

**Component determination** Weigh accurately about 0.5 g of pulverized Magnolia Bark, add 40 mL of diluted methanol (7 in 10), heat under a reflux condenser on a water bath for 20 minutes, cool, and filter. Repeat the above

procedure with the residue, using 40 mL of diluted methanol (7 in 10). Combine the whole filtrates, add diluted methanol (7 in 10) to make exactly 100 mL, and use this solution as the sample solution. Separately, dry magnolol for component determination in a desiccator (silica gel) for 1 hour or more. Weigh accurately about 10 mg of it, dissolve in diluted methanol (7 in 10) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of magnolol in each solution.

$$\text{Amount (mg) of magnolol} = W_S \times (A_T/A_S)$$

$W_S$ : Amount (mg) of magnolol for component determination

### Operating conditions—

**Detector:** An ultraviolet absorption photometer (wavelength: 289 nm).

**Column:** A stainless steel column 4 to 6 mm in inside diameter and 15 to 25 cm in length, packed with octadecylsilanized silica gel (5 to 10  $\mu$ m in particle diameter).

**Column temperature:** A constant temperature of about 20°C.

**Mobile phase:** A mixture of water, acetonitrile and acetic acid (100) (50:50:1).

**Flow rate:** Adjust the flow rate so that the retention time of magnolol is about 14 minutes.

### System suitability—

**System performance:** Dissolve 1 mg each of magnolol for component determination and honokiol in diluted methanol (7 in 10) to make 10 mL. When the procedure is run with 10  $\mu$ L of this solution under the above operating conditions, honokiol and magnolol are eluted in this order with the resolution between these peaks being not less than 5.

**System repeatability:** When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of magnolol is not more than 1.5%.

## Powdered Magnolia Bark

コウボク末

### Change the Component determination to read:

**Component determination** Weigh accurately about 0.5 g of Powdered Magnolia Bark, add 40 mL of diluted methanol (7 in 10), heat under a reflux condenser on a water bath for 20 minutes, cool, and filter. Repeat the above procedure with the residue, using 40 mL of diluted methanol (7 in 10). Combine the whole filtrates, add diluted methanol (7 in 10) to make exactly 100 mL, and use this solution as the sample solution. Separately, dry magnolol for component determination in a desiccator (silica gel) for 1 hour or more. Weigh accurately about 10 mg of it, dissolve in diluted methanol (7 in 10) to make exactly 100 mL, and use this

solution as the standard solution. Perform the test with exactly 10  $\mu\text{L}$  each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of magnolol in each solution.

$$\text{Amount (mg) of magnolol} = W_S \times (A_T/A_S)$$

$W_S$ : Amount (mg) of magnolol for component determination

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 289 nm).

Column: A stainless steel column 4 to 6 mm in inside diameter and 15 to 25 cm in length, packed with octadecylsilanized silica gel (5 to 10  $\mu\text{m}$  in particle diameter).

Column temperature: A constant temperature of about 20°C.

Mobile phase: A mixture of water, acetonitrile and acetic acid (100) (50:50:1).

Flow rate: Adjust the flow rate so that the retention time of magnolol is about 14 minutes.

*System suitability—*

System performance: Dissolve 1 mg each of magnolol for component determination and honokiol in diluted methanol (7 in 10) to make 10 mL. When the procedure is run with 10  $\mu\text{L}$  of this solution under the above operating conditions, honokiol and magnolol are eluted in this order with the resolution between these peaks being not less than 5.

System repeatability: When the test is repeated 6 times with 10  $\mu\text{L}$  of the standard solution under the above operating conditions, the relative standard deviation of the peak area of magnolol is not more than 1.5%.

## Mulberry Bark

ソウハクヒ

**Change the Purity to read:**

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of pulverized Mulberry Bark according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Mulberry Bark according to Method 4, and perform the test (not more than 5 ppm).

(3) Foreign matter <5.01>—The amount of the root xylem and other foreign matter is not more than 1.0%.

## Notopterygium Rhizome

キョウカツ

**Add the following next to Identification:**

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of

pulverized Notopterygium Rhizome according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Notopterygium Rhizome according to Method 4, and perform the test (not more than 5 ppm).

## Nuphar Rhizome

センコツ

**Change the Purity to read:**

**Purity (1)** Petiole—The amount of its petioles contained in Nuphar Rhizome does not exceed 3.0%.

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Nuphar Rhizome according to Method 4, and perform the test (not more than 5 ppm).

(3) Foreign matter <5.01>—The amount of foreign matter other than petiole is not more than 1.0%.

## Nux Vomica Extract

ホミカエキス

**Add the following next to Identification:**

**Purity** Heavy metals <1.07>—Prepare the test solution with 1.0 g of Nux Vomica Extract as directed in the Extracts (4) under General Rules for Preparations, and perform the test (not more than 30 ppm).

## Panax Japonicus Rhizome

チクセツニンジン

**Add the following next to Identification:**

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of pulverized Panax Japonicus Rhizome according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Panax Japonicus Rhizome according to Method 4, and perform the test (not more than 5 ppm).

## Powdered Panax Japonicus Rhizome

チクセツニンジン末

**Add the following next to Identification:**

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of Powdered Panax Japonicus Rhizome according to Method

3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered Panax Japonicus Rhizome according to Method 4, and perform the test (not more than 5 ppm).

## Peach Kernel

トウニン

### Change the Identification to read:

**Identification** To 1.0 g of ground Peach Kernel add 10 mL of methanol, immediately heat under a reflux condenser on a water bath for 10 minutes, cool, filter, and use the filtrate as the sample solution. Separately, dissolve 2 mg of amygdalin for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and water (20:5:4) to a distance of about 10 cm, and air-dry the plate. Spray evenly thymol-sulfuric acid-methanol TS for spraying upon the plate, and heat at 105°C for 5 minutes: one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the red-brown spot from the standard solution.

## Powdered Peach Kernel

トウニン末

### Change the Identification to read:

**Identification** (1) Grind Powdered Peach Kernel with water: the odor of benzaldehyde is perceptible.

(2) To 1.0 g of Powdered Peach Kernel add 10 mL of methanol, and immediately heat under a reflux condenser on a water bath for 10 minutes. After cooling, filter, and use the filtrate as the sample solution. Separately, dissolve 2 mg of amygdalin for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and water (20:5:4) to a distance of about 10 cm, and air-dry the plate. Spray evenly thymol-sulfuric acid-methanol TS for spraying on the plate, and heat at 105°C for 5 minutes: one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the red-brown spot from the standard solution.

## Perilla Herb

ソヨウ

### Change the Purity (1) to read:

**Purity** (1) Stem—Perilla Herb does not contain its stems equal to or greater than 3 mm in diameter.

### Add the following:

## Peucedanum Root

*Peucedani Radix*

ゼンコ

Peucedanum Root is the root of 1) *Peucedanum praeruptorum* Dunn or 2) *Angelica decursiva* Franchet et Savatier (*Peucedanum decursivum* Maximowicz) (*Umbelliferae*).

**Description** 1) *Peucedanum praeruptorum* Dunn

Slender obconical to cylindrical root, occasionally dichotomized at the lower part 3 to 15 cm in length, 0.8 to 1.8 cm in diameter at the crown; externally light brown to dark brown; ring-node-like wrinkles numerous at the crown, sometimes with hair-like remains of petioles; the root having somewhat deep longitudinal wrinkles and scars of cutting off of lateral roots; cross section surface light brown to whitish in color; brittle in texture.

Odor, characteristic; taste, slightly bitter.

Under a microscope <5.01>, a transverse section reveals the outermost layer composed of a cork layer, inner tangential walls of some cork cells thickened; collenchyma just inside of the cork layer; in cortex numerous oil canals scattered and intercellular air spaces observed; occasionally phloem fibers observed at the terminal portion of phloem; vessels and scattered oil canals in xylem; starch grains in parenchyma, 2 to 10 several-compound grains.

2) *Angelica decursiva* Franchet et Savatier

Similar to 1), but without hair-like remains of petioles at the crown.

Under a microscope <5.01>, a transverse section reveals, similar to 1), but cell wall of cork cells not thickened, phloem fibers not observed at the terminal portion of phloem, nor oil canals observed in xylem.

**Identification** (1) *Peucedanum praeruptorum* Dunn—To 1 g of pulverized Peucedanum Root add 10 mL of methanol, shake for 10 minutes, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of ( $\pm$ )-praeruptorin A for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mix-

ture of diethyl ether and hexane (3:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the blue-purple fluorescent spot from the standard solution.

(2) *Angelica decursiva* Franchet et Savatier—To 1 g of pulverized Peucedanum Root add 10 mL of methanol, shake for 10 minutes, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of nodakenin for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10  $\mu$ L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and water (12:2:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 365 nm): one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the purple fluorescent spot from the standard solution.

**Loss on drying** <5.01> Not more than 13.0%.

**Total ash** <5.01> Not more than 7.0%.

**Acid-insoluble ash** <5.01> Not more than 2.0%.

**Extract content** <5.01> Dilute ethanol-soluble extract: not less than 20.0%.

## Platycodon Fluidextract

キキョウ流エキス

### Change the Purity to read:

**Purity** (1) Heavy metals <1.07>—Prepare the test solution with 1.0 g of Platycodon Fluidextract as directed in the Fluidextracts (4) under General Rules for Preparations, and perform the test (not more than 30 ppm).

(2) Starch—Mix 1 mL of Platycodon Fluidextract with 4 mL of water, and add 1 drop of dilute iodine TS: no purple or blue color develops.

## Polygala Root

オンジ

### Change the Purity to read:

**Purity** (1) Stem—The amount of the stems contained in Polygala Root does not exceed 10.0%.

(2) Heavy metals <1.07>—Proceed with 3.0 g of pulverized Polygala Root according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(3) Arsenic <1.11>—Prepare the test solution with 0.40 g

of pulverized Polygala Root according to Method 4, and perform the test (not more than 5 ppm).

(4) Foreign matter <5.01>—The amount of foreign matter other than the stems is not more than 1.0%.

(5) Total BHC's and total DDT's <5.01>—Not more than 0.2 ppm, respectively.

## Powdered Polygala Root

オンジ末

### Change the Purity to read:

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of Powdered Polygala Root according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered Polygala Root according to Method 4, and perform the test (not more than 5 ppm).

(3) Foreign matter—Under a microscope <5.01>, Powdered Polygala Root does not show stone cells or starch grains.

(4) Total BHC's and total DDT's <5.01>—Not more than 0.2 ppm, respectively.

## Polygonum Root

カシュウ

### Add the following next to Identification:

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of pulverized Polygonum Root according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Polygonum Root according to Method 4, and perform the test (not more than 5 ppm).

## Polyporus Sclerotium

チヨレイ

### Add the following next to Identification:

**Purity** (1) Heavy metals <1.07>—Proceed with 3.0 g of pulverized Polyporus Sclerotium according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Polyporus Sclerotium according to Method 4, and perform the test (not more than 5 ppm).

## Powdered Polyporus Sclerotium

チヨレイ末

### Add the following next to Identification:

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of Powdered Polyporus Sclerotium according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered Polyporus Sclerotium according to Method 4, and perform the test (not more than 5 ppm).

## Processed Aconite Root

ブシ

### Change the Purity to read:

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of pulverized Processed Aconite Root according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.4 g of pulverized Processed Aconite Root according to Method 4, and perform the test (not more than 5 ppm).

(3) Aconitum diester alkaloids (aconitine, jesaconitine, hypaconitine and mesaconitine)—Weigh accurately about 0.5 g of pulverized Processed Aconite Root, put in a glass-stoppered centrifuge tube, suspend in 3.0 mL of water by shaking, and add 1.0 mL of ammonia TS and 20 mL of diethyl ether. Stopper tightly the tube, shake for 30 minutes, centrifuge, and separate the ether layer. To the residue add 1.0 mL of ammonia TS and 20 mL of diethyl ether, and repeat the above process twice more. Combine all extracts, evaporate to dryness under reduced pressure below 40°C, and dissolve the residue with exactly 10 mL of a mixture of phosphate buffer solution for processed aconite root and acetonitrile (1:1). Centrifuge this solution, and use the supernatant liquid as the sample solution. Perform the test with exactly 20 μL each of the sample solution and aconitum diester alkaloids standard solution for purity as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the heights of the peaks corresponding to aconitine,  $H_{TA}$  and  $H_{SA}$ , jesaconitine,  $H_{TJ}$  and  $H_{SJ}$ , hypaconitine,  $H_{TH}$  and  $H_{SH}$ , and mesaconitine,  $H_{TM}$  and  $H_{SM}$ , respectively, and calculate the amounts of them by the following formulae: the amounts of aconitine, jesaconitine, hypaconitine and mesaconitine per g calculated on the dried basis are not more than 60 μg, 60 μg, 280 μg and 140 μg, respectively, and the total amount of them is not more than 450 μg.

$$\begin{aligned} &\text{Amount } (\mu\text{g}) \text{ of aconitine } (C_{34}H_{47}NO_{11}) \\ &= (C_{SA}/W) \times (H_{TA}/H_{SA}) \times 10 \end{aligned}$$

$$\begin{aligned} &\text{Amount } (\mu\text{g}) \text{ of jesaconitine } (C_{35}H_{49}NO_{12}) \\ &= (C_{SJ}/W) \times (H_{TJ}/H_{SJ}) \times 10 \end{aligned}$$

$$\begin{aligned} &\text{Amount } (\mu\text{g}) \text{ of hypaconitine } (C_{33}H_{45}NO_{10}) \\ &= (C_{SH}/W) \times (H_{TH}/H_{SH}) \times 10 \end{aligned}$$

$$\begin{aligned} &\text{Amount } (\mu\text{g}) \text{ of mesaconitine } (C_{33}H_{45}NO_{11}) \\ &= (C_{SM}/W) \times (H_{TM}/H_{SM}) \times 10 \end{aligned}$$

$C_{SA}$ : Concentration (μg/mL) of aconitine for purity in aconitum diester alkaloids standard solution for purity

$C_{SJ}$ : Concentration (μg/mL) of jesaconitine for purity in aconitum diester alkaloids standard solution for purity

$C_{SH}$ : Concentration (μg/mL) of hypaconitine for purity in aconitum diester alkaloids standard solution for purity

$C_{SM}$ : Concentration (μg/mL) of mesaconitine for purity in aconitum diester alkaloids standard solution for purity

$W$ : Amount (g) of sample, calculated on the dried basis

### Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 231 nm for aconitine, hypaconitine and mesaconitine; 254 nm for jesaconitine).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μm in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of phosphate buffer solution for processed aconite root and tetrahydrofuran (183:17).

Flow rate: Adjust the flow rate so that the retention time of mesaconitine is about 31 minutes.

### System suitability—

System performance: When the procedure is run with 20 μL of aconitum diester alkaloids standard solution for purity under the above operating conditions, using 254 nm, mesaconitine, hypaconitine, aconitine and jesaconitine are eluted in this order, and each resolution between their peaks is not less than 1.5, respectively.

System repeatability: To 1 mL of aconitum diester alkaloids standard solution for purity add a mixture of phosphate buffer solution for processed aconite root and acetonitrile (1:1) to make 10 mL. When the test is repeated 6 times with 20 μL of this solution under the above operating conditions, using 231 nm, the relative standard deviation of the peak height of mesaconitine is not more than 1.5%.

## Powdered Processed Aconite Root

ブシ末

### Change the Purity to read:

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of

Powdered Processed Aconite Root according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.4 g of Powdered Processed Aconite Root according to Method 4, and perform the test (not more than 5 ppm).

(3) Aconitum diester alkaloids (aconitine, jesaconitine, hyaconitine and mesaconitine)—Weigh accurately about 0.5 g of Powdered Processed Aconite Root, put in a glass-stoppered centrifuge tube, suspend in 3.0 mL of water by shaking, and add 1.0 mL of ammonia TS and 20 mL of diethyl ether. Stopper tightly the tube, shake for 30 minutes, centrifuge, and separate the ether layer. To the residue add 1.0 mL of ammonia TS and 20 mL of diethyl ether, and repeat the above process two times. Combine all extracts, evaporate to dryness under reduced pressure below 40°C, and dissolve the residue with exactly 10 mL of a mixture of phosphate buffer solution for processed aconite root and acetonitrile (1:1). Centrifuge this solution, and use the supernatant liquid as the sample solution. Perform the test with exactly 20  $\mu$ L each of the sample solution and aconitum diester alkaloids standard solution for purity as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the heights of the peaks corresponding to aconitine,  $H_{TA}$  and  $H_{SA}$ , jesaconitine,  $H_{TJ}$  and  $H_{SJ}$ , hyaconitine,  $H_{TH}$  and  $H_{SH}$ , and mesaconitine,  $H_{TM}$  and  $H_{SM}$ , respectively, and calculate the amounts of them by the following formulae: the amounts of aconitine, jesaconitine, hyaconitine and mesaconitine per g calculated on the dried basis are not more than 55  $\mu$ g, 40  $\mu$ g, 55  $\mu$ g and 120  $\mu$ g, respectively, and the total amount of them is not more than 230  $\mu$ g.

$$\begin{aligned} &\text{Amount } (\mu\text{g}) \text{ of aconitine } (\text{C}_{34}\text{H}_{47}\text{NO}_{11}) \\ &= (C_{SA}/W) \times (H_{TA}/H_{SA}) \times 10 \end{aligned}$$

$$\begin{aligned} &\text{Amount } (\mu\text{g}) \text{ of jesaconitine } (\text{C}_{35}\text{H}_{49}\text{NO}_{12}) \\ &= (C_{SJ}/W) \times (H_{TJ}/H_{SJ}) \times 10 \end{aligned}$$

$$\begin{aligned} &\text{Amount } (\mu\text{g}) \text{ of hyaconitine } (\text{C}_{33}\text{H}_{45}\text{NO}_{10}) \\ &= (C_{SH}/W) \times (H_{TH}/H_{SH}) \times 10 \end{aligned}$$

$$\begin{aligned} &\text{Amount } (\mu\text{g}) \text{ of mesaconitine } (\text{C}_{33}\text{H}_{45}\text{NO}_{11}) \\ &= (C_{SM}/W) \times (H_{TM}/H_{SM}) \times 10 \end{aligned}$$

$C_{SA}$ : Concentration ( $\mu$ g/mL) of aconitine for purity in aconitum diester alkaloids standard solution for purity

$C_{SJ}$ : Concentration ( $\mu$ g/mL) of jesaconitine for purity in aconitum diester alkaloids standard solution for purity

$C_{SH}$ : Concentration ( $\mu$ g/mL) of hyaconitine for purity in aconitum diester alkaloids standard solution for purity

$C_{SM}$ : Concentration ( $\mu$ g/mL) of mesaconitine for purity in aconitum diester alkaloids standard solution for purity

$W$ : Amount (g) of the sample, calculated on the dried basis

*Operating conditions*—

Detector: An ultraviolet absorption photometer (wavelength: 231 nm for aconitine, hyaconitine and mesaconitine; 254 nm for jesaconitine).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of phosphate buffer solution for processed aconite root and tetrahydrofuran (183:17).

Flow rate: Adjust the flow rate so that the retention time of mesaconitine is about 31 minutes.

*System suitability*—

System performance: When the procedure is run with 20  $\mu$ L of aconitum diester alkaloids standard solution for purity under the above operating conditions, using 254 nm, mesaconitine, hyaconitine, aconitine and jesaconitine are eluted in this order, and each resolution between their peaks is not less than 1.5, respectively.

System repeatability: To 1 mL of aconitum diester alkaloids standard solution for purity add a mixture of phosphate buffer solution for processed aconite root and acetonitrile (1:1) to make 10 mL. When the test is repeated 6 times with 20  $\mu$ L of this solution under the above operating conditions, using 231 nm, the relative standard deviation of the peak height of mesaconitine is not more than 1.5%.

## Processed Ginger

カンキョウ

**Add the following next to Identification:**

**Purity** Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Processed Ginger according to Method 4, and perform the test (not more than 5 ppm).

## Rehmannia Root

ジオウ

**Change the Description to read:**

**Description** Thin and long, usually, fusiform root, 5 – 10 cm in length, 0.5 – 3.0 cm in diameter, often broken or markedly deformed in shape; externally yellow-brown to blackish brown, with deep, longitudinal wrinkles and constrictions; soft in texture and mucous; cross section yellow-brown to blackish brown, and cortex darker than xylem in color; pith hardly observable.

Odor, characteristic; taste, slightly sweet at first, followed by a slight bitterness.

Under a microscope <5.01>, a transverse section reveals 7 to 15 layers of cork; cortex composed entirely of parenchyma cells; outer region of cortex with scattered cells contain-

ing brown secretes; xylem practically filled with parenchyma; vessels radially lined, mainly reticulate vessels.

**Change to read:**

## Ryokeijutsukanto Extract

茶桂朮甘湯エキス

Ryokeijutsukanto Extract contains not less than 1 mg and not more than 4 mg of (*E*)-cinnamic acid, and not less than 21 mg and not more than 63 mg of glycyrrhizic acid (C<sub>42</sub>H<sub>62</sub>O<sub>16</sub>: 822.93) per a dried extract prepared as directed in the Method of preparation.

**Method of preparation** Prepare a dry or viscous extract as directed under Extracts, with 6 g of Poria Sclerotium, 4 g of Cinnamon Bark, 3 g of Atractylodes Rhizome or Atractylodes Lancea Rhizome and 2 g of Glycyrrhiza.

**Description** Ryokeijutsukanto Extract occurs as a brown to black-brown powder or viscous extract. It has an odor, and a sweet first then bitter taste.

**Identification (1)** To 1.0 g of dry extract (3.0 g for viscous extract) of Ryokeijutsukanto Extract add 10 mL of water, shake, then add 25 mL of diethyl ether, and shake. Take the diethyl ether layer, evaporate the layer under reduced pressure, add 2 mL of diethyl ether to the residue, and use this solution as the sample solution. Separately, dissolve 1 mg of (*E*)-cinnamic acid for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5 μL each of the sample solution and standard solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography, develop the plate with a mixture of hexane, ethyl acetate, formic acid and water (60:40:4:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the blue-purple spot from the standard solution (Cinnamon Bark).

(2) For preparation prescribed Atractylodes Rhizome—To 1.0 g of dry extract (3.0 g for viscous extract) of Ryokeijutsukanto Extract add 10 mL of water, shake, then add 25 mL of diethyl ether, and shake. Take the diethyl ether layer, evaporate the layer under reduced pressure, add 2 mL of diethyl ether to the residue, and use this solution as the sample solution. Separately, dissolve 1 mg of atractylenolide III for thin-layer chromatography in 2 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5 μL each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography, develop the plate with a mixture of ethyl acetate and hexane (1:1) to a distance of about 10

cm, and air-dry the plate. Spray evenly dilute sulfuric acid on the plate, heat at 105°C for 5 minutes, and examine under ultraviolet light (main wavelength: 365 nm): one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the bluish white fluorescent spot from the standard solution (Atractylodes Rhizome).

(3) For preparation prescribed Atractylodes Lancea Rhizome—To 2.0 g of dry extract (6.0 g for viscous extract) of Ryokeijutsukanto Extract add 10 mL of water, shake, then add 25 mL of hexane, and shake. Take the hexane layer, add anhydrous sodium sulfate to dry, and filter. Evaporate the filtrate under reduced pressure, add 2 mL of hexane to the residue, and use this solution as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 20 μL of the sample solution on a plate of silica gel with fluorescent indicator for thin-layer chromatography, develop the plate with a mixture of hexane and acetone (7:1) to a distance of about 10 cm, and air-dry the plate. Examine under ultraviolet light (main wavelength: 254 nm): a dark purple spot is observed at around *R<sub>f</sub>* 0.4. The spot shows a greenish brown color after being sprayed 4-dimethylaminobenzaldehyde TS for spraying, heated at 105°C for 5 minutes, and allowed to cool (Atractylodes Lancea Rhizome).

(4) To 1.0 g of dry extract (3.0 g for viscous extract) of Ryokeijutsukanto Extract add 10 mL of water, shake, then add 10 mL of 1-butanol, centrifuge, and use the supernatant liquid as the sample solution. Separately, dissolve 1 mg of liquoritin for thin-layer chromatography in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 5 μL each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, methanol and water (20:3:2) to a distance of about 10 cm, and air-dry the plate. Spray evenly dilute sulfuric acid on the plate, and heat at 105°C for 5 minutes: one of the spot among the several spots from the sample solution has the same color tone and *R<sub>f</sub>* value with the yellow-brown spot from the standard solution (Glycyrrhiza).

**Purity (1)** Heavy metals <1.07>—Prepare the test solution with 1.0 g of dry extract (or an amount of the viscous extract, equivalent to 1.0 g of the dried substance) of Ryokeijutsukanto Extract as directed in the Extracts (4) under General Rules for Preparations, and perform the test (not more than 30 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.67 g of dry extract (or an amount of the viscous extract, equivalent to 0.67 g of the dried substance) of Ryokeijutsukanto Extract according to Method 3, and perform the test (not more than 3 ppm).

**Loss on drying <2.41>** Dry extract: Not more than 8.5% (1 g, 105°C, 5 hours).

Viscous extract: Not more than 66.7% (1 g 105°C, 5 hours).

**Total ash <5.01>** Not more than 8.0%, calculated on the

dried basis.

**Assay (1) (*E*)-Cinnamic acid**—Conduct this procedure without exposure to light, using light-resistant vessels. Weigh accurately about 0.5 g of dry extract (for viscous extract an amount equivalent to about 0.5 g as dried substance) of Ryokeijutsukanto Extract, add exactly 50 mL of diluted methanol (1 in 2), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of (*E*)-cinnamic acid for component determination, previously dried in a desiccator (silica gel) for more than 24 hours, dissolve in diluted methanol (1 in 2) to make exactly 100 mL. Pipet 10 mL of this solution, add diluted methanol (1 in 2) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of (*E*)-cinnamic acid.

$$\begin{aligned} &\text{Amount (mg) of (E)-cinnamic acid} \\ &= W_S \times (A_T/A_S) \times (1/20) \end{aligned}$$

$W_S$ : Amount (mg) of (*E*)-cinnamic acid for component determination

**Operating conditions**—

Detector: An ultraviolet absorption photometer (wavelength: 273 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of water, acetonitrile and phosphoric acid (750:250:1).

Flow rate: 1.0 mL per minute. (the retention time of (*E*)-cinnamic acid is about 12 minutes.)

**System suitability**—

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of (*E*)-cinnamic acid are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of (*E*)-cinnamic acid is not more than 1.5%.

(2) Glycyrrhizic acid—Weigh accurately about 0.5 g of dry extract (for viscous extract an amount equivalent to about 0.5 g as dried substance) of Ryokeijutsukanto Extract, add exactly 50 mL of diluted methanol (1 in 2), shake for 15 minutes, filter, and use the filtrate as the sample solution. Separately, weigh accurately about 10 mg of Glycyrrhizic Acid Reference Standard (separately determine the water), dissolve in diluted methanol (1 in 2) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of glycyrrhizic acid.

matography <2.01> according to the following conditions, and determine the peak areas,  $A_T$  and  $A_S$ , of glycyrrhizic acid.

$$\begin{aligned} &\text{Amount (mg) of glycyrrhizic acid (C}_{42}\text{H}_{62}\text{O}_{16}) \\ &= W_S \times (A_T/A_S) \times (1/2) \end{aligned}$$

$W_S$ : Amount (mg) of Glycyrrhizic Acid Reference Standard, calculated on the anhydrous basis

**Operating conditions**—

Detector: An ultraviolet absorption photometer (wavelength: 254 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 40°C.

Mobile phase: A mixture of diluted acetic acid (31) (1 in 15) and acetonitrile (13:7).

Flow rate: 1.0 mL per minute. (the retention time of glycyrrhizic acid is about 12 minutes.)

**System suitability**—

System performance: When the procedure is run with 10  $\mu$ L of the standard solution under the above operating conditions, the number of theoretical plates and the symmetry factor of the peak of glycyrrhizic acid are not less than 5000 and not more than 1.5, respectively.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of glycyrrhizic acid is not more than 1.5%.

**Containers and storage** Containers—Tight containers.

## Saposhnikovia Root

ポウフウ

**Change the Purity to read:**

**Purity (1) Heavy metals <1.07>**—Proceed with 3.0 g of pulverized Saposhnikovia Root according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Saposhnikovia Root according to Method 4, and perform the test (not more than 5 ppm).

(3) Foreign matter <5.01>—The amount of stems and other foreign matter is not more than 2.0%.

## Saussurea Root

モッコウ

**Change the Purity to read:**

**Purity (1) Arsenic <1.11>**—Prepare the test solution with



0.40 g of pulverized Saussurea Root according to Method 4, and perform the test (not more than 5 ppm).

(2) Foreign matter—Add iodine TS dropwise to a transverse section: no blue-purple color develops.

## Scopolia Extract

ロートエキス

### Add the following next to Identification:

**Purity** Heavy metals <1.07>—Prepare the test solution with 1.0 g of Scopolia Extract as directed in the Extracts (4) under General Rules for Preparations, and perform the test (not more than 30 ppm).

## Scopolia Rhizome

ロートコン

### Add the following next to Identification:

**Purity** Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Scopolia Rhizome according to Method 4, and perform the test (not more than 5 ppm).

## Scutellaria Root

オウゴン

### Change the Assay to read:

**Assay** Weigh accurately about 0.5 g of pulverized Scutellaria Root, add 30 mL of diluted methanol (7 in 10), heat under a reflux condenser on a water bath for 30 minutes, and cool. Transfer the mixture to a glass-stoppered centrifuge tube, centrifuge, and separate the supernatant liquid. Wash the vessel for the reflux extraction with 30 mL of diluted methanol (7 in 10), transfer the washings to the glass-stoppered centrifuge tube, centrifuge after shaking for 5 minutes, and separate the supernatant liquid. To the residue add 30 mL of diluted methanol (7 in 10), shake for 5 minutes, centrifuge, and separate the supernatant liquid. Combine all the extracts, add diluted methanol (7 in 10) to make exactly 100 mL, then pipet 2 mL of the extract, add diluted methanol (7 in 10) to make exactly 20 mL, and use this solution as the sample solution. Separately, weigh accurately about 10 mg of Baicalin Reference Standard (separately determine the water), and dissolve in methanol to make exactly 20 mL. Pipet 2 mL of the solution, add diluted methanol (7 in 10) to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions. Determine the peak areas,  $A_T$  and  $A_S$ , of baicalin in each solution.

Amount (mg) of baicalin ( $C_{21}H_{18}O_{11}$ ) =  $W_S \times (A_T/A_S) \times 5$

$W_S$ : Amount (mg) of Baicalin Reference Standard, calculated on the anhydrous basis

### Operating conditions—

Detector: An ultraviolet absorption photometer (wavelength: 277 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 50°C.

Mobile phase: A mixture of diluted phosphoric acid (1 in 146) and acetonitrile (18:7).

Flow rate: Adjust the flow rate so that the retention time of baicalin is about 6 minutes.

### System suitability—

System performance: Dissolve 1 mg of Baicalin Reference Standard and 2 mg of methyl parahydroxybenzoate in methanol to make 100 mL. When the procedure is run with 10  $\mu$ L of this solution under the above operating conditions, baicalin and methyl parahydroxybenzoate are eluted in this order with the resolution between these peaks being not less than 3.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of baicalin is not more than 1.5%.

## Powdered Scutellaria Root

オウゴン末

### Change the Assay to read:

**Assay** Weigh accurately about 0.5 g of Powdered Scutellaria Root, add 30 mL of diluted methanol (7 in 10), heat under a reflux condenser on a water bath for 30 minutes, and cool. Transfer the mixture to a glass-stoppered centrifuge tube, centrifuge, and separate the supernatant liquid. Wash the vessel for the reflux extraction with 30 mL of diluted methanol (7 in 10), transfer the washings to the glass-stoppered centrifuge tube, centrifuge after shaking for 5 minutes, and separate the supernatant liquid. To the residue add 30 mL of diluted methanol (7 in 10), shake for 5 minutes, centrifuge, and separate the supernatant liquid. Combine all the extracts, add diluted methanol (7 in 10) to make exactly 100 mL, then pipet 2 mL of the extract, add diluted methanol (7 in 10) to make exactly 20 mL, and use this solution as the sample solution. Separately, weigh accurately about 10 mg of Baicalin Reference Standard (separately determine the water), and dissolve in methanol to make exactly 20 mL. Pipet 2 mL of the solution, add diluted methanol (7 in 10) to make exactly 20 mL, and use this solution as the standard solution. Perform the test with exactly 10  $\mu$ L each of the sample solution and standard solution as

directed under Liquid Chromatography <2.01> according to the following conditions. Determine the peak areas,  $A_T$  and  $A_S$ , of baicalin in each solution.

Amount (mg) of baicalin ( $C_{21}H_{18}O_{11}$ ) =  $W_S \times (A_T/A_S) \times 5$

$W_S$ : Amount (mg) of Baicalin Reference Standard, calculated on the anhydrous basis

*Operating conditions—*

Detector: An ultraviolet absorption photometer (wavelength: 277 nm).

Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5  $\mu$ m in particle diameter).

Column temperature: A constant temperature of about 50°C.

Mobile phase: A mixture of diluted phosphoric acid (1 in 146) and acetonitrile (18:7).

Flow rate: Adjust the flow rate so that the retention time of baicalin is about 6 minutes.

*System suitability—*

System performance: Dissolve 1 mg of Baicalin Reference Standard and 2 mg of methyl parahydroxybenzoate in methanol to make 100 mL. When the procedure is run with 10  $\mu$ L of this solution under the above operating conditions, baicalin and methyl parahydroxybenzoate are eluted in this order with the resolution between these peaks being not less than 3.

System repeatability: When the test is repeated 6 times with 10  $\mu$ L of the standard solution under the above operating conditions, the relative standard deviation of the peak area of baicalin is not more than 1.5%.

## Senega

セネガ

**Change the Purity to read:**

**Purity (1)** Stem—The amount of stems contained in Senega is not more than 2.0%.

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Senega according to Method 4, and perform the test (not more than 5 ppm).

(3) Foreign matter <5.01>—The amount of foreign matter other than stems contained in Senega is not more than 1.0%.

## Powdered Senega

セネガ末

**Change the Purity to read:**

**Purity (1)** Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered Senega according to Method 4, and per-

form the test (not more than 5 ppm).

(2) Foreign matter—Under a microscope <5.01>, stone cells, starch grains or crystals of calcium oxalate are not observable.

## Smilax Rhizome

サンキライ

**Add the following next to Description:**

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of pulverized Smilax Rhizome according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Smilax Rhizome according to Method 4, and perform the test (not more than 5 ppm).

## Powdered Smilax Rhizome

サンキライ末

**Change the Purity to read:**

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of Powdered Smilax Rhizome according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered Smilax Rhizome according to Method 4, and perform the test (not more than 5 ppm).

(3) Foreign matter—Under a microscope <5.01>, Powdered Smilax Rhizome does not show a large quantity of stone cells or thick-walled fibers.

## Sophora Root

クジン

**Change the Purity to read:**

**Purity (1)** Stem—The amount of its stems contained in Sophora Root does not exceed 10.0%.

(2) Heavy metals <1.07>—Proceed with 3.0 g of pulverized Sophora Root according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(3) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Sophora Root according to Method 4, and perform the test (not more than 5 ppm).

(4) Foreign matter <5.01>—The amount of foreign matter other than stems is not more than 1.0%.

## Powdered Sophora Root

クジン末

### Add the following next to Identification:

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of Powdered Sophora Root according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered Sophora Root according to Method 4, and perform the test (not more than 5 ppm).

## Turmeric

ウコン

### Add the following next to Identification:

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of pulverized Turmeric according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Turmeric according to Method 4, and perform the test (not more than 5 ppm).

### Add the following:

## Powdered Turmeric

*Curcumae Rhizoma Purveratum*

ウコン末

Powdered Turmeric is the powder of Turmeric.

**Description** Powdered Turmeric occurs as a yellow-brown to dark yellow-brown powder. It has a characteristic odor and a bitter, stimulant taste, and colors the saliva yellow on chewing.

Under a microscope <5.01>, all elements are yellow in color; it reveals parenchymatous cells containing mainly masses of gelatinized starch or yellow substances, also fragments of scalariform vessels; fragments of cork layers, epidermis, thick-walled xylem parenchymatous cells, and non-glandular hairs are occasionally observed.

**Identification** To 0.5 g of Powdered Turmeric add 20 mL of methanol, shake for 15 minutes, filter, and use the filtrate as the sample solution. Perform the test with the sample solution as directed under Thin-layer Chromatography <2.03>. Spot 5  $\mu$ L of the sample solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of ethyl acetate, hexane and acetic acid (100) (70:30:1) to a distance of about 10 cm, and air-dry the plate: a yellow

spot appears at around Rf 0.4.

**Purity (1)** Heavy metals <1.07>—Proceed with 3.0 g of Powdered Turmeric according to Method 3, and perform the test. Prepare the control solution with 3.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of Powdered Turmeric according to Method 4, and perform the test (not more than 5 ppm).

**Loss on drying** <5.01> Not more than 17.0% (6 hours).

**Total ash** <5.01> Not more than 7.5%.

**Acid-insoluble ash** <5.01> Not more than 1.0%.

**Extract content** <5.01> Dilute ethanol-soluble extract: not less than 9.0%.

## Uva Ursi Fluidextract

ウワウルシ流エキス

### Add the following next to Identification:

**Purity** Heavy metals <1.07>—Prepare the test solution with 1.0 g of Uva Ursi Fluidextract as direct in the Fluidextracts (4) under General Rules for Preparations, and perform the test (not more than 30 ppm).

## Zedoary

ガジュツ

### Add the following next to Description:

**Purity (1)** Heavy metals <1.07>—Proceed with 1.0 g of pulverized Zedoary according to Method 3, and perform the test. Prepare the control solution with 1.0 mL of Standard Lead Solution (not more than 10 ppm).

(2) Arsenic <1.11>—Prepare the test solution with 0.40 g of pulverized Zedoary according to Method 4, and perform the test (not more than 5 ppm).


**Delete the following Infrared Reference Spectra:**

**Fosfestrol**


**Sulfinpyrazone**

**Change to read the following 2 spectra:**

**Calcium Folate**




**Vincristine Sulfate**




Add the following 42 spectra:


**Acemetacin**




**Alminoprofen**




**Amlexanox**




**Amlodipine Besilate**




**Amosulalol Hydrochloride**




**Azelastine Hydrochloride**




**Biotin**



**Bisoprolol Fumarate**




**Buformin Hydrochloride**







**Buprenorphine Hydrochloride**




**Cetirizine Hydrochloride**




**Cibenzoline Succinate**




**Cilazapril Hydrate**




**Clobetasol Propionate**




**Clorazepate Dipotassium**




**L-Cysteine**




**L-Cysteine Hydrochloride Hydrate**




**Domperidone**




**Emorfazone**




**Enalapril Maleate**




**Felbinac**




**L-Glutamine**




**Ibudilast**




**Isoxsuprine Hydrochloride**




**Itraconazole**




**Labetalol Hydrochloride**




**Manidipine Hydrochloride**




**Medazepam**




**Mizoribine**




**Nabumetone**




**Nafamostat Mesilate**



**Nizatidine**




**Omeprazole**







**Ozagrel Sodium**




**Piperacillin Hydrate**




**Salicylic Acid**




**L-Serine**




**Sodium Starch Glycolate, Type A**




**Sodium Starch Glycolate, Type B**




**L-Tyrosine**



**Ubenimex**



**Zidovudine**




**Delete the following Ultraviolet-visible Reference Spectra:**

**Sulfinpyrazone**


**Tubocurarine Chloride Hydrochloride Hydrate**

**Add the following 30 spectra:**


**Acemetacin**




**Alminoprofen**




**Amlexanox**




**Amlodipine Besilate**




**Amosulalol Hydrochloride**




**Azelastine Hydrochloride**




**Bisoprolol Fumarate**




**Buformin Hydrochloride**




**Buprenorphine Hydrochloride**




**Cetirizine Hydrochloride**



**Cibenzoline Succinate**




**Clorazepate Dipotassium**







**Domperidone**




**Emorfazone**




**Felbinac**




**Ibudilast**




**Isoxsuprine Hydrochloride**




**Itraconazole**




**Labetalol Hydrochloride**




**Manidipine Hydrochloride**




**Mizoribine**




**Nabumetone**




**Nafamostat Mesilate**




**Nicorandil**




**Nizatidine**




**Omeprazole**




**Ozagrel Sodium**




**Salicylic Acid**



**L-Tyrosine**



**Ubenimex**



# GENERAL INFORMATION

## 8. International Harmonization Implemented in the Japanese Pharmacopoeia Fifteenth Edition

### *Add the following:*

May 2005 (Rev.1)

Harmonized items	JP15 (Supplement I)	Remarks
<b>Sodium Starch Glycolate</b>	<b>Sodium Starch Glycolate</b>	
Definition	origin, limit of sodium	
Identification A	Identification (1)	
Identification B	Identification (3)	
pH	pH	
Loss on drying	Loss on drying	
Limit of iron	Purity (2) Iron	
Limit of sodium chloride	Purity (4) Sodium chloride	
Limit of sodium glycolate	Purity (3) Sodium glycolate	
Assay	Assay	

### *Add the following:*

June 2006

Harmonized items	JP15 (Supplement I)	Remarks
<b>Hypromellose Phthalate</b>	<b>Hypromellose Phthalate</b>	
Definition	origin, limit of carboxybenzoyl	
Packaging and storage	Containers and storage	
Viscosity	Viscosity	
Water	Water	
Residue on ignition	Residue on ignition	
Chloride	Purity (1) Chloride	
Limit of free phthalic acid	Purity (3) Phthalic acid	
Phthalyl content	Assay	

**Add the following:**

Nov. 2005

Harmonized items	JP15 (Supplement I)	Remarks
<b>Anhydrous Dibasic Calcium Phosphate</b>	<b>Anhydrous Dibasic Calcium Phosphate</b>	
Definition	limit of content	
Identification (1)	Identification (1)	
Identification (2)	Identification (2)	
Acid-insoluble substances	Purity (1) Acid-insoluble substance	
Chloride	Purity (2) Chloride	
Sulfate	Purity (3) Sulfate	
Carbonate	Purity (4) Carbonate	
Barium	Purity (6) Barium	
Loss on ignition	Loss on drying	
Assay	Assay	

**Add the following:**

Nov. 2005

Harmonized items	JP15 (Supplement I)	Remarks
<b>Dibasic Calcium Phosphate</b>	<b>Dibasic Calcium Phosphate Hydrate</b>	
Definition	limit of content	
Identification (1)	Identification (1)	
Identification (2)	Identification (2)	
Acid-insoluble substances	Purity (1) Acid-insoluble substances	
Chloride	Purity (2) Chloride	
Sulfate	Purity (3) Sulfate	
Carbonate	Purity (4) Carbonate	
Barium	Purity (6) Barium	
Loss on ignition	Loss on drying	
Assay	Assay	

**Add the following:**

Nov. 2005

Harmonized items	JP15 (Supplement I)	Remarks
<b>Microbiological Examination of Non-sterile Products:</b>	<b>4.05 Microbiological Examination of Non-sterile Products</b>	
<b>Microbial Enumeration Tests</b>	I. Microbiological Examination of Non-sterile Products: Microbial Enumeration Tests	
Introduction	1. Introduction	
General procedures	2. General Procedures	
Enumeration methods	3. Enumeration Methods	
Growth promotion test and suitability of the counting method	4. Growth Promotion Test and Suitability of the Counting Method	



General considerations	4.1. General considerations
Preparation of test strains	4.2. Preparation of test strains
Negative control	4.3. Negative control
Growth promotion of the media	4.4. Growth promotion of the media
Suitability of the counting method in the presence of product	4.5. Suitability of the counting method in the presence of product
Results and interpretation	4.6. Results and interpretation
Testing of products	5. Testing of Products
Amount used for the test	5.1. Amount used for the test
Examination of the product	5.2. Examination of the product
Interpretation of the results	5.3. Interpretation of the results
<b>Microbiological Examination of Non-sterile Products: Tests for Specified Micro-organisms</b>	II. Microbiological Examination of Non-sterile Products: Tests for Specified Micro-organisms
Introduction	1. Introduction
General procedures	2. General Procedures
Growth promoting and inhibitory properties of the media and suitability of the test	3. Growth Promoting and Inhibitory Properties of the Media and Suitability of the Test
Preparation of test strains	3.1. Preparation of test strains
Negative control	3.2. Negative control
Growth promotion and inhibitory properties of the media	3.3. Growth promotion and inhibitory properties of the media
Suitability of the test method	3.4. Suitability of the test method
Testing of products	4. Testing of Products
Bile-tolerant gram-negative bacteria	4.1. Bile-tolerant gram-negative bacteria
<i>Escherichia coli</i>	4.2. <i>Escherichia coli</i>
<i>Salmonella</i>	4.3. <i>Salmonella</i>
<i>Pseudomonas aeruginosa</i>	4.4. <i>Pseudomonas aeruginosa</i>
<i>Staphylococcus aureus</i>	4.5. <i>Staphylococcus aureus</i>
Clostridia	4.6. Clostridia
<i>Candida albicans</i>	4.7. <i>Candida albicans</i>
Recommended solutions and culture media	5. Recommended Solutions and Culture Media

**Add the following:**

Nov. 2005

Harmonized items	JP15 (Supplement I)	Remarks
Microbiological Examination of Non-sterile Products:	General Information 12. Microbial Attributes of Non-sterile Pharmaceutical Products	JP's particular description: 1. Definitions 2. Scope

<p>Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical use</p> <p>Table 2. Acceptance Criteria for Microbiological Quality of Non-sterile Substances for Pharmaceutical use</p> <p>Table 1. Acceptance Criteria for Microbiological Quality of Non-sterile Dosage Forms</p>	<p>5. Microbial acceptance criteria for non-sterile pharmaceutical products</p> <p>Table 1. Acceptance criteria for microbiological quality of non-sterile substances for pharmaceutical use</p> <p>Table 2. Acceptance criteria for microbiological quality of non-sterile dosage forms</p>	<p>3. Sampling plan and frequency of testing</p> <p>4. Microbial control program</p> <p>JP's particular description: Explanation of the microbial acceptance criteria</p> <p>JP's particular description: 6. Acceptance criteria for herbal drugs and herbal drug containing preparations</p>
---	--	---

**Change to read:**

Jan. 2000

Harmonized items	JP 15 (Supplement I)	Remarks
<p><b>Bacterial Endotoxins Test</b></p> <p>(Introduction)</p> <p>Apparatus</p> <p>Preparation of standard endotoxin stock solution</p> <p>Preparation of standard endotoxin solution</p> <p>Preparation of sample solutions</p> <p>Determination of maximum valid dilution</p> <p>Gel-clot technique</p> <p>(1) Preparatory testing</p> <p>(i) Test for confirmation of labeled lysate sensitivity</p> <p>(ii) Test for interfering factors</p> <p>(2) Limit test</p> <p>(i) Procedure</p> <p>(ii) Interpretation</p> <p>(3) Assay</p> <p>(i) Procedure</p>	<p><b>4.01 Bacterial Endotoxins Test</b></p> <p>(Introduction)</p> <p>Apparatus</p> <p>Preparation of standard endotoxin stock solution</p> <p>Preparation of standard endotoxin solution</p> <p>Preparation of sample solutions</p> <p>Determination of maximum valid dilution</p> <p>Gel-clot technique</p> <p>(1) Preparatory testing</p> <p>(i) Test for confirmation of labeled lysate sensitivity</p> <p>(ii) Test for interfering factors</p> <p>(2) Limit test</p> <p>(i) Procedure</p> <p>(ii) Interpretation</p> <p>(3) Assay</p> <p>(i) Procedure</p>	<p>JP's particular description: Addition of the preparation of sample solutions for containers, and deletion of that for medical devices.</p> <p>JP's particular description: Addition of the concentration unit of sample solutions in the case where the endotoxin limit per equivalent is specified.</p>

(ii) Calculation and interpretation Photometric techniques (1) Turbidimetric techniques (2) Chromogenic technique (3) Preparatory testing (i) Assurance of criteria for the standard curve  (ii) Test for interfering factors   (4) Assay (i) Procedure (ii) Calculation  (iii) Interpretation Reagents, test solutions Amebocyte lysate Lysate TS Water for bacterial endotoxins test (BET)	(ii) Calculation and interpretation Photometric techniques (1) Turbidimetric techniques (2) Chromogenic technique (3) Preparatory testing (i) Assurance of criteria for the standard curve  (ii) Test for interfering factors   (4) Assay (i) Procedure (ii) Calculation  (iii) Interpretation	JP's particular description: The test for assurance of criteria for the standard curve must be carried out for each lot of lysate reagent.  JP's particular description: Two conditions which the test must meet are specified. Explanation of the test method where the interfering action is found. Explanation of the usual methods for eliminating the interference.  JP's particular description: Addition of the alternative requirement to which solution D must meet for valid test.  deletion deletion deletion deletion
--	--	---

**Change to read:**

Nov. 2005 (Rev. 2)

Harmonized items	JP15 (Supplement I)	Remarks
<b>Anhydrous Lactose</b>	<b>Anhydrous Lactose</b>	
Definition	origin	
Specific rotation	Optical rotation	
Clarity and color of solution	Purity (1) Clarity and color of solution	
Acidity or alkalinity	Purity (2) Acidity or alkalinity	
Protein and light-absorbing impurities	Purity (4) Proteins and light absorbing substances	
Loss on drying	Loss on drying	
Water	Water	
Residue on ignition	Residue on ignition	
Content of alpha and beta anomers	Isomer ratio	

**Change to read:**

## 12. Microbial Attributes of Non-sterile Pharmaceutical Products

This chapter is harmonized with the European Pharmacopoeia and the U.S. Pharmacopeia. The parts of the text that are not harmonized are marked with symbols (♦ ♦).

The presence of certain micro-organisms in non-sterile preparations may have the potential to reduce or even inactivate the therapeutic activity of the product and has a potential to adversely affect the health of the patient. Manufacturers have therefore to ensure a low bioburden of finished dosage forms by implementing current guidelines on Good Manufacturing Practice during the manufacture, storage and distribution of pharmaceutical preparations. ♦This chapter provides guidelines for acceptable limits of viable micro-organisms (bacteria and fungi) existing in raw materials and non-sterile pharmaceutical products. ♦ Microbial examination of non-sterile products is performed according to the methods given in the Microbial Limit Test <4.05> on Microbiological Examination of Non-sterile Products: *Microbial Enumeration Tests* and *Tests for Specified Micro-organisms*. ♦When these tests are carried out, a microbial control program must be established as an important part of the quality management system of the product. Personnel responsible for conducting the tests should have specialized training in microbiology, biosafety measures and in the interpretation of the testing results. ♦

### ♦1. Definitions

1.1 Non-sterile pharmaceutical products: Non-sterile drugs shown in monographs of the JP and non-sterile finished dosage forms.

1.2 Raw materials: All materials, including raw ingredients and excipients, used for the preparation of drugs, except for water and gases.

1.3 Bioburden: Number and type of viable micro-organisms existing in non-sterile pharmaceutical products.

1.4 Action levels: Established bioburden levels that require immediate follow-up and corrective action if they are exceeded.

1.5 Alert levels: Established bioburden levels that give early warning of a potential drift from normal bioburden level, but which are not necessary grounds for definitive corrective action, though they may require follow-up investigation.

1.6 Quality management system: The procedures, operation methods and organizational structure of a manufacturer (including responsibilities, authorities and relationships between these) needed to implement quality management.

### 2. Scope

In general, the test for total viable aerobic count is not

applied to drugs containing viable micro-organisms as an active ingredient.

### 3. Sampling plan and frequency of testing

#### 3.1 Sampling methods

Microbial contaminants are usually not uniformly distributed throughout the batches of non-sterile pharmaceutical products or raw materials. A biased sampling plan, therefore, cannot be used to estimate the real bioburden in the product. A sampling plan which can properly reflect the status of the product batch should be established on the basis of the bioburden data obtained by retrospective validation and/or concurrent validation. In general, a mixture of samples randomly taken from at least different three portions, almost the same amount for each portion, is used for the tests of the product. When the sampling is difficult in a clean area, special care is required during sampling to avoid introducing microbial contamination into the product or affecting the nature of the product bioburden. If it is confirmed that the product bioburden is stable for a certain period, as in the case of non-aqueous or dried products, it is not necessary to do the tests, immediately after the sampling.

#### 3.2 Testing frequency

The frequency of the tests should be established on the basis of a variety of factors unless otherwise specified. These factors include:

- Dosage forms of non-sterile pharmaceutical products (usage);
- Manufacturing processes;
- Manufacturing frequency;
- Characteristics of raw materials (natural raw material, synthetic compound, etc.);
- Batch sizes;
- Variations in bioburden estimates (changes in batches, seasonal variations, etc.);
- Changes affecting the product bioburden (changes in manufacturing process, supplier of raw materials, batch number of raw materials, etc.);
- Others.

In general, the tests may be performed at a high frequency during the initial production of a drug to get information on the microbiological attributes of the product or raw materials used for the production. However, this frequency may be reduced as bioburden data are accumulated through retrospective validation and/or concurrent validation. For example, the tests may be performed at a frequency based on time (e.g., weekly, monthly or seasonally), or on alternate batches.

### 4. Microbial control program

When the “Microbial Limit Test <4.05>” is applied to a non-sterile pharmaceutical product, the methods for the recovery, cultivation and estimation of the bioburden from the product must be validated and a “Microbial control program” covering the items listed below must be prepared.

- Subject pharmaceutical name (product name);
- Frequency of sampling and testing;
- Sampling methods (including responsible person, quan-

- tity, environment, etc. for sampling);
- d) Transfer methods of the samples to the testing area (including storage condition until the tests);
  - e) Treatment of the samples (recovery methods of microbial contaminants);
  - f) Enumeration of viable micro-organisms (including testing quantity, culture media, growth-supporting test of the media, culturing methods, etc.);
  - g) Detection of specified micro-organisms (including testing quantity, culture media, growth-supporting test of the media, culturing methods, etc.);
  - h) Estimation of the number of and characterization of microbial contaminants;
  - i) Establishment of "Microbial acceptance criteria" (including alert level and action level);
  - j) Actions to be taken when the levels exceed "Microbial acceptance criteria";
  - k) Persons responsible for the testing and evaluation, etc.;
  - l) Other necessary items. ♦

### 5. Microbial acceptance criteria for non-sterile pharmaceutical products

By establishing "Microbial acceptance criteria" for non-sterile pharmaceutical products based upon the total aerobic microbial count (TAMC) and the total combined yeasts/moulds count (TYMC), ♦it is possible to evaluate at the initial processing stage of the product whether the microbiological quality of the raw materials is adequate or not. Furthermore, it is then possible to implement appropriate corrective action as needed to maintain or improve the microbiological quality of the product. ♦ The target limits of microbial levels for raw materials (synthetic compounds and minerals) are shown in Table 1.

♦In general, synthetic compounds have low bioburden

levels due to the high temperatures, organic solvents, etc., used in their manufacturing processes. Raw materials originated from plants and animals in general have higher bioburdens than synthetic compounds.

The microbial quality of the water used in the processing of active ingredients or non-sterile pharmaceuticals may have a direct effect on the quality of the finished dosage form. This means it is necessary to keep the level of microbial contaminants in the water as low as possible. ♦

Acceptance criteria for microbiological quality for non-sterile finished dosage forms are shown in Table 2. ♦These microbial limits are based primarily on the type of dosage form, water activity, and so on. For oral liquids and pharmaceutical products having a high water activity, in general, low microbial acceptance criteria are given. ♦

Table 2 includes a list of specified micro-organisms for which acceptance criteria are set. The list is not necessarily exhaustive and for a given preparation it may be necessary to test for other micro-organisms depending on the nature of the starting materials and the manufacturing process.

If it has been shown that none of the prescribed tests will allow valid enumeration of micro-organisms at the level

**Table 1.** Acceptance criteria for microbiological quality of non-sterile substances for pharmaceutical use

	Total Aerobic Microbial Count (CFU/g or CFU/mL)	Total Combined Yeasts/Moulds Count (CFU/g or CFU/mL)
Substances for pharmaceutical use	10 <sup>3</sup>	10 <sup>2</sup>

**Table 2.** Acceptance criteria for microbiological quality of non-sterile dosage forms

Route of administration	Total Aerobic Microbial Count (CFU/g or CFU/mL)	Total Combined Yeasts/Moulds Count (CFU/g or CFU/mL)	Specified Micro-organism
Non-aqueous preparations for oral use	10 <sup>3</sup>	10 <sup>2</sup>	Absence of <i>Escherichia coli</i> (1 g or 1 mL)
Aqueous preparations for oral use	10 <sup>2</sup>	10 <sup>1</sup>	Absence of <i>Escherichia coli</i> (1 g or 1 mL)
Rectal use	10 <sup>3</sup>	10 <sup>2</sup>	—
Oromucosal use	10 <sup>2</sup>	10 <sup>1</sup>	Absence of <i>Staphylococcus aureus</i> (1 g or 1 mL)
Gingival use			Absence of <i>Pseudomonas aeruginosa</i> (1 g or 1 mL)
Cutaneous use			
Nasal use			
Auricular use			
Vaginal use	10 <sup>2</sup>	10 <sup>1</sup>	Absence of <i>Pseudomonas aeruginosa</i> (1 g or 1 mL) Absence of <i>Staphylococcus aureus</i> (1 g or 1 mL) Absence of <i>Candida albicans</i> (1 g or 1 mL)

Transdermal patches (limits for one patch including adhesive layer and backing)	10 <sup>2</sup>	10 <sup>1</sup>	Absence of <i>Staphylococcus aureus</i> (1 patch) Absence of <i>Pseudomonas aeruginosa</i> (1 patch)
Inhalation use (more rigorous requirements apply to liquid preparations for nebulization)	10 <sup>2</sup>	10 <sup>1</sup>	Absence of <i>Staphylococcus aureus</i> (1 g or 1 mL) Absence of <i>Pseudomonas aeruginosa</i> (1 g or 1 mL) Absence of bile-tolerant gram-negative bacteria (1g or 1 mL)

prescribed, a validated method with a limit of detection as close as possible to the indicated acceptance criterion is used.

In addition to the micro-organisms listed in Table 2, the significance of other micro-organisms recovered should be evaluated in terms of:

- the use of the product: hazard varies according to the route of administration (eye, nose, respiratory tract);
- the nature of the product: does the product support growth, does it have adequate antimicrobial preservation?
- the method of application;
- the intended recipient: risk may differ for neonates, infants, the debilitated;
- use of immunosuppressive agents, corticosteroids;
- presence of disease, wounds, organ damage.

Where warranted, a risk-based assessment of the relevant factors is conducted by personnel with specialized training in microbiology and the interpretation of microbiological data.

For raw materials, the assessment takes account of processing to which the product is subjected, the current technology of testing and the availability of materials of the desired quality. Acceptance criteria are based on individual results or on the average of replicate counts when replicate counts are performed (e.g. direct plating methods).

When an acceptance criterion for microbiological quality is prescribed it is interpreted as follows:

- 10<sup>1</sup> CFU: maximum acceptable count = 20,
- 10<sup>2</sup> CFU: maximum acceptable count = 200,
- 10<sup>3</sup> CFU: maximum acceptable count = 2000, and so forth.

#### ◆6. Acceptance criteria for herbal drugs

Target limits of microbial contamination for herbal drugs and herbal drug containing preparations are shown in Table 3. Category 1 indicates herbal drugs and their preparations to which boiling water is added before use, and category 2 indicates other herbal drugs and their preparations. In this guideline, enterobacteria and other gram-negative bacteria, *Escherichia coli*, *Salmonella*, and *Staphylococcus aureus* are mentioned as specified micro-organisms, but other micro-organisms such as certain species of *Bacillus cereus*, Clostridia, *Pseudomonas*, *Burkholderia*, *Asperigillus* and *Enterobacter* species are also necessary to be tested depending on the origin of the herbal drug raw materials or the prepara-

tion method of the preparations.◆

◆Table 3. Acceptance criteria for herbal drugs and their preparations

Micro-organisms	Category 1 (CFU/g or CFU/mL)	Category 2 (CFU/g or CFU/mL)
Aerobic bacteria	10 <sup>7</sup>	10 <sup>5</sup>
Molds and yeasts	10 <sup>4</sup>	10 <sup>3</sup>
Enterobacteria and other gram-negative bacteria	※	10 <sup>3</sup>
<i>Escherichia coli</i>	10 <sup>2</sup>	Not detected
<i>Salmonella</i>	Not detected	Not detected
<i>Staphylococcus aureus</i>	※	※

※ : The limits are not specified.◆

## 21. Quality Control of Water for Pharmaceutical Use

### Change the 3.4.1 Media and Incubation Conditions to read:

#### 3.4.1 Media and Incubation Conditions

There are many mesophilic bacteria of heterotrophic type that are adaptable to poor nutrient water environments. In many pharmaceutical water systems, heterotrophic bacteria may form bio-films and cause water quality deterioration. It, therefore, is useful to monitor the water quality by use of R2A Agar Medium, which is excellent for growing bacteria of oligotrophic type. On the other hand, in routine microbial monitoring, an approach that identifies the trend in microbiological quality change is widely employed; a standard agar plate is used for counting the total number of viable microorganisms capable of proliferating at 30–35°C in a comparatively short period of time.

Table 2 shows examples of measurement methods, minimum sample sizes, media, and incubation periods for estimating viable counts.

The media shown in Table 2 are as follows.

**Table 2.** Methods for Assessment of Viable Counts in Pharmaceutical Water

Method	Pharmaceutical Water		
	Water	Purified Water in Bulk	Water for Injection in Bulk
Measurement Method	Pour Plate Method or Membrane Filtration	Pour Plate Method or Membrane Filtration	Membrane Filtration
Minimum Sample Size	1.0 mL	1.0 mL	100 mL
Media	Standard Agar Medium	R2A Agar Medium, Standard Agar Medium	R2A Agar Medium, Standard Agar Medium
Incubation Period	Standard Agar Medium: 48 – 72 hours (or longer)	R2A Agar Medium: 4 – 7 days (or longer) Standard Agar Medium: 48 – 72 hours (or longer)	R2A Agar Medium: 4 – 7 days (or longer) Standard Agar Medium: 48 – 72 hours (or longer)
Incubation Temperature	Standard Agar Medium: 30 – 35°C	R2A Agar Medium: 20 – 25°C or 30 – 35°C Standard Agar Medium: 30 – 35°C	R2A Agar Medium: 20 – 25°C or 30 – 35°C Standard Agar Medium: 30 – 35°C

**Standard Agar Medium**

Casein peptone	5.0 g
Yeast extract	2.5 g
Glucose	1.0 g
Agar	15.0 g
Water	1000 mL

Mix all the ingredients, and sterilize by heating in an autoclave at 121°C for 15 to 20 minutes. pH after sterilization: 6.9–7.1.

**R2A Agar Medium**

Peptone (casein and animal tissue)	0.5 g
Casamino acid	0.5 g
Yeast extract	0.5 g
Sodium pyruvate	0.3 g
Glucose	0.5 g
Magnesium sulfate heptahydrate	0.05 g
Soluble starch	0.5 g
Dipotassium hydrogen phosphate	0.3 g
Agar	15 g
Water	1000 mL

Mix all the ingredients, and sterilize by heating in an autoclave at 121°C for 15 to 20 minutes. pH after sterilization: 7.1 – 7.3.

For the ingredients, which are not specified in the Japanese Pharmacopoeia, use the following reagents.

**Casamino acid** Prepared for microbial test, by the acid hydrolysis of casein.

*Loss on drying* <2.41>: Not more than 8% (0.5 g, 105°C, constant mass).

*Residue on ignition* <2.44>: Not more than 55% (0.5 g).

*Nitrogen content* <1.08>: Not less than 7% (105°C, constant mass, after drying).

**Sodium pyruvate**  $\text{CH}_3\text{COCOONa}$  White to pale yellow crystalline powder. Freely soluble in water, and slightly soluble in ethanol (99.5) and in acetone.

*Identification* (1) Determine the infrared absorption spectrum as directed in the potassium bromide disk method under Infrared Spectrophotometry <2.25>: it exhibits absorption at the wave numbers of about 1710  $\text{cm}^{-1}$ , 1630  $\text{cm}^{-1}$ , 1410  $\text{cm}^{-1}$ , 1360  $\text{cm}^{-1}$ , 1190  $\text{cm}^{-1}$ , 1020  $\text{cm}^{-1}$ , 980  $\text{cm}^{-1}$ , 830  $\text{cm}^{-1}$ , 750  $\text{cm}^{-1}$ , 630  $\text{cm}^{-1}$  and 430  $\text{cm}^{-1}$ .

(2) A solution (1 in 20) responds to the Qualitative Tests <1.09> (1) for sodium salt.

*Content*: not less than 97.0%. Assay—Dissolve about 0.4 g of sodium pyruvate, accurately weighed, in 200 mL of water. Transfer 20 mL of this solution into a ground joint iodine bottle, and cool to 10°C or lower. Add 40 mL of 0.05 mol/L iodine VS and 20 mL of 4 mol/L sodium hydroxide solution, then allow to stand in a dark place for 2 hours, and add 15 mL of diluted sulfuric acid (1 in 6). Titrate <2.50> with 0.1 mol/L sodium thiosulfate VS (indicator: starch TS). Perform a blank determination in the same manner, and make any necessary correction.

$$\begin{aligned} &\text{Each mL of 0.05 mol/L iodine VS} \\ &= 1.854 \text{ mg of } \text{C}_3\text{H}_3\text{NaO}_3 \end{aligned}$$

**Add the following:****31. Purity Tests on Crude Drugs Using Genetic Information**

The first step in the quality assurance of natural products is the use of raw materials from the right part of the right

origin (the right source). Therefore, it is clearly stated in Article 4 of the General Rules For Crude Drugs that the source of a crude drug is the approval or rejection criteria. There are various methods for differentiating the sources of crude drugs, such as morphological methods, organoleptic tests, and chemical methods, and appropriate methods for each are described in the individual monographs. Morphological methods, organoleptic tests, and chemical methods are discrimination methods for species that are based on the expression characteristics of the crude drugs. On the other hand, together with recent progress in molecular biology techniques and the accumulation of genetic information on plants, methods for differentiating species have been established by confirming the genotype of a crude drug. Methods such as these are different from morphological and other methods that differentiate based on phenotype in that they are not affected by the environment. Also, the methods have several advantages, such as specialized expertise and skill for classification are not needed, and objective results are easily obtained.

The evolution of living organisms is accomplished by genetic mutation, and differences among the base sequences of genes of closely related species reflect the strain relationships between the species. Based on this theory, in recent years methods that classify species phylogenetically using the base sequence of rDNA that codes for ribosomal RNA (rRNA) on the nuclear genome have been adopted. In the same way, the base sequence of this rDNA is also the most often used in the classification of higher plants using the genotype. In particular, it has become very easy to classify closely related species using the intergenic transcriber space (ITS) region of the rDNA region, since by comparison with the coded gene region base substitution is easily undertaken. Furthermore, since the genes on the nuclear genome originate from the parents, an advantage is interspecies hybrids can be confirmed. Higher plants also have mitochondrial genes and chloroplastic genes. Although the genes on these genomes are also often used for classification, interspecies hybrids cannot be confirmed because the genes are normally monogenic.

The methods presented here have been developed based on the reported identification methods of *Atractylodes Lancea* Rhizome and *Atractylodes Rhizome* (Y. Guo, *et al*, *J. Nat. Med.* 60, 149–156, 2006) utilizing the gene sequence of the ITS of rDNA. Cooperative studies on the validation of purity tests related to *Atractylodes Lancea* Rhizome in *Atractylodes Rhizome*, have been completed. The plant sources for *Atractylodes Lancea* Rhizome stipulated in the individual monographs are *Atractylodes lancea* De Candolle or *A. chinensis* Koidzumi (*Compositae*), while those for *Atractylodes Rhizome* are *A. japonica* Koidzumi ex Kitamura or *A. ovata* De Candolle (*Compositae*). The approval or rejection of the source of *Atractylodes Lancea* Rhizome is, in principle, determined by the description of the crude drug, including microscopy, while that of *Atractylodes Rhizome* is determined by the description of the crude drug, including microscopy, together with color reaction, which is an identification test. In the manuscript, it was

shown that these 4 types of plants can be clearly classified by comparing the base sequences of the ITS mentioned above, and that the species can be easily classified without performing base sequence analysis by performing PCR using a species specific primer set and determining the presence or absence of an amplification band.

In cooperative studies, the degree of simplicity of a study is given maximum consideration. We examined methods that observe PCR amplification bands using species specific primer sets and do not involve base sequence analyses. Test methods based on PCR which uses species specific primer sets are analytical methods with very high degrees of sensitivity. Therefore, when using them as identification tests for powdered crude drugs, amplification bands can be observed even if the vast majority of the crude drug for analysis is not suitable and there is only a minute amount of powder from a crude drug derived from a suitable plant. Consequently, in identification tests, either a cut or a whole crude drug must be used, as long as one is careful to avoid contamination by powder originating from other crude drugs. On the other hand, when used as a purity test, the form of the crude drug is irrelevant as long as the gene amplification is performed properly and the target gene is not polymorphic, so if amplification bands of an inappropriate plant are confirmed in the purity test, regardless of the form of the crude drug, it becomes clear there is contamination by an inappropriate crude drug.

The methods shown here are reference information and at the present stage results obtained using the methods do not affect the approval or rejection of the crude drug in each monograph. Furthermore, by performing the sequence outlined in the previous paper, it goes without saying that a more accurate decision concerning the source species can be made.

#### DNA Amplification Equipment

DNA amplification equipment is used to amplify the DNA which is extracted from a crude drug and then purified. Since there are slight differences in the methods of temperature control, and so on depending on the equipment used, there may be differences in the intensity, etc. of the PCR amplification bands even if PCR is carried out under the stipulated conditions. Therefore, when judging results based solely on the presence or absence of PCR amplification bands, confirm that only proper amplification bands are obtained when performing PCR using DNA obtained using samples confirmed beforehand to be the source species. If proper amplification bands are not obtained, the PCR temperature conditions should be slightly adjusted.

#### Procedure

The following is a sample procedure.

##### 1. Preparation of template DNA

Crude drugs are different from fresh plants in that they are dried products and a certain amount of time has passed since they were harvested. Therefore, in many cases the DNA has undergone fragmentation. Furthermore, various substances that can block or interfere with the PCR reaction may be present in the plant. For these reasons, the extraction



and purification of template DNA is the process that should receive the greatest amount of attention. In the case of *Atractylodes* crude drugs, the periderm should be removed using a clean scalpel or other clean instrument before pulverizing the sample because very often there are inhibitory substances present in the periderm.

There are various methods with which to extract and purify DNA from the samples. It is recommended that commercially available DNA extraction kits be used if one takes into consideration their advantages of not using any noxious reagents and not requiring any complicated purification procedures. In this case, attention should be paid to the final amount (concentration) of DNA obtained, and the amount of initial sample and the volume of liquid to elute the DNA need to be controlled. When extraction and purification are performed using silica gel membrane type kits stipulated in notifications (Notification No. 110, Director of Food Health Department, March 2001; Partial Amendment: Notification No. 0629002, 2.2.1.2, Director of Food Safety Department, June 2006) related to inspection methods for recombinant DNA foods, it is appropriate to use 200 mg of sample, 1 mL of AP1 buffer solution, 2  $\mu$ L of RNase A, and 325  $\mu$ L of AP2 buffer solution. Also, the most important things are that the supernatant loaded on the first column is clear and that there is no need to load 1 mL unreasonably. Furthermore, 50  $\mu$ L is an appropriate volume used in the final elution of the DNA, and normally the initial eluate is used as the DNA sample stock solution.

## 2. Confirmation of purity of DNA in DNA sample stock solution and assay of DNA

The purity of the DNA in the stock solution can be confirmed by the  $OD_{260\text{ nm}}/OD_{280\text{ nm}}$  ratio using a spectrophotometer. A ratio of 1.5 indicates that the DNA has been adequately purified. The amount of DNA is calculated using  $1\text{ }OD_{260\text{ nm}} = 50\text{ }\mu\text{g/mL}$ . The measurement mentioned above is performed using appropriately diluted DNA sample stock solution. Based on the results obtained, dilute with water to the concentration needed for the subsequent PCR reactions, use this solution as the DNA sample solution, pipet into micro test tubes, and if necessary store frozen at not over  $-20^{\circ}\text{C}$ . The pipeted DNA sample is used immediately after thawing and any remaining solution should be discarded and not refrozen. If the concentration of the DNA sample stock solution does not reach the concentration stipulated in PCR, it is used as a DNA sample solution.

## 3. PCR

When a commercially available enzyme is used with the qualitative PCR method mentioned in the above notification (Notification No. 0629002, 2.1.3.1.1, Director of Food Safety Department), to a solution consisting of 2.5  $\mu$ L of the PCR buffer solution containing magnesium that comes with the enzyme, dNTP (0.2 mmol/L) that also comes with the enzyme, 5' and 3' primer (0.4  $\mu$ mol/L), and Taq DNA polymerase (1.25 units), add 5  $\mu$ L of 10 ng/ $\mu$ L DNA sample solution (50 ng of DNA) on ice. It is appropriate to perform the reaction at a total volume of 25  $\mu$ L. When conducting purity tests on *Atractylodes Lancea* Rhizome in *Atractylodes* Rhizome, the primer sets used are C and D (C is posi-

tive with *A. lancea*, D is positive with *A. chinensis*) as described in the paper mentioned above (*J. Nat. Med.* 60, 149–156, 2006), however, when a combination of primer A and B is used, it is possible to confirm the source species of each of the respective specimens. In order to confirm that the DNA has been extracted correctly, the reaction solution containing the positive control primer (Pf and Pr) as shown below should be prepared. In addition, the negative control solutions which are not containing DNA sample or either of the primer sets should be prepared and simultaneously conduct PCR.

Pf: 5'-CAT TGT CGA AGC CTG CAC AGC A-3'

Pr: 5'-CGA TGC GTG AGC CGA GAT ATC C-3'

The PCR reaction is performed under the following conditions. After starting the reaction at  $95^{\circ}\text{C}$  for 10 minutes, followed by one cycle of 0.5 minutes at  $95^{\circ}\text{C}$  and 0.75 minutes at  $68^{\circ}\text{C}$  ( $69^{\circ}\text{C}$  only when using the primer set C), and 30 cycles of PCR amplification. Then terminate reaction at  $72^{\circ}\text{C}$  for 7 minutes, store at  $4^{\circ}\text{C}$ , and use the reaction solution obtained as the PCR amplification reaction solution.

## 4. Gel electrophoresis

After completion of the reaction, mix 5  $\mu$ L of the PCR amplification reaction solution with an appropriate volume of gel loading buffer solution, add the mixture to the wells of 2% agarose gel, and then perform electrophoresis using 1-fold TAE buffer solution (refer to General Information, Rapid Identification of Microorganisms Based on Molecular Biological Method). Run in parallel an appropriate DNA molecular mass standard. Electrophoresis is terminated when the bromophenol blue dye in the gel loading buffer has advanced to a point corresponding to 1/2 to 2/3 the length of the gel.

## 5. Detection and evaluation of PCR products

Counterstain the gel after electrophoresis when not using gel stained in advance with ethidium bromide. Place the gel that has undergone electrophoresis and staining in a gel image analyzer, irradiate with ultraviolet light (312 nm), and determine its electrophoresis pattern. Compare this to the DNA molecular mass standard and determine the absence or presence of the target amplification band. In the case of purity tests on *Atractylodes Lancea* Rhizome in *Atractylodes* Rhizome, first confirm a 305 bp band with the reaction solution to which the positive control primer set has been added, and confirm there are no bands in a solution with no primer sets and a solution with no DNA sample solution. Next, if a 226 bp band is confirmed when the primer set C is added or if a 200 bp band is confirmed when the primer set D is added, the sample is judged to be *Atractylodes Lancea* Rhizome (in the case of cut crude drug, contamination of *Atractylodes Lancea* Rhizome is observed) and it is rejected. The sample is judged not to be *Atractylodes Lancea* Rhizome (in the case of cut crude drug, there is no contamination of *Atractylodes Lancea* Rhizome) and the purity test is acceptable if a 305 bp band is confirmed with the positive control primer set, bands are not observed in reaction solution without primer and reaction solution

without DNA sample solution, and a 226 bp band is not observed with the primer set C and a 200 bp band is not observed with the primer set D. If a band is not observed with the positive control primer, it is to be concluded that the DNA extraction failed and the procedure should be started over again from the DNA extraction step. If bands are confirmed in reaction solutions without primer sets or without DNA sample solution, it should be assumed that there was an error in the PCR procedure and therefore the procedure should be repeated again from the step 3. PCR.

# INDEX

Page citations refer to the pages of the Supplement I, and to pages of the JP XV main volume, including those where the text being revised in the Supplement originally appeared. This Supplement I commences with page 1789 and succeeding Supplements will continue to be paged in sequence.

1 – 1788 Main Volume of JP XV  
1789 – 2040 Supplement I

## A

- Absorptive Ointment, 265  
Acacia, 1251  
    Powdered, 1251  
Acebutolol Hydrochloride, 265  
Aceglutamide Aluminum, 266  
Acemetacin, 1825  
Acetaminophen, 267  
Acetazolamide, 268  
Acetic Acid, 268  
    Glacial, 269  
Acetohexamide, 269  
Acetylcholine Chloride for Injection, 271, 1825  
Acetylsalicylic Acid, 318  
    Tablets, 319  
Achyranthes Root, 1252  
Aclarubicin Hydrochloride, 272  
Acrinol  
    and Zinc Oxide Oil, 273  
    and Zinc Oxide Ointment, 274  
    Hydrate, 274  
Actinomycin D, 275  
Adrenaline, 276  
    Injection, 276  
    Solution, 277  
Adsorbed  
    Diphtheria-Purified Pertussis-Tetanus Combined Vaccine, 596  
    Diphtheria-Tetanus Combined Toxoid, 596  
    Diphtheria Toxoid for Adult Use, 596  
    Habu-venom Toxoid, 716  
    Hepatitis B Vaccine, 716  
    Purified Pertussis Vaccine, 980  
    Tetanus Toxoid, 1156  
Afloqualone, 277  
Agar, 1252  
    Powdered, 1253  
Ajmaline, 278  
    Tablets, 279, 1826  
Akebia Stem, 1253  
Alacepril, 279  
    Tablets, 280  
Albumin Tannate, 282  
Alcohol, 638  
    Dehydrated, 639  
    for Disinfection, 640  
Aldioxa, 282  
Alimemazine Tartrate, 283  
Alisma Rhizome, 1253  
    Powdered, 1253  
Allopurinol, 284  
Alminoprofen, 1826  
    Tablets, 1827  
Aloe, 1254  
    Powdered, 1255  
Alpinia Officinarum Rhizome, 1256, 1937  
Alprazolam, 284  
Alprenolol Hydrochloride, 285  
Alprostadil, 286  
    Alfadex, 287  
    Injection, 1828  
Alum, 292  
    Solution, 293  
Aluminum  
    Acetylsalicylate, 319  
    Hydroxide Gel, Dried, 288  
    Hydroxide Gel Fine Granules, Dried, 289  
    Monostearate, 291  
    Potassium Sulfate, Dried, 292  
    Potassium Sulfate Hydrate, 292  
    Silicate, Natural, 289  
    Silicate, Synthetic, 290  
    Sucrose Sulfate Ester, 1118  
Amantadine Hydrochloride, 293  
Ambenonium Chloride, 294  
Amidotrizoic Acid, 295  
Amikacin Sulfate, 296  
    Injection, 1830  
Aminoacetic Acid, 704  
Aminobenzylpenicillin, 307  
    Anhydrous, 306  
    Hydrate, 307  
    Sodium, 308  
Aminophylline  
    Hydrate, 297  
    Injection, 297, 1831  
Amitriptyline Hydrochloride, 298  
    Tablets, 299, 1831  
Amlexanox, 1831  
    Tablets, 1833  
Amlodipine Besilate, 1834  
Ammonia Water, 299  
Amobarbital, 300  
    Sodium for Injection, 300  
Amomum Seed, 1256  
    Powdered, 1256  
Amorphous Insulin Zinc Injection (Aqueous Suspension), 764  
Amosulalol Hydrochloride, 1835  
    Tablets, 1836  
Amoxapine, 301  
Amoxicillin Hydrate, 302  
Amphotericin B, 303  
    for Injection, 304  
    Syrup, 305  
    Tablets, 305  
Ampicillin  
    Anhydrous, 306  
    Ethoxycarbonyloxyethyl Hydrochloride, 329  
    Hydrate, 307  
    Sodium, 308  
    Sodium for Injection, 1838  
Ampicillinphthalidyl Hydrochloride, 1138  
Amyl Nitrite, 309  
Anemarrhena Rhizome, 1256, 1937  
Anesthamine, 644  
Anesthetic Ether, 641  
Angelica Dahurica Root, 1257, 1937  
Anhydrous  
    Aminobenzylpenicillin, 306

Ampicillin, 306  
 Caffeine, 386  
 Citric Acid, 514  
 Dibasic Calcium Phosphate, 396, 1874  
 Ethanol, 639  
 Lactose, 802, 1900  
 Antipyrine, 310  
 Apricot Kernel, 1257, 1937  
 Water, 1257  
 Aralia Rhizome, 1937  
 Arbekacin Sulfate, 311  
 Injection, 312  
 Areca, 1258  
 L-Arginine, 313  
 Hydrochloride, 313  
 Hydrochloride Injection, 314, 1839  
 Aromatic Castor Oil, 415  
 Arotinolol Hydrochloride, 314  
 Arsenical Paste, 315  
 Arsenic Trioxide, 316  
 Arsenous Acid, 316  
 Artemisia Capillaris Flower, 1258  
 Ascorbic Acid, 316  
 Injection, 317, 1839  
 Powder, 317  
 Asiasarum Root, 1259, 1938  
 Asparagus Tuber, 1259, 1938  
 L-Aspartic Acid, 318  
 Aspirin, 318  
 Aluminum, 319  
 Tablets, 319  
 Aspoxicillin Hydrate, 320  
 Astragalus Root, 1260  
 Astromicin Sulfate, 322  
 Atenolol, 323  
 Atractylodes  
 Lancea Rhizome, 1260  
 Lancea Rhizome, Powdered, 1260  
 Rhizome, 1261, 1938  
 Rhizome, Powdered, 1261, 1939  
 Atropine Sulfate  
 Hydrate, 324  
 Injection, 324  
 Azathioprine, 325  
 Tablets, 326  
 Azelastine Hydrochloride, 1839  
 Azithromycin Hydrate, 327  
 Aztreonam, 328  
 for Injection, 1840

**B**

Bacampicillin Hydrochloride, 329  
 Bacitracin, 330  
 Baclofen, 331  
 Tablets, 332, 1841  
 Bamethan Sulfate, 333  
 Barbitol, 333  
 Barium Sulfate, 334  
 Bear Bile, 1262  
 Bearberry Leaf, 1262  
 Beclometasone Dipropionate, 335

Beef Tallow, 336  
 Beeswax  
 White, 336  
 Yellow, 336  
 Bekanamycin Sulfate, 337  
 Belladonna  
 Extract, 1263, 1939  
 Root, 1263  
 Benidipine Hydrochloride, 338  
 Tablets, 339  
 Benincasa Seed, 1264  
 Benoxinate Hydrochloride, 951  
 Benserazide Hydrochloride, 340  
 Bentonite, 341  
 Benzalkonium Chloride, 342  
 Concentrated Solution 50, 343  
 Solution, 342  
 Benzbromarone, 343  
 Benzethonium Chloride, 344  
 Solution, 345  
 Benzocaine, 644  
 Benzoic Acid, 345  
 Benzoin, 1265  
 Benzyl  
 Alcohol, 346  
 Benzoate, 347  
 Benzylpenicillin  
 Benzathine Hydrate, 348  
 Potassium, 349  
 Potassium for Injection, 1841  
 Berberine  
 Chloride Hydrate, 351  
 Tannate, 352  
 Betahistine Mesilate, 353, 1842  
 Tablets, 354  
 Betamethasone, 355  
 Dipropionate, 358  
 Sodium Phosphate, 359  
 Tablets, 356  
 Valerate, 360  
 Valerate and Gentamicin Sulfate  
 Cream, 361  
 Valerate and Gentamicin Sulfate  
 Ointment, 362  
 Bethanechol Chloride, 363  
 Bezafibrate, 364  
 Sustained Release Tablets, 365  
 Bifonazole, 366  
 Biotin, 1842  
 Biperiden Hydrochloride, 366  
 Bisacodyl, 367  
 Suppositories, 368, 1843  
 Bismuth  
 Subgallate, 368  
 Subnitrate, 369  
 Bisoprolol Fumarate, 1843  
 Tablets, 1844  
 Bitter  
 Cardamon, 1265  
 Orange Peel, 1265  
 Tincture, 1266  
 Bleomycin  
 Hydrochloride, 370

Sulfate, 372  
 Boric Acid, 374  
 Bromazepam, 374  
 Bromhexine Hydrochloride, 375  
 Bromocriptine Mesilate, 376  
 Bromovalerylurea, 377  
 Bucillamine, 377  
 Tablets, 1845  
 Bucumolol Hydrochloride, 378  
 Bufetolol Hydrochloride, 379  
 Bufexamac, 380  
 Cream, 380  
 Ointment, 381  
 Buformin Hydrochloride, 1846  
 Enteric-coated Tablets, 1847  
 Tablets, 1849  
 Bumetanide, 382  
 Bunazosin Hydrochloride, 383  
 Bupleurum Root, 1266  
 Bupranolol Hydrochloride, 383  
 Buprenorphine Hydrochloride, 1850  
 Burdock Fruit, 1267  
 Burnt Alum, 292  
 Busulfan, 384  
 Butropium Bromide, 385  
 Butyl Parahydroxybenzoate, 386

**C**

Cacao Butter, 386  
 Caffeine  
 and Sodium Benzoate, 388  
 Anhydrous, 386  
 Hydrate, 387  
 Calciferol, 624  
 Calcium  
 Carbonate, Precipitated, 389  
 Chloride Hydrate, 390  
 Chloride Injection, 390, 1851  
 Folate, 391, 1851  
 Gluconate Hydrate, 391  
 Hydroxide, 392  
 Lactate Hydrate, 393  
 Leucovorin, 391  
 Oxide, 393  
 Pantothenate, 394  
 Paraaminosalicylate Granules, 394  
 Paraaminosalicylate Hydrate, 395  
 Polystyrene Sulfonate, 398  
 Stearate, 400  
 Calumba, 1267, 1939  
 Powdered, 1268, 1939  
 Camellia Oil, 400  
 Camostat Mesilate, 400, 1852  
*d*-Camphor, 401  
*dl*-Camphor, 402  
 Capsicum, 1268  
 and Salicylic Acid Spirit, 1270  
 Powdered, 1269  
 Tincture, 1269  
 Capsules, 403  
**Capsules**  
 Cefaclor, 416

- Cefadroxil, 1852  
 Cefdinir, 435  
 Clindamycin Hydrochloride, 520  
 Clofibrate, 526  
 Clorazepate Dipotassium, 1869  
 Doxifluridine, 604  
 Flopropione, 667  
 Flurazepam, 678  
 Indometacin, 756, 1893  
 Nizatidine, 1913  
 Rifampicin, 1065  
 Roxatidine Acetate Hydrochloride  
   Extended-release, 1071  
 Sodium Iodide (<sup>123</sup>I), 1103  
 Sodium Iodide (<sup>131</sup>I), 1103  
 Sulfpiride, 1132  
 Tranexamic Acid, 1192  
 Vitamin A, 1230  
 Vitamin A Oil, 1230  
 Captopril, 403  
 Carbamazepine, 404  
 Carbazochrome Sodium Sulfonate  
   Hydrate, 405  
 Carbetapentane Citrate, 974  
 Carbetapentene Citrate, 974  
 Carbidopa Hydrate, 406  
 L-Carbocysteine, 407  
 Carboic Acid, 985  
   for Disinfection, 986  
   Liquefied, 986  
 Carbon Dioxide, 407  
 Carboxymethylcellulose, 408  
   Calcium, 409  
   Sodium, 410  
 Cardamon, 1271  
 Carmellose, 408  
   Calcium, 409  
   Sodium, 410  
 Carmofur, 411  
 Carnauba Wax, 411  
 Carteolol Hydrochloride, 412  
 Carumonam Sodium, 412  
 Cassia Seed, 1271  
 Castor Oil, 414  
   Aromatic, 415  
 Catalpa Fruit, 1271  
 Cefaclor, 415  
   Capsules, 416  
   Compound Granules, 419  
   Fine Granules, 417  
 Cefadroxil, 421  
   Capsules, 1852  
   for Syrup, 1853  
 Cefalexin, 422  
 Cefalotin Sodium, 423, 1854  
 Cefapirin Sodium, 424  
 Cefatrizine Propylene Glycolate, 425,  
   1854  
 Cefazolin Sodium, 426  
   for Injection, 1854  
   Hydrate, 428  
 Cefbuperazone Sodium, 429  
 Cefcapene Pivoxil Hydrochloride  
   Fine Granules, 432  
   Hydrate, 430  
   Tablets, 433  
 Cefdinir, 434  
   Capsules, 435  
   Fine Granules, 436  
 Cefditoren Pivoxil, 437  
   Fine Granules, 438  
   Tablets, 438  
 Cefepime Dihydrochloride  
   for Injection, 441  
   Hydrate, 439  
 Cefixime, 442  
 Cefmenoxime Hydrochloride, 443  
 Cefmetazole Sodium, 445  
   for Injection, 1855  
 Cefminox Sodium Hydrate, 446  
 Cefodizime Sodium, 447  
 Cefoperazone Sodium, 448  
 Cefotaxime Sodium, 449  
 Cefotetan, 451  
 Cefotiam  
   Hexetil Hydrochloride, 453  
   Hydrochloride, 455  
   Hydrochloride for Injection, 456  
 Cefozopran Hydrochloride, 457  
   for Injection, 458  
 Cefpiramide Sodium, 458  
 Cefpirome Sulfate, 460  
 Cefpodoxime Proxetil, 461  
 Cefroxadine Hydrate, 462  
 Cefsulodin Sodium, 464  
 Ceftazidime  
   for Injection, 1856  
   Hydrate, 466  
 Cefteram Pivoxil, 468  
   Fine Granules, 469  
 Ceftibuten Hydrate, 470  
 Ceftizoxime Sodium, 471  
 Ceftriaxone Sodium Hydrate, 472  
 Cefuroxime  
   Axetil, 474  
   Sodium, 476  
 Cellacelate, 480  
 Cellulose  
   Microcrystalline, 477  
   Powdered, 480  
 Celmoleukin (Genetical Recombina-  
   tion), 481  
 Cetanol, 484  
 Cetirizine Hydrochloride, 1856  
   Tablets, 1857  
 Cetraxate Hydrochloride, 485  
 Chenodeoxycholic Acid, 486  
 Chloral Hydrate, 487  
 Chloramphenicol, 487  
   Palmitate, 488  
   Sodium Succinate, 489  
 Chlordiazepoxide, 490  
   Powder, 491  
   Tablets, 492, 1858  
 Chlorhexidine  
   Gluconate Solution, 493  
   Hydrochloride, 493  
 Chlorinated Lime, 494  
 Chlormadinone Acetate, 494  
 Chlorobutanol, 495  
 Chlorphenesin Carbamate, 496, 1858  
   Tablets, 1859  
 Chlorpheniramine  
   and Calcium Powder, 497  
   Maleate, 498  
   Maleate Injection, 499  
   Maleate Powder, 499  
   Maleate Tablets, 500  
*d*-Chlorpheniramine Maleate, 501  
 Chlorpromazine Hydrochloride, 502  
   Injection, 503, 1860  
   Tablets, 503, 1861  
 Chlorpropamide, 504  
   Tablets, 505, 1861  
 Cholecalciferol, 506  
 Cholera Vaccine, 506  
 Cholesterol, 507  
 Chorionic Gonadotrophin, 707  
   for Injection, 708  
 Chrysanthemum Flower, 1271  
 Cibenzoline Succinate, 1861  
   Tablets, 1862  
 Ciclacillin, 507  
 Ciclosporin, 509  
   A, 509  
 Cilastatin Sodium, 509  
 Cilazapril  
   Hydrate, 1863  
   Tablets, 1864  
 Cilostazol, 511  
   Tablets, 512, 1866  
 Cimetidine, 513  
 Cimicifuga Rhizome, 1272, 1939  
 Cinchocaine Hydrochloride, 569  
 Cinnamon  
   Bark, 1272  
   Bark, Powdered, 1273  
   Oil, 1273  
 Cisplatin, 513  
 Citric Acid  
   Anhydrous, 514  
   Hydrate, 515  
 Citrus Unshiu Peel, 1273  
 Clarithromycin, 516  
   Tablets, 517  
 Clemastine Fumarate, 519  
 Clematis Root, 1274, 1939  
 Clindamycin Hydrochloride, 519  
   Capsules, 520  
 Clindamycin Phosphate, 521  
   Injection, 1866  
 Clinofibrate, 522  
 Clobetasol Propionate, 1867  
 Clozapamine Hydrochloride Hydrate,  
   523  
 Clofedanol Hydrochloride, 524  
 Clofibrate, 525  
   Capsules, 526  
 Clomifene Citrate, 526

- Tablets, 527  
 Clomipramine Hydrochloride, 528  
 Clonazepam, 528  
 Clonidine Hydrochloride, 529  
 Cloperastine Hydrochloride, 530  
 Clorazepate Dipotassium, 1868  
 Capsules, 1869  
 Clotiazepam, 531  
 Clotrimazole, 532  
 Clove, 1274  
 Oil, 1275  
 Powdered, 1274  
 Cloxacillin Sodium Hydrate, 533  
 Cloxazolam, 534  
 CMC, 408  
 Calcium, 409  
 Sodium, 410  
 Cnidium  
 Monnieri Fruit, 1275  
 Rhizome, 1275, 1939  
 Rhizome, Powdered, 1276, 1940  
 Cocaine Hydrochloride, 535  
 Coconut Oil, 535  
 Codeine Phosphate  
 Hydrate, 536  
 Powder, 1%, 536  
 Powder, 10%, 537  
 Tablets, 537  
 Cod Liver Oil, 538  
 Coix Seed, 1276  
 Powdered, 1276  
 Colchicine, 538  
 Colistin  
 Sodium Methanesulfonate, 540  
 Sulfate, 541  
 Colophonium, 1347  
 Compound  
 Acrinol and Zinc Oxide Oil, 273  
 Diastase and Sodium Bicarbonate  
 Powder, 567  
 Hycodone Injection, 952  
 Iodine Glycerin, 770  
 Methyl Salicylate Spirit, 879  
 Oxycodone and Atropine Injection,  
 953  
 Oxycodone Injection, 952  
 Phellodendron Powder for  
 Cataplasm, 1332  
 Rhubarb and Senna Powder, 1346  
 Salicylic Acid Spirit, 1080  
 Scopolia Extract and Diastase Pow-  
 der, 1355  
 Thianthol and Salicylic Acid Solu-  
 tion, 1165  
 Vitamin B Powder, 1230  
 Concentrated  
 Glycerin, 703  
 Glycerol, 703  
 Condurango, 1276  
 Fluidextract, 1277, 1940  
 Coptis Rhizome, 1277, 1940  
 Powdered, 1278, 1940  
 Corn  
 Oil, 542  
 Starch, 542  
 Cornus Fruit, 1279  
 Cortisone Acetate, 543  
 Corydalis Tuber, 1279, 1940  
 Powdered, 1940  
 Crataegus Fruit, 1941  
 Creosote, 544, 1870  
 Cresol, 544  
 Solution, Saponated, 545  
 Croconazole Hydrochloride, 546  
 Croscarmellose Sodium, 546  
 Crude Glycyrrhiza Extract, 1297,  
 1943  
 Crystalline Insulin Zinc Injection  
 (Aqueous Suspension), 765  
 Crystal Violet, 881  
 Cyanamide, 548  
 Cyanocobalamin, 548, 1870  
 Injection, 549, 1871  
 Cyclopentolate Hydrochloride, 549  
 Cyclophosphamide Hydrate, 550  
 Cycloserine, 551  
 Cyperus Rhizome, 1280, 1942  
 Powdered, 1280, 1942  
 Cyproheptadine Hydrochloride Hy-  
 drate, 551  
 L-Cysteine, 1871  
 Hydrochloride Hydrate, 1872  
 Cytarabine, 552
- D**
- Daiokanzoto Extract, 1280  
 Dantrolene Sodium Hydrate, 553  
 Daunorubicin Hydrochloride, 553  
 Deferoxamine Mesilate, 554, 1873  
 Dehydrated Alcohol, 639  
 Dehydrocholate Sodium Injection,  
 557  
 Dehydrocholic Acid, 556  
 Injection, 557, 1873  
 Purified, 556  
 Demethylchlortetracycline Hydro-  
 chloride, 558  
 Dental  
 Antiformin, 310  
 Iodine Glycerin, 771  
 Paraformaldehyde Paste, 969  
 Phenol with Camphor, 987  
 Sodium Hypochlorite Solution, 310  
 Triozinc Paste, 1210  
 Dermatol, 368  
 Deslanoside, 559  
 Injection, 560, 1873  
 Dexamethasone, 560  
 Dextran  
 40, 561, 1873  
 40 Injection, 562  
 70, 563  
 Sulfate Sodium Sulfur 5, 564  
 Sulfate Sodium Sulfur 18, 565  
 Dextrin, 565  
 Dextromethorphan Hydrobromide  
 Hydrate, 566  
 Diagnostic Sodium Citrate Solution,  
 1100  
 Diastase, 567  
 and Sodium Bicarbonate Powder,  
 567  
 Diazepam, 567  
 Dibasic  
 Calcium Phosphate, Anhydrous,  
 396, 1874  
 Calcium Phosphate Hydrate, 396,  
 1875  
 Sodium Phosphate Hydrate, 568  
 Dibekacin Sulfate, 569  
 Dibucaine Hydrochloride, 569  
 Dichlorphenamide, 571  
 Tablets, 572  
 Diclofenac Sodium, 570  
 Diclofenamide, 571  
 Tablets, 572  
 Dicloxacillin Sodium Hydrate, 573  
 Diethylcarbamazine Citrate, 574  
 Tablets, 574  
 Diethylstilbestrol Diphosphate, 683  
 Tablets, 684  
 Difenidol Hydrochloride, 575  
 Digenea, 1280  
 Digitoxin, 576  
 Tablets, 576  
 Digoxin, 578  
 Injection, 579  
 Tablets, 580  
 Dihydrocodeine Phosphate, 581  
 Powder, 1%, 582  
 Powder, 10%, 582  
 Dihydroergotamine Mesilate, 583  
 Dihydroergotoxine Mesilate, 584  
 Dilazep Hydrochloride Hydrate, 586  
 Diltiazem Hydrochloride, 586  
 Dilute  
 Hydrochloric Acid, 726  
 Iodine Tincture, 769  
 Diluted Opium Powder, 940  
 Dimemorfan Phosphate, 588  
 Dimenhydrinate, 588  
 Tablets, 589  
 Dimercaprol, 590  
 Injection, 590  
 Dimorpholamine, 591  
 Injection, 591  
 Dinoprost, 592  
 Dionin, 648  
 Dioscorea Rhizome, 1282, 1942  
 Powdered, 1282, 1942  
 Diphenhydramine, 593  
 and Bromovalerylurea Powder, 593  
 Hydrochloride, 594  
 ,Phenol and Zinc Oxide Liniment,  
 595  
 Tannate, 595  
 Diphenylhydantoin, 991  
 Powder, 992

Sodium for Injection, 992  
 Tablets, 992  
 Diphtheria  
 Tetanus Combined Toxoid, 596  
 Toxoid, 596  
 Dipyrindamole, 597  
 Disodium Edetate Hydrate, 598  
 Disopyramide, 598  
 Distigmine Bromide, 599  
 Tablets, 600  
 Disulfiram, 600  
 Dobutamine Hydrochloride, 601  
 Dolichos Seed, 1282  
 Domperidone, 1876  
 Dopamine Hydrochloride, 602  
 Injection, 602, 1877  
 Dover's Powder, 1324  
 Doxapram Hydrochloride Hydrate, 603  
 Doxifluridine, 604  
 Capsules, 604  
 Doxorubicin Hydrochloride, 605  
 for Injection, 1877  
 Doxycycline Hydrochloride Hydrate, 606  
 Dried  
 Aluminum Hydroxide Gel, 288  
 Aluminum Hydroxide Gel Fine Granules, 289  
 Aluminum Potassium Sulfate, 292  
 Sodium Carbonate, 1096  
 Sodium Sulfite, 1109  
 Thyroid, 1171  
 Yeast, 1241  
 Droperidol, 608  
 Dydrogesterone, 609  
 Tablets, 610

**E**

Ecarazine Hydrochloride, 1185  
 Ecothiopate Iodide, 610  
 Edrophonium Chloride, 611  
 Injection, 612, 1878  
 EDTA Sodium Hydrate, 598  
 Elcatonin, 612  
 Eleutherococcus Senticosus Rhizome, 1283  
 Emorfazone, 1878  
 Enalapril Maleate, 1879  
 Tablets, 1880  
 Enflurane, 615  
 Enoxacin Hydrate, 616  
 Enviomycin Sulfate, 616  
 Eperisone Hydrochloride, 618  
 Ephedra Herb, 1283  
 Ephedrine Hydrochloride, 619  
 Injection, 619, 1882  
 Powder, 620  
 Powder, 10%, 620  
 Tablets, 621, 1882  
 Epimedium Herb, 1284  
 Epinephrine, 276

Injection, 276  
 Solution, 277  
 Epirizole, 621  
 Epirubicin Hydrochloride, 622  
 Ergocalciferol, 624  
 Ergometrine Maleate, 625  
 Injection, 625  
 Tablets, 626  
 Ergotamine Tartrate, 627  
 Erythromycin, 627  
 Enteric-Coated Tablets, 1882  
 Ethylsuccinate, 629  
 Lactobionate, 629  
 Stearate, 630  
 Estazolam, 631  
 Estradiol Benzoate, 631  
 Injection, 632  
 Injection (Aqueous Suspension), 633  
 Estriol, 633  
 Injection (Aqueous Suspension), 634  
 Tablets, 635  
 Etacrynic Acid, 636  
 Tablets, 636  
 Ethacridine Lactate, 274  
 Ethambutol Hydrochloride, 637  
 Ethanol, 638  
 Anhydrous, 639  
 for Disinfection, 640  
 Ethenzamide, 640  
 Ether, 641  
 Anesthetic, 641  
 Ethinylestradiol, 642  
 Tablets, 642  
 Ethionamide, 643  
 Ethosuximide, 644  
 Ethoxybenzamide, 640  
 Ethyl  
 Aminobenzoate, 644  
 Cysteine Hydrochloride, 645  
 L-Cysteine Hydrochloride, 645  
 Icosapentate, 646  
 Parahydroxybenzoate, 647  
 Ethylenediamine, 648  
 Ethylmorphine Hydrochloride Hydrate, 648  
 Etidronate Disodium, 649  
 Tablets, 650  
 Etilefrine Hydrochloride, 650  
 Tablets, 651  
 Etizolam, 652  
 Fine Granules, 1883  
 Tablets, 1884  
 Etodolac, 653  
 Etoposide, 653  
 Eucalyptus Oil, 654  
 Eucommia Bark, 1284  
 Evodia Fruit, 1285  
 Exsiccated Gypsum, 1298  
**Extract**  
 Belladonna, 1263, 1939  
 Daikanzoto, 1280

Glycyrrhiza, 1296, 1943  
 Crude Glycyrrhiza, 1297, 1943  
 Hangekobokuto, 1943  
 Hochuekkito, 1298, 1945  
 Kakkonto, 1308, 1950  
 Kamishoyosan, 1310, 1952  
 Keishibukuryogan, 1955  
 Nux Vomica, 1322, 1960  
 Ryokeijutsukanto, 1347, 1965  
 Saireito, 1349  
 Scopolia, 1353, 1967

**F**

Famotidine, 655  
 for Injection, 656, 1885  
 Powder, 657  
 Tablets, 657  
 Faropenem Sodium  
 for Syrup, 659, 1886  
 Hydrate, 658, 1885  
 Tablets, 660, 1886  
 Felbinac, 1887  
 Fenbufen, 660  
 Fennel, 1285  
 Oil, 1286  
 Powdered, 1285  
 Fentanyl Citrate, 661  
 Ferrous Sulfate Hydrate, 661  
**Fine Granules**  
 Cefaclor, 417  
 Cefcapene Pivoxil Hydrochloride, 432  
 Cefdinir, 436  
 Cefditoren Pivoxil, 438  
 Cefteram Pivoxil, 469  
 Dried Aluminum Hydroxide Gel, 289  
 Etizolam, 1883  
 Flavin Adenine Dinucleotide Sodium, 662  
 Flavoxate Hydrochloride, 664  
 Flomoxef Sodium, 664  
 for Injection, 666  
 Flopropione, 667  
 Capsules, 667  
 Flucytosine, 668  
 Fludiazepam, 669  
**Fluidextract**  
 Condurango, 1277, 1940  
 Platycodon, 1334, 1962  
 Uva Ursi, 1371, 1969  
 Flunitrazepam, 670  
 Fluocinolone Acetonide, 670  
 Fluocinonide, 672  
 Fluorescein Sodium, 673  
 Fluorometholone, 673  
 Fluorouracil, 674  
 Fluoxymesterone, 675  
 Fluphenazine Enanthate, 676  
 Flurazepam, 677  
 Capsules, 678  
 Hydrochloride, 678

Flurbiprofen, 679  
 Foeniculated Ammonia Spirit, 1286  
 Folic Acid, 680  
 Injection, 681, 1888  
 Tablets, 681, 1888  
 Formalin, 681  
 Water, 682  
 Formoterol Fumarate Hydrate, 682  
 Forsythia Fruit, 1286  
 Fosfestrol, 683, 1888  
 Tablets, 684, 1888  
 Fosfomycin  
 Calcium Hydrate, 685  
 Sodium, 686  
 Sodium for Injection, 687  
 Fradiomycin Sulfate, 688  
 Freeze-dried  
 BCG Vaccine (for Percutaneous Use), 335  
 Botulism Antitoxin, Equine, 374  
 Diphtheria Antitoxin, Equine, 596  
 Habu Antivenom, Equine, 716  
 Inactivated Tissue Culture Rabies Vaccine, 1054  
 Japanese Encephalitis Vaccine, 786  
 Live Attenuated Measles Vaccine, 843  
 Live Attenuated Mumps Vaccine, 902  
 Live Attenuated Rubella Vaccine, 1074  
 Mamushi Antivenom, Equine, 841  
 Smallpox Vaccine, 1091  
 Smallpox Vaccine Prepared in Cell Culture, 1091  
 Tetanus Antitoxin, Equine, 1156  
 Fritillaria Bulb, 1287, 1942  
 Fructose, 689  
 Injection, 689, 1888  
 Furosemide, 690  
 Tablets, 691  
 Fursultiamine Hydrochloride, 692

**G**

Gabexate Mesilate, 693, 1889  
 $\beta$ -Galactosidase  
 (Aspergillus), 694  
 (Penicillium), 695  
 Gallium (<sup>67</sup>Ga) Citrate Injection, 696  
 Gambir, 1287  
 Powdered, 1287  
 Gardenia Fruit, 1288  
 Powdered, 1288  
 Gas Gangrene Antitoxin, Equine, 696  
 Gastrodia Tuber, 1289, 1943  
 Gelatin, 696  
 Purified, 697  
 Gentamicin Sulfate, 698  
 Gentian, 1290, 1943  
 and Sodium Bicarbonate Powder, 1290  
 Japanese, 1306, 1949

Powdered, 1290, 1943  
 Powdered, Japanese, 1306, 1949  
 Geranium Herb, 1291  
 Powdered, 1291  
 Ginger, 1291  
 Powdered, 1292  
 Ginseng, 1292  
 Powdered, 1293  
 Glacial Acetic Acid, 269  
 Glehnia Root, 1294, 1943  
 Glibenclamide, 699  
 Glucose, 700  
 Injection, 701, 1889  
 L-Glutamine, 1889  
 Glutathione, 701  
 Glycerin, 702  
 and Potash Solution, 704  
 Concentrated, 703  
 Glycerol, 702  
 Concentrated, 703  
 Glyceryl Monostearate, 704  
 Glycine, 704  
 Glycyrrhiza, 1295  
 Extract, 1296, 1943  
 Extract, Crude, 1297, 1943  
 Powdered, 1296  
 Gonadorelin Acetate, 705  
 Gonadotrophin  
 Chorionic, 707  
 for Injection, Chorionic, 708  
 for Injection, Human Chorionic, 708  
 Human Chorionic, 707  
 Human Menopausal, 708  
 Serum, 710  
 for Injection, Serum, 711  
 Gramicidin, 712  
**Granules**  
 Calcium Paraaminosalicylate, 394  
 Cefaclor Compound, 419  
 Pas-calcium Granules, 394  
 Griseofulvin, 713  
 Tablets, 1890  
 Guaiacol Glyceryl Ether, 714  
 Guaifenesin, 714  
 Guanabenz Acetate, 715  
 Guanethidine Sulfate, 716  
 Gypsum, 1297

**H**

Haloperidol, 717  
 Tablets, 718  
 Halothane, 719  
 Haloxazolam, 719  
 Hangekobokuto Extract, 1943  
 Hemp Fruit, 1298  
 Heparin Sodium, 721  
 Injection, 722  
 Hochuekkito Extract, 1298, 1945  
 Homatropine Hydrobromide, 722  
 Homochlorcyclizine Hydrochloride, 723

Honey, 1301  
 Houttuynia Herb, 1302  
 Human  
 Chorionic Gonadotrophin, 707  
 Chorionic Gonadotrophin for Injection, 708  
 Menopausal Gonadotrophin, 708  
 Normal Immunoglobulin, 724  
 Hycoato Injection, 953  
 Hydralazine Hydrochloride, 724  
 for Injection, 724  
 Powder, 725  
 Tablets, 725, 1890  
 Hydrochloric Acid, 725  
 Dilute, 726  
 Lemonade, 727  
 Hydrochlorothiazide, 727  
 Hydrocortisone, 728  
 Acetate, 729  
 and Diphenhydramine Ointment, 730  
 Butyrate, 730  
 Sodium Phosphate, 731  
 Sodium Succinate, 732  
 Succinate, 733  
 Hydrocotarnine Hydrochloride Hydrate, 734  
 Hydrogenated Oil, 735  
 Hydrophilic  
 Ointment, 735  
 Petrolatum, 981  
 Hydrous Lanolin, 807  
 Hydroxocobalamin Acetate, 736  
 Hydroxypropylcellulose, 736  
 Hydroxypropylmethylcellulose, 741  
 Hydroxyzine  
 Hydrochloride, 739  
 Pamoate, 739  
 Hymecromone, 740  
 Hypromellose, 741  
 Phthalate, 743, 1891

**I**

Ibudilast, 1892  
 Ibuprofen, 744  
 Ichthammol, 744  
 Idarubicin Hydrochloride, 745  
 for Injection, 746  
 Idoxuridine, 747  
 Ophthalmic Solution, 747, 1893  
 Ifenprodil Tartrate, 748  
 Imipenem  
 and Cilastatin for Injection, 750  
 Hydrate, 749  
 Imipramine Hydrochloride, 751  
 Tablets, 752, 1893  
 Immature Orange, 1302  
 Imperata Rhizome, 1302, 1949  
 Indenolol Hydrochloride, 753  
 Indigocarmine, 754  
 Injection, 755  
 Indium (<sup>111</sup>In) Chloride Injection, 755



- Indometacin, 755  
   Capsules, 756, 1893  
   Suppositories, 757  
 Influenza HA Vaccine, 758  
**Injection**  
   Acetylcholine Chloride for, 271, 1825  
   Adrenaline, 276  
   Alprostadil, 1828  
   Amikacin Sulfate, 1830  
   Aminophylline, 297, 1831  
   Amobarbital Sodium for, 300  
   Amphotericin B for, 304  
   Ampicillin Sodium for, 1838  
   Estradiol Benzoate, (Aqueous Suspension), 633  
   Estriol, (Aqueous Suspension), 634  
   Insulin Zinc, (Aqueous Suspension), 763  
   Insulin Zinc, Amorphous, (Aqueous Suspension), 764  
   Insulin Zinc, Crystalline, (Aqueous Suspension), 765  
   Insulin Zinc Protamine, (Aqueous Suspension), 766  
   Isothane Insulin, (Aqueous Suspension), 762  
   Arbekacin Sulfate, 312  
   L-Arginine Hydrochloride, 314, 1839  
   Ascorbic Acid, 317, 1839  
   Atropine Sulfate, 324  
   Aztreonam for, 1840  
   Benzylpenicillin Potassium for, 1841  
   Calcium Chloride, 390, 1851  
   Cefazolin Sodium for, 1854  
   Cefepime Dihydrochloride for, 441  
   Cefmetazole Sodium for, 1855  
   Cefotiam Hydrochloride for, 456  
   Cefozopran Hydrochloride for, 458  
   Ceftazidime for, 1856  
   Chlorpheniramine Maleate, 499  
   Chlorpromazine Hydrochloride, 503, 1860  
   Chorionic Gonadotrophin for, 708  
   Clindamycin Phosphate, 1866  
   Cyanocobalamin, 549, 1871  
   Dehydrocholate Sodium, 557  
   Dehydrocholic Acid, 557, 1873  
   Deslanoside, 560, 1873  
   Dextran 40, 562  
   Digoxin, 579  
   Dimercaprol, 590  
   Dimorpholamine, 591  
   Diphenylhydantoin Sodium for, 992  
   Dopamine Hydrochloride, 602, 1877  
   Doxorubicin Hydrochloride for, 1877  
   Edrophonium Chloride, 612, 1878  
   Ephedrine Hydrochloride, 619, 1882  
   Epinephrine, 276  
   Ergometrine Maleate, 625  
   Estradiol Benzoate, 632  
   Famotidine for, 656, 1885  
   Flomoxef Sodium for, 666  
   Folic Acid, 681, 1888  
   Fosfomycin Sodium for, 687  
   Fructose, 689, 1888  
   Gallium (<sup>67</sup>Ga) Citrate, 696  
   Glucose, 701, 1889  
   Heparin Sodium, 722  
   Human Chorionic Gonadotrophin for, 708  
   Hycato, 953  
   Hycodenone, Compound, 952  
   Hydralazine Hydrochloride for, 724  
   Idarubicin Hydrochloride for, 746  
   Imipenem and Cilastatin for, 750  
   Indigocarmine, 755  
   Indium (<sup>111</sup>In) Chloride, 755  
   Insulin, 762  
   Iodinated (<sup>131</sup>I) Human Serum Albumin, 768  
   Isoniazid, 781  
   Isotonic Sodium Chloride, 1098  
   Levallorphan Tartrate, 814, 1900  
   Lidocaine, 818  
   Lidocaine Hydrochloride, 818  
   Magnesium Sulfate, 839, 1900  
   D-Mannite, 842  
   D-Mannitol, 842, 1903  
   Meglumine Amidotrizoate, 851  
   Meglumine Iotalamate, 852  
   Meglumine Sodium Amidotrizoate, 853  
   Meglumine Sodium Iodamide, 854  
   Mepivacaine Hydrochloride, 860  
   Metenolone Enanthate, 866  
   Minocycline Hydrochloride for, 1904  
   Mitomycin C for, 1905  
   Morphine and Atropine, 899  
   Morphine Hydrochloride, 901  
   Neostigmine Methylsulfate, 910, 1912  
   Nicardipine Hydrochloride, 912, 1912  
   Nicotinic Acid, 921, 1912  
   Noradrenaline, 931, 1915  
   Noradrenaline Hydrochloride, 931  
   Norepinephrine, 931  
   Norepinephrine Hydrochloride, 931  
   Operidine, 981  
   Opium Alkaloids and Atropine, 942  
   Opium Alkaloids and Scopolamine, 943  
   Opium Alkaloids Hydrochlorides, 942  
   Oxycodone and Atropine, Compound, 953  
   Oxycodone, Compound, 952  
   Oxytocin, 960  
   Ozagrel Sodium for, 1917  
   Papaverine Hydrochloride, 965, 1918  
   Peplomycin Sulfate for, 1918  
   Pethidine Hydrochloride, 981, 1918  
   Phenolsulfonphthalein, 988  
   Phenytoin Sodium for, 992  
   Piperacillin Sodium for, 998  
   Prednisolone Sodium Succinate for, 1025, 1921  
   Procainamide Hydrochloride, 1029  
   Procaine Hydrochloride, 1030  
   Progesterone, 1034  
   Protamine Sulfate, 1042, 1922  
   Pyridoxine Hydrochloride, 1048, 1922  
   Reserpine, 1056, 1922  
   Riboflavin Phosphate, 1062  
   Riboflavin Sodium Phosphate, 1062, 1922  
   Serum Gonadotrophin for, 711  
   Sodium Bicarbonate, 1094, 1925  
   0.9% Sodium Chloride, 1098  
   10% Sodium Chloride, 1098, 1925  
   Sodium Chromate (<sup>51</sup>Cr), 1099  
   Sodium Citrate, for Transfusion, 1099, 1926  
   Sodium Iodohippurate (<sup>131</sup>I), 1103  
   Sodium Iotalamate, 1103  
   Sodium Pertechnetate (<sup>99m</sup>Tc), 1105  
   Sodium Thiosulfate, 1110, 1927  
   Sulfobromophthalein Sodium, 1130  
   Sulpyrine, 1134, 1927  
   Suxamethonium Chloride for, 1137, 1928  
   Suxamethonium Chloride, 1138, 1928  
   Teceleukin for, (Genetical Recombination), 1148, 1929  
   Testosterone Enanthate, 1154  
   Testosterone Propionate, 1155  
   Thallium (<sup>201</sup>Tl) Chloride, 1158  
   Thiamine Chloride Hydrochloride, 1161, 1930  
   Thiamylal Sodium for, 1164  
   Thiopental Sodium for, 1167, 1930  
   Tobramycin, 1930  
   Tranexamic Acid, 1193  
   Tubocurarine Chloride Hydrochloride, 1213, 1931  
   Tubocurarine Hydrochloride, 1213  
   Vancomycin Hydrochloride for, 1223  
   Vasopressin, 1223  
   Vinblastine Sulfate for, 1227  
   Vitamin B<sub>1</sub> Hydrochloride, 1161  
   Vitamin B<sub>2</sub> Phosphate Ester, 1062  
   Vitamin B<sub>6</sub>, 1048  
   Vitamin B<sub>12</sub>, 549

Vitamin C, 317  
 Water for, 1235, 1934  
 Weak Opium Alkaloids and Scopolamine, 945  
 Xylitol, 1241, 1935  
 Insulin, 758  
 Human (Genetical Recombination), 760  
 Injection, 762  
 Zinc Injection (Aqueous Suspension), 763  
 Amorphous, 764  
 Crystalline, 765  
 Zinc Protamine Injection (Aqueous Suspension), 766  
 Iodamide, 767  
 Iodinated (<sup>131</sup>I) Human Serum Albumin Injection, 768  
 Iodine, 768  
 Salicylic Acid and Phenol Spirit, 772  
 Tincture, 769  
 Iodoform, 773  
 Iopamidol, 773  
 Iotalamic Acid, 774  
 Iotroxid Acid, 775  
 Ipecac, 1303, 1949  
 Powdered, 1303, 1949  
 Syrup, 1304  
 Ipratropium Bromide Hydrate, 776  
 Iproveratril Hydrochloride, 1225  
 Isepamicin Sulfate, 777  
 Isoflurane, 778  
 L-Isoleucine, 780  
 Isoniazid, 780  
 Injection, 781  
 Tablets, 781  
 Isophane Insulin Injection (Aqueous Suspension), 762  
*l*-Isoprenaline Hydrochloride, 782  
 Isopropanol, 783  
 Isopropyl Alcohol, 783  
 Isopropylantipyrine, 783  
 Isosorbide, 784  
 Dinitrate, 785  
 Dinitrate Tablets, 786  
 Isotonic  
 Salt Solution, 1098  
 Sodium Chloride Injection, 1098  
 Sodium Chloride Solution, 1098, 1893  
 Isoxsuprine Hydrochloride, 1894  
 Tablets, 1895  
 Itraconazole, 1896

**J**

Japanese  
 Angelica Root, 1305  
 Angelica Root, Powdered, 1305  
 Encephalitis Vaccine, 786  
 Encephalitis Vaccine, Freeze-dried, 786

Gentian, 1306, 1949  
 Gentian, Powdered, 1306, 1949  
 Valerian, 1306, 1950  
 Valerian, Powdered, 1307, 1950  
 Josamycin, 786  
 Propionate, 788  
 Tablets, 1897  
 Jujube, 1307  
 Seed, 1307

**K**

Kainic Acid  
 and Santonin Powder, 790  
 Hydrate, 789  
 Kakkonto Extract, 1308, 1950  
 Kallidinogenase, 790  
 Kamishoyosan Extract, 1310, 1952  
 Kanamycin  
 Monosulfate, 793  
 Sulfate, 794  
 Kaolin, 795  
 Keishibukuryogan Extract, 1955  
 Ketamine Hydrochloride, 795  
 Ketoprofen, 796  
 Ketotifen Fumarate, 797  
 Kitasamycin, 798  
 Acetate, 799  
 Tartrate, 800

**L**

Labetalol Hydrochloride, 1898  
 Tablets, 1899  
 Lactic Acid, 801  
 Lactose, 803  
 Anhydrous, 802, 1900  
 Hydrate, 803  
 Lactulose, 804  
 Lanatoside C, 805  
 Tablets, 806  
 Lanolin  
 Hydrous, 807  
 Purified, 808  
 Lard, 808  
 Latamoxef Sodium, 809  
 Lauromacrogol, 810  
**Lemonade**  
 Hydrochloric Acid, 727  
 Lenampicillin Hydrochloride, 810  
 Leonurus Herb, 1958  
 L-Leucine, 812  
 Leucomycin, 798  
 Acetate, 799  
 Tartrate, 800  
 Levallorphan Tartrate, 813  
 Injection, 814, 1900  
 Levodopa, 814  
 Levomepromazine Maleate, 815  
 Levothyroxine Sodium  
 Hydrate, 816  
 Tablets, 817  
 Lidocaine, 818

Hydrochloride Injection, 818  
 Injection, 818  
 Light  
 Anhydrous Silicic Acid, 1087  
 Liquid Paraffin, 967  
 Lilium Bulb, 1958  
 Limaprost Alfadex, 819  
**Liniment**  
 Diphenhydramine, Phenol and Zinc Oxide, 595  
 Lincomycin Hydrochloride Hydrate, 820  
 Linderia Root, 1313, 1959  
 Lithyronine Sodium, 821  
 Tablets, 822  
 Liquefied  
 Carbolic Acid, 986  
 Phenol, 986  
 Liquid Paraffin, 966  
 Lisinopril  
 Hydrate, 823  
 Tablets, 824  
 Lithium Carbonate, 826  
 Lithospermum Root, 1313, 1959  
 Live Oral Poliomyelitis Vaccine, 1005  
 Longgu, 1313  
 Lonicera Leaf and Stem, 1314  
 Loquat Leaf, 1314  
 Lorazepam, 827  
**Lotion**  
 Sulfur and Camphor, 1130  
 Low Substituted Hydroxypropylcellulose, 738  
 Loxoprofen Sodium Hydrate, 828  
 Lycium  
 Bark, 1315, 1959  
 Fruit, 1315  
 Lysine Hydrochloride, 829  
 L-Lysine Hydrochloride, 829  
 Lysozyme Hydrochloride, 830

**M**

Macrogol  
 400, 830  
 1500, 831  
 4000, 832  
 6000, 832  
 20000, 833  
 Ointment, 833  
 Magnesium  
 Carbonate, 834  
 Oxide, 835  
 Silicate, 836  
 Stearate, 837  
 Sulfate Hydrate, 838  
 Sulfate Injection, 839, 1900  
 Sulfate Mixture, 839  
 Magnolia  
 Bark, 1315, 1959  
 Bark, Powdered, 1316, 1959  
 Flower, 1317  
 Mallotus Bark, 1317

- Maltose Hydrate, 840  
 Manidipine Hydrochloride, 1900  
   Tablets, 1902  
 D-Mannite Injection, 842  
 D-Mannitol, 841  
   Injection, 842, 1903  
 Maprotiline Hydrochloride, 842  
 Meclofenoxate Hydrochloride, 843  
 Mecobalamin, 844  
 Medazepam, 845, 1903  
 Medicinal  
   Carbon, 845  
   Soap, 846  
 Mefenamic Acid, 847  
 Mefloquine Hydrochloride, 848  
 Mefruside, 849  
   Tablets, 849, 1903  
 Meglumine, 850  
   Amidotrizoate Injection, 851  
   Totalamate Injection, 852  
   Sodium Amidotrizoate Injection,  
   853  
   Sodium Iodamide Injection, 854  
 Melphalan, 855  
 Menatetrenone, 855  
 Mentha  
   Herb, 1317  
   Oil, 1318  
   Water, 1318  
*dl*-Menthol, 856  
*l*-Menthol, 857  
 Mepenzolate Bromide, 857  
 Mepirizole, 621  
 Mepitiostane, 858  
 Mepivacaine Hydrochloride, 859  
   Injection, 860  
 Mequitazine, 861  
 Merbromin, 862  
   Solution, 863  
 Mercaptopurine Hydrate, 861  
 Mercurochrome, 862  
   Solution, 863  
 Meropenem Hydrate, 863  
 Mestranol, 864  
 Metenolone  
   Acetate, 865  
   Enanthate, 866  
   Enanthate Injection, 866  
 Metformin Hydrochloride, 867  
   Tablets, 867  
 Methamphetamine Hydrochloride,  
   868  
 L-Methionine, 869  
 Methotrexate, 869  
 Methoxsalen, 870  
 Methylbenactyzium Bromide, 871  
 Methylcellulose, 871  
 Methylidopa  
   Hydrate, 873  
   Tablets, 874, 1903  
*dl*-Methylephedrine Hydrochloride,  
   875  
   Powder, 876  
   Powder, 10%, 876  
 Methylergometrine Maleate, 876  
   Tablets, 877  
 Methyl  
   Parahydroxybenzoate, 878  
   Salicylate, 881  
 Methylprednisolone, 879  
   Succinate, 880  
 Methylrosanilinium Chloride, 881  
 Methyltestosterone, 882  
   Tablets, 883  
 Meticrane, 884  
 Metildigoxin, 885  
 Metoclopramide, 886  
   Tablets, 886  
 Metoprolol Tartrate, 887  
   Tablets, 888  
 Metronidazole, 889  
   Tablets, 889  
 Metyrapone, 890  
 Mexiletine Hydrochloride, 891  
 Miconazole, 892  
   Nitrate, 893  
 Microcrystalline Cellulose, 477  
 Micronomicin Sulfate, 893  
 Midecamycin, 894  
   Acetate, 895  
 Migrenin, 896  
 Minocycline Hydrochloride, 897  
   for Injection, 1904  
 Mitomycin C, 898  
   for Injection, 1905  
 Mizoribine, 1906  
   Tablets, 1907  
 Monobasic Calcium Phosphate  
   Hydrate, 397  
 Monosodium Trichloroethyl Phos-  
   phate, 1202  
   Syrup, 1203  
 Morphine  
   and Atropine Injection, 899  
   Hydrochloride Hydrate, 900  
   Hydrochloride Injection, 901  
   Hydrochloride Tablets, 902, 1908  
 Moutan Bark, 1318  
   Powdered, 1319  
 Mulberry Bark, 1320, 1960  
 Mupirocin Calcium Hydrate, 902
- N**
- Nabumetone, 1908  
   Tablets, 1910  
 Nadolol, 904  
 Nafamostat Mesilate, 1911  
 Nalidixic Acid, 905  
 Naloxone Hydrochloride, 906  
 Naphazoline  
   and Chlorpheniramine Solution,  
   906  
   Hydrochloride, 907  
   Nitrate, 908  
 Naproxen, 908
- Narcotine, 936  
   Hydrochloride, 937  
 Natamycin, 994  
 Natural Aluminum Silicate, 289  
 Nelumbo Seed, 1320  
 Neomycin Sulfate, 688  
 Neostigmine Methylsulfate, 909  
   Injection, 910, 1912  
 Netilmicin Sulfate, 910  
 Nicardipine Hydrochloride, 911  
   Injection, 912, 1912  
 Nicergoline, 913  
   Powder, 914  
   Tablets, 915  
 Niceritrol, 916  
 Nicomol, 917  
   Tablets, 918  
 Nicorandil, 919, 1912  
 Nicotinamide, 919  
 Nicotinic Acid, 920  
   Injection, 921, 1912  
 Nifedipine, 922  
 Nilvadipine, 923  
   Tablets, 924  
 Nitrazepam, 925  
 Nitrendipine, 926  
   Tablets, 927  
 Nitrogen, 928  
 Nitroglycerin Tablets, 928  
 Nitrous Oxide, 929  
 Nizatidine, 1912  
   Capsules, 1913  
 Noradrenaline, 930  
   Hydrochloride Injection, 931  
   Injection, 931, 1915  
 Norepinephrine, 930  
   Hydrochloride Injection, 931  
   Injection, 931  
 Norethisterone, 932  
 Norfloxacin, 932  
 Norgestrel, 933  
   and Ethinylestradiol Tablets, 934  
 Nortriptyline Hydrochloride, 935  
 Noscapine, 936  
   Hydrochloride Hydrate, 937  
 Notopterygium Rhizome, 1321, 1960  
 Nuphar Rhizome, 1321, 1960  
 Nux Vomica, 1321  
   Extract, 1322, 1960  
   Extract Powder, 1323  
   Tincture, 1323  
 Nystatin, 937
- O**
- Ofloxacin, 938  
**Ointment**  
   Absorptive, 265  
   Acrinol and Zinc Oxide, 274  
   Betamethasone Valerate and Gen-  
   tamicin Sulfate, 362  
   Bufexamac, 381

**Ointment** (*continued*)

- Hydrocortisone and Diphenhydramine, 730
- Hydrophilic, 735
- Macrogol, 833
- Polyethylene Glycol, 833
- Simple, 1089
- Sulfur, Salicylic Acid and Thianthol, 1131
- White, 1238
- Zinc Oxide, 1246
- Olive Oil, 939
- Omeprazole, 1915
- Operidine, 980
  - Injection, 981
- Ophiopogon Tuber, 1324
- Ophthalmic Solution**
  - Idoxuridine, 747, 1893
  - Silver Nitrate, 1088
  - Zinc Sulfate, 1247
- Opium
  - Ipecac Powder, 1324
  - Powdered, 939
  - Tincture, 940
- Opium Alkaloids
  - and Atropine Injection, 942
  - and Scopolamine Injection, 943
  - Hydrochlorides, 941
  - Hydrochlorides Injection, 942
- Orange
  - Oil, 946
  - Peel Syrup, 1325
  - Peel Tincture, 1325
- Orciprenaline Sulfate, 946
- Oriental Bezoar, 1325
- Oxapium Iodide, 947
- Oxaprozin, 948
- Oxazolam, 948
- Oxetacaine, 949
- Oxethazaine, 949
- Oxprenolol Hydrochloride, 950
- Oxybuprocaine Hydrochloride, 951
- Oxycodone Hydrochloride Hydrate, 951
- Oxydol, 954
- Oxygen, 955
- Oxymetholone, 956
- Oxytetracycline Hydrochloride, 956
- Oxytocin, 958
  - Injection, 960
- Oyster Shell, 1326
  - Powdered, 1326
- Ozagrel Sodium, 1916
  - for Injection, 1917

**P**

- Panax Japonicus Rhizome, 1326, 1960
  - Powdered, 1327, 1960
- Pancreatin, 961
- Pancuronium Bromide, 962
- Panipenem, 962
- Pantethine, 964
- Papaverine Hydrochloride, 965
  - Injection, 965, 1918
- Paracetamol, 267
- Paraffin, 966
  - Light Liquid, 967
  - Liquid, 966
- Paraformaldehyde, 968
- Parnaparin Sodium, 969
- Pas-calcium
  - Granules, 394
  - Hydrate, 395
- Paste
  - Arsenical, 315
  - Paraformaldehyde, Dental, 969
  - Triozinc, Dental, 1210
- Peach Kernel, 1327, 1961
  - Powdered, 1327, 1961
- Peanut Oil, 971
- Penbutolol Sulfate, 972
- Penicillin G Potassium, 349
- Pentazocine, 972
- Pentobarbital Calcium, 973
- Pentoxyverine Citrate, 974
- Peony Root, 1328
  - Powdered, 1329
- Peplomycin Sulfate, 975
  - for Injection, 1918
- Perilla Herb, 1329, 1961
- Perphenazine, 977
  - Maleate, 978
  - Maleate Tablets, 979
  - Tablets, 977
- Pethidine Hydrochloride, 980
  - Injection, 981, 1918
- Petrolatum
  - Hydrophilic, 981
  - White, 981
  - Yellow, 982
- Petroleum Benzin, 982
- Peucedanum Root, 1961
- Pharbitis Seed, 1330
- Phellodendron,
  - Albumin Tannate and Bismuth Subnitrate Powder, 1332
  - Bark, 1330
  - Bark, Powdered, 1331
- Phenazone, 310
- Phenethicillin Potassium, 983
- Phenobarbital, 984
  - Powder, 985
  - Powder, 10%, 985
- Phenol, 985
  - and Zinc Oxide Liniment, 987
  - for Disinfection, 986
  - Liquefied, 986
- Phenolated Water, 987
  - for Disinfection, 987
- Phenolsulfonphthalein, 988
  - Injection, 988
- L-Phenylalanine, 989
- Phenylbutazone, 990
- Phenylephrine Hydrochloride, 990
- Phenytoin, 991
  - Powder, 992
  - Sodium for Injection, 992
  - Tablets, 992
- Phytomenadione, 993
- Phytonadione, 993
- Picrasma Wood, 1333
  - Powdered, 1333
- Pilocarpine Hydrochloride, 994
- Pimaricin, 994
- Pindolol, 995
- Pinellia Tuber, 1333
- Pipemidic Acid Hydrate, 996
- Piperacillin
  - Hydrate, 1919
  - Sodium, 997
  - Sodium for Injection, 998
- Piperazine
  - Adipate, 999
  - Phosphate Hydrate, 999
  - Phosphate Tablets, 1000
- Pirarubicin, 1000
- Pirenoxine, 1001
- Pirenzepine Hydrochloride Hydrate, 1002
- Piroxicam, 1003
- Pivmecillinam Hydrochloride, 1004
- Plantago
  - Herb, 1334
  - Seed, 1334
- Platycodon
  - Fluidextract, 1334, 1962
  - Root, 1334
  - Root, Powdered, 1335
- Polyethylene Glycol
  - 400, 830
  - 1500, 831
  - 4000, 832
  - 6000, 832
  - 20000, 833
  - Ointment, 833
- Polygala Root, 1335, 1962
  - Powdered, 1335, 1962
- Polygonatum Rhizome, 1336
- Polygonum Root, 1336, 1962
- Polymixin B Sulfate, 1006
- Polyoxyethylene Lauryl Alcohol Ether, 810
- Polyoxyl 40 Stearate, 1007
- Polyporus Sclerotium, 1336, 1962
  - Powdered, 1337, 1963
- Polysorbate 80, 1007
- Polyvidone, 1015
- Polyvinylpyrrolidone, 1015
- Poria Sclerotium, 1337
  - Powdered, 1337
- Potash Soap, 1007
- Potassium
  - Bromide, 1008
  - Canrenoate, 1008
  - Carbonate, 1009
  - Chloride, 1009
  - Clavulanate, 1010

- Guaiacolsulfonate, 1011  
 Hydroxide, 1012  
 Iodide, 1013  
 Permanganate, 1013  
 Sulfate, 1014  
 Potato Starch, 1014  
 Povidone, 1015  
   Iodine, 1017  
**Powder**  
   Ascorbic Acid, 317  
   Chlordiazepoxide, 491  
   Chlorpheniramine and Calcium, 497  
   Chlorpheniramine Maleate, 499  
   Codeine Phosphate, 1%, 536  
   Codeine Phosphate, 10%, 537  
   Diastase and Sodium Bicarbonate, 567  
   Diastase and Sodium Bicarbonate, Compound, 567  
   Dihydrocodeine Phosphate, 1%, 582  
   Dihydrocodeine Phosphate, 10%, 582  
   Diluted Opium, 940  
   Diphenhydramine and Bromovalerylurea, 593  
   Diphenylhydantoin, 992  
   Dover's, 1324  
   Ephedrine Hydrochloride, 620  
   Ephedrine Hydrochloride, 10%, 620  
   Famotidine, 657  
   Gentian and Sodium Bicarbonate, 1290  
   Hydralazine Hydrochloride, 725  
   Kainic Acid and Santonin, 790  
   *dl*-Methylephedrine Hydrochloride, 876  
   *dl*-Methylephedrine Hydrochloride, 10%, 876  
   Nicergoline, 914  
   Nux Vomica Extract, 1323  
   Opium Ipecac, 1324  
   Phellodendron, Albumin Tannate and Bismuth Subnitrate, 1332  
   Phenobarbital, 985  
   Phenobarbital, 10%, 985  
   Phenytoin, 992  
   Reserpine, 1057  
   Reserpine, 0.1%, 1057  
   Rhubarb and Senna, Compound, 1346  
   Riboflavin, 1060  
   Salicylated Alum, 1078  
   Scopolia Extract, 1354  
   Scopolia Extract and Carbon, 1355  
   Scopolia Extract and Diastase, Compound, 1355  
   Scopolia Extract and Ethyl Aminobenzoate, 1355  
   Scopolia Extract, Papanerine and Ethyl Aminobenzoate, 1356  
   Swertia and Sodium Bicarbonate, 1367  
   Thiamine Chloride Hydrochloride, 1162  
   Vitamin B, Compound, 1230  
   Vitamin B<sub>1</sub> Hydrochloride, 1162  
   Vitamin B<sub>2</sub>, 1060  
   Vitamin C, 317  
   Zinc Oxide Starch, 1246  
**Powdered**  
   Acacia, 1251  
   Agar, 1253  
   Alisma Rhizome, 1253  
   Aloe, 1255  
   Amomum Seed, 1256  
   Atractylodes Lancea Rhizome, 1260  
   Atractylodes Rhizome, 1261, 1939  
   Calumba, 1268, 1939  
   Capsicum, 1269  
   Cellulose, 480  
   Cinnamon Bark, 1273  
   Clove, 1274  
   Cnidium Rhizome, 1276, 1940  
   Coix Seed, 1276  
   Coptis Rhizome, 1278, 1940  
   Corydalis Tuber, 1940  
   Cyperus Rhizome, 1280, 1942  
   Dioscorea Rhizome, 1282, 1942  
   Fennel, 1285  
   Gambir, 1287  
   Gardenia Fruit, 1288  
   Gentian, 1290, 1943  
   Geranium Herb, 1291  
   Ginger, 1292  
   Ginseng, 1293  
   Glycyrrhiza, 1296  
   Ipecac, 1303, 1949  
   Japanese Angelica Root, 1305  
   Japanese Gentian, 1306, 1949  
   Japanese Valerian, 1307, 1950  
   Magnolia Bark, 1316, 1959  
   Moutan Bark, 1319  
   Opium, 939  
   Oyster Shell, 1326  
   Panax Japonicus Rhizome, 1327, 1960  
   Peach Kernel, 1327, 1961  
   Peony Root, 1329  
   Phellodendron Bark, 1331  
   Picrasma Wood, 1333  
   Platycodon Root, 1335  
   Polygala Root, 1335, 1962  
   Polyporus Sclerotium, 1337, 1963  
   Poria Sclerotium, 1337  
   Processed Aconite Root, 1339, 1963  
   Rhubarb, 1345  
   Rose Fruit, 1346  
   Scutellaria Root, 1359, 1967  
   Senega, 1361, 1968  
   Senna Leaf, 1362  
   Smilax Rhizome, 1364, 1968  
   Sophora Root, 1364, 1969  
   Sweet Hydrangea Leaf, 1365  
   Swertia Herb, 1366  
   Tragacanth, 1369  
   Turmeric, 1969  
   Zanthoxylum Fruit, 1371  
 Pranopfen, 1018  
 Pravastatin Sodium, 1018  
 Prazepam, 1020  
   Tablets, 1021  
 Precipitated Calcium Carbonate, 389  
 Prednisolone, 1021  
   Acetate, 1023  
   Sodium Succinate for Injection, 1025, 1921  
   Succinate, 1024  
   Tablets, 1022  
 Primidone, 1026  
 Probenecid, 1027  
   Tablets, 1027  
 Procainamide Hydrochloride, 1028  
   Injection, 1029  
   Tablets, 1029  
 Procaine Hydrochloride, 1030  
   Injection, 1030  
 Procarbazine Hydrochloride, 1031  
 Procatamol Hydrochloride Hydrate, 1032  
 Processed  
   Aconite Root, 1338, 1963  
   Aconite Root, Powdered, 1339, 1963  
   Ginger, 1341, 1964  
 Prochlorperazine Maleate, 1033  
   Tablets, 1033  
 Progesterone, 1034  
   Injection, 1034  
 Proglumide, 1035  
 Promethazine Hydrochloride, 1036  
 Propantheline Bromide, 1036  
 Propranolol Hydrochloride, 1037  
   Tablets, 1038  
 Propyl Parahydroxybenzoate, 1039  
 Propylene Glycol, 1039  
 Propylthiouracil, 1040  
   Tablets, 1040  
 Propyphenazone, 783  
 Prostaglandin  
   E<sub>1</sub>, 286  
   E<sub>1</sub>  $\alpha$ -Cyclodextrin Clathrate Compound, 287  
   F<sub>2 $\alpha$</sub> , 592  
 Protamine Sulfate, 1041, 1921  
   Injection, 1042, 1922  
 Prothionamide, 1042  
 Protirelin, 1043  
   Tartrate Hydrate, 1044  
 Prunella Spike, 1341  
 Pueraria Root, 1341  
 Pullulan, 1045  
 Purified  
   Dehydrocholic Acid, 556  
   Gelatin, 697

Purified (*continued*)

Lanolin, 808  
 Shellac, 1085  
 Water, 1236  
 Water, Sterile, 1236  
 Pyrantel Pamoate, 1045  
 Pyrazinamide, 1046  
 Pyridostigmine Bromide, 1047  
 Pyridoxine Hydrochloride, 1047  
 Injection, 1048, 1922  
 Pyroxylin, 1049  
 Pyrrolnitrin, 1049

**Q**

Quick Lime, 393  
 Quinidine Sulfate Hydrate, 1050  
 Quinine  
 Ethyl Carbonate, 1051  
 Hydrochloride Hydrate, 1052  
 Sulfate Hydrate, 1053

**R**

Ranitidine Hydrochloride, 1054  
 Rape Seed Oil, 1055  
 Red Ginseng, 1342  
 Rehmannia Root, 1343, 1964  
 Reserpine, 1055  
 Injection, 1056, 1922  
 Powder, 1057  
 Powder, 0.1%, 1057  
 Tablets, 1057  
 Retinol  
 Acetate, 1058  
 Palmitate, 1059  
 Rhubarb, 1344  
 Powdered, 1345  
 Riboflavin, 1059  
 Butyrate, 1060  
 Phosphate, 1061  
 Phosphate Injection, 1062  
 Powder, 1060  
 Sodium Phosphate, 1061  
 Sodium Phosphate Injection, 1062, 1922  
 Ribostamycin Sulfate, 1063  
 Rice Starch, 1346  
 Rifampicin, 1064  
 Capsules, 1065  
 Ringer's Solution, 1066, 1922  
 Ritodrine Hydrochloride, 1067  
 Tablets, 1068  
 Rokitamycin, 1069  
 Tablets, 1923  
 Rose Fruit, 1346  
 Powdered, 1346  
 Rosin, 1347  
 Roxatidine Acetate Hydrochloride, 1070  
 Extended-release Capsules, 1071  
 Roxithromycin, 1073, 1923  
 Ryokeijutsukanto Extract, 1347, 1965

**S**

Saccharated Pepsin, 1074  
 Saccharin, 1075  
 Sodium, 1076  
 Sodium Hydrate, 1076  
 Safflower, 1348  
 Saffron, 1349  
 Saireito Extract, 1349  
 Salazosulfapyridine, 1077  
 Salbutamol Sulfate, 1078  
 Salicylated Alum Powder, 1078  
 Salicylic Acid, 1079, 1924  
 Plaster, Adhesive, 1080  
 Spirit, 1080  
 Santonin, 1081  
 Saponated Cresol Solution, 545  
 Saposhnikovia Root, 1352, 1966  
 Sappan Wood, 1352  
 Saussurea Root, 1352, 1966  
 Schisandra Fruit, 1352  
 Schizonepeta Spike, 1353  
 Scopolamine  
 Butylbromide, 1082  
 Hydrobromide Hydrate, 1083  
 Scopolia Extract, 1353, 1967  
 and Carbon Powder, 1355  
 and Ethyl Aminobenzoate Powder, 1355  
 and Tannic Acid Suppositories, 1357  
 ,Papaverine and Ethyl Aminobenzoate Powder, 1356  
 Powder, 1354  
 Rhizome, 1357, 1967  
 Scutellaria Root, 1358, 1967  
 Powdered, 1359, 1967  
 Senega, 1360, 1968  
 Powdered, 1361, 1968  
 Syrup, 1361  
 Senna Leaf, 1361  
 Powdered, 1362  
 L-Serine, 1925  
 Serrapeptase, 1083  
 Serum Gonadotrophin, 710  
 for Injection, 711  
 Sesame Oil, 1084  
 Shellac  
 Purified, 1085  
 Siccanin, 1086  
 Silver  
 Nitrate, 1088  
 Nitrate Ophthalmic Solution, 1088  
 Protein, 1088  
 Protein Solution, 1089  
 Simple  
 Ointment, 1089  
 Syrup, 1089  
 Sinomenium Stem, 1363  
 Sisomicin Sulfate, 1090  
 Slaked Lime, 392  
 Smilax Rhizome, 1364, 1968

Powdered, 1364, 1968

**Sodium**

Acetate Hydrate, 1091  
 Aurothiomalate, 1092  
 Benzoate, 1093  
 Bicarbonate, 1093  
 Bicarbonate and Bitter Tincture Mixture, 1364  
 Bicarbonate Injection, 1094, 1925  
 Bisulfite, 1094  
 Borate, 1095  
 Bromide, 1095  
 Carbonate, Dried, 1096  
 Carbonate Hydrate, 1096  
 Chloride, 1097  
 Chloride Injection, 0.9%, 1098  
 Chloride Injection, 10%, 1098, 1925  
 Chloride Solution, Isotonic, 1098, 1893  
 Chromate (<sup>51</sup>Cr) Injection, 1099  
 Citrate Hydrate, 1099  
 Citrate Injection for Transfusion, 1099, 1926  
 Citrate Solution, Diagnostic, 1100  
 Cromoglicate, 1100  
 Fusidate, 1101  
 Hydrogen Sulfite, 1094  
 Hydroxide, 1101  
 Iodide, 1102  
 Iodide (<sup>123</sup>I) Capsules, 1103  
 Iodide (<sup>131</sup>I) Capsules, 1103  
 Iodide (<sup>131</sup>I) Solution, 1103  
 Iodohippurate (<sup>131</sup>I) Injection, 1103  
 Iotalamate Injection, 1103  
 Lauryl Sulfate, 1104  
 Metabisulfite, 1108  
 Pertechnetate (<sup>99m</sup>Tc) Injection, 1105  
 Picosulfate Hydrate, 1105  
 Polystyrene Sulfonate, 1106  
 Prasterone Sulfate Hydrate, 1107  
 Pyrosulfate, 1108  
 Salicylate, 1108  
 Starch Glycolate, 1926  
 Sulfite, Dried, 1109  
 Thiosulfate Hydrate, 1109  
 Thiosulfate Injection, 1110, 1927  
 Valproate, 1110

**Solution**

Adrenaline, 277  
 Alum, 293  
 Benzalkonium Chloride, 342  
 Benzethonium Chloride, 345  
 Chlorhexidine Gluconate, 493  
 Cresol, 545  
 Dental Sodium Hypochlorite, 310  
 Diagnostic Sodium Citrate, 1100  
 Epinephrine, 277  
 Glycerin and Potash, 704  
 Isotonic Salt, 1098  
 Isotonic Sodium Chloride, 1098, 1893

- Merbromin, 863  
 Mercurochrome, 863  
 Naphazoline and Chlorpheniramine, 906  
 Ringer's, 1066, 1922  
 Saponated Cresol, 545  
 Silver Protein, 1089  
 Sodium Citrate, Diagnostic, 1100  
 Sodium Iodide (<sup>131</sup>I), 1103  
 D-Sorbitol, 1113  
 Thianthol and Salicylic Acid, Compound, 1165  
 Tolnaftate, 1189  
 Sophora Root, 1364, 1968  
   Powdered, 1364, 1969  
 Sorbitan Sesquioleate, 1111  
 D-Sorbitol, 1112  
   Solution, 1113  
 Soybean Oil, 1113  
 Spectinomycin Hydrochloride Hydrate, 1114  
 Spiramycin Acetate, 1114  
**Spirit**  
   Capsicum and Salicylic Acid, 1270  
   Foeniculated Ammonia, 1286  
   Iodine Salicylic Acid and Phenol, 772  
   Methyl Salicylate, Compound, 879  
   Salicylic Acid, 1080  
   Salicylic Acid, Compound, 1080  
 Spironolactone, 1116  
**Starch**  
   Corn, 542  
   Glycolate, Sodium, 1926  
   Potato, 1014  
   Rice, 1346  
   Wheat, 1237  
 Stearic Acid, 1116  
 Stearyl Alcohol, 1117  
 Sterile Purified Water, 1236  
 Streptomycin Sulfate, 1117  
 Sucralfate Hydrate, 1118  
 Sucrose, 1120  
 Sulbactam Sodium, 1122, 1927  
 Sulbenicillin Sodium, 1123  
 Sulfadiazine Silver, 1124  
 Sulfafurazole, 1128  
 Sulfamethizole, 1125  
 Sulfamethoxazole, 1126  
 Sulfamonomethoxine Hydrate, 1126  
 Sulfasalazine, 1077  
 Sulfinpyrazone, 1127, 1927  
   Tablets, 1128, 1927  
 Sulfisomezole, 1126  
 Sulfisoxazole, 1128  
 Sulfobromophthalein Sodium, 1129  
   Injection, 1130  
 Sulfur, 1130  
   and Camphor Lotion, 1130  
   ,Salicylic Acid and Thianthol Ointment, 1131  
 Sulpiride, 1131  
   Capsules, 1132  
   Tablets, 1132  
 Sulpyrine  
   Hydrate, 1133  
   Injection, 1134, 1927  
 Sultamicillin Tosilate Hydrate, 1134, 1927  
 Sultiame, 1136  
**Suppositories**  
   Bisacodyl, 368, 1843  
   Indometacin, 757  
   Scopolia Extract and Tannic Acid, 1357  
 Suxamethonium Chloride  
   for Injection, 1137, 1928  
   Hydrate, 1137  
   Injection, 1138, 1928  
 Sweet Hydrangea Leaf, 1365  
   Powdered, 1365  
 Swertia  
   and Sodium Bicarbonate Powder, 1367  
   Herb, 1365  
   Herb, Powdered, 1366  
**Synthetic**  
   Aluminum Silicate, 290  
   Camphor, 402  
**Syrup**  
   Amphotericin B, 305  
   Cefadroxil for, 1853  
   Faropenem Sodium for, 659, 1886  
   Ipecac, 1304  
   Monosodium Trichloroethyl Phosphate, 1203  
   Orange Peel, 1325  
   Senega, 1361  
   Simple, 1089  
   Triclofos Sodium, 1203
- T**
- Tablets**  
   Acetylsalicylic Acid, 319  
   Ajmaline, 279, 1826  
   Alacepril, 280  
   Alminoprofen, 1827  
   Amitriptyline Hydrochloride, 299, 1831  
   Amlexanox, 1833  
   Amosulalol Hydrochloride, 1836  
   Amphotericin B, 305  
   Aspirin, 319  
   Azathioprine, 326  
   Baclofen, 332, 1841  
   Benidipine Hydrochloride, 339  
   Betahistine Mesilate, 354  
   Betamethasone, 356  
   Bezafibrate Sustained Release, 365  
   Bisoprolol Fumarate, 1844  
   Bucillamine, 1845  
   Buformine Hydrochloride, 1849  
   Buformine Hydrochloride Enteric-coated, 1847  
   Cefcapene Pivoxil Hydrochloride, 433  
   Cefditoren Pivoxil, 438  
   Cetirizine Hydrochloride, 1857  
   Chlordiazepoxide, 492, 1858  
   Chlorphenesin Carbamate, 1859  
   Chlorpheniramine Maleate, 500  
   Chlorpromazine Hydrochloride, 503, 1861  
   Chlorpropamide, 505, 1861  
   Cibenzoline Succinate, 1862  
   Cilazapril, 1864  
   Cilostazol, 512, 1866  
   Clarithromycin, 517  
   Clomifene Citrate, 527  
   Codeine Phosphate, 537  
   Dichlorphenamide, 572  
   Diclofenamide, 572  
   Diethylcarbamazine Citrate, 574  
   Diethylstilbestrol Diphosphate, 684  
   Digitoxin, 576  
   Digoxin, 580  
   Dimenhydrinate, 589  
   Diphenylhydantoin, 992  
   Distigmine Bromide, 600  
   Dydrogesterone, 610  
   Enalapril Maleate, 1880  
   Ephedrine Hydrochloride, 621, 1882  
   Ergometrine Maleate, 626  
   Erythromycin Enteric-Coated, 1882  
   Estriol, 635  
   Etacrynic Acid, 636  
   Ethinylestradiol, 642  
   Etidronate Disodium, 650  
   Etilefrine Hydrochloride, 651  
   Etizolam, 1884  
   Famotidine, 657  
   Faropenem Sodium, 660, 1886  
   Folic Acid, 681, 1888  
   Fosfestrol, 684, 1888  
   Furosemide, 691  
   Griseofulvin, 1890  
   Haloperidol, 718  
   Hydralazine Hydrochloride, 725, 1890  
   Imipramine Hydrochloride, 752, 1893  
   Isoniazid, 781  
   Isosorbide Dinitrate, 786  
   Isoxsuprine Hydrochloride, 1895  
   Josamycin, 1897  
   Labetalol Hydrochloride, 1899  
   Lanatoside C, 806  
   Levothyroxine Sodium, 817  
   Liothyronine Sodium, 822  
   Lisinopril, 824  
   Manidipine Hydrochloride, 1902  
   Mefruside, 849, 1903  
   Metformin Hydrochloride, 867  
   Methyldopa, 874, 1903  
   Methylergometrine Maleate, 877  
   Methyltestosterone, 883  
   Metoclopramide, 886

**Tablets (continued)**

- Metoprolol Tartrate, 888  
 Metronidazole, 889  
 Mizoribine, 1907  
 Morphine Hydrochloride, 902, 1908  
 Nabumetone, 1910  
 Nicergoline, 915  
 Nicomol, 918  
 Nilvadipine, 924  
 Nitrendipine, 927  
 Nitroglycerin, 928  
 Norgestrel and Ethinylestradiol, 934  
 Perphenazine, 977  
 Perphenazine Maleate, 979  
 Phenytoin, 992  
 Piperazine Phosphate, 1000  
 Prazepam, 1021  
 Prednisolone, 1022  
 Probenecid, 1027  
 Procainamide Hydrochloride, 1029  
 Prochlorperazine Maleate, 1033  
 Propranolol Hydrochloride, 1038  
 Propylthiouracil, 1040  
 Reserpine, 1057  
 Ritodrine Hydrochloride, 1068  
 Rokitamycin, 1923  
 Sulfapyrazone, 1128, 1927  
 Sulpiride, 1132  
 Thiamazole, 1160  
 Tiaramide Hydrochloride, 1172  
 Tipepidine Hibenzate, 1177, 1930  
 Tolbutamide, 1188  
 Tranexamic Acid, 1193  
 Trichlormethiazide, 1199  
 Trihexyphenidyl Hydrochloride, 1204  
 Trimetazidine Hydrochloride, 1207  
 Trimethadione, 1209  
 Verapamil Hydrochloride, 1226  
 Voglibose, 1232  
 Warfarin Potassium, 1234  
 Zaltoprofen, 1243  
 Talampicillin Hydrochloride, 1138  
 Talc, 1139, 1928  
 Tamsulosin Hydrochloride, 1140  
 Tannic Acid, 1141  
 Tartaric Acid, 1141  
 Taurine, 1142  
 Teceleukin  
   for Injection (Genetical Recombination), 1148, 1929  
   (Genetical Recombination), 1143  
 Tegafur, 1149  
 Teicoplanin, 1150  
 Terbutaline Sulfate, 1153  
 Testosterone  
   Enanthate, 1154  
   Enanthate Injection, 1154  
   Propionate, 1155  
   Propionate Injection, 1155  
 Tetracaine Hydrochloride, 1156  
 Tetracycline Hydrochloride, 1157  
 Thallium (<sup>201</sup>Tl) Chloride Injection, 1158  
 Theophylline, 1158  
 Thiamazole, 1159  
   Tablets, 1160  
 Thiamine  
   Chloride Hydrochloride, 1160  
   Chloride Hydrochloride Injection, 1161, 1930  
   Chloride Hydrochloride Powder, 1162  
   Nitrate, 1162  
 Thiamylal Sodium, 1163  
   for Injection, 1164  
 Thianthol, 1165  
 Thiopental Sodium, 1166  
   for Injection, 1167, 1930  
 Thioridazine Hydrochloride, 1168  
 Thiotepa, 1168  
 L-Threonine, 1169  
 Thrombin, 1170  
 Thymol, 1170  
 Tiaramide Hydrochloride, 1171  
   Tablets, 1172  
 Ticlopidine Hydrochloride, 1173  
 Timepidium Bromide Hydrate, 1174  
 Timolol Maleate, 1174  
**Tincture**  
   Bitter, 1266  
   Capsicum, 1269  
   Iodine, 769  
   Iodine, Dilute, 769  
   Nux Vomica, 1323  
   Opium, 940  
   Orange Peel, 1325  
 Tinidazole, 1175  
 Tipepidine Hibenzate, 1176  
   Tablets, 1177, 1930  
 Titanium Oxide, 1178  
 Tizanidine Hydrochloride, 1179  
 Toad Venom, 1368  
 Tobramycin, 1180  
   Injection, 1930  
 Tocopherol, 1181  
   Acetate, 1182  
   Calcium Succinate, 1183  
   Nicotinate, 1184  
*dl*- $\alpha$ -Tocopherol, 1181  
   Acetate, 1182  
   Nicotinate, 1184  
 Todralazine Hydrochloride Hydrate, 1185  
 Tofisopam, 1186  
 Tolazamide, 1187  
 Tolbutamide, 1188  
   Tablets, 1188  
 Tolnaftate, 1189  
   Solution, 1189  
 Tolperisone Hydrochloride, 1190  
 Tragacanth, 1369  
   Powdered, 1369  
 Tranexamic Acid, 1191  
   Capsules, 1192  
   Injection, 1193  
   Tablets, 1193  
 Trapidil, 1194  
 Trepibutone, 1195  
 Tretoquinol Hydrochloride, 1209  
 Triamcinolone, 1195  
   Acetonide, 1196  
 Triamterene, 1197  
 Tribulus Fruit, 1369  
 Trichlormethiazide, 1198  
   Tablets, 1199  
 Trichomycin, 1201  
 Trichosanthes Root, 1369  
 Triclofos Sodium, 1202  
   Syrup, 1203  
 Trihexyphenidyl Hydrochloride, 1204  
   Tablets, 1204  
 Trimebutine Maleate, 1206  
 Trimetazidine Hydrochloride, 1207, 1931  
   Tablets, 1207  
 Trimethadione, 1208  
   Tablets, 1209  
 Trimetoquinol Hydrochloride Hydrate, 1209  
 Tropicamide, 1211  
 L-Tryptophan, 1211  
 Tubocurarine Chloride Hydrochloride Hydrate, 1212, 1931  
   Injection, 1213, 1931  
 Tubocurarine Hydrochloride, 1212  
   Injection, 1213  
 Tulobuterol Hydrochloride, 1213  
 Turmeric, 1367, 1969  
   Powdered, 1969  
 Turpentine Oil, 1214  
 L-Tyrosine, 1931

**U**

- Ubenimex, 1932  
 Ubidecarenone, 1214  
 Ulinastatin, 1215  
 Uncaria Hook, 1370  
 Urapidil, 1217  
 Urea, 1218  
 Urokinase, 1219  
 Ursodeoxycholic Acid, 1220  
 Uva Ursi Fluidextract, 1371, 1969

**V**

- Vaccine  
   BCG, Freeze-dried, (for Percutaneous Use), 335  
   Cholera, 506  
   Diphtheria-Purified Pertussis-Tetanus Combined, Adsorbed, 596  
   Hepatitis B, Adsorbed, 716  
   Inactivated Tissue Culture Rabies, Freeze-dried, 1054  
   Influenza HA, 758



Japanese Encephalitis, 786  
 Japanese Encephalitis, Freeze-dried, 786  
 Live Attenuated Measles, Freeze-dried, 843  
 Live Attenuated Mumps, Freeze-dried, 902  
 Live Attenuated Rubella, Freeze-dried, 1074  
 Live Oral Poliomyelitis, 1005  
 Purified Pertussis, Adsorbed, 980  
 Smallpox, Freeze-dried, 1091  
 Smallpox, Freeze-dried, Prepared in Cell Culture, 1091  
 Weil's Disease and Akiyami Combined, 1237  
 L-Valine, 1221  
 Vancomycin Hydrochloride, 1221  
   for Injection, 1223  
 Vasopressin Injection, 1223  
 Verapamil Hydrochloride, 1225  
   Tablets, 1226  
 Vinblastine Sulfate, 1226  
   for Injection, 1227  
 Vincristine Sulfate, 1228, 1933  
 Vitamin A  
   Acetate, 1058  
   Capsules, 1230  
   Oil, 1229  
   Oil Capsules, 1230  
   Palmitate, 1059  
 Vitamin B<sub>1</sub>  
   Hydrochloride, 1160  
   Hydrochloride Injection, 1161  
   Hydrochloride Powder, 1162  
   Nitrate, 1162

Vitamin B<sub>2</sub>, 1059  
   Phosphate Ester, 1061  
   Phosphate Ester Injection, 1062  
   Powder, 1060  
 Vitamin B<sub>6</sub>, 1047  
   Injection, 1048  
 Vitamin B<sub>12</sub>, 548  
   Injection, 549  
 Vitamin C, 316  
   Injection, 317  
   Powder, 317  
 Vitamin D<sub>2</sub>, 624  
 Vitamin D<sub>3</sub>, 506  
 Vitamin E, 1181  
   Acetate, 1182  
   Calcium Succinate, 1183  
   Nicotinate, 1184  
 Vitamin K<sub>1</sub>, 993  
 Voglibose, 1231  
   Tablets, 1232

**W**

Warfarin Potassium, 1233  
   Tablets, 1234  
 Water, 1235  
   for Injection, 1235, 1934  
   Purified, 1236  
   Sterile Purified, 1236  
 Weak Opium Alkaloids and Scopolamine Injection, 945  
 Weil's Disease and Akiyami Combined Vaccine, 1237  
 Wheat Starch, 1237  
 White  
   Beeswax, 336

Ointment, 1238  
 Petrolatum, 981  
 Shellac, 1085  
 Soft Sugar, 1121  
 Whole Human Blood, 1238  
 Wine, 1238  
 Wood Creosote, 1870

**X**

Xylitol, 1240  
   Injection, 1241, 1935

**Y**

Yellow  
   Beeswax, 336  
   Petrolatum, 982

**Z**

Zaltoprofen, 1242  
   Tablets, 1243  
 Zanthoxylum Fruit, 1371  
   Powdered, 1371  
 Zedoary, 1372, 1969  
 Zidovudine, 1935  
 Zinc  
   Chloride, 1244  
   Oxide, 1245  
   Oxide Oil, 1245  
   Oxide Ointment, 1246  
   Oxide Starch Powder, 1246  
   Sulfate Hydrate, 1246  
   Sulfate Ophthalmic Solution, 1247  
 Zinostatin Stimalamer, 1247

# INDEX IN LATIN NAME

## A

*Achyranthis Radix*, 1252  
*Adeps*  
  *Lanae Rurificatus*, 808  
  *Suillus*, 808  
*Agar*, 1252  
  *Pulveratum*, 1253  
*Akebiae Caulis*, 1253  
*Alismatis Rhizoma*, 1253  
  *Pulveratum*, 1253  
*Aloe*, 1254  
  *Pulverata*, 1255  
*Alpiniae*  
  *Fructus*, 1265  
  *Officinari Rhizoma*, 1256  
*Amomi Semen*, 1256  
  *Pulveratum*, 1256  
*Amylum*  
  *Maydis*, 542  
  *Oryzae*, 1346  
  *Solani*, 1014  
  *Tritici*, 1237  
*Anemarrhenae Rhizoma*, 1256  
*Angelicae Radix*, 1305  
  *Pulverata*, 1305  
*Araliae Cordatae Rhizoma*, 1937  
*Arctii Fructus*, 1267  
*Arecae Semen*, 1258  
*Armeniaca Semen*, 1257  
*Artemisiae Capillaris Flos*, 1258  
*Asiasari Radix*, 1259  
*Asparagi Tuber*, 1259  
*Astragali Radix*, 1260  
*Atractylodis*  
  *Lanceae Rhizoma*, 1260  
  *Lanceae Rhizoma Pulveratum*,  
    1260  
  *Rhizoma*, 1261  
  *Rhizoma Pulveratum*, 1261  
*Aurantii*  
  *Bobilis Pericarpium*, 1273  
  *Fructus Immaturus*, 1302  
  *Pericarpium*, 1265

## B

*Belladonnae Radix*, 1263  
*Benincasae Semen*, 1264  
*Benzoinum*, 1265  
*Bezoar Bovis*, 1325  
*Bufois Venenum*, 1368  
*Bupleuri Radix*, 1266

## C

*Calumbae Radix*, 1267  
  *Pulverata*, 1268  
*Cannabis Fructus*, 1298  
*Capsici Fructus*, 1268  
  *Pulveratus*, 1269  
*Cardamomi Fructus*, 1271  
*Carthami Flos*, 1348  
*Caryophylli Flos*, 1274  
  *Pulveratus*, 1274  
*Cassiae Semen*, 1271  
*Catalpae Fructus*, 1271  
*Cera*  
  *Alba*, 336  
  *Carnauba*, 411  
  *Flava*, 336  
*Chrysanthemii Flos*, 1271  
*Cimicifugae Rhizoma*, 1272  
*Cinnamomi Cortex*, 1272  
  *Pulveratus*, 1273  
*Clematidis Radix*, 1274  
*Cnidii*  
  *Monnieris Fructus*, 1275  
  *Rhizoma*, 1275  
  *Rhizoma Pulveratum*, 1276  
*Coicis Semen*, 1276  
  *Pulveratum*, 1276  
*Condurango Cortex*, 1276  
*Coptidis Rhizoma*, 1277  
  *Pulveratum*, 1278  
*Corni Fructus*, 1279  
*Corydalis Tuber*, 1279  
  *Pulveratum*, 1940  
*Crataegi Fructus*, 1941  
*Crocus*, 1349  
*Curcumae Rhizoma*, 1367  
  *Purveratum*, 1969  
*Cyperii Rhizoma*, 1280  
  *Pulveratum*, 1280

## D

*Digenea*, 1280  
*Dioscoreae Rhizoma*, 1282  
  *Pulveratum*, 1282  
*Dolichi Semen*, 1282

## E

*Eletherococci senticosi Rhizoma*,  
  1283  
*Ephdrae Herba*, 1283  
*Epimedii Herba*, 1284  
*Eriobotryae Folium*, 1314

*Eucommiae Cortex*, 1284  
*Evodiae Fructus*, 1285  
*Extractum Belladonnae*, 1263

## F

*Fel Ursi*, 1262  
*Foeniculi Fructus*, 1285  
  *Pulveratus*, 1285  
*Forsythiae Fructus*, 1286  
*Fossilia Ossis Mastodi*, 1313  
*Fritillariae Bulbus*, 1287

## G

*Gambir*, 1287  
  *Pulveratum*, 1287  
*Gardeniae Fructus*, 1288  
  *Pulveratus*, 1288  
*Gastrodiae Tuber*, 1289  
*Gentianae*  
  *Radix*, 1290  
  *Radix Pulverata*, 1290  
  *Scabrae Radix*, 1306  
  *Scabrae Radix Pulverata*, 1306  
*Geranii Herba*, 1291  
  *Pulverata*, 1291  
*Ginseng Radix*, 1292  
  *Pulverata*, 1293  
  *Rubra*, 1342  
*Glehniae Radix cum Rhizoma*, 1294  
*Glycyrrhizae Radix*, 1295  
  *Pulverata*, 1296  
*Gummi Arabicum*, 1251  
  *Pulveratum*, 1251  
*Gypsum*  
  *Exsiccatum*, 1298  
  *Fibrosum*, 1297

## H

*Houttuyniae Herba*, 1302  
*Hydrangeae Dulcis Folium*, 1365  
  *Pulveratum*, 1365

## I

*Imperatae Rhizoma*, 1302  
*Ipecacuanhae Radix*, 1303  
  *Pulverata*, 1303

## L

*Leonuri Herba*, 1958  
*Lilii Bulbus*, 1958  
*Linderae Radix*, 1313

*Lithospermi Radix*, 1313  
*Loniceræ Folium Cum Caulis*, 1314  
*Lycii*

*Cortex*, 1315  
*Fructus*, 1315

**M**

*Magnoliæ*  
*Cortex*, 1315  
*Cortex Pulveratus*, 1316  
*Flos*, 1317  
*Malloti Cortex*, 1317  
*Mel*, 1301  
*Menthæ Herba*, 1317  
*Mori Cortex*, 1320  
*Moutan Cortex*, 1318  
*Pulveratus*, 1319

**N**

*Nelumbis Semen*, 1320  
*Notopterygii Rhizoma*, 1321  
*Nupharis Rhizoma*, 1321

**O**

*Oleum*  
*Arachidis*, 971  
*Aurantii*, 946  
*Cacao*, 386  
*Camelliae*, 400  
*Caryophylli*, 1275  
*Cinnamomi*, 1273  
*Cocois*, 535  
*Eucalypti*, 654  
*Foeniculi*, 1286  
*Maydis*, 542  
*Menthæ Japonicæ*, 1318  
*Olivæ*, 939  
*Rapæ*, 1055  
*Ricini*, 414  
*Sesami*, 1084  
*Sojæ*, 1113  
*Terebinthinæ*, 1214  
*Ophiopogonis Tuber*, 1324  
*Opium Pulveratum*, 939  
*Ostreæ Testa*, 1326  
*Pulverata*, 1326

**P**

*Paeoniæ Radix*, 1328  
*Pulverata*, 1329  
*Panacis Japonici Rhizoma*, 1326  
*Pulveratum*, 1327  
*Perillæ Herba*, 1329  
*Persicæ Semen*, 1327  
*Pulveratum*, 1327  
*Peucedani Radix*, 1961  
*Pharbitidis Semen*, 1330  
*Phellodendri Cortex*, 1330  
*Pulveratus*, 1331  
*Picrasmæ Lignum*, 1333  
*Pulveratum*, 1333  
*Pinelliae Tuber*, 1333  
*Plantaginis*  
*Herba*, 1334  
*Semen*, 1334  
*Platycodi Radix*, 1334  
*Pulverata*, 1335  
*Polygalæ Radix*, 1335  
*Pulverata*, 1335  
*Polygonati Rhizoma*, 1336  
*Polygoni Multiflori Radix*, 1336  
*Polyporus*, 1336  
*Pulveratus*, 1337  
*Poria*, 1337  
*Pulveratum*, 1337  
*Processi Aconiti Radix*, 1338  
*Pulverata*, 1339  
*Prunellæ Spica*, 1341  
*Puerariæ Radix*, 1341

**R**

*Rehmanniæ Radix*, 1343  
*Resina Pini*, 1347  
*Rhei Rhizoma*, 1344  
*Pulveratum*, 1345  
*Rosæ Fructus*, 1346  
*Pulveratus*, 1346

**S**

*Saposhnikoviae Radix*, 1352  
*Sappan Lignum*, 1352  
*Saussureæ Radix*, 1352  
*Schisandriæ Fructus*, 1352  
*Schizonepetæ Spica*, 1353

*Scopoliae Rhizoma*, 1357  
*Scutellariæ Radix*, 1358  
*Pulverata*, 1359  
*Senegæ Radix*, 1360  
*Pulverata*, 1361  
*Sennæ Folium*, 1361  
*Pulveratum*, 1362  
*Sevum Bovinum*, 336  
*Sinomeni Caulis et Rhizoma*, 1363  
*Smilacis Rhizoma*, 1364  
*Pulveratum*, 1364  
*Sophoræ Radix*, 1364  
*Pulverata*, 1364  
*Strychni Semen*, 1321  
*Swertiæ Herba*, 1365  
*Pulverata*, 1366  
*Syrupus*  
*Ipecacuanha*, 1304  
*Senegæ*, 1361

**T**

*Tinctura Amara*, 1266  
*Tragacantha*, 1369  
*Pulverata*, 1369  
*Tribuli Fructus*, 1369  
*Trichosanthis Radix*, 1369

**U**

*Uncariæ Uncis Cum Ramulus*, 1370  
*Uvæ Ursi Folium*, 1262

**V**

*Valerianæ Radix*, 1306  
*Pulverata*, 1307

**Z**

*Zanthoxyli Fructus*, 1371  
*Pulveratus*, 1371  
*Zedoariæ Rhizoma*, 1372  
*Zingiberis*  
*Processum Rhizoma*, 1341  
*Rhizoma*, 1291  
*Rhizoma Pulveratum*, 1292  
*Zizyphi*  
*Fructus*, 1307  
*Semen*, 1307

# INDEX IN JAPANESE

## ア

- 亜鉛華デンプン 1246  
亜鉛華軟膏 1246  
アカメガシワ 1317  
アクチノマイシン D 275  
アクリルピシシ 塩酸塩 272  
アクリノール・亜鉛華軟膏 274  
アクリノール水和物 274  
アクリノール・チンク油 273  
アザチオプリン 325  
アザチオプリン錠 326  
亜酸化窒素 929  
アジスロマイシン水和物 327  
アジマリン 278  
アジマリン錠 279, 1826  
亜硝酸アミル 309  
アスコルビン酸 316  
アスコルビン酸散 317  
アスコルビン酸注射液 317, 1839  
アズトレオナム 328  
アストロマイシン硫酸塩 322  
L-アスパラギン酸 318  
アスピリン 318  
アスピリンアルミニウム 319  
アスピリン錠 319  
アスポキシシリン水和物 320  
アセグルタミドアルミニウム 266  
アセタゾラミド 268  
アセトアミノフェン 267  
アセトヘキサミド 269  
アセプトロール塩酸塩 265  
アセメタシン 1825  
アゼラスチン塩酸塩 1839  
アセンヤク 1287  
アセンヤク末 1287  
アテノロール 323  
アドレナリン 276  
アドレナリン液 277  
アドレナリン注射液 276  
アトロピン硫酸塩水和物 324  
アトロピン硫酸塩注射液 324  
亜ヒ酸パスタ 315  
アフロクアロン 277  
アヘンアルカロイド・アトロピン注射液 942  
アヘンアルカロイド塩酸塩 941  
アヘンアルカロイド塩酸塩注射液 942  
アヘンアルカロイド・スコボラミン注射液 943  
アヘン散 940  
アヘンチンキ 940  
アヘン・トコン散 1324  
アヘン末 939
- アマチャ 1365  
アマチャ末 1365  
アマンタジン塩酸塩 293  
アミカシン硫酸塩 296  
アミカシン硫酸塩注射液 1830  
アミドトリゾ酸 295  
アミドトリゾ酸ナトリウムメグルミン注射液 853  
アミドトリゾ酸メグルミン注射液 851  
アミトリプチリン塩酸塩 298  
アミトリプチリン塩酸塩錠 299, 1831  
アミノ安息香酸エチル 644  
アミノフィリン水和物 297  
アミノフィリン注射液 297, 1831  
アムホテリシン B 303  
アムホテリシン B 錠 305  
アムホテリシン B シロップ 305  
アムロジピンベシル酸塩 1834  
アモキサピン 301  
アモキシシリン水和物 302  
アモスラロール塩酸塩 1835  
アモスラロール塩酸塩錠 1836  
アモバルビタール 300  
アラセプリル 279  
アラセプリル錠 280  
アラビアゴム 1251  
アラビアゴム末 1251  
アリメマジン酒石酸塩 283  
亜硫酸水素ナトリウム 1094  
L-アルギニン 313  
L-アルギニン塩酸塩 313  
L-アルギニン塩酸塩注射液 314, 1839  
アルジオキサ 282  
アルプラゾラム 284  
アルプレノロール塩酸塩 285  
アルプロスタジル 286  
アルプロスタジールアルファデクス 287  
アルプロスタジル注射液 1828  
アルベカシン硫酸塩 311  
アルベカシン硫酸塩注射液 312  
アルミノプロフェン 1826  
アルミノプロフェン錠 1827  
アロエ 1254  
アロエ末 1255  
アロチノロール塩酸塩 314  
アロプリノール 284  
安息香酸 345  
安息香酸ナトリウム 1093  
安息香酸ナトリウムカフェイン 388  
安息香酸ベンジル 347  
アンソッコウ 1265  
アンチピリン 310
- アンピシリン水和物 307  
アンピシリンナトリウム 308  
アンベノニウム塩化物 294  
アンモニア・ウイキョウ精 1286  
アンモニア水 299  
アンレキサノクス 1831  
アンレキサノクス錠 1833

## イ

- イオウ 1130  
イオウ・カンフルローション 1130  
イオウ・サリチル酸・チアントール軟膏 1131  
イオタラム酸 774  
イオタラム酸ナトリウム注射液 1103  
イオタラム酸メグルミン注射液 852  
イオトロクス酸 775  
イオパミドール 773  
イクタモール 744  
イコサペント酸エチル 646  
イセバマイシン硫酸塩 777  
イソクスプリン塩酸塩 1894  
イソクスプリン塩酸塩錠 1895  
イソソルビド 784  
イソニアジド 780  
イソニアジド錠 781  
イソニアジド注射液 781  
イソフェンインスリン水性懸濁注射液 762  
イソフルラン 778  
L-イソプレナリン塩酸塩 782  
イソプロパノール 783  
イソプロピルアンチピリン 783  
L-イソロイシン 780  
イダルピシシ 塩酸塩 745  
イドクスウリジン 747  
イドクスウリジン点眼液 747, 1893  
イトラコナゾール 1896  
イフェンプロジル酒石酸塩 748  
イブジラスト 1892  
イブプロフェン 744  
イプラトロピウム臭化物水和物 776  
イミブラミン塩酸塩 751  
イミブラミン塩酸塩錠 752, 1893  
イミベナム水和物 749  
イレイセン 1274, 1939  
インジゴカルミン 754  
インジゴカルミン注射液 755  
インスリン 758  
インスリン亜鉛水性懸濁注射液 763  
インスリン注射液 762  
インチンコウ 1258  
インデノロール塩酸塩 753  
インドメタシン 755

インドメタシンカプセル 756, 1893  
 インドメタシン坐剤 757  
 インフルエンザ HA ワクチン 758  
 インヨウカク 1284

## ウ

ウイキョウ 1285  
 ウイキョウ末 1285  
 ウイキョウ油 1286  
 ウコン 1367, 1969  
 ウコン末 1969  
 ウベニメクス 1932  
 ウヤク 1313, 1959  
 ウラピジル 1217  
 ウリナスタチン 1215  
 ウルソデオキシコール酸 1220  
 ウロキナーゼ 1219  
 ウワウルシ 1262  
 ウワウルシ流エキス 1371, 1969

## エ

エイジツ 1346  
 エイジツ末 1346  
 液状フェノール 986  
 エコチオパートヨウ化物 610  
 エスタゾラム 631  
 エストラジオール安息香酸エステル 631  
 エストラジオール安息香酸エステル水性懸濁注射液 633  
 エストラジオール安息香酸エステル注射液 632  
 エストリオール 633  
 エストリオール錠 635  
 エストリオール水性懸濁注射液 634  
 エタクリン酸 636  
 エタクリン酸錠 636  
 エタノール 638  
 エタンプトール塩酸塩 637  
 エチオナミド 643  
 エチゾラム 652  
 エチゾラム細粒 1883  
 エチゾラム錠 1884  
 エチドロン酸二ナトリウム 649  
 エチドロン酸二ナトリウム錠 650  
 エチニルエストラジオール 642  
 エチニルエストラジオール錠 642  
 L-エチルシステイン塩酸塩 645  
 エチルモルヒネ塩酸塩水和物 648  
 エチレフリン塩酸塩 650  
 エチレフリン塩酸塩錠 651  
 エチレンジアミン 648  
 エデト酸ナトリウム水和物 598  
 エーテル 641  
 エテンザミド 640  
 エトスクシミド 644  
 エトドラク 653  
 エトポシド 653  
 エドロホニウム塩化物 611  
 エドロホニウム塩化物注射液 612, 1878

エナラプリルマレイン酸塩 1879  
 エナラプリルマレイン酸塩錠 1880  
 エノキサシン水和物 616  
 エピリゾール 621  
 エピルピシン塩酸塩 622  
 エフェドリン塩酸塩 619  
 エフェドリン塩酸塩散 10% 620  
 エフェドリン塩酸塩錠 621, 1882  
 エフェドリン塩酸塩注射液 619, 1882  
 エペリゾン塩酸塩 618  
 エモルファゾン 1878  
 エリスロマイシン 627  
 エリスロマイシンエチルコハク酸エステル 629  
 エリスロマイシンステアリン酸塩 630  
 エリスロマイシン腸溶錠 1882  
 エリスロマイシンラクトビオン酸塩 629  
 エルカトニン 612  
 エルゴカルシフェロール 624  
 エルゴタミン酒石酸塩 627  
 エルゴメトリンマレイン酸塩 625  
 エルゴメトリンマレイン酸塩錠 626  
 エルゴメトリンマレイン酸塩注射液 625  
 塩化亜鉛 1244  
 塩化インジウム(<sup>111</sup>In)注射液 755  
 塩化カリウム 1009  
 塩化カルシウム水和物 390  
 塩化カルシウム注射液 390, 1851  
 塩化タリウム(<sup>201</sup>Tl)注射液 1158  
 塩化ナトリウム 1097  
 10% 塩化ナトリウム注射液 1098, 1925  
 エンゴサク 1279, 1940  
 エンゴサク末 1940  
 塩酸 725  
 塩酸リモナーデ 727  
 エンビオマイシン硫酸塩 616  
 エンフルラン 615

## オ

オウギ 1260  
 オウゴン 1358, 1967  
 オウゴン末 1359, 1967  
 黄色ワセリン 982  
 オウセイ 1336  
 オウバク 1330  
 オウバク・タンナルビン・ビスマス散 1332  
 オウバク末 1331  
 オウレン 1277, 1940  
 オウレン末 1278, 1940  
 オキサゾラム 948  
 オキサビウムヨウ化物 947  
 オキサプロジン 948  
 オキシドロン塩酸塩水和物 951  
 オキシテトラサイクリン塩酸塩 956  
 オキシトシン 958  
 オキシトシン注射液 960

オキシドール 954  
 オキシブプロカイン塩酸塩 951  
 オキシメトロン 956  
 オキセサゼイン 949  
 オクスプレノロール塩酸塩 950  
 オザグレルナトリウム 1916  
 オフロキサシン 938  
 オメブラゾール 1915  
 オリブ油 939  
 オルシプレナリン硫酸塩 946  
 オレンジ油 946  
 オンジ 1335, 1962  
 オンジ末 1335, 1962

## カ

カイニン酸・サントニン散 790  
 カイニン酸水和物 789  
 カオリン 795  
 カカオ脂 386  
 加香ヒマシ油 415  
 カゴソウ 1341  
 カシュウ 1336, 1962  
 ガジュツ 1372, 1969  
 加水ラノリン 807  
 ガスエソウマ抗毒素 696  
 カッコン 1341  
 葛根湯エキス 1308, 1950  
 過テクネチウム酸ナトリウム(<sup>99m</sup>Tc)注射液 1105  
 果糖 689  
 果糖注射液 689, 1888  
 カナマイシン一硫酸塩 793  
 カナマイシン硫酸塩 794  
 カノコソウ 1306, 1950  
 カノコソウ末 1307, 1950  
 カフェイン水和物 387  
 カプセル 403  
 カプトプリル 403  
 ガベキサートメシル酸塩 693, 1889  
 過マンガン酸カリウム 1013  
 加味逍遙散エキス 1310, 1952  
 カモスタットメシル酸塩 400, 1852  
 β-ガラクトシダーゼ(アスペルギルス) 694  
 β-ガラクトシダーゼ(ペニシリウム) 695  
 カリジノゲナーゼ 790  
 カリ石ケン 1007  
 カルテオロール塩酸塩 412  
 カルナウバロウ 411  
 カルバゾクロムスルホン酸ナトリウム水和物 405  
 カルバマゼピン 404  
 カルビドパ水和物 406  
 L-カルボシステイン 407  
 カルメロース 408  
 カルメロースカルシウム 409  
 カルメロースナトリウム 410  
 カルモナムナトリウム 412  
 カルモフル 411  
 カロコン 1369  
 カンキョウ 1341, 1964

乾燥亜硫酸ナトリウム 1109  
 乾燥甲状腺 1171  
 乾燥酵母 1241  
 乾燥細胞培養痘そうワクチン 1091  
 乾燥ジフテリアウマ抗毒素 596  
 乾燥弱毒生おたふくかぜワクチン 902  
 乾燥弱毒生風しんワクチン 1074  
 乾燥弱毒生麻疹ワクチン 843  
 乾燥水酸化アルミニウムゲル 288  
 乾燥水酸化アルミニウムゲル細粒 289  
 乾燥組織培養不活化狂犬病ワクチン 1054  
 乾燥炭酸ナトリウム 1096  
 乾燥痘そうワクチン 1091  
 乾燥日本脳炎ワクチン 786  
 乾燥破傷風ウマ抗毒素 1156  
 乾燥はぶウマ抗毒素 716  
 乾燥 BCG ワクチン 335  
 乾燥ボツリススウマ抗毒素 374  
 乾燥まむしウマ抗毒素 841  
 乾燥硫酸アルミニウムカリウム 292  
 カンゾウ 1295  
 カンゾウエキス 1296, 1943  
 カンゾウ粗エキス 1297, 1943  
 カンゾウ末 1296  
 カンテン 1252  
 カンテン末 1253  
 含糖ペプシン 1074  
*d*-カンフル 401  
*dl*-カンフル 402  
 肝油 538  
 カンレノ酸カリウム 1008

## キ

希塩酸 726  
 キキョウ 1334  
 キキョウ末 1335  
 キキョウ流エキス 1334, 1962  
 キクカ 1271  
 キササゲ 1271  
 キジツ 1302  
 キシリトール 1240  
 キシリトール注射液 1241, 1935  
 キタサマイシン 798  
 キタサマイシン酢酸エステル 799  
 キタサマイシン酒石酸塩 800  
 キニジン硫酸塩水和物 1050  
 キニーネエチル炭酸エステル 1051  
 キニーネ塩酸塩水和物 1052  
 キニーネ硫酸塩水和物 1053  
 牛脂 336  
 吸水軟膏 265  
 キョウカツ 1321, 1960  
 キョウニン 1257, 1937  
 キョウニン水 1257  
 希ヨードチンキ 769  
 金チオリンゴ酸ナトリウム 1092

## ク

グアイフェネシン 714  
 グアナベンズ酢酸塩 715  
 グアネチジン硫酸塩 716  
 グアヤコールスルホン酸カリウム 1011  
 クエン酸カリウム (<sup>67</sup>Ga) 注射液 696  
 クエン酸水和物 515  
 クエン酸ナトリウム水和物 1099  
 クコシ 1315  
 クジン 1364, 1968  
 クジン末 1364, 1969  
 苦味重曹水 1364  
 苦味チンキ 1266  
 クラブラン酸カリウム 1010  
 グラミシジン 712  
 クラリスロマイシン 516  
 クラリスロマイシン錠 517  
 グリシン 704  
 グリセオフルビン 713  
 グリセオフルビン錠 1890  
 グリセリン 702  
 グリセリンカリ液 704  
 クリノフィブラート 522  
 グリベンクラミド 699  
 クリンダマイシン塩酸塩 519  
 クリンダマイシン塩酸塩カプセル 520  
 クリンダマイシンリン酸エステル 521  
 クリンダマイシンリン酸エステル注射液 1866  
 グルコン酸カルシウム水和物 391  
 グルタチオン 701  
 L-グルタミン 1889  
 クレオソート 544  
 クレゾール 544  
 クレゾール水 545  
 クレゾール石ケン液 545  
 クレマスチンフマル酸塩 519  
 クロカプラミン塩酸塩水和物 523  
 クロキサシリンナトリウム水和物 533  
 クロキサゾラム 534  
 クロコナゾール塩酸塩 546  
 クロスカルメロースナトリウム 546  
 クロチアゼパム 531  
 クロトリマゾール 532  
 クロナゼパム 528  
 クロニジン塩酸塩 529  
 クロフィブラート 525  
 クロフィブラートカプセル 526  
 クロフェダノール塩酸塩 524  
 クロベタゾールプロピオン酸エステル 1867  
 クロペラスチン塩酸塩 530  
 クロミフェンクエン酸塩 526  
 クロミフェンクエン酸塩錠 527  
 クロミプラミン塩酸塩 528  
 クロム酸ナトリウム (<sup>61</sup>Cr) 注射液 1099

クロモグリク酸ナトリウム 1100  
 クロラゼブ酸ナトリウム 1868  
 クロラゼブ酸ナトリウムカプセル 1869  
 クロラムフェニコール 487  
 クロラムフェニコールコハク酸エステルナトリウム 489  
 クロラムフェニコールパルミチン酸エステル 488  
 クロルジアゼポキシド 490  
 クロルジアゼポキシド散 491  
 クロルジアゼポキシド錠 492, 1858  
 クロルフェニラミン・カルシウム散 497  
 クロルフェニラミンマレイン酸塩 498  
*d*-クロルフェニラミンマレイン酸塩 501  
 クロルフェニラミンマレイン酸塩散 499  
 クロルフェニラミンマレイン酸塩錠 500  
 クロルフェニラミンマレイン酸塩注射液 499  
 クロルフェネシカルバミン酸エステル 496, 1858  
 クロルフェネシカルバミン酸エステル錠 1859  
 クロルプロパミド 504  
 クロルプロパミド錠 505, 1861  
 クロルプロマジン塩酸塩 502  
 クロルプロマジン塩酸塩錠 503, 1861  
 クロルプロマジン塩酸塩注射液 503, 1860  
 クロルヘキシジン塩酸塩 493  
 クロルヘキシジングルコン酸塩液 493  
 クロルマジノン酢酸エステル 494  
 クロロブタノール 495

## ケ

ケイガイ 1353  
 経口生ポリオワクチン 1005  
 ケイ酸マグネシウム 836  
 軽質無水ケイ酸 1087  
 軽質流動パラフィン 967  
 桂枝茯苓丸エキス 1955  
 ケイヒ 1272  
 ケイヒ末 1273  
 ケイヒ油 1273  
 ケタミン塩酸塩 795  
 結晶性インスリン亜鉛水性懸濁注射液 765  
 結晶セルロース 477  
 血清性性腺刺激ホルモン 710  
 ケツメイシ 1271  
 ケトチフェンフマル酸塩 797  
 ケトプロフェン 796  
 ケノデオキシコール酸 486  
 ケンゴシ 1330  
 ゲンタマイシン硫酸塩 698

ゲンチアナ 1290, 1943  
 ゲンチアナ・重曹散 1290  
 ゲンチアナ末 1290, 1943  
 ゲンノショウコ 1291  
 ゲンノショウコ末 1291

## コ

コウカ 1348  
 硬化油 735  
 コウジン 1342  
 合成ケイ酸アルミニウム 290  
 コウブシ 1280, 1942  
 コウブシ末 1280, 1942  
 コウボク 1315, 1959  
 コウボク末 1316, 1959  
 ゴオウ 1325  
 コカイン塩酸塩 535  
 ゴシツ 1252  
 ゴシユユ 1285  
 コデインリン酸塩散 1% 536  
 コデインリン酸塩散 10% 537  
 コデインリン酸塩錠 537  
 コデインリン酸塩水和物 536  
 ゴナドレリン酢酸塩 705  
 ゴボウシ 1267  
 ゴマ油 1084  
 ゴミシ 1352  
 コムギデンプン 1237  
 コメデンプン 1346  
 コリスチンメタンスルホン酸ナトリウム 540  
 コリスチン硫酸塩 541  
 コルチゾン酢酸エステル 543  
 コルヒチン 538  
 コレカルシフェロール 506  
 コレステロール 507  
 コレラワクチン 506  
 コロンボ 1267, 1939  
 コロンボ末 1268, 1939  
 コンズランゴ 1276  
 コンズランゴ流エキス 1277, 1940

## サ

サイクロセリン 551  
 サイコ 1266  
 サイシン 1259, 1938  
 柴苓湯エキス 1349  
 酢酸 268  
 酢酸ナトリウム水和物 1091  
 サッカリン 1075  
 サッカリンナトリウム水和物 1076  
 サフラン 1349  
 サラシ粉 494  
 サラシミツロウ 336  
 サラゾスルファピリジン 1077  
 サリチル酸 1079, 1924  
 サリチル酸精 1080  
 サリチル酸ナトリウム 1108  
 サリチル酸絆創膏 1080  
 サリチル酸メチル 881  
 サリチル・ミョウバン散 1078

ザルトプロフェン 1242  
 ザルトプロフェン錠 1243  
 サルブタモール硫酸塩 1078  
 酸化亜鉛 1245  
 酸化カルシウム 393  
 酸化チタン 1178  
 酸化マグネシウム 835  
 サンキライ 1364, 1968  
 サンキライ末 1364, 1968  
 サンザシ 1941  
 三酸化ヒ素 316  
 サンシシ 1288  
 サンシシ末 1288  
 サンシユユ 1279  
 サンショウ 1371  
 サンショウ末 1371  
 酸素 955  
 サンソウニン 1307  
 サントニン 1081  
 サンヤク 1282, 1942  
 サンヤク末 1282, 1942

## シ

ジアスターゼ 567  
 ジアスターゼ・重曹散 567  
 ジアゼパム 567  
 シアナミド 548  
 シアノコバラミン 548, 1870  
 シアノコバラミン注射液 549, 1871  
 ジエチルカルバマジンクエン酸塩 574  
 ジエチルカルバマジンクエン酸塩錠 574  
 ジオウ 1343, 1964  
 歯科用アンチホルミン 310  
 歯科用トリオジンクパスタ 1210  
 歯科用パラホルムパスタ 969  
 歯科用フェノール・カンフル 987  
 歯科用ヨード・グリセリン 771  
 ジギトキシン 576  
 ジギトキシン錠 576  
 シクラシリン 507  
 ジクロキシサリリンナトリウム水和物 573  
 シクロスポリン 508  
 ジクロフェナクナトリウム 570  
 ジクロフェナミド 571  
 ジクロフェナミド錠 572  
 シクロペントラート塩酸塩 549  
 シクロホスファミド水和物 550  
 シゴカ 1283  
 ジゴキシン 578  
 ジゴキシン錠 580  
 ジゴキシン注射液 579  
 ジコッピ 1315, 1959  
 シコン 1313, 1959  
 次硝酸ビスマス 369  
 ジスチグミン臭化物 599  
 ジスチグミン臭化物錠 600  
 L-システイン 1871  
 L-システイン塩酸塩水和物 1872  
 シスプラチン 513

ジスルフィラム 600  
 ジソピラミド 598  
 シソマイシン硫酸塩 1090  
 シタラビン 552  
 シッカニン 1086  
 シツリシ 1369  
 ジドブジン 1935  
 ジドロゲステロン 609  
 ジドロゲステロン錠 610  
 ジノスタチン スチマラマー 1247  
 ジノプロスト 592  
 ジヒドロエルゴタミンメシル酸塩 583  
 ジヒドロエルゴトキシメシル酸塩 584  
 ジヒドロコデインリン酸塩 581  
 ジヒドロコデインリン酸塩散 1% 582  
 ジヒドロコデインリン酸塩散 10% 582  
 ジピリダモール 597  
 ジフェニドール塩酸塩 575  
 ジフェンヒドラミン 593  
 ジフェンヒドラミン塩酸塩 594  
 ジフェンヒドラミン・バレリル尿素散 593  
 ジフェンヒドラミン・フェノール・亜鉛華リニメント 595  
 ジブカイン塩酸塩 569  
 ジフテリアトキシイド 596  
 ジフテリア破傷風混合トキシイド 596  
 シプロヘプタジン塩酸塩水和物 551  
 ジベカシン硫酸塩 569  
 シベンゾリンコハク酸塩 1861  
 シベンゾリンコハク酸塩錠 1862  
 シメチジン 513  
 ジメルファンリン酸塩 588  
 ジメルカプロール 590  
 ジメルカプロール注射液 590  
 ジメンヒドリナート 588  
 ジメンヒドリナート錠 589  
 次没食子酸ビスマス 368  
 ジモルホラミン 591  
 ジモルホラミン注射液 591  
 弱アヘンアルカロイド・スコボラミン注射液 945  
 シャクヤク 1328  
 シャクヤク末 1329  
 ジャシヨウシ 1275  
 シャゼンシ 1334  
 シャゼンソウ 1334  
 臭化カリウム 1008  
 臭化ナトリウム 1095  
 ジュウヤク 1302  
 シュクシャ 1256  
 シュクシャ末 1256  
 酒石酸 1141  
 ショウキョウ 1291  
 ショウキョウ末 1292  
 硝酸イソソルビド 785  
 硝酸イソソルビド錠 786  
 硝酸銀 1088

硝酸銀点眼液 1088  
 常水 1235  
 ショウズク 1271  
 焼セッコウ 1298  
 消毒用エタノール 640  
 消毒用フェノール 986  
 消毒用フェノール水 987  
 ショウマ 1272, 1939  
 ジョサマイシン 786  
 ジョサマイシン錠 1897  
 ジョサマイシンプロピオン酸エステル  
 788  
 シラザプリル錠 1864  
 シラザプリル水和物 1863  
 シラストチンナトリウム 509  
 ジラゼブ塩酸塩水和物 586  
 ジルチアゼム塩酸塩 586  
 シロスタゾール 511  
 シロスタゾール錠 512, 1866  
 シロップ用セファドロキシル 1853  
 シロップ用ファロペネムナトリウム  
 659, 1886  
 シンイ 1317  
 親水軟膏 735  
 親水ワセリン 981  
 診断用クエン酸ナトリウム液 1100

## ス

水酸化カリウム 1012  
 水酸化カルシウム 392  
 水酸化ナトリウム 1101  
 スキサメトニウム塩化物水和物  
 1137  
 スキサメトニウム塩化物注射液  
 1138, 1928  
 スクラルファート水和物 1118  
 スコポラミン臭化水素酸塩水和物  
 1083  
 ステアリルアルコール 1117  
 ステアリン酸 1116  
 ステアリン酸カルシウム 400  
 ステアリン酸ポリオキシル 40 1007  
 ステアリン酸マグネシウム 837  
 ストレプトマイシン硫酸塩 1117  
 スピラマイシン酢酸エステル 1114  
 スピロノラクトン 1116  
 スベクチノマイシン塩酸塩水和物  
 1114  
 スルタミシリンシロ酸塩水和物  
 1134, 1927  
 スルチアム 1136  
 スルバクタムナトリウム 1122, 1927  
 スルピリド 1131  
 スルピリドカプセル 1132  
 スルピリド錠 1132  
 スルピリン水和物 1133  
 スルピリン注射液 1134, 1927  
 スルファジアジン銀 1124  
 スルファメチゾール 1125  
 スルファメトキサゾール 1126  
 スルファモノメトキシ水和物  
 1126

スルフィソキサゾール 1128  
 スルフィンピラゾン 1127, 1927  
 スルフィンピラゾン錠 1128, 1927  
 スルベニシリンナトリウム 1123  
 スルホプロモフタレインナトリウム  
 1129  
 スルホプロモフタレインナトリウム注  
 射液 1130

## セ

成人用沈降ジフテリアトキシイド  
 596  
 精製水 1236  
 精製ゼラチン 697  
 精製セラック 1085  
 精製デヒドロコール酸 556  
 精製白糖 1120  
 精製ラノリン 808  
 生理食塩液 1098, 1893  
 石油ベンジン 982  
 セタノール 484  
 セチリジン塩酸塩 1856  
 セチリジン塩酸塩錠 1857  
 セッコウ 1297  
 セトラキサート塩酸塩 485  
 セネガ 1360, 1968  
 セネガシロップ 1361  
 セネガ末 1361, 1968  
 セファクロル 415  
 セファクロルカプセル 416  
 セファクロル細粒 417  
 セファクロル複合顆粒 419  
 セファゾリンナトリウム 426  
 セファゾリンナトリウム水和物 428  
 セファトリジンプロピレングリコール  
 425, 1854  
 セファドロキシル 421  
 セファドロキシルカプセル 1852  
 セファピリンナトリウム 424  
 セファレキシン 422  
 セファロチンナトリウム 423, 1854  
 セフィキシム 442  
 セフェピム塩酸塩水和物 439  
 セフォジジムナトリウム 447  
 セフォゾプラン塩酸塩 457  
 セフォタキシムナトリウム 449  
 セフォチアム塩酸塩 455  
 セフォチアムヘキセチル塩酸塩 453  
 セフォテタン 451  
 セフォペラゾンナトリウム 448  
 セフカベン ピボキシル塩酸塩細粒  
 432  
 セフカベン ピボキシル塩酸塩錠 433  
 セフカベン ピボキシル塩酸塩水和物  
 430  
 セフジトレン ピボキシル 437  
 セフジトレン ピボキシル細粒 438  
 セフジトレン ピボキシル錠 438  
 セフジニル 434  
 セフジニルカプセル 435  
 セフジニル細粒 436  
 セフスロジンナトリウム 464

セフタジジム水和物 466  
 セフチゾキシムナトリウム 471  
 セフチブテン水和物 470  
 セフテラム ピボキシル 468  
 セフテラム ピボキシル細粒 469  
 セフトリアキソンナトリウム水和物  
 472  
 セフピラミドナトリウム 458  
 セフピロム硫酸塩 460  
 セフペラゾンナトリウム 429  
 セフポドキシム プロキセチル 461  
 セフミノクスナトリウム水和物 446  
 セフメタゾールナトリウム 445  
 セフメノキシム塩酸塩 443  
 セフロキサジン水和物 462  
 セフロキシム アキセチル 474  
 セフロキシムナトリウム 476  
 セラセフェート 480  
 ゼラチン 696  
 セラペプターゼ 1083  
 L-セリン 1925  
 セルモロイキン(遺伝子組換え) 481  
 センキュウ 1275, 1939  
 センキュウ末 1276, 1940  
 ゼンコ 1961  
 センコツ 1321, 1960  
 センソ 1368  
 センナ 1361  
 センナ末 1362  
 センブリ 1365  
 センブリ・重曹散 1367  
 センブリ末 1366

## ソ

ソウジュツ 1260  
 ソウジュツ末 1260  
 ソウハクヒ 1320, 1960  
 ソボク 1352  
 ソヨウ 1329, 1961  
 ソルビタンセスキオレイン酸エステル  
 1111  
 D-ソルビトール 1112  
 D-ソルビトール液 1112

## タ

ダイオウ 1344  
 大黃甘草湯エキス 1280  
 ダイオウ末 1345  
 ダイズ油 1113  
 タイソウ 1307  
 ダウノルピシン塩酸塩 553  
 タウリン 1142  
 タクシャ 1253  
 タクシャ末 1253  
 タムスロシン塩酸塩 1140  
 タランピシリン塩酸塩 1138  
 タルク 1139, 1928  
 炭酸カリウム 1009  
 炭酸水素ナトリウム 1093  
 炭酸水素ナトリウム注射液 1094,  
 1925



炭酸ナトリウム水和物 1096  
 炭酸マグネシウム 834  
 炭酸リチウム 826  
 単シロップ 1089  
 ダントロレンナトリウム水和物 553  
 単軟膏 1089  
 タンニン酸 1141  
 タンニン酸アルブミン 282  
 タンニン酸ジフェンヒドラミン 595  
 タンニン酸ベルベリン 352

## チ

チアマゾール 1159  
 チアマゾール錠 1160  
 チアミラルナトリウム 1163  
 チアミン塩化物塩酸塩 1160  
 チアミン塩化物塩酸塩散 1162  
 チアミン塩化物塩酸塩注射液 1161, 1930  
 チアミン硝化物 1162  
 チアラミド塩酸塩 1171  
 チアラミド塩酸塩錠 1172  
 チアントール 1165  
 チオテパ 1168  
 チオペンタールナトリウム 1166  
 チオリダジン塩酸塩 1168  
 チオ硫酸ナトリウム水和物 1109  
 チオ硫酸ナトリウム注射液 1110, 1927  
 チクセツニンジン 1326, 1960  
 チクセツニンジン末 1327, 1960  
 チクロピジン塩酸塩 1173  
 チザニジン塩酸塩 1179  
 窒素 928  
 チニダゾール 1175  
 チペピジンヒベンズ酸塩 1176  
 チペピジンヒベンズ酸塩錠 1177, 1930  
 チメビジウム臭化物水和物 1174  
 チモ 1256, 1937  
 チモール 1170  
 チモロールマレイン酸塩 1174  
 注射用アズトレオナム 1840  
 注射用アセチルコリン塩化物 271, 1825  
 注射用アムホテリシン B 304  
 注射用アモバルビタールナトリウム 300  
 注射用アンピシリンナトリウム 1838  
 注射用イダルビシン塩酸塩 746  
 注射用イミペネム・シラスタチンナトリウム 750  
 注射用オザグレルナトリウム 1917  
 注射用血清性腺刺激ホルモン 711  
 注射用水 1235, 1934  
 注射用スキサメトニウム塩化物 1137, 1928  
 注射用セファゾリンナトリウム 1854  
 注射用セフェピム塩酸塩 441  
 注射用セフォゾラン塩酸塩 458

注射用セフォチアム塩酸塩 456  
 注射用セフタジジム 1856  
 注射用セフメタゾールナトリウム 1855  
 注射用チアミラルナトリウム 1164  
 注射用チオペンタールナトリウム 1167, 1930  
 注射用テセロイキン(遺伝子組換え) 1148, 1929  
 注射用ドキシソルピシン塩酸塩 1877  
 注射用バンコマイシン塩酸塩 1223  
 注射用ヒト絨毛性腺刺激ホルモン 708  
 注射用ヒドララジン塩酸塩 724  
 注射用ピペラシリンナトリウム 998  
 注射用ピンブラスチン硫酸塩 1227  
 注射用ファモチジン 656, 1885  
 注射用フェニトインナトリウム 992  
 注射用ブレドニゾロンコハク酸エステルナトリウム 1025, 1921  
 注射用フロモキシセフナトリウム 666  
 注射用ペプロマイシン硫酸塩 1918  
 注射用ベンジルペニシリンカリウム 1841  
 注射用ホスホマイシンナトリウム 687  
 注射用マイトマイシンC 1905  
 注射用ミノサイクリン塩酸塩 1904  
 チョウジ 1274  
 チョウジ末 1274  
 チョウジ油 1275  
 チョウトウコウ 1370  
 チョレイ 1336, 1962  
 チョレイ末 1337, 1963  
 L-チロジン 1931  
 チンク油 1245  
 沈降ジフテリア破傷風混合トキソイド 596  
 沈降精製百日せきジフテリア破傷風混合ワクチン 596  
 沈降精製百日せきワクチン 980  
 沈降炭酸カルシウム 389  
 沈降破傷風トキソイド 1156  
 沈降はぶトキソイド 716  
 沈降 B 型肝炎ワクチン 716  
 チンピ 1273

## ツ

ツバキ油 400  
 ツボクラリン塩化物塩酸塩水和物 1212, 1931  
 ツボクラリン塩化物塩酸塩注射液 1213, 1931  
 ツロブテロール塩酸塩 1213

## テ

テイコプラニン 1150  
 低置換度ヒドロキシプロピルセルロース 738  
 テオフィリン 1158

テガフル 1149  
 デキサメタゾン 560  
 デキストラン 40 561, 1873  
 デキストラン 40 注射液 562  
 デキストラン 70 563  
 デキストラン硫酸エステルナトリウムイオウ 5 564  
 デキストラン硫酸ナトリウムイオウ 18 565  
 デキストリン 565  
 デキストロメトルファン臭化水素酸塩水和物 566  
 テストステロンエナント酸エステル 1154  
 テストステロンエナント酸エステル注射液 1154  
 テストステロンプロピオン酸エステル 1155  
 テストステロンプロピオン酸エステル注射液 1155  
 デスラノシド 559  
 デスラノシド注射液 560, 1873  
 テセロイキン(遺伝子組換え) 1143  
 テトラカイン塩酸塩 1156  
 テトラサイクリン塩酸塩 1157  
 デヒドロコール酸 556  
 デヒドロコール酸注射液 557, 1873  
 デフェロキサミンメシル酸塩 554, 1873  
 デメチルクロルテトラサイクリン塩酸塩 558  
 テルブタリン硫酸塩 1153  
 テレピン油 1214  
 天然ケイ酸アルミニウム 289  
 デンブングリコール酸ナトリウム 1926  
 テンマ 1289, 1943  
 テンモンドウ 1259, 1938

## ト

トウガシ 1264  
 トウガラシ 1268  
 トウガラシ・サリチル酸精 1270  
 トウガラシチンキ 1269  
 トウガラシ末 1269  
 トウキ 1305  
 トウキ末 1305  
 トウニン 1327, 1961  
 トウニン末 1327, 1961  
 トウヒ 1265  
 トウヒシロップ 1325  
 トウヒチンキ 1325  
 トウモロコシデンブ 542  
 トウモロコシ油 542  
 ドキサプラム塩酸塩水和物 603  
 ドキシサイクリン塩酸塩水和物 606  
 ドキシフルリジン 604  
 ドキシフルリジンカプセル 604  
 ドキシソルピシン塩酸塩 605  
 ドクカツ 1937  
 トコフェロール 1181  
 トコフェロールコハク酸エステルカル

シウム 1183  
トコフェロール酢酸エステル 1182  
トコフェロールニコチン酸エステル 1184  
トコン 1303, 1949  
トコンシロップ 1304  
トコン末 1303, 1949  
トチュウ 1284  
トドララジン塩酸塩水和物 1185  
ドパミン塩酸塩 602  
ドパミン塩酸塩注射液 602, 1877  
トフィソパム 1186  
ドブタミン塩酸塩 601  
トブラマイシン 1180  
トブラマイシン注射液 1930  
トラガント 1369  
トラガント末 1369  
トラザミド 1187  
トラネキサム酸 1191  
トラネキサム酸カプセル 1192  
トラネキサム酸錠 1193  
トラネキサム酸注射液 1193  
トラビジル 1194  
トリアムシノロン 1195  
トリアムシノロンアセトニド 1196  
トリアムテレン 1197  
トリクロホスナトリウム 1202  
トリクロホスナトリウムシロップ 1203  
トリクロルメチアジド 1198  
トリクロルメチアジド錠 1199  
トリコマイシン 1201  
L-トリプトファン 1211  
トリヘキシフェニジル塩酸塩 1204  
トリヘキシフェニジル塩酸塩錠 1204  
トリメタジオン 1208  
トリメタジオン錠 1209  
トリメタジジン塩酸塩 1207, 1931  
トリメタジジン塩酸塩錠 1207  
トリメトキノール塩酸塩水和物 1209  
トリメプチンマレイン酸塩 1206  
トルナフタート 1189  
トルナフタート液 1189  
トルブタミド 1188  
トルブタミド錠 1188  
トルペリゾン塩酸塩 1190  
L-トレオニン 1169  
トレピプトン 1195  
トロピカミド 1211  
ドロペリドール 608  
トロンピン 1170  
豚脂 808  
ドンペリドン 1876

**ナ**

ナイスタチン 937  
ナタネ油 1055  
ナドロール 904  
ナファゾリン塩酸塩 907  
ナファゾリン・クロルフェニラミン液

906  
ナファゾリン硝酸塩 908  
ナファモスタットメシル酸塩 1911  
ナブメトン 1908  
ナブメトン錠 1910  
ナブロキセン 908  
ナリジクス酸 905  
ナロキソン塩酸塩 906

**ニ**

ニガキ 1333  
ニガキ末 1333  
ニカルジピン塩酸塩 911  
ニカルジピン塩酸塩注射液 912, 1912  
ニコチン酸 920  
ニコチン酸アミド 919  
ニコチン酸注射液 921, 1912  
ニコモール 917  
ニコモール錠 918  
ニコランジル 919, 1912  
ニザチジン 1912  
ニザチジンカプセル 1913  
二酸化炭素 407  
ニセリトロール 916  
ニセルゴリン 913  
ニセルゴリン散 914  
ニセルゴリン錠 915  
ニトラゼパム 925  
ニトレンジピン 926  
ニトレンジピン錠 927  
ニトログリセリン錠 928  
ニフェジピン 922  
日本脳炎ワクチン 786  
乳酸 801  
乳酸カルシウム水和物 393  
乳糖水和物 803  
尿素 1218  
ニルバジピン 923  
ニルバジピン錠 924  
ニンジン 1292  
ニンジン末 1293  
ニンドウ 1314

**ネ**

ネオスチグミンメチル硫酸塩 909  
ネオスチグミンメチル硫酸塩注射液 910, 1912  
ネチルマイシン硫酸塩 910

**ノ**

濃グリセリン 703  
濃ベンザルコニウム塩化物液 50 343  
ノスカピン 936  
ノスカピン塩酸塩水和物 937  
ノルアドレナリン 930  
ノルアドレナリン注射液 931, 1915  
ノルエチステロン 932  
ノルゲストレル 933  
ノルゲストレル・エチニルエストラジ

オール錠 934  
ノルトリプチリン塩酸塩 935  
ノルフロキサシン 932

**ハ**

バイモ 1287, 1942  
バカンピシリン塩酸塩 329  
白色セラック 1085  
白色軟膏 1238  
白色ワセリン 981  
白糖 1121  
バクモンドウ 1324  
バクロフェン 331  
バクロフェン錠 332, 1841  
バシトラシン 330  
バソプレシン注射液 1223  
ハチミツ 1301  
ハッカ 1317  
ハッカ水 1318  
ハッカ油 1318  
パップ用複方オウバク散 1332  
パニベネム 962  
パパベリン塩酸塩 965  
パパベリン塩酸塩注射液 965, 1918  
ハマボウフウ 1294, 1943  
バメタン硫酸塩 333  
パラアミノサリチル酸カルシウム顆粒 394  
パラアミノサリチル酸カルシウム水和物 395  
パラオキシ安息香酸エチル 647  
パラオキシ安息香酸ブチル 386  
パラオキシ安息香酸プロピル 1039  
パラオキシ安息香酸メチル 878  
パラフィン 966  
パラホルムアルデヒド 968  
L-バリリン 1221  
パルナパリンナトリウム 969  
バルビタール 333  
バルプロ酸ナトリウム 1110  
バレイショデンプン 1014  
ハロキサゾラム 719  
ハロタン 719  
ハロペリドール 717  
ハロペリドール錠 718  
パンクレアチン 961  
パンクロニウム臭化物 962  
ハンゲ 1333  
半夏厚朴湯エキス 1943  
バンコマイシン塩酸塩 1221  
バンテチン 964  
パントテン酸カルシウム 394

**ヒ**

ビオチン 1842  
ビコスルファートナトリウム水和物 1105  
ビスコジル 367  
ビスコジル坐剤 368, 1843  
ビスプロロールフマル酸塩 1843  
ビスプロロールフマル酸塩錠 1844

- ビタミン A 油 1229  
 ビタミン A 油カプセル 1230  
 ヒトインスリン(遺伝子組換え) 760  
 ヒト下垂体性腺刺激ホルモン 708  
 ヒト絨毛性腺刺激ホルモン 707  
 人全血液 1238  
 人免疫グロブリン 724  
 ヒドララジン塩酸塩 724  
 ヒドララジン塩酸塩散 725  
 ヒドララジン塩酸塩錠 725, 1890  
 ヒドロキシジン塩酸塩 739  
 ヒドロキシジパモ酸塩 739  
 ヒドロキシプロピルセルロース 736  
 ヒドロキシコバラミン酢酸塩 736  
 ヒドロクロロチアジド 727  
 ヒドロコタルニン塩酸塩水和物 734  
 ヒドロコルチゾン 728  
 ヒドロコルチゾンコハク酸エステル 733  
 ヒドロコルチゾンコハク酸エステルナトリウム 732  
 ヒドロコルチゾン酢酸エステル 729  
 ヒドロコルチゾン・ジフェンヒドラミン軟膏 730  
 ヒドロコルチゾン酪酸エステル 730  
 ヒドロコルチゾンリン酸エステルナトリウム 731  
 ビブメシリナム塩酸塩 1004  
 ヒプロメロース 741  
 ヒプロメロースフタル酸エステル 743, 1891  
 ピペミド酸水和物 996  
 ピペラシリン水和物 1919  
 ピペラシリンナトリウム 997  
 ピペラジンアジピン酸塩 999  
 ピペラジンリン酸塩錠 1000  
 ピペラジンリン酸塩水和物 999  
 ピペリデン塩酸塩 366  
 ビホナゾール 366  
 ヒマシ油 414  
 ビマリシン 994  
 ヒメクロモン 740  
 ジャクゴウ 1958  
 ジャクシ 1257, 1937  
 ジャクジュツ 1261, 1938  
 ジャクジュツ末 1261, 1939  
 氷酢酸 269  
 ビラジナミド 1046  
 ビラルビシン 1000  
 ビランテルパモ酸塩 1045  
 ビリドキシリン塩酸塩 1047  
 ビリドキシリン塩酸塩注射液 1048, 1922  
 ビリドスチグミン臭化物 1047  
 ビレノキシリン 1001  
 ビレンゼピン塩酸塩水和物 1002  
 ビロ亜硫酸ナトリウム 1108  
 ビロカルピン塩酸塩 994  
 ビロキシカム 1003  
 ビロキシリン 1049  
 ビロールニトリン 1049  
 ビワヨウ 1314  
 ビンクリスチン硫酸塩 1228, 1933  
 ピンドロール 995  
 ビンプラスチン硫酸塩 1226  
 ビンロウジ 1258  
 フ  
 ファモチジン 655  
 ファモチジン散 657  
 ファモチジン錠 657  
 ファロペネムナトリウム錠 660, 1886  
 ファロペネムナトリウム水和物 658, 1885  
 フィトナジオン 993  
 フェニトイン 991  
 フェニトイン散 992  
 フェニトイン錠 992  
 L-フェニルアラニン 989  
 フェニルブタゾン 990  
 フェニレフリン塩酸塩 990  
 フェネチシリンカリウム 983  
 フェノバルビタール 984  
 フェノバルビタール散 10% 985  
 フェノール 985  
 フェノール・亜鉛華リニメント 987  
 フェノール水 987  
 フェノールスルホンフタレイン 988  
 フェノールスルホンフタレイン注射液 988  
 フェルビナク 1887  
 フェンタニルクエン酸塩 661  
 フェンブフェン 660  
 複方アクリノール・チンク油 273  
 複方オキシコドン・アトロピン注射液 953  
 複方オキシコドン注射液 952  
 複方サリチル酸精 1080  
 複方サリチル酸メチル精 879  
 複方ジアスターゼ・重曹散 567  
 複方ダイオウ・センナ散 1346  
 複方チアントール・サリチル酸液 1165  
 複方ビタミン B 散 1230  
 複方ヨード・グリセリン 770  
 複方ロートエキス・ジアスターゼ散 1355  
 ブクモロール塩酸塩 378  
 ブクリョウ 1337  
 ブクリョウ末 1337  
 ブシ 1338, 1963  
 フシジン酸ナトリウム 1101  
 ブシ末 1339, 1963  
 ブシラミン 377  
 ブシラミン錠 1845  
 ブスルファン 384  
 ブチルスコポラミン臭化物 1082  
 ブドウ酒 1238  
 ブドウ糖 700  
 ブドウ糖注射液 701, 1889  
 ブトロピウム臭化物 385  
 ブナゾシン塩酸塩 383  
 ブフェキサマク 380  
 ブフェキサマククリーム 380  
 ブフェキサマク軟膏 381  
 ブフェトロール塩酸塩 379  
 ブプラノロール塩酸塩 383  
 ブプレノルフィン塩酸塩 1850  
 ブホルミン塩酸塩 1846  
 ブホルミン塩酸塩錠 1849  
 ブホルミン塩酸塩腸溶錠 1847  
 ブメタニド 382  
 フラジオマイシン硫酸塩 688  
 プラステロン硫酸エステルナトリウム水和物 1107  
 プラゼパム 1020  
 プラゼパム錠 1021  
 プラノプロフェン 1018  
 プラバスタチンナトリウム 1018  
 フラビンアデニンジヌクレオチドナトリウム 662  
 フラボキサート塩酸塩 664  
 プリミドン 1026  
 フルオキシメステロン 675  
 フルオシノニド 672  
 フルオシノロンアセトニド 670  
 フルオレセインナトリウム 673  
 フルオロウラシル 674  
 フルオロメトロン 673  
 フルジアゼパム 669  
 フルシトシン 668  
 フルスルチアミン塩酸塩 692  
 フルニトラゼパム 670  
 フルフェナジンエナンチオ酸エステル 676  
 フルラゼパム 677  
 フルラゼパム塩酸塩 678  
 フルラゼパムカプセル 678  
 フルラン 1045  
 フルルビプロフェン 679  
 プレオマイシン塩酸塩 370  
 プレオマイシン硫酸塩 372  
 プレドニゾロン 1021  
 プレドニゾロンコハク酸エステル 1024  
 プレドニゾロン酢酸エステル 1023  
 プレドニゾロン錠 1022  
 プロカインアミド塩酸塩 1028  
 プロカインアミド塩酸塩錠 1029  
 プロカインアミド塩酸注射液 1029  
 プロカイン塩酸塩 1030  
 プロカイン塩酸塩注射液 1030  
 プロカテロール塩酸水和物 1032  
 プロカルバジン塩酸塩 1031  
 プログルミド 1035  
 プロクロルペラジンマレイン酸塩 1033  
 プロクロルペラジンマレイン酸塩錠 1033  
 プロゲステロン 1034  
 プロゲステロン注射液 1034  
 フロセミド 690  
 フロセミド錠 691  
 プロタミンインスリン亜鉛水性懸濁注射液 766  
 プロタミン硫酸塩 1041, 1921  
 プロタミン硫酸塩注射液 1042, 1922

プロチオナミド 1042  
 プロチレリン 1043  
 プロチレリン酒石酸塩水和物 1044  
 プロテイン銀 1088  
 プロテイン銀液 1089  
 プロパンテリン臭化物 1036  
 プロピルチオウラシル 1040  
 プロピルチオウラシル錠 1040  
 プロピレングリコール 1039  
 プロプラノロール塩酸塩 1037  
 プロプラノロール塩酸塩錠 1038  
 フロプロピオン 667  
 フロプロピオンカプセル 667  
 プロベネシド 1027  
 プロベネシド錠 1027  
 プロマゼパム 374  
 プロムヘキシン塩酸塩 375  
 プロメタジン塩酸塩 1036  
 フロモキセフナトリウム 664  
 プロモクリプチンメシル酸塩 376  
 プロモバレリル尿素 377  
 粉末セルロース 480

## へ

ベカナマイシン硫酸塩 337  
 ベクロメタゾンプロピオン酸エステル  
 335  
 ベザフィブラート 364  
 ベザフィブラート徐放錠 365  
 ベタネコール塩化物 363  
 ベタヒスチンメシル酸塩 353, 1842  
 ベタヒスチンメシル酸塩錠 354  
 ベタメタゾン 355  
 ベタメタゾン吉草酸エステル 360  
 ベタメタゾン吉草酸エステル・ゲンタ  
 マイシン硫酸塩クリーム 361  
 ベタメタゾン吉草酸エステル・ゲンタ  
 マイシン硫酸塩軟膏 362  
 ベタメタゾンジプロピオン酸エステル  
 358  
 ベタメタゾン錠 356  
 ベタメタゾンリン酸エステルナトリウ  
 ム 359  
 ペチジン塩酸塩 980  
 ペチジン塩酸塩注射液 981, 1918  
 ベニジピン塩酸塩 338  
 ベニジピン塩酸塩錠 339  
 ヘパリンナトリウム 721  
 ヘパリンナトリウム注射液 722  
 ペプロマイシン硫酸塩 975  
 ベラドンナエキス 1263, 1939  
 ベラドンナコン 1263  
 ベラパミル塩酸塩 1225  
 ベラパミル塩酸塩錠 1226  
 ペルフェナジン 977  
 ペルフェナジン錠 977  
 ペルフェナジンマレイン酸塩 978  
 ペルフェナジンマレイン酸塩錠 979  
 ベルベリン塩化物水和物 351  
 ベンザルコニウム塩化物 342  
 ベンザルコニウム塩化物液 342  
 ベンジルアルコール 346

ベンジルペニシリンカリウム 349  
 ベンジルペニシリンベンザチン水和物  
 348  
 ヘンズ 1282  
 ベンズプロマロン 343  
 ベンゼトニウム塩化物 344  
 ベンゼトニウム塩化物液 345  
 ベンセラジド塩酸塩 340  
 ペンタゾシン 972  
 ペントキシベリンクエン酸塩 974  
 ベントナイト 341  
 ペントバルビタールカルシウム 973  
 ペンブトロール硫酸塩 972

## ホ

ボウイ 1363  
 ボウコン 1302, 1949  
 ホウ酸 374  
 ホウ砂 1095  
 抱水クロラル 487  
 ボウフウ 1352, 1966  
 ボグリボース 1231  
 ボグリボース錠 1232  
 ホスフェストロール 683, 1888  
 ホスフェストロール錠 684, 1888  
 ホスホマイシンカルシウム水和物  
 685  
 ホスホマイシンナトリウム 686  
 ボタンビ 1318  
 ボタンビ末 1319  
 補中益気湯エキス 1298, 1945  
 ポビドン 1015  
 ポビドンヨード 1017  
 ホマトロピン臭化水素酸塩 722  
 ホミカ 1321  
 ホミカエキス 1322, 1960  
 ホミカエキス散 1323  
 ホミカチンキ 1323  
 ホモクローシクリジン塩酸塩 723  
 ポリスチレンスルホン酸カルシウム  
 398  
 ポリスチレンスルホン酸ナトリウム  
 1106  
 ポリソルベート 80 1007  
 ホリナートカルシウム 391, 1851  
 ポリミキシン B 硫酸塩 1006  
 ホルマリン 681  
 ホルマリン水 682  
 ホルモテロールフマル酸塩水和物  
 682  
 ボレイ 1326  
 ボレイ末 1326

## マ

マイトマイシン C 898  
 マオウ 1283  
 マーキュロクロム 862  
 マーキュロクロム液 863  
 マクリ 1280  
 マクロゴール 400 830  
 マクロゴール 1500 831

マクロゴール 4000 832  
 マクロゴール 6000 832  
 マクロゴール 20000 833  
 マクロゴール軟膏 833  
 マシニン 1298  
 麻酔用エーテル 641  
 マニジピン塩酸塩 1900  
 マニジピン塩酸塩錠 1902  
 マプロチリン塩酸塩 842  
 マルトース水和物 840  
 D-マンニトール 841  
 D-マンニトール注射液 842, 1903

## ミ

ミグレニン 896  
 ミクロノマイシン硫酸塩 893  
 ミコナゾール 892  
 ミコナゾール硝酸塩 893  
 ミゾリピン 1906  
 ミゾリピン錠 1907  
 ミツロウ 336  
 ミデカマイシン 894  
 ミデカマイシン酢酸エステル 895  
 ミノサイクリン塩酸塩 897  
 ミョウバン水 293

## ム

無晶性インスリン亜鉛水性懸濁注射液  
 764  
 無水アンピシリン 306  
 無水エタノール 639  
 無水カフェイン 386  
 無水クエン酸 514  
 無水乳糖 802, 1900  
 無水リン酸水素カルシウム 396,  
 1874  
 ムピロシンカルシウム 水和物 902

## メ

メキシレチン塩酸塩 891  
 メキタジン 861  
 メグルミン 850  
 メクロフェノキサート塩酸塩 843  
 メコバラミン 844  
 メシル酸塩ガベキサート 693  
 メストラノール 864  
 メダゼパム 845, 1903  
 メタンフェタミン塩酸塩 868  
 L-メチオニン 869  
 メチ克蘭 884  
 メチラポン 890  
 dl-メチルエフェドリン塩酸塩 875  
 dl-メチルエフェドリン塩酸塩散 10%  
 876  
 メチルエルゴメトリンマレイン酸塩  
 876  
 メチルエルゴメトリンマレイン酸塩錠  
 877  
 メチルジゴキシン 885  
 メチルセルロース 871

メチルテストステロン 882  
 メチルテストステロン錠 883  
 メチルドパ錠 874, 1903  
 メチルドパ水和物 873  
 メチルプレドニゾロン 879  
 メチルプレドニゾロンコハク酸エステル 880  
 メチルベナクチジウム臭化物 871  
 メチルロザニリン塩化物 881  
 滅菌精製水 1236  
 メテノロンエナント酸エステル 866  
 メテノロンエナント酸エステル注射液 866  
 メテノロン酢酸エステル 865  
 メトキサレン 870  
 メトクロプラミド 886  
 メトクロプラミド錠 886  
 メトトレキサート 869  
 メトプロロール酒石酸塩 887  
 メトプロロール酒石酸塩錠 888  
 メトホルミン塩酸塩 867  
 メトホルミン塩酸塩錠 867  
 メトロニダゾール 889  
 メトロニダゾール錠 889  
 メナテトレノン 855  
 メピチオスタン 858  
 メピバカイン塩酸塩 859  
 メピバカイン塩酸塩注射液 860  
 メフェナム酸 847  
 メフルシド 849  
 メフルシド錠 849, 1903  
 メフロキソ塩酸塩 848  
 メペンゾラート臭化物 857  
 メルカプトプリン水和物 861  
 メルファラン 855  
 メロベネム 水和物 863  
 dl-メントール 856  
 l-メントール 857

## モ

木クレオソート 1870  
 モクツウ 1253  
 モッコウ 1352, 1966  
 モノステアリン酸アルミニウム 291  
 モノステアリン酸グリセリン 704  
 モルヒネ・アトロピン注射液 899  
 モルヒネ塩酸塩錠 902, 1908  
 モルヒネ塩酸塩水和物 900  
 モルヒネ塩酸塩注射液 901

## ヤ

ヤクチ 1265  
 ヤクモソウ 1958  
 薬用石ケン 846  
 薬用炭 845  
 ヤシ油 535

## ユ

ユウタン 1262  
 ユーカリ油 654

輸血用クエン酸ナトリウム注射液 1099, 1926  
 ユビデカレノン 1214

## ヨ

ヨウ化カリウム 1013  
 ヨウ化ナトリウム 1102  
 ヨウ化ナトリウム (<sup>123</sup>I) カプセル 1103  
 ヨウ化ナトリウム (<sup>131</sup>I) 液 1103  
 ヨウ化ナトリウム (<sup>131</sup>I) カプセル 1103  
 ヨウ化人血清アルブミン (<sup>131</sup>I) 注射液 768  
 ヨウ化ヒプル酸ナトリウム (<sup>131</sup>I) 注射液 1103  
 葉酸 680  
 葉酸錠 681, 1888  
 葉酸注射液 681, 1888  
 ヨウ素 768  
 ヨクイニン 1276  
 ヨクイニン末 1276  
 ヨーダミド 767  
 ヨーダミドナトリウムメグルミン注射液 854  
 ヨード・サリチル酸・フェノール精 772  
 ヨードチンキ 769  
 ヨードホルム 773

## ラ

ラウリル硫酸ナトリウム 1104  
 ラウロマクロゴール 810  
 ラクツロース 804  
 ラタモキセフナトリウム 809  
 ラッカセイ油 971  
 ラナトシド C 805  
 ラナトシド C 錠 806  
 ラニチジン塩酸塩 1054  
 ラベタロール塩酸塩 1898  
 ラベタロール塩酸塩錠 1899

## リ

リオチロニンナトリウム 821  
 リオチロニンナトリウム錠 822  
 リシノプリル錠 824  
 リシノプリル水和物 823  
 L-リジン塩酸塩 829  
 リゾチーム塩酸塩 830  
 リドカイン 818  
 リドカイン注射液 818  
 リトドリン塩酸塩 1067  
 リトドリン塩酸塩錠 1068  
 リファンピシシ 1064  
 リファンピシシカプセル 1065  
 リボスタマイシン硫酸塩 1063  
 リボフラビン 1059  
 リボフラビン散 1060  
 リボフラビン酪酸エステル 1060  
 リボフラビンリン酸エステルナトリウ

ム 1061

リボフラビンリン酸エステルナトリウム注射液 1062, 1922  
 リマプロスト アルファデクス 819  
 リュウコツ 1313  
 硫酸亜鉛水和物 1246  
 硫酸亜鉛点眼液 1247  
 硫酸アルミニウムカリウム水和物 292  
 硫酸カリウム 1014  
 硫酸鉄水和物 661  
 硫酸バリウム 334  
 硫酸マグネシウム水 839  
 硫酸マグネシウム水和物 838  
 硫酸マグネシウム注射液 839, 1900  
 リュウタン 1306, 1949  
 リュウタン末 1306, 1949  
 流動パラフィン 966  
 リョウキョウ 1256, 1937  
 荅桂朮甘湯エキス 1347, 1965  
 リンゲル液 1066, 1922  
 リンコマイシン塩酸塩水和物 820  
 リン酸水素カルシウム水和物 396, 1875  
 リン酸水素ナトリウム水和物 568  
 リン酸二水素カルシウム水和物 397

## レ

レセルピン 1055  
 レセルピン散 0.1% 1057  
 レセルピン錠 1057  
 レセルピン注射液 1056, 1922  
 レチノール酢酸エステル 1058  
 レチノールパルミチン酸エステル 1059  
 レナンピシリン塩酸塩 810  
 レバロルフアン酒石酸塩 813  
 レバロルフアン酒石酸塩注射液 814, 1900  
 レボチロキシナトリウム錠 817  
 レボチロキシナトリウム水和物 816  
 レボドパ 814  
 レボメプロマジンマレイン酸塩 815  
 レンギョウ 1286  
 レンニク 1320

## ロ

L-ロイシン 812  
 ロキサチジン酢酸エステル塩酸塩 1070  
 ロキサチジン酢酸エステル塩酸塩徐放カプセル 1071  
 ロキシスロマイシン 1073, 1923  
 ロキソプロフェンナトリウム水和物 828  
 ロキタマイシン 1069  
 ロキタマイシン錠 1923  
 ロジン 1347  
 ロートエキス 1353, 1967  
 ロートエキス・アネスタミン散 1355

ロートエキス・カーボン散 1355  
ロートエキス散 1353  
ロートエキス・タンニン坐剤 1357  
ロートエキス・パパベリン・アネスタミ  
ン散 1356  
ロートコン 1357, 1967  
ロラゼパム 827

ワ

ワイル病秋やみ混合ワクチン 1237  
ワルファリンカリウム 1233  
ワルファリンカリウム錠 1234